"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 3525134 A,107-316-317-575-445,1970-08-25,1970,US 3525134D A,1969-02-17,US 80509869 A,1969-02-17,YARN FLUID TREATING APPARATUS,,DU PONT,COON JOHN MARTIN,,https://lens.org/107-316-317-575-445,Granted Patent,no,4,41,1,1,0,D02G1/161;;D02G1/161,D02G1/16,28/1.4,0,0,,,,EXPIRED
2,ZA,B,ZA 929596 B,169-393-262-583-373,1993-07-19,1993,ZA 929596 A,1992-12-10,US 80518691 A,1991-12-10,Methods and compositions for reducing multi-drug resistance.,,RUSH PRESBYTERIAN ST LUKE,COON JOHN S,,https://lens.org/169-393-262-583-373,Granted Patent,no,0,0,1,18,0,,A61K/,,0,0,,,,EXPIRED
3,EP,A4,EP 0616493 A4,124-262-928-860-443,1994-11-09,1994,EP 93900961 A,1992-12-09,US 9210563 W;;US 80518691 A;;US 98276692 A,1991-12-10,METHODS AND COMPOSITIONS FOR REDUCING MULTI-DRUG RESISTANCE.,,RUSH PRESBYTERIAN ST LUKE,COON JOHN S,,https://lens.org/124-262-928-860-443,Search Report,no,0,0,9,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/60;;A61P35/00;;A61P43/00,A61K31/23;;A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/48;;A61K45/00;;A61P35/00;;A61P43/00;;C08L71/00;;C08L71/02,,7,3,078-379-639-309-287;;035-479-355-650-668;;072-054-424-022-015,1720770;;10.1016/0198-8859(91)90110-u;;10.1007/bf00199227;;3847290;;pmc1977900;;1637678;;10.1038/bjc.1992.217,"J.DAVIS ET AL.: ""SOLUTOL HS 15 REVERSES MULTIPLE DRUG RESISTANCE IN A HUMAN MDR-1-MOUSE MELANOMA SYSTEM"", PROC.ANNU.MEET.AM.SOC.CLIN.ONCOL., vol. 10, March 1991 (1991-03-01), pages 82;;J.S.COON ET AL.: ""Multidrug Resistance Activity in Human Lymphocytes"", HUMAN IMMUNOLOGY, vol. 32, no. 2, October 1991 (1991-10-01), pages 134 - 140;;N.BLOKSMA ET AL.: ""Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin"", CANCER IMMUNOL. IMMUNOTHER., vol. 19, no. 3, 1985, pages 205 - 210;;M.PAGÉ ET AL.: ""Elimination of P-170 mediated multidrug resistance by solubilization in pluronic micelles"", PROC.AM.ASSOC.CANCER RES.ANNU.MEET., vol. 33, March 1992 (1992-03-01), pages 552;;J.S.COON ET AL.: ""Survey of surfactants for reversing multidrug resistance."", PROC.AM.ASSOC.CANCER RES.ANNU.MEET., vol. 33, March 1992 (1992-03-01), pages 484;;D.M.WOODCOCK ET AL.: ""Reversal of multidrug resistance by surfactants"", BRITISH JOURNAL OF CANCER, vol. 66, no. 1, July 1992 (1992-07-01), pages 62 - 68;;See also references of WO 9311668A1",DISCONTINUED
4,MX,A,MX 9207150 A,039-668-460-875-98X,1993-12-01,1993,MX 9207150 A,1992-12-10,US 80518691 A;;US 98276692 A,1991-12-10,METODO Y COMPOSICIONES PARA REDUCIR LA RESISTENCIAA MULTIPLES FARMACOS.,"La presente invención incluye métodos y composiciones para reducir o eliminar la resistencia a múltiples fármacos en cánceres de seres humanos o animales. De conformidad con el método y la composición de la presente invención, se administra un éster anfipático no iónico de un ácido graso a un paciente, donde un cáncer humano o de animal exhibe una resistencia a múltiples fármacos, para el agente quimioterapéutico.",RUSH PRESBYTERIAN ST LUKE,COON JOHN S,,https://lens.org/039-668-460-875-98X,Patent Application,no,0,0,9,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/60;;A61P35/00;;A61P43/00,A61K31/23;;A61K45/00;;A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/48;;A61P35/00;;A61P43/00;;C08L71/00;;C08L71/02,,0,0,,,,PENDING
5,US,A,US 641273 A,141-801-878-025-314,1900-01-16,1900,US 1899/0719290 A,1899-06-03,US 1899/0719290 A,1899-06-03,COOKING UTENSIL.,,COON JOHN DENNIS,COON JOHN DENNIS,,https://lens.org/141-801-878-025-314,Granted Patent,no,0,4,1,1,0,B65D2543/00296;;B65D2543/00296;;A47J36/064,,,0,0,,,,EXPIRED
6,WO,A1,WO 1993/011668 A1,142-243-419-547-60X,1993-06-24,1993,US 9210563 W,1992-12-09,US 80518691 A;;US 98276692 A,1991-12-10,METHODS AND COMPOSITIONS FOR REDUCING MULTI-DRUG RESISTANCE,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers in humans or animals. According to the method and composition of the present invention, a non-ionic amphipathic ester of a fatty acid is administered to a patient in which a human or animal cancer exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH PRESBYTERIAN ST LUKE,COON JOHN S,,https://lens.org/142-243-419-547-60X,Patent Application,yes,12,11,9,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/60;;A61P35/00;;A61P43/00,A61K31/23;;A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/48;;A61K45/00;;A61P35/00;;A61P43/00;;C08L71/00;;C08L71/02,,5,4,119-437-082-629-053;;042-950-635-383-846;;037-971-434-683-369;;039-897-437-195-176,1988130;;1681415;;5030820;;2364376,"COON, ""Solutol HS 15, Nontoxic Polyoxyethylene Esters of 12-Hydroxystearic Acid, Reverses Multidrug Resistance"", Cancer Research, Vol. 51, pages 897-902, published 01 February 1991, see the Abstract and Results sections.;;LELONG, ""Fluorescent Verapamil Derivative for Monitoring Activity of the Multidrug Transporter"", Molecular Pharmacology, Vol. 40, pages 490-494, published 28 June 1991, see the Summary.;;RIEHM, ""Potentiation of Drug Effect by Tween 80 in Chinese Hamster Cells Resistant to Actinomycin D and Daunomycin"", Cancer Research, Vol. 32, pages 1195-1200, published June 1972, see the entire document.;;WOODCOCK, ""Reversal of the Multidrug Resistance Phenotype with Cremophor EL, a Common Vehicle for Water-insoluble Vitamins and Drugs"", Cancer Research, Vol. 50, pages 4199-4203, published 15 July 1990, see the entire document.;;See also references of EP 0616493A4",PENDING
7,CA,A,CA 37713 A,084-867-763-166-391,1891-11-02,1891,CA 37713D A,,CA 37713T A,,WIRE BALE-TIE,,COON JOHN D,COON JOHN D,,https://lens.org/084-867-763-166-391,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
8,AU,A,AU 1993/032433 A,146-828-542-113-726,1993-07-19,1993,AU 1993/032433 A,1992-12-09,US 80518691 A;;US 98276692 A,1991-12-10,Methods and compositions for reducing multi-drug resistance,,RUSH PRESBYTERIAN ST LUKES MEDICAL CENTER,COON JOHN S,,https://lens.org/146-828-542-113-726,Patent Application,no,0,0,9,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/60;;A61P35/00;;A61P43/00,A61K45/00;;A61K31/23;;A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/48;;A61P35/00;;A61P43/00;;C08L71/00;;C08L71/02,,0,0,,,,PENDING
9,CN,A,CN 1076358 A,104-174-138-950-211,1993-09-22,1993,CN 92115397 A,1992-12-10,US 80518691 A;;US 98276692 A,1991-12-10,METHODS AND COMPOSITIONS FOR REDUCING MULTI-DRUG RESISTANCE,,RUSH PRESBYTERIAN ST LUKE,COON JOHN S,,https://lens.org/104-174-138-950-211,Patent Application,no,0,0,9,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/60;;A61P35/00;;A61P43/00,A61K31/23;;A61K45/00;;A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/48;;A61P35/00;;A61P43/00;;C08L71/00;;C08L71/02,,0,0,,,,DISCONTINUED
10,CA,A,CA 60645 A,061-391-587-129-114,1898-07-19,1898,CA 60645D A,1898-06-15,CA 60645T A,1898-06-15,BREECH LOADING DOUBLE BARRELLED GUN,,COON JOHN D,COON JOHN D,,https://lens.org/061-391-587-129-114,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
11,CA,A,CA 66791 A,112-941-202-624-723,1900-03-28,1900,CA 66791D A,1900-03-14,CA 66791T A,1900-03-14,COOKING UTENSIL,,COON JOHN DENNIS,COON JOHN DENNIS,,https://lens.org/112-941-202-624-723,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
12,US,A,US 2467111 A,122-821-946-469-224,1949-04-12,1949,US 63862946 A,1946-01-02,US 63862946 A,1946-01-02,Plow,,COON JOHN E,COON JOHN E,,https://lens.org/122-821-946-469-224,Granted Patent,no,5,8,1,1,0,A01B5/06;;A01B5/06,A01B5/06,,0,0,,,,EXPIRED
13,US,A,US 1238641 A,145-171-084-647-076,1917-08-28,1917,US 17075617 A,1917-05-24,US 17075617 A,1917-05-24,PAINT-BRUSH HOLDER.,,COON JOHN HENRY,COON JOHN HENRY,,https://lens.org/145-171-084-647-076,Granted Patent,no,0,7,1,1,0,A47L15/507;;A47L15/507,,,0,0,,,,EXPIRED
14,EP,A1,EP 0616493 A1,027-775-190-050-969,1994-09-28,1994,EP 93900961 A,1992-12-09,US 9210563 W;;US 80518691 A;;US 98276692 A,1991-12-10,METHODS AND COMPOSITIONS FOR REDUCING MULTI-DRUG RESISTANCE.,"Procédés et compositions destinés à réduire ou à éliminer la multirésistance aux médicaments en cas de cancer humain ou animal, qui consistent à administrer un ester non ionique amphipathique d'un acide gras à un patient humain ou animal atteint d'un cancer présentant une multirésistance à l'agent chimiothérapeutique. Le procédé et la composition de la présente invention peuvent être employés avec une efficacité particulière en cas de cancer multirésistant à tout agent chimiothérapeutique.",RUSH PRESBYTERIAN ST LUKE,COON JOHN S,,https://lens.org/027-775-190-050-969,Patent Application,yes,0,0,9,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/60;;A61P35/00;;A61P43/00,A61K31/23;;A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/48;;A61K45/00;;A61P35/00;;A61P43/00;;C08L71/00;;C08L71/02,,0,0,,,,DISCONTINUED
15,CA,A1,CA 2125279 A1,170-429-993-230-421,1993-06-24,1993,CA 2125279 A,1992-12-09,US 80518691 A;;US 98276692 A;;US 9210563 W,1991-12-10,METHODS AND COMPOSITIONS FOR REDUCING MULTI-DRUG RESISTANCE,"METHODS AND COMPOSITIONS FOR REDUCING MULTI-DRUG RESISTANCE The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers in humans or animals. According to the method and composition of the present invention, a non-ionic amphipathic ester of a fatty acid is administered to a patient in which a human or animal cancer exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",,COON JOHN SAYLER,,https://lens.org/170-429-993-230-421,Patent Application,no,0,0,9,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/60;;A61P35/00;;A61P43/00,A61K31/23;;A61K31/70;;A61K45/00;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K47/48;;A61P35/00;;A61P43/00;;C08L71/00;;C08L71/02,,0,0,,,,DISCONTINUED
16,US,A,US 3685194 A,189-905-307-367-95X,1972-08-22,1972,US 3685194D A,1969-08-29,US 86260069 A,1969-08-29,HANDGUN TO RIFLE CONVERSION ASSEMBLY,,COON JOHN M,COON JOHN M,,https://lens.org/189-905-307-367-95X,Granted Patent,no,0,62,1,1,0,F41C23/12;;F41C23/12;;F41C23/10;;F41C23/10,F41C23/10;;F41C23/12,42/77;;42/72,0,0,,,,EXPIRED
17,JP,A,JP 2018161132 A,076-091-349-273-057,2018-10-18,2018,JP 2018105825 A,2018-06-01,US 22428109 P,2009-07-09,METHODS OF CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,"PROBLEM TO BE SOLVED: To provide a method for classifying a biological sample with respect to treatment with an inhibitor of the tyrosine kinase activity of EGFR or an agent that functions similarly to tyrosine kinase inhibitors.SOLUTION: A method includes: contacting a biological sample obtained from a human patient, with a set of chromosomal hybridization probes; detecting copy number for each of human Chromosome 7, human Chromosome locus 10q23.3 and human chromosome locus 3q26.3, in cells in a sample, to determine the copy numbers thereof; and classifying the sample based on a copy number profile as either having loss or gain relative to normal copy number.SELECTED DRAWING: None",ABBOTT MOLECULAR INC,JOHN COON;;LARRY MORRISON,,https://lens.org/076-091-349-273-057,Patent Application,no,0,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/6827,,0,0,,,,PENDING
18,JP,A,JP 2016101162 A,011-911-046-349-010,2016-06-02,2016,JP 2015231344 A,2015-11-27,US 22428109 P,2009-07-09,METHOD FOR CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,"PROBLEM TO BE SOLVED: To provide a method for classifying tissue samples of cancer patients or patients suspected of a cancer.SOLUTION: The method is configured to detect the copy number of human chromosome 7, human chromosome locus 10q23.3 and human chromosome locus 3q26.3 in the cells of biological samples from human patients in the treatment by e.g. an inhibitor of an activity of tyrosine kinase of EGFR, and the method comprises the step of classifying the samples based on the result of having a copy number profile of 10q23.3 loss, 3q26.3 gain and chromosome 7 loss relative to normal copy number for each, and the step of classifying into a human patient resistant to the treatment by the agents such as an inhibitor of an activity of tyrosine kinase of EGFR, when 10q23.3 loss, 3q26.3 gain and chromosome 7 loss relative to normal copy number for each is detected.SELECTED DRAWING: None",ABBOTT MOLECULAR INC,JOHN COON;;LARRY MORRISON,,https://lens.org/011-911-046-349-010,Patent Application,no,1,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68;;G01N33/53;;G01N33/574,,2,2,030-926-896-434-132;;045-014-778-430-184,pmc2689116;;10.1172/jci37127;;19451690;;19238210;;pmc2642732;;10.1371/journal.pone.0004576,"SOS M L ET AL., JOURNAL OF CLINICAL INVESTIGATION, vol. 119, no. 6, JPN5012016201, June 2009 (2009-06-01), pages 1727 - 1740;;PLOS ONE, vol. 4, 2, JPN6016036693, 2009, pages e4576",PENDING
19,WO,A1,WO 2011/006058 A1,047-276-618-966-791,2011-01-13,2011,US 2010/0041512 W,2010-07-09,US 22428109 P,2009-07-09,METHODS OF CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,Gene copy numbers of signaling components downstream of EGFR identify non- small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.,ABBOTT LAB;;COON JOHN;;MORRISON LARRY,COON JOHN;;MORRISON LARRY,,https://lens.org/047-276-618-966-791,Patent Application,yes,3,1,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68,,9,8,030-926-896-434-132;;016-525-033-813-028;;064-216-314-583-523;;021-629-394-896-751;;078-947-095-785-13X;;066-705-417-916-626;;084-162-736-494-955;;071-222-441-969-300,pmc2689116;;10.1172/jci37127;;19451690;;17409929;;10.1097/01243894-200609000-00006;;10.1016/s1556-0864(15)30374-9;;14555504;;10.1016/j.humpath.2005.05.006;;16084946;;19351834;;pmc2849653;;10.1158/0008-5472.can-08-4055;;pmc2874836;;18757405;;10.1158/0008-5472.can-07-5084;;18948947;;pmc2694412;;10.1038/nature07423;;18077425;;10.1073/pnas.0707498104;;pmc2148401,"SOS M L ET AL: ""Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions"", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US LNKD- DOI:10.1172/JCI37127, vol. 119, no. 6, 1 June 2009 (2009-06-01), pages 1727 - 1740, XP002555300, ISSN: 0021-9738, [retrieved on 20090518];;ENDOH HIDEKI ET AL: ""PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients."", JOURNAL OF THORACIC ONCOLOGY : OFFICIAL PUBLICATION OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER SEP 2006 LNKD- PUBMED:17409929, vol. 1, no. 7, September 2006 (2006-09-01), pages 629 - 634, XP002597655, ISSN: 1556-1380;;SHE QING-BAI ET AL: ""Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 OCT 2003 LNKD- PUBMED:14555504, vol. 9, no. 12, 1 October 2003 (2003-10-01), pages 4340 - 4346, XP002597656, ISSN: 1078-0432;;MARSIT CARMEN J ET AL: ""PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration."", HUMAN PATHOLOGY JUL 2005 LNKD- PUBMED:16084946, vol. 36, no. 7, July 2005 (2005-07-01), pages 768 - 776, XP002597657, ISSN: 0046-8177;;SOS MARTIN L ET AL: ""PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR."", CANCER RESEARCH 15 APR 2009 LNKD- PUBMED:19351834, vol. 69, no. 8, 15 April 2009 (2009-04-15), pages 3256 - 3261, XP002597658, ISSN: 1538-7445;;YAMAMOTO HIROMASA ET AL: ""PIK3CA mutations and copy number gains in human lung cancers."", CANCER RESEARCH 1 SEP 2008 LNKD- PUBMED:18757405, vol. 68, no. 17, 1 September 2008 (2008-09-01), pages 6913 - 6921, XP002597659, ISSN: 1538-7445;;DING LI ET AL: ""Somatic mutations affect key pathways in lung adenocarcinoma."", NATURE 23 OCT 2008 LNKD- PUBMED:18948947, vol. 455, no. 7216, 23 October 2008 (2008-10-23), pages 1069 - 1075, XP002597660, ISSN: 1476-4687;;MCDERMOTT ULTAN ET AL: ""Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 11 DEC 2007 LNKD- PUBMED:18077425, vol. 104, no. 50, 11 December 2007 (2007-12-11), pages 19936 - 19941, XP002597661, ISSN: 1091-6490;;L.E. MORRISON; J.S. COON, PROGNOSTIC TEST FOR EARLY STAGE NON SMALL CELL LUNG CANCER, 11 November 2008 (2008-11-11)",PENDING
20,EP,A1,EP 2451972 A1,188-620-439-258-573,2012-05-16,2012,EP 10734406 A,2010-07-09,US 2010/0041512 W;;US 22428109 P,2009-07-09,METHODS OF CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,,ABBOTT LAB,COON JOHN;;MORRISON LARRY,ABBOTT MOLECULAR INC. (2013-11-27),https://lens.org/188-620-439-258-573,Patent Application,yes,0,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68,,0,0,,,,ACTIVE
21,CA,C,CA 2767640 C,006-386-235-266-376,2018-10-30,2018,CA 2767640 A,2010-07-09,US 22428109 P;;US 2010/0041512 W,2009-07-09,METHODS OF CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,Gene copy numbers of signaling components downstream of EGFR identify non- small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.,ABBOTT LAB,COON JOHN;;MORRISON LARRY,,https://lens.org/006-386-235-266-376,Granted Patent,no,0,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/6827;;C12Q1/6881,,0,0,,,,INACTIVE
22,EP,A1,EP 3045546 A1,031-394-763-310-795,2016-07-20,2016,EP 16159330 A,2010-07-09,US 22428109 P;;EP 10734406 A,2009-07-09,METHODS OF CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING SURVIVAL IN RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,Gene copy numbers of signaling components downstream of EGFR identify non- small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.,ABBOTT MOLECULAR INC,COON JOHN;;MORRISON LARRY,,https://lens.org/031-394-763-310-795,Patent Application,yes,4,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/6886,,2,2,120-145-724-827-301;;030-926-896-434-132,16557391;;10.1007/s00401-006-0057-9;;pmc2689116;;10.1172/jci37127;;19451690,"ANDREY KORSHUNOV ET AL: ""Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH)"", ACTA NEUROPATHOLOGICA, SPRINGER, BERLIN, DE, vol. 111, no. 5, 24 March 2006 (2006-03-24), pages 465 - 474, XP019426155, ISSN: 1432-0533, DOI: 10.1007/S00401-006-0057-9;;SOS M L ET AL: ""Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions"", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US LNKD- DOI:10.1172/JCI37127, vol. 119, no. 6, 1 June 2009 (2009-06-01), pages 1727 - 1740, XP002555300, ISSN: 0021-9738, [retrieved on 20090518]",DISCONTINUED
23,EP,A1,EP 2362914 A1,172-586-943-358-576,2011-09-07,2011,EP 09759835 A,2009-11-11,US 2009/0064029 W;;US 26879708 A,2008-11-11,PROGNOSTIC TEST FOR EARLY STAGE NON SMALL CELL LUNG CANCER (NSCLC),,ABBOTT LAB,MORRISON LARRY;;COON JOHN,,https://lens.org/172-586-943-358-576,Patent Application,yes,0,0,4,4,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/106;;C12Q2600/106;;C12Q2600/156;;C12Q2600/156,C12Q1/68,,1,0,,,See references of WO 2010056747A1,DISCONTINUED
24,WO,A1,WO 2010/056747 A1,176-673-009-814-932,2010-05-20,2010,US 2009/0064029 W,2009-11-11,US 26879708 A,2008-11-11,PROGNOSTIC TEST FOR EARLY STAGE NON SMALL CELL LUNG CANCER (NSCLC),"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at chromosome 10q23.3 and centromere 10 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. The chromosome copy number can also be determined using, for example, PCR or array CGH. Assessment of the copy number abnormality patterns with a classifier based on the relative loss of 10q23.3 signals compared to the centromere 10 signals produced statistically significant prognostic classification for NSCLC. The ratio of PTEN/CEP 10 signals, using a cutoff of 0.80, was capable of dividing patients into a group of 41 (≥0.80) in which 33 (80.5%) had the favorable prognosis, and a group of 18 (<0.80) in which 6 (33.3%) had the favorable prognosis (p=0.0008). Median times to recurrence in the former and latter groups were 83.0 and 13.0 months, respectively (p<0.0001).",ABBOTT LAB;;MORRISON LARRY;;COON JOHN,MORRISON LARRY;;COON JOHN,,https://lens.org/176-673-009-814-932,Patent Application,yes,2,0,4,4,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/106;;C12Q2600/106;;C12Q2600/156;;C12Q2600/156,C12Q1/68,,3,3,023-772-308-222-369;;021-629-394-896-751;;026-735-185-637-164,10.1158/1078-0432.ccr-04-2087;;16061856;;10.1016/j.humpath.2005.05.006;;16084946;;10.1016/j.lungcan.2005.10.003;;16324768,"JIANG FENG ET AL: ""Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 AUG 2005, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5417 - 5424, XP002569221, ISSN: 1078-0432;;MARSIT ET AL: ""PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration"", HUMAN PATHOLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 36, no. 7, 1 July 2005 (2005-07-01), pages 768 - 776, XP005008216, ISSN: 0046-8177;;TANG J M ET AL: ""Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis"", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 51, no. 2, 1 February 2006 (2006-02-01), pages 181 - 191, XP024893851, ISSN: 0169-5002, [retrieved on 20060201]",PENDING
25,EP,B1,EP 2451972 B1,096-946-479-531-073,2016-05-04,2016,EP 10734406 A,2010-07-09,US 2010/0041512 W;;US 22428109 P,2009-07-09,METHODS OF CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,,ABBOTT MOLECULAR INC,COON JOHN;;MORRISON LARRY,ABBOTT MOLECULAR INC. (2013-11-27),https://lens.org/096-946-479-531-073,Granted Patent,yes,2,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68,,1,1,027-073-631-637-671,10.1038/bjc.2011.494;;pmc3251891;;22095222,"M J FIDLER ET AL: ""PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy"", BRITISH JOURNAL OF CANCER, vol. 105, no. 12, 17 November 2011 (2011-11-17), pages 1920 - 1926, XP055215815, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.494",ACTIVE
26,ES,T3,ES 2576084 T3,109-254-783-137-591,2016-07-05,2016,ES 10734406 T,2010-07-09,US 22428109 P;;US 2010/0041512 W,2009-07-09,Métodos de clasificación de muestras biológicas para predecir la respuesta al tratamiento con inhibidor de tirosina quinasa,"Un método para la clasificación de una muestra biológica con respecto al tratamiento con un inhibidor de la actividad de la tirosina quinasa de EGFR, comprendiendo el método: (a) poner en contacto una muestra biológica obtenida de un paciente humano con un conjunto de sondas de hibridación cromosómicas en condiciones suficientes para permitir la hibridación de las sondas a los cromosomas en la muestra en donde (i) una sonda está diseñada para detectar el número de copias del locus del cromosoma humano 10q23 0.3 en las células de la muestra y (ii) una sonda está diseñada para detectar el número de copias del locus del cromosoma humano 3q26.3 en las células de la muestra; (b) determinar el número de copias para cada uno del locus del cromosoma humano 10q23.3 y el locus del cromosoma humano 3q26.3; y (c) clasificar la muestra como resistente al tratamiento con un inhibidor de la actividad tirosina quinasa de EGFR basándose en los resultados de la etapa (b), por tener un perfil de número de copias de pérdida de 10q23.3 y aumento de 3q26.3, en relación con el número de copias normal de cada uno.",ABBOTT MOLECULAR INC,COON JOHN;;MORRISON LARRY,,https://lens.org/109-254-783-137-591,Granted Patent,no,0,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68,,0,0,,,,ACTIVE
27,CA,A1,CA 2767640 A1,138-911-038-090-745,2011-01-13,2011,CA 2767640 A,2010-07-09,US 22428109 P;;US 2010/0041512 W,2009-07-09,METHODS OF CLASSIFYING BIOLOGICAL SAMPLES FOR PREDICTING RESPONSE TO TYROSINE KINASE INHIBITOR TREATMENT,Gene copy numbers of signaling components downstream of EGFR identify non- small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.,ABBOTT LAB,COON JOHN;;MORRISON LARRY,,https://lens.org/138-911-038-090-745,Patent Application,no,0,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68,,0,0,,,,INACTIVE
28,US,A,US 2459501 A,035-138-105-335-088,1949-01-18,1949,US 54110044 A,1944-06-19,US 54110044 A,1944-06-19,Polymeric mono-isoolefinic materials and process of making same,,MELVIN COON JOHN;;RUST JOHN B,MELVIN COON JOHN;;RUST JOHN B,,https://lens.org/035-138-105-335-088,Granted Patent,no,4,1,1,1,0,C08F10/00;;C08F10/00,C08F10/00,,0,0,,,,EXPIRED
29,DE,T2,DE 60003651 T2,156-989-862-623-039,2004-06-24,2004,DE 60003651 T,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,VERFAHREN ZUR HERSTELLUNG EINES BOHRLOCHES IN EINER UNTERGRUNDFORMATION,,SHELL INT RESEARCH,COON JOE;;FRANK JOHN;;MARTIN JOHN,,https://lens.org/156-989-862-623-039,Granted Patent,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,EXPIRED
30,CA,A,CA 444754 A,185-213-054-557-428,1947-10-28,1947,CA 444754D A,,CA 444754T A,,OIL- AND HEAT-RESISTANT GASKET,,MONTCLAIR RES CORP,COON JOHN MELVIN;;RUST JOHN B,,https://lens.org/185-213-054-557-428,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
31,DE,D1,DE 60003651 D1,139-056-924-721-128,2003-08-07,2003,DE 60003651 T,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,VERFAHREN ZUR HERSTELLUNG EINES BOHRLOCHES IN EINER UNTERGRUNDFORMATION,,SHELL INT RESEARCH,COON JOE;;FRANK JOHN;;MARTIN JOHN,,https://lens.org/139-056-924-721-128,Granted Patent,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,EXPIRED
32,US,A,US 990111 A,067-093-584-567-736,1911-04-18,1911,US 1910/0574800 A,1910-08-01,US 1910/0574800 A,1910-08-01,VALVE.,,COON CHARLES N;;CANTLON JOHN,COON CHARLES N;;CANTLON JOHN,,https://lens.org/067-093-584-567-736,Granted Patent,no,0,2,1,1,0,F16K5/00;;F16K5/00;;Y10T137/6065;;Y10T137/6065,,,0,0,,,,EXPIRED
33,US,B2,US 8951725 B2,135-612-756-134-811,2015-02-10,2015,US 8270908 A,2008-04-14,US 8270908 A,2008-04-14,Diagnostic methods for determining prognosis of non-small cell lung cancer,"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≧0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≧1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6<1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.",MORRISON LARRY E;;COON JOHN;;ABBOTT LAB,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2015-01-01);;ABBOTT LABORATORIES (2008-04-29),https://lens.org/135-612-756-134-811,Granted Patent,yes,0,2,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68;;C07H21/02;;C07H21/04;;C12M1/34;;C12P19/34,435/6.1;;435/91.2;;435/287.1;;536/23.1;;536/24.3,11,8,127-879-159-581-667;;023-449-280-444-460;;009-367-283-416-506;;033-927-289-009-517;;004-855-085-988-627;;033-335-158-657-603;;030-840-628-879-461;;003-193-312-542-232,pmc1907319;;12707375;;10.1016/s1525-1578(10)60459-x;;pmc1885895;;10.1016/s0002-9440(10)64610-x;;10980136;;15743749;;10.1309/f5ad-juwv-d2wf-l8j5;;10.1309/f5adjuwvd2wfl8j5;;pmc4169497;;10.1371/journal.pone.0107958;;25233459;;18814932;;10.1016/j.lungcan.2008.07.016;;10.1016/j.cancergencyto.2007.12.004;;18328944;;17923754;;10.3346/jkms.2007.22.s.s47;;pmc2694384;;10.14670/hh-23.33;;17952855,"Romeo M.S. et al. Journal of Molecular Diagnostics, vol. 5, No. 2, May 2003, pp. 103-112.;;Carlson J. A. et al. American Journal of Pathology, vol. 157, No. 3, Sep. 2000, pp. 973-983.;;Thisted, R.A. 'What is a P-value?' (May 25, 1998) from www.stat.uchicago.edu/~thisted, pp. 1-6.;;Bubendorf L. et al. Am J Clin Pathol 2005;123:516-523.;;Yang Y. et al. ""Parallel Single Cancer Cell Whole Genome Amplification Using Button-Valve Assisted Mixing in Nanoliter Chambers"" PLOS One, Sep. 18, 2014, vol. 9, issue 9, pp. 1-8.;;Choi C M., et al., ""Chromosomal Instability Is a Risk Factor for Poor Prognosis of Adenocarcinoma of the Lung: Fluorescence in Situ Hybridization Analysis of Paraffin-Embedded Tissue From Korean Patients,"" Lung Cancer, 2009, vol. 64 (1), pp. 66-70.;;International Preliminary Report on Patentability and Written Opinion for Application No. PCT/US2009/040294, mailed on Oct. 19, 2010, 6 pages.;;International Search Report for Application No. PCT/US2009/040294, mailed on Jul. 6, 2009, 2 pages.;;Kang, et al., ""Gain at Chromosomal Region 5p15.33, Containing TERT, Is the Most Frequent Genetic Event in Early Stages of Non-Small Cell Lung Cancer,"" Cancer Genetics and Cytogenetics, 2008, vol. 182 (1), pp. 1-11.;;Kang Ji Un., et al., ""High Frequency of Genetic Alterations in Non-Small Cell Lung Cancer Detected by Multi-Target Fluorescence in Situ Hybridization,"" Journal of Korean Medical Science, 2007, Suppl. 22, pp. S47-S51.;;Zudaire I., et al., ""Molecular Characterization of Small Peripheral Lung Tumors Based on the Analysis of Fine Needle Aspirates,"" Histology and Histopathology, 2008, vol. 23 (1), pp. 33-40.",INACTIVE
34,US,A1,US 2013/0022970 A1,064-377-289-234-387,2013-01-24,2013,US 201013382443 A,2010-07-09,US 201013382443 A;;US 22428109 P;;US 2010/0041512 W,2009-07-09,Methods Of Classifying Biological Samples For Predicting Response To Tyrosine Kinase Inhibitor Treatment,Gene copy numbers of signaling components downstream of EGFR identify non-small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.,MORRISON LARRY E;;COON JOHN,MORRISON LARRY E;;COON JOHN,RUSH UNIVERSITY MEDICAL CENTER (2013-03-16);;ABBOTT MOLECULAR INC (2013-04-18),https://lens.org/064-377-289-234-387,Patent Application,yes,0,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68;;G01N21/64,435/6.11,0,0,,,,DISCONTINUED
35,EP,A1,EP 2281061 A1,013-289-099-446-792,2011-02-09,2011,EP 09732531 A,2009-04-13,US 2009/0040294 W;;US 8270908 A,2008-04-14,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBOTT LAB,MORRISON LARRY E;;COON JOHN,"ABBOTT MOLECULAR INC. (2014-02-17);;ABBOTT LABORATORIES (2013-12-11);;ABBOTT MOLECULAR INC. (N.D.GES.D. STAATES DELA, US (2014-01-16);;ABBOTT MOLECULAR, INC., US (2013-12-19)",https://lens.org/013-289-099-446-792,Patent Application,yes,0,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,,1,0,,,See references of WO 2009129154A1,ACTIVE
36,US,A1,US 2018/0291467 A1,047-660-827-985-071,2018-10-11,2018,US 201816006361 A,2018-06-12,US 201816006361 A;;US 201414584788 A;;US 8270908 A,2008-04-14,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≥0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≥1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6 <1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.",ABBOTT MOLECULAR INC,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2015-06-03),https://lens.org/047-660-827-985-071,Patent Application,yes,0,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/6886;;C12Q1/6841,,1,0,,,"GeneLoc: Display cytoband boundaries, Chromosome 5, Mb range of cytogenetic bands (according to the Ensembl Database), pages 1-2 printed on 9/10/19 from https://genecards.weizmann.ac.il/geneloc. (Year: 2019)",DISCONTINUED
37,US,B2,US 8785131 B2,094-100-038-405-264,2014-07-22,2014,US 26879708 A,2008-11-11,US 26879708 A,2008-11-11,Prognostic test for early stage non small cell lung cancer (NSCLC),"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at chromosome 10q23.3 and centromere 10 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. The chromosome copy number can also be determined using, for example, PCR or array CGH. Assessment of the copy number abnormality patterns with a classifier based on the relative loss of 10q23.3 signals compared to the centromere 10 signals produced statistically significant prognostic classification for NSCLC. The ratio of PTEN/CEP 10 signals, using a cutoff of 0.80, was capable of dividing patients into a group of 41 (≧0.80) in which 33 (80.5%) had the favorable prognosis, and a group of 18 (<0.80) in which 6 (33.3%) had the favorable prognosis (p=0.0008). Median times to recurrence in the former and latter groups were 83.0 and 13.0 months, respectively (p<0.0001).",MORRISON LARRY E;;COON JOHN;;ABBOTT LAB,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2015-01-01);;ABBOTT LABORATORIES (2008-11-12),https://lens.org/094-100-038-405-264,Granted Patent,yes,16,0,4,4,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/106;;C12Q2600/106;;C12Q2600/156;;C12Q2600/156,C12Q1/68;;C07H21/02,435/6.12;;536/23.1,29,27,023-449-280-444-460;;127-879-159-581-667;;066-188-479-197-302;;050-309-753-012-014;;016-525-033-813-028;;084-162-736-494-955;;071-222-441-969-300;;064-216-314-583-523;;078-947-095-785-13X;;066-705-417-916-626;;003-193-312-542-232;;007-883-420-994-272;;023-772-308-222-369;;021-629-394-896-751;;022-484-309-529-028;;005-415-432-367-823;;030-926-896-434-132;;026-735-185-637-164;;013-610-960-734-280;;091-490-597-848-923;;003-193-312-542-232;;018-447-753-688-44X;;041-309-424-116-14X;;004-833-219-417-698;;043-185-153-369-364;;127-879-159-581-667;;023-449-280-444-460,pmc1885895;;10.1016/s0002-9440(10)64610-x;;10980136;;pmc1907319;;12707375;;10.1016/s1525-1578(10)60459-x;;10.1016/j.cancergencyto.2006.04.003;;16938570;;12006535;;17409929;;10.1097/01243894-200609000-00006;;10.1016/s1556-0864(15)30374-9;;18948947;;pmc2694412;;10.1038/nature07423;;18077425;;10.1073/pnas.0707498104;;pmc2148401;;14555504;;19351834;;pmc2849653;;10.1158/0008-5472.can-08-4055;;pmc2874836;;18757405;;10.1158/0008-5472.can-07-5084;;10.14670/hh-23.33;;17952855;;18704985;;10.1002/cncr.23782;;pmc3529469;;10.1158/1078-0432.ccr-04-2087;;16061856;;10.1016/j.humpath.2005.05.006;;16084946;;10.1126/science.1162981;;pmc2849753;;18787170;;10.1002/gcc.20419;;17243161;;pmc2689116;;10.1172/jci37127;;19451690;;10.1016/j.lungcan.2005.10.003;;16324768;;15350627;;10.1016/j.cdp.2004.04.007;;10.1378/chest.130.3.694;;16963665;;10.14670/hh-23.33;;17952855;;17640552;;10.1016/j.humpath.2007.04.015;;10.3109/10520299809140502;;9554580;;7875039;;10.1002/cyto.990170407;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;pmc1907319;;12707375;;10.1016/s1525-1578(10)60459-x;;pmc1885895;;10.1016/s0002-9440(10)64610-x;;10980136,"Carison et al. Americon J. of Pathology, 2000, vol. 157(3), p. 973-983.;;Romeo et al. J. of Molecular Diagnostics, 2003, vol. 5(2), p. 103-112.;;Yoshimoto et al. Cancer Genetics and Cytogenetics, 2006, vol. 169, p. 128-137.;;SORIA, Clin Cancer Res, 2002, v8, pp. 1178-1184.;;Endoh et al., J. of Thoracic Oncology, 2006, vol. 1, No. 7, 629-634.;;Ding L., et al., ""Somatic Mutations Affect Key Pathways in Lung Adenocarcinoma,"" Nature, 2008, vol. 455 (7216), pp. 1069-1075.;;McDermott U., et al., ""Identification of Genotype-Correlated Sensitivity to Selective Kinase Inhibitors by Using High-throughput Tumor Cell Line Profiling,"" Proceedings of the National Academy of Sciences, 2007, vol. 104 (50), pp. 19936-19941.;;She Q.B., et al., ""Resistance to Gefitinib in PTEN-null HER-Overexpressing Tumor Cells can be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling,"" 2003, vol. 9 (12), pp. 4340-4346.;;Sos M.L., et al., ""PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR,"" Cancer Research, vol. 69 (8), pp. 3256-3261, 2009.;;Thisted R.A., ""What is a P-Value?"" www.stat.uchicago.edu/~thisted 1998, pp. 1-6.;;Yamamoto H., et al., ""PIK3CA Mutations and Copy Number Gains in Human Lung Cancers,"" Cancer Research, 2008, vol. 68 (17), pp. 6913-6921.;;Zudaire I., et al., ""Molecular Characterization Of Small Peripheral Lung Tumors Based On The Analysis Of Fine Needle Aspirates,"" Histology And Histopathology, 2008, vol. 23 (1), pp. 33-40.;;Freeman et al., Copy Number Gains in EGFR and Copy Number Losses in PTEN Are Common Events in Osteosarcoma Tumors, Cancer, 2008, vol. 113:1453-1461.;;Jiang et al., Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non-Small Cell Lung Cancer, Clinical Cancer Research, 2005, 11(15), 5417-5424.;;Marsit et al, PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration, Human Pathology, 2005, vol. 36:768-776.;;Mao et al., FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression, Science, 2008, vol. 321:1499-1502.;;Morrison et al., Effects of ERBB2 Amplicon Size and Genomic Alterations of Chromosomes 1, 3, and 10 on Patient Response to Trastuzumab in Metastatic Breast Cancer, Genes, Chromosomes & Cancer, 2007, vol. 46:397-405.;;Sos et al., Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions, J. of Clinical Investigation, 2009, vol. 119 (6), 1727-1740.;;Tang et al., Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis, Lung Cancer, 2006, vol. 51, 181-191.;;Varella-Garcia et al, Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer, Cancer Detection & Prevention, 2004, vol. 28 (4), 244-251.;;Halling et al, A Comparison of Cytology and Fluorescence in Situ Hybridization for the Detection of Lung Cancer in Bronchoscopic Specimens, Chest, 2006, 130:694-701.;;Zudaire et al, Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates, Histol. Histophathol., 2008, 23:33-40.;;Halling et al., Fluorescense in situ hybridization in diagnostic cytology, Hum. Path. 2007, 38: 1137-1144.;;Nath et al, Fluorescence in Situ Hybridization (FISH): DNA Probe Production and Hybridization Critereia, Biotechnic Histochem, 1998, 73 (1), 6-22.;;Wheeless et al, Bladder Irrigation Specimens Assayed by Fluorescence in Situ Hybridization to Interphase Nuclei, Cytometry, 1994, 17:319-326.;;Morrison et al., Labeling Fluorescence in Situ Hybridization Probes for Genomic Targets, Molecular Cytogenetics: Protocols & Applications, 2002, Chap. 2, 21-40.;;Romeo et al., Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization, Journal of Molecular Diagnostics, May 2003, vol. 5, No. 2, 103-112.;;Carlson et al., Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin, American Jorunal of Pathology, Sep. 2000, vol. 157, No. 3, 973-983.;;Thisted, R.A., (May 25, 1998) What is a P-value?, from www.stat.uchicago.edu/~thisted, 1-6.",INACTIVE
38,US,A1,US 2009/0258350 A1,030-775-925-438-621,2009-10-15,2009,US 8270908 A,2008-04-14,US 8270908 A,2008-04-14,Diagnostic methods for determining prognosis of non-small cell lung cancer,"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≧0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≧1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6<1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.",ABBOTT LAB,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2015-01-01);;ABBOTT LABORATORIES (2008-04-29),https://lens.org/030-775-925-438-621,Patent Application,yes,0,9,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,435/6,2,2,009-367-283-416-506;;033-927-289-009-517,15743749;;10.1309/f5ad-juwv-d2wf-l8j5;;10.1309/f5adjuwvd2wfl8j5;;pmc4169497;;10.1371/journal.pone.0107958;;25233459,"Bubendorf L. et al. Am J Clin Pathol 2005;123:516-523.;;Yang Y. et al. ""Parallel Single Cancer Cell Whole Genome Amplification Using Button-Valve Assisted Mixing in Nanoliter Chambers"" PLOS ONE, Sept. 18, 2014, volume 9, issue 9, pages 1-8",INACTIVE
39,GB,A,GB 2441633 A,165-159-600-394-217,2008-03-12,2008,GB 0716788 A,2007-08-29,US 46863106 A,2006-08-30,Control valve to prevent backflow in gas lift applications,A control valve 100 is used in conjunction with a gas lift valve downhole for selectively closing a flow path through a wellbore in a first direction to prevent backflow of gas or fluid from production tubing to an annulus. The control valve comprises a flapper check valve 150 which is allowed to close when a flow tube 155 is shifted against the bias of a spring 130 by a force acting against a piston surface 125 attached to the flow tube 155. The force is created by back pressure acting on closed hinged flaps 120 of the piston surface 125 when the force of a gas pressure which acts to open them is less than a biasing force to close them.,WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT,,https://lens.org/165-159-600-394-217,Patent Application,no,5,1,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B34/08;;E21B34/00,,0,0,,,,ACTIVE
40,GB,B,GB 2441633 B,005-164-386-479-790,2011-02-16,2011,GB 0716788 A,2007-08-29,US 46863106 A,2006-08-30,Injection valve,,WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT,,https://lens.org/005-164-386-479-790,Granted Patent,no,9,0,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B34/08;;E21B34/00,,0,0,,,,ACTIVE
41,US,A1,US 2015/0167102 A1,081-201-192-493-697,2015-06-18,2015,US 201414584788 A,2014-12-29,US 201414584788 A;;US 8270908 A,2008-04-14,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of 0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≧1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6 <1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.",ABBOTT LAB,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2015-06-03),https://lens.org/081-201-192-493-697,Patent Application,yes,2,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,,0,0,,,,INACTIVE
42,EP,B1,EP 2281061 B1,008-655-326-981-127,2013-10-23,2013,EP 09732531 A,2009-04-13,US 2009/0040294 W;;US 8270908 A,2008-04-14,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBOTT LAB,MORRISON LARRY E;;COON JOHN,"ABBOTT MOLECULAR INC. (2014-02-17);;ABBOTT LABORATORIES (2013-12-11);;ABBOTT MOLECULAR INC. (N.D.GES.D. STAATES DELA, US (2014-01-16);;ABBOTT MOLECULAR, INC., US (2013-12-19)",https://lens.org/008-655-326-981-127,Granted Patent,yes,0,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,,1,1,127-879-159-581-667,pmc1907319;;12707375;;10.1016/s1525-1578(10)60459-x,"ROMEO MAURA SANTOS ET AL: ""Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization."", THE JOURNAL OF MOLECULAR DIAGNOSTICS : JMD MAY 2003 LNKD- PUBMED:12707375, vol. 5, no. 2, May 2003 (2003-05-01), pages 103 - 112, XP002534344, ISSN: 1525-1578",ACTIVE
43,WO,A1,WO 2009/129154 A1,030-075-729-400-821,2009-10-22,2009,US 2009/0040294 W,2009-04-13,US 8270908 A,2008-04-14,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of =0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals =1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6 <1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.",ABBOTT LAB;;MORRISON LARRY E;;COON JOHN,MORRISON LARRY E;;COON JOHN,,https://lens.org/030-075-729-400-821,Patent Application,yes,0,12,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,,4,4,033-335-158-657-603;;030-840-628-879-461;;003-193-312-542-232;;004-855-085-988-627,10.1016/j.cancergencyto.2007.12.004;;18328944;;17923754;;10.3346/jkms.2007.22.s.s47;;pmc2694384;;10.14670/hh-23.33;;17952855;;18814932;;10.1016/j.lungcan.2008.07.016,"KANG ET AL: ""Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer"", CANCER GENETICS AND CYTOGENETICS, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 182, no. 1, 6 March 2008 (2008-03-06), pages 1 - 11, XP022513162, ISSN: 0165-4608;;KANG JI UN ET AL: ""High frequency of genetic alterations in non-small cell lung cancer detected by multi-target fluorescence in situ hybridization"", JOURNAL OF KOREAN MEDICAL SCIENCE, vol. 22, no. Suppl. S, September 2007 (2007-09-01), pages S47 - S51, XP008107686, ISSN: 1011-8934;;ZUDAIRE I ET AL: ""Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates"", HISTOLOGY AND HISTOPATHOLOGY, vol. 23, no. 1, January 2008 (2008-01-01), pages 33 - 40, XP008107684, ISSN: 0213-3911;;CHOI C M ET AL: ""Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: Fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients"", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 64, no. 1, 1 April 2009 (2009-04-01), pages 66 - 70, XP025965400, ISSN: 0169-5002, [retrieved on 20080923]",PENDING
44,ES,T3,ES 2440747 T3,070-698-547-496-49X,2014-01-30,2014,ES 09732531 T,2009-04-13,US 8270908 A;;US 2009/0040294 W,2008-04-14,Procedimientos de diagnóstico para determinar el pronóstico del cáncer de pulmón de células no pequeñas,"Un procedimiento para determinar el pronóstico del cáncer de pulmón en un paciente humano, comprendiendo elprocedimiento: (a) poner en contacto una muestra biológica obtenida de un paciente humano clasificado como quetiene un cáncer de pulmón de células no pequeñas en estadio temprano con un conjunto de sondas cromosómicasque comprende al menos dos sondas seleccionadas de entre el grupo que consiste en una sonda específica dellocus del cromosoma 5p15, una sonda específica del locus del cromosoma 8q24, una sonda de enumeración delcromosoma 6, y una sonda específica del locus del cromosoma 7p12 bajo condiciones suficientes para que seproduzca la hibridación de las sondas del conjunto a los cromosomas en la muestra, si existen; (b) identificación delpatrón de hibridación para un pronóstico favorable del conjunto de sondas cromosómicas en la muestra biológicaseleccionada a partir del patrón de hibridación que consiste en: (i) el clasificador de % de pérdida de 8q24/7p12 que utiliza un límite de >= 31% de células, (ii) el clasificador Rango3 y el patrón de % de pérdida 8q24/CEP6 con límites de >= 45% de células o >= 24% decélulas respectivamente (iii) la relación de señal total 8q24/5py la relación total 5p15/CEP6 con límites de < 0,80 o < 1,1respectivamente (iv) el Intervalo Medio de Señal y el patrón Rango3 con límites de < 2,5 o >= 42% de células, respectivamentey (c) determinar el pronóstico de cáncer de pulmón en un sujeto basándose en el patrón de hibridación identificadoen la etapa (b), en la que el clasificador Rango3 es el intervalo de células que muestran una diferencia en una basede célula por célula, de al menos tres señales de sonda de FISH en el locus cromosómico con el mayor número deseñales de FISH menos las señales de FISH en el locus cromosómico con el número más bajo de señales de FISHy en la que el Intervalo Medio de Señal se calcula determinando en cada célula del número total de células de lamuestra que se evalúa, la diferencia entre la sonda con el número más alto de señales de hibridación y la sonda conel menor número de señales de sonda, luego se recopila el número Rango de Señal individual celular y se divide porel número de células evaluadas.",ABBOTT LAB,MORRISON LARRY E;;COON JOHN,,https://lens.org/070-698-547-496-49X,Granted Patent,no,0,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,,0,0,,,,ACTIVE
45,US,A1,US 2016/0017440 A1,073-456-667-863-01X,2016-01-21,2016,US 201514869363 A,2015-09-29,US 201514869363 A;;US 201213382443 A;;US 2010/0041512 W;;US 22428109 P,2009-07-09,Methods Of Classifying Biological Samples For Predicting Response To Tyrosine Kinase Inhibitor Treatment,Gene copy numbers of signaling components downstream of EGFR identify non-small cell lung cancer (NSCLC) patients with poor outcomes on 2nd/3rd line gefitinib therapy.,ABBOTT MOLECULAR INC,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2016-02-02),https://lens.org/073-456-667-863-01X,Patent Application,yes,0,0,13,13,0,C12Q2543/10;;C12Q2600/106;;C12Q1/6886;;A61K31/5377;;C12Q2600/106;;C12Q2543/10;;C12Q1/6886;;A61K31/5377;;C12Q2600/112,C12Q1/68;;A61K31/5377,,1,1,044-456-317-114-56X,17909199;;10.1200/jco.2007.12.3026,"Herbst (J Clin Oncology, 2007, vol 25, pp. 4743-4750)",DISCONTINUED
46,US,A,US 3384820 A,112-087-116-687-832,1968-05-21,1968,US 45658165 A,1965-05-17,US 45658165 A,1965-05-17,VIBRATING ELEMENT ELECTROMETER WITH OUTPUT SIGNAL MAGNIFIED OVER INPUT SIGNAL BY A FUNCTION OF THE MECHANICAL Q OF THE VIBRATING ELEMENT,,NASA,DIMEFF JOHN;;COON GRANT W,,https://lens.org/112-087-116-687-832,Granted Patent,no,3,2,1,1,0,G01R5/28;;G01R5/28,G01R5/28,324/120,0,0,,,,EXPIRED
47,AU,A1,AU 2009/236418 A1,145-858-522-809-348,2009-10-22,2009,AU 2009/236418 A,2009-04-13,US 8270908 A;;US 2009/0040294 W,2008-04-14,Diagnostic methods for determining prognosis of non-small cell lung cancer,,ABBOTT MOLECULAR INC,COON JOHN;;MORRISON LARRY E,ABBOTT MOLECULAR INC. (2013-11-28),https://lens.org/145-858-522-809-348,Patent Application,no,0,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,,0,0,,,,DISCONTINUED
48,US,B2,US 9994909 B2,132-393-179-354-569,2018-06-12,2018,US 201414584788 A,2014-12-29,US 201414584788 A;;US 8270908 A,2008-04-14,Diagnostic methods for determining prognosis of non-small cell lung cancer,"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≥0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≥1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6<1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.",ABBOTT MOLECULAR INC,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2015-06-03),https://lens.org/132-393-179-354-569,Granted Patent,yes,2,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68;;C07H21/02;;C07H21/04;;C12M1/34;;C12P19/34,,11,8,009-367-283-416-506;;023-449-280-444-460;;004-855-085-988-627;;033-335-158-657-603;;030-840-628-879-461;;127-879-159-581-667;;033-927-289-009-517;;003-193-312-542-232,15743749;;10.1309/f5ad-juwv-d2wf-l8j5;;10.1309/f5adjuwvd2wfl8j5;;pmc1885895;;10.1016/s0002-9440(10)64610-x;;10980136;;18814932;;10.1016/j.lungcan.2008.07.016;;10.1016/j.cancergencyto.2007.12.004;;18328944;;17923754;;10.3346/jkms.2007.22.s.s47;;pmc2694384;;pmc1907319;;12707375;;10.1016/s1525-1578(10)60459-x;;pmc4169497;;10.1371/journal.pone.0107958;;25233459;;10.14670/hh-23.33;;17952855,"Bubendorf L., et al., “Multitarget FISH Analysis in the Diagnosis of Lung Cancer,” American Journal of Clinical Pathology, 2005, vol. 123 (4), pp. 516-523.;;Carlson J.A., et al., “Chromosome 17 Aneusomy Detected by Fluorescence in Situ Hybridization in Vulvar Squamous Cell Carcinomas and Synchronous Vulvar Skin,” American Journal of Pathology, 2000, vol. 157 (3), pp. 973-983.;;Choi C.M., et al., “Chromosomal Instability is a Risk Factor for Poor Prognosis of Adenocarcinoma of the Lung: Fluorescence in Situ Hybridization Analysis of Paraffin-Embedded Tissue from Korean Patients,” Lung Cancer, 2009, vol. 64 (1), pp. 66-70.;;International Preliminary Report on Patentability and Written Opinion for Application No. PCT/US2009/040294, dated Oct. 19, 2010, 6 pages.;;International Search Report for Application No. PCT/US2009/040294, dated Jul. 6, 2009, 2 pages.;;Kang J.U., et al., “Gain at Chromosomal Region 5p15.33, Containing TERT, Is the Most Frequent Genetic Event in Early Stages of Non-Small Cell Lung Cancer,” Cancer Genetics and Cytogenetics, 2008, vol. 182 (1), pp. 1-11.;;Kang J.U., et al., “High Frequency of Genetic Alterations in Non-Small Cell Lung Cancer Detected by Multi-Target Fluorescence in Situ Hybridization,” Journal of Korean Medical Science, 2007, Suppl. 22, pp. S47-S51.;;Romeo R.S., et al., “Chromosomal Abnormalities in Non-small Cell Lung Carcinomas and in Bronchial Epithelia of High-Risk Smokers Detected by Multi-Target Interphase Fluorescence in Situ Hybridization,” Journal of Molecular Diagnostics, 2003, vol. 5 (2), pp. 103-112.;;Thisted R.A. What is a P-value?. [retrieved on May 25, 1998] Retrieved from the Internet< URL: http://www.stat.uchicago.edu/faculty/thisted.shtml>, pp. 1-6.;;Yang Y., et al., “Parallel Single Cancer Cell Whole Genome Amplification Using Button-Valve Assisted Mixing in Nanoliter Chambers,” Plos One, 2014, vol. 9 (9), pp. 1-8.;;Zudaire I., et al., “Molecular Characterization of Small Peripheral Lung Tumors Based on the Analysis of Fine Needle Aspirates,” Histology and Histopathology, 2008, vol. 23 (1), pp. 33-40.",INACTIVE
49,US,A1,US 2010/0120027 A1,165-520-947-687-670,2010-05-13,2010,US 26879708 A,2008-11-11,US 26879708 A,2008-11-11,PROGNOSTIC TEST FOR EARLY STAGE NON SMALL CELL LUNG CANCER (NSCLC),"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at chromosome 10q23.3 and centromere 10 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. The chromosome copy number can also be determined using, for example, PCR or array CGH. Assessment of the copy number abnormality patterns with a classifier based on the relative loss of 10q23.3 signals compared to the centromere 10 signals produced statistically significant prognostic classification for NSCLC. The ratio of PTEN/CEP 10 signals, using a cutoff of 0.80, was capable of dividing patients into a group of 41 (≧0.80) in which 33 (80.5%) had the favorable prognosis, and a group of 18 (<0.80) in which 6 (33.3%) had the favorable prognosis (p=0.0008). Median times to recurrence in the former and latter groups were 83.0 and 13.0 months, respectively (p<0.0001).",ABBOTT LAB,MORRISON LARRY E;;COON JOHN,ABBOTT MOLECULAR INC (2015-01-01);;ABBOTT LABORATORIES (2008-11-12),https://lens.org/165-520-947-687-670,Patent Application,yes,13,5,4,4,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/106;;C12Q2600/106;;C12Q2600/156;;C12Q2600/156,C12Q1/68,435/6,0,0,,,,INACTIVE
50,CA,A1,CA 2721446 A1,136-506-424-103-389,2009-10-22,2009,CA 2721446 A,2009-04-13,US 8270908 A;;US 2009/0040294 W,2008-04-14,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of =0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals =1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6 <1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.",ABBOTT LAB,MORRISON LARRY E;;COON JOHN,,https://lens.org/136-506-424-103-389,Patent Application,no,0,0,12,12,0,C12Q1/6886;;C12Q1/6886;;C12Q1/6841;;C12Q1/6841;;C12Q2600/118;;C12Q2600/118,C12Q1/68,,0,0,,,,DISCONTINUED
51,CA,A1,CA 2651419 A1,002-234-186-086-564,2007-11-22,2007,CA 2651419 A,2007-05-08,US 79921606 P;;US 2007/0011047 W,2006-05-10,DIAGNOSTIC METHODS FOR DETERMINING TREATMENT,,ABBOTT LAB,COON JOHN S;;MORRISON LARRY E,,https://lens.org/002-234-186-086-564,Patent Application,no,0,0,6,6,0,C12Q1/6886;;C12Q2600/106;;G01N33/57407;;G01N33/57419;;G01N33/57423;;G01N2800/52;;G01N33/57419;;C12Q2600/106;;G01N2800/52;;C12Q1/6886;;G01N33/57407;;G01N33/57423,C12Q1/68;;A61K39/395;;C12N9/12;;C12Q1/48;;G01N31/00,,0,0,,,,DISCONTINUED
52,GB,A,GB 2471609 A,074-624-928-204-378,2011-01-05,2011,GB 201017328 A,2006-10-31,US 26375305 A;;GB 0621713 A,2005-10-31,One way valve to prevent backflow,"Valve apparatus for selectively closing a flow path through a wellbore. The valve comprises a body 105, a plurality of piston members 120 which form a piston surface 125 across the flow path. Each piston member is attached to the end of a shiftable member/flow tube 155 which is annularly disposed in the body. The piston members can rotate to form the piston surface. A flapper valve 150 closes to seal the flow path when the shiftable member is moved by flow acting on the piston surface 125. Each piston member may be biased towards the longitudinal axis of the body and can matingly engage together when the piston surface is formed.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/074-624-928-204-378,Patent Application,no,1,2,3,12,0,E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08,,0,0,,,,ACTIVE
53,AU,A,AU 1983/011509 A,091-179-766-858-443,1983-06-30,1983,AU 1983/011509 A,1982-12-14,US 33034881 A;;US 33034981 A;;US 33878882 A,1981-12-14,ENGRAVED IMAGE IDENTIFICATION CARD,,CALIFORNIA INTERFACE SOFTWARE LTD,SMALLEY HALL JOHN;;COON PHELPS BARRY,,https://lens.org/091-179-766-858-443,Patent Application,no,0,0,4,7,0,B42D2033/06;;B42D2033/08;;B42D2033/20;;B42D2033/42;;B42D2035/50;;B42D25/43;;B42D25/00;;B42D25/47;;B42D25/43,B42D15/10,,0,0,,,,DISCONTINUED
54,US,B2,US 7861790 B2,104-991-587-175-206,2011-01-04,2011,US 23418408 A,2008-09-19,US 23418408 A;;US 46863106 A;;US 26375305 A,2005-10-31,Injection valve and method,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2006-10-02),https://lens.org/104-991-587-175-206,Granted Patent,yes,11,4,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B43/12,166/374;;166/386;;166/321;;166/332.8,3,0,,,"GB Examination Report for Application No. GB0621713.7 dated Nov. 13, 2009.;;Canadian Office Action for Application No. 2,599,073 dated Apr. 22, 2010.;;GB Search and Examination Report for GB Application No. GB1017328.4 dated Oct. 28, 2010.",ACTIVE
55,CN,B,CN 1983196 B,181-382-083-598-95X,2010-09-29,2010,CN 200610168179 A,2006-12-15,US 30555805 A,2005-12-16,System and method for grouping execution threads,"Multiple threads are divided into buddy groups of two or more threads, so that each thread has assigned to it one or more buddy threads. Only one thread in each buddy group actively executes instructions and this allows buddy threads to share hardware resources, such as registers. When an active thread encounters a swap event, such as a swap instruction, the active thread suspends execution and one of its buddy threads begins execution using that thread's private hardware resources and the buddy group's shared hardware resources. As a result, the thread count can be increased without replicating all of the per-thread hardware resources.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN E,,https://lens.org/181-382-083-598-95X,Granted Patent,no,0,1,7,7,0,G06F9/3009;;G06F9/3851;;G06F9/4843;;G06F9/3851;;G06F9/3009;;G06F9/4843,G06F9/46,,0,0,,,,ACTIVE
56,US,A,US 3265619 A,008-609-920-030-247,1966-08-09,1966,US 27770663 A,1963-05-03,US 27770663 A,1963-05-03,Heavy duty lubricants,,SHELL OIL CO,MALONE BOBBY W;;COON JOHN S,,https://lens.org/008-609-920-030-247,Granted Patent,no,3,0,3,4,0,C07F9/04;;C07F9/04;;C10M135/18;;C10M135/18;;C10M149/10;;C10M149/10;;C10M159/04;;C10M159/04;;C10M159/18;;C10M159/18;;C10M167/00;;C10M167/00;;C10M2203/10;;C10M2203/10;;C10M2203/102;;C10M2203/102;;C10M2203/104;;C10M2203/104;;C10M2203/106;;C10M2203/106;;C10M2203/108;;C10M2203/108;;C10M2205/22;;C10M2205/22;;C10M2207/09;;C10M2207/09;;C10M2209/084;;C10M2209/084;;C10M2209/101;;C10M2209/101;;C10M2215/04;;C10M2215/04;;C10M2215/26;;C10M2215/26;;C10M2217/028;;C10M2217/028;;C10M2217/06;;C10M2217/06;;C10M2219/044;;C10M2219/044;;C10M2219/046;;C10M2219/046;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2219/082;;C10M2219/082;;C10M2223/045;;C10M2223/045;;C10M2223/063;;C10M2223/063;;C10M2223/12;;C10M2223/12;;C10M2225/04;;C10M2225/04;;C10M2225/041;;C10M2225/041;;C10M2227/09;;C10M2227/09;;C10N2010/04;;C10N2010/04;;C10N2040/02;;C10N2040/02;;C10N2040/135;;C10N2040/135;;C10N2040/25;;C10N2040/25;;C10N2040/251;;C10N2040/251;;C10N2040/255;;C10N2040/255;;C10N2040/28;;C10N2040/28,C07F9/04;;C10M167/00,C5F F617          -;;C5F F639          -;;C5F F682          -;;C5F F684          -;;C5F F762          -;;C5F F793          -;;C5F F794          -,0,0,,,,EXPIRED
57,CA,A1,CA 2565998 A1,047-774-143-789-040,2007-04-30,2007,CA 2565998 A,2006-10-27,US 26375305 A,2005-10-31,FULL BORE INJECTION VALVE,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surfac e formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,COON ROBERT J;;LEMBCKE JEFFREY JOHN,,https://lens.org/047-774-143-789-040,Patent Application,no,0,0,9,12,0,E21B34/08;;E21B2200/05;;E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08,,0,0,,,,ACTIVE
58,GB,B,GB 2471609 B,102-575-130-882-597,2011-02-16,2011,GB 201017328 A,2006-10-31,US 26375305 A;;GB 0621713 A,2005-10-31,Full bore injection valve,,WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/102-575-130-882-597,Granted Patent,no,1,0,3,12,0,E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08,,0,0,,,,ACTIVE
59,CA,C,CA 2565998 C,127-610-769-825-76X,2010-10-19,2010,CA 2565998 A,2006-10-27,US 26375305 A,2005-10-31,FULL BORE INJECTION VALVE,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/127-610-769-825-76X,Granted Patent,no,0,0,9,12,0,E21B34/08;;E21B2200/05;;E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08;;E21B34/06;;E21B34/14;;F16K1/20;;F16K15/03;;F16K15/18,,0,0,,,,ACTIVE
60,CA,A,CA 668295 A,147-607-289-936-004,1963-08-06,1963,CA 668295D A,,CA 668295T A,,ROTARY HOOK FOR TRAVELING BLOCK FOR CRANES,,DRAFTO CORP,COON LAWRENCE H;;KRAELING JOHN B,,https://lens.org/147-607-289-936-004,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
61,US,A,US 3215631 A,125-850-339-939-054,1965-11-02,1965,US 25710363 A,1963-02-08,US 25710363 A,1963-02-08,Lubricants containing ashless nitrogencontaining polymeric detergents and complexes of acid aryl phosphates,,SHELL OIL CO,HENDERSON BENNETT M;;COON JOHN S,,https://lens.org/125-850-339-939-054,Granted Patent,no,7,1,4,4,0,C07D207/412;;C07D207/412;;C07F9/12;;C07F9/12;;C08F8/40;;C08F8/40;;C08F26/06;;C08F26/06;;C08L33/08;;C08L33/08;;C08L39/08;;C08L39/08;;C10M141/10;;C10M141/10;;C10M157/08;;C10M157/08;;C10M161/00;;C10M161/00;;C10M2203/10;;C10M2203/10;;C10M2205/00;;C10M2205/00;;C10M2207/022;;C10M2207/022;;C10M2207/023;;C10M2207/023;;C10M2207/024;;C10M2207/024;;C10M2207/026;;C10M2207/026;;C10M2207/046;;C10M2207/046;;C10M2207/40;;C10M2207/40;;C10M2207/402;;C10M2207/402;;C10M2207/404;;C10M2207/404;;C10M2209/04;;C10M2209/04;;C10M2209/06;;C10M2209/06;;C10M2209/062;;C10M2209/062;;C10M2209/103;;C10M2209/103;;C10M2209/104;;C10M2209/104;;C10M2209/105;;C10M2209/105;;C10M2215/04;;C10M2215/04;;C10M2215/065;;C10M2215/065;;C10M2215/086;;C10M2215/086;;C10M2215/26;;C10M2215/26;;C10M2215/28;;C10M2215/28;;C10M2217/022;;C10M2217/022;;C10M2217/023;;C10M2217/023;;C10M2217/028;;C10M2217/028;;C10M2217/046;;C10M2217/046;;C10M2217/06;;C10M2217/06;;C10M2219/082;;C10M2219/082;;C10M2219/083;;C10M2219/083;;C10M2223/04;;C10M2223/04;;C10M2223/041;;C10M2223/041;;C10M2223/042;;C10M2223/042;;C10M2223/047;;C10M2223/047;;C10M2223/065;;C10M2223/065;;C10M2223/12;;C10M2223/12;;C10M2225/04;;C10M2225/04;;C10M2229/02;;C10M2229/02;;C10M2229/041;;C10M2229/041;;C10M2229/05;;C10M2229/05;;C10N2040/252;;C10N2040/252;;C10N2040/253;;C10N2040/253,C07D207/40;;C07D207/412;;C07F9/12;;C08F8/40;;C08F26/06;;C08L33/08;;C08L39/08;;C10M141/10;;C10M157/08;;C10M161/00,C5F F472          -;;C5F F476          -;;C5F F482          -;;C5F F492          -;;C5F F540          -;;C5F F595          -;;C5F F605          -;;C5F F614          -;;C5F F617          -;;C5F F619          -;;C5F F640          -;;C5F F642          -;;C5F F661          -;;C5F F672          -;;C5F F673          -;;C5F F674          -;;C5F F677          -;;C5F F683          -;;C5F F739          -;;C5F F795          -;;C5F F796          -,0,0,,,,EXPIRED
62,GB,A,GB 2431677 A,131-133-236-232-676,2007-05-02,2007,GB 0621713 A,2006-10-31,US 26375305 A,2005-10-31,Flapper check valve to prevent backflow when a pump is deactivated,"The check valve is intended to provide backflow protection when electrical submersible pumps (ESP) or similar are removed for repair or maintenance. The check valve comprises primarily flapper element <B>150</B> and sliding tube <B>155.</B> When the pump is inoperative spring <B>130</B> moves the tube down, allowing the flapper to close of the fluid flow (Fig. 5) When the pump is operating fluid pressure against piston surfaces <B>120</B> forces the tube upwards against the spring. When the force is sufficient the tube pushes the flapper out of the flow path and holds it against the outside housing (Fig. 4). The piston elements are hinged to allow them to provide high resistance at low flow but present a minimal blockage at high flow. The valve should experience less wear then ball and seat type check valves and allow a wider flow path.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/131-133-236-232-676,Patent Application,no,3,8,9,12,0,E21B34/08;;E21B2200/05;;E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08,E1F FLP           FLP;;E1F F302          FLP,0,0,,,,ACTIVE
63,CA,A1,CA 2599073 A1,146-770-769-423-957,2008-02-29,2008,CA 2599073 A,2007-08-28,US 46863106 A,2006-08-30,INJECTION VALVE,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,COON ROBERT J;;LEMBCKE JEFFREY JOHN,,https://lens.org/146-770-769-423-957,Patent Application,no,0,0,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B43/12,,0,0,,,,ACTIVE
64,US,B1,US 6640297 B1,168-110-435-173-454,2003-10-28,2003,US 59628000 A,2000-06-19,US 59628000 A,2000-06-19,Link pipe system for storage and retrieval of sequences of branch addresses,"
    The speed of processing of a sequence of indirect branch instructions in a pipelined processor is increased by overlapping the latencies in the sequence of indirect branch instructions. The architecture of a digital processor is modified to include a link pipe system that allows the sequence of branch addresses required by the indirect branches to be written to a single location within the processor, and to be read from a single location in the processor. The link pipe system contains a plurality of registers (  3, 5  &  7  ) for storage of respective branch target addresses. Each WRITE of a branch address is automatically directed (  9  ) to individual registers within the link pipe system for storing the respective branch addresses; and each READ of a branch address is automatically directed (  11  ) to the register containing the earliest WRITE of an address that was not previously read by the processor, whereby branch target addresses are retrieved on a first in, first out basis. 
",TRANSMETA CORP,BANNING JOHN;;COON BRETT;;HAO ERIC,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27);;INTELLECTUAL VENTURE FUNDING LLC (2009-01-28);;TRANSMETA CORPORATION (2000-09-08);;MIND FUSION LLC (2023-02-14);;TRANSMETA LLC (2009-01-27);;INTELLECTUAL VENTURES ASSETS 186 LLC (2022-12-22),https://lens.org/168-110-435-173-454,Granted Patent,yes,8,19,1,1,0,G06F9/3806;;G06F9/3806;;G06F9/30054;;G06F9/30054;;G06F9/30061;;G06F9/30101;;G06F9/30101;;G06F9/322;;G06F9/322,G06F9/30;;G06F9/38,712/238,0,0,,,,EXPIRED
65,GB,A,GB 2403489 A,000-316-883-626-163,2005-01-05,2005,GB 0414573 A,2004-06-29,US 61030903 A;;US 84855804 A,2003-06-30,A method of completing a wellbore,"A method of completing a wellbore 400 comprises the steps of running a first tubular 410 into a wellbore, suspending the tubular at a selected depth within the well, and expanding a portion 420 of it. Thereafter, a second tubular 425 is run into the well, located at a region proximate the first tubular so that part of the tubulars overlap, before a portion of the second tubular is also expanded. The inner diameter of the mating portion 415 of the first tubular is configured to sealingly receive the outer diameter of the second tubular, and may be a polished bore receptacle (PBR). The first tubular may be expanded against an unlined portion of the wellbore, or against a cased portion, and frictional or anchoring means in the form of slips may be employed to hold the first tubular against the casing 405. In a separate embodiment, the first and second tubulars are expanded concurrently. Also disclosed is a tubular assembly for forming an anchor.",WEATHERFORD LAMB,HARRALL SIMON JOHN;;COON ROBERT J,,https://lens.org/000-316-883-626-163,Patent Application,no,4,0,9,35,0,E21B29/10;;E21B33/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B43/103;;E21B43/106;;E21B43/105;;E21B33/10;;E21B43/103;;E21B29/10,E21B33/10;;E21B43/10,E1F FLA           FLA,0,0,,,,INACTIVE
66,US,B2,US 7836276 B2,011-056-091-856-48X,2010-11-16,2010,US 29261405 A,2005-12-02,US 29261405 A,2005-12-02,System and method for processing thread groups in a SIMD architecture,"A SIMD processor efficiently utilizes its hardware resources to achieve higher data processing throughput. The effective width of a SIMD processor is extended by clocking the instruction processing side of the SIMD processor at a fraction of the rate of the data processing side and by providing multiple execution pipelines, each with multiple data paths. As a result, higher data processing throughput is achieved while an instruction is fetched and issued once per clock. This configuration also allows a large group of threads to be clustered and executed together through the SIMD processor so that greater memory efficiency can be achieved for certain types of operations like texture memory accesses performed in connection with graphics processing.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,NVIDIA CORPORATION (2005-12-01),https://lens.org/011-056-091-856-48X,Granted Patent,yes,51,8,8,21,0,G06F9/3838;;G06F9/3851;;G06F9/3869;;G06F9/3885;;G06F9/3887;;G06F9/3885;;G06F9/3851;;G06F9/3869;;G06F9/3838;;G06F9/3887,G06F9/38;;G06F9/30,712/206;;712/10;;712/11,10,4,002-062-256-975-845;;111-207-670-000-134;;020-961-679-464-619;;018-485-097-317-022,10.1145/263326.263382;;10.1145/232973.232993;;10.1109/40.621209;;10.1145/882262.882301,"Hinton et al, The Microarchitecture of the Pentium 4 Processor, Intel Technology Journal Q1, 2001, p. 1-12.;;Intel, IA-32 Architecture Software Developer's Manual, vol. 2B, p. 4-72.;;Intel, IA-32 Intel Architecture Software Developer's Manual, vol. 1, pp. 11-23 through 11-25.;;Lo, Jack L.; Eggers, Susan J.; Emer, Joel S.; Levy, Jenry M.; Stamm, Rebecca L.; and Tullsen, Dean M., ""Converting Thread-Level Parallelism to Instruction-Level Parallelism via Simultaneous Multithreading"", ACM Transactions on Computer Systems, vol. 15, No. 3, Aug. 1997. pp. 322-354.;;Tullsen, Dean M.; Eggers, Susan J.; Emer, Joel S.; Levy, Henry M.; Lo, Jack L.; and Stamm, Rebecca L., ""Exploiting Choice: Instruction Fetch and Issue on an Implementable Simultaneous Multithreading Processor"", Proceedings of the 23rd Annual International Symposium on Computer Architectur, May 1996. pp. 1-12.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;English abstract of JP 2003-35589 with additional translated information.;;Translated Japanese Office Action dated Jun. 9, 2008 (provided as an explanation of relevance of Citation No. B1).;;Sen et al., ""Shadow Silhouette Maps"" Jul. 2003, ACM Transactions on Graphics 22, 3, pp. 521-526.;;Office Action, U.S. Appl. No. 11/458,633, mailed Oct. 1, 2009.",ACTIVE
67,GB,B,GB 2431677 B,066-326-629-320-04X,2010-12-01,2010,GB 0621713 A,2006-10-31,US 26375305 A,2005-10-31,Full bore injection valve,,WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/066-326-629-320-04X,Granted Patent,no,3,0,9,12,0,E21B34/08;;E21B2200/05;;E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08,,0,0,,,,ACTIVE
68,DE,T2,DE 60018169 T2,141-509-237-366-209,2006-05-04,2006,DE 60018169 T,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,SELEKTIVES ABSCHNITTSWEISES ISOLIEREN IN EINEM GESCHLITZTEN LINER,,SHELL INT RESEARCH,NAZZAL RICHARD;;FRANK JOHN;;COON JOE,,https://lens.org/141-509-237-366-209,Granted Patent,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/10;;E21B43/08,,0,0,,,,EXPIRED
69,EP,A1,EP 0096071 A1,148-829-274-878-702,1983-12-21,1983,EP 83900376 A,1982-12-14,US 33034881 A;;US 33034981 A;;US 33878882 A,1981-12-14,ENGRAVED IMAGE IDENTIFICATION CARD.,"Cartes d'identification gravées par une machine. Les cartes d'identification de l'art antérieur utilisent une base opaque d'une couleur recouverte d'une couche opaque de couleur contrastante de manière à permettre que la lumière tombant sur la surface gravée de la carte soit renvoyée de manière variable vers l'oeil de l'observateur, selon l'emplacement et la quantité de couches supérieures enlevées pour exposer la couche de fond et former une image visible. Les cartes de l'art antérieur utilisent uniquement la réflectivité variable de la lumière provenant des deux couches opaques sur la partie antérieure de la carte gravée. La lumière de fond n'a par conséquent aucune influence. La présente carte (10) possède une couche de base translucide (30) pourvue d'entailles gravées (36) s'étendant au travers d'une couche supérieure opaque (34) dans la couche de base, une image ""négative"" apparaissant lorsque la lumière de fond est en dessous d'une valeur déterminable et une image ""positive lattente"" apparaissant lorsque la lumière de fond traversant la base translucide dépasse la valeur déterminable.",CALIFORNIA INTERFACE SOFTWARE,HALL JOHN SMALLEY;;PHELPS BARRY COON,,https://lens.org/148-829-274-878-702,Patent Application,yes,0,0,4,7,0,B42D25/43;;B42D25/43;;B42D25/00;;B42D25/47;;B42D2033/06;;B42D2033/08;;B42D2033/20;;B42D2033/42;;B42D2035/50,B42D15/10,,0,0,,,,DISCONTINUED
70,CA,A,CA 31267 A,016-253-022-406-746,1889-05-04,1889,CA 31267D A,,CA 31267T A,,TRANSPLANTING IMPLEMENT,,MIDDLETON JOHN H;;COON THOMAS R,MIDDLETON JOHN H;;COON THOMAS R,,https://lens.org/016-253-022-406-746,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
71,US,A,US 3400661 A,040-037-215-817-633,1968-09-10,1968,US 55005066 A,1966-05-13,US 55005066 A,1966-05-13,Projectile,,JOHN M. COON;;ROLLAND G. STURM,COON JOHN M;;STURM ROLLAND G,,https://lens.org/040-037-215-817-633,Granted Patent,no,7,17,1,1,0,F41A21/46;;F42B14/06;;F41A21/46;;F42B14/06,F41A21/46;;F42B14/06,102/93,0,0,,,,EXPIRED
72,US,B1,US 7543136 B1,094-196-575-687-788,2009-06-02,2009,US 18049905 A,2005-07-13,US 18049905 A,2005-07-13,System and method for managing divergent threads using synchronization tokens and program instructions that include set-synchronization bits,"One embodiment of a computing system configured to manage divergent threads in a thread group includes a stack configured to store at least one token and a multithreaded processing unit. The multithreaded processing unit is configured to perform the steps of fetching a program instruction, determining that the program instruction is a branch instruction, determining that the program instruction is not a return or break instruction, determining whether the program instruction includes a set-synchronization bit, and updating an active program counter, where the manner in which the active program counter is updated depends on a branch instruction type.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,NVIDIA CORPORATION (2005-06-29),https://lens.org/094-196-575-687-788,Granted Patent,yes,13,42,2,3,0,G06F9/30181;;G06F9/322;;G06F9/3851;;G06F9/3851;;G06F9/322;;G06F9/30181,G06F7/38;;G06F9/00;;G06F9/44;;G06F15/00,712/228;;712/234,1,1,020-961-679-464-619,10.1109/40.621209,"Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
73,US,A1,US 2013/0193643 A1,126-271-632-569-099,2013-08-01,2013,US 201313750646 A,2013-01-25,US 201313750646 A;;US 201261591003 P,2012-01-26,Board Game,"A game, including a game board having a path between homelessness and having a home, the path having a plurality of spaces; and a game piece for showing a player's position on said path. A method of playing a game, including: providing a game board having a path between homelessness and having a home, the path having a plurality of spaces; and a game piece for showing a player's position on said path; and moving said piece along said path.",COON LIZ;;CIFKA LYNN;;DANIELS JOHN,COON LIZ;;CIFKA LYNN;;DANIELS JOHN,,https://lens.org/126-271-632-569-099,Patent Application,yes,24,2,1,1,0,A63F3/00006;;A63F3/00006,A63F3/00,273/242,0,0,,,,DISCONTINUED
74,US,A,US 3613615 A,170-732-750-699-542,1971-10-19,1971,US 3613615D A,1969-08-15,US 85037569 A,1969-08-15,"MANNED, MOBILE SUBMERSIBLE",,ROLLAND G STURM;;COON JOHN M,STURM ROLLAND G;;COON JOHN M,,https://lens.org/170-732-750-699-542,Granted Patent,no,6,6,1,1,0,B63H11/14;;B63H11/14;;B63G8/08;;B63G8/08;;B63G8/16;;B63G8/16,B63G8/00;;B63H11/14,114/16,0,0,,,,EXPIRED
75,CN,A,CN 1983165 A,080-723-104-705-592,2007-06-20,2007,CN 200610161033 A,2006-12-04,US 29261405 A,2005-12-02,System and method for processing thread groups in a SIMD architecture,"A SIMD processor efficiently utilizes its hardware resources to achieve higher data processing throughput. The effective width of a SIMD processor is extended by clocking the instruction processing side of the SIMD processor at a fraction of the rate of the data processing side and by providing multiple execution pipelines, each with multiple data paths. As a result, higher data processing throughput is achieved while an instruction is fetched and issued once per clock. This configuration also allows a large group of threads to be clustered and executed together through the SIMD processor so that greater memory efficiency can be achieved for certain types of operations like texture memory accesses performed in connection with graphics processing.",NVIDIA CORP,COON BRETT W LINDHOLM JOHN E,,https://lens.org/080-723-104-705-592,Patent Application,no,0,3,8,21,0,G06F9/3838;;G06F9/3851;;G06F9/3869;;G06F9/3885;;G06F9/3887;;G06F9/3885;;G06F9/3851;;G06F9/3869;;G06F9/3838;;G06F9/3887,G06F9/38;;G06F15/80,,0,0,,,,ACTIVE
76,US,A1,US 2007/0275403 A1,106-426-986-507-643,2007-11-29,2007,US 80087507 A,2007-05-08,US 80087507 A;;US 79921606 P,2006-05-10,Diagnostic methods for determining treatment,The present invention provides methods for identifying cancer patients susceptible to effective treatment with inhibitors of the tyrosine kinase activity of EGFR. The invention is based on the discovery that polysomy of chromosome 7 can be used to selectively identify cancer patients that are likely to be successfully treated with EGFR tyrosine kinase inhibitors or agents that otherwise function similarly to tyrosine kinase inhibitors. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The methods for identifying cancer patients of the invention can be enhanced by determination of expression of pAKT protein in patient samples. The invention also contemplates the treatment of those patients with tyrosine kinase inhibitors.,MORRISON LARRY E;;COON JOHN S,MORRISON LARRY E;;COON JOHN S,RUSH UNIVERSITY MEDICAL CENTER (2009-02-13);;ABBOTT LABORATORIES (2007-09-21),https://lens.org/106-426-986-507-643,Patent Application,yes,1,11,6,6,0,C12Q1/6886;;C12Q2600/106;;G01N33/57407;;G01N33/57419;;G01N33/57423;;G01N2800/52;;G01N33/57419;;C12Q2600/106;;G01N2800/52;;C12Q1/6886;;G01N33/57407;;G01N33/57423,C12Q1/68,435/6,0,0,,,,DISCONTINUED
77,EP,A1,EP 2016172 A1,142-793-354-780-14X,2009-01-21,2009,EP 07776845 A,2007-05-08,US 2007/0011047 W;;US 79921606 P,2006-05-10,DIAGNOSTIC METHODS FOR DETERMINING TREATMENT,,ABBOTT LAB,MORRISON LARRY E;;COON JOHN S,RUSH UNIVERSITY MEDICAL CENTER (2011-08-31);;ABBOTT LABORATORIES (2011-08-31),https://lens.org/142-793-354-780-14X,Patent Application,yes,0,0,6,6,0,C12Q1/6886;;C12Q2600/106;;G01N33/57407;;G01N33/57419;;G01N33/57423;;G01N2800/52;;G01N33/57419;;C12Q2600/106;;G01N2800/52;;C12Q1/6886;;G01N33/57407;;G01N33/57423,C12N5/06;;A61K39/395;;G01N31/00,,0,0,,,,DISCONTINUED
78,DE,A1,DE 1594557 A1,031-440-860-023-274,1969-09-11,1969,DE 1594557 A,1964-04-30,US 27770663 A,1963-05-03,Schwerbelastungsschmiermittel,,SHELL INT RESEARCH,WRIGHT MALONE BOBBY;;SAYLER COON JOHN,,https://lens.org/031-440-860-023-274,Patent Application,no,0,0,3,4,0,C07F9/04;;C07F9/04;;C10M135/18;;C10M135/18;;C10M149/10;;C10M149/10;;C10M159/04;;C10M159/04;;C10M159/18;;C10M159/18;;C10M167/00;;C10M167/00;;C10M2203/10;;C10M2203/10;;C10M2203/102;;C10M2203/102;;C10M2203/104;;C10M2203/104;;C10M2203/106;;C10M2203/106;;C10M2203/108;;C10M2203/108;;C10M2205/22;;C10M2205/22;;C10M2207/09;;C10M2207/09;;C10M2209/084;;C10M2209/084;;C10M2209/101;;C10M2209/101;;C10M2215/04;;C10M2215/04;;C10M2215/26;;C10M2215/26;;C10M2217/028;;C10M2217/028;;C10M2217/06;;C10M2217/06;;C10M2219/044;;C10M2219/044;;C10M2219/046;;C10M2219/046;;C10M2219/066;;C10M2219/066;;C10M2219/068;;C10M2219/068;;C10M2219/082;;C10M2219/082;;C10M2223/045;;C10M2223/045;;C10M2223/063;;C10M2223/063;;C10M2223/12;;C10M2223/12;;C10M2225/04;;C10M2225/04;;C10M2225/041;;C10M2225/041;;C10M2227/09;;C10M2227/09;;C10N2010/04;;C10N2010/04;;C10N2040/02;;C10N2040/02;;C10N2040/135;;C10N2040/135;;C10N2040/25;;C10N2040/25;;C10N2040/251;;C10N2040/251;;C10N2040/255;;C10N2040/255;;C10N2040/28;;C10N2040/28,C07F9/04;;C10M167/00,,0,0,,,,DISCONTINUED
79,GB,B,GB 2428721 B,050-910-595-924-508,2008-02-06,2008,GB 0620603 A,2004-06-29,GB 0414573 A;;US 61030903 A;;US 84855804 A;;GB 0620603 A,2003-06-30,Expandable tubulars,,WEATHERFORD LAMB,HARRALL SIMON JOHN;;COON ROBERT J,,https://lens.org/050-910-595-924-508,Granted Patent,no,3,0,3,35,0,E21B19/16;;E21B29/00;;E21B43/103;;E21B43/103;;E21B43/106,E21B43/10;;E21B19/16;;E21B29/00,,0,0,,,,INACTIVE
80,CA,A1,CA 2746623 A1,100-266-455-309-578,2008-02-29,2008,CA 2746623 A,2007-08-28,US 46863106 A;;CA 2599073 A,2006-08-30,INJECTION VALVE,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/100-266-455-309-578,Patent Application,no,0,0,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B43/12,,0,0,,,,ACTIVE
81,TW,A,TW 200745953 A,026-527-140-002-118,2007-12-16,2007,TW 95147158 A,2006-12-15,US 30555805 A,2005-12-16,System and method for grouping execution threads,"Multiple threads are divided into buddy groups of two or more threads, so that each thread has assigned to it one or more buddy threads. Only one thread in each buddy group actively executes instructions and this allows buddy threads to share hardware resources, such as registers. When an active thread encounters a swap event, such as a swap instruction, the active thread suspends execution and one of its buddy threads begins execution using that thread's private hardware resources and the buddy group's shared hardware resources. As a result, the thread count can be increased without replicating all of the per-thread hardware resources.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,,https://lens.org/026-527-140-002-118,Patent of Addition,no,0,0,7,7,0,G06F9/3009;;G06F9/3851;;G06F9/4843;;G06F9/3851;;G06F9/3009;;G06F9/4843,G06F9/48,,0,0,,,,ACTIVE
82,US,A,US 3894480 A,083-032-489-048-437,1975-07-15,1975,US 47248474 A,1974-05-22,US 47248474 A,1974-05-22,Laboratory bench assembly,A laboratory bench assembly having an exhaust plenum with an inlet vent extending along the bottom thereof just above the bench top. The plenum may be divided into one or more exhaust chambers each of which has an exhaust conduit having an intake mouth disposed within the chamber at an elevation higher than the inlet vent. The bench top extends substantially beyond at least one end of the exhaust plenum and has a sink opening in the extending end. A second inlet vent extends across the end of the plenum adjacent to the sink opening for exhausting the sink area. An umbilical box extends over the exhaust plenum to accomodate service facilities for the bench assembly.,WARF INST INC,BIRDSALL JOHN J;;COON FRANCIS B,,https://lens.org/083-032-489-048-437,Granted Patent,no,5,5,1,1,0,B01L9/02;;B08B15/00;;B08B2215/006;;B25H1/20;;B25H1/20;;B01L9/02;;B08B15/00;;B08B2215/006,B01L9/02;;B08B15/00;;B25H1/20,98115LH,0,0,,,,EXPIRED
83,US,A1,US 2007/0143582 A1,123-165-896-961-950,2007-06-21,2007,US 30555805 A,2005-12-16,US 30555805 A,2005-12-16,System and method for grouping execution threads,"Multiple threads are divided into buddy groups of two or more threads, so that each thread has assigned to it one or more buddy threads. Only one thread in each buddy group actively executes instructions and this allows buddy threads to share hardware resources, such as registers. When an active thread encounters a swap event, such as a swap instruction, the active thread suspends execution and one of its buddy threads begins execution using that thread's private hardware resources and the buddy group's shared hardware resources. As a result, the thread count can be increased without replicating all of the per-thread hardware resources.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN E,NVIDIA CORPORATION (2005-12-09),https://lens.org/123-165-896-961-950,Patent Application,yes,5,20,7,7,0,G06F9/3009;;G06F9/3851;;G06F9/4843;;G06F9/3851;;G06F9/3009;;G06F9/4843,G06F15/00,712/235,0,0,,,,DISCONTINUED
84,CA,A1,CA 2710008 A1,005-252-902-254-871,2007-04-30,2007,CA 2710008 A,2006-10-27,US 26375305 A;;CA 2565998 A,2005-10-31,FULL BORE INJECTION VALVE,,WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/005-252-902-254-871,Patent Application,no,0,0,9,12,0,E21B34/08;;E21B2200/05;;E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08;;E21B34/06;;E21B34/14;;F16K1/20;;F16K15/03;;F16K15/18,,0,0,,,,ACTIVE
85,GB,B,GB 2403489 B,013-771-895-729-81X,2007-03-21,2007,GB 0414573 A,2004-06-29,US 61030903 A;;US 84855804 A,2003-06-30,Expandable tubulars,,WEATHERFORD LAMB,HARRALL SIMON JOHN;;COON ROBERT J,,https://lens.org/013-771-895-729-81X,Granted Patent,no,12,0,9,35,0,E21B29/10;;E21B33/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B43/103;;E21B43/106;;E21B43/105;;E21B33/10;;E21B43/103;;E21B29/10,E21B43/10;;E21B29/00;;E21B33/10,E1F FLA           FLA,0,0,,,,INACTIVE
86,CA,C,CA 2746623 C,102-095-810-737-075,2013-11-05,2013,CA 2746623 A,2007-08-28,US 46863106 A;;CA 2599073 A,2006-08-30,INJECTION VALVE,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/102-095-810-737-075,Granted Patent,no,0,0,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B43/12,,0,0,,,,ACTIVE
87,CA,A,CA 766744 A,122-878-845-986-086,1967-09-05,1967,CA 766744D A,,CA 766744T A,,LUBRICATING COMPOSITION,,SHELL OIL CO,COON JOHN S;;HENDERSON BENNETT M,,https://lens.org/122-878-845-986-086,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
88,US,A1,US 2023/0034536 A1,151-688-912-513-153,2023-02-02,2023,US 202217816331 A,2022-07-29,US 202217816331 A;;US 202163227289 P,2021-07-29,REMOTE HOT TUB CONTROL SYSTEM,"A remote hot tub control system for a hot tub includes a controller and an input device. The controller is configured to execute a draining and filling cycle of the hot tub. Upon receiving a user command at the input device to initiate the cycle, the controller commands an output valve to open and a water pump to pump used water out of the hot tub via the output valve. Upon receiving a first signal indicating that the hot tub has been drained of the used water, the controller commands the output valve to close, the water pump to stop pumping, and an input valve to open to permit fresh water to enter the hot tub. Upon receiving a second signal indicating that the hot tub has been filled, the controller commands the input valve to close.",COON JEREMY JOHN;;ONEILL CARSEN FINN,COON JEREMY JOHN;;O'NEILL CARSEN FINN,,https://lens.org/151-688-912-513-153,Patent Application,yes,0,0,1,1,0,A61H33/005;;A61H33/6068;;A61H2033/0058;;A61H33/005;;A61H2033/0058;;A61H33/6068,A61H33/00,,0,0,,,,PENDING
89,NO,B1,NO 339486 B1,134-110-132-397-588,2016-12-19,2016,NO 20074402 A,2007-08-29,US 46863106 A,2006-08-30,"FREMGANGSMÅTE FOR A OPERERE EN GASSLØFTEVENTIL, OG EN SAMMENSTILLING SOM OMFATTER GASSLØFTEVENTILEN",,WEATHERFORD TECH HOLDINGS LLC,COON ROBERT JOE;;LEMBCKE JEFFREY JOHN,"WEATHERFORD TECHNOLOGY HOLDINGS, US (2015-03-09)",https://lens.org/134-110-132-397-588,Granted Patent,no,2,0,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B34/08;;E21B43/12,,0,0,,,,ACTIVE
90,US,B1,US 7418576 B1,155-656-985-931-283,2008-08-26,2008,US 99164004 A,2004-11-17,US 99164004 A,2004-11-17,Prioritized issuing of operation dedicated execution unit tagged instructions from multiple different type threads performing different set of operations,"A graphics processor buffers vertex thread and pixel threads. The different types of threads issue instructions corresponding to different sets of operations. A plurality of different types of execution units are provided, each type of execution unit servicing a different class of operations, such as an executing unit supporting texture operations, an execution unit supporting blending operations, and an execution unit supporting mathematical operations. Current instructions of the threads are buffered and prioritized in a common instruction buffer. A set of high priority instructions is issued per cycle to the plurality of different types of execution units.",NVIDIA CORP,LINDHOLM JOHN E;;COON BRETT W,NVIDIA CORPORATION (2004-11-12),https://lens.org/155-656-985-931-283,Granted Patent,yes,10,26,3,3,0,G06F9/3851;;G06F9/3851;;G06F9/3838;;G06F9/3838;;G06F9/3853;;G06F9/3853;;G06F9/3867;;G06F9/3867;;G06F9/3885;;G06F9/3885,G06F9/50,712/214;;718/103;;718/107,0,0,,,,ACTIVE
91,US,B2,US 7984277 B2,030-914-669-746-242,2011-07-19,2011,US 69880910 A,2010-02-02,US 69880910 A;;US 67279003 A;;US 48822203 P,2003-07-16,System and method of instruction modification,"A method and system of instruction modification. A first machine language instruction, which may comprise a plurality of discrete instructions, is fetched. Responsive to a trigger pattern in the first machine language instruction, a segment of the first machine language instruction is modified. Information can be substituted into the segment based on specifics outlined in the trigger pattern. Alternatively, information can be combined with the segment via logical and/or arithmetic operations. Modification of the segment produces a second machine language instruction that is executed by units of the processor. In one embodiment, information may be taken from a queue and used to replace data from the segment. How information is taken from the queue and how the information so taken is used to replace fields of the segment are defined by the trigger pattern.",BANNING JOHN;;HAO ERIC;;COON BRETT,BANNING JOHN;;HAO ERIC;;COON BRETT,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27),https://lens.org/030-914-669-746-242,Granted Patent,yes,72,0,5,5,0,G06F9/3017;;G06F9/3017,G06F9/30,712/226,37,7,042-060-457-200-212;;008-082-443-743-245;;011-472-147-631-873;;021-217-729-402-688;;039-533-571-422-256;;003-564-565-469-862;;035-378-437-114-639,10.1109/pact.1998.727184;;10.1145/36177.36201;;10.1145/68182.68183;;10.1145/75395.75401;;10.1109/pccc.1990.101732;;10.1145/285930.285981;;10.1109/40.87564,"Hennessy, John L. et al., Computer Architecture A Quantitative Approach, 1996, Morgan Kaufmann Publishers, Inc., 2nd Ed., pp. 130 and 284-289.;;Ozer et al., A Fast Interrupt Handling Scheme for VLIW Processors, Oct. 12-18, 1998, Proceedings of International Conference on Parallel Architectures and Compilation Techniques, pp. 136-141.;;Title: A VLIW architecture for a trace scheduling compiler, author: Colwell et al, ACM, 1987.;;Title: Architecture and compiler tradeoffs for a long instruction wordprocessor, author: Cohn et al, ACM 1989.;;Title: Combining as a compilation technique for VLIW architectures, Author: Nakatani et al, ACM, 1989.;;Title: Core-Based RNS ALU with customized instructions, author: Ray, IEEE, 1990.;;Title: RISC I: a reduced instruction set VLSI computer, author: Patterson, ACM, 1998.;;Final Office Action Dated Jun. 25, 2003; Patent No: 6738892.;;Non-Final Office Action Dated Apr. 11, 2002; Patent No. 6738892.;;Non-Final Office Action Dated Dec. 20, 2002; Patent No. 6738892.;;Final Office Action Dated May 2, 2003; Patent No. 6754892.;;Non Final Office Action Dated Nov. 25, 2002; Patent No. 6754892.;;Notice of Allowance Dated Oct. 27, 2003; Patent No. 6754892.;;Notice of Allowance Dated Dec. 22, 2003; Patent No. 6738892.;;Notice of Allowance Dated Jun. 10, 2009; Patent No. 7606997.;;Advisory Action Dated Jul. 5, 2007; Patent No. 7606997.;;Non Final Office Action Dated Dec. 9, 2005; Patent No. 7606997.;;Non Final Office Action Dated Nov. 2, 2006; Patent No. 7606997.;;Non Final Office Action Dated Sep. 17, 2007; Patent No. 7606997.;;Amendment Dated Aug. 31, 2006; Patent No. 7606997.;;Non Final Office Action Dated Aug. 4, 2008; Patent No. 7606997.;;Final Office Action Dated Mar. 14, 2007; Patent No. 7606997.;;Final Office Action Dated Mar. 6, 2008; Patent No. 7606997.;;Final Office Action Dated Jan. 27, 2009; Patent No. 7606997.;;Notice of Allowance Dated Oct. 30, 2009; Patent No. 7698539.;;Final Office Action Dated Apr. 11, 2008; Patent No. 7698539.;;Non Final Office Action Dated Apr. 13, 2009; Patent No. 7698539.;;Non Final Office Action Dated Sep. 24, 2007; Patent No. 7698539.;;Final Office Action Dated Dec. 20, 2006; Patent No. 7698539.;;Non Final Office Action Dated Jun. 26, 2006; Patent No. 7698539.;;:Examiner Interview Summary Dated Apr. 1, 2009; Patent No. 7606997.;;Final Office Action Dated May 31, 2006; Patent No. 7606997.;;TRANSMETA P2000 (project name: Fred); Instruction Set Architecture and Programmer's Reference Manual. Version 1.01 Jun. 28, 2001.;;Williams Stalling, Ph.D; Data and Computer Communications; Third Edition. Macmillan Publishing Company. New York, New York. 1991.;;Val Popescu; et al. The Metaflow Architecture; 1991.;;Enterprise Systems Architecture/390 Principles of Operation. Eight Edition, Jul. 2001. pp. 7-1 to 7-5, 9-1 to 9-4 and 9-8 to 9-9.;;Mike Johnson. Superscalar Microprocessor Design. 1991 by PTR Prentice-Hall, In., A Pearson Education Company Upper Saddle River, NJ 07458.",EXPIRED
92,US,B2,US 7455116 B2,036-674-565-889-941,2008-11-25,2008,US 46863106 A,2006-08-30,US 46863106 A;;US 26375305 A,2005-10-31,Injection valve and method,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2006-10-02),https://lens.org/036-674-565-889-941,Granted Patent,yes,19,20,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B34/08;;E21B43/12,166/374;;166/386;;166/321;;166/332.8,0,0,,,,ACTIVE
93,US,A,US 4891522 A,040-046-767-485-053,1990-01-02,1990,US 25572988 A,1988-10-11,US 25572988 A,1988-10-11,Modular multi-element high energy particle detector,"Multi-element high energy particle detector modules comprise a planar heavy metal carrier of tungsten alloy with planar detector units uniformly distributed over one planar surface. The detector units are secured to the heavy metal carrier by electrically conductive adhesive so that the carrier serves as a common ground. The other surface of each planar detector unit is electrically connected to a feedthrough electrical terminal extending through the carrier for front or rear readout. The feedthrough electrical terminals comprise sockets at one face of the carrier and mating pins porjecting from the other face, so that any number of modules may be plugged together to create a stack of modules of any desired number of radiation lengths. The detector units each comprise four, preferably rectangular, p-i-n diode chips arranged around the associated feedthrough terminal to form a square detector unit providing at least 90% detector element coverage of the carrier. Integral spacers projecting from the carriers extend at least partially along the boundaries between detector units to space the p-i-n diode chips from adjacent carriers in a stack. The spacers along the perimeters of the modules are one-half the width of the interior spacers so that when stacks of modules are arranged side by side to form a large array of any size or shape, distribution of the detector units is uniform over the entire array.",MICROTRONICS ASSOCIATES INC,COON DARRYL D;;ELLIOTT JOHN P,MICROTRONICS ASSOCIATES INC. A PA CORP (1989-10-02),https://lens.org/040-046-767-485-053,Granted Patent,yes,5,35,3,3,0,H01L31/117;;G01T1/242;;G01T1/243;;H01L31/117;;G01T1/242;;G01T1/243,G01T1/24;;H01L31/117,H1K KEBA          EBA,2,0,,,"A. Nakamoto et al., A Si(Li) Pb Shower Calorimeter For p p Collider Experiments, Nuclear Instruments and Methods in Physics Research A238 (1985) 53 60.;;A. Nakamoto et al., A 4 Inch Silicon/Tungsten Calorimeter for p p Collider Experiments, Nuclear Instruments and Methods in Physics Research A251 (1986) 275 285.",EXPIRED
94,JP,A,JP 2007200288 A,071-233-236-983-684,2007-08-09,2007,JP 2006338917 A,2006-12-15,US 30555805 A,2005-12-16,SYSTEM AND METHOD FOR GROUPING EXECUTION THREADS,"<P>PROBLEM TO BE SOLVED: To provide a method for grouping execution threads so that execution hardware is utilized more efficiently. <P>SOLUTION: A plurality of threads are divided into buddy groups of two or more threads, so that each thread has assigned to it one or more buddy threads. Only one thread in each buddy group actively executes instructions and this allows buddy threads to share hardware resources, such as registers. When an active thread encounters a swap event, such as a swap instruction, the active thread suspends execution and one of its buddy threads begins execution using that thread's private hardware resources and the buddy group's shared hardware resources. As a result, the thread count can be increased without replicating all of the per-thread hardware resources. <P>COPYRIGHT: (C)2007,JPO&INPIT",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN E,,https://lens.org/071-233-236-983-684,Patent Application,no,0,4,7,7,0,G06F9/3009;;G06F9/3851;;G06F9/4843;;G06F9/3851;;G06F9/3009;;G06F9/4843,G06F9/38,,0,0,,,,ACTIVE
95,US,A1,US 2011/0238961 A1,072-197-743-815-141,2011-09-29,2011,US 201113155291 A,2011-06-07,US 201113155291 A;;US 69880910 A;;US 67279003 A;;US 48822203 P,2003-07-16,SYSTEM AND METHOD OF INSTRUCTION MODIFICATION,"A method and system of instruction modification. A first machine language instruction, which may comprise a plurality of discrete instructions, is fetched. Responsive to a trigger pattern in the first machine language instruction, a segment of the first machine language instruction is modified. Information can be substituted into the segment based on specifics outlined in the trigger pattern. Alternatively, information can be combined with the segment via logical and/or arithmetic operations. Modification of the segment produces a second machine language instruction that is executed by units of the processor. In one embodiment, information may be taken from a queue and used to replace data from the segment. How information is taken from the queue and how the information so taken is used to replace fields of the segment are defined by the trigger pattern.",BANNING JOHN;;HAO ERIC;;COON BRETT,BANNING JOHN;;HAO ERIC;;COON BRETT,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27),https://lens.org/072-197-743-815-141,Patent Application,yes,74,5,5,5,0,G06F9/3017;;G06F9/3017,G06F9/30,712/226;;X712E09028,0,0,,,,EXPIRED
96,GB,A,GB 2428721 A,162-016-718-033-866,2007-02-07,2007,GB 0620603 A,2004-06-29,GB 0414573 A;;US 61030903 A;;US 84855804 A;;GB 0620603 A,2003-06-30,Method of completing a wellbore,"A first tubular (2010) is suspended along a lower portion of a cased well (2005) by means such as a slip mechanism (2035) and overlaps with a portion of the casing 2005) . A second tubular (2025) is lowered into a wellbore (2000) in the direction indicated by arrow (2045, figure 20A) by means such as on a run-in string (not shown) and includes an expansion cone (2050) to form a PBR proximate the upper end of the first tubular (2010) . The second tubular (2025) also includes a plurality of seal sets (2055) and an anchor member (2060) . This method is particularly useful in forming a monobore tieback and allows the first tubular (2010) and the second tubular (2025) to have approximately the same diameter along their length, causing the path for fluid flow through the tubulars to remain substantially consistent along their length.",WEATHERFORD LAMB,HARRALL SIMON JOHN;;COON ROBERT J,,https://lens.org/162-016-718-033-866,Patent Application,no,3,4,3,35,0,E21B19/16;;E21B29/00;;E21B43/103;;E21B43/103;;E21B43/106,E21B43/10;;E21B19/16;;E21B29/00,E1F FJR           FJR;;E1F FLA           FLA;;NOT CLASSIFIED    NONE,0,0,,,,INACTIVE
97,WO,A1,WO 2007/133516 A1,004-965-752-557-992,2007-11-22,2007,US 2007/0011047 W,2007-05-08,US 79921606 P,2006-05-10,DIAGNOSTIC METHODS FOR DETERMINING TREATMENT,The present invention provides methods for identifying cancer patients susceptible to effective treatment with inhibitors of the tyrosine kinase activity of EGFR. The invention is based on the discovery that polysomy of chromosome 7 can be used to selectively identify cancer patients that are likely to be successfully treated with EGFR tyrosine kinase inhibitors or agents that otherwise function similarly to tyrosine kinase inhibitors. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The methods for identifying cancer patients of the invention can be enhanced by determination of expression of pAKT protein in patient samples. The invention also contemplates the treatment of those patients with tyrosine kinase inhibitors.,ABBOTT LAB,MORRISON LARRY E;;COON JOHN S,,https://lens.org/004-965-752-557-992,Patent Application,yes,0,5,6,6,0,C12Q1/6886;;C12Q2600/106;;G01N33/57407;;G01N33/57419;;G01N33/57423;;G01N2800/52;;G01N33/57419;;C12Q2600/106;;G01N2800/52;;C12Q1/6886;;G01N33/57407;;G01N33/57423,A61K39/395;;C12N5/06;;G01N31/00,,1,1,021-323-521-292-044,10.1093/jnci/dji112;;15870435,"CAPPUZZO F. ET AL.: ""Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 97, no. 9, 4 May 2005 (2005-05-04), pages 643 - 655, XP009068788",PENDING
98,WO,A1,WO 1983/002081 A1,003-662-734-790-382,1983-06-23,1983,US 8201740 W,1982-12-14,US 33034881 A;;US 33034981 A;;US 33878882 A,1981-12-14,ENGRAVED IMAGE IDENTIFICATION CARD,"Machine engraved identification cards. Prior identification cards required an opaque base of one color overlaid with an opaque layer of a contrasting color so that light impinging on the engraved surface of the card is variably reflected back to the eye of the observer according to the location and amount of the top layer removed to expose the bottom layer to form an observable image. Prior cards rely solely upon the variable reflectivity of light from the two opaque layers on the front of the engraved card. Thus, background light is irrelevant. The present card (10) has a translucent base layer (30) with engraved scores (36) extending through an opaque top layer (34) into the base layer whereby a ""negative"" image appears when the background light is below a determinable value and a latent, ""positive"" image appears when the background light passing through the translucent base is above the determinable value.",CALIFORNIA INTERFACE SOFTWARE,HALL JOHN SMALLEY;;PHELPS BARRY COON,,https://lens.org/003-662-734-790-382,Patent Application,yes,7,6,4,7,0,B42D25/43;;B42D25/43;;B42D25/00;;B42D25/47;;B42D2033/06;;B42D2033/08;;B42D2033/20;;B42D2033/42;;B42D2035/50,B42D15/10,B6A AC13          ATC;;B6A AC41          ATC;;B6A AC52          ATC;;B6A ATC           ATC,1,0,,,See also references of EP 0096071A4,PENDING
99,US,B1,US 8667256 B1,048-883-514-216-751,2014-03-04,2014,US 47608809 A,2009-06-01,US 47608809 A;;US 18049905 A,2005-07-13,Systems and method for managing divergent threads in a SIMD architecture,"One embodiment of a computing system configured to manage divergent threads in a thread group includes a stack configured to store at least one token and a multithreaded processing unit. The multithreaded processing unit is configured to perform the steps of fetching a program instruction, determining that the program instruction is a branch instruction, determining that the program instruction is not a return or break instruction, determining whether the program instruction includes a set-synchronization bit, and updating an active program counter, where the manner in which the active program counter is updated depends on a branch instruction type.",COON BRETT W;;LINDHOLM JOHN ERIK;;NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,,https://lens.org/048-883-514-216-751,Granted Patent,yes,7,4,2,3,0,G06F9/30181;;G06F9/322;;G06F9/3851;;G06F9/3851;;G06F9/322;;G06F9/30181,G06F7/38;;G06F9/00;;G06F9/44;;G06F15/00,712/228,4,2,053-079-802-562-767;;020-961-679-464-619,10.1109/71.80147;;10.1109/40.621209,"Bronson et al.; Experimental Application-Driven Architecture Analysis of an SIMD/MIMD Parallel Processing System; 1990; IEEE.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19. Sep./Oct. 1997.;;Office Action. U.S. Appl. No. 11/557,082. Apr. 2, 2009.",ACTIVE
100,US,A1,US 2009/0014183 A1,100-126-768-293-808,2009-01-15,2009,US 23418408 A,2008-09-19,US 23418408 A;;US 46863106 A;;US 26375305 A,2005-10-31,INJECTION VALVE AND METHOD,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",LEMBCKE JEFFREY JOHN;;COON ROBERT J,LEMBCKE JEFFREY JOHN;;COON ROBERT J,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2006-10-02),https://lens.org/100-126-768-293-808,Patent Application,yes,10,2,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B34/00;;E21B43/18,166/321;;166/323;;166/370,0,0,,,,ACTIVE
101,CA,C,CA 2710008 C,159-208-403-123-734,2013-04-16,2013,CA 2710008 A,2006-10-27,US 26375305 A;;CA 2565998 A,2005-10-31,FULL BORE INJECTION VALVE,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/159-208-403-123-734,Granted Patent,no,0,0,9,12,0,E21B34/08;;E21B2200/05;;E21B34/08;;E21B34/08;;E21B2200/05,E21B34/08;;E21B34/06;;E21B34/14;;F16K1/20;;F16K15/03;;F16K15/18,,0,0,,,,ACTIVE
102,US,A1,US 2010/0138638 A1,178-397-345-362-079,2010-06-03,2010,US 69880910 A,2010-02-02,US 69880910 A;;US 67279003 A;;US 48822203 P,2003-07-16,SYSTEM AND METHOD OF INSTRUCTION MODIFICATION,"A method and system of instruction modification. A first machine language instruction, which may comprise a plurality of discrete instructions, is fetched. Responsive to a trigger pattern in the first machine language instruction, a segment of the first machine language instruction is modified. Information can be substituted into the segment based on specifics outlined in the trigger pattern. Alternatively, information can be combined with the segment via logical and/or arithmetic operations. Modification of the segment produces a second machine language instruction that is executed by units of the processor. In one embodiment, information may be taken from a queue and used to replace data from the segment. How information is taken from the queue and how the information so taken is used to replace fields of the segment are defined by the trigger pattern.",BANNING JOHN;;HAO ERIC;;COON BRETT,BANNING JOHN;;HAO ERIC;;COON BRETT,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27),https://lens.org/178-397-345-362-079,Patent Application,yes,72,1,5,5,0,G06F9/3017;;G06F9/3017,G06F9/38;;G06F9/30,712/226;;X712E09059,0,0,,,,EXPIRED
103,EP,A3,EP 0365203 A3,006-150-152-341-683,1991-03-06,1991,EP 89310380 A,1989-10-11,US 25572988 A,1988-10-11,MODULAR MULTI-ELEMENT HIGH ENERGY PARTICLE DETECTOR,"Multi-element high energy particle detector modules (1) comprise a planar heavy metal carrier (3) of tungsten alloy with planar detector units (9) uniformly distributed over one planar surface (5). The detector units (9) are secured to the heavy metal carrier (3) by electrically conductive adhesive (29) so that the carrier serves as a common ground. The other surface (7) of each planar detector unit (9) is electrically connected to a feedthrough electrical terminal (13) extending through the carrier for front or rear readout. The feedthrough electrical terminals (13) comprise sockets (15) at one face of the carrier (3) and mating pins (19) projecting from the other face, so that any number of modules (1) may be plugged together to create a stack of modules (37) of any desired number of radiation lengths. The detector units (9) each comprise four, preferably rectangular, p-i-n diode chips (27) arranged around the associated feedthrough terminal (13) to form a square detector unit providing at least 90% detector element coverage of the carrier (3). Integral spacers (11) projecting from the carriers (3) extend at least partially along the boundaries between detector units (9) to space the p-i-n diode chips (27) from adjacent carriers in a stack. The spacers (11) along the perimeters of the modules are one-half the width of the interior spacers (11) so that when stacks of modules (37) are arranged side by side to form a large array (39) of any size or shape, distribution of the detector units (9) is uniform over the entire array.  ","MICROTRONICS ASSOCIATES, INC.","COON, DARRYL D;;ELLIOTT, JOHN P",,https://lens.org/006-150-152-341-683,Search Report,yes,5,0,3,3,0,H01L31/117;;G01T1/242;;G01T1/243;;H01L31/117;;G01T1/242;;G01T1/243,G01T1/24;;H01L31/117,,1,0,,,"NUCLEAR INSTRUMENTS AND METHODS. vol. A251, 1986, AMSTERDAM NL pages 275 - 285; A.NAKAMOTO ET AL.: ""A 4-INCH SILICON TUNGSTEN CALORIMETER FOR p-p COLLIDER EXPERIMENTS""",DISCONTINUED
104,DE,D1,DE 60018169 D1,026-686-227-336-557,2005-03-24,2005,DE 60018169 T,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,SELEKTIVES ABSCHNITTSWEISES ISOLIEREN IN EINEM GESCHLITZTEN LINER,,SHELL INT RESEARCH,NAZZAL RICHARD;;FRANK JOHN;;COON JOE,,https://lens.org/026-686-227-336-557,Granted Patent,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
105,TW,B,TW I338861 B,048-601-618-284-822,2011-03-11,2011,TW 95147158 A,2006-12-15,US 30555805 A,2005-12-16,System and method for grouping execution threads,,NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,,https://lens.org/048-601-618-284-822,Granted Patent,no,0,0,7,7,0,G06F9/3009;;G06F9/3851;;G06F9/4843;;G06F9/3851;;G06F9/3009;;G06F9/4843,,,0,0,,,,ACTIVE
106,US,B1,US 7353369 B1,060-703-591-711-135,2008-04-01,2008,US 18038805 A,2005-07-13,US 18038805 A,2005-07-13,System and method for managing divergent threads in a SIMD architecture,"One embodiment of a computing system configured to manage divergent threads in a thread group includes a stack configured to store at least one token and a multithreaded processing unit. The multithreaded processing unit is configured to perform the steps of fetching a program instruction, determining that the program instruction is not a branch instruction, determining whether the program instruction includes a pop-synchronization bit, and updating an active program counter, where the fashion in which the active program counter is updated relates to whether the program instruction includes a pop-synchronization bit.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,NVIDIA CORPORATION (2005-06-29),https://lens.org/060-703-591-711-135,Granted Patent,yes,8,89,1,1,0,G06F9/3851;;G06F9/3851;;G06F9/30072;;G06F9/30072;;G06F9/30101;;G06F9/30101;;G06F9/30145;;G06F9/30145;;G06F9/321;;G06F9/321;;G06F9/3887;;G06F9/3887,G06F9/00,712/234;;712/220,0,0,,,,INACTIVE
107,US,A1,US 2007/0130447 A1,134-406-413-922-361,2007-06-07,2007,US 29261405 A,2005-12-02,US 29261405 A,2005-12-02,System and method for processing thread groups in a SIMD architecture,"A SIMD processor efficiently utilizes its hardware resources to achieve higher data processing throughput. The effective width of a SIMD processor is extended by clocking the instruction processing side of the SIMD processor at a fraction of the rate of the data processing side and by providing multiple execution pipelines, each with multiple data paths. As a result, higher data processing throughput is achieved while an instruction is fetched and issued once per clock. This configuration also allows a large group of threads to be clustered and executed together through the SIMD processor so that greater memory efficiency can be achieved for certain types of operations like texture memory accesses performed in connection with graphics processing.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN E,NVIDIA CORPORATION (2005-12-01),https://lens.org/134-406-413-922-361,Patent Application,yes,43,22,8,21,0,G06F9/3838;;G06F9/3851;;G06F9/3869;;G06F9/3885;;G06F9/3887;;G06F9/3885;;G06F9/3851;;G06F9/3869;;G06F9/3838;;G06F9/3887,G06F9/30,712/215,0,0,,,,ACTIVE
108,NO,L,NO 20074402 L,156-715-774-404-188,2008-03-03,2008,NO 20074402 A,2007-08-29,US 46863106 A,2006-08-30,Injeksjon ventil,Den foreliggende oppfinnelse angår generelt styring av fluidstrømningen i et brønn (10). I ett aspekt er det tilveiebrakt en ventil (100) for selektiv lukking av en strømningsbane (110) gjennom en brønn (10) i en første retning. Ventilen (100) innbefatter et legeme (105) og en stempelflate (125) som kan tildannes over strømningsbanen (110) i den første retning. Stempelflaten (125) tildannes ved en ende av et forskyvbart element ringformet anbrakt i legemet (105). Ventilen (100) innbefatter videre et klaffelement (150) hvor klaffelementet (150) er lukkbart for tetting av strømningsbanen (110) når det forskyvbare element beveger seg fra en første stilling og til en andre stilling beroende på fluidstrømning som virker på stempelflaten (125). I et annet aspekt er det tilveiebrakt en ventil (100) for selektiv lukking av en strømningsbane (110) gjennom en brønn (10) i en enkelt retning. I enda et annet aspekt er det tilveiebrakt en framgangsmåte for selektiv lukking av en strømningsbane (110) gjennom en brønn (10) i en enkelt retning.,WEATHERFORD LAMB,COON ROBERT JOE;;LEMBCKE JEFFREY JOHN,"WEATHERFORD TECHNOLOGY HOLDINGS, US (2015-03-09)",https://lens.org/156-715-774-404-188,Abstract,no,0,0,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B34/06;;E21B34/10;;F16K1/18,,0,0,,,,ACTIVE
109,CN,A,CN 1983196 A,003-909-816-620-004,2007-06-20,2007,CN 200610168179 A,2006-12-15,US 30555805 A,2005-12-16,System and method for grouping execution threads,"Multiple threads are divided into buddy groups of two or more threads, so that each thread has assigned to it one or more buddy threads. Only one thread in each buddy group actively executes instructions and this allows buddy threads to share hardware resources, such as registers. When an active thread encounters a swap event, such as a swap instruction, the active thread suspends execution and one of its buddy threads begins execution using that thread's private hardware resources and the buddy group's shared hardware resources. As a result, the thread count can be increased without replicating all of the per-thread hardware resources.",NVIDIA CORP,COON BRETT W LINDHOLM JOHN E,,https://lens.org/003-909-816-620-004,Patent Application,no,0,5,7,7,0,G06F9/3009;;G06F9/3851;;G06F9/4843;;G06F9/3851;;G06F9/3009;;G06F9/4843,G06F9/46,,0,0,,,,ACTIVE
110,EP,A4,EP 0096071 A4,035-391-317-452-306,1984-04-27,1984,EP 83900376 A,1982-12-14,US 33034881 A;;US 33034981 A;;US 33878882 A,1981-12-14,ENGRAVED IMAGE IDENTIFICATION CARD.,,CALIFORNIA INTERFACE SOFTWARE,HALL JOHN SMALLEY;;PHELPS BARRY COON,,https://lens.org/035-391-317-452-306,Search Report,no,0,0,4,7,0,B42D25/43;;B42D25/43;;B42D25/00;;B42D25/47;;B42D2033/06;;B42D2033/08;;B42D2033/20;;B42D2033/42;;B42D2035/50,B42D15/10,,3,0,,,No further relevant documents have been disclosed;;No further relevant documents have been disclosed;;See also references of WO 8302081A1,DISCONTINUED
111,US,A,US 3037804 A,066-267-765-792-546,1962-06-05,1962,US 261060 A,1960-01-15,US 261060 A,1960-01-15,Rotary hook for traveling block for cranes,,DRAFTO CORP,KRAELING JOHN B;;COON LAWRENCE H,,https://lens.org/066-267-765-792-546,Granted Patent,no,5,6,1,1,0,B66C1/34;;B66C1/34,B66C1/34,,0,0,,,,EXPIRED
112,CA,A,CA 752375 A,137-112-263-970-629,1967-02-07,1967,CA 752375D A,,CA 752375T A,,HEAVY DUTY LUBRICANTS,,SHELL OIL CO,COON JOHN S;;MALONE BOBBY W,,https://lens.org/137-112-263-970-629,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
113,TW,B,TW I331300 B,135-826-857-461-68X,2010-10-01,2010,TW 95144756 A,2006-12-01,US 29261405 A,2005-12-02,System and method for processing thread groups in a simd architecture,,NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,,https://lens.org/135-826-857-461-68X,Granted Patent,no,0,4,8,21,0,G06F9/3838;;G06F9/3851;;G06F9/3869;;G06F9/3885;;G06F9/3887;;G06F9/3885;;G06F9/3851;;G06F9/3869;;G06F9/3838;;G06F9/3887,,,0,0,,,,ACTIVE
114,US,A,US 1442336 A,029-110-560-204-010,1923-01-16,1923,US 42145520 A,1920-11-03,US 42145520 A,1920-11-03,"Apparatus for treating cream, etc.",,HANNA,HANNA JOHN T;;COON LAWRENCE E,,https://lens.org/029-110-560-204-010,Granted Patent,no,0,1,1,1,0,A01J13/00;;A01J13/00,A01J13/00,,0,0,,,,EXPIRED
115,EP,A4,EP 2016172 A4,032-914-361-323-676,2009-11-11,2009,EP 07776845 A,2007-05-08,US 2007/0011047 W;;US 79921606 P,2006-05-10,DIAGNOSTIC METHODS FOR DETERMINING TREATMENT,,ABBOTT LAB,MORRISON LARRY E;;COON JOHN S,RUSH UNIVERSITY MEDICAL CENTER (2011-08-31);;ABBOTT LABORATORIES (2011-08-31),https://lens.org/032-914-361-323-676,Search Report,no,1,0,6,6,0,C12Q1/6886;;C12Q2600/106;;G01N33/57407;;G01N33/57419;;G01N33/57423;;G01N2800/52;;G01N33/57419;;C12Q2600/106;;G01N2800/52;;C12Q1/6886;;G01N33/57407;;G01N33/57423,C12N5/06;;A61K39/395;;C12Q1/68;;G01N31/00,,3,3,021-323-521-292-044;;124-044-202-232-194;;009-430-073-500-012,10.1093/jnci/dji112;;15870435;;15998906;;10.1200/jco.2005.01.2823;;10.1200/jco.2005.97.008;;16145056,"CAPPUZZO F ET AL: ""EPIDERMAL GROWTH FACTOR RECEPTOR GENE AND PROTEIN AND GEFITINIB SENSITIVITY IN NON-SMALL-CELL LUNG CANCER"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 97, no. 7, 4 May 2005 (2005-05-04), pages 643 - 655, XP009068788, ISSN: 0027-8874;;HIRSCH F R ET AL: ""INCREASED EPIDERMAL GROWTH FACTOR RECEPTOR GENE COPY NUMBER DETECTED BY FLUORESCENCE IN SITU HYBRIDIZATION ASSOCIATES WITH INCREASED SENSITIVITY TO GEFITINIB IN PATIENTS WITH BRONCHIOLOALVEOLAR CARCINOMA SUBTYPES A SOUTHWEST ONCOLOGY GROUP STUDY"", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 28, 1 October 2005 (2005-10-01), pages 6838 - 6845, XP009068790, ISSN: 0732-183X;;JOHNSON BRUCE E ET AL: ""Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?"", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 OCT 2005, vol. 23, no. 28, 1 October 2005 (2005-10-01), pages 6813 - 6816, XP002537140, ISSN: 0732-183X",DISCONTINUED
116,CN,A,CN 1803682 A,074-460-286-736-832,2006-07-19,2006,CN 200510103230 A,2005-09-19,US 707504 A,2004-12-07,Apparatus and method for making fibers,,EVANITE FIBER CORP,RON COON LARRY K WINDISCH JOHN,HOLLINS WIRTH + VOSS FIBER COMPANY (2014-12-10),https://lens.org/074-460-286-736-832,Patent Application,no,0,5,11,11,0,C03B37/048;;C03B37/048,C03B37/04;;D01D5/18,,0,0,,,,ACTIVE
117,TW,A,TW 200809615 A,121-802-133-043-162,2008-02-16,2008,TW 95144756 A,2006-12-01,US 29261405 A,2005-12-02,System and method for processing thread groups in a SIMD architecture,"A SIMD processor efficiently utilizes its hardware resources to achieve higher data processing throughput. The effective width of a SIMD processor is extended by clocking the instruction processing side of the SIMD processor at a fraction of the rate of the data processing side and by providing multiple execution pipelines, each with multiple data paths. As a result, higher data processing throughput is achieved while an instruction is fetched and issued once per clock. This configuration also allows a large group of threads to be clustered and executed together through the SIMD processor so that greater memory efficiency can be achieved for certain types of operations like texture memory accesses performed in connection with graphics processing.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK,,https://lens.org/121-802-133-043-162,Patent of Addition,no,0,0,8,21,0,G06F9/3838;;G06F9/3851;;G06F9/3869;;G06F9/3885;;G06F9/3887;;G06F9/3885;;G06F9/3851;;G06F9/3869;;G06F9/3838;;G06F9/3887,G06F9/38,,0,0,,,,ACTIVE
118,US,A,US 1247375 A,191-457-005-125-563,1917-11-20,1917,US 10165416 A,1916-06-03,US 10165416 A,1916-06-03,AIR-MOISTENER FOR STEAM-CONTAINERS.,,SYLVESTER J MCNAMARA;;CLARK JOHN A;;COON CLIFFORD H,CLARK JOHN A;;COON CLIFFORD H,,https://lens.org/191-457-005-125-563,Granted Patent,no,0,1,1,1,0,F24D19/0082;;F24D19/0082,,,0,0,,,,EXPIRED
119,EP,A2,EP 0365203 A2,023-844-785-758-57X,1990-04-25,1990,EP 89310380 A,1989-10-11,US 25572988 A,1988-10-11,Modular multi-element high energy particle detector.,"Multi-element high energy particle detector modules (1) comprise a planar heavy metal carrier (3) of tungsten alloy with planar detector units (9) uniformly distributed over one planar surface (5). The detector units (9) are secured to the heavy metal carrier (3) by electrically conductive adhesive (29) so that the carrier serves as a common ground. The other surface (7) of each planar detector unit (9) is electrically connected to a feedthrough electrical terminal (13) extending through the carrier for front or rear readout. The feedthrough electrical terminals (13) comprise sockets (15) at one face of the carrier (3) and mating pins (19) projecting from the other face, so that any number of modules (1) may be plugged together to create a stack of modules (37) of any desired number of radiation lengths. The detector units (9) each comprise four, preferably rectangular, p-i-n diode chips (27) arranged around the associated feedthrough terminal (13) to form a square detector unit providing at least 90% detector element coverage of the carrier (3). Integral spacers (11) projecting from the carriers (3) extend at least partially along the boundaries between detector units (9) to space the p-i-n diode chips (27) from adjacent carriers in a stack. The spacers (11) along the perimeters of the modules are one-half the width of the interior spacers (11) so that when stacks of modules (37) are arranged side by side to form a large array (39) of any size or shape, distribution of the detector units (9) is uniform over the entire array.  ",MICROTRONICS ASSOCIATES INC,COON DARRYL D;;ELLIOTT JOHN P,,https://lens.org/023-844-785-758-57X,Patent Application,yes,0,1,3,3,0,H01L31/117;;G01T1/242;;G01T1/243;;H01L31/117;;G01T1/242;;G01T1/243,G01T1/24;;H01L31/117,,0,0,,,,DISCONTINUED
120,NO,L,NO 20064945 L,135-068-161-930-070,2007-05-02,2007,NO 20064945 A,2006-10-30,US 26375305 A,2005-10-31,Full diameter injeksjonsventil,"Den foreliggende oppfinnelse vedrører generelt kontroll av fluidstrømningen i en brønn (10). I ett aspekt er det tilveiebrakt en ventil (100) for selektiv lukking av en strømningsvei (110) gjennom en brønn (10) i en første retning. Ventilen (100) innbefatter et legeme (105) og en stempeloverflate (125) som kan tildannes tvers over strømningsveien (110) i den første retning. Stempeloverflaten (125) er tilformet på en ende av et forskyvbart element (155) som er anordnet ringformet i legemet (105). Ventilen (100) innbefatter videre et klaffelement (150), hvor klaffelementet (150) er lukkbart for tetting av strømningsveien (110) når det forskyvbare element (155) beveger seg fra en første stilling til en andre stilling på grunn av fluidstrømning som virker på stempeloverflaten (125). I et annet aspekt er det tilveiebrakt en ventil (100) for selektiv lukking av en strømningsvei (110) gjennom en brønn (10) i en eneste retning. I enda et annet aspekt er det tilveiebrakt en fremgangsmåte for selektiv lukking av en strømningsvei (110) gjennom en brønn (10) i en første retning.",WEATHERFORD LAMB,COON ROBERT JOE;;LEMBCKE JEFFREY JOHN,"WEATHERFORD TECHNOLOGY HOLDINGS, US (2015-03-09)",https://lens.org/135-068-161-930-070,Abstract,no,0,0,9,12,0,E21B34/08;;E21B2200/05;;E21B34/08;;E21B34/08;;E21B2200/05,E21B34/14;;E21B34/06;;E21B43/12,,0,0,,,,DISCONTINUED
121,US,A,US 3172143 A,141-006-713-498-911,1965-03-09,1965,US 23618062 A,1962-10-29,US 23618062 A,1962-10-29,Machine for cleaning large surface areas,,YUCIS,YUCIS EDWARD A;;COON JOHN H,,https://lens.org/141-006-713-498-911,Granted Patent,no,19,13,1,1,0,E01H1/0863;;E01H1/14;;B03C1/0335;;B03C1/28;;B03C1/30;;B03C2201/20;;E01H1/0863;;E01H1/14;;B03C2201/20;;B03C1/30;;B03C1/0335;;B03C1/28,E01H1/08;;E01H1/14,,0,0,,,,EXPIRED
122,US,A1,US 2005/0034873 A1,165-642-948-947-222,2005-02-17,2005,US 64240203 A,2003-08-15,US 64240203 A,2003-08-15,Placing fiber optic sensor line,"The present invention generally relates to a method and an apparatus for placing fiber optic control line in a wellbore. In one aspect, a method for placing a line in a wellbore is provided. The method includes providing a tubular in the wellbore, the tubular having a first conduit operatively attached thereto, whereby the first conduit extends substantially the entire length of the tubular. The method further includes aligning the first conduit with a second conduit operatively attached to a downhole component and forming a hydraulic connection between the first conduit and the second conduit thereby completing a passageway therethrough. Additionally, the method includes urging the line through the passageway. In another aspect, a method for placing a control line in a wellbore is provided. In yet another aspect, an assembly for an intelligent well is provided.",COON ROBERT J.;;SETTERBERG JOHN R.,COON ROBERT J;;SETTERBERG JOHN R,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2004-01-26),https://lens.org/165-642-948-947-222,Patent Application,yes,11,27,9,9,0,E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135;;E21B23/08;;E21B47/135,E21B23/08;;E21B47/12,16638;;166/66,0,0,,,,EXPIRED
123,JP,A,JP 2007157154 A,155-093-293-170-931,2007-06-21,2007,JP 2006327322 A,2006-12-04,US 29261405 A,2005-12-02,SYSTEM AND METHOD FOR PROCESSING THREAD GROUPS IN SIMD ARCHITECTURE,"<P>PROBLEM TO BE SOLVED: To provide a SIMD processor which utilizes its hardware resources to achieve higher data processing throughput. <P>SOLUTION: The effective width of the SIMD processor is extended by clocking the instruction processing side of the SIMD processor at a fraction of the rate of the data processing side and by providing multiple execution pipelines, each with multiple data paths. As a result, higher data processing throughput is achieved while an instruction is fetched and issued once per clock. This configuration also allows a large group of threads to be clustered and executed together through the SIMD processor so that greater memory efficiency can be achieved for a certain type of operation like texture memory access performed in connection with graphics processing. <P>COPYRIGHT: (C)2007,JPO&INPIT",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN E,,https://lens.org/155-093-293-170-931,Patent Application,no,0,2,8,21,0,G06F9/3838;;G06F9/3851;;G06F9/3869;;G06F9/3885;;G06F9/3887;;G06F9/3885;;G06F9/3851;;G06F9/3869;;G06F9/3838;;G06F9/3887,G06F9/38,,0,0,,,,ACTIVE
124,CA,C,CA 2599073 C,183-355-800-304-328,2011-09-27,2011,CA 2599073 A,2007-08-28,US 46863106 A,2006-08-30,INJECTION VALVE,"The present invention generally relates to controlling the flow of fluids in a wellbore. In one aspect, a valve for selectively closing a flow path through a wellbore in a first direction is provided. The valve includes a body and a piston surface formable across the flow path in the first direction. The piston surface is formed at an end of a shiftable member annularly disposed in the body. The valve further includes a flapper member, the flapper member closable to seal the flow path when the shiftable member moves from a first position to a second position due to fluid flow acting on the piston surface. In another aspect, a valve for selectively closing a flow path through a wellbore in a single direction is provided. In yet another aspect, a method for selectively closing a flow path through a wellbore in a first direction is provided.",WEATHERFORD LAMB,LEMBCKE JEFFREY JOHN;;COON ROBERT J,,https://lens.org/183-355-800-304-328,Granted Patent,no,0,0,13,13,0,E21B34/08;;E21B43/123;;E21B2200/05;;E21B34/08;;E21B2200/05;;E21B43/123;;E21B34/08;;E21B43/123;;E21B34/08;;E21B43/123;;E21B2200/05,E21B43/12,,0,0,,,,ACTIVE
125,US,A,US 5168187 A,132-811-720-650-104,1992-12-01,1992,US 65820591 A,1991-02-20,US 65820591 A,1991-02-20,Axial pole stepping motor,"An axial pole stepping motor having a stator assembly on one or both sides of a disc-shaped rotor and including a plurality of teeth extending parallel to the rotational axis of the motor's drive shaft with the teeth arranged into at least two groups and evenly spaced within each of the two groups such that the teeth of each group may be axially aligned with the north-south poles of the permanent magnets evenly spaced about the circumference of the rotor. The two groups of teeth are circumferentially offset from each other such that the teeth of both groups cannot be simultaneously aligned with the north-south poles of the rotor. The circumferential offsetting of the two groups defines a stepping angle for the rotation of the motor shaft. A continuous skein winding woven in a labyrinth pattern between and among the teeth of each group transforms the teeth into salient poles. The windings may be energized in several modes. In order to provide stability in all modes of energization, at least one extra tooth not associated with the windings can be provided in the circumferential intergroup gap separating adjacent groups of teeth in the single stator assembly.",DANA CORP WARNER ELECTRIC BRAK,BAER JOHN S;;COON WILLIAM R;;FRUS JOHN,DANA CORPORATION (1991-01-22),https://lens.org/132-811-720-650-104,Granted Patent,yes,28,60,1,1,0,H02K3/04;;H02K3/28;;H02K37/125;;H02K1/2795;;H02K37/125;;H02K3/04;;H02K3/28;;H02K1/2795,H02K1/27;;H02K3/04;;H02K3/28;;H02K37/12,310 49R;;310/268;;310/185,0,0,,,,EXPIRED
126,CA,C,CA 2476720 C,023-401-596-992-188,2008-01-22,2008,CA 2476720 A,2004-08-06,US 64240203 A,2003-08-15,PLACING FIBER OPTIC SENSOR LINE,"The present invention generally relates to a method and an apparatus for placing fiber optic control line in a wellbore. In one aspect, a method for placing a line in a wellbore is provided. The method includes providing a tubular in the wellbore, the tubular having a first conduit operatively attached thereto, whereby the first conduit extends substantially the entire length of the tubular. The method further includes aligning the first conduit with a second conduit operatively attached to a downhole component and forming a hydraulic connection between the first conduit and the second conduit thereby completing a passageway therethrough. Additionally, the method includes urging the line through the passageway. In another aspect, a method for placing a control line in a wellbore is provided. In yet another aspect, an assembly for an intelligent well is provided.",WEATHERFORD LAMB,SETTERBERG JOHN R JR;;COON ROBERT J,,https://lens.org/023-401-596-992-188,Granted Patent,no,0,0,9,9,0,E21B23/08;;E21B47/135;;E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135,E21B23/08;;E21B47/12,,0,0,,,,INACTIVE
127,US,B2,US 7163055 B2,062-913-159-678-24X,2007-01-16,2007,US 25307205 A,2005-10-18,US 25307205 A;;US 64240203 A,2003-08-15,Placing fiber optic sensor line,"The present invention generally relates to a method and an apparatus for placing fiber optic control line in a wellbore. In one aspect, a method for placing a line in a wellbore is provided. The method includes providing a tubular in the wellbore, the tubular having a first conduit operatively attached thereto, whereby the first conduit extends substantially the entire length of the tubular. The method further includes aligning the first conduit with a second conduit operatively attached to a downhole component and forming a hydraulic connection between the first conduit and the second conduit thereby completing a passageway therethrough. Additionally, the method includes urging the line through the passageway. In another aspect, a method for placing a control line in a wellbore is provided. In yet another aspect, an assembly for an intelligent well is provided.",WEATHERFORD LAMB,COON ROBERT J;;SETTERBERG JR JOHN R,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01),https://lens.org/062-913-159-678-24X,Granted Patent,yes,16,27,9,9,0,E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135;;E21B23/08;;E21B47/135,E21B33/08;;E21B23/08;;E21B47/12,166/250.01;;166/66,1,0,,,"U.K. Search Report, Application No. GB 0417656.6, dated Dec. 1, 2004.",EXPIRED
128,US,A1,US 2006/0086508 A1,067-476-034-435-817,2006-04-27,2006,US 25307205 A,2005-10-18,US 25307205 A;;US 64240203 A,2003-08-15,Placing fiber optic sensor line,"The present invention generally relates to a method and an apparatus for placing fiber optic control line in a wellbore. In one aspect, a method for placing a line in a wellbore is provided. The method includes providing a tubular in the wellbore, the tubular having a first conduit operatively attached thereto, whereby the first conduit extends substantially the entire length of the tubular. The method further includes aligning the first conduit with a second conduit operatively attached to a downhole component and forming a hydraulic connection between the first conduit and the second conduit thereby completing a passageway therethrough. Additionally, the method includes urging the line through the passageway. In another aspect, a method for placing a control line in a wellbore is provided. In yet another aspect, an assembly for an intelligent well is provided.",WEATHERFORD LAMB,COON ROBERT J;;SETTERBERG JOHN R JR,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01),https://lens.org/067-476-034-435-817,Patent Application,yes,14,14,9,9,0,E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135;;E21B23/08;;E21B47/135,E21B19/16;;E21B23/08;;E21B47/12,166/380;;166/65.1,0,0,,,,EXPIRED
129,US,B2,US 8549266 B2,137-384-778-472-863,2013-10-01,2013,US 201113155291 A,2011-06-07,US 201113155291 A;;US 69880910 A;;US 67279003 A;;US 48822203 P,2003-07-16,System and method of instruction modification,"A method and system of instruction modification. A first machine language instruction, which may comprise a plurality of discrete instructions, is fetched. Responsive to a trigger pattern in the first machine language instruction, a segment of the first machine language instruction is modified. Information can be substituted into the segment based on specifics outlined in the trigger pattern. Alternatively, information can be combined with the segment via logical and/or arithmetic operations. Modification of the segment produces a second machine language instruction that is executed by units of the processor. In one embodiment, information may be taken from a queue and used to replace data from the segment. How information is taken from the queue and how the information so taken is used to replace fields of the segment are defined by the trigger pattern.",BANNING JOHN P;;HAO ERIC;;COON BRETT,BANNING JOHN P;;HAO ERIC;;COON BRETT,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27),https://lens.org/137-384-778-472-863,Granted Patent,yes,74,2,5,5,0,G06F9/3017;;G06F9/3017,G06F9/30,712/226;;712/213,12,5,042-060-457-200-212;;008-082-443-743-245;;021-217-729-402-688;;039-533-571-422-256;;035-378-437-114-639,10.1109/pact.1998.727184;;10.1145/36177.36201;;10.1145/75395.75401;;10.1109/pccc.1990.101732;;10.1109/40.87564,"Hennessy, John L. et al., ""Computer Architecture A Quantitative Approach,"" Morgan Kaufmann Publishers, Inc., 2nd Ed., Jan. 1996, pp. 130 and 284-289.;;Ozer et al., ""A Fast Interrupt Handling Scheme for VLIW Processors,"" Proceedings of International Conference on Parallel Architectures and Compilation Techniques, Oct. 12, 1998, pp. 136-141.;;Colwell et al., ""A VLIW architecture for a Trace Scheduling Compiler,"" ACM, Jan. 1987, pp. 180-192.;;Cohn et al., ""Architecture and Compiler Tradeoffs for a Long Instruction Word Processor,"" ACM, Jan. 1989, Whole Document.;;Nakatani et al., ""'Combining' as a Compilation Technique for VLIW architectures,"" ACM, Jan. 1990, pp. 43-55.;;Ray, G. A., ""Core-Based RNS ALU with Customized Instructions,"" IEEE Ninth Annual International Conference on Computers and Communications, Mar. 21, 1990, p. 891.;;Patterson et al., ""RISC I: A Reduced Instruction Set VLSI Computer,"" ISCA Proceedings of the 8th Annual Symposium on Computer Architecture, Jan. 1981, pp. 216-230.;;TRANSMETA P2000 (project name: Fred), ""Instruction Set Architecture and Programmer's Reference Manual,"" Version 1.01, Jan. 31, 2001, pp. 801-804.;;Stallings, W., ""Data and Computer Communications,"" Third Edition. Macmillan Publishing Company. New York, New York, Jan. 1991, pp. 184-185, 193, and 201.;;Popescu, Val et al., ""The Metaflow Architecture,"" IEEE, Jun. 1991, pp. 10-13 and 63-73.;;""Enterprise Systems Architecture/390 Principles of Operation,"" Eight Edition, IBM, Jul. 2001, pp. 9-1 to 9-4, 9-8 to 9-9, and 7-1 to 7-6.;;Johnson, M., ""Superscalar Microprocessor Design,"" PTR Prentice-Hall, In., A Pearson Education Company Upper Saddle River, NJ 07458, Jan. 1991, Whole Document.",EXPIRED
130,CA,A1,CA 2476720 A1,038-618-821-051-731,2005-02-15,2005,CA 2476720 A,2004-08-06,US 64240203 A,2003-08-15,PLACING FIBER OPTIC SENSOR LINE,"The present invention generally relates to a method and an apparatus fo r placing fiber optic control line in a wellbore. In one aspect, a method for placing a line in a wellbore is provided. The method includes providing a tubular in t he wellbore, the tubular having a first conduit operatively attached thereto, whereby the first conduit extends substantially the entire length of the tubular. The method further includes aligning the first conduit with a second conduit operativel y attached to a downhole component and forming a hydraulic connection between the first conduit and the second conduit thereby completing a passageway therethrough. Additionally, the method includes urging the line through the passageway. In another aspect, a method for placing a control line in a wellbore is provide d. In yet another aspect, an assembly for an intelligent well is provided.",WEATHERFORD LAMB,COON ROBERT J;;SETTERBERG JOHN R JR,,https://lens.org/038-618-821-051-731,Patent Application,no,0,0,9,9,0,E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135;;E21B23/08;;E21B47/135,E21B23/08;;E21B47/12,,0,0,,,,INACTIVE
131,GB,A,GB 2404938 A,142-328-427-557-19X,2005-02-16,2005,GB 0417656 A,2004-08-09,US 64240203 A,2003-08-15,Placing fibre optic sensor line,"A method and apparatus for placing a fibre optic control line in a wellbore 100. In one aspect, a method for placing a line in a wellbore 100 is provided, comprising providing a tubular 185 in the wellbore 100, the tubular 185 having a first conduit 190 operatively attached thereto, whereby the first conduit extends substantially the entire length of the tubular 185. The method further includes aligning the first conduit 190 with a second conduit 175 operatively attached to a downhole component 160 and forming a hydraulic connection 195 between the first conduit 190 and the second conduit 175 thereby completing a passageway 210 there through. Additionally, the method includes urging the line through the passageway 210. In another aspect, a method for placing a fiber in metal tubing sensor line in a wellbore by pushing or pumping through with the aid of flow cups (fig:7, 230) is disclosed. A disclosure of an assembly for an intelligent well is also provided.",WEATHERFORD LAMB,COON ROBERT J;;SETTERBERG JR JOHN R,,https://lens.org/142-328-427-557-19X,Patent Application,no,3,10,9,9,0,E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135;;E21B23/08;;E21B47/135,E21B23/08;;E21B47/12,E1F FHK           FHK,0,0,,,,INACTIVE
132,GB,B,GB 2404938 B,042-380-146-140-147,2006-11-29,2006,GB 0417656 A,2004-08-09,US 64240203 A,2003-08-15,Placing fiber optic sensor line,,WEATHERFORD LAMB,COON ROBERT J;;SETTERBERG JOHN R JR,,https://lens.org/042-380-146-140-147,Granted Patent,no,4,0,9,9,0,E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135;;E21B23/08;;E21B47/135,E21B23/08;;E21B47/12,E1F FHK           FHK,0,0,,,,INACTIVE
133,US,B2,US 10874414 B2,074-454-707-013-763,2020-12-29,2020,US 201816107726 A,2018-08-21,US 201816107726 A;;US 201762535483 P,2017-07-21,Tissue release instrument and methods of use,A device for releasing soft tissue includes a distractor and blade assembly. The distractor may include a guide channel positioned along an edge of the distractor and the blade assembly fits into the guide channel and is configured to slide within the channel of the distractor.,NEXTREMITY SOLUTIONS INC,PEPPER JOHN R;;EARLY JOHN;;SCHLOTTERBACK RYAN;;COON MICHAEL,NEXTREMITY SOLUTIONS INC (2018-10-23);;ZIMMER INC (2022-04-29),https://lens.org/074-454-707-013-763,Granted Patent,yes,20,0,2,2,0,A61B17/320016;;A61B17/320036;;A61B2017/320052;;A61B17/025;;A61B17/320016;;A61B2017/320052;;A61B17/320036,A61B17/32;;A61B17/02,,0,0,,,,ACTIVE
134,CA,C,CA 2365966 C,174-520-369-501-155,2008-09-23,2008,CA 2365966 A,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,METHOD OF CREATING A WELLBORE IN AN UNDERGROUND FORMATION,"A method of creating a wellbore in an underground formation comprising drilling a borehole in the underground formation using a drilling tubular, capable of being expanded, to which a downhole motor driving a drill bit has been connected, and, after drilling to the desired casing setting depth, expanding the drilling tubular into place to line the borehole by applying a radial load to the drilling tubular and removing said load from the drilling tubular. A sealing material in a fluidic state is preferably pumped between the drilling tubular and the wellbore wall prior to applying said radial load to the drilling tubular which sealing material sets after the radial expansion.",SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/174-520-369-501-155,Granted Patent,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B43/10;;E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14,,0,0,,,,EXPIRED
135,EP,A1,EP 1169547 A1,000-737-923-372-993,2002-01-09,2002,EP 00917054 A,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,METHOD OF CREATING A WELLBORE IN AN UNDERGROUND FORMATION,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/000-737-923-372-993,Patent Application,yes,0,1,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,1,0,,,See references of WO 0061915A1,EXPIRED
136,WO,A1,WO 2000/061915 A1,141-817-254-462-985,2000-10-19,2000,EP 0003105 W,2000-04-06,US 28988299 A,1999-04-09,METHOD OF CREATING A WELLBORE IN AN UNDERGROUND FORMATION,"A method of creating a wellbore in an underground formation comprising drilling a borehole in the underground formation using a drilling tubular, capable of being expanded, to which a downhole motor driving a drill bit has been connected, and, after drilling to the desired casing setting depth, expanding the drilling tubular into place to line the borehole by applying a radial load to the drilling tubular and removing said load from the drilling tubular. A sealing material in a fluidic state is preferably pumped between the drilling tubular and the wellbore wall prior to applying said radial load to the drilling tubular which sealing material sets after the radial expansion.",SHELL INT RESEARCH;;COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/141-817-254-462-985,Patent Application,yes,18,15,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,3,0,,,"ASM INTERNATIONAL, METAL PARK: ""FORMING AND FORMING"", THE METAL HANDBOOK, 9TH EDITION, vol. 14, OHIO;;J.A. COLLINS, FAILURE OF MATERIALS IN MECHANICAL DESIGN, SECOND EDITION ISSUED BY JOHN WILEY AND SONS, 1993, NEW YORK;;METAL FORMING-MECHANICS AND METALLURGY, 2ND EDITION, ISSUED BY PRENTICE HALL CHAPTER 3 AND 17, 1993, NEW JERSEY",PATENTED
137,US,B2,US 6955218 B2,089-950-445-559-295,2005-10-18,2005,US 64240203 A,2003-08-15,US 64240203 A,2003-08-15,Placing fiber optic sensor line,"The present invention generally relates to a method and an apparatus for placing fiber optic control line in a wellbore. In one aspect, a method for placing a line in a wellbore is provided. The method includes providing a tubular in the wellbore, the tubular having a first conduit operatively attached thereto, whereby the first conduit extends substantially the entire length of the tubular. The method further includes aligning the first conduit with a second conduit operatively attached to a downhole component and forming a hydraulic connection between the first conduit and the second conduit thereby completing a passageway therethrough. Additionally, the method includes urging the line through the passageway. In another aspect, a method for placing a control line in a wellbore is provided. In yet another aspect, an assembly for an intelligent well is provided.",WEATHERFORD LAMB,COON ROBERT J;;SETTERBERG JR JOHN R,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2004-01-26),https://lens.org/089-950-445-559-295,Granted Patent,yes,13,13,9,9,0,E21B47/017;;E21B47/135;;E21B23/08;;E21B47/135;;E21B23/08;;E21B47/135,E21B23/08;;E21B47/12,166/250.01;;166/66,1,0,,,"U.K. Search Report, Application No. GB 0417656.6, dated Dec. 1, 2004.",EXPIRED
138,EP,B1,EP 1169547 B1,137-714-878-656-044,2003-07-02,2003,EP 00917054 A,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,METHOD OF CREATING A WELLBORE IN AN UNDERGROUND FORMATION,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/137-714-878-656-044,Granted Patent,yes,7,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,EXPIRED
139,US,A1,US 2019/0216488 A1,085-039-017-365-965,2019-07-18,2019,US 201816107726 A,2018-08-21,US 201816107726 A;;US 201762535483 P,2017-07-21,TISSUE RELEASE INSTRUMENT AND METHODS OF USE,"Instruments, devices and methods for releasing soft tissue are disclosed. A tissue release instrument may include a distractor and blade assembly. The distractor may include a guide channel positioned along an edge of the distractor and wherein the blade assembly fits into the guide channel and is configured to slide within the channel of the distractor. Methods for assembling and using the instrument and devices to release soft tissue are also disclosed.",NEXTREMITY SOLUTIONS INC,PEPPER JOHN R;;EARLY JOHN;;SCHLOTTERBACK RYAN;;COON MICHAEL,NEXTREMITY SOLUTIONS INC (2018-10-23);;ZIMMER INC (2022-04-29),https://lens.org/085-039-017-365-965,Patent Application,yes,5,1,2,2,0,A61B17/320016;;A61B17/320036;;A61B2017/320052;;A61B17/025;;A61B17/320016;;A61B2017/320052;;A61B17/320036,A61B17/32;;A61B17/02,,0,0,,,,ACTIVE
140,NO,B1,NO 331907 B1,107-394-995-361-108,2012-04-30,2012,NO 20014901 A,2001-10-08,EP 0003105 W;;US 28988299 A,1999-04-09,Fremgangsmate for a danne et borehull i en undergrunnsformasjon,"Fremgangsmåte for å danne et borehull i en undergrunnsformasjon omfattende å bore et borehull i undergrunnsformasjonen ved bruk av et borerør som er i stand til å ekspanderes, hvortil en ned-i- hull-motor som driver en borekrone er blitt tilkoblet, og etter boring til den tilsiktede fôringsinnsettingsdybde, ekspanderes borerøret på plass til å fore borehullet ved å påføre en radiell last på borerøret og å fjerne nevnte last fra borerøret. Et tettemateriale i en fluid tilstand blir fortrinnsvis pumpet mellom borerøret og brannveggen før påføring av nevnte radielle last på borerøret, hvilket tettemateriale herder etter den radielle ekspansjon.",SHELL INT RESEARCH,FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN;;COON ROBERT J,,https://lens.org/107-394-995-361-108,Granted Patent,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B43/10;;E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14,,0,0,,,,EXPIRED
141,US,B1,US 7698539 B1,110-830-853-219-241,2010-04-13,2010,US 67279003 A,2003-09-26,US 67279003 A;;US 48822203 P,2003-07-16,System and method of instruction modification,"A method and system of instruction modification. A first machine language instruction, which may comprise a plurality of discrete instructions, is fetched. Responsive to a trigger pattern in the first machine language instruction, a segment of the first machine language instruction is modified. Information can be substituted into the segment based on specifics outlined in the trigger pattern. Alternatively, information can be combined with the segment via logical and/or arithmetic operations. Modification of the segment produces a second machine language instruction that is executed by units of the processor. In one embodiment, information may be taken from a queue and used to replace data from the segment. How information is taken from the queue and how the information so taken is used to replace fields of the segment are defined by the trigger pattern.",BANNING JOHN P;;HAO ERIC;;COON BRETT,BANNING JOHN P;;HAO ERIC;;COON BRETT,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27);;INTELLECTUAL VENTURE FUNDING LLC (2009-01-28);;TRANSMETA CORPORATION (2004-02-10);;TRANSMETA LLC (2009-01-27),https://lens.org/110-830-853-219-241,Granted Patent,yes,69,2,5,5,0,G06F9/3017;;G06F9/3017,G06F9/30,712/226,31,7,042-060-457-200-212;;008-082-443-743-245;;011-472-147-631-873;;021-217-729-402-688;;039-533-571-422-256;;003-564-565-469-862;;035-378-437-114-639,10.1109/pact.1998.727184;;10.1145/36177.36201;;10.1145/68182.68183;;10.1145/75395.75401;;10.1109/pccc.1990.101732;;10.1145/285930.285981;;10.1109/40.87564,"Hennessy, John L. et al., Computer Architecture A Quantitative Approach, 1996, Morgan Kaufmann Publishers, Inc., 2nd Ed., pp. 130 and 284-289.;;Ozer et al., A Fast Interrupt Handling Scheme for VLIW Processors, Oct. 12-18, 1998, Proceedings of International Conference on Parallel Architectures and Compilation Techniques, pp. 136-141.;;Title: A VLIW architecture for a trace scheduling compiler, author: Colwell et al, ACM, 1987.;;Title: Architecture and compiler tradeoffs for a long instruction wordprocessor, author: Cohn et al, ACM 1989.;;Title: Combining as a compilation technique for VLIW architectures, Author: Nakatani et al, ACM, 1989.;;Title: Core-Based RNS ALU with customized instructions, author: Ray, IEEE, 1990.;;Title: RISC I: a reduced instruction set VLSI computer, author: Patterson, ACM, 1998.;;Final Office Action Dated Jun. 25, 2003; Patent No. 6738892.;;Non-Final Office Action Dated Apr. 11, 2002; Patent No. 6738892.;;Non-Final Office Action Dated Dec. 20, 2002; Patent No. 6738892.;;Final Office Action Dated May 2, 2003; Patent No. 6754892.;;Non Final Office Action Dated Nov. 25, 2002; Patent No. 6754892.;;Notice of Allowance Dated Oct. 27, 2003; Patent No. 6754892.;;Notice of Allowance Dated Dec. 22, 2003; Patent No. 6738892.;;Issue Notification Dated May 18, 2004; Patent No. 6738892.;;Issue Notification Dated Jun. 22, 2004; Patent No. 6754892.;;Non Final Office Action Dated Dec. 9, 2005.;;Non Final Office Action Dated Nov. 2, 2006.;;Non Final Office Action Dated Sep. 17, 2007.;;Amendment Dated Aug. 31, 2006.;;Non Final Office Action Dated Aug. 4, 2008.;;Final Office Action Dated Mar. 14, 2007.;;Final Office Action Dated Mar. 6, 2008.;;Final Office Action Dated Jan. 27, 2009.;;Enterprise Systems Architecture/390 Principles of Operation. Eight Edition, Jul. 2001. pp. 7-1 to 7-5, 9-1 to 9-4 and 9-8 to 9-9.;;Advisory Action Dated Jul. 5, 2007.;;Notice of Allowance Dated Jun. 10, 2009; U.S. Appl. No. 10/623,101.;;Transmeta P2000 (project name: Fred); Instruction Set Architecture and Programmer's Reference Manual. Version 1.01 Jun. 28, 2001.;;Williams Stalling, Ph.D; Data and Computer Communications; Third Edition. Macmillan Publishing Company. New York, New York. 1991.;;Val Popescu; et al. The Metaflow Architecture; 1991.;;Mike Johnson. Superscalar Microprocessor Design. 1991 by P T R Prentice-Hall, In. A Pearson Education Company Upper Saddle River, NJ 07458.",ACTIVE
142,NO,D0,NO 20014901 D0,123-448-406-192-512,2001-10-08,2001,NO 20014901 A,2001-10-08,EP 0003105 W;;US 28988299 A,1999-04-09,Fremgangsmåte for å danne et borehull i en undergrunnsformasjon,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/123-448-406-192-512,Patent Application,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,EXPIRED
143,DK,T3,DK 1169547 T3,154-603-459-970-826,2003-08-18,2003,DK 00917054 T,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,Fremgangsmåde til frembringelse af en borebrønd i en underjordisk formation,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/154-603-459-970-826,Granted Patent,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,EXPIRED
144,NO,L,NO 20014901 L,195-349-654-503-090,2001-10-08,2001,NO 20014901 A,2001-10-08,EP 0003105 W;;US 28988299 A,1999-04-09,Fremgangsmåte for å danne et borehull i en undergrunnsformasjon,"Fremgangsmåte for å danne et borehull i en undergrunnsformasjon omfattende å bore et borehull i undergrunnsformasjonen ved bruk av et borerør som er i stand til å ekspanderes, hvortil en ned-i-hull-motor som driver en borekrone er blitt tilkoblet, og etter boring til den tilsiktede foringsinnsettingsdybde, ekspanderes borerøret på plass til å fore borehullet ved å påføre en radiell last på borerøret og å fjerne nevnte last fra borerøret. Et tettemateriale i en fluid tilstand blir fortrinnsvis pumpet mellom borerøret og brannveggen før påføring av nevnte radielle last på borerøret, hvilket tettemateriale herder etter den radielle ekspansjon.",SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/195-349-654-503-090,Abstract,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,EXPIRED
145,CA,A1,CA 2365966 A1,053-645-324-474-802,2000-10-19,2000,CA 2365966 A,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,METHOD OF CREATING A WELLBORE IN AN UNDERGROUND FORMATION,"A method of creating a wellbore in an underground formation comprising drilling a borehole in the underground formation using a drilling tubular, capable of being expanded, to which a downhole motor driving a drill bit has been connected, and, after drilling to the desired casing setting depth, expanding the drilling tubular into place to line the borehole by applying a radial load to the drilling tubular and removing said load from the drilling tubular. A sealing material in a fluidic state is preferably pumped between the drilling tubular and the wellbore wall prior to applying said radial loa d to the drilling tubular which sealing material sets after the radial expansi on.",SHELL INT RESEARCH,MARTIN DAVID JOHN;;COON ROBERT JOE;;FRANK TIMOTHY JOHN,,https://lens.org/053-645-324-474-802,Patent Application,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,EXPIRED
146,AU,A,AU 2000/038185 A,114-410-563-484-922,2000-11-14,2000,AU 2000/038185 A,2000-04-06,EP 0003105 W;;US 28988299 A,1999-04-09,Method of creating a wellbore in an underground formation,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MARTIN DAVID JOHN,,https://lens.org/114-410-563-484-922,Patent Application,no,0,0,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,,0,0,,,,DISCONTINUED
147,US,B2,US 7676657 B2,064-140-971-449-983,2010-03-09,2010,US 54827206 A,2006-10-10,US 54827206 A;;US 74251403 A,2003-12-18,Across-thread out-of-order instruction dispatch in a multithreaded microprocessor,"Instruction dispatch in a multithreaded microprocessor such as a graphics processor is not constrained by an order among the threads. Instructions for each thread are fetched, and a dispatch circuit determines which instructions in the buffer are ready to execute. The dispatch circuit may issue any ready instruction for execution, and an instruction from one thread may be issued prior to an instruction from another thread regardless of which instruction was fetched first. If multiple functional units are available, multiple instructions can be dispatched in parallel.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT;;MOY SIMON S,NVVIDIA CORPORATION (2006-11-05),https://lens.org/064-140-971-449-983,Granted Patent,yes,12,34,12,12,0,G06F9/3802;;G06F9/3802;;G06F9/3851;;G06F9/3851,G06F9/00;;G06F9/38;;G06F9/46,712/220;;712/215;;712/216;;718/100;;718/102,7,4,130-463-754-851-202;;020-961-679-464-619;;020-961-679-464-619;;111-207-670-000-134,10.1109/isca.1995.524578;;10.1109/40.621209;;10.1109/40.621209;;10.1145/232973.232993,"Tullsen et al., ""Simultaneous multithreading: maximizing on-chip parallelism"", Proceedings of the 22nd annual international symposium on Computer architecture, ACM, May 1995, pp. 392-403.;;Eggers et al., Simultaneous Multithreading: A Platform for Next Generation Processors, IEEE Micro, Sep./Oct. 1997, pp. 12-19.;;Mauricio J. Serrano, Performance Tradeoffs in Multistreamed Superscalar Architectures, Doctoral Dissertation, University of California, Santa Barbara, Mar. 1994.;;Eggers et al. ""Simultaneous multithreading: a platform for next generation processors"" IEEE Micro, Sep./Oct. 1997 (vol. 17, No. 5) pp. 12-19.;;Marr et al. Hyper Threading Technology Architecture and Microarchitecture, Intel Technology Journal Q1, 2002.;;Tullsen et al. Institute of Electrical and Electronics Engineers Association for Computing Machinery ""Exploiting Choice: Instruction Fetch and Issue on a Implementable Simultaneous Multithreading Processor"" Proceedings of the 23rd Annual Symposium on Computer Architecture, New York, vol. SYMP, 23, May 22, 1996, pp. 191-202.;;European Patent Application No. 04029906.7, Examination Report dated Jun. 25, 2008, 5 pages.",ACTIVE
148,GB,A,GB 2427981 A,087-792-633-967-065,2007-01-10,2007,GB 0513533 A,2005-07-01,GB 0513533 A,2005-07-01,Optimising a contention period of a superframe for a wireless network,"A communications controller is described which provides flexible control of, for instance, an IEEE802.11(n) superframe. The communications controller provides control of the length of the superframe and the proportion of the superframe reserved as the Contention free Period, on the basis of an optimisation. A preferred approach to optimisation is also described, based on non-linear optimisation and more particularly a barrier method.",TOSHIBA RES EUROP LTD,HAINES RUSSELL JOHN;;LEWIS TIMOTHY ADRIAN;;COON JUSTIN,,https://lens.org/087-792-633-967-065,Patent Application,no,2,1,3,3,0,H04J3/1682;;H04W74/02;;H04W28/06;;H04W84/12,H04J3/16;;H04L12/28;;H04L12/56,H4L LRRMB         LRRMB;;H4L L205          LRRMB;;H4M MTP1          MTP1;;NOT CLASSIFIED    NONE,0,0,,,,INACTIVE
149,CA,A1,CA 2527378 A1,063-599-021-456-613,2006-06-07,2006,CA 2527378 A,2005-11-18,US 707504 A,2004-12-07,APPARATUS AND METHOD FOR MAKING FIBERS,"A duct assembly is employed for directing a central air flow upwardly toward the rotating spinner assembly of a rotary-type fiberizer that produce s a downwardly flowing column of fibers. The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flo w. In another embodiment, a conduit extends through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly within the interior of th e fiber column.",EVANITE FIBER CORP,COON LARRY;;REHER RON;;SVOBODA PATRICK;;WINDISCH JOHN,,https://lens.org/063-599-021-456-613,Patent Application,no,0,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04;;C03B37/08;;D01D5/08;;D01D5/18,,0,0,,,,INACTIVE
150,US,A,US 4105417 A,085-426-149-300-653,1978-08-08,1978,US 46023474 A,1974-04-11,US 46023474 A,1974-04-11,Fuel additive,"A certain fuel-soluble nitrogen-hydrocarbyl-substituted nitrogenous composition has been found to display a previously unreported detergency in the internal combustion engine when present in fuels to the extent of 10-4,000 ppm. The nitrogenous composition is composed of a hydrocarbyl group bonded to a nitrogenous substrate. The hydrocarbyl substituent contains from 30 to about 400 carbon atoms, and the nitrogenous substrate is a carbamate, urea or amide.",COON MARVIN D;;MACPHERSON AGENT BY JOHN HUGH,COON MARVIN D;;MACPHERSON AGENT BY JOHN HUGH,,https://lens.org/085-426-149-300-653,Granted Patent,yes,13,14,1,1,0,C07C273/1827;;C07C273/1827;;C07D233/36;;C07D233/36;;C08F8/30;;C08F8/30;;C10L1/238;;C10L1/238;;C10L1/2383;;C10L1/2383,C07C273/18;;C07C275/28;;C07D233/36;;C08F8/30;;C10L1/22;;C10L1/238,44/63,0,0,,,,EXPIRED
151,US,B2,US 6371203 B2,042-350-677-205-23X,2002-04-16,2002,US 77100501 A,2001-01-26,US 77100501 A;;US 28988299 A,1999-04-09,Method of creating a wellbore in an underground formation,"
    A method of creating a wellbore in an underground formation comprising drilling a borehole in the underground formation using a drilling tubular, capable of being expanded, to which a downhole motor driving a drill bit has been connected, and, after drilling to the desired casing setting depth, expanding the drilling tubular into place to line the borehole by applying a radial load to the drilling tubular and removing said load from the drilling tubular. 
",SHELL OIL CO,FRANK TIMOTHY JOHN;;COON ROBERT JOE;;MARTIN DAVID,SHELL OIL COMPANY (1999-01-14),https://lens.org/042-350-677-205-23X,Granted Patent,yes,20,47,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,166/207;;175/23,5,0,,,"Metal Forming-Mechanics and Metallurgy, Chapter 3, 2nd Ed.. Prentice Hall. New Jersey, 1993.;;International Search Report dated Jul. 14, 2000.;;Metal Forming-Mechanics and Metallurgy, Chapters 3 and 17, 2nd Ed., Prentice Hall, New Jersey, 1993.;;Metals Handbook, Forming and Forging, pp. 7, 373-387, and 874-899, 9th Ed., vol. 14, ASM International, Metals Park, OH (USA) 1993.;;Failure of Materials in Mechanical Design, J.A. Collins, Chapter 3.5, pp. 34-37, 2nd Ed., John Wiley & Sons, New York (USA) 1993.",EXPIRED
152,DE,D1,DE 60014613 D1,055-493-852-613-805,2004-11-11,2004,DE 60014613 T,2000-04-06,US 28992899 A;;EP 0003104 W,1999-04-09,VERFAHREN ZUR SELEKTIVEN PLASTISCHEN AUSDEHNUNG VON TEILEN EINES BOHRROHRS,,SHELL INT RESEARCH,COON JOE;;FRANK JOHN;;LOHBECK CHRISTIANUS;;NAZZAL RICHARD,,https://lens.org/055-493-852-613-805,Granted Patent,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
153,US,A1,US 2001/0002626 A1,099-398-733-179-023,2001-06-07,2001,US 77100501 A,2001-01-26,US 77100501 A;;US 28988299 A,1999-04-09,Method of creating a wellbore in an underground formation,"
   A method of creating a wellbore in an underground formation comprising drilling a borehole in the underground formation using a drilling tubular, capable of being expanded, to which a downhole motor driving a drill bit has been connected, and, after drilling to the desired casing setting depth, expanding the drilling tubular into place to line the borehole by applying a radial load to the drilling tubular and removing said load from the drilling tubular. 
",FRANK TIMOTHY JOHN;;COON ROBERT JOE;;MARTIN DAVID,FRANK TIMOTHY JOHN;;COON ROBERT JOE;;MARTIN DAVID,SHELL OIL COMPANY (1999-01-14),https://lens.org/099-398-733-179-023,Patent Application,yes,0,32,14,14,0,E21B7/20;;E21B7/20;;E21B17/20;;E21B17/20;;E21B29/10;;E21B29/10;;E21B33/14;;E21B33/14;;E21B43/103;;E21B43/103,E21B7/20;;E21B17/20;;E21B29/10;;E21B33/14;;E21B43/10,175/57;;175/171;;X17532;;166/207,0,0,,,,EXPIRED
154,AT,T1,AT E479895 T1,068-844-493-821-55X,2010-09-15,2010,AT 05727506 T,2005-03-11,US 55287604 P;;US 57288404 P;;US 59934104 P;;US 2005/0008148 W,2004-03-12,ELEKTRONENTRANSFERDISSOZIATION ZUR BIOPOLYMER- SEQUENZANALYSE,"The invention relates to a method of fragmenting positively charged peptide ions in an RF field mass spectrometer or an RF'field ion containment device, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide ion, resulting in the fragmentation of the positively charged sample ion. The invention also provides a method of performing sequence analysis of a peptide or protein by mass spectrometry, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide or protein ion, resulting in the fragmentation of the positively charged sample ion.",UNIV VIRGINIA,HUNT DONALD;;COON JOSHUA;;SYKA JOHN;;MARTO JARROD,,https://lens.org/068-844-493-821-55X,Granted Patent,no,0,0,20,20,0,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,0,0,,,,INACTIVE
155,CA,C,CA 2527378 C,063-146-818-100-655,2009-01-06,2009,CA 2527378 A,2005-11-18,US 707504 A,2004-12-07,APPARATUS AND METHOD FOR MAKING FIBERS,"A duct assembly is employed for directing a central air flow upwardly toward the rotating spinner assembly of a rotary-type fiberizer that produce s a downwardly flowing column of fibers. The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flo w. In another embodiment, a conduit extends through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly within the interior of th e fiber column.",EVANITE FIBER CORP,COON LARRY;;REHER RON;;SVOBODA PATRICK;;WINDISCH JOHN,,https://lens.org/063-146-818-100-655,Granted Patent,no,0,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04;;C03B37/08;;D01D5/08;;D01D5/18,,0,0,,,,INACTIVE
156,US,A1,US 2010/0122067 A1,182-129-531-739-224,2010-05-13,2010,US 69022510 A,2010-01-20,US 69022510 A;;US 54827206 A;;US 74251403 A,2003-12-18,ACROSS-THREAD OUT-OF-ORDER INSTRUCTION DISPATCH IN A MULTITHREADED MICROPROCESSOR,"Instruction dispatch in a multithreaded microprocessor such as a graphics processor is not constrained by an order among the threads. Instructions for each thread are fetched, and a dispatch circuit determines which instructions in the buffer are ready to execute. The dispatch circuit may issue any ready instruction for execution, and an instruction from one thread may be issued prior to an instruction from another thread regardless of which instruction was fetched first. If multiple functional units are available, multiple instructions can be dispatched in parallel.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT;;MOY SIMON S,NVIDIA CORPORATION (2006-11-05),https://lens.org/182-129-531-739-224,Patent Application,yes,14,41,12,12,0,G06F9/3802;;G06F9/3802;;G06F9/3851;;G06F9/3851,G06F9/312;;G06F9/38;;G06F9/46,712/205;;712/214;;X712E09033,1,0,,,"Campione, Mary. Walrath, Kathy. ""The Java Tutorial: Object-Oriented Programming for the Internet"". July 8, 1997. 5 pages.",DISCONTINUED
157,DE,T3,DE 69933374 T3,032-674-388-262-666,2012-05-31,2012,DE 69933374 T,1999-03-19,US 7966798 P;;US 5053498 A;;EP 99914957 A;;US 9906089 W,1998-03-27,OPERATIONSLEUCHTENSTEUERUNG,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",HILL ROM SERVICES INC,BORDERS RICHARD;;COON DENNIS;;KRAHE RONALD;;BULKO JOHN,,https://lens.org/032-674-388-262-666,Amended Patent,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;F21S8/04;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
158,US,B1,US 6390201 B1,063-419-778-437-405,2002-05-21,2002,US 60921000 A,2000-07-05,US 60921000 A,2000-07-05,Method of creating a downhole sealing and hanging device,"
    A method of creating a downhole sealing and hanging device comprising the steps of lowering a first tubular in a well bore, then lowering through the first tubular a second tubular with slightly smaller external diameter than the internal diameter of the first tubular, and made of formable steel, in such a way that the upper section of the second tubular remains within the lower section of the first tubular, and finally plastically expanding at least the upper section of the second tubular by application of a radial force to the interior of the upper section of the second tubular thereby creating an interference fit capable of forming a bond and a hydraulic seal between the first and second tubular. 
",SHELL OIL CO,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;MAKOHL FRIEDHELM,SHELL OIL COMPANY (1999-07-15),https://lens.org/063-419-778-437-405,Granted Patent,yes,4,19,1,1,0,E21B43/103;;E21B43/103,E21B43/10,166/380;;166/207,2,0,,,"Hosford, William F. and Robert M. Caddell, Metal Forming Mechanics and Metallurgy, 2nd ed., Prentice Hall, Englewood Cliffs, NJ, 1993, pp. 49-67.;;Hosford, William F. and Robert M. Caddell, Metal Forming Mechanics and Metallurgy, 2nd ed., Prentice Hall, Englewood Cliffs, NJ, 1993, pp. 344-359.",EXPIRED
159,DE,T2,DE 60014613 T2,019-303-984-088-939,2005-11-24,2005,DE 60014613 T,2000-04-06,US 28992899 A;;EP 0003104 W,1999-04-09,VERFAHREN ZUR SELEKTIVEN PLASTISCHEN AUSDEHNUNG VON TEILEN EINES BOHRROHRS,,SHELL INT RESEARCH,COON JOE;;FRANK JOHN;;LOHBECK CHRISTIANUS;;NAZZAL RICHARD,,https://lens.org/019-303-984-088-939,Granted Patent,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
160,US,A1,US 2007/0214343 A1,082-627-064-246-805,2007-09-13,2007,US 54827206 A,2006-10-10,US 54827206 A;;US 74251403 A,2003-12-18,ACROSS-THREAD OUT-OF-ORDER INSTRUCTION DISPATCH IN A MULTITHREADED MICROPROCESSOR,"Instruction dispatch in a multithreaded microprocessor such as a graphics processor is not constrained by an order among the threads. Instructions for each thread are fetched, and a dispatch circuit determines which instructions in the buffer are ready to execute. The dispatch circuit may issue any ready instruction for execution, and an instruction from one thread may be issued prior to an instruction from another thread regardless of which instruction was fetched first. If multiple functional units are available, multiple instructions can be dispatched in parallel.",NVIDIA CORP,LINDHOLM JOHN E;;COON BRETT;;MOY SIMON S,NVVIDIA CORPORATION (2006-11-05),https://lens.org/082-627-064-246-805,Patent Application,yes,4,48,12,12,0,G06F9/3802;;G06F9/3802;;G06F9/3851;;G06F9/3851,G06F9/45;;G06F9/38;;G06F9/46,712/220,0,0,,,,EXPIRED
161,US,A1,US 2007/0161008 A1,168-356-811-109-385,2007-07-12,2007,US 37129406 A,2006-03-08,US 37129406 A;;US 65996105 P,2005-03-09,Diagnostic methods for determining treatment,The present invention provides methods for identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab. The invention is based on the discovery that certain chromosomal abnormalities can be used to selectively identify cancer patients that are likely to be successfully treated with medication that inhibits the signaling capability of the HER-2 receptor protein or otherwise function similarly to trastuzumab. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The present invention also provides kits and sets of probes for use in identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.,MORRISON LARRY E;;JEWELL SUSAN;;COON JOHN S,MORRISON LARRY E;;JEWELL SUSAN;;COON JOHN S,RUSH UNIVERSITY MEDICAL CENTER (2011-10-31);;ABBOTT MOLECULAR INC (2014-04-01);;ABBOTT LABORATORIES (2014-03-01),https://lens.org/168-356-811-109-385,Patent Application,yes,2,12,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68;;C07H21/04,435/6;;536/24.3,0,0,,,,ACTIVE
162,US,B2,US 8105768 B2,010-491-066-870-933,2012-01-31,2012,US 37129406 A,2006-03-08,US 37129406 A;;US 65996105 P,2005-03-09,Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number,The present invention provides methods for identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab. The invention is based on the discovery that certain chromosomal abnormalities can be used to selectively identify cancer patients that are likely to be successfully treated with medication that inhibits the signaling capability of the HER-2 receptor protein or otherwise function similarly to trastuzumab. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The present invention also provides kits and sets of probes for use in identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.,MORRISON LARRY E;;JEWELL SUSAN;;COON JOHN S;;ABBOTT LAB;;UNIV RUSH MEDICAL CENTER,MORRISON LARRY E;;JEWELL SUSAN;;COON JOHN S,RUSH UNIVERSITY MEDICAL CENTER (2011-10-31);;ABBOTT MOLECULAR INC (2014-04-01);;ABBOTT LABORATORIES (2014-03-01),https://lens.org/010-491-066-870-933,Granted Patent,yes,5,0,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68,435/6,33,25,000-722-768-094-935;;032-665-931-215-809;;028-871-509-142-475;;104-088-379-500-616;;034-134-907-055-024;;002-901-080-021-582;;036-294-839-691-525;;086-617-534-349-291;;016-023-356-720-504;;080-122-586-951-273;;000-032-742-203-955;;024-952-714-664-810;;130-623-311-554-41X;;000-032-742-203-955;;024-952-714-664-810;;154-845-772-305-218;;036-562-524-563-754;;040-517-417-313-268;;049-825-053-633-341;;056-569-518-373-45X;;051-282-562-348-139;;067-136-737-652-171;;077-631-062-384-957;;020-305-957-911-744;;016-541-812-854-101,10.1023/a:1023077507295;;12755489;;10.1046/j.0956-5507.2003.00088.x;;14632728;;10.1200/jco.20.3.719;;11821453;;10.1200/jco.2002.20.3.719;;10.2174/138620703106298635;;12871052;;1563002;;10.1038/sj.clpt.6100160;;17392727;;10.1038/ncponc0509;;16683005;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;16896006;;10.1200/jco.2005.05.4221;;10.1158/1078-0432.ccr-07-0460;;17947484;;11248153;;10.1056/nejm200103153441101;;12973420;;10.3816/cbc.2000.s.012;;11970752;;11248153;;10.1056/nejm200103153441101;;12973420;;10.1023/a:1021874224490;;12602919;;17100565;;10.2174/156800906778742497;;12006526;;16682721;;10.1200/jco.2006.05.9113;;12628842;;10.1016/s0959-8049(02)00745-1;;10.1016/j.ejca.2006.06.013;;16935488;;10.1200/jco.2005.11.007;;16234514;;15762277;;10.1309/p3chdx9ly6h2ly0g;;11956098;;15665275,"Järvinen and Liu (Breast Cancer Research and Treatment, 2003, 78:299-311).;;Bofin et al (Cytopathology, 2003, 14:314-319).;;Vysis LSI® TOP2A/CEP® 17 Probe Mixture product description, 2 pages.;;Vogel et al (J of Clinical Oncology, 2002, 20:719-726).;;Jarvinen and Liu (Combinatorial Chemistry & High Throughput Screening, 2003, 6:455-470).;;Abbott Molecular PathVysion® Product Description for HER-2 DNA Probe Kit, 6 pages.;;Tockman et al (Cancer Res., 1992, 52:2711s-2718s).;;Feldman et al (Clinical Pharmacology & Therapeutics, 2007, 81:887-892).;;Nahta et al (Nature Clinical Practice Oncology, May 2006, 3:269-280).;;Stancovski et al (PNAS 1991, 88:8691-8695).;;Gordon et al (J Clinical Oncology, 2006, 24:4324-4332).;;Herbst et al (Clinical Cancer Research 2007, 13:6175-6181).;;Slamon D.J. et al.: ""Use of Chemotherapy Plus a Monoclonal Antibody Against Her2 for Metastatic Breast Cancer that Overexpresses Her2"", New England Journal of Medicine, The Massachusetts Medical Society, Waltham, MA, US, vol. 344, No. 11, Mar. 15, 2001, pp. 783-792.;;Albanell J. et al.: ""Tratuzumab, A Humanized Anti-Her2 Monoclonal Antibody, for the Treatment of Breast Cancer"" Drugs of Today/Medicamentos De Actualidad, J.R. Prous SS.A. International Publishers, ES, vol. 35, No. 12, 1999, pp. 931-946.;;Levine M.: ""Epirubicin in Breast Cancer: Present and Future"", Clinical Breast Cancer, vol. 1, No. Suppl 1, Sep. 2000, pp. S62-S67.;;Slamon, DJ, Use of Chemotherapy Plus a Monoclonal Antibody Against Her2 for Metastatic Breast Cancer That Overexpresses Her2, 2001, New England Journal of Medicine, vol. 344, No. 11, Mar. 15, 2001, pp. 783-792.;;Albanell, J, Tratuzumab, A Humanized Anti-Her2 Monoclonal Antibody for the Treatment of Breast Cancer, 1999, Drugs of Today/ Medicamentos De Actualidad, vol. 35, No. 12, 1999, pp. 931-946.;;Levine, M, Epirubicin in Breast Cancer: Present and Future, Clinical Breast Cancer, vol. 1, No. Suppl 1, Sep. 2000, pp. S62-S67.;;V. Durbecq et al., Breast Cancer Research and Treatment, 77: 199-204 (2003).;;Tero A.H. Jarvinen et al., Current Cancer Drug Targets, 6, 579-602 (2006).;;Angelo Di Leo et al., Clinical Cancer Research, vol. 8, 1107-1116 (May 2002).;;Aman U. Buzdar, et al., Journal of Clinical Oncology, vol. 24, No. 16, 2409-2411 (Jun. 1, 2006).;;K. Park et al., European Journal of Cancer 39, 631-634 (2003).;;Edurne Arriola et al., European Journal of Cancer 42, 2954-2960 (2006).;;Ann S. Knoop et al., Journal of Clinical Oncology, vol. 23, No. 30, 7483-7490 (Oct. 20, 2005).;;Minna Tanner, et al., Journal of Clinical Oncology, vol. 24, No. 16 (Jun. 1, 2006).;;Jules Bordet Institute et al., Clinicaltrials.Gov, Identifier: NCT00162812 (Sep. 2005).;;""Human Genome U95 Set"", Internet Citation, Oct. 2, 2001, URL:http://www.affymetrix.com (1 page).;;""Genechip Human Genome U133 Set"", Internet Citation, Feb. 26, 2003, URL:http://affymetrix.com/support/techincal/batasheets/hgu133-datasheet.pdf (2 pages).;;Constantine L et al: ""Use of GeneChip high-density oligonucleotide arrays for gene monitoring"", Life Science News, Amersham Life Science, US, Jan. 1, 1998 pp. 11-14, XP002964122, ISSN: 0969-0190 (4 pages).;;Hansel, et al., ""A Subset of Pancreatic Adenocarcinomas Demonstrates Coamplification of Topoisomerase IIx and HER2/neu-Use of Immunolabeling and Multicolor FISH for Potential Patient Screening and Treatment"", American Society for Clinical Pathology, 2005, pp. 28-35 (8 pages).;;Heselmeyer-Haddad, et al., ""Detection of Chromosomal Aneuploidies and Gene Copy Number Changes in Fine Needle Aspirates is a Specific, Sensitive, and Objective Genetic Test for the Diagnosis of Breast Cancer"", American Association for Cancer Research, 2002, pp. 2365-2369 (5 pages).;;Chu, et al., ""The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer"", American Association for Cancer Research, 2005, Cover page with pp. 18-25 (9 pages).",ACTIVE
163,GB,B,GB 2427981 B,022-719-946-896-545,2007-09-26,2007,GB 0513533 A,2005-07-01,GB 0513533 A,2005-07-01,Wireless communications system,,TOSHIBA RES EUROP LTD,HAINES RUSSELL JOHN;;LEWIS TIMOTHY ADRIAN;;COON JUSTIN,,https://lens.org/022-719-946-896-545,Granted Patent,no,2,0,3,3,0,H04J3/1682;;H04W74/02;;H04W28/06;;H04W84/12,H04J3/16;;H04L12/28;;H04L12/56,,0,0,,,,INACTIVE
164,US,A1,US 2020/0116384 A1,027-256-559-815-120,2020-04-16,2020,US 201916715265 A,2019-12-16,US 201916715265 A;;US 201715817428 A;;US 201662425297 P,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,MESTEK MACHINERY INC (2017-12-07),https://lens.org/027-256-559-815-120,Patent Application,yes,0,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,F24F13/02;;B21D51/06;;B23K10/00,,0,0,,,,PENDING
165,EP,A1,EP 1856292 A1,109-917-675-654-924,2007-11-21,2007,EP 06737407 A,2006-03-08,US 2006/0008231 W;;US 65996105 P,2005-03-09,DIAGNOSTIC METHODS FOR IDENTIFYING CANDIDATE PATIENTS FOR THE TREATMENT WITH TRASTUZUMAB.,,ABBOTT LAB;;RUSH PRESBYTERIAN ST LUKE,MORRISON LARRY E;;JEWELL SUSAN S;;COON JOHN S,"ABBOTT MOLECULAR INC. (2014-09-03);;ABBOTT MOLECULAR INC., DES PLAINES, US (2013-10-31)",https://lens.org/109-917-675-654-924,Patent Application,yes,0,0,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68,,0,0,,,,ACTIVE
166,EP,A1,EP 1169148 A1,142-966-198-547-495,2002-01-09,2002,EP 00926862 A,2000-04-07,EP 0003196 W;;US 28992799 A,1999-04-09,PROCESS FOR THE MANUFACTURE OF A CYLINDRICAL PIPE,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS,,https://lens.org/142-966-198-547-495,Patent Application,yes,0,0,6,6,0,B21C37/08;;B21C37/0803;;E21B17/20;;E21B19/22;;E21B43/103,B21C37/08;;E21B17/20;;E21B19/22;;E21B43/10,,1,0,,,See references of WO 0061310A1,DISCONTINUED
167,TW,A,TW 200639132 A,175-203-602-577-189,2006-11-16,2006,TW 94141777 A,2005-11-28,US 707504 A,2004-12-07,Apparatus and method for making fibers,"To provide an improved apparatus and method for making fibers from a thermoplastic material. A duct assembly is employed for directing a central air flow upwardly toward the rotating spinner assembly of a rotary-type fiberizer that produces a downwardly flowing column of fibers. The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flow. In another embodiment, a conduit extends through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly into the interior of the fiber column.",EVANITE FIBER CORP,WINDISCH JOHN;;SVOBODA PATRICK;;REHER RON;;COON LARRY K,,https://lens.org/175-203-602-577-189,Patent of Addition,no,0,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04,,0,0,,,,PENDING
168,GB,A,GB 2486132 A,001-665-713-006-801,2012-06-06,2012,GB 201204964 A,2010-09-23,US 24522209 P;;US 24604009 P;;US 88840910 A;;US 2010/0049978 W,2009-09-23,Instructions for managing a parallel cache hierarchy,"A method for managing a parallel cache hierarchy in a processing unit. The method includes receiving an instruction from a scheduler unit, where the instruction comprises a load instruction or a store instruction; determining that the instruction includes a cache operations modifier that identifies a policy for caching data associated with the instruction at one or more levels of the parallel cache hierarchy; and executing the instruction and caching the data associated with the instruction based on the cache operations modifier.",NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,,https://lens.org/001-665-713-006-801,Patent Application,no,6,0,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F12/12;;G06F12/08,,0,0,,,,DISCONTINUED
169,US,A1,US 2006/0117803 A1,033-150-858-867-598,2006-06-08,2006,US 707504 A,2004-12-07,US 707504 A,2004-12-07,Apparatus and method for making fibers,"A duct assembly is employed for directing a central air flow upwardly toward the rotating spinner assembly of a rotary-type fiberizer that produces a downwardly flowing column of fibers. The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flow. In another embodiment, a conduit extends through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly within the interior of the fiber column.",EVANITE FIBER CORP,WINDISCH JOHN;;SVOBODA PATRICK;;REHER RON;;COON LARRY K,HOLLINGSWORTH & VOSE FIBER COMPANY (2004-12-06),https://lens.org/033-150-858-867-598,Patent Application,yes,9,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04,65/522,0,0,,,,ACTIVE
170,ID,A,ID 29767 A,058-651-004-562-339,2001-10-11,2001,ID 20011822 A,2000-02-24,US 12145299 P,1999-02-24,PENGISOLASIAN ZONA SELEKTIF DIDALAM SULUR BERALUR,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;NAZZAL GREGORY RICHARD,,https://lens.org/058-651-004-562-339,Patent Application,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,PENDING
171,CA,A,CA 1273074 A,124-630-912-440-125,1990-08-21,1990,CA 527015 A,1987-01-09,CA 527015 A,1987-01-09,"RIBBON CABLE, TRANSPOSED RIBBON CABLE AND METHOD AND APPARATUS FOR MAKING THE SAME AND AN ELECTROMAGNETIC DEVICE","RIBBON CABLE, TRANSPOSED RIBBON CABLE AND METHOD AND APPARATUS FOR MAKING THE SAME AND AN ELECTROMAGNETIC DEVICE An improved ribbon cable comprising a plurality of insulated wires in a fixed relationship to each other. The conductors have axes in a common plane, and extend the full length of the cable. The conductors may be bonded to a ribbon of flexible insulation material in a spaced apart relation with the longitudinal axes of the ribbon material and the conductors generally parallel to each other. The conductors may be juxtaposed in a fixed relationship. The improved transposed cable has the conductors of the cable in the form of a continuous helix. The method and apparatus for manufacturing both the ribbon cable and the transposed cable by folding the ribbon cable angularly with respect to the longitudinal axis repeatedly while advancing the ribbon cable incrementally.",PHELPS DODGE IND INC,KAUFFMAN JOHN C;;WESTENFELD RICHARD A;;COON JESSIE H,,https://lens.org/124-630-912-440-125,Granted Patent,no,0,0,1,1,0,H02K2203/15,H01B7/08;;H01B7/30,337-76,0,0,,,,EXPIRED
172,CA,A1,CA 2986523 A1,150-797-544-604-380,2018-05-22,2018,CA 2986523 A,2017-11-21,US 201662425297 P,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/150-797-544-604-380,Patent Application,no,0,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B21D51/06;;B23K10/00,,0,0,,,,ACTIVE
173,DE,T5,DE 112010003758 T5,179-337-638-116-762,2012-10-25,2012,DE 112010003758 T,2010-09-23,US 24522209 P;;US 24604009 P;;US 88840910 A;;US 2010/0049978 W,2009-09-23,Instruktionen zum Verwalten einer parallelen Cache-Hierarchie,"Ein Verfahren zum Verwalten einer parallelen Cache-Hierarchie in einer Prozessiereinheit. Das Verfahren enthält ein Empfangen einer Instruktion von einer Scheduler-Einheit, wobei die Instruktion eine Lade-Instruktion oder eine Speicher-Instruktion aufweist, Bestimmen, dass die Instruktion einen Cache-Operations-Modifizierer enthält, welcher eine Strategie zum Cachen von Daten, die mit der Instruktion assoziiert sind, auf einem oder mehreren Niveaus der parallelen Cache-Hierarchie identifiziert; und Ausführen der Instruktionen und Cachen der Daten, die mit der Instruktion assoziiert sind, basierend auf dem Cache-Operations-Modifizierer.",NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,,https://lens.org/179-337-638-116-762,Patent Application,no,0,0,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F9/30,,0,0,,,,PENDING
174,US,B2,US 7481076 B2,101-995-705-916-458,2009-01-27,2009,US 707504 A,2004-12-07,US 707504 A,2004-12-07,Apparatus for making fibers,"A duct assembly is employed for directing a central air flow upwardly toward the rotating spinner assembly of a rotary-type fiberizer that produces a downwardly flowing column of fibers. The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flow. In another embodiment, a conduit extends through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly within the interior of the fiber column.",EVANITE FIBER CORP,WINDISCH JOHN;;SVOBODA PATRICK;;REHER RON;;COON LARRY K,HOLLINGSWORTH & VOSE FIBER COMPANY (2004-12-06),https://lens.org/101-995-705-916-458,Granted Patent,yes,26,14,11,11,0,C03B37/048;;C03B37/048,C03B37/04,65/516;;65/517;;65/522;;425/8,3,0,,,"European Search Report for corresponding European Application No. 5257254.;;Drawing of Spinner Shield Assembly (prior to Dec. 7, 2003).;;Document titled ""Evanite Fiber Corporation Glass Fiber Plant Line 2 Production Alert"" (not published, dated May 12, 2003) regarding ductwork for a fiberizer for making glass fibers.",ACTIVE
175,NO,D0,NO 20014038 D0,175-303-533-709-456,2001-08-20,2001,NO 20014038 A,2001-08-20,US 12145299 P;;US 0004683 W,1999-02-24,Selektiv soneisolasjon i en slisset foring,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;NAZZAL GREGORY RICHARD,,https://lens.org/175-303-533-709-456,Patent Application,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
176,AU,A1,AU 2017/265033 A1,171-634-914-441-706,2018-06-07,2018,AU 2017/265033 A,2017-11-21,US 201662425297 P,2016-11-22,Method and apparatus for manipulating metal workpieces,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section. K-zn C (C (Ni",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/171-634-914-441-706,Patent Application,no,0,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00,,0,0,,,,ACTIVE
177,KR,A,KR 20210008949 A,000-350-322-370-419,2021-01-25,2021,KR 20217001604 A,2017-11-20,US 201662425297 P;;KR 20197014061 A;;US 2017/0062470 W,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"웨브 재료로부터 덕트 섹션을 형성하는 방법은: 웨브 재료에 일련의 천공들을 형성하는 단계로서, 일련의 천공들은 마감된 덕트 섹션에 홀이나 노치 중 한가지의 윤곽을 정의하는, 단계; 웨브 재료의 마주보는 제 1 엣지들에 수형 락 벤드와 암형 락 시임을 형성하는 단계; 웨브 재료의 마주보는 제 2 엣지들에 플랜지들을 형성하는 단계; 홀이나 노치를 형성하기 위해서 일련의 천공들의 내부에 있는 재료의 일부를 제거하는 단계; 및 마감된 덕트 섹션을 형성하기 위해서 웨브 재료를 구부리는 단계;를 포함한다.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/000-350-322-370-419,Patent Application,no,1,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00;;B21D51/06;;F24F13/02,,0,0,,,,ACTIVE
178,WO,A1,WO 2018/098057 A1,060-759-095-756-345,2018-05-31,2018,US 2017/0062470 W,2017-11-20,US 201662425297 P,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/060-759-095-756-345,Patent Application,yes,4,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B26D5/00;;B26F1/28;;B26D7/00;;B26D7/20;;B26F1/00;;B26F1/26;;B26F1/38,,0,0,,,,PENDING
179,CA,C,CA 2810777 C,098-950-465-513-741,2018-12-04,2018,CA 2810777 A,2011-09-23,US 38588910 P;;US 201161537403 P;;CA 2011001066 W,2010-09-23,APPARATUS AND METHOD FOR FLUID TREATMENT OF A WELL,A wellbore fluid treatment apparatus includes a tubing string including a first port with a first closure disposed thereover to close the first port to fluid flow and a second port spaced axially uphole from the first port and having a second closure disposed thereover to close the second port to fluid flow; and an actuator tool configured to move through the tubing string and (i) to set a seal in the tubing string downhole of the first port; (ii) to actuate the first closure to open the first port; and (iii) to actuate the second closure to open the second port. A method for treating a well may employ the tool.,PACKERS PLUS ENERGY SERV INC,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE,,https://lens.org/098-950-465-513-741,Granted Patent,no,0,0,6,6,0,E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066;;E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066,E21B34/14;;E21B43/14;;E21B43/26,,0,0,,,,INACTIVE
180,WO,A1,WO 2000/061310 A1,105-506-988-051-479,2000-10-19,2000,EP 0003196 W,2000-04-07,US 28992799 A,1999-04-09,PROCESS FOR THE MANUFACTURE OF A CYLINDRICAL PIPE,"A process is disclosed for the manufacture of a substantially cylindrical pipe at a workshop on site for use in a hole or tube, in which a flat metal stock, coiled on a reel, is unreeled, the unreeled flat metal stock is formed to a substantially round pipe shape with a seam which runs parallel to the axis of the pipe, the seam is closed and bonded, and the produced substantially cylindrical pipe is run into the hole or tube.",SHELL INT RESEARCH;;COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS,,https://lens.org/105-506-988-051-479,Patent Application,yes,8,9,6,6,0,B21C37/08;;B21C37/0803;;E21B17/20;;E21B19/22;;E21B43/103,B21C37/08;;E21B17/20;;E21B19/22;;E21B43/10,,0,0,,,,PENDING
181,US,B1,US 6253850 B1,159-012-141-308-768,2001-07-03,2001,US 51089500 A,2000-02-23,US 51089500 A;;US 12145299 P,1999-02-24,Selective zonal isolation within a slotted liner,"Selective isolation of a zone within a slotted liner completion of a wellbore is accomplished by expanding the original slotted liner to the full inner diameter of the wellbore into the annular area normally found around slotted liners. At least one solid tubular is run into the expanded area of the slotted liner and expanded at least in that section of the wellbore to be isolated. A custom expandable slotted liner can be run and expanded within the existing expanded slotted liner if excessive splits or rips should occur in the existing slotted liner due to expansion. Epoxies, rubber, or other sealing materials can also be utilized to better effect a seal between the liners.",SHELL OIL CO,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,SHELL OIL COMPANY (2001-08-17),https://lens.org/159-012-141-308-768,Granted Patent,yes,14,118,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,166/277;;166/207;;166/212;;166/387,0,0,,,,EXPIRED
182,WO,A1,WO 2011/038106 A1,158-947-243-624-451,2011-03-31,2011,US 2010/0049978 W,2010-09-23,US 24522209 P;;US 24604009 P;;US 88840910 A,2009-09-23,INSTRUCTIONS FOR MANAGING A PARALLEL CACHE HIERARCHY,"A method for managing a parallel cache hierarchy in a processing unit. The method includes receiving an instruction from a scheduler unit, where the instruction comprises a load instruction or a store instruction; determining that the instruction includes a cache operations modifier that identifies a policy for caching data associated with the instruction at one or more levels of the parallel cache hierarchy; and executing the instruction and caching the data associated with the instruction based on the cache operations modifier.",NVIDIA CORP;;NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,,https://lens.org/158-947-243-624-451,Patent Application,yes,6,0,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F9/30,,0,0,,,,PENDING
183,CA,A1,CA 2369266 A1,000-239-808-032-270,2000-10-19,2000,CA 2369266 A,2000-04-07,EP 0003196 W;;US 28992799 A,1999-04-09,PROCESS FOR THE MANUFACTURE OF A CYLINDRICAL PIPE,"A process is disclosed for the manufacture of a substantially cylindrical pi pe at a workshop on site for use in a hole or tube, in which a flat metal stock , coiled on a reel, is unreeled, the unreeled flat metal stock is formed to a substantially round pipe shape with a seam which runs parallel to the axis o f the pipe, the seam is closed and bonded, and the produced substantially cylindrical pipe is run into the hole or tube.",SHELL INT RESEARCH,LOHBECK WILHELMUS CHRISTIANUS;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/000-239-808-032-270,Patent Application,no,0,0,6,6,0,B21C37/08;;B21C37/0803;;E21B17/20;;E21B19/22;;E21B43/103,B21C37/08;;E21B17/20;;E21B19/22;;E21B43/10,,0,0,,,,DISCONTINUED
184,US,A1,US 2017/0235581 A1,011-420-557-072-029,2017-08-17,2017,US 201715583258 A,2017-05-01,US 201715583258 A;;US 88840910 A;;US 24522209 P;;US 24604009 P,2009-09-23,INSTRUCTIONS FOR MANAGING A PARALLEL CACHE HIERARCHY,"A technique for managing a parallel cache hierarchy that includes receiving an instruction from a scheduler unit, where the instruction comprises a load instruction or a store instruction; determining that the instruction includes a cache operations modifier that identifies a policy for caching data associated with the instruction at one or more levels of the parallel cache hierarchy; and executing the instruction and caching the data associated with the instruction based on the cache operations modifier.",NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,NVIDIA CORPORATION (2010-09-24),https://lens.org/011-420-557-072-029,Patent Application,yes,5,22,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F9/38;;G06F9/30;;G06F12/0875;;G06F12/0897,,0,0,,,,ACTIVE
185,WO,A1,WO 2000/050733 A1,076-818-975-579-12X,2000-08-31,2000,US 0004684 W,2000-02-24,US 12145199 P,1999-02-24,INTERNAL JUNCTION REINFORCEMENT,"An internal junction stabilizer is formed with an outer dimension less than the internal bore of a junction to be strengthened. The stabilizer is inserted into the junction, and expanded into tight fit. Multiple stabilizers may be expanded one inside another to form a laminate for reinforcement in high pressure applications. Each layer of metal expanded to the next outermost section provides an additive effective on the mechanical properties of the junction. Expansion can be performed in a number of ways, including mechanical, hydraulic, explosive methods. Use of directional or selective swaging can be used to further effect a fit. Further embodiments of the invention include the use of sealing compounds, elastomers, and plastics to effect a hydraulic seal and fill gaps for strength purposes.",SHELL OIL CO,NAZZAI GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/076-818-975-579-12X,Patent Application,yes,10,18,3,3,0,E21B17/00;;E21B41/0042;;E21B43/103;;F16L55/179;;E21B41/0042;;F16L55/179;;E21B17/00;;E21B43/103,E21B17/00;;E21B41/00;;E21B43/10;;F16L55/179,,0,0,,,,PENDING
186,WO,A1,WO 2006/098978 A1,058-574-552-632-039,2006-09-21,2006,US 2006/0008231 W,2006-03-08,US 65996105 P,2005-03-09,DIAGNOSTICS METHOD FOR IDENTIFYING CANDIDATE PATIENTS FOR THE TREATMENT WITH TRASTUZUMAB,The present invention provides methods for identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab. The invention is based on the discovery that certain chromosomal abnormalities can be used to selectively identify cancer patients that are likely to be successfully treated with medication that inhibits the signaling capability of the HER-2 receptor protein or otherwise function similarly to trastuzumab. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The present invention also provides kits and sets of probes for use in identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.,ABBOTT LAB;;RUSH PRESBYTERIAN ST LUKE;;MORRISON LARRY E;;JEWELL SUSAN S;;COON JOHN S,MORRISON LARRY E;;JEWELL SUSAN S;;COON JOHN S,,https://lens.org/058-574-552-632-039,Patent Application,yes,9,34,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68,,10,9,000-032-742-203-955;;024-952-714-664-810;;130-623-311-554-41X;;041-309-424-116-14X;;043-185-153-369-364;;027-151-749-867-166;;021-389-101-611-119;;092-015-778-795-49X;;067-720-820-355-779,11248153;;10.1056/nejm200103153441101;;12973420;;10.3816/cbc.2000.s.012;;11970752;;10.3109/10520299809140502;;9554580;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;10.1097/01.pai.0000158400.58030.c4;;16280662;;10.1093/clinchem/47.5.844;;11325887;;7514954;;10.1002/1097-0142(19940601)73:11<2771::aid-cncr2820731120>3.0.co;2-k;;11293897;;10.1309/vp4w-5c55-7m09-6tx3,"SLAMON D.J. ET AL.: ""USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2"", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 344, no. 11, 15 March 2001 (2001-03-15), pages 783 - 792, XP008019806, ISSN: 0028-4793;;ALBANELL J. ET AL.: ""TRATUZUMAB, A HUMANIZED ANTI-HER2 MONOCLONAL ANTIBODY, FOR THE TREATMENT OF BREAST CANCER"", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 35, no. 12, 1999, pages 931 - 946, XP000916613, ISSN: 0025-7656;;LEVINE M.: ""EPIRUBICIN IN BREAST CANCER: PRESENT AND FUTURE"", CLINICAL BREAST CANCER, vol. 1, no. SUPPL 1, September 2000 (2000-09-01), pages S62 - S67, XP008019803, ISSN: 1526-8209;;NATH ET AL., BIOTECHNIC HISTOCHEM, vol. 73, no. 1, 1998, pages 6 - 22;;WHEELESS ET AL., CYTOMETRY, vol. 17, 1994, pages 319 - 327;;L. MORRISON: ""Molecular Cytogenetics: Protocols and Applications"", 2002, HUMANA PRESS, article ""Labeling Fluorescence In Situ Hybridization Probes for Genomic Targets"", pages: 21 - 40;;WILLMORE ET AL., APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY, vol. 13, no. 4, 2005, pages 333 - 341;;LYON ET AL., CLINICAL CHEMISTRY, vol. 47, no. 5, 2001, pages 844 - 851;;LI ET AL., CLINICAL CHEMISTRY, vol. 73, no. 11, 1994, pages 2771 - 2778;;O'MALLEY ET AL., AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 115, no. 4, 2001, pages 504 - 511",PENDING
187,KR,A,KR 20190070947 A,025-096-561-705-075,2019-06-21,2019,KR 20197014061 A,2017-11-20,US 201662425297 P;;US 2017/0062470 W,2016-11-22,금속 작업부재를 조작하기 위한 방법 및 장비,"웨브 재료로부터 덕트 섹션을 형성하는 방법은: 웨브 재료에 일련의 천공들을 형성하는 단계로서, 일련의 천공들은 마감된 덕트 섹션에 홀이나 노치 중 한가지의 윤곽을 정의하는, 단계; 웨브 재료의 마주보는 제 1 엣지들에 수형 락 벤드와 암형 락 시임을 형성하는 단계; 웨브 재료의 마주보는 제 2 엣지들에 플랜지들을 형성하는 단계; 홀이나 노치를 형성하기 위해서 일련의 천공들의 내부에 있는 재료의 일부를 제거하는 단계; 및 마감된 덕트 섹션을 형성하기 위해서 웨브 재료를 구부리는 단계;를 포함한다.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/025-096-561-705-075,Patent Application,no,2,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00;;B21D51/06;;F24F13/02,,0,0,,,,ACTIVE
188,US,B2,US 10955166 B2,041-315-690-478-11X,2021-03-23,2021,US 201715817428 A,2017-11-20,US 201715817428 A;;US 201662425297 P,2016-11-22,Method and apparatus for manipulating metal workpieces,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,MESTEK MACHINERY INC (2017-12-07),https://lens.org/041-315-690-478-11X,Granted Patent,yes,11,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00;;B21D51/06;;F24F13/02,,2,0,,,"European Search Report dated Apr. 19, 2018.;;International Search Report and Written Opinion dated Feb. 1, 2018 issued in the corresponding PCT Patent Application No. PCT/US2017/062470.",ACTIVE
189,US,B1,US 7542043 B1,062-062-158-796-751,2009-06-02,2009,US 13634605 A,2005-05-23,US 13634605 A,2005-05-23,Subdividing a shader program,"Methods and apparatus for subdividing a shader program into regions or “phases” of instructions identifiable by phase identifiers (IDs) inserted into the shader program are provided. The phase IDs may be used to constrain execution of the shader program to prohibit texture fetches in later phases from being executed before a texture fetch in a current phase has completed. Other operations (e.g., math operations) within the current phase, however, may be allowed to execute while waiting for the current phase texture fetch to complete.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;TAROLLI GARY M,NVIDIA CORPORATION (2005-05-18),https://lens.org/062-062-158-796-751,Granted Patent,yes,5,22,2,2,0,G06F8/4442;;G06F9/3834;;G06F9/3851;;G06F9/3885;;G06T1/60;;G06T1/60;;G06F9/3851;;G06F8/4442;;G06F9/3834;;G06F9/3885,G06T1/20,345/506;;345/501;;345/505;;345/552;;345/557;;345/582,0,0,,,,ACTIVE
190,US,A1,US 2021/0062599 A1,066-143-965-856-896,2021-03-04,2021,US 202017003275 A,2020-08-26,US 202017003275 A;;US 201962891492 P,2019-08-26,Frac Plug with Integral Setting Tool,"A system combining a setting tool and a frac plug into one assembly thus producing a much shorter and more reliable assembly. More specifically, a downhole assembly comprising a plug section, which itself comprises a top sub, a bottom sub, a slip, and an elastomeric element. The downhole assembly further comprises a power section comprising a body comprising a power charge and one or more ignitors, a firing head, a shearing pin, and a setting tool piston. Additionally, the downhole assembly comprises a check valve, wherein the check valve is positioned downhole from the power charge and inside the setting tool piston; a mandrel comprising a hydraulic chamber and a ball, wherein the mandrel is positioned inside and adjacent to the setting tool piston and the top sub; and a dog.",PETROQUIP ENERGY SERVICES LLC,COON ROBERT JOE;;SMITH RODDIE R;;EMERSON JOHN LEE,PETROQUIP ENERGY SERVICES LLC (2020-11-30),https://lens.org/066-143-965-856-896,Patent Application,yes,0,3,2,2,0,E21B23/065;;E21B34/142;;E21B23/0414;;E21B23/0414;;E21B23/0415;;E21B23/042;;E21B23/065;;E21B33/1291;;E21B34/142,E21B23/06;;E21B23/04;;E21B34/14,,0,0,,,,ACTIVE
191,JP,A,JP 2013046620 A,094-079-928-308-577,2013-03-07,2013,JP 2012220059 A,2012-10-02,US 65996105 P,2005-03-09,DIAGNOSTICS METHOD FOR IDENTIFYING CANDIDATE PATIENT FOR TREATMENT WITH TRASTUZUMAB,PROBLEM TO BE SOLVED: To provide a method for identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.SOLUTION: Certain chromosomal abnormalities can be used to selectively identify cancer patients that are likely to be successfully treated with medication that inhibits the signaling capability of the HER-2 receptor protein or otherwise function similarly to trastuzumab. Nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. There are also provided kits and sets of probes for use in identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.,ABBOTT LAB;;RUSH PRESBYTERIAN ST LUKE,MORRISON LARRY E;;JEWELL SUSAN S;;COON JOHN S,,https://lens.org/094-079-928-308-577,Patent Application,no,0,0,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68;;C12N15/09,,4,0,,,"JPN6012017602; Ａｍ． Ｊ． Ｏｂｓｔ． Ｃｙｎｅｃｏｌ． Ｖｏｌ．１９１, 2004, ｐ．１１７３-１１８２;;JPN6012017603; Ｃａｎ． Ｇｅｎｅｔ． Ｃｙｔｏｇｅｎ． Ｖｏｌ．１５５, 2004, ｐ．１０８-１１８;;JPN6012017604; Ｊ． Ｐａｔｈｏｌ． Ｖｏｌ．２０１, 2003, ｐ．４３９-４５０;;JPN6012017605; Ｂｒａｉｎ Ｔｕｍｏｒ Ｐａｔｈｏｌ． Ｖｏｌ．２１, 2004, ｐ．２７-３４",INACTIVE
192,BR,A,BR 0008470 A,181-837-606-241-262,2002-02-05,2002,BR 0008470 A,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,"Método para proporcionar isolamento seletivo dentro de uma zona de um poço encamisado com uma camisa fendilhada expandida, e, sistema de isolamento zonal seletivo","""MéTODO PARA PROPORCIONAR ISOLAMENTO SELETIVO DENTRO DE UMA ZONA DE UM POçO ENCAMISADO COM UMA CAMISA FENDILHADA EXPANDIDA, E, SISTEMA DE ISOLAMENTO ZONAL SELETIVO"". Isolamento seletivo de uma zona dentro de uma finalização de camisa fendilhada de um furo de sondagem é obtido expandindo-se a camisa fendilhada original até o diâmetro interno total do furo de sondagem, dentro da área anular normalmente encontrada em torno de camisas fendilhadas. Pelo menos, uma tubulação sólida passa dentro da área expandida da camisa fendilhada, e é expandida, pelo menos, nessa seção do furo de sondagem a ser isolada. Uma camisa fendilhada expansível especial pode ser introduzida e expandida dentro da camisa fendilhada expandida existente, caso venham ocorrer separações, ou rupturas, excessivas na camisa fendilhada existente, em virtude da expansão. Epóxi, borracha, ou outros materiais vedantes podem também ser utilizados para promover uma melhor vedação entre as camisas.",SHELL INT RESEARCH,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/181-837-606-241-262,Patent Application,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
193,NO,L,NO 20014038 L,095-745-583-088-051,2001-08-20,2001,NO 20014038 A,2001-08-20,US 12145299 P;;US 0004683 W,1999-02-24,Selektiv soneisolasjon i en slisset foring,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;NAZZAL GREGORY RICHARD,,https://lens.org/095-745-583-088-051,Abstract,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
194,ES,T3,ES 2441019 T3,089-953-292-856-558,2014-01-31,2014,ES 06737407 T,2006-03-08,US 65996105 P;;US 2006/0008231 W,2005-03-09,Métodos de diagnóstico para identificar pacientes candidatos para el tratamiento con trastuzumab,"Un método para identificar un paciente candidato para tratamiento con medicación que inhibe la capacidad deseñalización de la proteína receptora HER-2, comprendiendo el método: (a) poner en contacto un conjunto de sondas cromosómicas en condiciones suficientes para permitir la hibridaciónde las sondas a cromosomas en una muestra biológica del paciente, donde las sondas son capaces de detectarnúmeros de copias para HER- 2/neu y uno o más de loci genéticos TOP2A, 1q25, PTGS2 y cromosoma en lascélulas y una o más sondas de referencia; y (b) identificar al candidato como adecuado para el tratamiento con medicación que inhibe la capacidad deseñalización de la proteína receptora HER-2 a través de la cuantificación de los números de copias paraHER-2/neu y uno o más de los loci genéticos TOP2A, 1q25, PTGS2 y cromosoma mediante la hibridación conlas sondas.",ABBOTT LAB;;RUSH PRESBYTERIAN ST LUKE,MORRISON LARRY E;;JEWELL SUSAN S;;COON JOHN S,,https://lens.org/089-953-292-856-558,Granted Patent,no,0,0,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68,,0,0,,,,ACTIVE
195,CA,C,CA 2986523 C,197-818-786-964-827,2020-02-18,2020,CA 2986523 A,2017-11-21,US 201662425297 P,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/197-818-786-964-827,Granted Patent,no,0,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B21D51/06;;B23K10/00,,0,0,,,,ACTIVE
196,GB,A,GB 2492324 A,044-235-362-957-110,2013-01-02,2013,GB 201110630 A,2011-06-22,GB 201110630 A,2011-06-22,Using cognitive radio for relaying in a wireless communication network,"A wireless communications system comprising at least one primary communication node P1 operable to relay a signal from a source node S to a destination node D via a primary communication path LSP1, LDP1 over a portion of a physical communication medium, and at least one secondary communication node S1 operable to detect an unused sub-portion of said portion of said physical communication medium, and further operable to relay said signal and/or a further signal between said source node and said destination node via a secondary communication path LSS1, LDS1 over said unused sub-portion of said portion of said physical communication medium. The arrangement uses cognitive radio techniques to utilize unused bandwidth (or â spectrum holesâ ) to either provide diversity (re-transmission of the same information) via a relay route or to provide further complementary information to that transmitted on the primary path via a relay route (secondary path) (i.e. to â enhanceâ the communication via the primary path). The further information could comprise control information, parity or error correction information, channel state information or feedback information and the like. The primary communication node is a licensed node and the secondary communication node is an opportunistic unlicensed node utilising detected unused bandwidth. At least one of the secondary communication nodes may be operable to monitor a channel condition of the primary communication path to determine whether the primary communication paths satisfies a predetermined channel condition and if it fails to do so the secondary node may be further operable to obtain channel information relating to the primary communication path to control the relaying.",TOSHIBA RES EUROP LTD,WANG YUE;;HAINES RUSSELL JOHN;;COON JUSTIN;;HUANG GILLIAN,,https://lens.org/044-235-362-957-110,Patent Application,no,7,0,2,2,0,H04B7/15542;;H04L27/0006;;H04W40/12;;H04W72/541,H04W84/18;;H04L27/00;;H04W28/00;;H04W40/00;;H04W72/00;;H04W88/04,,0,0,,,,DISCONTINUED
197,EP,A1,EP 1155218 A1,053-653-535-691-292,2001-11-21,2001,EP 00914681 A,2000-02-24,US 0004683 W;;US 12145299 P,1999-02-24,SELECTIVE ZONAL ISOLATION WITHIN A SLOTTED LINER,,SHELL INTERNATIONALE RES BR MI,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/053-653-535-691-292,Patent Application,yes,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,1,0,,,See references of WO 0050732A1,EXPIRED
198,US,B2,US 9639479 B2,060-055-473-980-622,2017-05-02,2017,US 88840910 A,2010-09-22,US 88840910 A;;US 24522209 P;;US 24604009 P,2009-09-23,Instructions for managing a parallel cache hierarchy,"A method for managing a parallel cache hierarchy in a processing unit. The method includes receiving an instruction from a scheduler unit, where the instruction comprises a load instruction or a store instruction; determining that the instruction includes a cache operations modifier that identifies a policy for caching data associated with the instruction at one or more levels of the parallel cache hierarchy; and executing the instruction and caching the data associated with the instruction based on the cache operations modifier.",NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C;;NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,NVIDIA CORPORATION (2010-09-24),https://lens.org/060-055-473-980-622,Granted Patent,yes,7,1,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F12/121;;G06F9/30;;G06F12/0811;;G06F12/0862,,6,2,099-679-727-715-249;;011-087-805-183-582,10.1145/1375527.1375572;;10.1007/11859802_7,"International Search Report, PCT Appl. No. PCT/US 10/49978, mailed Jan. 6, 2011.;;Koopman, P.: 18-548/15-548 Memory System Architecture, “4 Cache Organization”, Carnegie Mellon University, ECE Department, Sep. 2, 1998, 8 pages. URL: https://www.ece.cmu.edu/˜ece548/handouts/04cachor.pdf [called up on May 11, 2013].;;Song Ho Ahn,: OpenGL, “OpenGL. Vertex Buffer Object (VBO)”, 2005, pp. 1 to 4. URL: http://www.songho.ca/opengl/gl—vbo.html archived in http://www.archive.org on Jul. 9, 2009 [called up on May 11, 2013].;;Silberstein, M. et al.: “Efficient Computation of Sum-products on GPUs Through Software-Managed Cache”, Proceedings of the 22nd annual international conference on Supercomputing, ICS '08, New York, NY, USA: ACM, 2008, pp. 309 to 318.—ISBN 978-1-60558-158-3, http://doi.acm.org/10.1145/1375527.1375572 [called up on May 11, 2013].;;Fu, Rao et al.: “A Study of the Performance Potential for Dynamic Instruction Hints Selection”, Advances in Computer Systems Architecture, Lecture Notes in Computer Science. Berlin Heidelberg : Springer, 2006, pp. 67 to 80—ISBN 978-3-540-40056-1, http://dx.doi.org/10.1007/11859802—7 [called up on May 11, 2013].;;Tumeo, A.: “Massively Parallel Computing with CUDA”, In: OGF25/EGEE User Forum & OGF Europe's 2nd International Event, 2 to Jun. 3, 2009, pp. 1 to 32. Material for “OGF-EU Community Outreach Seminar: Software development tools for distributed computing”, http://ww.ogf.org/OGF25/materials/1546/CUDA—Programming.pdf [called up on May 11, 2013].",ACTIVE
199,NO,L,NO 20014898 L,146-085-674-940-34X,2001-10-08,2001,NO 20014898 A,2001-10-08,EP 0003196 W;;US 28992799 A,1999-04-09,Fremgangsmåte for fremstilling av et sylindrisk rör,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS,,https://lens.org/146-085-674-940-34X,Abstract,no,0,0,6,6,0,B21C37/08;;B21C37/0803;;E21B17/20;;E21B19/22;;E21B43/103,B21C37/08;;E21B17/20;;E21B19/22;;E21B43/10,,0,0,,,,DISCONTINUED
200,CA,A1,CA 2366863 A1,002-264-861-436-079,2000-08-31,2000,CA 2366863 A,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,SELECTIVE ZONAL ISOLATION WITHIN A SLOTTED LINER,"Selective isolation of a zone within a slotted liner completion of a wellbor e is accomplished by expanding the original slotted liner to the full inner diameter of the wellbore into the annular area normally found around slotted liners. At least one solid tubular is run into the expanded area of the slotted liner and expanded at least in that section of the wellbore to be isolated. A custom expandable slotted liner can be run and expanded within t he existing expanded slotted liner if excessive splits or rips should occur in the existing slotted liner due to expansion. Epoxies, rubber, or other seali ng materials can also be utilized to better effect a seal between the liners.</ SDOAB>",SHELL INT RESEARCH,COON ROBERT JOE;;NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN,,https://lens.org/002-264-861-436-079,Patent Application,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
201,NO,D0,NO 20014898 D0,060-379-438-671-008,2001-10-08,2001,NO 20014898 A,2001-10-08,EP 0003196 W;;US 28992799 A,1999-04-09,Fremgangsmåte for fremstilling av et sylindrisk rör,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS,,https://lens.org/060-379-438-671-008,Patent Application,no,0,0,6,6,0,B21C37/08;;B21C37/0803;;E21B17/20;;E21B19/22;;E21B43/103,B21C37/08;;E21B17/20;;E21B19/22;;E21B43/10,,0,0,,,,DISCONTINUED
202,AU,B2,AU 2017/265033 B2,122-849-289-447-571,2019-07-11,2019,AU 2017/265033 A,2017-11-21,US 201662425297 P,2016-11-22,Method and apparatus for manipulating metal workpieces,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section. K-zn (C (Ni",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/122-849-289-447-571,Granted Patent,no,2,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00,,0,0,,,,ACTIVE
203,DE,B2,DE 2359033 B2,131-990-709-122-642,1981-02-12,1981,DE 2359033 A,1973-11-27,US 30994772 A,1972-11-27,DE 2359033 B2,,"THE CORNELIUS CO., ST. LOUIS PARK, MINN. (V.ST.A.)","HASSELL, DAVID ALLEN, COON RAPIDS;;MCMILLIN, JOHN RICHARD, MAPLEWOOD",,https://lens.org/131-990-709-122-642,Patent Application,no,0,0,9,9,0,F25D31/002;;B67D1/0058;;B01F23/2363;;F25D31/002;;B67D1/0058;;B01F23/2363,B01F1/00;;B01F3/04;;F25D31/00,,0,0,,,,EXPIRED
204,CA,A1,CA 2810777 A1,145-482-663-400-703,2012-03-29,2012,CA 2810777 A,2011-09-23,US 38588910 P;;US 201161537403 P;;CA 2011001066 W,2010-09-23,APPARATUS AND METHOD FOR FLUID TREATMENT OF A WELL,A wellbore fluid treatment apparatus includes a tubing string including a first port with a first closure disposed thereover to close the first port to fluid flow and a second port spaced axially uphole from the first port and having a second closure disposed thereover to close the second port to fluid flow; and an actuator tool configured to move through the tubing string and (i) to set a seal in the tubing string downhole of the first port; (ii) to actuate the first closure to open the first port; and (iii) to actuate the second closure to open the second port. A method for treating a well may employ the tool.,PACKERS PLUS ENERGY SERV INC,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE,,https://lens.org/145-482-663-400-703,Patent Application,no,0,0,6,6,0,E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066;;E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066,E21B34/14;;E21B43/14;;E21B43/26,,0,0,,,,INACTIVE
205,CA,C,CA 2366863 C,196-492-927-421-874,2009-07-28,2009,CA 2366863 A,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,SELECTIVE ZONAL ISOLATION WITHIN A SLOTTED LINER,"Selective isolation of a zone within a slotted liner completion of a wellbore is accomplished by expanding the original slotted liner to the full inner diameter of the wellbore into the annular area normally found around slotted liners. At least one solid tubular is run into the expanded area of the slotted liner and expanded at least in that section of the wellbore to be isolated. A custom expandable slotted liner can be run and expanded within the existing expanded slotted liner if excessive splits or rips should occur in the existing slotted liner due to expansion. Epoxies, rubber, or other sealing materials can also be utilized to better effect a seal between the liners.",SHELL INT RESEARCH,FRANK TIMOTHY JOHN;;NAZZAL GREGORY RICHARD;;COON ROBERT JOE,,https://lens.org/196-492-927-421-874,Granted Patent,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/10;;E21B43/08,,0,0,,,,EXPIRED
206,US,B2,US 9797221 B2,046-724-161-225-722,2017-10-24,2017,US 201113821410 A,2011-09-23,US 201113821410 A;;US 38588910 P;;US 201161537403 P;;CA 2011001066 W,2010-09-23,Apparatus and method for fluid treatment of a well,A wellbore fluid treatment apparatus includes a tubing string including a first port with a first closure disposed thereover to close the first port to fluid flow and a second port spaced axially uphole from the first port and having a second closure disposed thereover to close the second port to fluid flow; and an actuator tool configured to move through the tubing string and (i) to set a seal in the tubing string downhole of the first port; (ii) to actuate the first closure to open the first port; and (iii) to actuate the second closure to open the second port. A method for treating a well may employ the tool.,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE;;PACKERS PLUS ENERGY SERV INC,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE,PACKERS PLUS ENERGY SERVICES INC (2011-02-03),https://lens.org/046-724-161-225-722,Granted Patent,yes,83,0,6,6,0,E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066;;E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066,E21B34/14;;E21B34/00;;E21B43/14;;E21B43/25,,0,0,,,,INACTIVE
207,US,A1,US 2011/0072213 A1,054-861-423-784-016,2011-03-24,2011,US 88840910 A,2010-09-22,US 88840910 A;;US 24522209 P;;US 24604009 P,2009-09-23,INSTRUCTIONS FOR MANAGING A PARALLEL CACHE HIERARCHY,"A method for managing a parallel cache hierarchy in a processing unit. The method includes receiving an instruction from a scheduler unit, where the instruction comprises a load instruction or a store instruction; determining that the instruction includes a cache operations modifier that identifies a policy for caching data associated with the instruction at one or more levels of the parallel cache hierarchy; and executing the instruction and caching the data associated with the instruction based on the cache operations modifier.",NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,NVIDIA CORPORATION (2010-09-24),https://lens.org/054-861-423-784-016,Patent Application,yes,7,23,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F12/00;;G06F12/08,711/122;;X711E12001;;X711E12024,0,0,,,,ACTIVE
208,CA,C,CA 2599445 C,056-650-540-725-632,2022-05-03,2022,CA 2599445 A,2006-03-08,US 65996105 P;;US 2006/0008231 W,2005-03-09,DIAGNOSTICS METHOD FOR IDENTIFYING CANDIDATE PATIENTS FOR THE TREATMENT WITH TRASTUZUMAB,The present invention provides methods for identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab. The invention is based on the discovery that certain chromosomal abnormalities can be used to selectively identify cancer patients that are likely to be successfully treated with medication that inhibits the signaling capability of the HER-2 receptor protein or otherwise function similarly to trastuzumab. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The present invention also provides kits and sets of probes for use in identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.,ABBOTT LAB;;RUSH PRESBYTERIAN ST LUKES MEDICAL CENTER,MORRISON LARRY E;;JEWELL SUSAN S;;COON JOHN S,,https://lens.org/056-650-540-725-632,Granted Patent,no,0,0,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68;;C07K16/28;;C12Q1/6809;;C12Q1/6813;;C12Q1/6876,,0,0,,,,PENDING
209,CA,A1,CA 2599445 A1,073-798-832-312-474,2006-09-21,2006,CA 2599445 A,2006-03-08,US 65996105 P;;US 2006/0008231 W,2005-03-09,DIAGNOSTICS METHOD FOR IDENTIFYING CANDIDATE PATIENTS FOR THE TREATMENT WITH TRASTUZUMAB,,RUSH PRESBYTERIAN ST LUKE;;ABBOTT LAB,JEWELL SUSAN S;;MORRISON LARRY E;;COON JOHN S,,https://lens.org/073-798-832-312-474,Patent Application,no,0,0,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68,,0,0,,,,PENDING
210,EP,A1,EP 3326744 A1,093-015-679-872-88X,2018-05-30,2018,EP 17202787 A,2017-11-21,US 201662425297 P,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations (25) in a web of material, the series of perforations (25) defining an outline of one of a hole (21) or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.
",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/093-015-679-872-88X,Patent Application,yes,2,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00;;F24F13/02,,0,0,,,,PENDING
211,AU,A1,AU 2019/204682 A1,097-805-527-551-632,2019-07-18,2019,AU 2019/204682 A,2019-07-01,AU 2019/204682 A;;AU 2017/265033 A;;US 201662425297 P,2016-11-22,Method and apparatus for manipulating metal workpieces,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section. II /-2",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/097-805-527-551-632,Patent Application,no,0,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00,,0,0,,,,ACTIVE
212,US,B2,US 11015408 B2,113-508-613-969-645,2021-05-25,2021,US 202017003275 A,2020-08-26,US 202017003275 A;;US 201962891492 P,2019-08-26,Frac plug with integral setting tool,"A system combining a setting tool and a frac plug into one assembly thus producing a much shorter and more reliable assembly. More specifically, a downhole assembly comprising a plug section, which itself comprises a top sub, a bottom sub, a slip, and an elastomeric element. The downhole assembly further comprises a power section comprising a body comprising a power charge and one or more ignitors, a firing head, a shearing pin, and a setting tool piston. Additionally, the downhole assembly comprises a check valve, wherein the check valve is positioned downhole from the power charge and inside the setting tool piston; a mandrel comprising a hydraulic chamber and a ball, wherein the mandrel is positioned inside and adjacent to the setting tool piston and the top sub; and a dog.",PETROQUIP ENERGY SERVICES LLC,COON ROBERT JOE;;SMITH RODDIE R;;EMERSON JOHN LEE,PETROQUIP ENERGY SERVICES LLC (2020-11-30),https://lens.org/113-508-613-969-645,Granted Patent,yes,5,0,2,2,0,E21B23/065;;E21B34/142;;E21B23/0414;;E21B23/0414;;E21B23/0415;;E21B23/042;;E21B23/065;;E21B33/1291;;E21B34/142,E21B23/04;;E21B23/06;;E21B34/14,,0,0,,,,ACTIVE
213,US,A1,US 2018/0142916 A1,116-736-700-906-291,2018-05-24,2018,US 201715817428 A,2017-11-20,US 201715817428 A;;US 201662425297 P,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,MESTEK MACHINERY INC (2017-12-07),https://lens.org/116-736-700-906-291,Patent Application,yes,7,1,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,F24F13/02;;B21D51/06;;B23K10/00,,0,0,,,,ACTIVE
214,JP,A,JP 2006160601 A,118-955-855-683-574,2006-06-22,2006,JP 2005345084 A,2005-11-30,US 707504 A,2004-12-07,APPARATUS AND METHOD FOR MAKING FIBER,"<P>PROBLEM TO BE SOLVED: To provide an improved apparatus and method for making fibers from a thermoplastic material. <P>SOLUTION: A duct assembly is employed for directing a central air flow upwardly toward the rotating spinner assembly of a rotary-type fiberizer that produces a downwardly flowing column of fibers. The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flow. In another embodiment, a conduit extends through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly into the interior of the fiber column. <P>COPYRIGHT: (C)2006,JPO&NCIPI",EVANITE FIBER CORP,WINDISCH JOHN;;SVOBODA PATRICK;;REHER RON;;COON LARRY K,,https://lens.org/118-955-855-683-574,Patent Application,no,0,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04;;D01D5/08,,0,0,,,,PENDING
215,CA,A,CA 648746 A,157-272-792-648-174,1962-09-18,1962,CA 648746D A,,CA 648746T A,,LUBRICATING COMPOSITIONS,,SHELL OIL CO,GREER PRATT L;;COON JOHN S;;BERGSTROM ROLAND F,,https://lens.org/157-272-792-648-174,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
216,EP,A1,EP 1669330 A1,031-657-416-949-916,2006-06-14,2006,EP 05257254 A,2005-11-25,US 707504 A,2004-12-07,Apparatus and Method for making fibers,"A duct assembly (50) is employed for directing a central air flow (52) upwardly toward the rotating spinner assembly of a rotary-type fiberizer (12) that produces a downwardly flowing column of fibers (46). The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion (54) of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member (28) can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flow. In another embodiment, a conduit extends from above through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly within the interior of the fiber column.
",EVANITE FIBER CORP,WINDISCH JOHN;;SVOBODA PATRICK;;REHER RON;;COON LARRY K,HOLLINGSWORTH & VOSE FIBER COMPANY (2015-04-01),https://lens.org/031-657-416-949-916,Patent Application,yes,9,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04,,0,0,,,,ACTIVE
217,US,A1,US 2021/0164686 A1,062-050-651-094-552,2021-06-03,2021,US 202117174474 A,2021-02-12,US 202117174474 A;;US 201715817428 A;;US 201662425297 P,2016-11-22,METHOD AND APPARATUS FOR MANIPULATING METAL WORKPIECES,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section.",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,MESTEK MACHINERY INC (2017-12-07),https://lens.org/062-050-651-094-552,Patent Application,yes,7,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,F24F13/02;;B21D51/06;;B23K10/00,,1,0,,,"what-materials-can-a-plasma-cutter-cut, Machitech Automation, pages 1-2 (Year: 2021)",PENDING
218,EP,A1,EP 2619405 A1,071-571-538-406-569,2013-07-31,2013,EP 11826257 A,2011-09-23,US 201161537403 P;;US 38588910 P;;CA 2011001066 W,2010-09-23,APPARATUS AND METHOD FOR FLUID TREATMENT OF A WELL,,PACKERS PLUS ENERGY SERV INC,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE,,https://lens.org/071-571-538-406-569,Patent Application,yes,0,0,6,6,0,E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066;;E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066,E21B34/14;;E21B43/14;;E21B43/26,,0,0,,,,DISCONTINUED
219,NZ,A,NZ 513560 A,121-660-001-143-101,2003-10-31,2003,NZ 51356000 A,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,Selective zonal isolation within a slotted liner,"Selective isolation of a zone within a slotted liner completion of a wellbore is accomplished by expanding the original slotted liner to the full inner diameter of the wellbore into the annular area normally found around slotted liners. At least one solid tubular is run into the expanded area of the slotted liner and expanded at least in that section of the wellbore to be isolated. A custom expandable slotted liner can be run and expanded within the existing expanded slotted liner if excessive splits or rips should occur in the existing slotted liner due to expansion. Epoxies, rubber, or other sealing materials can also be utilized to better effect a seal between the liners.",SHELL INT RESEARCH,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/121-660-001-143-101,Patent Application,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,DISCONTINUED
220,WO,A1,WO 2000/050732 A1,004-360-832-629-886,2000-08-31,2000,US 0004683 W,2000-02-24,US 12145299 P,1999-02-24,SELECTIVE ZONAL ISOLATION WITHIN A SLOTTED LINER,"Selective isolation of a zone within a slotted liner completion of a wellbore is accomplished by expanding the original slotted liner to the full inner diameter of the wellbore into the annular area normally found around slotted liners. At least one solid tubular is run into the expanded area of the slotted liner and expanded at least in that section of the wellbore to be isolated. A custom expandable slotted liner can be run and expanded within the existing expanded slotted liner if excessive splits or rips should occur in the existing slotted liner due to expansion. Epoxies, rubber, or other sealing materials can also be utilized to better effect a seal between the liners.",SHELL OIL CO,NAZZAI GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/004-360-832-629-886,Patent Application,yes,4,23,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,PATENTED
221,AU,B2,AU 757264 B2,017-900-467-085-898,2003-02-13,2003,AU 2000/036038 A,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,Selective zonal isolation within a slotted liner,,SHELL INT RESEARCH,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/017-900-467-085-898,Granted Patent,no,3,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
222,US,B1,US 8159496 B1,001-622-170-473-445,2012-04-17,2012,US 47613709 A,2009-06-01,US 47613709 A;;US 13634605 A,2005-05-23,Subdividing a shader program,"Methods and apparatus for subdividing a shader program into regions or “phases” of instructions identifiable by phase identifiers (IDs) inserted into the shader program are provided. The phase IDs may be used to constrain execution of the shader program to prohibit texture fetches in later phases from being executed before a texture fetch in a current phase has completed. Other operations (e.g., math operations) within the current phase, however, may be allowed to execute while waiting for the current phase texture fetch to complete.",LINDHOLM JOHN ERIK;;COON BRETT W;;TAROLLI GARY M;;NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;TAROLLI GARY M,,https://lens.org/001-622-170-473-445,Granted Patent,yes,3,2,2,2,0,G06F8/4442;;G06F9/3834;;G06F9/3851;;G06F9/3885;;G06T1/60;;G06T1/60;;G06F9/3851;;G06F8/4442;;G06F9/3834;;G06F9/3885,G06T1/20;;G06F15/80;;G06T1/00;;G09G5/00,345/506;;345/501;;345/505;;345/552;;345/557;;345/582,1,1,020-961-679-464-619,10.1109/40.621209,"Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
223,US,B2,US 10365930 B2,014-611-274-690-135,2019-07-30,2019,US 201715583258 A,2017-05-01,US 201715583258 A;;US 88840910 A;;US 24522209 P;;US 24604009 P,2009-09-23,Instructions for managing a parallel cache hierarchy,"A technique for managing a parallel cache hierarchy that includes receiving an instruction from a scheduler unit, where the instruction comprises a load instruction or a store instruction; determining that the instruction includes a cache operations modifier that identifies a policy for caching data associated with the instruction at one or more levels of the parallel cache hierarchy; and executing the instruction and caching the data associated with the instruction based on the cache operations modifier.",NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,NVIDIA CORPORATION (2010-09-24),https://lens.org/014-611-274-690-135,Granted Patent,yes,12,0,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F12/00;;G06F9/30;;G06F9/38;;G06F12/0811;;G06F12/0862;;G06F12/0871;;G06F12/0875;;G06F12/0897;;G06F12/121;;G06F13/00;;G06F13/28,,6,2,099-679-727-715-249;;011-087-805-183-582,10.1145/1375527.1375572;;10.1007/11859802_7,"International Search Report, PCT Appl. No. PCT/US 10/49978, dated Jan. 6, 2011.;;Koopman, P.: 18-548/15-548 Memory System Architecture, “4 Cache Organization”, Carnegie Mellon University, EGE Department, Sep. 2, 1998, 8 pages. URL: hllps://www.ece.cmu.edu/-ece548/handouts/04cachor.pdf [called up on May 11, 2013].;;Song Ho Ahn,: OpenGL, “OpenGL. Vertex Buffer Object (VBO)”, 2005, pp. 1 to 4. URL: http://www.songho.ca/opengl/gl_vbo.html archived in http://www.archive.org on Jul. 9, 2009 [called up on May 11, 2013].;;Silberstein, M. et al: “Efficient Computation of Sum-products on GPUs Through Software-Managed Cache”, Proceedings of the 22nd annual international conference on Supercomputing, ICS '08, New York, NY, USA: ACM, 2008, pp. 309 to 318.—ISBN 978-1-60558-158-3, hllp://doi.acm.org/10.1145/1375527.1375572 [called up on May 11, 2013].;;Fu, Rao et al.: “A Study of the Performance Potential for Dynamic Instruction Hints Selection”, Advances in Computer Systems Architecture, Lecture Notes in Computer Science. Berlin Heidelberg : Springer, 2006, pp. 67 to 80—ISBN 978-3-540-40056-1, http://dx.doi.org/10.1007/11859802_7 [called up on May 11, 2013].;;Tumeo, A.: “Massively Parallel Computing with CUDA”, In: OGF25/EGEE User Forum & OGF Europe's 2nd International Event, 2 to Jun. 3, 2009, pp. 1 to 32. Material for “OGF-EU Community Outreach Seminar: Software development tools for distributed computing”, http://ww.ogf.org/OGF25/materials/1546/CUDA_Programming.pdf [called up on May 11, 2013].",ACTIVE
224,CN,A,CN 102713837 A,040-599-506-238-812,2012-10-03,2012,CN 201080053153 A,2010-09-23,US 2010/0049978 W;;US 24522209 P;;US 24604009 P;;US 88840910 A,2009-09-23,Instructions for managing a parallel cache hierarchy,"A method for managing a parallel cache hierarchy in a processing unit. The method includes receiving an instruction from a scheduler unit, where the instruction comprises a load instruction or a store instruction; determining that the instruction includes a cache operations modifier that identifies a policy for caching data associated with the instruction at one or more levels of the parallel cache hierarchy; and executing the instruction and caching the data associated with the instruction based on the cache operations modifier.",NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;SHEBANOW MICHAEL C,,https://lens.org/040-599-506-238-812,Patent Application,no,5,4,10,10,0,G06F12/0862;;G06F9/30043;;G06F12/121;;G06F12/0888;;G06F12/0802;;G06F12/121;;G06F12/0811;;G06F12/0871;;G06F12/0862;;G06F9/30043;;G06F12/121;;G06F9/3009;;G06F9/3836;;G06F9/3887;;G06F12/0875;;G06F12/0897;;G06F2212/452,G06F9/30,,0,0,,,,ACTIVE
225,EP,B1,EP 1669330 B1,035-247-836-240-958,2017-01-11,2017,EP 05257254 A,2005-11-25,US 707504 A,2004-12-07,Apparatus and Method for making fibers,,HOLLINGSWORTH & VOSE FIBER COMPANY,WINDISCH JOHN;;SVOBODA PATRICK;;REHER RON;;COON LARRY K,HOLLINGSWORTH & VOSE FIBER COMPANY (2015-04-01),https://lens.org/035-247-836-240-958,Granted Patent,yes,9,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04,,0,0,,,,ACTIVE
226,EP,A1,EP 0274173 A1,076-469-159-953-15X,1988-07-13,1988,EP 87300181 A,1987-01-09,EP 87300181 A,1987-01-09,"Ribbon cable, transposed ribbon cable, and method and apparatus for making the same and electromagnetic device.","An improved ribbon cable (410) comprising a plurality of insulated wires (101) in a fixed relationship to each other. The conductors (101) have axes in a common plane, and extend the full length of the cable. The conductors may be bonded to a ribbon of flexible insulation material in a spaced apart relation with the longitudinal axes of the ribbon material and the conductors generally parallel to each other. The conductors (101) may be juxtaposed in a fixed relationship. The improved transposed cable (410) has the conductors (101) of the cable in the form of a continuous helix. The method and apparatus for manufacturing both the ribbon cable (410) and the transposed cable (410) by folding the ribbon cable angularly with respect to the longitudinal axis repeatedly while advancing the ribbon cable (410) incrementally.  ",PHELPS DODGE IND INC,KAUFFMAN JOHN CLYDE;;COON JESSIE HARRIS;;WESTENFELD RICHARD ALAN,,https://lens.org/076-469-159-953-15X,Patent Application,yes,9,5,1,5,0,H01B7/08;;H01B7/0853;;H01B7/306;;H02K3/04;;H02K3/14;;H02K2203/15,H01B7/08;;H01B7/30;;H02K3/04;;H02K3/14,,0,0,,,,DISCONTINUED
227,AU,B2,AU 2019/204682 B2,132-243-047-650-741,2021-06-17,2021,AU 2019/204682 A,2019-07-01,AU 2019/204682 A;;AU 2017/265033 A;;US 201662425297 P,2016-11-22,Method and apparatus for manipulating metal workpieces,"A method of forming a duct section from a web of material includes the steps of forming a series of perforations in a web of material, the series of perforations defining an outline of one of a hole or notch in a finished duct section, forming a male lock bend and a female lock seam in first opposed edges of the web of material, forming flanges in second opposed edges of the web of material, removing the portion of material interior to the series of perforations to form the hole or notch, and bending the web of material to form the finished duct section. II /-2",MESTEK MACHINERY INC,KERSKA STEVEN J;;WELTY JOHN R;;COON TIMOTHY A,,https://lens.org/132-243-047-650-741,Granted Patent,no,4,0,16,16,0,B23K10/00;;F24F13/0245;;B21D51/06;;B23K10/003;;F24F13/0245;;H05H1/34;;B21D51/06;;B23K10/00;;F24F13/0245,B23K10/00,,0,0,,,,ACTIVE
228,AU,A,AU 2000/045467 A,187-987-780-458-872,2000-11-14,2000,AU 2000/045467 A,2000-04-07,EP 0003196 W;;US 28992799 A,1999-04-09,Process for the manufacture of a cylindrical pipe,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS,,https://lens.org/187-987-780-458-872,Patent Application,no,0,0,6,6,0,B21C37/08;;B21C37/0803;;E21B17/20;;E21B19/22;;E21B43/103,B21C37/08;;E21B17/20;;E21B19/22;;E21B43/10,,0,0,,,,DISCONTINUED
229,WO,A1,WO 2012/037661 A1,011-691-083-348-453,2012-03-29,2012,CA 2011001066 W,2011-09-23,US 201161537403 P;;US 38588910 P,2010-09-23,APPARATUS AND METHOD FOR FLUID TREATMENT OF A WELL,A wellbore fluid treatment apparatus includes a tubing string including a first port with a first closure disposed thereover to close the first port to fluid flow and a second port spaced axially uphole from the first port and having a second closure disposed thereover to close the second port to fluid flow; and an actuator tool configured to move through the tubing string and (i) to set a seal in the tubing string downhole of the first port; (ii) to actuate the first closure to open the first port; and (iii) to actuate the second closure to open the second port. A method for treating a well may employ the tool.,PACKERS PLUS ENERGY SERV INC;;THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE,,https://lens.org/011-691-083-348-453,Patent Application,yes,8,5,6,6,0,E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066;;E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066,E21B43/14;;E21B34/14;;E21B43/26,,0,0,,,,PENDING
230,EP,B1,EP 1155218 B1,035-993-445-100-936,2005-02-16,2005,EP 00914681 A,2000-02-24,US 0004683 W;;US 12145299 P,1999-02-24,SELECTIVE ZONAL ISOLATION WITHIN A SLOTTED LINER,,SHELL INT RESEARCH,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/035-993-445-100-936,Granted Patent,yes,3,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
231,AU,A,AU 2000/037058 A,195-041-263-603-659,2000-09-14,2000,AU 2000/037058 A,2000-02-24,US 12145199 P;;US 0004684 W,1999-02-24,Internal junction reinforcement,,SHELL OIL CO,NAZZAI GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/195-041-263-603-659,Patent Application,no,0,0,3,3,0,E21B17/00;;E21B41/0042;;E21B43/103;;F16L55/179;;E21B41/0042;;F16L55/179;;E21B17/00;;E21B43/103,E21B17/00;;E21B41/00;;E21B43/10;;F16L55/179,,0,0,,,,DISCONTINUED
232,AU,A,AU 2000/036038 A,036-414-314-584-966,2000-09-14,2000,AU 2000/036038 A,2000-02-24,US 12145299 P;;US 0004683 W,1999-02-24,Selective zonal isolation within a slotted liner,,SHELL INT RESEARCH,NAZZAI GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/036-414-314-584-966,Patent Application,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
233,US,A1,US 2013/0168090 A1,014-561-323-294-188,2013-07-04,2013,US 201113821410 A,2011-09-23,US 201113821410 A;;US 38588910 P;;US 201161537403 P;;CA 2011001066 W,2010-09-23,APPARATUS AND METHOD FOR FLUID TREATMENT OF A WELL,A wellbore fluid treatment apparatus includes a tubing string including a first port with a first closure disposed thereover to close the first port to fluid flow and a second port spaced axially uphole from the first port and having a second closure disposed thereover to close the second port to fluid flow; and an actuator tool configured to move through the tubing string and (i) to set a seal in the tubing string downhole of the first port; (ii) to actuate the first closure to open the first port; and (iii) to actuate the second closure to open the second port. A method for treating a well may employ the tool.,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE;;PACKERS PLUS ENERGY SERV INC,THEMIG DANIEL JON;;COON ROBERT JOE;;EMERSON JOHN LEE,PACKERS PLUS ENERGY SERVICES INC (2011-02-03),https://lens.org/014-561-323-294-188,Patent Application,yes,7,21,6,6,0,E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066;;E21B43/14;;E21B43/25;;E21B2200/06;;E21B34/066,E21B43/14;;E21B34/14,166/285;;166/316;;166/179;;166/193;;166/135;;166/194;;166/305.1,0,0,,,,INACTIVE
234,US,B1,US 6253846 B1,040-411-977-312-76X,2001-07-03,2001,US 51188300 A,2000-02-23,US 51188300 A;;US 12145199 P,1999-02-24,Internal junction reinforcement and method of use,"An internal junction stabilizer is formed with an outer dimension less than the internal bore of a junction to be strengthened The stabilizer is inserted into the junction, and expanded into tight fit. Multiple stabilizers may be expanded one inside another to form a laminate for reinforcement in high pressure applications. Each layer of metal expanded to the next outermost section provides an additive effective on the mechanical properties of the junction. Expansion can be performed in a number of ways, including mechanical, hydraulic, explosive methods. Use of directional or selective swaging can be used to further effect a fit. Further embodiments of the invention include the use of sealing compounds, elastomers, and plastics to effect a hydraulic seal and fill gaps for strength purposes.",SHELL OIL CO,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,SHELL OIL COMPANY (2001-08-17),https://lens.org/040-411-977-312-76X,Granted Patent,yes,12,46,3,3,0,E21B17/00;;E21B41/0042;;E21B43/103;;F16L55/179;;E21B41/0042;;F16L55/179;;E21B17/00;;E21B43/103,E21B17/00;;E21B41/00;;E21B43/10;;F16L55/179,166/242.2;;166/50;;166/207;;166/313,0,0,,,,EXPIRED
235,EP,B1,EP 1856292 B1,091-775-995-463-948,2013-10-30,2013,EP 06737407 A,2006-03-08,US 2006/0008231 W;;US 65996105 P,2005-03-09,DIAGNOSTIC METHODS FOR IDENTIFYING CANDIDATE PATIENTS FOR THE TREATMENT WITH TRASTUZUMAB.,,ABBOTT LAB;;RUSH PRESBYTERIAN ST LUKE,MORRISON LARRY E;;JEWELL SUSAN S;;COON JOHN S,"ABBOTT MOLECULAR INC. (2014-09-03);;ABBOTT MOLECULAR INC., DES PLAINES, US (2013-10-31)",https://lens.org/091-775-995-463-948,Granted Patent,yes,0,0,12,12,0,C12Q1/6827;;C12Q1/6841;;C12Q1/6886;;C12Q2600/106;;C12Q1/6827;;C12Q1/6886;;C12Q1/6841;;C12Q2600/106,C12Q1/68,,2,2,032-665-931-215-809;;039-641-397-469-929,10.1046/j.0956-5507.2003.00088.x;;14632728;;14566826;;10.1002/ijc.11477,"A. M. BOFIN ET AL: ""TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas"", CYTOPATHOLOGY, vol. 14, no. 6, 1 December 2003 (2003-12-01), pages 314 - 319, XP055042583, ISSN: 0956-5507, DOI: 10.1046/j.0956-5507.2003.00088.x;;RONALD SIMON ET AL: ""HER-2 andTOP2A coamplification in urinary bladder cancer"", INTERNATIONAL JOURNAL OF CANCER, vol. 107, no. 5, 10 December 2003 (2003-12-10), pages 764 - 772, XP055042585, ISSN: 0020-7136, DOI: 10.1002/ijc.11477",ACTIVE
236,OA,A,OA 12195 A,096-866-445-952-558,2006-05-09,2006,OA 1200100225 A,2000-02-24,US 12145299 P,1999-02-24,Selective zonal isolation within a slotted liner.,,SHELL INT RESEARCH,NAZZAL GREGORY RICHARD;;FRANK TIMOTHY JOHN;;COON ROBERT JOE,,https://lens.org/096-866-445-952-558,Granted Patent,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/08;;E21B43/10,,0,0,,,,EXPIRED
237,NO,B1,NO 330567 B1,115-575-060-017-988,2011-05-16,2011,NO 20014038 A,2001-08-20,US 12145299 P;;US 0004683 W,1999-02-24,Metode og innretning for selektiv soneisolasjon i en slisset foring,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;NAZZAL GREGORY RICHARD,,https://lens.org/115-575-060-017-988,Granted Patent,no,0,0,19,19,0,E21B43/108;;E21B43/108;;E21B43/086;;E21B43/086;;E21B43/103;;E21B43/103,E21B33/13;;E21B43/10;;E21B43/08,,0,0,,,,EXPIRED
238,US,B1,US 7617384 B1,132-271-387-583-213,2009-11-10,2009,US 66951307 A,2007-01-31,US 66951307 A;;US 86457406 P,2006-11-06,Structured programming control flow using a disable mask in a SIMD architecture,One embodiment of a computing system configured to manage divergent threads in a SIMD thread group includes a stack configured to store state information for processing control instructions. A parallel processing unit is configured to perform the steps of determining if one or more threads diverge during execution of a conditional control instruction. Threads that exit a program are identified as idle by a disable mask. Other threads that are disabled may be enabled once the divergent threads reach an instruction that enables the disabled threads. Use of the disable mask allows for the use of conditional return and break instructions in a multithreaded SIMD architecture.,NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK;;TZVETKOV SVETOSLAV D,NVIDIA CORPORATION (2007-01-25),https://lens.org/132-271-387-583-213,Granted Patent,yes,10,79,2,2,0,G06F9/3851;;G06F9/3885;;G06F9/3887;;G06F9/30072;;G06F9/3851;;G06F9/3885;;G06F9/3887;;G06F9/30072,G06F15/80,712/220,3,2,074-507-939-370-096;;020-961-679-464-619,10.1109/asap.1994.331811;;10.1109/40.621209,"Kuszmaul,Bradly C., Synchronized MIMD Computing, 1994, MIT, 162 pages.;;Chou,W.H. etal., Register Transfer Modeling and Simulation for Array Processors, 1994, IEEE, pp. 111-122.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
239,CN,B,CN 1803682 B,143-513-447-246-437,2011-06-01,2011,CN 200510103230 A,2005-09-19,US 707504 A,2004-12-07,Apparatus and method for making fibers,"A duct assembly is employed for directing a central air flow upwardly toward the rotating spinner assembly of a rotary-type fiberizer that produces a downwardly flowing column of fibers. The central air flow eliminates the low-pressure zone that normally occurs beneath the spinner assembly of conventional fiberizers. The cross-sectional profile of a lower portion of the duct is vertically elongated where the duct passes through the fiber column so as to facilitate the flow of the fiber column over the duct. A shielding member can be positioned to deflect the central air flow away from the spinner assembly and against the interior of the fiber column to insulate the spinner assembly from the relative cool air flow. In another embodiment, a conduit extends through the fiberizer spinner assembly and directs a cooling gas beneath the spinner assembly within the interior of the fiber column.",EVANITE FIBER CORP,RON REHER;;COON LARRY K;;PATRICK SVOBODA;;JOHN WINDISCH,HOLLINS WIRTH + VOSS FIBER COMPANY (2014-12-10),https://lens.org/143-513-447-246-437,Granted Patent,no,0,0,11,11,0,C03B37/048;;C03B37/048,C03B37/04;;D01D5/18,,0,0,,,,ACTIVE
240,US,B2,US 7456835 B2,099-165-562-705-879,2008-11-25,2008,US 33993706 A,2006-01-25,US 33993706 A;;US 78973504 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/099-165-562-705-879,Granted Patent,yes,8,5,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T11/40;;G06T1/00;;G06T11/60;;G06T15/00;;G09G5/00;;G09G5/36,345/501;;345/582;;345/522;;345/552;;345/559;;711/125;;382/305,1,0,,,"Alexander, ""Der Stack Frame"" Online!, 2003, pp. 1-5, XPooo2328991 retrieved from the internet: URL:http://www.a-m-l.de/tips/stack/stack.php.",ACTIVE
241,TW,B,TW I370996 B,179-733-884-009-30X,2012-08-21,2012,TW 94104699 A,2005-02-17,US 78973504 A,2004-02-27,Register based queuing for texture requests,,NVIDIA CORP,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/179-733-884-009-30X,Granted Patent,no,0,0,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T11/60;;G09G5/36,,0,0,,,,ACTIVE
242,US,B1,US 7761697 B1,178-062-024-219-461,2010-07-20,2010,US 55708206 A,2006-11-06,US 55708206 A;;US 18049905 A,2005-07-13,Processing an indirect branch instruction in a SIMD architecture,"One embodiment of a computing system configured to manage divergent threads in a thread group includes a stack configured to store at least one token and a multithreaded processing unit. The multithreaded processing unit is configured to perform the steps of fetching a program instruction, determining that the program instruction is an indirect branch instruction, and processing the indirect branch instruction as a sequence of two-way branches to execute an indirect branch instruction with multiple branch addresses. Indirect branch instructions may be used to allow greater flexibility since the branch address or multiple branch addresses do not need to be determined at compile time.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK;;MILLS PETER C;;NICKOLLS JOHN R,NVIDIA CORPORATION (2006-11-03),https://lens.org/178-062-024-219-461,Granted Patent,yes,1,49,1,3,0,G06F9/322;;G06F9/3851;;G06F9/30072;;G06F9/3009;;G06F9/30185;;G06F9/3887;;G06F9/30061;;G06F9/30072;;G06F9/322;;G06F9/3851;;G06F9/30185;;G06F9/3887;;G06F9/3009,G06F7/38;;G06F9/00;;G06F9/44,712/233;;712/235;;712/236,1,1,020-961-679-464-619,10.1109/40.621209,"Eggers, et al., ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
243,US,A1,US 2006/0119607 A1,159-471-917-948-264,2006-06-08,2006,US 33993706 A,2006-01-25,US 33993706 A;;US 78973504 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP,LINDHOLM JOHN E;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/159-471-917-948-264,Patent Application,yes,7,41,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T11/60;;G06T11/40;;G09G5/00;;G09G5/36,345/552;;345/582,0,0,,,,EXPIRED
244,TW,A,TW 200535731 A,092-750-915-743-372,2005-11-01,2005,TW 94104699 A,2005-02-17,US 78973504 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing, the texture arguments in this register does not consume any additional registers,",NVIDIA CORP,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/092-750-915-743-372,Patent of Addition,no,0,0,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T11/60;;G09G5/36,,0,0,,,,ACTIVE
245,US,A1,US 2005/0190195 A1,014-773-424-083-480,2005-09-01,2005,US 78973504 A,2004-02-27,US 78973504 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP,LINDHOLM JOHN E;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,NVIDIA CORPORATION (2004-02-24),https://lens.org/014-773-424-083-480,Patent Application,yes,8,2,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T11/60;;G09G5/36,345/582,0,0,,,,EXPIRED
246,EP,A1,EP 1725989 A1,007-195-969-321-009,2006-11-29,2006,EP 05713143 A,2005-02-09,US 2005/0003999 W;;US 78973504 A,2004-02-27,REGISTER BASED QUEUING FOR TEXTURE REQUESTS,,NVIDIA CORP,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/007-195-969-321-009,Patent Application,yes,0,0,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T15/00;;G06T11/60;;G09G5/36,,0,0,,,,ACTIVE
247,EP,B1,EP 1725989 B1,074-291-051-704-487,2014-04-16,2014,EP 05713143 A,2005-02-09,US 2005/0003999 W;;US 78973504 A,2004-02-27,REGISTER BASED QUEUING FOR TEXTURE REQUESTS,,NVIDIA CORP,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/074-291-051-704-487,Granted Patent,yes,6,0,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T15/00;;G06T11/60;;G09G5/36,,1,0,,,"ALEXANDER MULLER: ""Der Stack Frame""[Online] 2003, pages 1-5, XP002328991 Retrieved from the Internet: URL:http://www.a-m-i.de/tips/stack/stack.p hp> [retrieved on 2005-05-20]",ACTIVE
248,US,B1,US 7877585 B1,043-914-674-674-521,2011-01-25,2011,US 84542907 A,2007-08-27,US 84542907 A;;US 86457406 P,2006-11-06,Structured programming control flow in a SIMD architecture,"One embodiment of a computing system configured to manage divergent threads in a SIMD thread group includes a stack configured to store state information for processing control instructions. A parallel processing unit is configured to perform the steps of determining if one or more threads diverge during execution of a conditional control instruction. A disable mask allows for the use of conditional return and break instructions in a multithreaded SIMD architecture. Additional control instructions are used to set up thread processing target addresses for synchronization, breaks, and returns.",NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;LINDHOLM JOHN ERIK;;TZVETKOV SVETOSLAV D,NVIDIA CORPORATION (2007-07-30),https://lens.org/043-914-674-674-521,Granted Patent,yes,11,47,2,2,0,G06F9/3851;;G06F9/3885;;G06F9/3887;;G06F9/30072;;G06F9/3851;;G06F9/3885;;G06F9/3887;;G06F9/30072,G06F15/76;;G06F7/38;;G06F9/00;;G06F9/44,712/233;;712/22;;712/234;;X712 E9058;;X712 E9071,4,3,089-944-969-917-814;;020-961-679-464-619;;074-507-939-370-096,10.1007/978-1-4615-2690-2_6;;10.1109/40.621209;;10.1109/asap.1994.331811,"Saumya et al., Call Forwarding: A Simple Low-Level Code Optimization Technique, 1994.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;Kuszmaul, Bradley C., ""Synchronized MIMD Computing,"" 1994, MIT, pp. 1-162.;;Chou, W.H., et al., ""Register Transfer Modeling and Simulation for Array Processors,"" 1994, IEEE, pp. 111-122.",ACTIVE
249,CN,B,CN 1938730 B,109-611-737-886-009,2012-05-30,2012,CN 200580009868 A,2005-02-09,US 2005/0003999 W;;US 78973504 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than thetexture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP,MOY SIMON S;;COON BRETT W;;ERIK LINDHOLM JOHN;;NICKOLLS JOHN R,,https://lens.org/109-611-737-886-009,Granted Patent,no,0,0,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T15/04;;G06T11/60;;G09G5/36,,0,0,,,,ACTIVE
250,US,B2,US 7027062 B2,017-298-804-963-569,2006-04-11,2006,US 78973504 A,2004-02-27,US 78973504 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,NVIDIA CORPORATION (2004-02-24),https://lens.org/017-298-804-963-569,Granted Patent,yes,9,18,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T11/40;;G06T11/60;;G09G5/36,345/552;;345/582;;345/559,1,0,,,"Alexander ""Der Stack Frame"" Online! 2003, pp. 1-5, XP002328991 Retrieved from the Internet: URL:http://www.a-m-l.de/tips/stack/stack.php (English Translation enclosed).",EXPIRED
251,WO,A1,WO 2005/093665 A1,071-013-684-220-416,2005-10-06,2005,US 2005/0003999 W,2005-02-09,US 78973504 A,2004-02-27,REGISTER BASED QUEUING FOR TEXTURE REQUESTS,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP;;LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/071-013-684-220-416,Patent Application,yes,6,2,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T11/60;;G09G5/36,,1,0,,,"ALEXANDER MULLER: ""Der Stack Frame"", 2003, pages 1 - 5, XP002328991, Retrieved from the Internet <URL:http://www.a-m-i.de/tips/stack/stack.php> [retrieved on 20050520]",PENDING
252,CN,A,CN 102750664 A,172-513-201-404-601,2012-10-24,2012,CN 201210120467 A,2005-02-09,US 78973504 A;;CN 200580009868 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP,LINDHOLM JOHN E;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/172-513-201-404-601,Patent Application,no,3,2,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T1/60;;G06T11/60;;G09G5/36,,0,0,,,,ACTIVE
253,US,B1,US 7864185 B1,108-389-379-692-456,2011-01-04,2011,US 25684808 A,2008-10-23,US 25684808 A;;US 33993706 A;;US 78973504 A,2004-02-27,Register based queuing for texture requests,"A graphics processing unit can queue a large number of texture requests to balance out the variability of texture requests without the need for a large texture request buffer. A dedicated texture request buffer queues the relatively small texture commands and parameters. Additionally, for each queued texture command, an associated set of texture arguments, which are typically much larger than the texture command, are stored in a general purpose register. The texture unit retrieves texture commands from the texture request buffer and then fetches the associated texture arguments from the appropriate general purpose register. The texture arguments may be stored in the general purpose register designated as the destination of the final texture value computed by the texture unit. Because the destination register must be allocated for the final texture value as texture commands are queued, storing the texture arguments in this register does not consume any additional registers.",NVIDIA CORP,LINDHOLM JOHN ERIK;;NICKOLLS JOHN R;;MOY SIMON S;;COON BRETT W,,https://lens.org/108-389-379-692-456,Granted Patent,yes,14,0,15,15,0,G06T11/60;;G09G5/363;;G06T11/60;;G09G5/363,G06T1/00;;G06T11/40;;G06T11/60;;G06T15/00;;G06T15/20;;G09G5/36,345/559;;345/501;;345/522;;345/564;;345/574;;382/305;;711/100;;711/125;;711/2;;365/230.01,1,0,,,"Muller, Alexander, ""Der Stack Frame"" Online 2003, pp. 1-5, XP002328991 retrieved from the internet: URL:http://www.a-m-l.de/tips/stack/stack.php retrieved on May 20, 2005.",ACTIVE
254,WO,A2,WO 2006/042187 A2,108-094-720-603-704,2006-04-20,2006,US 2005/0036337 W,2005-10-07,US 61712504 P,2004-10-08,SIMULTANEOUS SEQUENCE ANALYSIS OF AMINO- AND CARBOXY- TERMINI,"The present invention relates to a new method for identifying polypeptides by deducing the amino acid sequence of the carboxy and amino termini by a mass spectrometer analysis. The method comprises the steps of dissociating highly charged peptide precursor ions (e.g., z ᡶ 4) using electron transfer dissociation inducing anions followed by removal of those reagents and introduction of a second, proton transfer inducing anion type. The second PTR reaction duration is adjusted to convert the ETD products to primarily the + 1 charge-state to reduce the highly charged c and z-type fragments, producing an m/z spectrum containing a series of c and z-type fragment ions that are easily interpreted to reveal the sequence of the amino and carboxy terminus, respectively.",HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP,,https://lens.org/108-094-720-603-704,Patent Application,yes,0,32,14,14,10,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68,,0,0,,,,PENDING
255,EP,A1,EP 0759753 A1,004-667-203-600-251,1997-03-05,1997,EP 95922084 A,1995-05-19,US 9506167 W;;US 24603794 A,1994-05-19,METHODS AND COMPOSITIONS FOR REDUCING MULTIDRUG RESISTANCE,,RUSH PRESBYTERIAN ST LUKE,COON JOHN S;;BALASUBRAMANIAN MANNARSAMY;;EMANUELE R MARTIN;;SHAH HIMASHU,,https://lens.org/004-667-203-600-251,Patent Application,yes,0,0,5,18,0,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08;;A61K38/08;;A61K31/785,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08,,0,0,,,,DISCONTINUED
256,US,A1,US 2022/0049575 A1,017-442-933-522-587,2022-02-17,2022,US 202117403705 A,2021-08-16,US 202117403705 A;;US 202063065864 P,2020-08-14,Shutoff Valve,"A shutoff valve device for permitting and preventing fluid flow in a production string. In one embodiments, the shutoff valve device comprising: a body comprising a borehole, wherein the body is a top sub coupled to a bottom sub via a threaded fastener; a flow tube disposed within the body's borehole and capable of axial movement within the body's borehole, comprising a flow tube borehole; a bi-directional actuator attached to a bottom opening of the flow tube, comprising flexible flaps; and a flapper valve disposed within the body's borehole, wherein the flapper valve is hingedly coupled to a top surface of the bottom sub and capable of moving between a fully opened and fully closed position.",PETROQUIP ENERGY SERVICES LLC,COON ROBERT;;SMITH RODDIE;;EMERSON JOHN LEE;;FLORES ANTONIO B,,https://lens.org/017-442-933-522-587,Patent Application,yes,6,1,1,1,0,E21B34/14;;E21B2200/05;;E21B2200/05;;E21B34/085;;E21B34/108;;E21B34/103,E21B34/12,,0,0,,,,DISCONTINUED
257,GB,A,GB 2434028 A,120-769-604-669-690,2007-07-11,2007,GB 0707012 A,2005-10-07,US 2005/0036337 W;;US 61712504 P,2004-10-08,Simultaneous sequence analysis of amino- and carboxy-termini,"The present invention relates to a new method for identifying polypeptides by deducing the amino acid sequence of the carboxy and amino termini by a mass spectrometer analysis. The method comprises the steps of dissociating highly charged peptide precursor ions (e.g., z > 4) using electron transfer dissociation inducing anions followed by removal of those reagents and introduction of a second, proton transfer inducing anion type. The second PTR reaction duration is adjusted to convert the ETD products to primarily the +1 charge-state to reduce the highly charged c and z-type fragments, producing an m/z spectrum containing a series of c and z-type fragment ions that are easily interpreted to reveal the sequence of the amino and carboxy terminus, respectively.",UNIV VIRGINIA,HUNT DONALD F;;SYKA JOHN EDWARD PHILIP;;COON JOSHUA J,,https://lens.org/120-769-604-669-690,Patent Application,no,1,0,14,14,0,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68;;H01J49/02,H1D DMH           MH;;H1D D21X          MH;;H1D D51           MH,3,3,073-803-555-225-017;;043-610-381-684-918;;031-099-180-915-969,15210983;;pmc470779;;10.1073/pnas.0402700101;;11838679;;10.1021/ac015618l;;15983376;;pmc1172258;;10.1073/pnas.0503189102,"J Syka et al, ""Proceedings of the National Academy of Sciences of USA"", 29 June 2004, pages 9528-9533;;Analytical Chemistry Vol. 74, No. 3, 1 February 2002, pages 577-583;;J Coon et al, ""Proceedings of the National Academy of Sciences of USA"", July 2005, pages 9463-9468",ACTIVE
258,US,A,US 5681812 A,034-271-286-920-097,1997-10-28,1997,US 44519195 A,1995-05-19,US 44519195 A;;US 24603794 A;;US 98276692 A;;US 80518691 A,1991-12-10,Methods and compositions for reducing multidrug resistance,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH PRESBYTERIAN ST LUKE,COON JOHN S;;BALASUBRAMANIAN MANNARSAMY;;EMANUELE R MARTIN;;SHAH HIMANSHU,RUSH PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER (1995-06-21),https://lens.org/034-271-286-920-097,Granted Patent,yes,1,6,3,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K38/08;;A61K47/60;;A61K31/70;;A61K31/785;;A61K31/77;;A61K38/04;;A61K38/08;;A61K31/765;;A61K47/60,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K38/08;;A61K47/48,514/10;;514/34;;514/35;;514/183;;514/283;;514/411;;514/506;;514/515;;514/765;;514/950;;424/498,6,4,047-834-192-684-511;;035-358-782-608-447;;022-673-243-503-601;;119-437-082-629-053,10.3892/ijo.5.6.1305;;21559714;;10.1002/ijc.2910620413;;7635569;;8093856;;10.1007/bf01754414;;1988130,"Paradis, R. et al., Use of pluronic micelles to overcome multidrug resistance, International Journal of Oncology, 5:1305 1308 (1994).;;Page, M. et al., Elimination of P 170 Mediated Multi Drug Resistance by Solubilization in Pluronic Micelles, Database BIOSIS, Philadelphia, PA, (1992) and Proc. Am. Assoc. Cancer Res. Ann. Meet., 33: 552 (1992).;;Buckingham, L.E. et al., Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants and multidrug resistance modification agents, Int. J. Cancer, 62(4):436 442 (1995).;;Chong, A.S. et al. Diverse multidrug resistance modification agents inhibit cytolytic activity of natural killer cells, Cancer Immunol. Immunother., 36(2):133 139 (1993).;;Coon, et al., SOLUTOL HS15, nontoxic polyoxyethylene esters of 12 hydroxystearic acid, reverse multi drug resistance, Cancer Research, vol. 51, pp. 897 902 (Feb. 1991).;;Coon, J.S., et al., Survey of surfactants for reversing multidrug resistance, Proc. Am. Assoc. Cancer Res. Annu. Meet., vol. 33, p. 484 (Mar. 1992).",EXPIRED
259,BR,A,BR PI0505410 A,172-818-511-784-184,2006-09-12,2006,BR PI0505410 A,2005-12-07,US 707504 A,2004-12-07,aparelho e método para a fabricação de fibras,"""APARELHO E MéTODO PARA A FABRICAçãO DE FIBRAS"". A presente invenção refere-se a uma montagem de duto é empregada de modo a direcionar um fluxo de ar central em um sentido ascendente para a montagem de rotor rotativa de um fibralizador do tipo rotativo que produz uma coluna de fibras que flui em um sentido descendente. O fluxo de ar central elimina a zona de baixa pressão que normalmente ocorre abaixo da montagem de rotor de fibralizadores convencionais. O perfil em seção transversal de uma porção inferior do duto é verticalmente alongado, onde o duto atravessa a coluna de fibras de modo a facilitar o fluxo da coluna de fibras sobre o duto. Um elemento de blindagem pode ser posicionado de modo a defletir o fluxo de ar central para longe da montagem de rotor e contra o interior da coluna de fibras de modo a isolar a montagem de rotor do fluxo de ar relativamente frio. Em uma outra modalidade, um conduto se estende através da montagem de rotor de fibralizador e direciona um gás refrigerante abaixo da montagem de rotor dentro do interior da coluna de fibra.",EVANITE FIBER CORP,WINDISCH JOHN D;;SVOBODA PATRICK;;REHER RON;;COON LARRY K,,https://lens.org/172-818-511-784-184,Patent Application,no,0,0,11,11,0,C03B37/048;;C03B37/048,,,0,0,,,,DISCONTINUED
260,CA,A1,CA 2582578 A1,170-298-703-121-853,2006-04-20,2006,CA 2582578 A,2005-10-07,US 61712504 P;;US 2005/0036337 W,2004-10-08,SIMULTANEOUS SEQUENCE ANALYSIS OF AMINO- AND CARBOXY- TERMINI,,UNIV VIRGINIA,HUNT DONALD F;;SYKA JOHN EDWARD PHILIP;;COON JOSHUA J,,https://lens.org/170-298-703-121-853,Patent Application,no,0,0,14,14,10,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68,,0,0,,,,ACTIVE
261,DE,B4,DE 112005002484 B4,016-060-026-129-669,2022-12-22,2022,DE 112005002484 T,2005-10-07,US 61712504 P;;US 2005/0036337 W,2004-10-08,Simultane Sequenzanalyse von Amino- und Carboxy-Endgruppen,"Die vorliegende Erfindung bezieht sich auf ein neues Verfahren zum Identifizieren von Polypeptiden durch Ableiten der Aminosäure-Sequenz der Carboxy- und Amino-Endgruppen aus einer Massenspektrometer-Analyse. Das Verfahren umfasst die Stufen: das Dissoziieren von hoch geladenen Peptid-Vorläuferionen (wie z.B. z > 4) unter Verwendung von eine Elektronentransfer-Dissoziation induzierenden Anionen, woran sich anschließt die Entfernung dieser Reagenzien und die Einführung eines zweiten, einen Protonentransfer induzierenden Anionen-Typs. Die zweite PTR-Reaktionsdauer wird so eingestellt, dass die ETD-Produkte hauptsächlich umgewandelt werden in solche mit dem Ladungszustand + 1, um die hoch geladenen Fragmente vom c- und z-Typ zu vermindern, zur Herstellung eines m/z-Spektrums, das eine Reihe von Fragmentionen vom c- und z-Typ enthält, die leicht interpretiert werden können zur Erkennung der Sequenz der Amino-Endgruppe bzw. Carboxy-Endgruppe.",THE UNIV OF VIRGINIA PATENT FOUNDATION,COON JOSHUA J;;HUNT DONALD F;;SYKA JOHN EDWARD PHILIP,,https://lens.org/016-060-026-129-669,Granted Patent,no,3,0,14,14,0,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68;;G01N27/62,,1,1,073-803-555-225-017,15210983;;pmc470779;;10.1073/pnas.0402700101,"en (vgl. J. E. P. Syka; J. J. Coon; M. J. Schroeder; J. Shabanowitz und D. F. Hunt, „Proceedings of the National Academy of Sciences of the United States of America“, 2004, 101, 9528 - 9533; und J. J. Coon; J. E. P. Syka; J. C. Schwartz; J. Shabanowitz und D. F. Hunt, „International Journal of Mass Spectrometry“, 2004, (im Druck 2004)",ACTIVE
262,US,A1,US 2008/0044915 A1,126-053-259-940-236,2008-02-21,2008,US 66466105 A,2005-10-07,US 66466105 A;;US 61712504 P;;US 2005/0036337 W,2004-10-08,Simultaneous Sequence Analysis of Amino- and Carboxy-Termini,"The present invention relates to a new method for identifying polypeptides by deducing the amino acid sequence of the carboxy and amino termini by a mass spectrometer analysis. The method comprises the steps of dissociating highly charged peptide precursor ions (e.g., z>4) using electron transfer dissociation inducing anions followed by removal of those reagents and introduction of a second, proton transfer inducing anion type. The second PTR reaction duration is adjusted to convert the ETD products to primarily the +1 charge-state to reduce the highly charged c and z-type fragments, producing an m/z spectrum containing a series of c and z-type fragment ions that are easily interpreted to reveal the sequence of the amino and carboxy terminus, respectively.",HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN E P,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN E P,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2006-01-17);;UNIVERSITY OF VIRGINIA (2006-03-17),https://lens.org/126-053-259-940-236,Patent Application,yes,3,27,14,14,10,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/00,436/89,0,0,,,,ACTIVE
263,US,S,US D0789886 S,148-179-853-442-880,2017-06-20,2017,US 201529530645 F,2015-06-18,US 201529530645 F,2015-06-18,Charging dock,,MICROSOFT CORP,SOCHA-LEIALOHA JOHN BRONN;;COON THOMAS SCOTT;;CHARLTON DANIEL SAMUEL,MICROSOFT CORPORATION (2015-06-15),https://lens.org/148-179-853-442-880,Design Right,no,0,9,3,3,0,,,1302;;D13/108;;D14/434,0,0,,,,ACTIVE
264,US,B1,US 6208459 B1,198-915-131-985-230,2001-03-27,2001,US 11147998 A,1998-07-08,US 11147998 A;;US 56365695 A,1995-11-28,Method and system for multi-spectral imaging in the visible and infrared spectrums,"Multi-spectral images are detected using a refractive objective lens system. Magnesium oxide (MgO) and calcium fluoride (CaF.sub.2) lenses are used to image scenes in both the visible and infra-red (IR) spectrums. The inventors have discovered that the combination of magnesium oxide, only recently made available in a pure crystal form, and calcium fluoride can be used to fabricate an objective lens for imaging objects in both the visible and infra-red spectrums. Moreover, the combination of magnesium oxide and calcium fluoride results in a super-achromatic condition across visible and infra-red spectrums. This chromatically-corrected spectral range includes wavelengths between 0.4 and 5.9 microns which covers medium-wave IR (MWIR), short-wave IR (SWIR), and the near-IR/visible windows. Combinations of MgO and CaF.sub.2 lenses are used in different compound objective lens designs including doublet, Petzval, inverted telephoto, and telephoto arrangements. Visible and/or IR applications for the multi-spectral objective lens system include telescopes, reconnaissance planes, satellites, forward-looking IR (FLIR) and staring sensor systems, night-vision goggles, and other optic and/or electro-optic detection systems.",LOCKHEED CORP,COON BRYAN;;MCGEE III JOHN F;;SHERMAN NEIL;;MONTULLI LOU,,https://lens.org/198-915-131-985-230,Granted Patent,yes,19,69,7,7,0,G02B1/02;;G02B13/146;;G02B1/02;;G02B13/146,G02B1/02;;G02B13/14,359/355;;359/356;;359/350;;359/717,2,0,,,"Born, M., et al., Principles of Optics, 6th ed., Pergamon Press, Elmsford, NY, 1980, pp. 235-237.;;Dialog File 348 (European Patents) English Language Patent Abstract for EP 0683411 A1, Published Nov. 22, 1995, Base 1.",EXPIRED
265,TW,S,TW D177986 S,098-252-220-860-042,2016-09-01,2016,TW 104307067 F,2015-12-18,US 201529530645 F,2015-06-18,PORTION OF CHARGING DOCK,【物品用途】;本設計係關於一種充電基座。;【設計說明】;圖式所揭露之虛線部分，為本案不主張設計之部分。,微軟公司;;MICROSOFT CORP,SOCHA-LEIALOHA JOHN BRONN;;COON THOMAS SCOTT;;CHARLTON DANIEL SAMUEL,,https://lens.org/098-252-220-860-042,Design Right,no,0,0,3,3,0,,,14-99,0,0,,,,ACTIVE
266,US,B2,US 8919602 B2,151-407-580-883-049,2014-12-30,2014,US 201313891307 A,2013-05-10,US 201313891307 A;;US 201261645669 P,2012-05-11,Safety shield for fuel gas tank,"A protective shield fits onto a fuel cylinder that is mounted on a propane-powered or LNG-powered vehicle, with a cylindrical flange on the tank surrounds a tank valve. The protective shield is formed of a cylindrical wall of a rubber-like material that fits snugly onto the cylindrical flange of the fuel tank, and has a window affixed into its upper end of the cylindrical wall. The window can be a disk of transparent plexiglass. There are openings in the cylindrical wall to access the tank valve. The shield provides visibility of the tank valve but prevents any spray of the fuel that may escape from the tank valve from reaching the worker's face or other exposed skin.",TANK RIGHT SYSTEMS LLC,NOLAN SHAWN;;FEY MICHAEL;;COON RICHARD R;;FITZSIMMONS JOHN J,TANK RIGHT SYSTEMS LLC (2013-05-03),https://lens.org/151-407-580-883-049,Granted Patent,yes,20,1,2,2,0,F17C2205/0308;;F17C2201/0109;;F17C2201/058;;F17C2203/0639;;F17C2205/018;;F17C2221/035;;F17C2223/0153;;F17C2223/033;;F17C2260/037;;F17C2260/038;;F17C13/06;;F17C13/06;;F17C2203/0639;;F17C2223/033;;F17C2201/058;;F17C2205/0308;;F17C2260/038;;F17C2223/0153;;F17C2205/018;;F17C2260/037;;F17C2201/0109;;F17C2221/035;;B65D43/0222,B65D43/02;;B65D55/00;;B65D51/18;;F17C13/06,220/731;;220/602;;220/724,0,0,,,,INACTIVE
267,WO,A3,WO 1995/031981 A3,165-770-310-755-682,1996-07-18,1996,US 9506167 W,1995-05-19,US 24603794 A,1994-05-19,METHODS AND COMPOSITIONS FOR REDUCING MULTIDRUG RESISTANCE,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH PRESBYTERIAN ST LUKE,COON JOHN S;;BALASUBRAMANIAN MANNARSAMY;;EMANUELE R MARTIN;;SHAH HIMASHU,,https://lens.org/165-770-310-755-682,Search Report,yes,1,0,5,18,0,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08;;A61K38/08;;A61K31/785,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08,,6,4,047-834-192-684-511;;035-358-782-608-447;;119-437-082-629-053;;022-673-243-503-601,10.3892/ijo.5.6.1305;;21559714;;10.1002/ijc.2910620413;;7635569;;1988130;;8093856;;10.1007/bf01754414,"DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, M. PAGE ET AL.: ""Elimination of P-170 mediated multidrug resistance by solubilization in pluronic micelles"", XP002000101;;R. PARADIS ET AL.: ""Use of pluronic micelles to overcome multidrug resistance"", INT. J. ONCOL., vol. 5, no. 6, 1994, pages 1305 - 1308, XP002000096;;L.E. BUCKINGHAM ET AL.: ""Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents"", INT. J. CANCER, vol. 62, no. 4, August 1995 (1995-08-01), pages 436 - 442, XP002000097;;J.S. COON ET AL.: ""Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid reverses multidrug resistance"", CANCER RESEARCH, vol. 51, February 1991 (1991-02-01), pages 897 - 902, XP002000098;;J.S. COON: ""Survey of surfactants for reversing multidrug resistance"", PROC. AM. ASSOC. CANCER. RES. ANN. MEET., vol. 33, no. 0, 1992, pages 484, XP002000099;;A.S.-F- CHONG ET AL.: ""Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells"", CANCER IMMUNOL. IMMUNOTHER., vol. 36, no. 2, 1993, pages 133 - 139, XP002000100",PENDING
268,GB,B,GB 2434028 B,174-027-221-821-946,2011-05-04,2011,GB 0707012 A,2005-10-07,US 2005/0036337 W;;US 61712504 P,2004-10-08,Simultaneous sequence analysis of amino- and carboxy-termini,,UNIV VIRGINIA,HUNT DONALD F;;SYKA JOHN EDWARD PHILIP;;COON JOSHUA J,,https://lens.org/174-027-221-821-946,Granted Patent,no,1,0,14,14,0,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68;;H01J49/02,,3,3,073-803-555-225-017;;043-610-381-684-918;;031-099-180-915-969,15210983;;pmc470779;;10.1073/pnas.0402700101;;11838679;;10.1021/ac015618l;;15983376;;pmc1172258;;10.1073/pnas.0503189102,"J Syka et al, ""Proceedings of the National Academy of Sciences of USA"", 29 June 2004, pages 9528-9533;;Analytical Chemistry Vol. 74, No. 3, 1 February 2002, pages 577-583;;J Coon et al, ""Proceedings of the National Academy of Sciences of USA"", July 2005, pages 9463-9468",ACTIVE
269,ES,T3,ES 2644277 T3,036-502-275-323-295,2017-11-28,2017,ES 10771303 T,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,Métodos de diagnóstico para determinar la prognosis del cáncer de pulmón de células no pequeñas,,ABBOTT MOLECULAR INC,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK;;COON JOHN,,https://lens.org/036-502-275-323-295,Granted Patent,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,0,0,,,,ACTIVE
270,AU,A,AU 1995/026894 A,120-962-854-692-476,1995-12-18,1995,AU 1995/026894 A,1995-05-19,US 24603794 A;;US 9506167 W,1994-05-19,Methods and compositions for reducing multidrug resistance,,RUSH PRESBYTERIAN ST LUKE,COON JOHN S;;BALASUBRAMANIAN MANNARSAMY;;EMANUELE R MARTIN;;SHAH HIMASHU,,https://lens.org/120-962-854-692-476,Patent Application,no,0,0,5,18,0,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08;;A61K38/08;;A61K31/785,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08,,0,0,,,,PENDING
271,DE,T5,DE 112005002484 T5,039-936-051-418-161,2008-01-17,2008,DE 112005002484 T,2005-10-07,US 61712504 P;;US 2005/0036337 W,2004-10-08,Simultane Sequenzanalyse von Amino- und Carboxy-Endgruppen,,UNIV VIRGINIA,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP,,https://lens.org/039-936-051-418-161,Patent Application,no,0,0,14,14,0,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68;;G01N27/62,,0,0,,,,ACTIVE
272,CA,C,CA 2582578 C,060-863-147-543-748,2013-08-20,2013,CA 2582578 A,2005-10-07,US 61712504 P;;US 2005/0036337 W,2004-10-08,SIMULTANEOUS SEQUENCE ANALYSIS OF AMINO- AND CARBOXY- TERMINI,"The present invention relates to a new method for identifying polypeptides by deducing the amino acid sequence of the carboxy and amino termini by a mass spectrometer analysis. The method comprises the steps of dissociating highly charged peptide precursor ions (e.g., z > 4) using electron transfer dissociation inducing anions followed by removal of those reagents and introduction of a second, proton transfer inducing anion type. The second PTR reaction duration is adjusted to convert the ETD products to primarily the + 1 charge-state to reduce the highly charged c and z-type fragments, producing an m/z spectrum containing a series of c and z-type fragment ions that are easily interpreted to reveal the sequence of the amino and carboxy terminus, respectively.",UNIV VIRGINIA PATENT FOUND,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP,,https://lens.org/060-863-147-543-748,Granted Patent,no,0,0,14,14,10,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68,,0,0,,,,ACTIVE
273,EP,A1,EP 2835642 A1,155-704-344-325-99X,2015-02-11,2015,EP 14182039 A,2005-03-11,US 55287604 P;;US 57288404 P;;US 59934104 P;;EP 10169367 A;;EP 05727506 A,2004-03-12,Electron transfer dissociation for biopolymer sequence analysis,"The invention relates to a method of fragmenting positively charged peptide ions in an RF field mass spectrometer or an RF'field ion containment device, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide ion, resulting in the fragmentation of the positively charged sample ion. The invention also provides a method of performing sequence analysis of a peptide or protein by mass spectrometry, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide or protein ion, resulting in the fragmentation of the positively charged sample ion.
",UNIV VIRGINIA PATENT FOUND,HUNT DONALD;;COON JOSHUA;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD,,https://lens.org/155-704-344-325-99X,Patent Application,yes,3,0,20,20,71,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,17,14,033-543-562-828-538;;073-803-555-225-017;;100-670-378-310-085;;031-739-013-565-001;;036-293-959-621-316;;115-238-949-200-640;;139-344-218-489-129;;040-286-853-815-47X;;054-947-093-781-361;;025-523-151-463-02X;;030-460-807-381-496;;044-059-272-957-811;;005-608-730-830-354;;039-744-701-942-955,10.1021/cr990076h;;11712248;;15210983;;pmc470779;;10.1073/pnas.0402700101;;10.1016/j.jasms.2005.01.015;;15907703;;10.1016/s1387-3806(00)00339-0;;10.1016/s0168-1176(96)04510-7;;10.1021/ja973478k;;2138240;;10.1016/0076-6879(90)82049-8;;10.1111/j.1749-6632.1992.tb38648.x;;1482093;;10.1021/ac50008a014;;10.1021/ac50035a017;;10.1016/s1044-0305(02)00384-7;;12056566;;11008759;;10.1021/ac000497v;;10.1038/nbt0302-301;;11875433;;10.1016/1044-0305(94)80016-2;;24226387,"AEBERSOLD R ET AL: ""Mass spectrometry in proteomics"", CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 101, no. 2, February 2001 (2001-02-01), pages 269 - 295, XP002306061, ISSN: 0009-2665;;SYKA JOHN E P ET AL: ""Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 29 JUN 2004, vol. 101, no. 26, 29 June 2004 (2004-06-29), pages 9528 - 9533, XP009051646, ISSN: 0027-8424;;COON J J ET AL: ""Electron Transfer Dissociation of Peptide Anions"", JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, vol. 16, no. 6, 1 June 2005 (2005-06-01), ELSEVIER SCIENCE INC, US, pages 880 - 882, XP004904047, ISSN: 1044-0305, DOI: 10.1016/J.JASMS.2005.01.015;;PAYNE, A.H. ET AL: ""Gas-phase ion/ion interactions between peptides or proteins and iron ions in a quadrupole ion trap"", INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, vol. 204, 2001, pages 47 - 54, XP002732713;;JAMES L STEPHENSON, SCOTT A MCLUCKEY: ""Adaptation of the Paul Trap for study of the reaction of multiply charged anions with singly charged anions"", INTERNATIONAL JOURNAL OF MASS SPECTROMETRY AND ION PROCESSES, vol. 162, 1997, pages 89 - 106, XP002732714;;BUNDY J L ET AL: ""Fragmentation of multiply-charged macromolecules of opposite polarity in a quadrupole ion trap."", PROCEEDINGS OF 50TH ASMS CONFERENCE ON MASS SPECTROMETRY AND ALLIED TOPICS. ORLANDO, FL, 2 June 2002 (2002-06-02) - 6 June 2002 (2002-06-06), pages 1 - 2, XP002732715;;MCLAFFERTY ET AL., J. AM. CHEM. SOC., vol. 120, 1998, pages 3265 - 3266;;T. E. CREIGHTON: ""PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES"", 1993, W. H. FREEMAN AND COMPANY;;""POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS"", 1983, ACADEMIC PRESS, pages: 1 - 12;;SEIFTER ET AL., METH ENZYMOL, vol. 182, 1990, pages 626 - 646;;RATTAN ET AL., ANN NY ACAD SCI, vol. 663, 1992, pages 48 - 62;;HUNT ET AL., ANAL. CHEM., vol. 48, 1976, pages 2098;;HUNT ET AL., ANAL. CHEM., vol. 50, 1978, pages 1781 - 1784;;SCHWARTZ, J. AM. SOC. MASS SPECTROM., vol. 13, 2002, pages 659 - 669;;MARTIN ET AL., ANAL CHEM., vol. 72, 2000, pages 4266 - 4274;;FICARRO ET AL., NAT. BIOTECHNOL., vol. 20, 2002, pages 301 - 305;;ENG ET AL., J. AM. SOC. MASS SPECTROM., vol. 5, 1994, pages 976 - 989",INACTIVE
274,US,A,US 5776891 A,014-581-746-895-506,1998-07-07,1998,US 48058295 A,1995-06-07,US 48058295 A;;US 44519195 A;;US 24603794 A;;US 98276692 A;;US 80518691 A,1991-12-10,Compositions for reducing multidrug resistance,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH PREBYTERIAN ST LUKE MEDIC,COON JOHN S;;BALASUBRAMANIAN MANNARSAMY;;EMANUELE R MARTIN;;SHAH HIMANSHU,RUSH PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER (1995-07-26),https://lens.org/014-581-746-895-506,Granted Patent,yes,16,12,3,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K38/08;;A61K47/60;;A61K31/70;;A61K31/785;;A61K31/77;;A61K38/04;;A61K38/08;;A61K31/765;;A61K47/60,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K38/08;;A61K47/48,514/10;;514/34;;514/35;;514/183;;514/283;;514/411;;514/506;;514/515;;514/765;;514/950,50,47,047-834-192-684-511;;035-358-782-608-447;;022-673-243-503-601;;119-437-082-629-053;;039-897-437-195-176;;037-971-434-683-369;;072-054-424-022-015;;036-785-375-873-692;;086-378-184-009-266;;016-018-646-557-905;;007-222-496-771-886;;018-556-800-235-746;;051-285-326-497-347;;004-185-224-654-759;;051-870-389-854-660;;101-667-114-885-562;;159-538-400-711-954;;030-111-405-797-119;;033-807-008-821-976;;032-998-418-535-321;;002-966-950-935-095;;002-983-452-841-832;;027-640-927-117-34X;;072-614-477-610-622;;085-799-967-891-485;;076-921-233-571-765;;006-200-528-711-033;;111-157-639-857-903;;095-460-103-606-528;;070-287-001-960-450;;027-646-417-200-044;;006-779-421-891-260;;069-316-535-749-718;;060-285-179-840-446;;006-444-184-357-771;;029-271-145-472-402;;016-273-016-183-900;;071-418-010-988-379;;006-837-075-345-488;;014-182-871-517-039;;040-197-906-739-868;;013-658-838-125-169;;062-602-961-341-953;;120-498-104-909-799;;042-950-635-383-846;;101-365-513-459-743;;029-652-583-748-834,10.3892/ijo.5.6.1305;;21559714;;10.1002/ijc.2910620413;;7635569;;8093856;;10.1007/bf01754414;;1988130;;2364376;;5030820;;pmc1977900;;1637678;;10.1038/bjc.1992.217;;10.1146/annurev.bi.58.070189.001033;;2570548;;10.1146/annurev.biochem.58.1.137;;1868977;;10.1096/fasebj.5.11.1868977;;3459160;;10.1073/pnas.83.11.3847;;pmc323621;;1581902;;10.1016/0092-8674(86)90595-7;;2876781;;2412130;;10.1038/316820a0;;571759;;10.1038/324485a0;;2878368;;10.1177/35.12.2890686;;2890686;;10.1016/s0021-9258(19)57324-0;;2891711;;10.1016/0005-2736(76)90160-7;;990323;;3711108;;10.1016/s0021-9258(19)57466-x;;1359116;;10.1093/jnci/81.2.116;;2562856;;10.1016/0092-8674(86)90594-5;;3768958;;6728022;;10.1038/309626a0;;10.1126/science.3576227;;3576227;;2421411;;10.1126/science.2421411;;2431283;;10.1128/mcb.6.5.1671;;pmc367694;;10.1128/mcb.6.5.1671-1678.1986;;3022150;;10.1038/323728a0;;10.1200/jco.1987.5.12.1922;;3681376;;pmc323769;;3459187;;10.1073/pnas.83.12.4538;;pmc391393;;10.1073/pnas.82.22.7661;;3865187;;10.1016/s0021-9258(19)75806-2;;3027054;;pmc280426;;10.1073/pnas.85.12.4350;;3380797;;10.1073/pnas.84.1.265;;2432605;;pmc304184;;10.1093/jnci/80.4.269;;2895190;;3457471;;10.1126/science.3457471;;2890168;;pmc299368;;10.1073/pnas.84.21.7701;;10.1126/science.1360704;;1360704;;4855907;;10.1002/jcp.1040830114;;3856953;;10.1007/bf01534700;;3860286;;4005839;;719649;;3495806;;10.1073/pnas.84.12.4288;;pmc305070;;1671173;;10.1073/pnas.88.2.547;;pmc50848;;1681415;;2576349;;3335222;;10.1016/0014-4827(88)90152-8,"Paradis, R. et al., Use of pluronic micelles to overcome multidrug resistance, International Journal of Oncology , 5:1305 1308 (1994).;;Pages, M. et al., Elimination of P 170 Mediated Multi Drug Resistance by Solubilization in Pluronic Micelles, Database BIOSIS , Philadelphia, PA (1992) and Proc. Am. Assoc. Cancer Res. Ann. Meet. , 33: 552 (1992).;;Buckingham, L.E. et al., Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents, Int. J. Cancer, 62(4):436 442 (1995).;;Chong, A.S. et al. Diverse multidrug resistance modification agents inhibit cytolytic activity of natural killer cells, Cancer Immunol. Immunother., 36(2):133 139 (1993).;;Coon, et al., SOLUTOL HS15, nontoxic polyoxyethylene esters of 12 hydroxystearic acid, reverses multidrug resistance, Cancer Research , vol. 15, pp. 897 902 (Feb. 1991).;;Coon, J.S., et al., Survey of surfactants for reversing multidrug resistance, Proc. Am. Assoc. Cancer Res. Annu. Meet. , vol. 33, p. 484 (Mar. 1992).;;Woodcock, D., et al., Reversal of the Multidrug Resistance Phenotype with Cremophor EL, a Common Vehicle for Water insoluble Vitamins and Drugs, Cancer Research , vol. 50, pp. 4199 4230 (Jul. 15, 1990).;;Riehm, H., et al., Potentiation of Drug Effect by Tween 80 in Chinese Hamster Cells Resistant to Actinomycin D. and Daunomycin, Cancer Research , vol. 32, pp. 1195 1200(Jun. 1972).;;Woodcock, D., et al., Reversal of Multidrug resistance by surfactants, Br. J. Cancer , vol. 66, pp. 62 88 (Jul. 1992).;;Endicott, J., et al., The Biochemistry of P Glycoprotein Mediated Multidrug Resistance, Annu. Rev. Biochem. , vol. 58, pp. 137 171 (1989).;;Pastan, I., et al., Molecular Manipulations of the Multidrug Transporter: A New Role for Transgenic Mice, FASEB Journal , vol. 5, pp. 2523 2528 (1991).;;Drug & Market Development, Multidrug Resistance in Cancer Therapy, Drug & Market Development , vol. 3, No. 1/2 (Jul. 6, 1992).;;Cornwell, M., et al., Membrane Vesicles from Multidrug Resistant Human Cancer Cells Contain a Specific 150 to 170 kDA Protein Detected by Photoaffinity Labeling, Proc. Natl. Acad. Sci., USA , vol. 83, pp. 3847 3850 (1986).;;Sehested, M., et al., Relationship of VP 16 to the Classical Multidrug Resistance Phenotype, Cancer Research , vol. 52, pp. 2874 2879 (May 15, 1992).;;Chen, C., et al., Internal Duplication and Homology with Bacterial Transport Proteins in the MDR1 (P Glycoprotein) Gene from Multidrug Resistant Human Cells, Cell , vol. 47, pp. 381 389 (1986).;;Kartner, N., et al., Detection of P Glycoprotein in Mutidrug Resistant Cell Lines by Monoclonal Antibodies, Nature , vol. 316, pp. 820 823 (1985).;;Beck, W., et al., Altered Surface Membrane Glycoproteins in Vinca Alkoloid resistant Human Leukemic Lymphoblasts, Cancer Research , vol. 39, pp. 2070 2076 (1979).;;Gerlack, J., et al., Homology Between P Glycoprotein and a Bacterial Haemolysin Transport Protein Suggess a Model for Multidrug Resistant, Nature , vol. 324, pp. 485 489 (1986).;;Willingham, M., et al., Immunocytochemical Localization of P170 at the Plasma Membrane of Multidrug Resistant Human Cells, Journal of Histochemistry and Cytochemistry , vol. 35, No. 12, pp. 1451 1456 (1987).;;Hamada, H., et al., Purification of the 170 to 180 Kilodalton Membrane Glycoprotein Associated with Multidrug Resistance, Journal of Biological Chemistry , vol. 263, No. 3, pp. 1454 1458 (1988).;;Juliano, R., et al., A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants, Biochemica et Biophysica Acta , vol. 455, pp. 152 162 (1976).;;Shen, D., et al., Multiple Drug Resistant Human KB Carcinoma Cells Independently Selected for High Level Resistance to Colchicine, Adriamycin, or Vinblastine Show Changes in Expression of Specific Proteins, Journal of Biological Chemistry , vol. 261, No. 17, pp. 7762 7770 (1986).;;Dordal, M., et al., Kinetic Analysis of P Glycoprotein Mediated Doxorubicin Efflux, The Journal of Pharmacology and Experimental Theerapeutics , vol. 263, pp. 752 766 (Nov. 1992).;;Goldstein, L., et al., Expression of a Multidrug Resistance Gene in Human Cancers, Journal of the National Cancer Institute , vol. 81, No. 2, pp. 116 124 (1989).;;Gros, P., et al., Mammalian Multidrug Resistance Gene: Complete cDNA Sequence Indicates Strong Homology to Bacterial Transport Proteins, Cell , vol. 47, pp. 371 380 (1986).;;Roninson, I., et al., Amplification of Specific DNA Sequences Correlates with Multi drug Resistance in Chinese Hamster Cells, Nature , vol. 309, pp. 626 628 (1984).;;Thorgeirsson, S., et al., Expression of the Multidrug Resistant Gene in Hepatocarcinogenesis and Regenerating Rat Liver, Science , vol. 236, pp. 1120 1122 (1987).;;Scotto, K., et al., Amplifications and Expression of Genes Associated with Multidrug Resistance in Mammalian Cells, Science , vol. 232, pp. 751 755 (May 9, 1986).;;Van der Bliek, A., et al., Overexpression and Amplification of Five Genes in a Multidrug Resistant Chinese Hamster Ovary Cell Line, Molecular and Cellular Biology , vol. 6, No. 5, pp. 1671 1678 (1986).;;Gros, P., et al., Isolation and Expression of a Complementary DNA that Confers Multidrug Resistance, Nature , vol. 323, pp. 728 732 (1986).;;Fojo, A., et al., Intrinsic Drug Resistance in Human Kidney Cancer is Associated with Expression of a Human Multidrug Resistance Gene, Journal of Clinical Oncology , vol. 5, No. 12, pp. 1922 1927 (1987).;;Roninson, I., et al., Isolation of Human mdr DNA Sequences Amplified in Multidrug Resistant KB Carcinoma Cells, Proc. Natl. Acad. Sci., USA , vol. 83, pp. 4538 4542 (1986).;;Fojo, A., et al., Amplification of DNA Sequences in Human Multidrug Resistant KB Carcinoma Cells, Proc. Natl. Acad. Sci. USA , vol. 82, pp. 7661 7665 (1985).;;Ueda, K., et al., The Human Multidrug Resistant (mdrl) Gene, Journal of Biological Chemistry vol. 262, pp. 505 508 (1987).;;Arceci, R., et al., The Gene Encoding Multidrug Resistance is Induced and Expressed at high Levels During Pregnancy in the Secretory Epithelium of the Uterus, Proc. Natl., Acad. Sci., USA , vol. 85, pp. 4350 4354 (1988).;;Fojo, A., et al., Expression of a Multidrug resistance Gene in Human Tumors and Tissues, Proc. Natl. Acad. Sci., USA , vol. 84, pp. 265 269 (1987).;;Mukhopadhyay, T., et al., Expression of the mdr (P Glycoprotein) Gene in Chinese Hamster Digestive Tracts, Journal of the National Cancer Institute , vol. 80, No. 4, pp. 269 275 (1988).;;Shen, D., et al., Human Multidrug Resistant Cell Lines: Increased mdrl Expression Can Precede Gene Amplification, Science , vol. 232, pp. 643 645 (1986).;;Fairchild, C., et al., Carcinogen Induced mdr Overexpression is Associated with Xenobiotic Resistance in Rat Preneoplastic Liver Nodules and Hepatocellular Carcinomas, Proc. Natl. Acad. Sci., USA , vol. 84, pp. 7701 7705 (1987).;;Cole, S., et al., Overexpression of a Transporter Gene in a Multidrug Resistant Human Lung Cancer Cell Line, Science , vol. 258, pp. 1650 1654 (Dec. 4, 1992).;;Ling, V., et al., Reduced Permeability in CHO Cells as a Mechanism of Resistance to Colchinine, J. Cell. Physiol. , vol. 83, pp. 103 116 (1974).;;Akiyama, S., et al., Isolation and Genetic Characterization of Human KB Cell Lines Resistant to Multiple Drugs, Somatic Cell and Molecular Genetics , vol. 11, No. 1, pp. 117 126 (1985).;;Bhalla, K., et al., Isolation and Characterization of an Anthracycline Resistant Human Leukemic Cell Line, Cancer Research , vol. 45, pp. 3657 3662 (1985).;;Fojo, A., et al., Reduced Drug Accumulation in Multiple Drug Resistant Human KB Carcinoma Cell Lines, Cancer Research , vol. 45, pp. 3002 3007 (1985).;;Skovsgaard, T., Mechanism of Cross Resistance between Vincristin and Daunorubicin in Ehrlich Ascites Tumor Cells, Cancer Research , vol. 38, pp. 4722 4727 (1978).;;FitzGerald, D., et al., A Monoclonal Antibody Pseudomonas Toxin Conjugate that Specifically Kills Multidrug Resistant Cells, Proc. Natl. Acad. Sci., USA , vol. 84, pp. 4288 4292 (1987).;;Micklisch, G., et al., Transgenic Mice the Express the Human Multidrug Resistance Gene in Bone Marrow Enable a Rapid Identification of Agents that Reverse Drug Resistance, Proc. Natl. Acad. Sci., USA , vol. 88, pp. 547 551 (1991).;;Lelong, I., et al., Fluorescent Verpamil Derivative for Monitoring Activity of the Multidrug Transporter, Molecular Pharmacology , vol. 40, pp. 490 494 (1991).;;Efferth, T., et al., Reciprocal Correlation Between Expression of P Glycoprotein and Accumulation of Rhodamine 123 in Human Tumors, Anticancer Res. , vol. 9, pp. 1633 1638 (1989).;;Neyfakh, A.A., et al., Use of Fluorescent Dyes as Molecular Probes for the Study of Multidrug Resistance, Exp. Cell Res. , vol. 174, pp. 168 176 (1988).",EXPIRED
275,US,A,US 5781336 A,046-728-321-873-170,1998-07-14,1998,US 56365695 A,1995-11-28,US 56365695 A,1995-11-28,Method and system for multi-spectral imaging in the visible and infrared spectrums,"Multi-spectral images are detected using a refractive objective lens system. Magnesium oxide (MgO) and calcium fluoride (CaF.sub.2) lenses are used to image scenes in both the visible and infra-red (IR) spectrums. The inventors have discovered that the combination of magnesium oxide, only recently made available in a pure crystal form, and calcium fluoride can be used to fabricate an objective lens for imaging objects in both the visible and infra-red spectrums. Moreover, the combination of magnesium oxide and calcium fluoride results in a super-achromatic condition across visible and infra-red spectrums. This chromatically-corrected spectral range includes wavelengths between 0.4 and 5.9 microns which covers medium-wave IR (MWIR), short-wave IR (SWIR), and the near-IR/visible windows. Combinations of MgO and CaF.sub.2 lenses are used in different compound objective lens designs including doublet, Petzval, inverted telephoto, and telephoto arrangements. Visible and/or IR applications for the multi-spectral objective lens system include telescopes, reconnaissance planes, satellites, forward-looking IR (FLIR) and staring sensor systems, night-vision goggles, and other optic and/or electro-optic detection systems.",LOCKHEED CORP,COON BRYAN;;MCGEE III JOHN F;;SHERMAN NEIL;;MONTULLI LOU,BAE SYSTEMS INFORMATION AND ELECTRONIC SYSTEMS INTEGRATION INC (2000-11-27);;LORAL FAIRCHILD CORPORATION (1996-02-26);;LOCKHEED MARTIN CORPORATION (1998-05-01),https://lens.org/046-728-321-873-170,Granted Patent,yes,17,63,7,7,0,G02B1/02;;G02B13/146;;G02B1/02;;G02B13/146,G02B1/02;;G02B13/14,G2J JB7CX         JB7CX;;G2J JB7C19        JB7CX;;G2J JB7C2         JB7CX;;G2J JB7C3         JB7CX;;G2J JB7C7         JB7CX,1,0,,,"Born, M., et al., Principles of Optics , 6th ed., Pergamon Press, Elmsford, NY, 1980, pp. 235 237.",EXPIRED
276,CA,A1,CA 2190636 A1,065-876-867-453-550,1995-11-30,1995,CA 2190636 A,1995-05-19,US 24603794 A,1994-05-19,METHODS AND COMPOSITIONS FOR REDUCING MULTIDRUG RESISTANCE,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH PRESBYTERIAN ST LUKE,BALASUBRAMANIAN MANNARSAMY;;SHAH HIMANSHU;;COON JOHN S;;EMANUELE R MARTIN,,https://lens.org/065-876-867-453-550,Patent Application,no,0,0,5,18,0,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08;;A61K38/08;;A61K31/785,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08,,0,0,,,,DISCONTINUED
277,WO,A3,WO 1995/031981 A3,064-394-955-636-877,1995-11-30,1995,US US9506167,1995-05-19,"US 8/246,037",1994-05-19,METHODS AND COMPOSITIONS FOR REDUCING MULTIDRUG RESISTANCE,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH-PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER,"COON, John, S.;;BALASUBRAMANIAN, Mannarsamy;;EMANUELE, R., Martin;;SHAH, Himashu",,https://lens.org/064-394-955-636-877,Search Report,yes,0,0,1,1,0,,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08,,0,0,,,,UNKNOWN
278,EP,B1,EP 2835642 B1,078-774-936-783-110,2018-01-17,2018,EP 14182039 A,2005-03-11,US 55287604 P;;US 57288404 P;;US 59934104 P;;EP 10169367 A;;EP 05727506 A,2004-03-12,Electron transfer dissociation for biopolymer sequence analysis,"The invention relates to a method of fragmenting positively charged peptide ions in an RF field mass spectrometer or an RF'field ion containment device, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide ion, resulting in the fragmentation of the positively charged sample ion. The invention also provides a method of performing sequence analysis of a peptide or protein by mass spectrometry, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide or protein ion, resulting in the fragmentation of the positively charged sample ion.",UNIV VIRGINIA PATENT FOUNDATION,HUNT DONALD;;COON JOSHUA;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD,,https://lens.org/078-774-936-783-110,Granted Patent,yes,7,0,20,20,0,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,17,12,144-870-721-279-20X;;116-488-492-444-589;;076-814-972-077-732;;036-293-959-621-316;;029-594-486-513-774;;010-322-299-590-660;;073-803-555-225-017;;010-880-868-431-579;;031-739-013-565-001;;036-566-413-093-233;;071-937-348-115-14X;;098-112-355-585-100,10.1255/ejms.517;;10.1021/j100170a006;;24234636;;10.1016/1044-0305(92)87082-a;;10.1016/s0168-1176(96)04510-7;;11006587;;10.1002/1097-0231(20001015)14:19<1793::aid-rcm95>3.0.co;2-q;;10.1016/j.ijms.2004.05.005;;15210983;;pmc470779;;10.1073/pnas.0402700101;;15762593;;10.1021/ac0483872;;pmc1564063;;10.1016/s1387-3806(00)00339-0;;10.1021/ac990811p;;10695143;;10.1002/mas.20048;;15706594;;10.1021/ja00151a021,"ROMAN A. ZUBAREV ET AL.: ""Towards An Understanding of the Mechanism of Electron-Capture Dissociation: A Historical Perspective and Modern Ideas"", EUR. J. MASS SPECTROM., vol. 8, no. 5, 2002, pages 337 - 349, XP055525716;;""Naphthalene"", DATASHEETS FOR GAS PHASE ION ENERGETICS DATA RETRIEVED FROM NIST CHEMISTRY WEBBOOK FOR NAPHTHALENE, ANTHRACENE, PYRENE AND CHRYSENE, 2017, XP055525730;;RACHEL R. OGORZALEK LOO ET AL.: ""Evidence of Charge Inversion In the Reaction of Singly Charged Anions with Multiply Charged Macrolons"", J. PHYS. CHEM., vol. 95, 1991, pages 6412 - 6415, XP055525740;;RACHEL R. OGORZALEK LOO ET AL.: ""A New Approach for the Study of Gas-Phase Ion-Ion Reactions Using electrospray Ionization"", J. AM. SOC. MASS SPECTROM., vol. 3, 1992, pages 695 - 705, XP007917555;;JAMES L. STEPHENSON JR. ET AL.: ""Adaptation of the Paul Trap for study of the reaction of multiply charged anions with singly charged anions"", INTERNATIONAL JOURNAL OF MASS SPECTROMETRY AND ION PROCESSES, vol. 162, no. 1-3, 1997, pages 89 - 106, XP002732714;;ALLAN STENSBALLE ET AL.: ""Electron capture dissociation of singly and multiply phosphorylated peptides"", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 14, 2000, pages 1793 - 1800, XP055525760;;JOSHUA J. COON ET AL.: ""Anion dependence in the partitioning between proton and electron transfer in ion/ion reactions"", INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, vol. 236, no. 1-3, 19 June 2004 (2004-06-19), pages 33 - 42, XP027554913;;SYKA ET AL.: ""PEPTIDE AND PROTEIN SEQUENCE ANALYSIS BY ELECTRON TRANSFER DISSOCIATION MASS SPECTROMETRY"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 101, no. 26, 29 June 2004 (2004-06-29), pages 9528 - 9533, XP009051646;;SHARON J. PITTERI ET AL.: ""Electron Transfer Ion/Ion Reactions in a Three-Dimensional Quadrupole Ion Trap: Reactions of Doubly and Triply Protonated Peptides with SO2"", ANAL. CHEM., vol. 77, no. 6, 5 February 2005 (2005-02-05), pages 1831 - 1839, XP055525778;;ANNE H. PAYNE ET AL.: ""Gas-phase ion/ion interactions between peptides or proteins and iron ions in a quadrupole ion trap"", INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, vol. 204, no. 1-3, 2001, pages 47 - 54, XP002732713;;COON JOSHUA J. ET AL.: ""Electron Transfer Dissociation: a non-ergodic process for the masses"", PROCEEDINGS OF THE 52ND ASMS CONFERENCE ON MASS SPECTROMETRY AND ALLIED TOPICS, 23 May 2004 (2004-05-23), Nashville, Tennessee, XP055525790;;ROMAN A. ZUBAREV ET AL.: ""Electron Capture Dissociation for Structural Characterization of Multiply Charged Protein Cations"", ANAL. CHEM., vol. 72, no. 284, 5 January 2000 (2000-01-05), pages 563 - 573, XP055525797;;SHARON J. PITTERI ET AL.: ""RECENT DEVELOPMENTS IN THE ION/ION CHEMISTRY OF HIGH-MASS MULTIPLY CHARGED IONS"", MASS SPECTROMETRY REVIEWS, vol. 24, no. 6, 10 February 2005 (2005-02-10), pages 931 - 958, XP007905556;;WILLIAM J. HERRON ET AL.: ""Gas-Phase Electron Transfer Reactions from Multiply-Charged Anions to Rare Gas Cations"", J. AM. CHEM. SOC., vol. 117, no. 46, 1995, pages 11555 - 11562, XP055525803;;MELANIE J. SCHROEDER ET AL.: ""Analysis of Phosphopeptides with Electron Transfer Dissociation on a Chromatographic Time Scale"", ASMS, April 2004 (2004-04-01), XP055525807;;MELANIE J. ET AL.: ""Analysis of Phosphopeptides with Electron Transfer Dissociation on a Chromatographic Time Scale"", PROCEEDINGS OF THE 52ND ASMS CONFERENCE ON MASS SPECTROMETRY AND ALLIED TOPICS, August 2004 (2004-08-01), XP055525811;;JOHN E. P. SYKA ET AL.: ""Simultaneous Trapping of Positive and Negative Ions in RF Linear Multipole Ion Traps For Performing Ion/Ion Experiments"", ASMS, August 2004 (2004-08-01), XP055525814",INACTIVE
279,EP,A1,EP 2239574 A1,000-775-801-346-604,2010-10-13,2010,EP 10169367 A,2005-03-11,EP 05727506 A;;US 55287604 P;;US 57288404 P;;US 59934104 P,2004-03-12,Electron transfer dissociation for biopolymer sequence analysis,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.
",UNIV VIRGINIA,HUNT DONALD;;COON JOSHUA;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD,,https://lens.org/000-775-801-346-604,Patent Application,yes,1,1,20,20,71,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,11,11,073-803-555-225-017;;100-670-378-310-085;;115-238-949-200-640;;139-344-218-489-129;;040-286-853-815-47X;;054-947-093-781-361;;025-523-151-463-02X;;030-460-807-381-496;;044-059-272-957-811;;005-608-730-830-354;;039-744-701-942-955,15210983;;pmc470779;;10.1073/pnas.0402700101;;10.1016/j.jasms.2005.01.015;;15907703;;10.1021/ja973478k;;2138240;;10.1016/0076-6879(90)82049-8;;10.1111/j.1749-6632.1992.tb38648.x;;1482093;;10.1021/ac50008a014;;10.1021/ac50035a017;;10.1016/s1044-0305(02)00384-7;;12056566;;11008759;;10.1021/ac000497v;;10.1038/nbt0302-301;;11875433;;10.1016/1044-0305(94)80016-2;;24226387,"SYKA JOHN E P ET AL: ""Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 29 JUN 2004, vol. 101, no. 26, 29 June 2004 (2004-06-29), pages 9528 - 9533, XP009051646, ISSN: 0027-8424;;COON JOSHUA J ET AL: ""Electron transfer dissociation of peptide anions."", June 2005, JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY. JUN 2005, VOL. 16, NR. 6, PAGE(S) 880 - 882, ISSN: 1044-0305, XP004904047;;MCLAFFERTY ET AL., J. AM. CHEM. SOC. 1998, vol. 120, 1998, pages 3265 - 3266;;SEIFTER ET AL., METH ENZYMOL, vol. 182, 1990, pages 626 - 646;;RATTAN ET AL., ANN NY ACAD SCI, vol. 663, 1992, pages 48 - 62;;HUNT ET AL., ANAL. CHEM., vol. 48, 1976, pages 2098;;HUNT ET AL., ANAL. CHEM., vol. 50, 1978, pages 1781 - 1784;;SCHWARTZ, J. AM. SOC. MASS SPECTROM., vol. 13, 2002, pages 659 - 669;;MARTIN ET AL., ANAL CHEM., vol. 72, 2000, pages 4266 - 4274;;FICARRO ET AL., NAT. BIOTECHNOL., vol. 20, 2002, pages 301 - 305;;ENG ET AL., J. AM. SOC. MASS SPECTROM., vol. 5, 1994, pages 976 - 989",DISCONTINUED
280,US,A,US 5591715 A,118-024-187-527-49X,1997-01-07,1997,US 47499495 A,1995-06-07,US 47499495 A;;US 44519195 A;;US 24603794 A;;US 98276692 A;;US 80518691 A,1991-12-10,Methods and compositions for reducing multidrug resistance,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH PRESBYTERIAN ST LUKE,COON JOHN S;;BALASUBRAMANIAN MANNARSAMY;;EMANUELE R MARTIN;;SHAH HIMANSHU,RUSH PRESBYTERIAN-ST. LUKE'S MEDICAL CENTER (1995-07-21),https://lens.org/118-024-187-527-49X,Granted Patent,yes,14,25,3,18,0,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K38/08;;A61K47/60;;A61K31/70;;A61K31/785;;A61K31/77;;A61K38/04;;A61K38/08;;A61K31/765;;A61K47/60,A61K31/70;;A61K31/765;;A61K31/77;;A61K31/785;;A61K38/04;;A61K38/08;;A61K47/48,514/10;;514/34;;514/35;;514/183;;514/283;;514/411;;514/506;;514/515;;514/765;;514/950,47,46,039-897-437-195-176;;037-971-434-683-369;;072-054-424-022-015;;036-785-375-873-692;;086-378-184-009-266;;016-018-646-557-905;;007-222-496-771-886;;018-556-800-235-746;;051-285-326-497-347;;004-185-224-654-759;;051-870-389-854-660;;101-667-114-885-562;;159-538-400-711-954;;030-111-405-797-119;;033-807-008-821-976;;032-998-418-535-321;;002-966-950-935-095;;002-983-452-841-832;;027-640-927-117-34X;;072-614-477-610-622;;085-799-967-891-485;;076-921-233-571-765;;006-200-528-711-033;;111-157-639-857-903;;095-460-103-606-528;;070-287-001-960-450;;027-646-417-200-044;;006-779-421-891-260;;069-316-535-749-718;;060-285-179-840-446;;006-444-184-357-771;;029-271-145-472-402;;016-273-016-183-900;;071-418-010-988-379;;006-837-075-345-488;;014-182-871-517-039;;040-197-906-739-868;;013-658-838-125-169;;062-602-961-341-953;;120-498-104-909-799;;119-437-082-629-053;;042-950-635-383-846;;101-365-513-459-743;;029-652-583-748-834;;035-358-782-608-447;;022-673-243-503-601,2364376;;5030820;;pmc1977900;;1637678;;10.1038/bjc.1992.217;;10.1146/annurev.bi.58.070189.001033;;2570548;;10.1146/annurev.biochem.58.1.137;;1868977;;10.1096/fasebj.5.11.1868977;;3459160;;10.1073/pnas.83.11.3847;;pmc323621;;1581902;;10.1016/0092-8674(86)90595-7;;2876781;;2412130;;10.1038/316820a0;;571759;;10.1038/324485a0;;2878368;;10.1177/35.12.2890686;;2890686;;10.1016/s0021-9258(19)57324-0;;2891711;;10.1016/0005-2736(76)90160-7;;990323;;3711108;;10.1016/s0021-9258(19)57466-x;;1359116;;10.1093/jnci/81.2.116;;2562856;;10.1016/0092-8674(86)90594-5;;3768958;;6728022;;10.1038/309626a0;;10.1126/science.3576227;;3576227;;2421411;;10.1126/science.2421411;;2431283;;10.1128/mcb.6.5.1671;;pmc367694;;10.1128/mcb.6.5.1671-1678.1986;;3022150;;10.1038/323728a0;;10.1200/jco.1987.5.12.1922;;3681376;;pmc323769;;3459187;;10.1073/pnas.83.12.4538;;pmc391393;;10.1073/pnas.82.22.7661;;3865187;;10.1016/s0021-9258(19)75806-2;;3027054;;pmc280426;;10.1073/pnas.85.12.4350;;3380797;;10.1073/pnas.84.1.265;;2432605;;pmc304184;;10.1093/jnci/80.4.269;;2895190;;3457471;;10.1126/science.3457471;;2890168;;pmc299368;;10.1073/pnas.84.21.7701;;10.1126/science.1360704;;1360704;;4855907;;10.1002/jcp.1040830114;;3856953;;10.1007/bf01534700;;3860286;;4005839;;719649;;3495806;;10.1073/pnas.84.12.4288;;pmc305070;;1671173;;10.1073/pnas.88.2.547;;pmc50848;;1988130;;1681415;;2576349;;3335222;;10.1016/0014-4827(88)90152-8;;10.1002/ijc.2910620413;;7635569;;8093856;;10.1007/bf01754414,"Woodcock, D., et al., Reversal of the Multidrug Resistance Phenotype with Cremophor EL, a Common Vehicle for Water insoluble Vitamins and Drugs, Cancer Research, vol. 50, pp. 4199 4230 (Jul. 15, 1990).;;Riehm, H., et al., Potentiation of Drug Effect by Tween 80 in Chinese Hamster Cells Resistant to Actinomycin D. and Daunomycin, Cancer Research, vol. 32, pp. 1195 1200 (Jun. 1972).;;Woodcock, D., et al., Reversal of Multidrug resistance by surfactants, Br. J. Cancer, vol. 66, pp. 62 88 (Jul. 1992).;;Endicott, J., et al., The Biochemistry of P Glycoprotein Mediated Multidrug Resistance, Annu. Rev. Biochem., vol. 58, pp. 137 171 (1989).;;Pastan, I., et al., Molecular Manipulations of the Multidrug Transporter: A New Role for Transgenic Mice, FASEB Journal, vol. 5, pp. 2523 2528 (1991).;;Drug & Market Development, Multidrug Resistance in Cancer Therapy, Drug & Market Development, vol. 3, No. 1/2 (Jul. 6, 1992).;;Cornwell, M., et al., Membrane Vesicles from Multidrug Resistant Human Cancer Cells Contain a Specific 150 to 170 kDA Protein Detected by Photoaffinity Labeling, Proc. Natl. Acad. Sci., USA, vol. 83, pp. 3847 3850 (1986).;;Sehested, M., et al., Relationship of VP 16 to the Classical Multidrug Resistance Phenotype, Cancer Research, vol. 52, pp. 2874 2879 (May 15, 1992).;;Chen, C., et al., Internal Duplication and Homology with Bacterial Transport Proteins in the MDRI (P Glycoprotein) Gene from Multidrug Resistant Human Cells, Cell, vol. 47, pp. 381 389 (1986).;;Kartner, N., et al., Detection of P Glycoprotein in Multidrug Resistant Cell Lines by Monoclonal Antibodies, Nature, vol. 316, pp. 820 823 (1985).;;Beck, W., et al., Altered Surface Membrane Glycoproteins in Vinca Alkoloid resistant Human Leukemic Lymphoblasts, Cancer Research, vol. 39, pp. 2070 2076 (1979).;;Gerlack, J., et al., Homology Between P Glycoprotein and a Bacterial Haemolysin Transport Protein Suggess a Model for Multidrug Resist ant, Nature, vol. 324, pp. 485 489 (1986).;;Willingham, M., et al., Immunocytochemical Localization of P170 at the Plasma Membrane of Multidrug Resistant Human Cells, Journal of Histochemistry and Cytochemistry, vol. 35, No. 12, pp. 1451 1456 (1987).;;Hamada, H., et al., Purification of the 170 to 180 Kilodalton Membrane Glycoprotein Associated with Multidrug Resistance, Journal of Biological Chemistry, vol. 263, No. 3, pp. 1454 1458 (1988).;;Juliano, R., et al., A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants, Biochemica et Biophysica Acta, vol. 455, pp. 152 162 (1976).;;Shen, D., et al., Multiple Drug Resistant Human KB Carcinoma Cells Independently Selected for High Level Resistance to Colchicine, Adriamycin, or Vinblastine Show Changes in Expression of Specific Proteins, Journal of Biological Chemistry, vol. 261, No. 17, pp. 7762 7770 (1986).;;Dordal, M., et al., Kinetic Analysis of P Glycoprotein Mediated Doxorubicin Efflux, The Journal of Pharmacology and Experimental Theerapeutics, vol. 263, pp. 752 766 (Nov. 1992).;;Goldstein, L., et al., Expression of a Multidrug Resistance Gene in Human Cancers, Journal of the National Cancer Institute, vol. 81, No. 2, pp. 116 124 (1989).;;Gros, P., et al., Mammalian Multidrug Resistance Gene: Complete cDNA Sequence Indicates Strong Homology to Bacterial Transport Proteins, Cell, vol. 47, pp. 371 380 (1986).;;Roninson, I., et al., Amplification of Specific DNA Sequences Correlates with Multi drug Resistance in Chinese Hamster Cells, Nature, vol. 309, pp. 626 628 (1984).;;Thorgeirsson, S., et al., Expression of the Multidrug Resistant Gene in Hepatocarcinogenesis and Regenerating Rat Liver, Science, vol. 236, pp. 1120 1122 (1987).;;Scotto, K., et al., Amplification and Expression of Genes Associated with Multidrug Resistance in Mammalian Cells, Science, vol. 232, pp. 751 755 (May 9, 1986).;;Van der Bliek, A., et al., Overexpression and Amplification of Five Genes in a Multidrug Resistant Chinese Hamster Ovary Cell Line, Molecular and Cellular Biology, vol. 6, No. 5, pp. 1671 1678 (1986).;;Gros, P., et al., Isolation and Expression of a Complementary DNA that Confers Multidrug Resistance, Nature, vol. 323, pp. 728 732 (1986).;;Fojo, A., et al., Intrinsic Drug Resistance in Human Kidney Cancer is Associated with Expression of a Human Multidrug Resistance Gene, Journal of Clinical Oncology, vol. 5, No. 12, pp. 1922 1927 (1987).;;Roninson, I., et al., Isolation of Human mdr DNA Sequences Amplified in Multidrug Resistant KB Carcinoma Cells, Proc. Natl. Acad. Sci., USA, vol. 83, pp. 4538 4542 (1986).;;Fojo, A., et al., Amplification of DNA Sequences in Human Multidrug Resistant KB Carcinoma Cells, Proc. Natl. Acad. Sci. USA, vol. 82, pp. 7661 7665 (1985).;;Ueda, K., et al., The Human Multidrug Resistant (mdrl) Gene, Journal of Biological Chemistry, vol. 262, pp. 505 508 (1987).;;Arceci, R., et al., The Gene Encoding Multidrug Resistance is Induced and Expressed at High Levels During Pregnancy in the Secretory Epithelium of the Uterus, Proc. Natl., Acad. Sci., USA, vol. 85, pp. 4350 4354 (1988).;;Fojo, A., et al., Expression of a Multidrug resistance Gene in Human Tumors and Tissues, Proc. Natl. Acad. Sci., USA, vol. 84, pp. 265 269 (1987).;;Mukhopadhyay, T., et al., Expression of the mdr (P Glycoprotein) Gene in Chinese Hamster Digestive Tracts, Journal of the National Cancer Institute, vol. 80, No. 4, pp. 269 275 (1988).;;Shen, D., et al., Human Multidrug Resistant Cell Lines: Increased mdrl Expression Can Precede Gene Amplification, Science, vol. 232, pp. 643 645 (1986).;;Fairchild, C., et al., Carcinogen Induced mdr Overexpression is Associated with Xenobiotic Resistance in Rat Preneoplastic Liver Nodules and Hepatocellular Carcinomas, Proc. Natl. Acad. Sci., USA, vol. 84, pp. 7701 7705 (1987).;;Cole, S., et al., Overexpression of a Transporter Gene in a Multidrug Resistant Human Lung Cancer Cell Line, Science, vol. 258, pp. 1650 1654 (Dec. 4, 1992).;;Ling, V., et al., Reduced Permeability in CHO Cells as a Mechanism of Resistance to Colchinine, J. Cell. Physiol., vol. 83, pp. 103 116 (1974).;;Akiyama, S., et al., Isolation and Genetic Characterization of Human KB Cell Lines Resistant to Multiple Drugs, Somatic Cell and Molecular Genetics, vol. 11, No. 1, pp. 117 126 (1985).;;Bhalla, K., et al., Isolation and Characterization of an Anthracycline Resistant Human Leukemic Cell Line, Cancer Research, vol. 45, pp. 3657 3662 (1985).;;Fojo, A., et al., Reduced Drug Accumulation in Multiple Drug Resistant Human KB Carcinoma Cell Lines, Cancer Research, vol. 45, pp. 3002 3007 (1985).;;Skovsgaard, T., Mechanism of Cross Resistance between Vincristin and Daunorubicin in Ehrlich Ascites Tumor Cells, Cancer Research, vol. 38, pp. 4722 4727 (1978).;;FitzGerald, D., et al., A Monoclonal Antibody Pseudomonas Toxin Conjugate that Specifically Kills Multidrug Resistant Cells, Proc. Natl. Acad. Sci., USA, vol. 84, pp. 4288 4292 (1987).;;Micklisch, G., et al., Transgenic Mice that Express the Human Multidrug Resistance Gene in Bone Marrow Enable a Rapid Identification of Agents that Reverse Drug Resistance, Proc. Natl. Acad. Sci., USA, vol. 88, pp. 547 551 (1991).;;Coon, et al., SOLUTOL HS15, nontoxic polyoxyethylene esters of 12 hydroxystearic acid, reverses multidrug resistance, Cancer Research, vol. 51, pp. 897 902 (Feb. 1991).;;Lelong, I., et al., Fluorescent Verapamil Derivative for Monitoring Activity of the Multidrug Transporter, Molecular Pharmacology, vol. 40, pp. 490 494 (1991).;;Efferth, T., et al., Reciprocal Correlation Between Expression of P Glycoprotein and Accumulation of Rhodamine 123 in Human Tumors, Anticancer Res., vol. 9, pp. 1633 1638 (1989).;;Neyfakh, A. A., et al., Use of Fluorescent Dyes as Molecular Probes for the Study of Multidrug Resistance, Exp. Cell Res., vol. 174, pp. 168 176 (1988).;;Buckingham, L. E. et al., Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents, Int. J. Cancer, 62(4):436 442 (1995).;;Chong, A. S. et al. Diverse multidrug resistance modification agents inhibit cytolytic activity of natural killer cells, Cancer Immunol. Immunother., 36(2):133 139 (1993).",EXPIRED
281,WO,A3,WO 2006/042187 A3,186-478-238-155-079,2006-08-24,2006,US 2005/0036337 W,2005-10-07,US 61712504 P,2004-10-08,SIMULTANEOUS SEQUENCE ANALYSIS OF AMINO- AND CARBOXY- TERMINI,"The present invention relates to a new method for identifying polypeptides by deducing the amino acid sequence of the carboxy and amino termini by a mass spectrometer analysis. The method comprises the steps of dissociating highly charged peptide precursor ions (e.g., z ᡶ 4) using electron transfer dissociation inducing anions followed by removal of those reagents and introduction of a second, proton transfer inducing anion type. The second PTR reaction duration is adjusted to convert the ETD products to primarily the + 1 charge-state to reduce the highly charged c and z-type fragments, producing an m/z spectrum containing a series of c and z-type fragment ions that are easily interpreted to reveal the sequence of the amino and carboxy terminus, respectively.",UNIV VIRGINIA;;HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP,,https://lens.org/186-478-238-155-079,Search Report,yes,1,0,14,14,0,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N33/68,,3,3,073-803-555-225-017;;043-610-381-684-918;;031-099-180-915-969,15210983;;pmc470779;;10.1073/pnas.0402700101;;11838679;;10.1021/ac015618l;;15983376;;pmc1172258;;10.1073/pnas.0503189102,"SYKA J E P ET AL: ""PEPTIDE AND PROTEIN SEQUENCE ANALYSIS BY ELECTRON TRANSFER DISSOCIATION MASS SPECTROMETRY"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 26, 29 June 2004 (2004-06-29), pages 9528 - 9533, XP009051646, ISSN: 0027-8424;;REID GAVIN E ET AL: ""Tandem mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions."", ANALYTICAL CHEMISTRY. 1 FEB 2002, vol. 74, no. 3, 1 February 2002 (2002-02-01), pages 577 - 583, XP002385857, ISSN: 0003-2700;;COON JOSHUA J ET AL: ""Protein identification using sequential ion/ion reactions and tandem mass spectrometry"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 27, July 2005 (2005-07-01), pages 9463 - 9468, XP002385858, ISSN: 0027-8424",PENDING
282,WO,A2,WO 1995/031981 A2,073-573-679-201-972,1995-11-30,1995,US 9506167 W,1995-05-19,US 24603794 A,1994-05-19,METHODS AND COMPOSITIONS FOR REDUCING MULTIDRUG RESISTANCE,"The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.",RUSH PRESBYTERIAN ST LUKE,COON JOHN S;;BALASUBRAMANIAN MANNARSAMY;;EMANUELE R MARTIN;;SHAH HIMASHU,,https://lens.org/073-573-679-201-972,Patent Application,no,0,0,5,18,0,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08;;A61K38/08;;A61K31/785,A61K31/765;;A61K31/77;;A61K31/785;;A61K38/08,,0,0,,,,PENDING
283,US,A1,US 2014/0332544 A1,127-956-800-415-688,2014-11-13,2014,US 201313891307 A,2013-05-10,US 201313891307 A;;US 201261645669 P,2012-05-11,Safety Shield for Fuel Gas Tank,"A protective shield fits onto a fuel cylinder that is mounted on a propane-powered or LNG-powered vehicle, with a cylindrical flange on the the tank surrounds a tank valve. The protective shield is formed of a cylindrical wall of a rubber-like material that fits snugly onto the cylindrical flange of the fuel tank, and has a window affixed into its upper end of the cylindrical wall. The window can be a disk of transparent Plexiglas. There are openings in the cylindrical wall to access the tank valve. The shield provides visibility of the tank valve but prevents any spray of the fuel that may escape from the tank valve from reaching the worker's face or other exposed skin.",NOLAN SHAWN;;FEY MICHAEL;;COON RICHARD R;;FITZSIMMONS JOHN J;;TANK RIGHT SYSTEMS LLC,NOLAN SHAWN;;FEY MICHAEL;;COON RICHARD R;;FITZSIMMONS JOHN J,TANK RIGHT SYSTEMS LLC (2013-05-03),https://lens.org/127-956-800-415-688,Patent Application,yes,11,8,2,2,0,F17C2205/0308;;F17C2201/0109;;F17C2201/058;;F17C2203/0639;;F17C2205/018;;F17C2221/035;;F17C2223/0153;;F17C2223/033;;F17C2260/037;;F17C2260/038;;F17C13/06;;F17C13/06;;F17C2203/0639;;F17C2223/033;;F17C2201/058;;F17C2205/0308;;F17C2260/038;;F17C2223/0153;;F17C2205/018;;F17C2260/037;;F17C2201/0109;;F17C2221/035;;B65D43/0222,F17C13/06;;B65D43/02,220/731,0,0,,,,INACTIVE
284,US,B2,US 7749769 B2,044-076-465-062-269,2010-07-06,2010,US 66466105 A,2005-10-07,US 66466105 A;;US 61712504 P;;US 2005/0036337 W,2004-10-08,Simultaneous sequence analysis of amino- and carboxy-termini,"The present invention relates to a new method for identifying polypeptides by deducing the amino acid sequence of the carboxy and amino termini by a mass spectrometer analysis. The method comprises the steps of dissociating highly charged peptide precursor ions (e.g., z>4) using electron transfer dissociation inducing anions followed by removal of those reagents and introduction of a second, proton transfer inducing anion type. The second PTR reaction duration is adjusted to convert the ETD products to primarily the +1 charge-state to reduce the highly charged c and z-type fragments, producing an m/z spectrum containing a series of c and z-type fragment ions that are easily interpreted to reveal the sequence of the amino and carboxy terminus, respectively.",UNIV VIRGINIA,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2006-01-17);;UNIVERSITY OF VIRGINIA (2006-03-17),https://lens.org/044-076-465-062-269,Granted Patent,yes,5,45,14,14,10,G01N33/6818;;G01N33/6848;;Y10T436/25875;;Y10T436/24;;G01N33/6818;;H01J49/02;;Y10T436/25875;;Y10T436/24;;G01N33/6848;;G01N33/6818,G01N24/00;;H01J49/00,436/173;;436/181;;250/290,41,39,000-668-228-617-649;;031-099-180-915-969;;043-610-381-684-918;;073-803-555-225-017;;115-238-949-200-640;;033-543-562-828-538;;100-670-378-310-085;;001-606-043-013-366;;005-608-730-830-354;;098-112-355-585-100;;019-516-456-791-769;;064-538-289-011-209;;044-059-272-957-811;;060-261-856-877-988;;060-271-576-596-355;;036-293-959-621-316;;023-322-087-682-952;;029-989-480-458-141;;004-660-596-110-998;;118-237-876-274-626;;010-322-299-590-660;;038-868-176-197-587;;039-744-701-942-955;;132-515-506-234-445;;054-830-868-444-813;;054-947-093-781-361;;025-523-151-463-02X;;056-323-467-883-90X;;000-668-228-617-649;;040-286-853-815-47X;;060-106-417-058-040;;086-149-134-310-342;;030-460-807-381-496;;139-344-218-489-129;;009-873-623-830-140;;073-803-555-225-017;;125-695-351-039-457;;006-171-750-125-393;;115-238-949-200-640,10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.0.co;2-j;;10360331;;10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.3.co;2-a;;15983376;;pmc1172258;;10.1073/pnas.0503189102;;11838679;;10.1021/ac015618l;;15210983;;pmc470779;;10.1073/pnas.0402700101;;10.1021/ja973478k;;10.1021/cr990076h;;11712248;;10.1016/j.jasms.2005.01.015;;15907703;;10.1002/mas.20004;;15389865;;10.1038/nbt0302-301;;11875433;;10.1021/ja00151a021;;pmc1570753;;10.1021/ja0526057;;16144411;;10.1016/1044-0305(94)85067-4;;24226512;;11008759;;10.1021/ac000497v;;9530009;;10.1021/ac9710137;;10.1021/ac970399i;;10.1016/s0168-1176(96)04510-7;;10.1016/s1044-0305(97)00023-8;;10.1021/ac9802832;;9737205;;10.1016/s1044-0305(01)00364-6;;12056562;;10.1021/ac034900k;;14750868;;10.1016/j.ijms.2004.05.005;;10.1139/o04-043;;15284902;;10.1016/1044-0305(94)80016-2;;24226387;;10.1021/pr0499491;;15473683;;10.1002/jms.458;;12644985;;10.1021/ac50008a014;;10.1021/ac50035a017;;0009305837;;9305837;;10.1038/38444;;10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.0.co;2-j;;10360331;;10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.3.co;2-a;;10.1111/j.1749-6632.1992.tb38648.x;;1482093;;10.1021/ja025966k;;12071744;;12124999;;10.1002/jms.346;;10.1016/s1044-0305(02)00384-7;;12056566;;2138240;;10.1016/0076-6879(90)82049-8;;10.1021/pr0499794;;15253445;;15210983;;pmc470779;;10.1073/pnas.0402700101;;10.1021/ac9605657;;8916454;;10.1021/ja035051l;;12797797;;10.1021/ja973478k,"McLuckey et al, (Ion/Ion Chemistry of High-Mass Multiply Charged Ions, Mass Spectrometry Reviews, vol. 17, pp. 369-407 (1998)).;;Coon, Joshua J. et al.: ""Protein Identification Using Sequential Ion/Ion Reactions And Tandem Mass Spectrometry"" Proceedings of the National Academy of Sciences of U.S.A. , vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468, XP002385858.;;Reid, Gavin E. et al.: ""Tandem Mass Spectrometry Of Ribonuclease A and B:N-Linked Glycosylation Site Analysis Of Whole Protein Ions"" Analytical Chemistry , vol. 74, No. 3, Feb. 1, 2002, pp. 577-583, XP002385857.;;Syka, John, Edward, Philip et al.: ""Peptide And Protein Sequence Analysis By Electron Transfer Dissociation Mass Spectrometry"" Proceedings of the National Academy of Sciences of U.S.A. , vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533, XP009051646.;;McLafferty at al., ""Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process"", J. Am. Chem. Soc., vol. 120, 1998, pp. 3265-3266.;;Aebersold, Ruedi et al.; ""Mass Spectrometry in Proteomics,"" Chem. Rev, vol. 101, No. 2, Feb. 2001, pp. 269-295.;;Coon, Joshua J. et al., ""Electron Transfer Dissociation of Peptide Anions,"" American Society for Mass Spectrometry, vol. 16, Nr. 6, Jun. 2005, pp. 880-882.;;Douglas, et al., ""Linear Ion Traps in Mass Spectrometry"", 2005, Mass Spectrometry Reviews, No. 24, pp. 1-29.;;Ficarro, et al., ""Phosphoproteome Analysis by Mass Spectrometry and its Application to Saccharomyces cerevisiae"", J. Am. Chem. Soc., vol. 20, 2002, pp. 301-305.;;Herron, et al., ""Gas-Phase Electron Transfer Reactions from Multiply-Charged Anions to Rare Gas Cations"", J. Am. Chem. Soc., vol. 117, 1995, pp. 11555-11562.;;Gunawardena, et al., ""Electron Transfer Versus Proton Transfer in Gas-Phase Ion/Ion Reactions of Polyprotonated Peptides"", American Chem. Soc., vol. 127, 2005, pp. 12627-12639.;;Loo, et al., ""Proton Transfer Reaction Studies of Multiply Charge Proteins in a High Mass-to-Charge Ratio Quadrupole Mass Spectrometry"", J. Am. Soc. Mass Spectrometry, vol. 5, 1994, pp. 1064-1071.;;Martin, et al., ""Subfemtomole MS and MS/MS Peptide Sequence Analysis Using Nano-IIPLC Micro-ESI Fourier Transform Ion Cyclotron Resonance Mass Spectrometry"", Anal. Chem., vol. 72, 2000, pp. 4266-4274.;;McLuckey, et al., ""Ion/Ion Proton-Transfer Kinetics: Implications for Analysis of Ions Derived from Electrospray of Protein Mixtures"", Anal. Chem., vol. 70, 1998, pp. 1198-1202.;;Stephenson, et al., ""Anion Effects on Storage and Resonance Ejection of High Mass-to-Charge Cations in Quadrupole Ion Trap Mass Spectrometry"", Anal. Science, vol. 69, 1997, pp. 3760-3766.;;Stephenson, et al., ""Adaptation of the Paul Trap for Study of the Reaction of Multiply Charged Cations with Singly Charged Ions"", International Jouranl of Mass Spectrometry and Ion Process, vol. 162, 1997, pp. 89-106.;;Stephenson, et al., ""Ion-Ion Proton Transfer Reactions of Bio-Ions Involving Noncovalent Interactions: Holomyoglobin"", J. Am. Soc. Mass Spectrometry, vol. 8, 1997, pp. 637-644.;;Stephenson, et al., ""Simplification of Product Ion Spectra Derived from Multiply Charged Ions via Ion/Ion Chemistry"", Anal. Chem., vol. 70, 1998, pp. 3533-3544.;;Wells, et al., ""Dueling"" ESI: Instrumentation to Study Ion/Ion Reactions of Electrospray-Generated Cations and Anions, American Society of Mass Spectrometry, vol. 13, 2002, pp. 614-622.;;Amunugama, R., et al., ""Whole Protein Dissociation in a Quadrupole Ion Trap: Identification of an a Priori Unknown Modified Protein"", Feb. 1, 2004, Analytical Chemistry, vol. 76, No. 3, pp. 720-727.;;Coon, Joshua J., et al., ""Anion Dependence in the Partitioning Between Proton and Electron Transfer in lon/Ion Reactions"", Jun. 19, 2004, International Journal of Mass Spectrometry, No. 236, pp. 33-42.;;Creighton, T. E., ""Proteins-Structure And Molecular Properties"", 2nd Ed., 1993, W. H. Freeman and Company, New York.;;Dryhurst, Deanna, et al., ""New Twists on H2A.Z: A Histone Variant with a Controversial Structural and Functional Past"", 2004, Biochem. Cell Biology, vol. 82, pp. 490-497.;;Eng, Jimmy K., et al., ""An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequences in a Protein Database"", Jun. 29, 1994, American Society for Mass Spectrometry, No. 5, pp. 976-989.;;Geer, Lewis Y., et al., ""Open Mass Spectrometry Search Algorithm"", 2004, Journal of Proteome Research, vol. 3, No. 5. pp. 958-964.;;Hogan. Jason M., et al.. ""Charge State Dependent Collision-Induced Dissociation of Native and Reduced Porcine Elastase"", Mar. 3, 2003, Journal of Mass Spectrometry, No. 38, pp. 245-256.;;Hunt, Donald F., et al.. ""Pulsed Positive Negative Ion Chemical Ionization Mass Spectrometry"". Dec. 1976. Analytical Chemistry, vol. 48, No. 14, pp. 2098-2104.;;Hunt, Donald F., et al., ""Electron Capture Negative Ion Chemical Ionization Mass Spectrometry"", Nov. 1978, Analytical Chemistry, vol. 50, No. 13, pp. 1781-1784.;;Johnson, B. Connor, ""Posttranslational Covalent Modifications of Proteins"", 1893, Academic Press, New York, pp. 1-17.;;Lugar, Karolin, et al. ""Crystal Structure of the Nucleosome Core Particle at 2.8 A Resolution"", Sep. 18, 1997, Nature, vol. 389, pp. 251-260.;;McLuckey, Scott A., et al., ""Ion/Ion Chemistry of High-Mass Multiply Charged Ions"", 1998, Mass Spectrometry Reviews No. 17, pp. 369-407.;;Rattan, Suresh. I. S., et al., ""Protein Synthesis, Posttranslational Modifications, and Aging"", 1992, Annals New York Academy of Sciences, No. 663, pp. 48-62.;;Reid, Gavin E., et al., ""Gas-Phase Concentration, Purification, and Identification of Whole Proteins from Complex Mixtures"", Feb. 18, 2002, American Chemical Society, vol. 124, No. 25, pp. 7353-7362.;;Reid, Gavin E., et al., ""Top Down Protein Characterization Via Tandem Mass Spectrometry"", Jul. 3, 2002, Journal of Mass Spectrometry, No. 37, pp. 663-675.;;Schwartz, Jae C., et al., ""A Two-Dimensional Quadrupole Ion Trap Mass Spectrometer"", Mar. 11, 2002, American Society for Mass Spectrometry, No. 13, pp. 659-669.;;Seifter, Sam, et al., ""Analysis for Protein Modifications and Nonprotein Cofactors"", 1990, Methods in Enzymology, vol. 182, pp. 626-646.;;Syka, John E. P., et al., ""Novel Linear Quadrupole Ion Trap/FT Mass Spectrometer: Performance Characterization and Use in the Comparative Analysis of Histone H3 Post-Translational Modifications"", 2004, Journal of Proteome Research, vol. 3, No. 3, pp. 621-626.;;Syka, John E. P., et al., ""Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry"", Jun. 29, 2004, PNAS, vol. 101, No. 26, pp. 9528-9533.;;Stephenson, James L., et al., ""Ion/Ion Proton Transfer Reactions for Protein Mixture Analysis"", Nov. 15, 1996, Analytical Chemistry, vol. 68, No. 22, pp. 4026-4032.;;Wells, J. Mitchell, et al., ""Formation and Characterization of Protein-Protein Complexes in Vacuo"", 2003, Journal American Chem. Society, vol. 125, No. 24, pp. 7238-7249.;;Zubarev, Roman, A., et al., ""Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process"", 1998, Journal American Chemical Society, vol. 120, No. 13, pp. 3265-3266.",ACTIVE
285,JP,A,JP 2009230757 A,039-699-195-576-461,2009-10-08,2009,JP 2009060702 A,2009-03-13,US 5426708 A,2008-03-24,LOCK MECHANISM FOR PERFORMING ATOMIC UPDATE TO SHARED MEMORY,"<P>PROBLEM TO BE SOLVED: To provide an improved lock mechanism for performing access to a shared memory for executing an atomic memory operation. <P>SOLUTION: A system and method for locking and unlocking access to a shared memory for atomic operation includes giving instantaneous feedback to instruct whether or not lock has been successfully performed. Read data and a lock state are returned to a request origin. The lock state is simultaneously changed when the access is locked under reading or unlocked under reading. Therefore, it is not necessary to check the lock state as any individual transaction before or during a reading/change/writing operation. Furthermore, it is possible to clearly designate lock or unlock to each atomic memory operation. Thus, in the case of an operation requiring no change in the content of the memory position, any lock operation is not executed. <P>COPYRIGHT: (C)2010,JPO&INPIT",NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,,https://lens.org/039-699-195-576-461,Patent Application,no,3,3,7,7,0,G06F9/526;;G06F12/084;;G06F9/3004;;G06F9/30087;;G06F9/30185;;G06F2209/521;;G06F12/084;;G06F9/526;;G06F9/30087;;G06F9/3004;;G06F9/30185;;G06F2209/521,G06F9/52;;G06F12/00,,0,0,,,,ACTIVE
286,US,B2,US 8751771 B2,036-763-966-165-762,2014-06-10,2014,US 201113247855 A,2011-09-28,US 201113247855 A;;US 38794410 P,2010-09-29,Efficient implementation of arrays of structures on SIMT and SIMD architectures,"One embodiment of the present invention sets forth a technique providing an optimized way to allocate and access memory across a plurality of thread/data lanes. Specifically, the device driver receives an instruction targeted to a memory set up as an array of structures of arrays. The device driver computes an address within the memory using information about the number of thread/data lanes and parameters from the instruction itself. The result is a memory allocation and access approach where the device driver properly computes the target address in the memory. Advantageously, processing efficiency is improved where memory in a parallel processing subsystem is internally stored and accessed as an array of structures of arrays, proportional to the SIMT/SIMD group width (the number of threads or lanes per execution group).",FAHS BRIAN;;MORETON HENRY PACKARD;;COON BRETT W;;NICKOLLS KATHLEEN ELLIOTT;;NVIDIA CORP,FAHS BRIAN;;NICKOLLS JOHN R;;MORETON HENRY PACKARD;;COON BRETT W,NVIDIA CORPORATION (2011-09-28);;LINARES MEDICAL DEVICES LLC (2009-04-09),https://lens.org/036-763-966-165-762,Granted Patent,yes,5,6,2,2,0,G06F9/3009;;G06F9/30123;;G06F9/345;;G06F9/3824;;G06F9/3887;;G06F12/0207;;G06T1/20;;G06F9/3851;;G06F12/0207;;G06F9/3887;;G06F9/3824;;G06F9/3009;;G06F9/345;;G06F9/30123;;G06T1/20;;G06F9/30036;;G06F9/3851;;G06F9/3885,G06F12/00;;G06F9/26;;G06F9/30;;G06F9/34;;G06F9/38;;G06F13/00;;G06F13/28,711/220;;711/154,0,0,,,,ACTIVE
287,US,B2,US 8375176 B2,084-593-886-836-716,2013-02-12,2013,US 201113276224 A,2011-10-18,US 201113276224 A;;US 5426708 A,2008-03-24,Lock mechanism to enable atomic updates to shared memory,"A system and method for locking and unlocking access to a shared memory for atomic operations provides immediate feedback indicating whether or not the lock was successful. Read data is returned to the requestor with the lock status. The lock status may be changed concurrently when locking during a read or unlocking during a write. Therefore, it is not necessary to check the lock status as a separate transaction prior to or during a read-modify-write operation. Additionally, a lock or unlock may be explicitly specified for each atomic memory operation. Therefore, lock operations are not performed for operations that do not modify the contents of a memory location.",NVIDIA CORP;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,,https://lens.org/084-593-886-836-716,Granted Patent,yes,10,5,7,7,0,G06F9/526;;G06F12/084;;G06F9/3004;;G06F9/30087;;G06F9/30185;;G06F2209/521;;G06F12/084;;G06F9/526;;G06F9/30087;;G06F9/3004;;G06F9/30185;;G06F2209/521,G06F12/00,711/152;;711/147;;X711E12091,0,0,,,,ACTIVE
288,CA,C,CA 2834210 C,104-474-779-092-012,2019-09-03,2019,CA 2834210 A,2012-05-02,US 201161481987 P;;US 201161509748 P;;CA 2012000412 W,2011-05-03,SLIDING SLEEVE VALVE AND METHOD FOR FLUID TREATING A SUBTERRANEAN FORMATION,"A sliding sleeve valve for wellbore operations includes: a tubular body including a tubular wall including an outer surface and an inner surface defining an inner bore; a fluid port extending through the tubular wall and providing fluidic communication between the outer surface and the inner bore; a sliding sleeve in the inner bore slidably moveable between a port closed position and a port open position, the sliding sleeve including a ball seat on which a plug is landed to move the sleeve from the port closed position to the port open position; an initial sleeve holding mechanism for holding the sliding sleeve in the port closed position, the initial sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve; and a second sleeve holding mechanism for holding the sliding sleeve in the port closed position after the sliding sleeve is reclosed from the port open position to the port closed position, the second sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve.",PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,,https://lens.org/104-474-779-092-012,Granted Patent,no,0,0,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,F16K31/46;;E21B34/14;;E21B43/12;;E21B43/26;;F16K3/26;;F16K3/30,,0,0,,,,INACTIVE
289,US,B2,US 8055856 B2,114-639-102-350-943,2011-11-08,2011,US 5426708 A,2008-03-24,US 5426708 A,2008-03-24,Lock mechanism to enable atomic updates to shared memory,"A system and method for locking and unlocking access to a shared memory for atomic operations provides immediate feedback indicating whether or not the lock was successful. Read data is returned to the requestor with the lock status. The lock status may be changed concurrently when locking during a read or unlocking during a write. Therefore, it is not necessary to check the lock status as a separate transaction prior to or during a read-modify-write operation. Additionally, a lock or unlock may be explicitly specified for each atomic memory operation. Therefore, lock operations are not performed for operations that do not modify the contents of a memory location.",NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,NVIDIA CORPORATION (2008-03-24),https://lens.org/114-639-102-350-943,Granted Patent,yes,10,14,7,7,0,G06F9/526;;G06F12/084;;G06F9/3004;;G06F9/30087;;G06F9/30185;;G06F2209/521;;G06F12/084;;G06F9/526;;G06F9/30087;;G06F9/3004;;G06F9/30185;;G06F2209/521,G06F12/00,711/152;;711/147;;X711E12091,2,1,020-961-679-464-619,10.1109/40.621209,"Eggers, et al., ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;Moss, et al. ""Toward Acceleration of RSA Using 3D Graphics Hardware,"" LNCS 4887, Dec. 2007, pp. 369-388.",ACTIVE
290,US,A1,US 2012/0073827 A1,020-109-744-360-960,2012-03-29,2012,US 201113247583 A,2011-09-28,US 201113247583 A;;US 38785010 P,2010-09-29,DOWNHOLE CATCHER FOR AN ACTUATING BALL AND METHOD,"A ball catching device has been invented that catches an actuator ball used in a wellbore to actuate a downhole tool. The device catches the ball downhole as it begins to flow back with fluids toward surface. The device is configured such that when a ball flows back with wellbore fluids, the ball can flow through the device and if the ball reverses direction, as by falling back due to decreased or stopped production back flow, then the device will catch the ball and keep it from falling back past the device into the well.",KENYON MICHAEL;;COON ROBERT JOE;;THEMIG DANIEL JON;;ZUKOWSKI JOHN THOMAS;;PACKERS PLUS ENERGY SERV INC,KENYON MICHAEL;;COON ROBERT JOE;;THEMIG DANIEL JON;;ZUKOWSKI JOHN THOMAS,PACKERS PLUS ENERGY SERVICES INC (2010-11-05),https://lens.org/020-109-744-360-960,Patent Application,yes,6,28,2,2,0,E21B34/142;;E21B34/107;;E21B34/142,E21B34/06;;E21B33/12,166/373;;166/193,0,0,,,,DISCONTINUED
291,US,A1,US 2008/0293513 A1,126-011-221-006-397,2008-11-27,2008,US 80550607 A,2007-05-22,US 80550607 A,2007-05-22,Direction and distance correcting golf putter,"A golf putter has a putter head with an actively compliant beam which is parallel to the face of the putter. The beam connects to a shaft along its length and is separated from the head except for its ends. The force of impact between the face of the putter and the ball on the putter face sweet spot causes a stress to develop in the beam, resulting in a deflection in the beam proportional to the force of the impact, while maintaining the putter face orientation with respect to the putting line. Impacts which miss the sweet spot will cause the putter face to skew to an angle with respect to the putting line, also introducing a proportional flexure of the beam, depending on the distance between the sweet spot and the point of impact. The beam has a characteristic time such that as the force between the ball and the putter face decreases to zero after impact, the beam flexure simultaneously recovers causing the putter face to return to its original putting line orientation at almost the same instant the ball leaves the putter face, thereby providing distance and directional correction for mishit putts. Additionally, when a putter head with a suitable moment of inertia is coupled with an actively compliant beam, feel and alignment are substantially enhanced. The putter also uses a unique visual alignment sight line groove on the top surface of the putter head, extending from the face to the back of the putter. The groove is perpendicular to the face of the putter and may have tapered side walls. It is positioned directly above and parallel to the center of mass and the sweet spot, so that it can be positioned directly over the intended putting line when the putter is properly located on the putting surface. The base of the groove has contrasting stripes, so that when the golfer's dominant eye is properly located over the groove, the entire stripped base of the groove is visible to the golfer.",BITKO DAVID M;;BITKO SHELDON S;;COON ROBERT A;;PIOTROWSKI JOHN,BITKO DAVID M;;BITKO SHELDON S;;COON ROBERT A;;PIOTROWSKI JOHN,,https://lens.org/126-011-221-006-397,Patent Application,yes,38,9,2,2,0,A63B53/0487;;A63B53/0487;;A63B53/0408;;A63B53/0408;;A63B53/0441;;A63B53/0441;;A63B60/02;;A63B60/02;;A63B69/3682;;A63B69/3682;;A63B2053/0491,A63B53/04,473/340,0,0,,,,INACTIVE
292,JP,A,JP 2009230756 A,158-140-402-540-603,2009-10-08,2009,JP 2009056460 A,2009-03-10,US 5425508 A,2008-03-24,INDIRECT FUNCTION CALL INSTRUCTION IN SYNCHRONOUS PARALLEL THREAD PROCESSOR,"<P>PROBLEM TO BE SOLVED: To provide an SIMI architecture for performing indirect function calling by using a function pointer. <P>SOLUTION: An indirect branch instruction is applied by defining an address register as an argument for giving an indirect function calling capability with respect a single instruction multiple thread (SIMT) processor architecture. The indirect branch instruction is used for improving processing in comparison with the use of the successive chain of test and branch by executing indirect function calling, virtual function calling and switch statement. <P>COPYRIGHT: (C)2010,JPO&INPIT",NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN E,,https://lens.org/158-140-402-540-603,Patent Application,no,1,7,10,10,0,G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/30061;;G06F15/8007;;G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/38,G06F9/42;;G06F9/46;;G06T1/20,,0,0,,,,ACTIVE
293,AR,A1,AR 086265 A1,055-821-141-632-92X,2013-12-04,2013,AR P120101567 A,2012-05-03,US 201161481987 P;;US 201161509748 P,2011-05-03,VALVULA DE CAMISA CORREDIZA Y METODO PARA TRATAR CON FLUIDO UNA FORMACION SUBTERRANEA,"Una válvula de camisa corrediza para las operaciones de pozo que incluye: Un cuerpo tubular comprendiendo una pared tubular y comprendiendo una superficie exterior y una superficie interior que definen así una perforación interior; una lumbrera de fluido que se extiende a través de la pared tubular proporcionando una comunicación fluídica entre la superficie exterior y la perforación interior, un manguito corredizo en la perforación interior que es móvil de manera deslizante entre una posición de lumbrera cerrada y una posición de lumbrera abierta, la camisa corrediza incluye un asiento de bola sobre el que se descarga un obturador para mover la camisa desde la posición de lumbrera cerrada a la posición de lumbrera abierta; un primer mecanismo de sujeción de camisa para sujetar la camisa corrediza en la posición de lumbrera cerrada, el primer mecanismo de sujeción de camisa seleccionado para ser dominado mediante la descarga de un obturador sobre el asiento de bola para mover la camisa corrediza; un segundo mecanismo de sujeción de camisa para sujetar la camisa corrediza en la posición de lumbrera cerrada después que se ha cerrado nuevamente la camisa corrediza de la posición de lumbrera abierta a la posición de lumbrera cerrada, siendo el segundo mecanismo de sujeción de camisa seleccionado para ser dominado mediante la descarga de un obturador sobre el asiento de bola para mover la camisa corrediza.",PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,,https://lens.org/055-821-141-632-92X,Patent Application,no,0,0,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,E21B34/14;;E21B43/12,,0,0,,,,ACTIVE
294,US,B2,US 7674186 B2,034-649-685-372-288,2010-03-09,2010,US 80550607 A,2007-05-22,US 80550607 A,2007-05-22,Direction and distance correcting golf putter,"A golf putter has a putter head with an actively compliant beam which is parallel to the face of the putter. The beam connects to a shaft along its length and is separated from the head except for its ends. The force of impact between the face of the putter and the ball on the putter face sweet spot causes a stress to develop in the beam, resulting in a deflection in the beam proportional to the force of the impact, while maintaining the putter face orientation with respect to the putting line. Impacts which miss the sweet spot will cause the putter face to skew to an angle with respect to the putting line, also introducing a proportional flexure of the beam, depending on the distance between the sweet spot and the point of impact. The beam has a characteristic time such that as the force between the ball and the putter face decreases to zero after impact, the beam flexure simultaneously recovers causing the putter face to return to its original putting line orientation at almost the same instant the ball leaves the putter face, thereby providing distance and directional correction for mishit putts. Additionally, when a putter head with a suitable moment of inertia is coupled with an actively compliant beam, feel and alignment are substantially enhanced. The putter also uses a unique visual alignment sight line groove on the top surface of the putter head, extending from the face to the back of the putter. The groove is perpendicular to the face of the putter and may have tapered side walls. It is positioned directly above and parallel to the center of mass and the sweet spot, so that it can be positioned directly over the intended putting line when the putter is properly located on the putting surface. The base of the groove has contrasting stripes, so that when the golfer's dominant eye is properly located over the groove, the entire stripped base of the groove is visible to the golfer.",BITKO DAVID M;;BITKO SHELDON S;;COON ROBERT A;;PIOTROWSKI JOHN,BITKO DAVID M;;BITKO SHELDON S;;COON ROBERT A;;PIOTROWSKI JOHN,,https://lens.org/034-649-685-372-288,Granted Patent,yes,64,7,2,2,0,A63B53/0487;;A63B53/0487;;A63B53/0408;;A63B53/0408;;A63B53/0441;;A63B53/0441;;A63B60/02;;A63B60/02;;A63B69/3682;;A63B69/3682;;A63B2053/0491,A63B53/04;;A63B53/06,473/329;;473/333;;473/340;;473/350,0,0,,,,INACTIVE
295,US,A1,US 2012/0036329 A1,047-513-887-847-148,2012-02-09,2012,US 201113276224 A,2011-10-18,US 201113276224 A;;US 5426708 A,2008-03-24,LOCK MECHANISM TO ENABLE ATOMIC UPDATES TO SHARED MEMORY,"A system and method for locking and unlocking access to a shared memory for atomic operations provides immediate feedback indicating whether or not the lock was successful. Read data is returned to the requestor with the lock status. The lock status may be changed concurrently when locking during a read or unlocking during a write. Therefore, it is not necessary to check the lock status as a separate transaction prior to or during a read-modify-write operation. Additionally, a lock or unlock may be explicitly specified for each atomic memory operation. Therefore, lock operations are not performed for operations that do not modify the contents of a memory location.",COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,,https://lens.org/047-513-887-847-148,Patent Application,yes,9,11,7,7,0,G06F9/526;;G06F12/084;;G06F9/3004;;G06F9/30087;;G06F9/30185;;G06F2209/521;;G06F12/084;;G06F9/526;;G06F9/30087;;G06F9/3004;;G06F9/30185;;G06F2209/521,G06F12/14,711/152;;X711E12094,0,0,,,,ACTIVE
296,AU,A1,AU 2012/250456 A1,130-132-211-498-557,2013-11-14,2013,AU 2012/250456 A,2012-05-02,US 201161509748 P;;US 201161481987 P;;CA 2012000412 W,2011-05-03,Sliding sleeve valve and method for fluid treating a subterranean formation,"A sliding sleeve valve for wellbore operations includes: a tubular body including a tubular wall including an outer surface and an inner surface defining an inner bore; a fluid port extending through the tubular wall and providing fluidic communication between the outer surface and the inner bore; a sliding sleeve in the inner bore slidably moveable between a port closed position and a port open position, the sliding sleeve including a ball seat on which a plug is landed to move the sleeve from the port closed position to the port open position; an initial sleeve holding mechanism for holding the sliding sleeve in the port closed position, the initial sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve; and a second sleeve holding mechanism for holding the sliding sleeve in the port closed position after the sliding sleeve is reclosed from the port open position to the port closed position, the second sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve.",PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,,https://lens.org/130-132-211-498-557,Patent Application,no,0,0,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,F16K31/46;;E21B34/14;;E21B43/12;;E21B43/26;;F16K3/26;;F16K3/30,,0,0,,,,DISCONTINUED
297,US,B2,US 11879320 B2,100-550-065-667-394,2024-01-23,2024,US 202117557692 A,2021-12-21,US 202117557692 A;;US 202163177248 P,2021-04-20,Particle trap apparatus and method,"An apparatus and method for trapping particles disposed in a fluid. The apparatus may comprise one or more cavities disposed axially along a length of a tubular housing, one or more connecting components disposed at opposing ends of the housing, and may optionally comprise a check valve system. Alternate embodiments are provided for forming each of the one or more cavities, which may comprise a combination of a cavity frame and cavity surface. The method may comprise flowing a fluid into a first end of a particle trap apparatus at a rate of fluid flow, directing the fluid flow at least partially through one or more cavity sub-assemblies disposed in the particle trap apparatus, collecting the particulate matter in one or more of the cavity sub-assemblies when the rate of fluid flow may slow or become suspended, and clearing collected particles from the one or more cavity sub-assemblies upon restoration of fluid flow in a primary direction of travel.",PETROQUIP ENERGY SERVICES LLC,COON ROBERT JOE;;SMITH RODDIE R;;EMERSON JOHN LEE;;HORNSBY JOSH,PETROQUIP ENERGY SERVICES LLC (2022-01-25),https://lens.org/100-550-065-667-394,Granted Patent,yes,6,0,2,2,0,B01D21/0024;;B01D21/0066;;B01D21/0087;;E21B43/122;;E21B43/128;;E21B43/35;;E21B43/38;;B01D21/0066;;B01D21/0087;;E21B43/128;;E21B43/35;;E21B43/122;;B01D21/0024;;E21B43/38,E21B43/34;;B01D21/00;;E21B43/12;;E21B43/38,,0,0,,,,ACTIVE
298,WO,A1,WO 2012/149638 A1,154-605-709-993-641,2012-11-08,2012,CA 2012000412 W,2012-05-02,US 201161481987 P;;US 201161509748 P,2011-05-03,SLIDING SLEEVE VALVE AND METHOD FOR FLUID TREATING A SUBTERRANEAN FORMATION,"A sliding sleeve valve for wellbore operations includes: a tubular body including a tubular wall including an outer surface and an inner surface defining an inner bore; a fluid port extending through the tubular wall and providing fluidic communication between the outer surface and the inner bore; a sliding sleeve in the inner bore slidably moveable between a port closed position and a port open position, the sliding sleeve including a ball seat on which a plug is landed to move the sleeve from the port closed position to the port open position; an initial sleeve holding mechanism for holding the sliding sleeve in the port closed position, the initial sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve; and a second sleeve holding mechanism for holding the sliding sleeve in the port closed position after the sliding sleeve is reclosed from the port open position to the port closed position, the second sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve.",PACKERS PLUS ENERGY SERV INC;;COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,,https://lens.org/154-605-709-993-641,Patent Application,yes,5,23,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,E21B34/14;;F16K31/46;;E21B43/12;;E21B43/26;;F16K3/26;;F16K3/30,,1,0,,,See also references of EP 2705287A4,PENDING
299,GB,B,GB 2458556 B,070-679-235-663-291,2010-07-07,2010,GB 0904014 A,2009-03-09,US 5425508 A,2008-03-24,Indirect function call instructions in a synchronous parallel thread processor,,NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK,,https://lens.org/070-679-235-663-291,Granted Patent,no,6,0,10,10,0,G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/30061;;G06F15/8007;;G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/38,G06F9/40;;G06F15/80,,1,1,050-483-545-912-345,10.1109/micro.2007.4408272,"FUNG et al. Dynamic Warp Formation and Scheduling for Efficient GPU Control Flow, 40th IEEE/ACM International Symposium on Microarchitecture, 1-5 December 2007, Chicago, IL, USA",ACTIVE
300,US,A1,US 2014/0048271 A1,079-094-217-812-939,2014-02-20,2014,US 201214113788 A,2012-05-02,US 201214113788 A;;US 201161481987 P;;US 201161509748 P;;CA 2012000412 W,2011-05-03,SLIDING SLEEVE VALVE AND METHOD FOR FLUID TREATING A SUBTERRANEAN FORMATION,"A sliding sleeve valve for wellbore operations includes: a tubular body including a tubular wall including an outer surface and an inner surface defining an inner bore; a fluid port extending through the tubular wall and providing fluidic communication between the outer surface and the inner bore; a sliding sleeve in the inner bore slidably moveable between a port closed position and a port open position, the sliding sleeve including a ball seat on which a plug is landed to move the sleeve from the port closed position to the port open position; an initial sleeve holding mechanism for holding the sliding sleeve in the port closed position, the initial sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve; and a second sleeve holding mechanism for holding the sliding sleeve in the port closed position after the sliding sleeve is reclosed from the port open position to the port closed position, the second sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve.",COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO;;PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,PACKERS PLUS ENERGY SERVICES INC (2012-08-02),https://lens.org/079-094-217-812-939,Patent Application,yes,4,38,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,E21B43/16;;E21B34/06;;E21B43/26,166/308.1;;166/318;;166/317,0,0,,,,INACTIVE
301,CA,A1,CA 2834210 A1,057-938-245-112-357,2012-11-08,2012,CA 2834210 A,2012-05-02,US 201161481987 P;;US 201161509748 P;;CA 2012000412 W,2011-05-03,SLIDING SLEEVE VALVE AND METHOD FOR FLUID TREATING A SUBTERRANEAN FORMATION,"A sliding sleeve valve for wellbore operations includes: a tubular body including a tubular wall including an outer surface and an inner surface defining an inner bore; a fluid port extending through the tubular wall and providing fluidic communication between the outer surface and the inner bore; a sliding sleeve in the inner bore slidably moveable between a port closed position and a port open position, the sliding sleeve including a ball seat on which a plug is landed to move the sleeve from the port closed position to the port open position; an initial sleeve holding mechanism for holding the sliding sleeve in the port closed position, the initial sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve; and a second sleeve holding mechanism for holding the sliding sleeve in the port closed position after the sliding sleeve is reclosed from the port open position to the port closed position, the second sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve.",PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,,https://lens.org/057-938-245-112-357,Patent Application,no,0,1,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,F16K31/46;;E21B34/14;;E21B43/12;;E21B43/26;;F16K3/26;;F16K3/30,,0,0,,,,INACTIVE
302,EP,A1,EP 2705287 A1,164-271-926-311-462,2014-03-12,2014,EP 12780001 A,2012-05-02,US 201161481987 P;;US 201161509748 P;;CA 2012000412 W,2011-05-03,SLIDING SLEEVE VALVE AND METHOD FOR FLUID TREATING A SUBTERRANEAN FORMATION,,PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,,https://lens.org/164-271-926-311-462,Patent Application,yes,0,1,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,F16K31/46;;E21B34/14;;E21B43/12;;E21B43/26;;F16K3/26;;F16K3/30,,0,0,,,,DISCONTINUED
303,US,A1,US 2013/0138926 A1,101-960-264-063-399,2013-05-30,2013,US 201213674890 A,2012-11-12,US 201213674890 A;;US 5425508 A,2008-03-24,INDIRECT FUNCTION CALL INSTRUCTIONS IN A SYNCHRONOUS PARALLEL THREAD PROCESSOR,"An indirect branch instruction takes an address register as an argument in order to provide indirect function call capability for single-instruction multiple-thread (SIMT) processor architectures. The indirect branch instruction is used to implement indirect function calls, virtual function calls, and switch statements to improve processing performance compared with using sequential chains of tests and branches.",NVIDIA CORP;;NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK,NVIDIA CORPORATION (2008-03-21),https://lens.org/101-960-264-063-399,Patent Application,yes,3,7,10,10,0,G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/30061;;G06F15/8007;;G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/38,G06F9/38,712/220,1,1,050-483-545-912-345,10.1109/micro.2007.4408272,"Fung et al. (Dynamic Warp Formation and Scheduling for Efficient GPU Control Flow, December 2007, pgs. 407-420)",ACTIVE
304,GB,A,GB 2458556 A,034-106-404-325-530,2009-09-30,2009,GB 0904014 A,2009-03-09,US 5425508 A,2008-03-24,Indirect function calls in a synchronous parallel thread processor,"A SIMT control instruction is applied to multiple independent threads in parallel which are free to execute and branch independently. The control instruction references a set of pointers to one or more functions in a program. If two or more pointers corresponding to active threads in a thread group are different, this indicates that the active threads diverge during function calls executed by the control instruction. When the threads diverge, a token including the address of the control instruction is pushed onto an execution stack, and the active program counter is updated to specify an address of a first function to be called. The token preferably includes a not-taken mask indentifying previously active threads that do not call the first function. An active mask indicates currently active threads in a group that should be processed in parallel. The invention serialises execution of indirect function calls for each unique pointer.",NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK,,https://lens.org/034-106-404-325-530,Patent Application,no,6,9,10,10,0,G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/30061;;G06F15/8007;;G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/38,G06F9/40;;G06F15/80,,1,1,050-483-545-912-345,10.1109/micro.2007.4408272,"FUNG et al. Dynamic Warp Formation and Scheduling for Efficient GPU Control Flow, 40th IEEE/ACM International Symposium on Microarchitecture, 1-5 December 2007, Chicago, IL, USA",ACTIVE
305,US,A1,US 2022/0331714 A1,040-215-944-443-650,2022-10-20,2022,US 202117557692 A,2021-12-21,US 202117557692 A;;US 202163177248 P,2021-04-20,Particle Trap Apparatus and Method,"An apparatus and method for trapping particles disposed in a fluid. The apparatus may comprise one or more cavities disposed axially along a length of a tubular housing, one or more connecting components disposed at opposing ends of the housing, and may optionally comprise a check valve system. Alternate embodiments are provided for forming each of the one or more cavities, which may comprise a combination of a cavity frame and cavity surface. The method may comprise flowing a fluid into a first end of a particle trap apparatus at a rate of fluid flow, directing the fluid flow at least partially through one or more cavity sub-assemblies disposed in the particle trap apparatus, collecting the particulate matter in one or more of the cavity sub-assemblies when the rate of fluid flow may slow or become suspended, and clearing collected particles from the one or more cavity sub-assemblies upon restoration of fluid flow in a primary direction of travel.",PETROQUIP ENERGY SERVICES LLC,COON ROBERT JOE;;SMITH RODDIE R;;EMERSON JOHN LEE;;HORNSBY JOSH,PETROQUIP ENERGY SERVICES LLC (2022-01-25),https://lens.org/040-215-944-443-650,Patent Application,yes,0,2,2,2,0,B01D21/0024;;B01D21/0066;;B01D21/0087;;E21B43/122;;E21B43/128;;E21B43/35;;E21B43/38;;B01D21/0066;;B01D21/0087;;E21B43/128;;E21B43/35;;E21B43/122;;B01D21/0024;;E21B43/38,B01D21/00;;E21B43/34,,0,0,,,,ACTIVE
306,US,A1,US 2018/0131731 A1,061-318-534-435-15X,2018-05-10,2018,US 201615343243 A,2016-11-04,US 201615343243 A,2016-11-04,"SYSTEMS, METHODS, AND COMPUTER PROGRAMS FOR ESTABLISHING A SCREEN SHARE SESSION FOR A REMOTE VOICE CALL","Systems, methods, and computer systems are disclosed for establishing a screen share session. One such method comprises a collaboration server receiving a message from an application executing on a mobile communication device. The message identifies that a voice call remote to the collaboration server has been initiated by the mobile communication device and established between a calling party using the mobile communication device and one or more called parties. The collaboration server determines that the calling party and the one or more called parties in the remote voice call have an active collaboration presence with the collaboration server. The collaboration server initiates a display of a screen share user interface control on a first computing device associated with the calling party and one or more second computing devices associated with the one or more called parties. The screen share user interface control is configured to enable the calling party and the one or more called parties to establish a screen share session.",AMERICAN TELECONFERENCING SERV,JONES BOLAND TIMOTHY;;GUTHRIE DAVID MICHAEL;;COON MICHAEL;;PERKINS JOHN ROBERT,AMERICAN TELECONFERENCING SERVICES LTD (2015-12-02),https://lens.org/061-318-534-435-15X,Patent Application,yes,0,15,2,2,0,G06F3/0488;;H04M2250/22;;H04M2250/62;;G06F3/1423;;H04M3/567;;H04N7/15;;G09G2352/00;;G09G2370/022;;G09G2370/042;;H04M7/0027;;H04M2201/42;;H04L65/1089;;H04L65/4015;;H04L65/1069;;H04L65/1059;;H04L65/403;;G06F3/0486;;G06F3/0482;;H04M1/72403;;H04M1/72469;;H04L65/1089;;H04L65/4015;;H04L65/1069;;H04L65/1059;;H04L65/403;;G06F3/0486;;G06F3/0482;;G06F3/0488;;H04M2250/22;;H04M2250/62;;H04M3/567;;H04M2201/42;;G09G2370/042;;G06F3/1423;;G09G2352/00;;G09G2370/022;;H04N7/15;;H04M7/0027;;H04M1/72403;;H04M1/72469;;G06F3/1454,H04L29/06;;G06F3/14;;H04M1/72403;;H04M1/72469,,0,0,,,,INACTIVE
307,US,A1,US 2009/0240931 A1,039-249-048-589-272,2009-09-24,2009,US 5425508 A,2008-03-24,US 5425508 A,2008-03-24,Indirect Function Call Instructions in a Synchronous Parallel Thread Processor,"An indirect branch instruction takes an address register as an argument in order to provide indirect function call capability for single-instruction multiple-thread (SIMT) processor architectures. The indirect branch instruction is used to implement indirect function calls, virtual function calls, and switch statements to improve processing performance compared with using sequential chains of tests and branches.",COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK,NVIDIA CORPORATION (2008-03-21),https://lens.org/039-249-048-589-272,Patent Application,yes,29,70,10,10,0,G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/30061;;G06F15/8007;;G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/38,G06F9/38,712/234;;X712E09045,0,0,,,,ACTIVE
308,US,B2,US 9639365 B2,090-804-780-788-204,2017-05-02,2017,US 201213674890 A,2012-11-12,US 201213674890 A;;US 5425508 A,2008-03-24,Indirect function call instructions in a synchronous parallel thread processor,"An indirect branch instruction takes an address register as an argument in order to provide indirect function call capability for single-instruction multiple-thread (SIMT) processor architectures. The indirect branch instruction is used to implement indirect function calls, virtual function calls, and switch statements to improve processing performance compared with using sequential chains of tests and branches.",NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK,NVIDIA CORPORATION (2008-03-21),https://lens.org/090-804-780-788-204,Granted Patent,yes,7,6,10,10,0,G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/30061;;G06F15/8007;;G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/38,G06F15/00;;G06F7/38;;G06F9/00;;G06F9/30;;G06F9/38;;G06F9/44,,1,1,050-483-545-912-345,10.1109/micro.2007.4408272,"Fung et al. (Dynamic Warp Formation and Scheduling for Efficient GPU Control Flow, Dec. 2007, pp. 407-420).",ACTIVE
309,US,A1,US 2009/0240860 A1,054-048-415-237-918,2009-09-24,2009,US 5426708 A,2008-03-24,US 5426708 A,2008-03-24,Lock Mechanism to Enable Atomic Updates to Shared Memory,"A system and method for locking and unlocking access to a shared memory for atomic operations provides immediate feedback indicating whether or not the lock was successful. Read data is returned to the requestor with the lock status. The lock status may be changed concurrently when locking during a read or unlocking during a write. Therefore, it is not necessary to check the lock status as a separate transaction prior to or during a read-modify-write operation. Additionally, a lock or unlock may be explicitly specified for each atomic memory operation. Therefore, lock operations are not performed for operations that do not modify the contents of a memory location.",COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,NVIDIA CORPORATION (2008-03-24),https://lens.org/054-048-415-237-918,Patent Application,yes,7,38,7,7,0,G06F9/526;;G06F12/084;;G06F9/3004;;G06F9/30087;;G06F9/30185;;G06F2209/521;;G06F12/084;;G06F9/526;;G06F9/30087;;G06F9/3004;;G06F9/30185;;G06F2209/521,G06F12/14,710/200,0,0,,,,ACTIVE
310,EP,A4,EP 2705287 A4,183-455-359-379-596,2016-04-27,2016,EP 12780001 A,2012-05-02,US 201161481987 P;;US 201161509748 P;;CA 2012000412 W,2011-05-03,SLIDING SLEEVE VALVE AND METHOD FOR FLUID TREATING A SUBTERRANEAN FORMATION,,PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,,https://lens.org/183-455-359-379-596,Search Report,no,1,0,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,F16K31/46;;E21B34/14;;E21B43/12;;E21B43/26;;F16K3/26;;F16K3/30,,0,0,,,,DISCONTINUED
311,US,B2,US 9464506 B2,196-226-259-677-871,2016-10-11,2016,US 201214113788 A,2012-05-02,US 201214113788 A;;US 201161481987 P;;US 201161509748 P;;CA 2012000412 W,2011-05-03,Sliding sleeve valve and method for fluid treating a subterranean formation,"A sliding sleeve valve for wellbore operations includes: a tubular body including a tubular wall including an outer surface and an inner surface defining an inner bore; a fluid port extending through the tubular wall and providing fluidic communication between the outer surface and the inner bore; a sliding sleeve in the inner bore slidably moveable between a port closed position and a port open position, the sliding sleeve including a ball seat on which a plug is landed to move the sleeve from the port closed position to the port open position; an initial sleeve holding mechanism for holding the sliding sleeve in the port closed position, the initial sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve; and a second sleeve holding mechanism for holding the sliding sleeve in the port closed position after the sliding sleeve is reclosed from the port open position to the port closed position, the second sleeve holding mechanism selected to be overcome by landing a plug on the ball seat to move the sliding sleeve.",COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO;;PACKERS PLUS ENERGY SERV INC,COON ROBERT JOE;;THEMIG DANIEL JON;;EMERSON JOHN LEE;;MENDOZA GUSTAVO,PACKERS PLUS ENERGY SERVICES INC (2012-08-02),https://lens.org/196-226-259-677-871,Granted Patent,yes,25,5,10,10,0,E21B34/102;;E21B34/103;;E21B2200/06;;E21B43/26;;E21B34/142;;E21B34/102;;E21B34/103;;E21B2200/06;;E21B34/142;;E21B34/06;;E21B34/063;;E21B43/16;;E21B43/26,E21B34/06;;E21B34/00;;E21B34/10;;E21B34/14;;E21B43/16;;E21B43/26,,0,0,,,,INACTIVE
312,CA,A1,CA 2753622 A1,094-544-372-803-994,2012-03-29,2012,CA 2753622 A,2011-09-28,US 38785010 P,2010-09-29,DOWNHOLE CATCHER FOR AN ACTUATING BALL AND METHOD,"A ball catching device has been invented that catches an actuator ball used in a wellbore to actuate a downhole tool. The device catches the ball downhole as it begins to flow back with fluids toward surface. The device is configured such that when a ball flows back with wellbore fluids, the ball can flow through the device and if the ball reverses direction, as by falling back due to decreased or stopped production back flow, then the device will catch the ball and keep it from falling back past the device into the well.",PACKERS PLUS ENERGY SERV INC,KENYON MICHAEL;;COON ROBERT JOE;;THEMIG DANIEL JON;;ZUKOWSKI JOHN THOMAS,,https://lens.org/094-544-372-803-994,Patent Application,no,0,1,2,2,0,E21B34/142;;E21B34/107;;E21B34/142,E21B23/04;;E21B31/00;;E21B37/00,,0,0,,,,DISCONTINUED
313,US,B2,US 10218749 B2,174-762-506-996-230,2019-02-26,2019,US 201615343243 A,2016-11-04,US 201615343243 A,2016-11-04,"Systems, methods, and computer programs for establishing a screen share session for a remote voice call","Systems, methods, and computer systems are disclosed for establishing a screen share session. One such method comprises a collaboration server receiving a message from an application executing on a mobile communication device. The message identifies that a voice call remote to the collaboration server has been initiated by the mobile communication device and established between a calling party using the mobile communication device and one or more called parties. The collaboration server determines that the calling party and the one or more called parties in the remote voice call have an active collaboration presence with the collaboration server. The collaboration server initiates a display of a screen share user interface control on a first computing device associated with the calling party and one or more second computing devices associated with the one or more called parties. The screen share user interface control is configured to enable the calling party and the one or more called parties to establish a screen share session.",AMERICAN TELECONFERENCING SERV,JONES BOLAND TIMOTHY;;GUTHRIE DAVID MICHAEL;;COON MICHAEL;;PERKINS JOHN ROBERT,AMERICAN TELECONFERENCING SERVICES LTD (2015-12-02),https://lens.org/174-762-506-996-230,Granted Patent,yes,26,1,2,2,0,G06F3/0488;;H04M2250/22;;H04M2250/62;;G06F3/1423;;H04M3/567;;H04N7/15;;G09G2352/00;;G09G2370/022;;G09G2370/042;;H04M7/0027;;H04M2201/42;;H04L65/1089;;H04L65/4015;;H04L65/1069;;H04L65/1059;;H04L65/403;;G06F3/0486;;G06F3/0482;;H04M1/72403;;H04M1/72469;;H04L65/1089;;H04L65/4015;;H04L65/1069;;H04L65/1059;;H04L65/403;;G06F3/0486;;G06F3/0482;;G06F3/0488;;H04M2250/22;;H04M2250/62;;H04M3/567;;H04M2201/42;;G09G2370/042;;G06F3/1423;;G09G2352/00;;G09G2370/022;;H04N7/15;;H04M7/0027;;H04M1/72403;;H04M1/72469;;G06F3/1454,H04L29/06;;G06F3/0482;;G06F3/0486;;G06F3/0488;;G06F3/14;;H04M1/72403;;H04M1/72469,,0,0,,,,INACTIVE
314,DE,A1,DE 102009012766 A1,012-325-651-326-727,2009-10-15,2009,DE 102009012766 A,2009-03-12,US 5426708 A,2008-03-24,"Ein Zugriffssperrenvorgang, um atomare Aktualisierungen zu einem geteilten Speicher zu ermöglichen","Ein System und Verfahren zum Sperren und Entsperren des Zugriffs auf einen geteilten Speicher für atomare Operationen stellt eine unmittelbare Rückmeldung bereit, die anzeigt, ob die Sperre erfolgreich war oder nicht. Gelesene Daten werden an den Antragsteller mit dem Sperrstatus zurückgesendet. Der Sperrstatus kann gleichzeitig mit dem Sperren während eines Lesens oder Entsperren während eines Schreibens geändert werden. Daher ist es nicht notwendig, den Sperrstatus als eine separate Transaktion vor oder während einer Lese-Ändern-Schreib-Operation zu überprüfen. Zusätzlich kann eine Sperre oder Entsperrung explizit für jede atomare Speicheroperation spezifiziert werden. Daher werden Speicheroperationen nicht für Operationen durchgeführt, die die Inhalte eines Speicherorts nicht modifizieren.",NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C,,https://lens.org/012-325-651-326-727,Patent Application,no,0,0,7,7,0,G06F9/526;;G06F12/084;;G06F9/3004;;G06F9/30087;;G06F9/30185;;G06F2209/521;;G06F12/084;;G06F9/526;;G06F9/30087;;G06F9/3004;;G06F9/30185;;G06F2209/521,G06F15/167;;G06F12/02,,0,0,,,,DISCONTINUED
315,US,B2,US 8312254 B2,070-245-771-887-688,2012-11-13,2012,US 5425508 A,2008-03-24,US 5425508 A,2008-03-24,Indirect function call instructions in a synchronous parallel thread processor,"An indirect branch instruction takes an address register as an argument in order to provide indirect function call capability for single-instruction multiple-thread (SIMT) processor architectures. The indirect branch instruction is used to implement indirect function calls, virtual function calls, and switch statements to improve processing performance compared with using sequential chains of tests and branches.",COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK;;NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;MILLS PETER C;;LINDHOLM JOHN ERIK,NVIDIA CORPORATION (2008-03-21),https://lens.org/070-245-771-887-688,Granted Patent,yes,40,9,10,10,0,G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/30061;;G06F15/8007;;G06F9/30054;;G06F9/30101;;G06F9/3851;;G06F9/3885;;G06F9/38,G06F9/00,712/234;;X712 E9076,7,4,020-961-679-464-619;;074-507-939-370-096;;089-944-969-917-814;;050-483-545-912-345,10.1109/40.621209;;10.1109/asap.1994.331811;;10.1007/978-1-4615-2690-2_6;;10.1109/micro.2007.4408272,"Eggers, et al., ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;Moss, et al. ""Toward Acceleration of RSA Using 3D Graphics Hardware,"" LNCS 4887, Dec. 2007, pp. 369-388.;;Kuszmaul, Bradley C., ""Synchronized MIMD Computing,"" 1994, MIT, pp. 1-162.;;Chou,et al., ""Register Transfer Modeling and Simulation for Array Processors,"" 1994, IEEE, pp. 111-122.;;Debray, et al., ""Call Forwarding: A Simple Low-Level Code Optimization Technique,"" 1994.;;Combined Search and Examination Report, GB App. No. 0904014.8, Jun. 19, 2009 (provided as explanation of relevance of foreign patent documents).;;Fung, et al. ""Dynamic Warp Formation and Scheduling for Efficient GPU Control Flow,"" 40th IEEE/ACM Intl. Symposium on Microarchitecture, Dec. 1-5, 2007, Chicago, IL, USA.",ACTIVE
316,WO,A2,WO 1999/050593 A2,030-804-218-220-025,1999-10-07,1999,US 9906089 W,1999-03-19,US 7966798 P;;US 5053498 A,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical light apparatus (30) includes a lighthead (36, 38) having a sterile field thereon, a bulb (68, 70) located within the lighthead (36, 38), a controller (106) coupled to the bulb (68, 70), and an actuator (74) coupled to the controller (106) to adjust an intensity of light emitted from the bulb (68, 70). The actuator (74) is located in the sterile field on the lighthead (36, 38).",HILL ROM CO INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/030-804-218-220-025,Patent Application,no,4,9,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,A61B19/00;;F21S2/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,PATENTED
317,EP,A2,EP 1084364 A2,040-064-937-336-755,2001-03-21,2001,EP 99914957 A,1999-03-19,US 9906089 W;;US 7966798 P;;US 5053498 A,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",HILL ROM CO INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,"HILL-ROM SERVICES, INC. (2006-09-06)",https://lens.org/040-064-937-336-755,Patent Application,yes,0,1,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;F21S8/04;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
318,US,B1,US 7809928 B1,092-079-545-032-726,2010-10-05,2010,US 31387205 A,2005-12-20,US 31387205 A;;US 29076405 A,2005-11-29,Generating event signals for performance register control using non-operative instructions,"One embodiment of an instruction decoder includes an instruction parser configured to process a first non-operative instruction and to generate a first event signal corresponding to the first non-operative instruction, and a first event multiplexer configured to receive the first event signal from the instruction parser, to select the first event signal from one or more event signals and to transmit the first event signal to an event logic block. The instruction decoder may be implemented in a multithreaded processing unit, such as a shader unit, and the occurrences of the first event signal may be tracked when one or more threads are executed within the processing unit. The resulting event signal count may provide a designer with a better understanding of the behavior of a program, such as a shader program, executed within the processing unit, thereby facilitating overall processing unit and program design.",NVIDIA CORP,ALLEN ROGER L;;COON BRETT W;;BUCK IAN A;;NICKOLLS JOHN R,NVIDIA CORPORATION (2005-12-12),https://lens.org/092-079-545-032-726,Granted Patent,yes,25,8,1,2,0,G06T1/20;;G06F9/30072;;G06F9/30076;;G06F11/3466;;G06F2201/86;;G06F2201/865;;G06F2201/88;;G06T1/20;;G06F9/30072;;G06F9/30076;;G06F2201/86;;G06F2201/88;;G06F2201/865;;G06F11/3466,G06F17/00;;G06F9/30;;G09G5/02,712/208;;345/418;;345/589,1,1,020-961-679-464-619,10.1109/40.621209,"Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
319,TW,B,TW 490545 B,117-563-857-388-983,2002-06-11,2002,TW 88104842 A,1999-03-26,US 7966798 P;;US 5053498 A,1998-03-27,Controls for a surgical light apparatus,"A surgical light apparatus (30) includes a lighthead (36, 38) having a sterile field thereon, a bulb (68, 70) located within the lighthead (36, 38), a controller (106) coupled to the bulb (68, 70), and an actuator (74) coupled to the controller (106) to adjust an intensity of light emitted from the bulb (68, 70). The actuator (74) is located in the sterile field on the lighthead (36, 38).",HILL ROM CO INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/117-563-857-388-983,Granted Patent,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,A61B19/00;;F21S2/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
320,US,B1,US 7111096 B1,124-034-944-283-469,2006-09-19,2006,US 46323303 A,2003-06-17,US 46323303 A;;US 59627900 A,2000-06-19,Fast look-up of indirect branch destination in a dynamic translation system,"Dynamic translation of indirect branch instructions of a target application by a host processor is enhanced by including a cache to provide access to the addresses of the most frequently used translations of a host computer, minimizing the need to access the translation buffer. Entries in the cache have a host instruction address and tags that may include a logical address of the instruction of the target application, the physical address of that instruction, the code segment limit to the instruction, and the context value of the host processor associated with that instruction. The cache may be a software cache apportioned by software from the main processor memory or a hardware cache separate from main memory.",TRANSMETA CORP,BANNING JOHN;;COON BRETT;;TORVALDS LINUS;;CHOY BRIAN;;WING MALCOLM;;GAINER PATRICK,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27);;INTELLECTUAL VENTURE FUNDING LLC (2009-01-28);;TRANSMETA CORPORATION (2000-09-18);;TRANSMETA LLC (2009-01-27),https://lens.org/124-034-944-283-469,Granted Patent,yes,29,51,3,3,0,G06F9/45504;;G06F9/30061;;G06F9/45504,G06F9/30;;G06F9/06;;G06F9/45;;G06F9/455;;G06F15/00,710/100;;717/136;;717/139;;711/118;;711/203,4,2,127-533-499-577-375;;155-430-967-691-122,10.1109/csac.2002.1176292;;10.1049/el:19971159,"""Hardware support for control transfers in code caches"" by Kim, H.S.; Smith, J.E. (abstract only) Publication date: Dec. 3-5, 2003.;;""Safe virtual execution using software dynamic translation "" by Scott, K. ; Davidson, J. (abstract only) Publication Date: Dec. 9-13, 2002.;;""Indirectly-compared cache tag memory using a shared tag in a TLB"" by Lee et al. (abstract only) Publication Date: Oct. 9, 1997.;;""Fault-tolerant features in the Hal memory management unit"" by Saxena et al. (abstract only) Publication Date: Feb., 1995.",EXPIRED
321,EP,B2,EP 1084364 B2,015-141-570-196-740,2012-02-29,2012,EP 99914957 A,1999-03-19,US 9906089 W;;US 7966798 P;;US 5053498 A,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",HILL ROM SERVICES INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,"HILL-ROM SERVICES, INC. (2006-09-06)",https://lens.org/015-141-570-196-740,Granted Patent,yes,2,1,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;F21S8/04;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
322,KR,A,KR 20120093982 A,023-768-415-125-28X,2012-08-23,2012,KR 20127013385 A,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/023-768-415-125-28X,Patent Application,no,0,8,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,G01N33/574;;C12N15/11;;C12Q1/68,,0,0,,,,ACTIVE
323,WO,A1,WO 2011/038257 A1,034-629-719-801-469,2011-03-31,2011,US 2010/0050240 W,2010-09-24,US 56763709 A,2009-09-25,UNIFIED ADDRESSING AND INSTRUCTIONS FOR ACCESSING PARALLEL MEMORY SPACES,One embodiment of the present invention sets forth a technique for unifying the addressing of multiple distinct parallel memory spaces into a single address space for a thread. A unified memory space address is converted into an address that accesses one of the parallel memory spaces for that thread. A single type of load or store instruction may be used that specifies the unified memory space address for a thread instead of using a different type of load or store instruction to access each of the distinct parallel memory spaces.,NVIDIA CORP;;NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,,https://lens.org/034-629-719-801-469,Patent Application,yes,6,1,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F15/167,,0,0,,,,PENDING
324,EP,A1,EP 1169541 A1,050-033-829-578-715,2002-01-09,2002,EP 00929343 A,2000-04-06,EP 0003104 W;;US 28992899 A,1999-04-09,METHOD OF SELECTIVE PLASTIC EXPANSION OF SECTIONS OF A TUBING,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,,https://lens.org/050-033-829-578-715,Patent Application,yes,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,1,0,,,See references of WO 0061908A1,EXPIRED
325,EP,A3,EP 0577423 A3,084-658-446-046-950,1994-05-18,1994,EP 93305172 A,1993-07-01,US 90785392 A,1992-07-02,ENDOSCOPIC INSTRUMENT SYSTEM,"An endoscopic instrument (10) system has a handle portion (14) with means for gripping the instrument, the shaft (56) extending from the gripping means and, means for actuating the instrument. A plurality of instrument end tools (14) are removably mountable on the end of the shaft (56) and each include means for engaging the actuating means so that an attached end tool (14) can be operated by the actuating means.",MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;COON DONALD B;;NELSON JOHN T;;PETRUSCHKE HAANS K,,https://lens.org/084-658-446-046-950,Search Report,yes,6,0,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B10/06;;A61B17/00;;A61B1/00;;A61B17/28;;A61B17/32;;A61B19/00,,0,0,,,,EXPIRED
326,TW,A,TW 201122480 A,093-892-040-560-679,2011-07-01,2011,TW 99136361 A,2010-10-25,US 25496809 P,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/093-892-040-560-679,Patent of Addition,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,G01N33/574;;C12Q1/68;;G01N33/58,,0,0,,,,PENDING
327,EP,B2,EP 0577423 B2,098-553-955-331-925,2001-11-14,2001,EP 93305172 A,1993-07-01,US 90785392 A,1992-07-02,Endoscopic instrument system,,MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;COON DONALD B;;NELSON JOHN T;;PETRUSCHKE HAANS K,,https://lens.org/098-553-955-331-925,Granted Patent,yes,0,1,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B10/06;;A61B17/00;;A61B1/00;;A61B17/28;;A61B17/32;;A61B19/00,,1,0,,,"Aesculap-HNO-Catalogue, April 1988, pages 194-195",EXPIRED
328,US,A1,US 2011/0078406 A1,116-845-545-643-34X,2011-03-31,2011,US 56763709 A,2009-09-25,US 56763709 A,2009-09-25,Unified Addressing and Instructions for Accessing Parallel Memory Spaces,One embodiment of the present invention sets forth a technique for unifying the addressing of multiple distinct parallel memory spaces into a single address space for a thread. A unified memory space address is converted into an address that accesses one of the parallel memory spaces for that thread. A single type of load or store instruction may be used that specifies the unified memory space address for a thread instead of using a different type of load or store instruction to access each of the distinct parallel memory spaces.,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,NVIDIA CORPORATION (2009-09-25),https://lens.org/116-845-545-643-34X,Patent Application,yes,6,20,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F12/10,711/202;;X711E12058,0,0,,,,ACTIVE
329,FR,A1,FR 2741725 A1,130-803-817-386-466,1997-05-30,1997,FR 9614535 A,1996-11-27,US 56365695 A,1995-11-28,"SYSTEME DE LENTILLES POUR VISIBLE ET INFRAROUGE, ET PROCEDE DE DETECTION D'IMAGES VISIBLES ET INFRAROUGES","<P>L'invention concerne la détection d'images visibles et infrarouges.<BR/>Elle se rapporte à un système de lentilles formant un objectif à plusieurs spectres, destiné à former une image de la lumière dans une plage de longueurs d'onde qui comprend les longueurs d'onde visibles et infrarouges. Il comprend une première lentille (110) formée d'oxyde de magnésium, et une seconde lentille (120) formée de fluorure de calcium. La plage de longueurs d'onde est comprise approximativement entre 0,55 et 5,35 mum. La première lentille et la seconde lentille (110, 120) corrigent chromatiquement la lumière visible et la lumière infrarouge.<BR/>Application à la détection d'images visibles et infrarouges pour la reconnaissance aérienne.</P>",LORAL FAIRCHILD CORP,COON BRYAN H;;MCGEE III JOHN F;;SHERMAN NEIL;;MONTULLI LOUIS T,,https://lens.org/130-803-817-386-466,Patent Application,no,2,0,7,7,0,G02B1/02;;G02B13/146;;G02B1/02;;G02B13/146,G02B1/02;;G02B13/14,,0,0,,,,EXPIRED
330,US,A1,US 2011/0078692 A1,182-991-933-016-312,2011-03-31,2011,US 88708110 A,2010-09-21,US 88708110 A;;US 24604709 P,2009-09-25,COALESCING MEMORY BARRIER OPERATIONS ACROSS MULTIPLE PARALLEL THREADS,"One embodiment of the present invention sets forth a technique for coalescing memory barrier operations across multiple parallel threads. Memory barrier requests from a given parallel thread processing unit are coalesced to reduce the impact to the rest of the system. Additionally, memory barrier requests may specify a level of a set of threads with respect to which the memory transactions are committed. For example, a first type of memory barrier instruction may commit the memory transactions to a level of a set of cooperating threads that share an L1 (level one) cache. A second type of memory barrier instruction may commit the memory transactions to a level of a set of threads sharing a global memory. Finally, a third type of memory barrier instruction may commit the memory transactions to a system level of all threads sharing all system memories. The latency required to execute the memory barrier instruction varies based on the type of memory barrier instruction.",NICKOLLS JOHN R;;HEINRICH STEVEN JAMES;;COON BRETT W;;SHEBANOW MICHAEL C,NICKOLLS JOHN R;;HEINRICH STEVEN JAMES;;COON BRETT W;;SHEBANOW MICHAEL C,NVIDIA CORPORATION (2010-09-16),https://lens.org/182-991-933-016-312,Patent Application,yes,3,43,2,4,0,G06F9/3834;;G06F9/3834;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/3851;;G06F9/3851,G06F9/46,718/103,0,0,,,,ACTIVE
331,KR,A,KR 20120101016 A,189-532-187-498-162,2012-09-12,2012,KR 20127013387 A,2010-10-25,US 25495509 P;;US 2010/0053900 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL-CELL LUNG CANCER,,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/189-532-187-498-162,Patent Application,no,0,2,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,G01N33/52;;C12Q1/68,,0,0,,,,ACTIVE
332,US,B1,US 6419025 B1,041-805-149-850-819,2002-07-16,2002,US 28992899 A,1999-04-09,US 28992899 A,1999-04-09,Method of selective plastic expansion of sections of a tubing,"
    A method of selective plastic expansion of sections of a tubing to create one or more recesses in the tubing with a larger diameter than that of the original tubing in which the tubing is radially symmetrically or asymmetrically expanded at one or more locations by application of a radial force to the interior of the tubing thereby inducing a plastic radial deformation of the tubing and removing said radial force from the interior of the tubing. 
",SHELL OIL CO,LOHBECK WILHELMUS CHRISTIANUS;;FRANK TIMOTHY JOHN;;COON ROBERT JOE;;NAZZAL GREGORY RICHARD,SHELL OIL COMPANY (1999-01-14),https://lens.org/041-805-149-850-819,Granted Patent,yes,17,47,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,166/380;;166/277;;166/207,1,0,,,"Metal Forming-Mechanics and Metallurgy, Chapters 3 and 17, 2nd Ed., Prentice Mail, New Jersey, 1993.",EXPIRED
333,CN,A,CN 102656458 A,083-503-435-575-467,2012-09-05,2012,CN 201080059371 A,2010-10-25,US 2010/0053893 W;;US 25496809 P,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,DIMITRI SEMINAROV;;XIN LU;;KE ZHANG;;LESNIEWSKI RICK R;;COON JOHN S,"ABBOTT HOSPITAL CO., LTD. (2013-12-11);;ABBOTT GMBH. + CO. KG (2014-10-10)",https://lens.org/083-503-435-575-467,Patent Application,no,3,27,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,G01N33/574;;C12Q1/68,,4,4,095-613-011-399-677;;020-762-711-661-486;;065-867-313-439-381;;044-537-720-986-944,16575401;;10.1038/modpathol.3800593;;16322280;;10.1158/1078-0432.ccr-05-1157;;10.1158/0008-5472.can-04-4603;;15994928;;19176396;;10.1158/0008-5472.can-08-1116,"SY LEUNG ET AL.: ""Comprehensive analysis of 19q12 amplicon in human gastric cancers"", 《MODERN PATHOLOGY》;;TAE-MIN KIM ET AL.: ""Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non-Small Cell Lung Cancers"", 《 CLINICAL CANCER RESEARCH》;;XIAOJUN ZHAO ET AL.: ""Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis"", 《CANCER RES》;;PHILIPPE BROËT ET AL.: ""Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection"", 《CANCER RESEARCH》",INACTIVE
334,JP,A,JP 2016105710 A,089-232-294-421-830,2016-06-16,2016,JP 2015245932 A,2015-12-17,US 25495509 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"PROBLEM TO BE SOLVED: To provide methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who have an unfavorable prognosis for the recurrence of lung cancer after surgical resection.SOLUTION: The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus including the cyclin E1 gene and the ZNF536 gene. The presence of a copy number gain in the cyclin E1 gene and the ZNF536 gene is predictive of poor disease outcome.SELECTED DRAWING: None",ABBOTT LAB,DIMITRI SEMIZAROV;;LU XIN;;ZHANG KE;;RICK R LESNIEWSKI;;COON JOHN S,,https://lens.org/089-232-294-421-830,Patent Application,no,3,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,4,1,011-022-708-056-373,14510182;;10.1586/14737159.3.5.617,"医学のあゆみ, vol. 199, JPN6015001982, 2001, pages 631 - 635, ISSN: 0003488895;;CLINICAL CANCER RESEARCH, vol. 6, JPN6015001983, 2000, pages 11 - 16, ISSN: 0003488896;;YASMEEN A: ""E- AND A-TYPE CYCLINS AS MARKERS FOR CANCER DIAGNOSIS AND PROGNOSIS"", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. V3 N5, JPN5013000276, 1 September 2003 (2003-09-01), GB, pages 617 - 633, ISSN: 0003488897;;GENES,CHROMOSOMES AND CANCER, vol. 49, JPN6015001984, 2010, pages 9 - 16, ISSN: 0003488898",INACTIVE
335,US,B2,US 9291625 B2,107-335-017-696-935,2016-03-22,2016,US 91089110 A,2010-10-25,US 91089110 A;;US 25496809 P,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S;;ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC (2016-02-12);;ABBOTT LABORATORIES (2011-01-14),https://lens.org/107-335-017-696-935,Granted Patent,yes,19,2,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68;;G01N33/574,,44,31,020-762-711-661-486;;000-387-999-206-564;;011-510-783-528-097;;032-512-204-912-336;;044-537-720-986-944;;007-715-602-525-570;;019-596-074-346-283;;052-305-055-316-795;;086-358-557-736-303;;113-976-640-220-362;;057-228-563-045-472;;018-447-753-688-44X;;015-757-740-631-30X;;057-833-970-309-223;;095-613-011-399-677;;005-958-677-306-202;;190-215-680-405-229;;046-249-495-864-946;;026-496-182-157-514;;043-185-153-369-364;;089-863-076-892-504;;052-278-913-854-354;;041-309-424-116-14X;;035-356-341-734-705;;101-372-582-111-156;;004-833-219-417-698;;011-022-708-056-373;;065-867-313-439-381;;030-798-050-767-538;;066-537-561-189-38X;;028-004-568-678-637,16322280;;10.1158/1078-0432.ccr-05-1157;;10.1158/1078-0432.ccr-04-2661;;15930332;;17873171;;10.1378/chest.07-1378;;pmc2527324;;10.1186/1755-8794-1-25;;18549475;;19176396;;10.1158/0008-5472.can-08-1116;;19255323;;10.1200/jco.2008.19.1635;;pmc3341799;;pmc3656305;;23543735;;10.1074/jbc.m113.458737;;9680343;;10.1182/blood.v92.3.770;;19193619;;10.1158/1078-0432.ccr-08-1564;;pmc2670486;;19787784;;10.1002/gcc.20714;;10.1158/1078-0432.ccr-09-2151;;20028770;;pmc2805048;;17640552;;10.1016/j.humpath.2007.04.015;;10.1200/jco.2003.11.069;;12953099;;22244930;;10.1016/j.cca.2011.12.020;;16575401;;10.1038/modpathol.3800593;;9426687;;10.1002/(sici)1097-0215(19980105)75:1<34::aid-ijc6>3.0.co;2-2;;10.1101/gr.4.2.80;;7580889;;15782172;;10.1038/nmeth718;;10.1016/s0169-5002(00)80618-2;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;11212263;;10.1002/ijc.22609;;17351921;;10.3109/10520299809140502;;9554580;;10.1111/j.1349-7006.2005.00092.x;;16232197;;10.1002/path.1356;;12845634;;7875039;;10.1002/cyto.990170407;;14510182;;10.1586/14737159.3.5.617;;10.1158/0008-5472.can-04-4603;;15994928;;10.1073/pnas.0709618105;;18632575;;pmc2465804;;10714208;;19208797;;10.1158/1078-0432.ccr-08-2188,"Kim et al., Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non-Small Cell Lung Cancers, Clin Cancer Res 2005:11(23) Jun. 1, 2005.;;Singhal et al., Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review, Clin Cancer Res 2005:11(11) Jun. 1, 2005.;;Scott et al., Treatment of Non-small Cell Lung Cancer Stage I and Stage II, Chest / 132 / 3 / Sep. 2007 Supplement.;;Bions H., et al., ""Genome Wide Snp Comparative Analysis Between Egfr and Kras Mutated Nscic and Characterization of Two Models of Oncogenic Cooperation in Non-small Cell Lung Carcinoma,"" BMC Medical Genomics, 2008, vol. 1, pp. 25.;;Broet P., et al., ""Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection,"" Cancer Research, 2009, vol. 69 (3), pp. 1055-1062.;;Cappuzzo F., et al., ""Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients,"" Journal of Clinical Oncology, 2009, vol. 27 (10), pp. 1667-1674.;;Chen L., et al., ""Lysine Acetyltransferase GCN5 Potentiates the Growth of Non-Small Cell Lung Cancer Via Promotion of E2F1, Cyclin D1, and Cyclin E1 Expression,"" Journal of Biological Chemistry, 2013, vol. 288 (20), pp. 14510-14521.;;Elf® 97 mRNA in Situ Hybridization Kits, Product Information, by Molecular Probes, Revised: Feb. 2, 2001, MP 06604.;;Erlanson M., et al., ""Expression of Cyclin E and the Cyclin-dependent Kinase Inhibitor p27 in Malignant lymphomas-prognostic Implications,"" Blood, 1998, vol. 92 (3), pp. 770-777.;;Etemadmoghadam D., et al., ""Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas,"" Clinical Cancer Research, 2009, vol. 15 (4), pp. 1417-1427.;;Final Office Action mailed Jan. 4, 2013 for U.S. Appl. No. 12/910,892 filed Oct. 25, 2010.;;Freier K., et al., ""Recurrent Copy Number Gain of Transcription Factor SOX2 and Corresponding High Protein Expression in Oral Squamous Cell Carcinoma,"" Genes, Chromosomes and Cancer, 2010, vol. 49 (1), pp. 9-16.;;Galimberti F., et al., ""Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe,"" Clinical Cancer Research, 2010, vol. 16 (1), pp. 109-120.;;Halling K.C., et al., ""Fluorescence in Situ Hybridization in Diagnostic Cytology,"" Human Pathology, 2007, vol. 38, pp. 1137-1144.;;Hirsch F.R., et al., ""Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis,"" Journal of Clinical Oncology, 2003, vol. 21 (20), pp. 3798-3807.;;Huang L.N., et al., ""Meta-Analysis for Cyclin E in Lung Cancer Survival,"" Clinical Chimica Acta, 2012, vol. 413 (7-8), pp. 663-668.;;International Preliminary Report on Patentability for Application No. PCT/US2010/053893, mailed on May 1, 2012, 1 page.;;International Preliminary Report on Patentability for Application No. PCT/US2010/053900, mailed on May 1, 2012, 1 page.;;International Search Report and Written Opinion for Application No. PCT/US2010/053893, mailed on Jun. 10, 2011, 12 pages.;;International Search Report and Written Opinion for Application No. PCT/US2010/053900, mailed on Feb. 11, 2011, 12 pages.;;Invitation to Pay Additional Fees for Application No. PCT/US2010/053893, mailed on Mar. 28, 2011, 6 pages.;;Leung S.Y., et al., ""Comprehensive Analysis of 19q12 Amplicon in Human Gastric Cancers,"" Modern Pathology, 2006, vol. 19 (6), pp. 854-863.;;Marone M., et al., ""Analysis of Cyclin E and CDK2 in Ovarian Cancer: Gene Amplification and RNA Overexpression,"" International Journal of Cancer, 1998, vol. 75, pp. 34-39.;;Marshall R.L., et al., ""Detection of HCV RNA by the Asymmetric Gap Ligase Chain Reaction,"" PCR Methods and Applications, 1994, vol. 4 (2), pp. 80-84.;;Matsuzaki H., et al., ""Genotyping Over 100,000 SNPs on a Pair of Oligonucleotide Arrays,"" Nature Methods, 2004, vol. 1 (2), pp. 109-111.;;Mishina T., et al., ""Cyclin E Expression, a Potential Prognostic Marker for Non-Small Cell Lung Cancers,"" Clinical Cancer Research, 2000, vol. 6 (1), pp. 11-16.;;Morrison, L.E. et al., ""Labeling Fluorescence in Situ Hybridization Probes for Genomic Targets,"" Methods in Molecular Biology, 2002, vol. 204, pp. 21-40.;;Muller, et al., ""Cyclin E is the Only Cyclin-dependent Kinase 2-associated Cyclin that Predicts Metastasis and Survival in Early Stage Non-Small Cell Lung Cancer,"" Cancer Research, 2001, vol. 61, pp. 647-653.;;Nakayama K., et al., ""Amplicon Profiles in Ovarian Serous Carcinomas,"" International Journal of Cancer , 2007, vol. 120 (12), pp. 2613-2617.;;Nath J., et al. ""Fluorescence in Situ Hybridization (FISH): DNA Probe Production and Hybridization Criteria,"" Biotechnic & Histochemistry, 1997, vol. 73 (1), pp. 6-22.;;Non-Final Office Action mailed May 8, 2012 for U.S. Appl. No. 12/910,892 filed Oct. 25, 2010.;;Non-Final Office Action mailed Jun. 21, 2013 for U.S. Appl. No. 12/910,892 filed Oct. 25, 2010.;;Peng W.X., et al., ""Array-Based Comparative Genomic Hybridization Analysis of High-Grade Neuroendocrine Tumors of the Lung,"" Cancer Science , 2005, vol. 96 (10), pp. 661-667.;;Schrami P., et al., ""Cyclin E Overexpression and Amplification in Human Tumours,"" The Journal of Pathology, 2003, vol. 200 (3), pp. 375-382.;;Wheeless L.L., et al., ""Bladder Irrigation Specimens Assayed by Fluorescence in Situ Hybridization to Interphase Nuclei,"" Cytometry, 1994, vol. 17 (4), pp. 319-326.;;Yasmeen A., et al., ""E- and A-Type Cyclins as Markers for Cancer Diagnosis and Prognosis,"" Expert Review of Molecular Diagnostics , 2003, vol. 3 (5), pp. 617-633.;;Non-Final Office Action mailed Dec. 30, 2013 for U.S. Appl. No. 12/910,892 filed Oct. 25, 2010.;;Zhao, Xiaojun et al., ""Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis,"" Cancer Research, vol. 65(13), Jul. 1, 2005, pp. 5561-5570.;;Non-Final Office Action mailed Jul. 10, 2014 for U.S. Appl. No. 12/910,892 filed Oct. 25, 2010.;;Aviel-Ronen S., et al., ""Genomic Markers for Malignant Progression in Pulmonary Adenocarcinoma with Bronchioloalveolar Features,"" Proceedings of the National Academy of Sciences, USA, 2008, vol. 105 (29), pp. 10155-10160.;;Final Office Action mailed Jan. 7, 2015 for U.S. Appl. No. 12/910,892 filed Oct. 25, 2010.;;Muller K.M., et al., ""New Aspects of Lung Tumor Pathology,"" Verhandlungen Der Deutschen Gesellschaft Fur Pathologie, 1999, vol. 83, pp. 168-183. Only English Abstract is considered.;;Non-Final Office Action mailed May 7, 2015 for U.S. Appl. No. 12/910,892 filed Oct. 25, 2010.;;Wrage M., et al., ""Genomic Profiles Associated With Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion,"" Clinical Cancer Research, 2009, vol. 15 (5), pp. 1566-1574.",ACTIVE
336,EP,A4,EP 2480985 A4,106-521-543-078-435,2014-04-23,2014,EP 10819552 A,2010-09-24,US 56763709 A;;US 2010/0050240 W,2009-09-25,UNIFIED ADDRESSING AND INSTRUCTIONS FOR ACCESSING PARALLEL MEMORY SPACES,,NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,,https://lens.org/106-521-543-078-435,Search Report,no,2,0,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F12/02;;G06F12/10;;G06F15/167,,0,0,,,,ACTIVE
337,WO,A3,WO 1999/050593 A3,155-556-024-502-692,1999-12-02,1999,US 9906089 W,1999-03-19,US 7966798 P;;US 5053498 A,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical light apparatus (30) includes a lighthead (36, 38) having a sterile field thereon, a bulb (68, 70) located within the lighthead (36, 38), a controller (106) coupled to the bulb (68, 70), and an actuator (74) coupled to the controller (106) to adjust an intensity of light emitted from the bulb (68, 70). The actuator (74) is located in the sterile field on the lighthead (36, 38).",HILL ROM CO INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/155-556-024-502-692,Search Report,yes,9,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,A61B19/00;;F21S8/00;;F21S2/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,PATENTED
338,US,B1,US 7644210 B1,005-752-226-883-146,2010-01-05,2010,US 52404406 A,2006-09-19,US 52404406 A;;US 46323303 A;;US 59627900 A,2000-06-19,Method and system for storing and retrieving a translation of target program instruction from a host processor using fast look-up of indirect branch destination in a dynamic translation system,"Dynamic translation of indirect branch instructions of a target application by a host processor is enhanced by including a cache to provide access to the addresses of the most frequently used translations of a host computer, minimizing the need to access the translation buffer. Entries in the cache have a host instruction address and tags that may include a logical address of the instruction of the target application, the physical address of that instruction, the code segment limit to the instruction, and the context value of the host processor associated with that instruction. The cache may be a software cache apportioned by software from the main processor memory or a hardware cache separate from main memory.",BANNING JOHN;;COON BRETT;;TORVALDS LINUS;;CHOY BRIAN;;WING MALCOLM;;GAINER PATRICK,BANNING JOHN;;COON BRETT;;TORVALDS LINUS;;CHOY BRIAN;;WING MALCOLM;;GAINER PATRICK,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27);;INTELLECTUAL VENTURE FUNDING LLC (2009-01-28);;TRANSMETA LLC (2009-01-27),https://lens.org/005-752-226-883-146,Granted Patent,yes,84,47,3,3,0,G06F9/45504;;G06F9/30061;;G06F9/45504,G06F9/30;;G06F9/06;;G06F9/45;;G06F9/455;;G06F15/00,710/100;;717/136;;717/139;;711/118;;711/203,19,6,127-533-499-577-375;;155-430-967-691-122;;155-430-967-691-122;;127-533-499-577-375;;073-245-482-608-346;;034-421-585-026-029,10.1109/csac.2002.1176292;;10.1049/el:19971159;;10.1049/el:19971159;;10.1109/csac.2002.1176292;;10.1109/icsm.1996.565037;;10.1145/351397.351414,"""Fault-tolerant features in the Hal memory management unit"" by Saxena et al. (abstract only) Publication Date: Feb. 1995.;;""Hardware support for control transfers in code caches"" by Kim et al. (abstract only) Publication Date: Dec. 3-5, 2003.;;""Safe virtual execution using software dynamic translation"" by Scott et al. (abstract only) Publication Date: Dec. 9-13, 2002.;;""Indirectly -connected cache tag memory using a shared tag in a TLB"" by Lee et al. (abstract only) Publication Date: Oct. 9, 1997.;;""Fault-tolerant features in the Hal memory management unit"" by Saxena et al. (abstract only) Publication Date: Feb., 1995*.;;""Indirectly-compared cache tag memory using a shared tag in a TLB"" by Lee et al. (abstract only) Publication Date: Oct 9, 1997*.;;""Safe virtual execution using software dynamic translation"" by Scott, K.; Davidson, J. (abstract only) publication Date Dec. 9-13, 2002*.;;Bala et al.; ""Transparent Dynamic Optimization:The Design and Implementation of Dynamo;"" HP Laboratories Cambridge HPL-1999-78; Jun. 1999.;;Cifuentes, Cristina and Malhotra, Vishv, Binary Translation: Static, Dynamic, Retargetable?, International Conference on Software Mainteance, Nov. 4-8, 1996.;;Holzle, Urs, Adaptive Optimization for SELF: Reconciling High Performance with Exploratory Programming, Dotorial Dissertation, Aug. 1994.;;Ung et al.; ""Dynamic Re-Engineering of Binary Code With Run-Time Feedbacks;"" Department of Computer Science and Electrical Engineering, University of Queensland, QLD, Australia; 2000.;;Ung et al.; ""Machine-Adaptable Dynamic Binary Translation;"" Proceedings of the ACM Sigplan Workshop on Dynamic and Adapative Compilation and Optimization, Jan. 2000 pp. 30-40.;;Advisory Action Dated Aug. 18, 2005; U.S. Appl. No. 10/463,233.;;Non Final OA Dated Jul. 16, 2004; U.S. Appl. No. 10/463,233.;;Notice of Allowance Dated Nov. 3, 2005; U.S. Appl. No. 10/463,233.;;Final OA Dated Feb. 2, 2005; U.S. Appl. No. 10/463,233.;;Notice of Allowance Dated May 8, 2006; U.S. Appl. No. 10/463,233.;;Non Final OA Dated Dec. 3, 2002; U.S. Appl. No. 09/596,279.;;Notice of Allowance Dated Mar. 21, 2003; U.S. Appl. No. 09/596,279.",EXPIRED
339,EP,B1,EP 1169541 B1,131-028-682-939-001,2004-10-06,2004,EP 00929343 A,2000-04-06,EP 0003104 W;;US 28992899 A,1999-04-09,METHOD OF SELECTIVE PLASTIC EXPANSION OF SECTIONS OF A TUBING,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,,https://lens.org/131-028-682-939-001,Granted Patent,yes,3,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
340,WO,A1,WO 2000/061908 A1,138-001-550-161-917,2000-10-19,2000,EP 0003104 W,2000-04-06,US 28992899 A,1999-04-09,METHOD OF SELECTIVE PLASTIC EXPANSION OF SECTIONS OF A TUBING,"A method of selective plastic expansion of sections of a tubing to create one or more recesses in the tubing with a larger diameter than that of the original tubing in which the tubing is radially symmetrically or asymmetrically expanded at one or more locations by application of a radial force to the interior of the tubing thereby inducing a plastic radial deformation of the tubing and removing said radial force from the interior of the tubing. The tubing can be a downhole tubing and the created recesses are preferably utilized to hold at least one downhole device, which is advantageously a gas lift mandrel or a sensor.",SHELL INT RESEARCH;;COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,,https://lens.org/138-001-550-161-917,Patent Application,yes,14,8,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,1,0,,,"METAL FORMING-MECHANICS AND METALLURGY (2ND EDITION) PRENTICE MAIL, 1 January 1993 (1993-01-01), NEW JERSEY USA 1993",PATENTED
341,CA,A1,CA 2778004 A1,159-011-115-444-032,2011-05-12,2011,CA 2778004 A,2010-10-25,US 25495509 P;;US 2010/0053900 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL-CELL LUNG CANCER,"Disclosed are methods for identifying early-stage non- small - cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chrl9, 34.7 Mb - 35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with f luorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus, which includes the cyclin El gene.",ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/159-011-115-444-032,Patent Application,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,0,0,,,,INACTIVE
342,DE,T2,DE 69310037 T2,173-819-293-943-116,1997-09-25,1997,DE 69310037 T,1993-07-01,US 90785392 A,1992-07-02,Endoskopisches Instrumentensystem,,MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;COON DONALD B;;NELSON JOHN T;;PETRUSCHKE HAANS K,,https://lens.org/173-819-293-943-116,Granted Patent,no,0,4,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B10/06;;A61B17/00;;A61B1/00;;A61B17/28;;A61B17/32;;A61B19/00,,0,0,,,,EXPIRED
343,NO,L,NO 20014899 L,033-302-456-306-229,2001-12-06,2001,NO 20014899 A,2001-10-08,EP 0003104 W;;US 28992899 A,1999-04-09,Fremgangsmåte for selektiv plastisk ekspansjon av seksjoner av et rör,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,,https://lens.org/033-302-456-306-229,Abstract,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
344,EP,B1,EP 1084364 B1,034-932-162-617-85X,2006-09-27,2006,EP 99914957 A,1999-03-19,US 9906089 W;;US 7966798 P;;US 5053498 A,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",HILL ROM SERVICES INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,"HILL-ROM SERVICES, INC. (2006-09-06)",https://lens.org/034-932-162-617-85X,Granted Patent,yes,9,3,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;F21S8/04;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
345,JP,A,JP 2017158573 A,033-130-511-323-227,2017-09-14,2017,JP 2017091143 A,2017-05-01,US 25496809 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON SMALL CELL LUNG CANCER,"PROBLEM TO BE SOLVED: To provide methods for identifying patients of early stage non small cell lung cancer (NSCLC) potentially having an unfavorable prognosis for the recurrence of lung cancer after surgical resection.SOLUTION: Provided is a method for predicting disease outcome in a patient being treated for lung cancer, comprising the steps of: determining a copy number of a cancer outcome marker in a test sample obtained from a patient; comparing the copy number of the cancer outcome marker in the test sample against two base line copy numbers to determine the presence or absence of a copy number change for the cancer outcome marker in the test sample; identifying the patient as one having an increased risk of a poor disease outcome, based on the presence or absence of a copy number change for the cancer outcome marker in the test sample in comparison with a baseline measure of disease outcome in patients having no copy number change in the cancer outcome marker, where the presence of a copy number change in the cancer outcome marker is predictive of poor disease outcome.SELECTED DRAWING: None",ABBOTT MOLECULAR INC,DIMITRI SEMIZAROV;;LU XIN;;ZHANG KE;;RICK R LESNIEWSKI;;COON JOHN S,,https://lens.org/033-130-511-323-227,Patent Application,no,3,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,2,0,,,"CANCER RES., 2009, 69(3), PP.1055-1062 (EPUB 2009 JAN 27), JPN6014054690;;GENES,CHROMOSOMES AND CANCER, vol. Vol.49, JPN6015001984, 2010, pages 9 - 16",PENDING
346,BR,B1,BR 9909185 B1,172-827-257-003-032,2009-01-13,2009,BR 9909185 A,1999-03-19,US 7966798 P;;US 5053498 A;;US 9906089 W,1998-03-27,aparelho de iluminação cirúrgica.,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/172-827-257-003-032,Granted Patent,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
347,WO,A9,WO 1999/050593 A9,168-701-275-321-482,2000-04-06,2000,US 9906089 W,1999-03-19,US 7966798 P;;US 5053498 A,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical light apparatus (30) includes a lighthead (36, 38) having a sterile field thereon, a bulb (68, 70) located within the lighthead (36, 38), a controller (106) coupled to the bulb (68, 70), and an actuator (74) coupled to the controller (106) to adjust an intensity of light emitted from the bulb (68, 70). The actuator (74) is located in the sterile field on the lighthead (36, 38).",HILL ROM CO INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/168-701-275-321-482,Patent Application,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,A61B19/00;;F21S8/00;;F21S2/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,PATENTED
348,GB,B,GB 2307757 B,044-149-220-156-202,2000-03-29,2000,GB 9624543 A,1996-11-25,US 56365695 A,1995-11-28,Method and system for multi-spectral imaging in the visible and infrared spectrums,,LORAL FAIRCHILD CORP,COON BYAN H;;MCGEE III JOHN F;;SHERMAN NEIL;;MONTULLI LOUIS T,,https://lens.org/044-149-220-156-202,Granted Patent,no,1,0,7,7,0,G02B1/02;;G02B13/146;;G02B1/02;;G02B13/146,G02B1/02;;G02B13/14,G2J JB7CX         JB7CX;;G2J JB7C10        JB7CX;;G2J JB7C19        JB7CX;;G2J JB7C2         JB7CX;;G2J JB7C4         JB7CX;;G2J JB7C6         JB7CX;;G2J JB7C7         JB7CX,0,0,,,,EXPIRED
349,US,B1,US 6615300 B1,069-612-451-211-757,2003-09-02,2003,US 59627900 A,2000-06-19,US 59627900 A,2000-06-19,Fast look-up of indirect branch destination in a dynamic translation system,"
    Dynamic translation of indirect branch instructions of a target application by a host processor is enhanced by including a cache to provide access to the addresses of the most frequently used translations of a host computer, minimizing the need to access the translation buffer. Each entry in the cache includes a host instruction address, a logical address of the instruction of the target application, the physical address of that instruction, the code segment limit to the instruction, and the context value of the host processor associated with that instruction, the last four named components constituting tags to the host instruction address, and a valid-invalid bit. In a basic embodiment, the cache is a software cache apportioned by software from the main processor memory chips. 
",TRANSMETA CORP,BANNING JOHN;;COON BRETT;;TORVALDS LINUS;;CHOY BRIAN;;WING MALCOLM;;GAINER PATRICK,INTELLECTUAL VENTURES HOLDING 81 LLC (2015-08-27);;INTELLECTUAL VENTURE FUNDING LLC (2009-01-28);;TRANSMETA CORPORATION (2000-10-26);;TRANSMETA LLC (2009-01-27),https://lens.org/069-612-451-211-757,Granted Patent,yes,5,37,3,3,0,G06F9/45504;;G06F9/30061;;G06F9/45504,G06F9/06;;G06F9/45;;G06F9/455;;G06F15/00,710/100;;711/118;;711/202;;712/205,0,0,,,,EXPIRED
350,WO,A3,WO 1999/050593 A3,088-699-022-458-165,1999-10-07,1999,US US9906089,1999-03-19,"US 60/0/079,667;;US 09/0/050,534",1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical light apparatus (30) includes a lighthead (36, 38) having a sterile field thereon, a bulb (68, 70) located within the lighthead (36, 38), a controller (106) coupled to the bulb (68, 70), and an actuator (74) coupled to the controller (106) to adjust an intensity of light emitted from the bulb (68, 70). The actuator (74) is located in the sterile field on the lighthead (36, 38).","HILL-ROM, INC.","BORDERS, Richard, L.;;COON, Dennis, C.;;KRAHE, Ronald, P.;;BULKO, John, M.",,https://lens.org/088-699-022-458-165,Search Report,yes,0,0,1,1,0,,F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,UNKNOWN
351,CN,A,CN 104232762 A,154-310-416-967-265,2014-12-24,2014,CN 201410436502 A,2010-10-25,US 25496809 P;;CN 201080059371 A,2009-10-26,Diagnostic methods for determining prognosis of non-small-cell lung cancer,The present disclosure provides diagnostic methods for determining prognosis of non-small-cell lung cancer and methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/154-310-416-967-265,Patent Application,no,1,1,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,2,2,020-762-711-661-486;;065-867-313-439-381,16322280;;10.1158/1078-0432.ccr-05-1157;;10.1158/0008-5472.can-04-4603;;15994928,"TAE-MIN KIM ET AL.: ""Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non-Small Cell Lung Cancers"", 《CLINICAL CANCER RESEARCH》;;XIAOJUN ZHAO ET AL.: ""Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis"", 《CANCER RES》",INACTIVE
352,US,B2,US 9297045 B2,016-596-788-097-857,2016-03-29,2016,US 91089210 A,2010-10-25,US 91089210 A;;US 25495509 P,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,"Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus.",SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S;;ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC (2015-01-01);;ABBOTT LABORATORIES (2011-01-14),https://lens.org/016-596-788-097-857,Granted Patent,yes,20,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,45,33,089-863-076-892-504;;015-757-740-631-30X;;101-372-582-111-156;;052-305-055-316-795;;095-613-011-399-677;;032-512-204-912-336;;011-510-783-528-097;;011-510-783-528-097;;007-715-602-525-570;;086-358-557-736-303;;113-976-640-220-362;;018-447-753-688-44X;;095-613-011-399-677;;005-958-677-306-202;;190-215-680-405-229;;046-249-495-864-946;;026-496-182-157-514;;043-185-153-369-364;;052-278-913-854-354;;041-309-424-116-14X;;035-356-341-734-705;;000-387-999-206-564;;004-833-219-417-698;;011-022-708-056-373;;044-537-720-986-944;;019-596-074-346-283;;057-228-563-045-472;;057-833-970-309-223;;020-762-711-661-486;;030-798-050-767-538;;066-537-561-189-38X;;028-004-568-678-637;;065-867-313-439-381,11212263;;10.1200/jco.2003.11.069;;12953099;;10.1002/path.1356;;12845634;;9680343;;10.1182/blood.v92.3.770;;16575401;;10.1038/modpathol.3800593;;pmc2527324;;10.1186/1755-8794-1-25;;18549475;;17873171;;10.1378/chest.07-1378;;17873171;;10.1378/chest.07-1378;;19255323;;10.1200/jco.2008.19.1635;;pmc3341799;;19193619;;10.1158/1078-0432.ccr-08-1564;;pmc2670486;;19787784;;10.1002/gcc.20714;;17640552;;10.1016/j.humpath.2007.04.015;;16575401;;10.1038/modpathol.3800593;;9426687;;10.1002/(sici)1097-0215(19980105)75:1<34::aid-ijc6>3.0.co;2-2;;10.1101/gr.4.2.80;;7580889;;15782172;;10.1038/nmeth718;;10.1016/s0169-5002(00)80618-2;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;10.1002/ijc.22609;;17351921;;10.3109/10520299809140502;;9554580;;10.1111/j.1349-7006.2005.00092.x;;16232197;;10.1158/1078-0432.ccr-04-2661;;15930332;;7875039;;10.1002/cyto.990170407;;14510182;;10.1586/14737159.3.5.617;;19176396;;10.1158/0008-5472.can-08-1116;;pmc3656305;;23543735;;10.1074/jbc.m113.458737;;10.1158/1078-0432.ccr-09-2151;;20028770;;pmc2805048;;22244930;;10.1016/j.cca.2011.12.020;;16322280;;10.1158/1078-0432.ccr-05-1157;;10.1073/pnas.0709618105;;18632575;;pmc2465804;;10714208;;19208797;;10.1158/1078-0432.ccr-08-2188;;10.1158/0008-5472.can-04-4603;;15994928,"Muller et al., Cyclin E is the Only Cyclin-dependent Kinase 2-associated Cyclin that Predicts Metastasis and Survival in Early Stage Non-Small Cell Lung Cancer, Cancer Research 61, 647-653, Jan. 15, 2001.;;Hirsch et al., Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis, Journal of Clinical Oncology, vol. 21, No. 20 Oct. 15, 2003: pp. 3798-3807.;;Schraml et al., Cyclin E overexpression and amplification in human tumours, J Pathol 2003; 200: 375-382.;;Erlanson et al., Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas-Prognostic Implications, Blood, vol. 92, No. 3 Aug. 1, 1998: pp. 770-777.;;Leung et al., Comprehensive analysis of 19q12 amplicon in human gastric cancers, Modern Pathology (2006) 19, 854-863.;;ELF® 97 mRNA In Situ Hybridization Kits, Product Information, by Molecular Probes, Revised: Feb. 2, 2001, MP 06604.;;Blons et al., Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma, BMC Medical Genomics 2008, 1:25.;;Scott et al., Treatment of Non-small Cell Lung Cancer Stage I and Stage II ACCP Evidence-Based Clinical Practice Guidelines. Chest,132, 3, Sep. 2007 Supplement, pp. 234S-242S.;;Scott, Treatment of Non-small Cell Lung Cancer Stage I and Stage II, Chest,132:3, Sep. 2007 Supplement, pp. 234S-242S.;;Cappuzzo F., et al., ""Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients,"" Journal of Clinical Oncology, 2009, vol. 27 (10), pp. 1667-1674.;;Etemadmoghadam D., et al., ""Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas,"" Clinical Cancer Research, 2009, vol. 15 (4), pp. 1417-1427.;;Freier K., et al., ""Recurrent Copy Number Gain of Transcription Factor SOX2 and Corresponding High Protein Expression in Oral Squamous Cell Carcinoma,"" Genes, Chromosomes and Cancer, 2010, vol. 49 (1), pp. 9-16.;;Halling K.C., et al., ""Fluorescence In Situ Hybridization in Diagnostic Cytology,"" Human Pathology, 2007, vol. 38, pp. 1137-1144.;;International Search Report and Written Opinion for Application No. PCT/US2010/053900 , mailed on Feb. 11, 2011, 12 pages.;;Leung S.Y., et al., ""Comprehensive Analysis of 19q12 Amplicon in Human Gastric Cancers,"" Modern Pathology, 2006, vol. 19 (6), pp. 854-863.;;Marone M., et al., ""Analysis of Cyclin E and CDK2 in Ovarian Cancer: Gene Amplification and RNA Overexpression,"" International Journal of Cancer, 1998, vol. 75, pp. 34-39.;;Marshall R.L., et al., ""Detection of HCV RNA by the Asymmetric Gap Ligase Chain Reaction,"" PCR Methods and Applications, 1994, vol. 4 (2), pp. 80-84.;;Matsuzaki H., et al., ""Genotyping Over 100,000 SNPs on a Pair of Oligonucleotide Arrays,"" Nature Methods, 2004, vol. 1 (2), pp. 109-111.;;Mishina T., et al., ""Cyclin E Expression, a Potential Prognostic Marker for Non-Small Cell Lung Cancers,"" Clinical Cancer Research, 2000, vol. 6 (1), pp. 11-16.;;Morrison, L.E. et al., ""Labeling Fluorescence In Situ Hybridization Probes for Genomic Targets,"" Methods in Molecular Biology, 2002, vol. 204, pp. 21-40.;;Nakayama K., et al., ""Amplicon Profiles in Ovarian Serous Carcinomas,"" International Journal of Cancer, 2007, vol. 120 (12), pp. 2613-2617.;;Nath J., et al., ""Fluorescence in Situ Hybridization (FISH): DNA Probe Production and Hybridization Criteria,"" Biotechnic & Histochemistry, 1997, vol. 73 (1), pp. 6-22;;Peng W.X., et al., ""Array-Based Comparative Genomic Hybridization Analysis of High-Grade Neuroendocrine Tumors of the Lung,"" Cancer Science, 2005, vol. 96 (10), pp. 661-667.;;Singhal S., et al., ""Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non -Small Cell Lung Cancer: A Review,"" Clinical Cancer Research, 2005, vol. 11 (11), pp. 3974-3986.;;Wheeless L.L., et al., ""Bladder Irrigation Specimens Assayed by Fluorescence In Situ Hybridization to Interphase Nuclei,"" Cytometry, 1994, vol. 17 (4), pp. 319-326.;;Yasmeen A., et al., ""E- and A-Type Cyclins as Markers for Cancer Diagnosis and Prognosis,"" Expert Review of Molecular Diagnostics, 2003, vol. 3, (5), pp. 617-633.;;Broet P., et al., ""Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection,"" Cancer Research, 2009, vol. 69 (3), pp. 1055-1062.;;Chen L., et al., ""Lysine Acetyltransferase GCN5 Potentiates the Growth of Non-Small Cell Lung Cancer Via Promotion of E2F1, Cyclin D1, and Cyclin El Expression,"" Journal of Biological Chemistry, 2013, vol. 288 (20), pp. 14510-14521.;;Final Office Action mailed Jul. 31, 2013 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Galimberti F., et al., ""Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe,"" Clinical Cancer Research, 2010, vol. 16 (1), pp. 109-120.;;Huang L.N., et al., ""Meta-Analysis for Cyclin E in Lung Cancer Survival,"" Clinical Chimica Acta, 2012, vol. 413 (7-8), pp. 663-668.;;International Preliminary Report on Patentability for Application No. PCT/US2010/053893, mailed on May 1, 2012, 1 page.;;International Preliminary Report on Patentability for Application No. PCT/US2010/053900, mailed on May 1, 2012, 1 page.;;International Search Report and Written Opinion for Application No. PCT/US2010/053893, mailed on Jun. 10, 2011, 12 pages.;;Invitation to Pay Additional Fees for Application No. PCT/US2010/053893, mailed on Mar. 28, 2011, 6 pages.;;Kim T.M., et al., ""Genome-Wide Screening of Genomic Alterations and their Clinicopathologic Implications in Non-Small Cell Lung Cancers,"" Clinical Cancer Research, 2005, vol. 11 (23), pp. 8235-8242.;;Non-Final Office Action mailed Oct. 12, 2012 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Non-Final Office Action mailed Jan. 29, 2014 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Non-Final Office Action mailed Jul. 9, 2014 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Aviel-Ronen S., et al., ""Genomic Markers for Malignant Progression in Pulmonary Adenocarcinoma with Bronchioloalveolar Features,"" Proceedings of the National Academy of Sciences, USA, 2008, vol. 105 (29), pp. 10155-10160.;;Final Office Action mailed Jan. 2, 2015 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Muller K.M., et al., ""New Aspects of Lung Tumor Pathology,"" Verhandlungen Der Deutschen Gesellschaft Fur Pathologie, 1999, vol. 83, pp. 168-183.;;Non-Final Office Action mailed May 7, 2015 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Wrage M., et al., ""Genomic Profiles Associated With Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion,"" Clinical Cancer Research, 2009, vol. 15 (5), pp. 1566-1574.;;Zhao X., et al., ""Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis,"" Cancer Research, 2005, vol. 65 (13), pp. 5561-5570.",INACTIVE
353,CA,A1,CA 2777169 A1,052-133-477-658-105,2011-05-12,2011,CA 2777169 A,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/052-133-477-658-105,Patent Application,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,G01N33/574;;C12Q1/68,,0,0,,,,INACTIVE
354,AU,A1,AU 2010/315601 A1,084-775-414-923-210,2012-05-10,2012,AU 2010/315601 A,2010-10-25,US 25495509 P;;US 2010/0053900 W,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,"Disclosed are methods for identifying early-stage non- small - cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chrl9, 34.7 Mb - 35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with f luorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus, which includes the cyclin El gene.",ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/084-775-414-923-210,Patent Application,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,0,0,,,,DISCONTINUED
355,US,A1,US 2011/0130295 A1,097-510-206-266-832,2011-06-02,2011,US 91089210 A,2010-10-25,US 91089210 A;;US 25495509 P,2009-10-26,Diagnostic Methods For Determining Prognosis Of Non-Small Cell Lung Cancer,"Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus.",ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC (2015-01-01);;ABBOTT LABORATORIES (2011-01-14),https://lens.org/097-510-206-266-832,Patent Application,yes,11,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C40B30/00;;C12Q1/68;;C40B40/06,506/7;;435/6.14;;435/6.13;;435/6.12;;435/6.11;;506/16,9,8,089-863-076-892-504;;015-757-740-631-30X;;101-372-582-111-156;;052-305-055-316-795;;095-613-011-399-677;;032-512-204-912-336;;011-510-783-528-097;;011-510-783-528-097,11212263;;10.1200/jco.2003.11.069;;12953099;;10.1002/path.1356;;12845634;;9680343;;10.1182/blood.v92.3.770;;16575401;;10.1038/modpathol.3800593;;pmc2527324;;10.1186/1755-8794-1-25;;18549475;;17873171;;10.1378/chest.07-1378;;17873171;;10.1378/chest.07-1378,"Muller et al., Cyclin E is the Only Cyclin-dependent Kinase 2-associated Cyclin that Predicts Metastasis and Survival in Early Stage Non-Small Cell Lung Cancer, CANCER RESEARCH 61, 647-653, January 15, 2001;;Hirsch et al., Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis, Journal of Clinical Oncology, Vol 21, No 20 (October 15), 2003: pp 3798-3807;;Schraml et al., Cyclin E overexpression and amplification in human tumours, J Pathol 2003; 200: 375-382;;Erlanson et al., Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas-Prognostic Implications, Blood, Vol 92, No 3 (August 1), 1998: pp 770-777.;;Leung et al., Comprehensive analysis of 19q12 amplicon in human gastric cancers, Modern Pathology (2006) 19, 854-863;;ELF® 97 mRNA In Situ Hybridization Kits, Product Information, by Molecular Probes, Revised: 02.February.2001, MP 06604;;Blons et al., Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma, BMC Medical Genomics 2008, 1:25;;Scott et al., Treatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines. CHEST,132, 3, SEPTEMBER, 2007 SUPPLEMENT, pp. 234S-242S;;Scott, Treatment of Non-small Cell Lung Cancer Stage I and Stage II, CHEST,132:3, SEPTEMBER, 2007 SUPPLEMENT, pp. 234S-242S",INACTIVE
356,US,A,US 5571137 A,124-325-299-546-333,1996-11-05,1996,US 29209494 A,1994-08-17,US 29209494 A;;US 90785392 A,1992-07-02,Endoscopic instrument system and method,"An endoscopic instrument system which includes a handle portion with a scissors grip, a shaft extending from the scissors grip and shaped to extend through a cannula, and a plurality of disposable end tools, each mountable on the end of the shaft and actuatable by the scissors handle. In a preferred embodiment, the scissors handle actuates a rod extending through the shaft which is connected to the end tool. The end tool includes a pair of jaws pivotally mounted on the support and connected to a reciprocating stub shaft by links. The stub shaft is connected to the actuating rod of the handle portion so that movement of the scissors handle causes the jaws to pivot relative to each other. The end tool may take the form of a scissor, grasper, biopsy or dissector, depending upon the specific shape of the jaws. An advantage of the invention is that the support of the end tools is made of a relatively inexpensive plastic material such that the end tools may be discarded when the jaws become dull, thus obviating the need for repeated cleaning and sharpening and eliminating the most difficult portion to clean.",MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;PETRUSCHKE HAANS K;;COON DONALD B;;NELSON JOHN T,COOPERSURGICAL INC (2007-10-23);;MARLOW ACQUISITION CORP (1997-04-03);;THE COOPER COMPANIES INC (2007-10-26),https://lens.org/124-325-299-546-333,Granted Patent,yes,31,201,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B1/00;;A61B10/06;;A61B17/00;;A61B17/28;;A61B17/32;;A61B19/00,606/207;;606/167;;606/205,0,0,,,,EXPIRED
357,EP,B1,EP 2494360 B1,127-889-704-699-599,2017-08-16,2017,EP 10771303 A,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBOTT MOLECULAR INC,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBVIE BAHAMAS LTD. (2014-01-22);;ABBOTT MOLECULAR INC. (2016-06-15);;ABBOTT LABORATORIES (2015-03-04),https://lens.org/127-889-704-699-599,Granted Patent,yes,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,1,0,,,"BROËT PHILIPPE ET AL: ""Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection."", CANCER RESEARCH, vol. 69, no. 3, 1 February 2009 (2009-02-01), pages 1055-1062, XP002618984, ISSN: 1538-7445",ACTIVE
358,KR,A,KR 20180014059 A,146-490-854-093-466,2018-02-07,2018,KR 20177037598 A,2010-10-25,US 25495509 P;;US 2010/0053900 W,2009-10-26,- DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL-CELL LUNG CANCER,"본원에는 외과적 절제 후 폐암의 재발에 대한 불량한 예후를 가질 조기-단계 비-소세포 폐암(NSCLC) 환자를 확인하는 방법이 기재되어 있다. 당해 방법은 Chr19, 34.7Mb 내지 35.6Mb에서 염색체 카피 수 증가가 예후적 분류에 사용될 수 있다는 발견에 일부 기초로 한다. 당해 방법은 바람직하게는 동소교잡법시 형광성을 사용하여 형광적으로 표지된 핵산 프로브를 환자 시료에 교잡시켜, 사이클린 E1 유전자를 포함하는 당해 유전자의 유전자자리의 염색체 카피 수를 정량화한다.",ABBOTT MOLECULAR INC,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/146-490-854-093-466,Patent Application,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,G01N33/52;;C12Q1/68,,0,0,,,,DISCONTINUED
359,US,A1,US 2011/0105341 A1,178-566-499-662-466,2011-05-05,2011,US 91089110 A,2010-10-25,US 91089110 A;;US 25496809 P,2009-10-26,Diagnostic Methods For Determining Prognosis Of Non-Small Cell Lung Cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC (2016-02-12);;ABBOTT LABORATORIES (2011-01-14),https://lens.org/178-566-499-662-466,Patent Application,yes,11,11,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C40B30/00;;C12Q1/68,506/7;;435/6,3,3,020-762-711-661-486;;000-387-999-206-564;;011-510-783-528-097,16322280;;10.1158/1078-0432.ccr-05-1157;;10.1158/1078-0432.ccr-04-2661;;15930332;;17873171;;10.1378/chest.07-1378,"Kim et al., Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non-Small Cell Lung Cancers, Clin Cancer Res 2005:11(23) June 1, 2005.;;Singhal et al., Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review, Clin Cancer Res 2005:11(11) June 1, 2005.;;Scott et al., Treatment of Non-small Cell Lung Cancer Stage I and Stage II, CHEST / 132 / 3 / SEPTEMBER, 2007 SUPPLEMENT",ACTIVE
360,CN,A,CN 102696023 A,065-943-725-376-737,2012-09-26,2012,CN 201080053742 A,2010-09-24,US 2010/0050240 W;;US 56763709 A,2009-09-25,Unified addressing and instructions for accessing parallel memory spaces,One embodiment of the present invention sets forth a technique for unifying the addressing of multiple distinct parallel memory spaces into a single address space for a thread. A unified memory space address is converted into an address that accesses one of the parallel memory spaces for that thread. A single type of load or store instruction may be used that specifies the unified memory space address for a thread instead of using a different type of load or store instruction to access each of the distinct parallel memory spaces.,NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;STEVEN GLANVILLE ROBERT,,https://lens.org/065-943-725-376-737,Patent Application,no,5,6,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F15/167,,0,0,,,,ACTIVE
361,NO,D0,NO 20014899 D0,084-542-747-627-922,2001-10-08,2001,NO 20014899 A,2001-10-08,EP 0003104 W;;US 28992899 A,1999-04-09,Fremgangsmåte for selektiv plastisk ekspansjon av seksjoner av et rör,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,,https://lens.org/084-542-747-627-922,Patent Application,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
362,US,A1,US 2016/0237504 A1,128-715-371-561-917,2016-08-18,2016,US 201615019829 A,2016-02-09,US 201615019829 A;;US 91089110 A;;US 25496809 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC (2016-02-12);;ABBOTT LABORATORIES (2011-01-14),https://lens.org/128-715-371-561-917,Patent Application,yes,0,1,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,1,1,124-044-202-232-194,15998906;;10.1200/jco.2005.01.2823,"Hirsch et al., Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study, J. Clinical Oncology, VOLUME 23 _ NUMBER 28 _ OCTOBER 1 2005",ACTIVE
363,US,B2,US 6644837 B2,141-493-840-227-365,2003-11-11,2003,US 9522902 A,2002-03-11,US 9522902 A;;US 5053498 A;;US 7966798 P,1998-03-27,Controls for a surgical light apparatus,"
    A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb. 
",HILL ROM SERVICES INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/141-493-840-227-365,Granted Patent,yes,60,36,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,A61B19/00;;F21S2/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,362/399;;362/294;;362/295;;362/804;;362/373;;362/285;;362/287;;362/269,2,0,,,"Berchtold Corporation, ""Chromophare C-571 Superior lighting technology is the secret of our success"", Feb. 1995, 8 pages.;;Berchtold Corporation, chromphare C-570 Service Manuel, date unknown, 2 pages.",EXPIRED
364,EP,A2,EP 2494360 A2,013-606-235-411-719,2012-09-05,2012,EP 10771303 A,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBVIE BAHAMAS LTD. (2014-01-22);;ABBOTT MOLECULAR INC. (2016-06-15);;ABBOTT LABORATORIES (2015-03-04),https://lens.org/013-606-235-411-719,Patent Application,yes,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,0,0,,,,ACTIVE
365,DE,D1,DE 602005023278 D1,041-071-171-690-778,2010-10-14,2010,DE 602005023278 T,2005-03-11,US 55287604 P;;US 57288404 P;;US 59934104 P;;US 2005/0008148 W,2004-03-12,ELEKTRONENTRANSFERDISSOZIATION ZUR BIOPOLYMER-SEQUENZANALYSE,"The invention relates to a method of fragmenting positively charged peptide ions in an RF field mass spectrometer or an RF'field ion containment device, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide ion, resulting in the fragmentation of the positively charged sample ion. The invention also provides a method of performing sequence analysis of a peptide or protein by mass spectrometry, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide or protein ion, resulting in the fragmentation of the positively charged sample ion.",UNIV VIRGINIA,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD;;MARTO JARROD A,,https://lens.org/041-071-171-690-778,Granted Patent,no,0,0,20,20,0,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,0,0,,,,ACTIVE
366,CN,A,CN 105586433 A,138-242-677-143-326,2016-05-18,2016,CN 201610160180 A,2010-10-25,US 25495509 P;;CN 201080059353 A,2009-10-26,Diagnostic Methods For Determining Prognosis Of Non-Small Cell Lung Cancer,"Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chrl9, 34.7 Mb - 35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with f luorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus, which includes the cyclin El gene.",ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/138-242-677-143-326,Patent Application,no,1,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,4,0,,,"TAKAYUKI MISHINA等: ""Cyclin E Expression，a Potential Prognostic Marker for Non-Small Cell Lung Cancers"", 《CLINICAL CANCER RESEARCH》;;AMBER YASMEEN等: ""E- and A-type cyclins as markers for cancer diagnosis and prognosis"", 《EXPERT REVIEW OF MOLECULAR DIAGNOSTICS》;;KOLJA FREIER等: ""Recurrent Copy Number Gain of Transcrip tion Factor SOX2 and Corresponding High Protein Expression in Oral Squamous Cell Carcinoma"", 《GENES, CHROMOSOMES & CANCER》;;KENTARO NAKAYAMA等: ""Amplicon profiles in ovarian serous carcinomas"", 《INTERNATIONAL JOURNAL OF CANCER》",DISCONTINUED
367,EP,A1,EP 2480985 A1,162-832-228-263-146,2012-08-01,2012,EP 10819552 A,2010-09-24,US 56763709 A;;US 2010/0050240 W,2009-09-25,UNIFIED ADDRESSING AND INSTRUCTIONS FOR ACCESSING PARALLEL MEMORY SPACES,,NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,,https://lens.org/162-832-228-263-146,Patent Application,yes,0,0,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F12/02;;G06F12/10;;G06F15/167,,0,0,,,,ACTIVE
368,GB,A,GB 2307757 A,187-029-827-745-408,1997-06-04,1997,GB 9624543 A,1996-11-25,US 56365695 A,1995-11-28,A multi-spectral objective lens system having magnesium oxide and calcium fluoride lenses,"Multi-spectral images are detected using a refractive objective lens system in which magnesium oxide 110 and calcium fluoride 120 lenses are used to image scenes in both the visible and infra-red spectrums. The combination of magnesium oxide and calcium fluoride results in a super-achromatic condition across visible and infra-red spectrums. This chromatically corrected spectral range includes wavelengths of between 0.4 and 5.9 microns. Combinations of magnesium oxide and calcium fluoride lenses can be used in doublet, Petzval, inverted telephoto and telephoto arrangements. Applications for the multi-spectral objective lens system include telescopes, reconnaissance plants, satellites, forwarding-looking infrared and staring sensor systems and night-vision goggles.",LORAL FAIRCHILD CORP,COON BYAN H;;MCGEE III JOHN F;;SHERMAN NEIL;;MONTULLI LOUIS T,,https://lens.org/187-029-827-745-408,Patent Application,no,1,4,7,7,0,G02B1/02;;G02B13/146;;G02B1/02;;G02B13/146,G02B1/02;;G02B13/14,G2J JB7CX         JB7CX;;G2J JB7C10        JB7CX;;G2J JB7C19        JB7CX;;G2J JB7C2         JB7CX;;G2J JB7C4         JB7CX;;G2J JB7C6         JB7CX;;G2J JB7C7         JB7CX,0,0,,,,EXPIRED
369,CN,B,CN 102696023 B,193-449-586-161-329,2015-02-25,2015,CN 201080053742 A,2010-09-24,US 2010/0050240 W;;US 56763709 A,2009-09-25,Unified addressing and instructions for accessing parallel memory spaces,,NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,,https://lens.org/193-449-586-161-329,Granted Patent,no,0,0,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F15/167,,0,0,,,,ACTIVE
370,CN,A,CN 107090490 A,009-602-757-098-368,2017-08-25,2017,CN 201610879355 A,2010-10-25,US 25496809 P;;CN 201080059371 A,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/009-602-757-098-368,Patent Application,no,5,2,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,0,0,,,,DISCONTINUED
371,EP,A2,EP 0577423 A2,057-240-717-890-903,1994-01-05,1994,EP 93305172 A,1993-07-01,US 90785392 A,1992-07-02,Endoscopic instrument system.,"An endoscopic instrument (10) system has a handle portion (14) with means for gripping the instrument, the shaft (56) extending from the gripping means and, means for actuating the instrument. A plurality of instrument end tools (14) are removably mountable on the end of the shaft (56) and each include means for engaging the actuating means so that an attached end tool (14) can be operated by the actuating means.",MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;COON DONALD B;;NELSON JOHN T;;PETRUSCHKE HAANS K,,https://lens.org/057-240-717-890-903,Patent Application,yes,0,21,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B10/06;;A61B1/00;;A61B17/00;;A61B17/28;;A61B17/32;;A61B19/00,,0,0,,,,EXPIRED
372,US,B1,US 7788468 B1,147-542-964-557-610,2010-08-31,2010,US 30378005 A,2005-12-15,US 30378005 A,2005-12-15,Synchronization of threads in a cooperative thread array,"A “cooperative thread array,” or “CTA,” is a group of multiple threads that concurrently execute the same program on an input data set to produce an output data set. Each thread in a CTA has a unique thread identifier assigned at thread launch time that controls various aspects of the thread's processing behavior such as the portion of the input data set to be processed by each thread, the portion of an output data set to be produced by each thread, and/or sharing of intermediate results among threads. Different threads of the CTA are advantageously synchronized at appropriate points during CTA execution using a barrier synchronization technique in which barrier instructions in the CTA program are detected and used to suspend execution of some threads until a specified number of other threads also reaches the barrier point.",NVIDIA CORP,NICKOLLS JOHN R;;LEW STEPHEN D;;COON BRETT W;;MILLS PETER C,NVIDIA CORPORATION (2005-12-09),https://lens.org/147-542-964-557-610,Granted Patent,yes,25,144,1,1,0,G06F9/3851;;G06F9/3851;;G06F9/30087;;G06F9/30087;;G06F9/3009;;G06F9/3009;;G06F9/3834;;G06F9/3834;;G06F9/3887;;G06F9/3887;;G06F9/522;;G06F9/522,G06F15/00;;G06F15/76,712/22,18,5,027-038-283-688-320;;020-961-679-464-619;;069-916-961-419-542;;135-362-244-062-800;;017-784-726-036-279,10.1145/792548.611936;;10.1109/40.621209;;10.1109/hpca.1995.386528;;10.6027/9789289332552-4-en;;10.1007/bfb0022289,"Johnson et al.; A Distributed Hardware Mechanism for Process Synchronization on Shared-Bus Multiprocessors; 1994; IEEE Computer Society; ICCP '94, pp. 268-275.;;Ortiz; Teaching the SIMD Execution Model: Assembling a Few Parallel Programming Skills; Feb. 2003; SIGCSE'03; ACM.;;Eggers et al. ""Simultaneous multithreading: A platform for next-generation processors"" IEEE Micro, Sep./Oct. 1997(vol. 17, No. 5) pp. 12-19.;;Garg et al., ""Architectural support for inter-stream communication in a MSIMD system""; High-Performance Computer Architecture. 1995. Proceedings. First IEEE Symposium on; Publication Date: 1995; pp. 348-357.;;Garzia (ATI Stream Computing) Seminar on General-Purpose computing on GPUs, 2009.;;Brook + Release Notes (Brook + Release Notes, Stream Computing SDK 1.4), 2009.;;AMD Developer Forums (Thread title: LDS: More info requested), 2008.;;Derek Wilson (Anandtech: OpenCL 1.0: The Road to Pervasive GPU Computing), Dec. 31, 2008.;;Aaftab Munshi (The OpenCI Specification) May 16, 2009.;;User Guide (ATI Stream Computing User Guide); first two pages attached; Apr. 2009.;;Technical Overview (ATI Stream Computing Technical Overview); 2009.;;B3D Forum (Beyond3D Forums, thread title: GPGPU capabilities in Radeon HD 3000/4000; 2008.;;Doom9's Forum (Doom 9 Forum, thread title ""Nvidia submits its OpenCL 1.0 drivers for certification""), 2009.;;U.S. Appl. No. 11/305,479, Notice of Allowance mailed Jul. 6, 2009, 14 pages.;;Feitelson, ""Packing Schemes for Gang Scheduling"", Proceedings of the Workshop on Job Scheduling Strategies for Parallel Processing, Lecture Notes in Computer Science, vol. 1162, 1996, pp. 89-110.;;Mersenne Twister Algorithm (last modified on Feb. 26, 2004), downloaded on Sep. 29, 2009 from http://www.umiacs.umd.edu/~yangcj/mtrnd.h.;;U.S. Appl. No. 11/608,762, Office Action mailed Mar. 31, 2010, 10 pages.;;U.S. Appl. No. 11/305,178, Office Action mailed Apr. 27, 2010, 27 pages.",ACTIVE
373,AU,A1,AU 2010/315600 A1,130-125-984-920-304,2012-05-10,2012,AU 2010/315600 A,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/130-125-984-920-304,Patent Application,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68;;G01N33/574,,0,0,,,,DISCONTINUED
374,DE,D1,DE 69310037 D1,142-006-189-969-946,1997-05-28,1997,DE 69310037 T,1993-07-01,US 90785392 A,1992-07-02,Endoskopisches Instrumentensystem,,MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;COON DONALD B;;NELSON JOHN T;;PETRUSCHKE HAANS K,,https://lens.org/142-006-189-969-946,Granted Patent,no,0,0,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B10/06;;A61B17/00;;A61B1/00;;A61B17/28;;A61B17/32;;A61B19/00,,0,0,,,,EXPIRED
375,US,B2,US 9223578 B2,150-217-283-578-159,2015-12-29,2015,US 88708110 A,2010-09-21,US 88708110 A;;US 24604709 P,2009-09-25,Coalescing memory barrier operations across multiple parallel threads,"One embodiment of the present invention sets forth a technique for coalescing memory barrier operations across multiple parallel threads. Memory barrier requests from a given parallel thread processing unit are coalesced to reduce the impact to the rest of the system. Additionally, memory barrier requests may specify a level of a set of threads with respect to which the memory transactions are committed. For example, a first type of memory barrier instruction may commit the memory transactions to a level of a set of cooperating threads that share an L1 (level one) cache. A second type of memory barrier instruction may commit the memory transactions to a level of a set of threads sharing a global memory. Finally, a third type of memory barrier instruction may commit the memory transactions to a system level of all threads sharing all system memories. The latency required to execute the memory barrier instruction varies based on the type of memory barrier instruction.",NICKOLLS JOHN R;;HEINRICH STEVEN JAMES;;COON BRETT W;;SHEBANOW MICHAEL C;;NVIDIA CORP,NICKOLLS JOHN R;;HEINRICH STEVEN JAMES;;COON BRETT W;;SHEBANOW MICHAEL C,NVIDIA CORPORATION (2010-09-16),https://lens.org/150-217-283-578-159,Granted Patent,yes,3,4,2,4,0,G06F9/3834;;G06F9/3834;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/3851;;G06F9/3851,G06F9/46;;G06F9/30;;G06F9/38,,0,0,,,,ACTIVE
376,WO,A1,WO 2011/056490 A1,190-069-459-675-913,2011-05-12,2011,US 2010/0053900 W,2010-10-25,US 25495509 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"Disclosed are methods for identifying early-stage non- small - cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chrl9, 34.7 Mb - 35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with f luorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus, which includes the cyclin El gene.",ABBOTT LAB;;SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/190-069-459-675-913,Patent Application,yes,14,1,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,16,15,011-022-708-056-373;;052-278-913-854-354;;026-496-182-157-514;;113-976-640-220-362;;035-356-341-734-705;;086-358-557-736-303;;095-613-011-399-677;;007-715-602-525-570;;018-447-753-688-44X;;000-387-999-206-564;;005-958-677-306-202;;190-215-680-405-229;;041-309-424-116-14X;;043-185-153-369-364;;046-249-495-864-946,14510182;;10.1586/14737159.3.5.617;;10.1002/ijc.22609;;17351921;;10.1016/s0169-5002(00)80618-2;;19787784;;10.1002/gcc.20714;;10.1111/j.1349-7006.2005.00092.x;;16232197;;19193619;;10.1158/1078-0432.ccr-08-1564;;pmc2670486;;16575401;;10.1038/modpathol.3800593;;19255323;;10.1200/jco.2008.19.1635;;pmc3341799;;17640552;;10.1016/j.humpath.2007.04.015;;10.1158/1078-0432.ccr-04-2661;;15930332;;9426687;;10.1002/(sici)1097-0215(19980105)75:1<34::aid-ijc6>3.0.co;2-2;;10.1101/gr.4.2.80;;7580889;;10.3109/10520299809140502;;9554580;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;15782172;;10.1038/nmeth718,"YASMEEN A ET AL: ""E- and A-type cyclins as markers for cancer diagnosis and prognosis"", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, FUTURE DRUGS, LONDON, GB, vol. 3, no. 5, 1 September 2003 (2003-09-01), pages 617 - 633, XP009125199, ISSN: 1473-7159, DOI: DOI:10.1586/14737159.3.5.617;;NAKAYAMA KENTARO ET AL: ""Amplicon profiles in ovarian serous carcinomas."", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 15 JUN 2007 LNKD- PUBMED:17351921, vol. 120, no. 12, 15 June 2007 (2007-06-15), pages 2613 - 2617, XP002619172, ISSN: 0020-7136;;MISHINA T ET AL: ""Cyclin E expression, a potential prognostic marker for non-small cell lung cancers."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JAN 2000 LNKD- PUBMED:10656426, vol. 6, no. 1, January 2000 (2000-01-01), pages 11 - 16, XP002619173, ISSN: 1078-0432;;FREIER KOLJA ET AL: ""Recurrent copy number gain of transcription factor SOX2 and corresponding high protein expression in oral squamous cell carcinoma."", GENES, CHROMOSOMES & CANCER JAN 2010 LNKD- PUBMED:19787784, vol. 49, no. 1, 29 September 2009 (2009-09-29), pages 9 - 16, XP002619174, ISSN: 1098-2264;;PENG WEI-XIA ET AL: ""Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung"", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 96, no. 10, 1 October 2005 (2005-10-01), pages 661 - 667, XP002480131, ISSN: 1347-9032, DOI: DOI:10.1111/J.1349-7006.2005.00092.X;;ETEMADMOGHADAM DARIUSH ET AL: ""Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 FEB 2009 LNKD- PUBMED:19193619, vol. 15, no. 4, 15 February 2009 (2009-02-15), pages 1417 - 1427, XP002619175, ISSN: 1078-0432;;LEUNG SUET YI ET AL: ""Comprehensive analysis of 19q12 amplicon in human gastric cancers."", MODERN PATHOLOGY : AN OFFICIAL JOURNAL OF THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC JUN 2006 LNKD- PUBMED:16575401, vol. 19, no. 6, June 2006 (2006-06-01), pages 854 - 863, XP002619176, ISSN: 0893-3952;;CAPPUZZO FEDERICO ET AL: ""Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients."", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 APR 2009 LNKD- PUBMED:19255323, vol. 27, no. 10, 1 April 2009 (2009-04-01), pages 1667 - 1674, XP002619177, ISSN: 1527-7755;;HALLING, K.C. KIPP, B.R.: ""Fluorescence in situ hybridization in diagnostic cytology"", HUMAN PATHOLOGY., SAUNDERS, PHILADELPHIA, PA, US, vol. 38, no. 8, 16 July 2007 (2007-07-16), US, pages 1137 - 1144, XP022154434, ISSN: 0046-8177, DOI: 10.1016/j.humpath.2007.04.015;;SINGHAL ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 3974 - 3986;;M. MARONE ET AL., INTEMAT'L J. CANCER, vol. 75, 1998, pages 34 - 39;;R. L. MARSHALL ET AL., PCR METHODS AND APPLICATIONS, vol. 4, 1994, pages 80 - 84;;NATH ET AL., BIOTECHNIC HISTOCHEM, vol. 73, no. 1, 1998, pages 6 - 22;;WHEELESS ET AL., CYTOMETRY, vol. 17, 1994, pages 319 - 327;;L. MORRISON: ""Molecular Cytogenetics: Protocols and Applications"", 2002, HUMANA PRESS, article ""Labeling Fluorescence In Situ Hybridization Probes for Genomic Targets"", pages: 21 - 40;;MATSUZAKI HAJIME; DONG SHOULIAN; LOI HALINA; DI XIAOJUN; LIU GUOYING; HUBBELL EARL; LAW JANE; BERNTSEN TAM; CHADHA MONICA; HUI HEN: ""GENOTYPING OVER 100,000 SNPS ON A PAIR OF OLIGONUCLEOTIDE ARRAYS."", NATURE METHODS, NATURE PUB. GROUP, NEW YORK, vol. 1, no. 2, 1 November 2004 (2004-11-01), New York, pages 109 - 111, XP009082656, ISSN: 1548-7091, DOI: 10.1038/nmeth718",PENDING
377,MX,A,MX 2012004907 A,189-002-681-857-070,2012-06-14,2012,MX 2012004907 A,2010-10-25,US 25495509 P;;US 2010/0053900 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER.,"Disclosed are methods for identifying early-stage non- small - cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chrl9, 34.7 Mb - 35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with f luorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus, which includes the cyclin El gene.",ABBOTT LAB,LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;SEMINAROV DIMITRI;;COON JOHN S,,https://lens.org/189-002-681-857-070,Patent Application,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,0,0,,,,DISCONTINUED
378,US,B1,US 7366878 B1,069-971-590-620-942,2008-04-29,2008,US 40419606 A,2006-04-13,US 40419606 A;;US 99164004 A,2004-11-17,Scheduling instructions from multi-thread instruction buffer based on phase boundary qualifying rule for phases of math and data access operations with better caching,"A processor buffers asynchronous threads. Current instructions requiring operations provided by a plurality of execution units are divided into phases, each phase having at least one math operation and at least one texture cache access operation. Instructions within each phase are qualified and prioritized, with texture cache access operations in a subsequent phase not qualified until all of the texture cache access operations in a current phase have completed. The instructions may be qualified based on the status of the execution unit needed to execute one or more of the instructions. The instructions may also be qualified based on an age of each instruction, a divergence potential, locality, thread diversity, and resource requirements. Qualified instructions may be prioritized based on execution units needed to execute current instructions and the execution units in use. One or more of the prioritized instructions is issued per cycle to the plurality of execution units.",NVIDIA CORP,MILLS PETER C;;LINDHOLM JOHN ERIK;;COON BRETT W;;TAROLLI GARY M;;BURGESS JOHN MATTHEW,NVIDIA CORPORATION (2006-04-10),https://lens.org/069-971-590-620-942,Granted Patent,yes,7,46,3,3,0,G06F9/3851;;G06F9/3851;;G06F9/3838;;G06F9/3838;;G06F9/3853;;G06F9/3853;;G06F9/3867;;G06F9/3867;;G06F9/3885;;G06F9/3885,G06F9/50,712/214;;718/103,0,0,,,,ACTIVE
379,CA,C,CA 2778004 C,001-084-205-015-730,2018-03-13,2018,CA 2778004 A,2010-10-25,US 25495509 P;;US 2010/0053900 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL-CELL LUNG CANCER,"The disclosure provides a method of aiding in the diagnosis of a patient suffering from Stage I-II non-small cell lung cancer. The method involves assessing the copy number for the cyclin E1, C19orf12, C19orf2, PLEKHF1, POP4, ribonuclease P/MRP subunit, and ZNF536 genes in a lung cancer patient, wherein the presence of copy number gains for each of these genes in the patient is predictive of decreased overall survival time and/or shorter time to recurrence in the patient.",ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/001-084-205-015-730,Granted Patent,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/6841,,0,0,,,,INACTIVE
380,BR,A2,BR 112012009885 A2,010-744-865-348-597,2016-11-29,2016,BR 112012009885 A,2010-10-25,US 2010/0053900 W;;US 25495509 P,2009-10-26,"""processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena""","""processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena"" são mostrados processos para identificação de pacientes de câncer de pulmão de célula não-pequena de estágio inicial (nsclc) que terão um prognóstico desfavorável para a recorrência de câncer de pulmão após ressecção cirúrgica. os processos são baseados em parte na verificação de que ganhos de número de cópias cromossômicas em chr19, 34,7 mb - 35,6 mb podem ser usados para classificação de prognóstico. os processos preferivelmente usam fluorescência de hibridização in situ com sondas de ácido nucléico marcadas fluorescentemente para hibridização para amostras de pacientes para quantificação de número de cópias cromossômicas deste locus genético, que inclui o gene ciclina e1.",ABBOTT LAB,SEMINAROV DIMITRI;;COON JOHN S;;ZHANG KE;;LESNIEWSKI RICK R;;LU XIN,,https://lens.org/010-744-865-348-597,Patent Application,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,0,0,,,,DISCONTINUED
381,WO,A2,WO 2011/056489 A2,151-570-231-744-50X,2011-05-12,2011,US 2010/0053893 W,2010-10-25,US 25496809 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB;;SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/151-570-231-744-50X,Patent Application,yes,12,7,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68;;G01N33/574,,8,6,018-447-753-688-44X;;000-387-999-206-564;;190-215-680-405-229;;041-309-424-116-14X;;043-185-153-369-364;;046-249-495-864-946,17640552;;10.1016/j.humpath.2007.04.015;;10.1158/1078-0432.ccr-04-2661;;15930332;;10.1101/gr.4.2.80;;7580889;;10.3109/10520299809140502;;9554580;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;15782172;;10.1038/nmeth718,"L. MORRISON ET AL., METHODS AND PROBES FOR THE DETECTION OF CANCER, 23 March 2006 (2006-03-23);;K. HALLING ET AL.: ""Fluorescence in situ hybridization in diagnostic cytology"", HUM. PATH., vol. 38, 2007, pages 1137 - 1144;;SINGHAL ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 3974 - 3986;;R. L. MARSHALL ET AL., PCR METHODS AND APPLICATIONS, vol. 4, 1994, pages 80 - 84;;NATH ET AL., BIOTECHNIC HISTOCHEM, vol. 73, no. 1, 1998, pages 6 - 22;;WHEELESS ET AL., CYTOMETRY, vol. 17, 1994, pages 319 - 327;;L. MORRISON: ""Molecular Cytogenetics: Protocols and Applications"", 2002, HUMANA PRESS, article ""Labeling Fluorescence In Situ Hybridization Probes for Genomic Targets"", pages: 21 - 40;;MATSUZAKI H; DONG S; LOI H ET AL., GENOTYPING OVER 100,000 SNPS ON A PAIR OF OLIGONUCLEOTIDE ARRAYS. NAT METHODS, vol. 1, 2004, pages 109 - 11",PENDING
382,US,A,US 5618303 A,153-893-674-250-129,1997-04-08,1997,US 12592693 A,1993-09-23,US 12592693 A;;US 90785392 A,1992-07-02,Endoscopic instrument system and method,"An endoscopic instrument system which includes a handle portion with a scissors grip, a shaft extending from the scissors grip and shaped to extend through a cannula, and a plurality of disposable end tools, each mountable on and removable from the end of the shaft by hand without tools and actuatable by the scissors handle. In a preferred embodiment, the scissors handle actuates a rod extending through the shaft which is connected to the end tool. The end tool includes a pair of jaws pivotally mounted on the support and connected to a reciprocating stub shaft by links. The stub shaft is connected to the actuating rod of the handle portion so that movement of the scissors handle causes the jaws to pivot relative to each other. The end tool may take the form of a scissor, grasper, biopsy or dissector, depending upon the specific shape of the jaws. An advantage of the invention is that the support of the end tools is made of a relatively inexpensive plastic material such that the end tools may be discarded when the jaws become dull, thus obviating the need for repeated cleaning and sharpening and eliminating the most difficult portion to clean.",MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;PETRUSCHKE HAANS K;;COON DONALD B;;NELSON JOHN T,COOPERSURGICAL INC (2007-10-23);;MARLOW ACQUISITION CORP (1997-04-03);;MARLOW SURGICAL TECHNOLOGIES (1994-02-02);;THE COOPER COMPANIES INC (2007-10-26),https://lens.org/153-893-674-250-129,Granted Patent,yes,4,1277,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B1/00;;A61B10/06;;A61B17/00;;A61B17/28;;A61B17/32;;A61B19/00,606/205;;606/170;;606/174;;128/751,2,0,,,"Medicon Instrument Catalogue, pp. 440, 441, 443, 451, 585, 686, copyright 1986.;;V. Mueller, The Surgical Armamentarium, Baxter Healthcare Corporation copyright 1988, pp. F176 F177.",EXPIRED
383,US,B1,US 7949855 B1,185-408-894-301-804,2011-05-24,2011,US 11094208 A,2008-04-28,US 11094208 A;;US 40419606 A;;US 99164004 A,2004-11-17,Scheduler in multi-threaded processor prioritizing instructions passing qualification rule,"A processor buffers asynchronous threads. Instructions requiring operations provided by a plurality of execution units are divided into phases, each phase having at least one computation operation and at least one memory access operation. Instructions within each phase are qualified and prioritized. The instructions may be qualified based on the status of the execution unit needed to execute one or more of the current instructions. The instructions may also be qualified based on an age of each instruction, status of the execution units, a divergence potential, locality, thread diversity, and resource requirements. Qualified instructions may be prioritized based on execution units needed to execute instructions and the execution units in use. One or more of the prioritized instructions is issued per cycle to the plurality of execution units.",NVIDIA CORP,MILLS PETER C;;LINDHOLM JOHN ERIK;;COON BRETT W;;TAROLLI GARY M;;BURGESS JOHN MATTHEW,,https://lens.org/185-408-894-301-804,Granted Patent,yes,14,12,3,3,0,G06F9/3851;;G06F9/3851;;G06F9/3838;;G06F9/3838;;G06F9/3853;;G06F9/3853;;G06F9/3867;;G06F9/3867;;G06F9/3885;;G06F9/3885,G06F9/38,712/214;;712/219,1,1,020-961-679-464-619,10.1109/40.621209,"Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
384,TW,A,TW 201120449 A,012-020-089-844-721,2011-06-16,2011,TW 99136363 A,2010-10-25,US 25495509 P,2009-10-26,Diagnostic methods for determining prognosis of non-small-cell lung cancer,"Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus.",ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/012-020-089-844-721,Patent of Addition,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,G01N33/574;;G01N33/533,,0,0,,,,PENDING
385,CA,A1,CA 2326170 A1,022-880-884-061-809,1999-10-07,1999,CA 2326170 A,1999-03-19,US 7966798 P;;US 5053498 A;;US 9906089 W,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical light apparatus (30) includes a lighthead (36, 38) having a sterile field thereon, a bulb (68, 70) located within the lighthead (36, 38), a controller (106) coupled to the bulb (68, 70), and an actuator (74) coupled to the controller (106) to adjust an intensity of light emitted from the bulb (68, 70). The actuator (74) is located in the sterile field on the lighthead (36, 38).",HILL ROM CO INC,BULKO JOHN M;;COON DENNIS C;;BORDERS RICHARD L;;KRAHE RONALD P,,https://lens.org/022-880-884-061-809,Patent Application,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
386,AU,A,AU 2000/047468 A,036-285-741-818-781,2000-11-14,2000,AU 2000/047468 A,2000-04-06,EP 0003104 W;;US 28992899 A,1999-04-09,Method of selective plastic expansion of sections of a tubing,,SHELL INT RESEARCH,COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,,https://lens.org/036-285-741-818-781,Patent Application,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,DISCONTINUED
387,ZA,B,ZA 201203011 B,078-004-642-466-899,2012-12-27,2012,ZA 201203011 A,2012-04-24,US 25495509 P;;US 2010/0053900 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBVIE BAHAMAS LTD,SEMINAROV DIMITRI;;ZHANG KE;;COON JOHN S;;LU XIN;;LESNIEWSKI RICK R,,https://lens.org/078-004-642-466-899,Granted Patent,no,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q/,,0,0,,,,ACTIVE
388,EP,A1,EP 2682482 A1,187-381-833-231-553,2014-01-08,2014,EP 13187129 A,2010-10-25,US 25495509 P;;EP 10774088 A,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,"Disclosed is a method of predicting disease outcome in a patient being treated for lung cancer. The method is based in part on the discovery that chromosomal copy number gains at Chr 19,34.7 Mb-35.6 Mb can be used for prognostic classification. In particular, the method comprises the steps of: a) providing a test sample from a patient; b) determining a copy number for the cyclin El gene in the test sample; c) comparing the copy number of the cyclin El gene in the test sample against a baseline copy number of two cyclin El genes, thereby determining the presence or absence of a copy number gain for the cyclin El gene in the test sample; and d) based on the presence or absence of a copy number gain for the cyclin El gene in the test sample, identifying the patient as having an increased risk of a poor disease outcome when compared to a baseline measure of disease outcome in patients having no copy number gain in the cyclin El gene, wherein the presence of a copy number gain in the cyclin El gene is predictive of poor disease outcome.
",ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC. (2016-06-22),https://lens.org/187-381-833-231-553,Patent Application,yes,13,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,16,15,011-022-708-056-373;;026-496-182-157-514;;052-278-913-854-354;;113-976-640-220-362;;035-356-341-734-705;;086-358-557-736-303;;095-613-011-399-677;;007-715-602-525-570;;018-447-753-688-44X;;000-387-999-206-564;;005-958-677-306-202;;190-215-680-405-229;;041-309-424-116-14X;;043-185-153-369-364;;046-249-495-864-946,14510182;;10.1586/14737159.3.5.617;;10.1016/s0169-5002(00)80618-2;;10.1002/ijc.22609;;17351921;;19787784;;10.1002/gcc.20714;;10.1111/j.1349-7006.2005.00092.x;;16232197;;19193619;;10.1158/1078-0432.ccr-08-1564;;pmc2670486;;16575401;;10.1038/modpathol.3800593;;19255323;;10.1200/jco.2008.19.1635;;pmc3341799;;17640552;;10.1016/j.humpath.2007.04.015;;10.1158/1078-0432.ccr-04-2661;;15930332;;9426687;;10.1002/(sici)1097-0215(19980105)75:1<34::aid-ijc6>3.0.co;2-2;;10.1101/gr.4.2.80;;7580889;;10.3109/10520299809140502;;9554580;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;15782172;;10.1038/nmeth718,"YASMEEN A ET AL: ""E- and A-type cyclins as markers for cancer diagnosis and prognosis"", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, FUTURE DRUGS, LONDON, GB, vol. 3, no. 5, September 2003 (2003-09-01), pages 617 - 633, XP009125199, ISSN: 1473-7159, DOI: 10.1586/14737159.3.5.617;;MISHINA T ET AL: ""Cyclin E expression, a potential prognostic marker for non-small cell lung cancers."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JAN 2000 LNKD- PUBMED:10656426, vol. 6, no. 1, January 2000 (2000-01-01), pages 11 - 16, XP002619173, ISSN: 1078-0432;;NAKAYAMA KENTARO ET AL: ""Amplicon profiles in ovarian serous carcinomas."", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 15 JUN 2007 LNKD- PUBMED:17351921, vol. 120, no. 12, 15 June 2007 (2007-06-15), pages 2613 - 2617, XP002619172, ISSN: 0020-7136;;FREIER KOLJA ET AL: ""Recurrent copy number gain of transcription factor SOX2 and corresponding high protein expression in oral squamous cell carcinoma."", GENES, CHROMOSOMES & CANCER JAN 2010 LNKD- PUBMED:19787784, vol. 49, no. 1, 29 September 2009 (2009-09-29), pages 9 - 16, XP002619174, ISSN: 1098-2264;;PENG WEI-XIA ET AL: ""Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung"", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 96, no. 10, October 2005 (2005-10-01), pages 661 - 667, XP002480131, ISSN: 1347-9032, DOI: 10.1111/J.1349-7006.2005.00092.X;;ETEMADMOGHADAM DARIUSH ET AL: ""Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 FEB 2009 LNKD- PUBMED:19193619, vol. 15, no. 4, 15 February 2009 (2009-02-15), pages 1417 - 1427, XP002619175, ISSN: 1078-0432;;LEUNG SUET YI ET AL: ""Comprehensive analysis of 19q12 amplicon in human gastric cancers."", MODERN PATHOLOGY : AN OFFICIAL JOURNAL OF THE UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, INC JUN 2006 LNKD- PUBMED:16575401, vol. 19, no. 6, June 2006 (2006-06-01), pages 854 - 863, XP002619176, ISSN: 0893-3952;;CAPPUZZO FEDERICO ET AL: ""Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients."", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 APR 2009 LNKD- PUBMED:19255323, vol. 27, no. 10, 1 April 2009 (2009-04-01), pages 1667 - 1674, XP002619177, ISSN: 1527-7755;;K. HALTING: ""Fluorescence in situ hybridization in diagnostic cytology"", HUM. PATH., vol. 38, 2007, pages 1137 - 1144;;SINGHAL ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 3974 - 3986;;M. MARONE ET AL., INTERNAT'L J. CANCER, vol. 75, 1998, pages 34 - 39;;R. L. MARSHALL ET AL., PCR METHODS AND APPLICATIONS, vol. 4, 1994, pages 80 - 84;;NATH ET AL., BIOTECHNIC HISTOCHCM, vol. 73, no. 1, 1998, pages 6 - 22;;WHEELESS ET AL., CYTOMETTY, vol. 17, 1994, pages 319 - 327;;L. MORRISON: ""Molecular Cytogenetics: Protocols and Applications"", 2002, HUMANA PRESS, article ""Labeling Fluorescence In Situ Hybridization Probes for Genomic Targets"", pages: 21 - 40;;MATSUZAKI II; DONG S; LOI H ET AL.: ""Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays"", NAT METHODS, vol. 1, 2004, pages 109 - 11, XP009082656, DOI: doi:10.1038/nmeth718",DISCONTINUED
389,DK,T3,DK 1169541 T3,012-417-896-020-783,2005-01-24,2005,DK 00929343 T,2000-04-06,US 28992899 A,1999-04-09,Fremgangsmåde til selektiv plastisk ekspansion af rörsektioner,,SHELL INT RESEARCH,FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS;;COON ROBERT JOE;;NAZZAL GREGORY RICHARD,,https://lens.org/012-417-896-020-783,Granted Patent,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
390,CA,C,CA 2777169 C,028-348-172-485-766,2018-11-20,2018,CA 2777169 A,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/028-348-172-485-766,Granted Patent,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,G01N33/574,,0,0,,,,INACTIVE
391,JP,A,JP 2017136071 A,081-751-687-328-366,2017-08-10,2017,JP 2017039029 A,2017-03-02,US 25495509 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"PROBLEM TO BE SOLVED: To provide a method for identifying an early-stage non-small-cell lung cancer (NSCLC) patient who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection.SOLUTION: According to the present invention, a method is based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The method preferably uses fluorescence in situ hybridization with a fluorescence-labeled nucleic acid probe to hybridize to a patient sample to quantify the chromosomal copy number of this genetic locus including cyclin E1 gene.SELECTED DRAWING: None",ABBOTT MOLECULAR INC,DIMITRI SEMIZAROV;;LU XIN;;ZHANG KE;;RICK R LESNIEWSKI;;COON JOHN S,,https://lens.org/081-751-687-328-366,Patent Application,no,3,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,5,1,011-022-708-056-373,14510182;;10.1586/14737159.3.5.617,"医学のあゆみ, vol. Vol.199, JPN6015001982, 2001, pages 631 - 635;;CLINICAL CANCER RESEARCH, vol. Vol.6, JPN6015001983, 2000, pages 11 - 16;;YASMEEN A: ""E- AND A-TYPE CYCLINS AS MARKERS FOR CANCER DIAGNOSIS AND PROGNOSIS"", EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, vol. V3 N5, JPN5013000276, 1 September 2003 (2003-09-01), GB, pages 17 - 633;;CANCER RES., 2009, 69(3), PP.1055-1062 (EPUB 2009 JAN 27), JPN6014054690;;GENES,CHROMOSOMES AND CANCER, vol. Vol.49, JPN6015001984, 2010, pages 9 - 16",PENDING
392,WO,A3,WO 2011/056489 A3,123-469-112-670-227,2011-08-25,2011,US 2010/0053893 W,2010-10-25,US 25496809 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB;;SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/123-469-112-670-227,Search Report,yes,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68;;G01N33/574,,1,1,044-537-720-986-944,19176396;;10.1158/0008-5472.can-08-1116,"BROËT PHILIPPE ET AL: ""Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection."", CANCER RESEARCH, vol. 69, no. 3, 1 February 2009 (2009-02-01), pages 1055 - 1062, XP002618984, ISSN: 1538-7445",PENDING
393,US,B2,US 8271763 B2,155-719-260-480-759,2012-09-18,2012,US 56763709 A,2009-09-25,US 56763709 A,2009-09-25,Unified addressing and instructions for accessing parallel memory spaces,One embodiment of the present invention sets forth a technique for unifying the addressing of multiple distinct parallel memory spaces into a single address space for a thread. A unified memory space address is converted into an address that accesses one of the parallel memory spaces for that thread. A single type of load or store instruction may be used that specifies the unified memory space address for a thread instead of using a different type of load or store instruction to access each of the distinct parallel memory spaces.,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN;;NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,NVIDIA CORPORATION (2009-09-25),https://lens.org/155-719-260-480-759,Granted Patent,yes,9,7,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F12/10,711/202;;711/147;;X711E12058,3,1,020-961-679-464-619,10.1109/40.621209,"International Search Report, PCT Appl. No. PCT/US 10/50240, mailed Dec. 28, 2010.;;Moss, et al. ""Toward Acceleration of RSA Using 3D Graphics Hardware,"" LNCS 4887, Dec. 2007, pp. 369-388.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.",ACTIVE
394,US,B2,US 10047403 B2,146-741-613-459-803,2018-08-14,2018,US 201615019829 A,2016-02-09,US 201615019829 A;;US 91089110 A;;US 25496809 P,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT MOLECULAR INC,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC (2016-02-12);;ABBOTT LABORATORIES (2011-01-14),https://lens.org/146-741-613-459-803,Granted Patent,yes,21,5,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68;;C12Q1/6886;;G01N33/574,,58,36,124-044-202-232-194;;030-798-050-767-538;;032-512-204-912-336;;044-537-720-986-944;;007-715-602-525-570;;019-596-074-346-283;;052-305-055-316-795;;086-358-557-736-303;;047-549-578-606-345;;113-976-640-220-362;;057-228-563-045-472;;007-012-720-705-571;;032-699-407-084-764;;018-447-753-688-44X;;015-757-740-631-30X;;057-833-970-309-223;;020-762-711-661-486;;095-613-011-399-677;;005-958-677-306-202;;190-215-680-405-229;;046-249-495-864-946;;034-824-636-268-113;;026-496-182-157-514;;043-185-153-369-364;;089-863-076-892-504;;066-537-561-189-38X;;052-278-913-854-354;;041-309-424-116-14X;;035-356-341-734-705;;101-372-582-111-156;;011-510-783-528-097;;000-387-999-206-564;;004-833-219-417-698;;028-004-568-678-637;;011-022-708-056-373;;065-867-313-439-381,15998906;;10.1200/jco.2005.01.2823;;10.1073/pnas.0709618105;;18632575;;pmc2465804;;pmc2527324;;10.1186/1755-8794-1-25;;18549475;;19176396;;10.1158/0008-5472.can-08-1116;;19255323;;10.1200/jco.2008.19.1635;;pmc3341799;;pmc3656305;;23543735;;10.1074/jbc.m113.458737;;9680343;;10.1182/blood.v92.3.770;;19193619;;10.1158/1078-0432.ccr-08-1564;;pmc2670486;;8980399;;pmc2074830;;10.1038/bjc.1996.662;;19787784;;10.1002/gcc.20714;;10.1158/1078-0432.ccr-09-2151;;20028770;;pmc2805048;;10.1371/journal.pone.0001722;;18320023;;pmc2254495;;9635835;;10.1038/bjc.1998.263;;pmc2150078;;17640552;;10.1016/j.humpath.2007.04.015;;10.1200/jco.2003.11.069;;12953099;;22244930;;10.1016/j.cca.2011.12.020;;16322280;;10.1158/1078-0432.ccr-05-1157;;16575401;;10.1038/modpathol.3800593;;9426687;;10.1002/(sici)1097-0215(19980105)75:1<34::aid-ijc6>3.0.co;2-2;;10.1101/gr.4.2.80;;7580889;;15782172;;10.1038/nmeth718;;10526531;;10.1016/s0165-4608(99)00035-7;;10.1016/s0169-5002(00)80618-2;;12397788;;10.1385/1-59259-300-3:21;;12397787;;10.1385/1-59259-300-3:41;;11212263;;10714208;;10.1002/ijc.22609;;17351921;;10.3109/10520299809140502;;9554580;;10.1111/j.1349-7006.2005.00092.x;;16232197;;10.1002/path.1356;;12845634;;17873171;;10.1378/chest.07-1378;;10.1158/1078-0432.ccr-04-2661;;15930332;;7875039;;10.1002/cyto.990170407;;19208797;;10.1158/1078-0432.ccr-08-2188;;14510182;;10.1586/14737159.3.5.617;;10.1158/0008-5472.can-04-4603;;15994928,"Hirsch et al., Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study, J. Clinical Oncology, vol. 23 _ No. 28 _ Oct. 1, 2005.;;Aviel-Ronen S., et al., “Genomic Markers for Malignant Progression in Pulmonary Adenocarcinoma with Bronchioloalveolar Features,” Proceedings of the National Academy of Science, USA, 2008, vol. 105 (29), pp. 10155-10160.;;Bions H., et al., “Genome Wide Snp Comparative Analysis Between Egfr and Kras Mutated Nscic and Characterization of Two Models of Oncogenic Cooperation in Non-small Cell Lung Carcinoma,” BMC Medical Genomics, 2008, vol. 1, pp. 25.;;Broet P., et al., “Prediction of Clinical Outcome in Multiple Lung Cancer Cohorts by Integrative Genomics: Implications for Chemotherapy Selection,” Cancer Research, 2009, vol. 69 (3), pp. 1055-1062.;;Cappuzzo F., et al., “Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients,” Journal of Clinical Oncology, 2009, vol. 27 (10), pp. 1667-1674.;;Chen L., et al., “Lysine Acetyltransferase GCN5 Potentiates the Growth of Non-Small Cell Lung Cancer via Promotion of E2F1, Cyclin D1, and Cyclin E1 Expression,” Journal of Biological Chemistry, 2013, vol. 288 (20), pp. 14510-14521.;;ELF® 97 mRNA In Situ Hybridization Kits, Product Information, by Molecular Probes, Revised: Feb. 2, 2001, MP 06604.;;Erlanson M., et al., “Expression of Cyclin E and the Cyclin-dependent Kinase Inhibitor p27 in Malignant lymphomas-prognostic Implications,” Blood, 1998, vol. 92 (3), pp. 770-777.;;Etemadmoghadam D., et al., “Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas,” Clinical Cancer Research, 2009, vol. 15 (4), pp. 1417-1427.;;European Search Report for Application No. EP13187129, dated Oct. 25, 2013, 10 pages.;;Final Office Action dated Jan. 7, 2015 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Final Office Action dated Jul. 31, 2013 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Final Office Action dated Jan. 4, 2013 for U.S. Appl. No. 12/910,892, filed Oct. 25, 2010.;;Final Office Action dated Jan. 7, 2015 for U.S. Appl. No. 12/910,892, filed Oct. 25, 2010.;;Fong K.M., et al., “MYCL Genotypes and Loss of Heterozygosity in Non-Small-Cell Lung Cancer,” British Journal of Cancer, 1996, vol. 74 (12), pp. 1975-1978.;;Freier K., et al., “Recurrent Copy Number Gain of Transcription Factor SOX2 and Corresponding High Protein Expression in Oral Squamous Cell Carcinoma,” Genes, Chromosomes and Cancer, 2010, vol. 49 (1), pp. 9-16.;;Galimberti F., et al., “Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe,” Clinical Cancer Research, 2010, vol. 16 (1), pp. 109-120.;;Gallegos Ruiz M.I., et al., “Integration of Gene Dosage and Gene Expression in Non-small Cell Lung Cancer, Identification of HSP90 as Potential Target,” Plos One, 2008, vol. 3 (3), pp. E1722.;;Gasparian A.V., et al., “Allelic Imbalance and Instability of Microsatellite Loci on Chromosome 1p in Human Non-Small-Cell Lung Cancer,” British Journal of Cancer, 1998, vol. 77 (10), pp. 1604-1611.;;Halling K.C., et al., “Fluorescence In Situ Hybridization in Diagnostic Cytology,” Human Pathology, 2007, vol. 38, pp. 1137-1144.;;Hirsch F.R., et al., “Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis,” Journal of Clinical Oncology, 2003, vol. 21 (20), pp. 3798-3807.;;Huang L.N., et al., “Meta-Analysis for Cyclin E in Lung Cancer Survival,” Clinica Chimica Acta, 2012, vol. 413 (7-8), pp. 663-668.;;International Preliminary Report on Patentability for Application No. PCT/US2010/053893, dated May 1, 2012, 1 page.;;International Preliminary Report on Patentability for Application No. PCT/US2010/053900, dated May 1, 2012, 1 page.;;International Search Report and Written Opinion for Application No. PCT/US2010/053893, dated Jun. 10, 2011, 12 pages.;;International Search Report and Written Opinion for Application No. PCT/US2010/053900, dated Feb. 11, 2011, 12 pages.;;Invitation to Pay Additional Fees for Application No. PCT/US2010/053893, dated Mar. 28, 2011, 6 pages.;;Kim T.M., et al., “Genome-Wide Screening of Genomic Alterations and their Clinicopathologic Implications in Non-Small Cell Lung Cancers,” Clinical Cancer Research, 2005, vol. 11 (23), pp. 8235-8242.;;Leung S.Y., et al., “Comprehensive Analysis of 19q12 Amplicon in Human Gastric Cancers,” Modern Pathology, 2006, vol. 19 (6), pp. 854-863.;;Marone M., et al., “Analysis of Cyclin E and CDK2 in Ovarian Cancer: Gene Amplification and RNA Overexpression,” International Journal of Cancer, 1998, vol. 75, pp. 34-39.;;Marshall R.L., et al., “Detection of HCV RNA by the Asymmetric Gap Ligase Chain Reaction,” PCR Methods and Applications, 1994, vol. 4 (2), pp. 80-84.;;Matsuzaki H., et al., “Genotyping Over 100,000 SNPs on a Pair of Oligonucleotide Arrays,” Nature Methods, 2004, vol. 1 (2), pp. 109-111.;;Michelland S., et al., “Comparison of Chromosomal Imbalances in Neuroendocrine and Non-small-cell Lung Carcinomas,” Cancer Genetics and Cytogenetics, 1999, vol. 114 (1), pp. 22-30.;;Mishina T., et al., “Cyclin E Expression, a Potential Prognostic Marker for Non-Small Cell Lung Cancers,” Clinical Cancer Research, 2000, vol. 6 (1), pp. 11-16.;;Morrison, L.E. et al., “Labeling Fluorescence In Situ Hybridization Probes for Genomic Targets,” Methods in Molecular Biology, 2002, vol. 204, pp. 21-40.;;Muller, et al., “Cyclin E is the Only Cyclin-dependent Kinase 2-associated Cyclin that Predicts Metastasis and Survival in Early Stage Non-Small Cell Lung Cancer,” Cancer Research, 2001, vol. 61, pp. 647-653.;;Muller K.M., et al., “New Aspects of Lung Tumor Pathology,” Verhandlungen der Deutschen Gesellschaft fur Pathology, 1999, vol. 83, pp. 168-183.;;Nakayama K., et al., “Amplicon Profiles in Ovarian Serous Carcinomas,” International Journal of Cancer , 2007, vol. 120 (12), pp. 2613-2617.;;Nath J., et al., “Fluorescence in Situ Hybridization (FISH): DNA Probe Production and Hybridization Criteria,” Biotechnic & Histochemistry, 1998, vol. 73 (1), pp. 6-22.;;Non-Final Office Action dated May 7, 2015 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Non-Final Office Action dated Jul. 9, 2014 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Non-Final Office Action dated Oct. 12, 2012 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Non-Final Office Action dated Jun. 21, 2013 for U.S. Appl. No. 12/910,892, filed Oct. 25, 2010.;;Non-Final Office Action dated Jan. 29, 2014 for U.S. Appl. No. 12/910,891, filed Oct. 25, 2010.;;Non-Final Office Action dated May 7, 2015 for U.S. Appl. No. 12/910,892, filed Oct. 25, 2010.;;Non-Final Office Action dated May 8, 2012 for U.S. Appl. No. 12/910,892, filed Oct. 25, 2010.;;Non-Final Office Action dated Jul. 10, 2014 for U.S. Appl. No. 12/910,892, filed Oct. 25, 2010.;;Non-Final Office Action dated Dec. 30, 2013 for U.S. Appl. No. 12/910,892, filed Oct. 25, 2010.;;Peng W.X., et al., “Array-Based Comparative Genomic Hybridization Analysis of High-Grade Neuroendocrine Tumors of the Lung,” Cancer Science , 2005, vol. 96 (10), pp. 661-667.;;Schrami P., et al., “Cyclin E Overexpression and Amplification in Human Tumours,” The Journal of Pathology, 2003, vol. 200 (3), pp. 375-382.;;Scott W.J., et al., “Treatment of Non-Small Cell Lung Cancer Stage I and Stage II: ACCP Evidence-Based Clinical Practice Guidelines,” Chest, 2007, vol. 132 (3 Suppl.), pp. 234S-242S.;;Singhal S., et al., “Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review,” Clinical Cancer Research, 2005, vol. 11 (11), pp. 3974-3986.;;Wheeless L.L., et al., “Bladder Irrigation Specimens Assayed by Fluorescence In Situ Hybridization to Interphase Nuclei,” Cytometry, 1994, vol. 17 (4), pp. 319-326.;;Wrage M., et al., “Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion,” Clinical Cancer Research, 2009, vol. 15 (5), pp. 1566-1574.;;Yasmeen A., et al., “E- and A-Type Cyclins as Markers for Cancer Diagnosis and Prognosis,” Expert Review of Molecular Diagnostics , 2003, vol. 3 (5), pp. 617-633.;;Zhao X., et al., “Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis,” Cancer Research, 2005, vol. 65 (13), pp. 5561-5570.;;United States Patent Office Action for U.S. Appl. No. 15/019,689 dated May 18, 2017 (19 pages).;;United States Patent Office Action for U.S. Appl. No. 15/019,689 dated Oct. 20, 2017 (9 pages).",ACTIVE
395,EP,B1,EP 2480985 B1,000-209-717-910-43X,2018-03-21,2018,EP 10819552 A,2010-09-24,US 56763709 A;;US 2010/0050240 W,2009-09-25,UNIFIED ADDRESSING AND INSTRUCTIONS FOR ACCESSING PARALLEL MEMORY SPACES,,NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;BUCK IAN A;;GLANVILLE ROBERT STEVEN,,https://lens.org/000-209-717-910-43X,Granted Patent,yes,8,0,8,8,0,G06F13/404;;G06F12/0284;;G06F2212/302;;G06F2212/656;;G06F12/1054;;G06F12/1036;;G06F13/404;;G06F12/0284;;G06F2212/656;;G06F2212/302,G06F12/02;;G06F12/109;;G06F13/40,,0,0,,,,ACTIVE
396,US,A,US 5368606 A,046-090-382-643-221,1994-11-29,1994,US 90785392 A,1992-07-02,US 90785392 A,1992-07-02,Endoscopic instrument system,"An endoscopic instrument system which includes a handle portion with a scissors grip, a shaft extending from the scissors grip and shaped to extend through a cannula, and a plurality of disposable end tools, each mountable on the end of the shaft and actuatable by the scissors handle. In a preferred embodiment, the scissors handle actuates a rod extending through the shaft which is connected to the end tool. The end tool includes a pair of jaws pivotally mounted on the support and connected to a reciprocating stub shaft by links. The stub shaft is connected to the actuating rod of the handle portion so that movement of the scissors handle causes the jaws to pivot relative to each other. The end tool may take the form of a scissor, grasper, biopsy or dissector, depending upon the specific shape of the jaws. An advantage of the invention is that the support of the end tools is made of a relatively inexpensive plastic material such that the end tools may be discarded when the jaws become dull, thus obviating the need for repeated cleaning and sharpening and eliminating the most difficult portion to clean.",MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;PETRUSCHKE HAANS K;;COON DONALD B;;NELSON JOHN T,MARLOW SURGICAL TECHNOLOGIES INC (1992-08-26);;COOPERSURGICAL INC (2007-10-23);;MARLOW ACQUISITION CORP (1997-04-03);;THE COOPER COMPANIES INC (2007-10-26),https://lens.org/046-090-382-643-221,Granted Patent,yes,26,165,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B1/00;;A61B10/06;;A61B17/00;;A61B17/28;;A61B17/32;;A61B19/00,606/170;;606/174;;606/207,0,0,,,,EXPIRED
397,AU,A,AU 1999/033586 A,075-596-081-306-109,1999-10-18,1999,AU 1999/033586 A,1999-03-19,US 7966798 P;;US 5053498 A;;US 9906089 W,1998-03-27,Controls for a surgical light apparatus,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",HILL ROM CO INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/075-596-081-306-109,Patent Application,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,DISCONTINUED
398,JP,A,JP 2016119900 A,088-389-709-755-293,2016-07-07,2016,JP 2015245934 A,2015-12-17,US 25496809 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"PROBLEM TO BE SOLVED: To provide methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection.SOLUTION: The present invention relates to the method of predicting disease outcome in a patient being treated for lung cancer, the method comprising the following steps of a), b): a) determining a copy number of a cancer outcome marker in a test sample obtained from a patient; b) based on the presence or absence of a copy number change for the cancer outcome marker in the test sample against a baseline copy number of two, identifying the patient as having an increased risk of a poor disease outcome when compared to a baseline measure of disease outcome in patients having no copy number change in the cancer outcome marker, wherein the presence of the copy number change in the cancer outcome marker is predictive of poor disease outcome.SELECTED DRAWING: None",ABBOTT LAB,DIMITRI SEMIZAROV;;LU XIN;;ZHANG KE;;RICK R LESNIEWSKI;;COON JOHN S,,https://lens.org/088-389-709-755-293,Patent Application,no,2,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,0,0,,,,INACTIVE
399,BR,A2,BR 112012009879 A2,168-984-121-829-294,2016-11-22,2016,BR 112012009879 A,2010-10-25,US 2010/0053893 W;;US 25496809 P,2009-10-26,"""métodos diagnósticos para determinar o prognóstico de câncer de pulmão de não pequenos células""","""métodos diagnósticos para determinar o prognóstico de câncer de pulmão de não pequenas células"" a presente invenção provê métodos para identificar pacientes com câncer de pulmão de não pequenas células (nsclc) em estágio inicial que terão prognóstico desfavorável para a recidiva do câncer de pulmão após a ressecção cirúrgica. os métodos fundamentam-se em parte na descoberta de anormalidades no número de cópias cromossômicas que podem ser utilizadas para classificação prognóstica. os métodos utilizam de preferência hibridização in situ por fluorescência com sondas de ácidos nucleicos marcados com fluorescência que se hibridizam com amostras do paciente para quantificar o número de cópias cromossômicas destes loci genéticos.",ABBOTT LAB,SEMINAROV DIMITRI;;COON JOHN S;;ZHANG KE;;LESNIEWSKI RICK R;;LU XIN,,https://lens.org/168-984-121-829-294,Patent Application,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,G01N33/574;;C12Q1/68,,0,0,,,,DISCONTINUED
400,CN,A,CN 106399506 A,025-904-091-439-202,2017-02-15,2017,CN 201610834283 A,2010-10-25,US 25496809 P;;CN 201080059371 A,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,,https://lens.org/025-904-091-439-202,Patent Application,no,1,9,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68,,2,0,,,"PHILIPPE BROET等: ""prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics：implications for chemotherapy selection"", 《CANCER RES》;;TAKAYUKI MISHINA等: ""cyclin E expression, a potential prognostic marker for non-small cell lung cancer"", 《CLINICAL CANCER RESEARCH》",DISCONTINUED
401,ZA,B,ZA 201203010 B,059-115-785-987-547,2014-03-26,2014,ZA 201203010 A,2012-04-24,US 25496809 P;;US 2010/0053893 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBOTT LAB,SEMINAROV DIMITRI;;ZHANG KE;;COON JOHN S;;LU XINBO;;LESNIEWSKI RICK R,,https://lens.org/059-115-785-987-547,Granted Patent,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,G01N/;;C12Q/,,0,0,,,,ACTIVE
402,FR,B1,FR 2741725 B1,061-419-663-018-945,1999-12-03,1999,FR 9614535 A,1996-11-27,US 56365695 A,1995-11-28,"SYSTEME DE LENTILLES POUR VISIBLE ET INFRAROUGE, ET PROCEDE DE DETECTION D'IMAGES VISIBLES ET INFRAROUGES",,LORAL FAIRCHILD CORP,COON BRYAN H;;MCGEE III JOHN F;;SHERMAN NEIL;;MONTULLI LOUIS T,,https://lens.org/061-419-663-018-945,Granted Patent,no,0,0,7,7,0,G02B1/02;;G02B13/146;;G02B1/02;;G02B13/146,G02B1/02;;G02B13/14,,0,0,,,,EXPIRED
403,EP,A1,EP 2494071 A1,079-211-841-517-482,2012-09-05,2012,EP 10774088 A,2010-10-25,US 25495509 P;;US 2010/0053900 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,,ABBOTT LAB,SEMINAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBVIE BAHAMAS LTD. (2014-01-22);;ABBOTT MOLECULAR INC. (2016-06-15);;ABBOTT LABORATORIES (2015-03-04),https://lens.org/079-211-841-517-482,Patent Application,yes,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,0,0,,,,DISCONTINUED
404,US,A1,US 2016/0160298 A1,074-900-855-486-738,2016-06-09,2016,US 201615019689 A,2016-02-09,US 201615019689 A;;US 91089210 A;;US 25495509 P,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER,"Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus.",ABBOTT LAB,SEMIZAROV DIMITRI;;LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;COON JOHN S,ABBOTT MOLECULAR INC (2016-02-12);;ABBOTT LABORATORIES (2011-01-14),https://lens.org/074-900-855-486-738,Patent Application,yes,0,0,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,0,0,,,,DISCONTINUED
405,DE,T3,DE 69310037 T3,108-577-139-492-058,2002-05-02,2002,DE 69310037 T,1993-07-01,US 90785392 A,1992-07-02,Endoskopisches Instrumentensystem,,MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;COON DONALD B;;NELSON JOHN T;;PETRUSCHKE HAANS K,,https://lens.org/108-577-139-492-058,Amended Patent,no,0,0,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B10/06;;A61B17/00;;A61B1/00;;A61B17/28;;A61B17/32;;A61B19/00,,0,0,,,,EXPIRED
406,US,A1,US 2002/0089857 A1,106-743-456-348-859,2002-07-11,2002,US 9522902 A,2002-03-11,US 9522902 A;;US 5053498 A;;US 7966798 P,1998-03-27,Controls for a surgical light apparatus,"
   A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb. 
",BORDERS RICHARD L.;;COON DENNIS C.;;KRAHE RONALD P.;;BULKO JOHN M.,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/106-743-456-348-859,Patent Application,yes,0,34,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,A61B19/00;;F21S2/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,362/399;;362/804;;362/294,0,0,,,,EXPIRED
407,CN,A,CN 102656281 A,114-670-455-942-843,2012-09-05,2012,CN 201080059353 A,2010-10-25,US 2010/0053900 W;;US 25495509 P,2009-10-26,Diagnostic methods for determining prognosis of non-small cell lung cancer,"Disclosed are methods for identifying early-stage non-small cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chrl9,34.7Mb-35.6Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with f luorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus, which includes the cyclin El gene.",ABBOTT LAB,DIMITRI SEMINAROV;;XIN LU;;KE ZHANG;;LESNIEWSKI RICK R;;COON JOHN S,"ABBOTT HOSPITAL CO., LTD. (2013-12-10);;ABBOTT GMBH. + CO. KG (2015-02-04)",https://lens.org/114-670-455-942-843,Patent Application,no,1,2,25,71,0,C12Q1/6886;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;A61P11/00;;A61P35/00;;C12Q1/6886;;G01N33/52;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/156;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q1/6886;;C12Q2600/158,C12Q1/68,,4,4,086-358-557-736-303;;052-278-913-854-354;;011-022-708-056-373;;026-496-182-157-514,19193619;;10.1158/1078-0432.ccr-08-1564;;pmc2670486;;10.1002/ijc.22609;;17351921;;14510182;;10.1586/14737159.3.5.617;;10.1016/s0169-5002(00)80618-2,"ETEMADMOGHADAM DARIUSH ET.AL.: ""Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas"", 《CLINICAL CANCER RESEARCH》;;KENTARO NAKAYAMA ET.AL.: ""Amplicon profiles in ovarian serous carcinomas"", 《INTERNATIONAL JOURNAL OF CANCER》;;AMBER YASMEEN ET.AL.: ""E- and A-type cyclins as markers for cancer diagnosis and prognosis"", 《EXPERT REVIEW OF MOLECULAR DIAGNOSTICS，FUTURE DRUGS》;;TAKAYUKI MISHINA ET.AL.: ""“Cyclin E Expression，a Potential Prognostic Marker for Non-Small Cell Lung Cancers”"", 《CLINICAL CANCER RESEARCH》",INACTIVE
408,CA,A1,CA 2365960 A1,146-164-445-508-372,2000-10-19,2000,CA 2365960 A,2000-04-06,EP 0003104 W;;US 28992899 A,1999-04-09,METHOD OF SELECTIVE PLASTIC EXPANSION OF SECTIONS OF A TUBING,"A method of selective plastic expansion of sections of a tubing to create on e or more recesses in the tubing with a larger diameter than that of the original tubing in which the tubing is radially symmetrically or asymmetrically expanded at one or more locations by application of a radial force to the interior of the tubing thereby inducing a plastic radial deformation of the tubing and removing said radial force from the interior o f the tubing. The tubing can be a downhole tubing and the created recesses are preferably utilized to hold at least one downhole device, which is advantageously a gas lift mandrel or a sensor.",SHELL INT RESEARCH,NAZZAL GREGORY RICHARD;;COON ROBERT JOE;;FRANK TIMOTHY JOHN;;LOHBECK WILHELMUS CHRISTIANUS,,https://lens.org/146-164-445-508-372,Patent Application,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
409,BR,A,BR 9909185 A,173-430-684-510-03X,2001-09-04,2001,BR 9909185 A,1999-03-19,US 7966798 P;;US 5053498 A;;US 9906089 W,1998-03-27,Aparelho de iluminação cirúrgica,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",HILL ROM CO INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/173-430-684-510-03X,Patent Application,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
410,AT,T1,AT E340965 T1,177-664-307-734-027,2006-10-15,2006,AT 99914957 T,1999-03-19,US 7966798 P;;US 5053498 A,1998-03-27,OPERATIONSLEUCTHTENSTEUERUNG,"A surgical lighthead includes a reflector, a lens coupled to the reflector, and a handle located adjacent the lens. The handle defines an air passage to facilitate installation of a shield over the handle. A lamp assembly includes a support and at least one bulb located on the support between the reflector and the lens. Tubes are mounted in an interior region of the lighthead between the reflector and the lens, and rods are configured to engage the support. Each rod extends through the support and into a corresponding tube. The rods include at least one threaded portion configured to secure the lamp assembly within the interior region. The rods are slidable relative to the tubes upon disengagement of the threaded portions of the rods to permit the lamp assembly to move out of the interior region of the lighthead. The rods include stops to prevent separation of the lamp assembly from the lighthead. A controller turns the bulb on and off and adjusts the intensity level of light emitted from the bulb. Spaced apart first and second displays are coupled to the controller. Each displays an indication of the intensity level of the bulb.",HILL ROM SERVICES INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,,https://lens.org/177-664-307-734-027,Granted Patent,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
411,CA,C,CA 2326170 C,181-017-608-476-301,2004-11-30,2004,CA 2326170 A,1999-03-19,US 7966798 P;;US 5053498 A;;US 9906089 W,1998-03-27,CONTROLS FOR A SURGICAL LIGHT APPARATUS,"A surgical light apparatus (30) includes a light-head (36, 38) having a sterile field thereon, a bulb (68, 70) located within the lighthead (36, 38), a controller (106) coupled to the bulb (68, 70), and an actuator (74) coupled to the controller (106) to adjust an intensity of light emitted from the bulb (68, 70). The actuator (74) is located in the sterile field on the light-head (36, 38).",HILL ROM CO INC,BULKO JOHN M;;KRAHE RONALD P;;COON DENNIS C;;BORDERS RICHARD L,,https://lens.org/181-017-608-476-301,Granted Patent,no,0,0,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,F21S2/00;;A61B19/00;;F21S8/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,,0,0,,,,EXPIRED
412,US,B1,US 6402351 B1,093-980-499-651-283,2002-06-11,2002,US 5053498 A,1998-03-30,US 5053498 A;;US 7966798 P,1998-03-27,Controls for a surgical light apparatus,"
    A surgical light apparatus comprising a lighthead coupled to an arm adapted for mounting to a surface of a surgical room, and wherein the lighthead has a sterile field at an outlet end thereon, and with a bulb located within the lighthead, a controller coupled to the bulb, and an actuator coupled to the controller to adjust an intensity of light of the bulb itself, and wherein the actuator is located in the sterile field on the lighthead. 
",HILL ROM SERVICES INC,BORDERS RICHARD L;;COON DENNIS C;;KRAHE RONALD P;;BULKO JOHN M,HILL-ROM SERVICES INC (2001-02-15);;HILL-ROM INC (1998-08-20),https://lens.org/093-980-499-651-283,Granted Patent,yes,53,51,21,80,0,F21V7/09;;F21V9/04;;F21V14/02;;F21V21/403;;F21W2131/202;;F21W2131/205;;Y10S362/804;;F21V29/85;;A61B2090/308;;F21V21/403;;F21W2131/205;;F21V14/02;;F21V7/09;;F21W2131/202;;F21V9/04;;Y10S362/804;;F21V29/85;;A61B2090/308,A61B19/00;;F21S8/00;;F21S2/00;;F21V7/09;;F21V9/04;;F21V14/02;;F21V21/40;;F21V29/00,362/395;;362/399;;362/804,2,0,,,"Berchtold Corporation, ""Chromophare(R) C-571 Superior lighting technology is the secret of our success"", 2/95, 8 pages.;;Berchtold Corporation, Chromphare(R) C-570 Service Manual, date unknown, 2 pages.",EXPIRED
413,MX,A,MX 2012004908 A,152-861-475-400-822,2012-06-14,2012,MX 2012004908 A,2010-10-25,US 25496809 P;;US 2010/0053893 W,2009-10-26,DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER.,The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.,ABBOTT LAB,LU XIN;;ZHANG KE;;LESNIEWSKI RICK R;;SEMINAROV DIMITRI;;COON JOHN S,,https://lens.org/152-861-475-400-822,Patent Application,no,0,0,30,71,0,C12Q1/6886;;G01N33/57423;;C12Q2600/156;;C12Q2600/178;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423;;C12N15/11;;C12Q1/6886;;G01N33/57423;;G01N2800/56;;G01N2800/52;;G01N2800/54;;C12Q2600/156;;C12Q2600/178;;C12Q2600/112;;C12Q2600/106;;C12Q2600/118;;C12Q2600/106;;C12Q2600/112;;C12Q2600/118;;C12Q2600/156;;C12Q2600/178;;G01N2800/52;;G01N2800/54;;G01N2800/56;;G01N2800/60;;C12Q1/6886;;G01N33/57423,C12Q1/68;;G01N33/574,,0,0,,,,DISCONTINUED
414,CA,C,CA 2365960 C,152-474-430-217-784,2007-08-07,2007,CA 2365960 A,2000-04-06,EP 0003104 W;;US 28992899 A,1999-04-09,METHOD OF SELECTIVE PLASTIC EXPANSION OF SECTIONS OF A TUBING,"A method of selective plastic expansion of sections of a tubing to create on e or more recesses in the tubing with a larger diameter than that of the original tubing in which the tubing is radially symmetrically or asymmetrically expanded at one or more locations by application of a radial force to the interior of the tubing thereby inducing a plastic radial deformation of the tubing and removing said radial force from the interior o f the tubing. The tubing can be a downhole tubing and the created recesses are preferably utilized to hold at least one downhole device, which is advantageously a gas lift mandrel or a sensor.",SHELL INT RESEARCH,FRANK TIMOTHY JOHN;;COON ROBERT JOE;;LOHBECK WILHELMUS CHRISTIANUS;;NAZZAL GREGORY RICHARD,,https://lens.org/152-474-430-217-784,Granted Patent,no,0,1,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/00;;E21B29/10;;E21B43/10,,0,0,,,,EXPIRED
415,EP,B1,EP 0577423 B1,173-798-718-760-906,1997-04-23,1997,EP 93305172 A,1993-07-01,US 90785392 A,1992-07-02,Endoscopic instrument system,,MARLOW SURGICAL TECHNOLOGIES I,MARLOW SCOTT C;;COON DONALD B;;NELSON JOHN T;;PETRUSCHKE HAANS K,,https://lens.org/173-798-718-760-906,Granted Patent,yes,6,1,12,12,0,A61B10/06;;A61B17/29;;A61B17/320016;;A61B2017/0023;;A61B2017/00464;;A61B2017/2929;;A61B2017/2931;;A61B90/70;;A61B17/29;;A61B17/320016;;A61B2017/00464;;A61B2017/0023;;A61B2017/2931;;A61B10/06;;A61B2017/2929;;A61B90/70,A61B10/00;;A61B10/06;;A61B17/00;;A61B1/00;;A61B17/28;;A61B17/32;;A61B19/00,,0,0,,,,EXPIRED
416,US,B2,US 7534622 B2,088-747-185-486-391,2009-05-19,2009,US 7914705 A,2005-03-14,US 7914705 A;;US 55287604 P;;US 57288404 P;;US 59934104 P,2004-03-12,Electron transfer dissociation for biopolymer sequence mass spectrometric analysis,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",UNIV VIRGINIA,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD A,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2005-06-08);;UNIVERSITY OF VIRGINIA (2006-03-17),https://lens.org/088-747-185-486-391,Granted Patent,yes,3,78,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N24/00;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,436/173,19,19,004-660-596-110-998;;115-238-949-200-640;;001-606-043-013-366;;098-112-355-585-100;;125-695-351-039-457;;060-271-576-596-355;;023-322-087-682-952;;060-261-856-877-988;;029-989-480-458-141;;000-668-228-617-649;;064-538-289-011-209;;073-803-555-225-017;;115-238-949-200-640;;030-460-807-381-496;;044-059-272-957-811;;005-608-730-830-354;;039-744-701-942-955;;033-543-562-828-538;;100-670-378-310-085,10.1016/s1044-0305(01)00364-6;;12056562;;10.1021/ja973478k;;10.1002/mas.20004;;15389865;;10.1021/ja00151a021;;10.1021/ac9605657;;8916454;;10.1021/ac970399i;;10.1016/s1044-0305(97)00023-8;;9530009;;10.1021/ac9710137;;10.1021/ac9802832;;9737205;;10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.0.co;2-j;;10360331;;10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.3.co;2-a;;10.1016/1044-0305(94)85067-4;;24226512;;15210983;;pmc470779;;10.1073/pnas.0402700101;;10.1021/ja973478k;;10.1016/s1044-0305(02)00384-7;;12056566;;11008759;;10.1021/ac000497v;;10.1038/nbt0302-301;;11875433;;10.1016/1044-0305(94)80016-2;;24226387;;10.1021/cr990076h;;11712248;;10.1016/j.jasms.2005.01.015;;15907703,"Wells et al. """"Dueling"" ESI: Instrumentation to Study Ion/Ion Reactions of Electrospray-generated Cations and Anions"", J Am Soc Mass Spectrom 2002, 13, 614-622.;;Zubarev et al. ""Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process"", J. Am. Chem. Soc. 1998, 120, 3265-3266.;;Douglas et al. ""Linear Ion Traps in Mass Spectrometry"", Mass Spectrometry Reviews, 2005, 24, 1-29.;;Herron et al., ""Gas-Phase Electron Transfer Reactions from Multiply-Charged Anions to Rare Gas Cations"", J. Am. Chem. Soc., vol. 117, 1995, pp. 11555-11562.;;Stephenson et al., ""Ion/Ion Proton Transfer Reactions for Protein Mixture Analysis"", Anal. Chem., vol. 68, 1996, pp. 4026-4032.;;Stephenson et al., ""Anion Effects on Storage and Resonance Ejection of High Mass-to-Charge Cations in Quadrupole Ion Trap Mass Spectrometry"", Anal. Science, vol. 69, 1997, pp. 3760-3766.;;Stephenson et al., ""Ion-Ion Proton Transfer Reactions of Bio-Ions Involving Noncovalent Interactions: Holomyoglobin"", J. Am. Soc. Mass. Spectrometry, vol. 8, 1997, pp. 637-644.;;McLuckey et al., ""Ion/Ion Proton-Transfer Kinetics: Implications for Analysis of Ions Derived from Electrospray of Protein Mixtures"", Anal. Chem., vol. 70, 1998, pp. 1198-1202.;;Stephenson et al., ""Simplification of Product Ion Spectra Derived from Multiply Charged Ions via Ion/Ion Chemistry"", Anal. Chem., vol. 70, 1998, pp. 3533-3544.;;McLuckey et al., ""Ion/Ion Chemistry of High-Mass Multiply Charged Ions"", Mass Spectrometry Reviews, vol. 17, 1998, pp. 369-407.;;Loo et al., ""Proton Transfer Reaction Studies of Multiply Charge Proteins in a High Mass-to-Charge Ratio Quadrupole Mass Spectrometry"", J. Am. Soc. Mass Spectrometry, vol. 5, 1994, pp. 1064-1071.;;Syka et al., ""Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry"", PNAS, vol. 101, No. 26, Jun. 2004, pp. 9528-9533.;;McLafferty et al., ""Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process"", J. Am. Chem. Soc., vol. 120, 1998, pp. 3265-3266.;;Schwartz et al., ""A Two-Dimensional Quadrupole Ion Trap Mass Spectrometer"", J. Am. Soc. Mass Spectrometry, vol. 13, 2002, pp. 659-669.;;Martin et al., ""Subfemtomole MS and MS/MS Peptide Sequence Analysis Using Nano-HPLC Micro-ESI Fourier Transform Ion Cyclotron Resonance Mass Spectrometry"", Anal. Chem., vol. 72, 2000, pp. 4266-4274.;;Ficarro et al., ""Phosphoproteome Analysis by Mass Spectrometry and its Application to Saccharomyces cerevisiae"", J. Am. Chem. Soc., vol. 20, 2002, pp. 301-305.;;Eng et al., ""An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequence in a Protein Database"", J. Am. Soc. Mass Spectrometry, vol. 5, 1994, pp. 976-989.;;Aebersold, Ruedi et al.; ""Mass Spectrometry in Proteomics,"" Chem. Rev, vol. 101, No. 2, Feb. 2001, pp. 269-295.;;Coon, Joshua J. et al., ""Electron Transfer Dissociation of Peptide Anions,"" American Society for Mass Spectrometry, vol. 16, Nr. 6, Jun. 2005, pp. 880-882.",ACTIVE
417,US,A1,US 2008/0202753 A1,177-999-534-560-025,2008-08-28,2008,US 11921608 A,2008-05-12,US 11921608 A;;US 86382504 A;;US 96908901 A;;US 46969099 A,1999-12-22,METHOD AND APPARATUS FOR EXPANDING AND SEPARATING TUBULARS IN A WELLBORE,"Embodiments of the present invention provide an apparatus and method for expanding a tubular. In one aspect, embodiments of the prevent invention provide an expander tool having at least two expansion members radially extendable from the expander tool into contact with a surrounding inside surface of the tubular, the at least two expansion members radially extendable at different times and axially spaced after radially extending. In another aspect, embodiments include a method for isolating a first portion of a wellbore from a second portion of a wellbore comprising locating an expandable tubular within the wellbore between the first and second portions, the expandable tubular having a weakened portion therein, isolating the first portion from the second portion of the wellbore, and expanding the expandable tubular proximate to the weakened portion to sever the expandable tubular.",HARRALL SIMON JOHN;;MAGUIRE PATRICK G;;COON ROBERT J;;SIMPSON NEIL ANDREW ABERCROMBI,HARRALL SIMON JOHN;;MAGUIRE PATRICK G;;COON ROBERT J;;SIMPSON NEIL ANDREW ABERCROMBI,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2004-09-28),https://lens.org/177-999-534-560-025,Patent Application,yes,73,11,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B29/00;;E21B/;;E21B17/00;;E21B17/08;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,166/297;;166/55,0,0,,,,EXPIRED
418,CA,A1,CA 2559260 A1,036-230-011-993-985,2005-09-29,2005,CA 2559260 A,2005-03-11,US 55287604 P;;US 57288404 P;;US 59934104 P;;US 2005/0008148 W,2004-03-12,ELECTRON TRANSFER DISSOCIATION FOR BIOPOLYMER SEQUENCE ANALYSIS,"The invention relates to a method of fragmenting positively charged peptide ions in an RF field mass spectrometer or an RF'field ion containment device, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide ion, resulting in the fragmentation of the positively charged sample ion. The invention also provides a method of performing sequence analysis of a peptide or protein by mass spectrometry, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide or protein ion, resulting in the fragmentation of the positively charged sample ion.",UNIV VIRGINIA,COON JOSHUA J;;MARTO JARROD A;;SYKA JOHN EDWARD PHILIP;;HUNT DONALD F,,https://lens.org/036-230-011-993-985,Patent Application,no,0,0,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,0,0,,,,ACTIVE
419,GB,A,GB 2415001 A,133-280-490-259-594,2005-12-14,2005,GB 0511598 A,2005-06-07,US 86382504 A,2004-06-08,"Tubing expander and method of expanding, sealing and separating tubulars in a wellbore","A tubing expander has radially extendable expansion members that are axially (longitudinally) spaced around its body in rows. The rows' expansion members can be deployed at different times. The tubing to be expanded has a weakened section or scribe which will break, snap or separate on expansion. Slips and sealing members between the expandable tubular and a wellbore casing allow the apparatus to act as a casing hanger and the casing above the weakened point can be removed; for example it can be lifted from the well using the tubing expander (figure 13D). The expandable tubular (315) can have a closed end (315B) such that it acts as a plug and allows two parts (305, 310) of a wellbore to be separated. The plug is removed by expanding the tubular at the weak point such that it breaks. Alternatively the weak points or scribes can be within the closed end of the plug so that it opens on expansion (figures 15A-I). Another embodiment includes temporarily covering or straddling a section of wellbore (figure 13).",WEATHERFORD LAMB,HARRALL SIMON JOHN;;MAGUIRE PATRICK G;;COON ROBERT J;;SIMPSON NEIL ANDREW ABERCROMBI,,https://lens.org/133-280-490-259-594,Patent Application,no,1,3,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,E1F FJR           FJR;;E1F FKA           FKA;;E1F FLA           FLA;;NOT CLASSIFIED    NONE,0,0,,,,INACTIVE
420,US,B2,US 8539204 B2,001-138-754-343-981,2013-09-17,2013,US 89022710 A,2010-09-24,US 89022710 A;;US 24604509 P,2009-09-25,Cooperative thread array reduction and scan operations,"One embodiment of the present invention sets forth a technique for performing aggregation operations across multiple threads that execute independently. Aggregation is specified as part of a barrier synchronization or barrier arrival instruction, where in addition to performing the barrier synchronization or arrival, the instruction aggregates (using reduction or scan operations) values supplied by each thread. When a thread executes the barrier aggregation instruction the thread contributes to a scan or reduction result, and waits to execute any more instructions until after all of the threads have executed the barrier aggregation instruction. A reduction result is communicated to each thread after all of the threads have executed the barrier aggregation instruction and a scan result is communicated to each thread as the barrier aggregation instruction is executed by the thread.",FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS;;NVIDIA CORP,FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS,NVIDIA CORPORATION (2010-09-23),https://lens.org/001-138-754-343-981,Granted Patent,yes,7,1,6,6,0,G06F9/522;;G06F9/522;;G06F8/458;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/30145;;G06F9/3851;;G06F9/3851,G06F9/30;;G06F9/40;;G06F15/00,712/214,0,0,,,,ACTIVE
421,NO,A1,NO 20150057 A1,001-660-443-858-453,2015-01-12,2015,NO 20150057 A,2015-01-12,US 86382504 A,2004-06-08,Metode for midlertidig separering av en første borehullsdel på et borehull fra en annen borehullsdel på borehullet,,WEATHERFORD LAMB INC,SIMPSON NEIL ANDREW ABERCROMBIE;;MAGUIRE PATRICK G;;HARRALL SIMON JOHN;;COON ROBERT J,,https://lens.org/001-660-443-858-453,Patent Application,no,0,0,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B43/10;;E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/12,,0,0,,,,PENDING
422,US,A1,US 2014/0019724 A1,101-480-257-923-677,2014-01-16,2014,US 201314025482 A,2013-09-12,US 201314025482 A;;US 89022710 A;;US 24604509 P,2009-09-25,COOPERATIVE THREAD ARRAY REDUCTION AND SCAN OPERATIONS,"One embodiment of the present invention sets forth a technique for performing aggregation operations across multiple threads that execute independently. Aggregation is specified as part of a barrier synchronization or barrier arrival instruction, where in addition to performing the barrier synchronization or arrival, the instruction aggregates (using reduction or scan operations) values supplied by each thread. When a thread executes the barrier aggregation instruction the thread contributes to a scan or reduction result, and waits to execute any more instructions until after all of the threads have executed the barrier aggregation instruction. A reduction result is communicated to each thread after all of the threads have executed the barrier aggregation instruction and a scan result is communicated to each thread as the barrier aggregation instruction is executed by the thread.",NVIDIA CORP,FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS,NVIDIA CORPORATION (2010-09-23),https://lens.org/101-480-257-923-677,Patent Application,yes,4,1,6,6,0,G06F9/522;;G06F9/522;;G06F8/458;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/30145;;G06F9/3851;;G06F9/3851,G06F9/30,712/216,0,0,,,,ACTIVE
423,NO,B1,NO 326530 B1,175-202-976-069-23X,2008-12-29,2008,NO 20014899 A,2001-10-08,EP 0003104 W;;US 28992899 A,1999-04-09,"Fremgangsmate for selektiv plastisk ekspansjon av seksjoner av et ror, og anvendelse av fremgangsmaten",,SHELL INT RESEARCH,LOHBECK WILHELMUS CHRISTIANUS MARIA;;FRANK TIMOTHY JOHN;;NAZZAL GREGORY RICHARD;;COON ROBERT J,,https://lens.org/175-202-976-069-23X,Granted Patent,no,0,0,13,13,0,E21B29/10;;E21B29/10;;E21B43/103;;E21B43/103,E21B29/10;;E21B29/00;;E21B43/10,,0,0,,,,EXPIRED
424,US,B2,US 9830197 B2,192-077-595-929-597,2017-11-28,2017,US 201615238428 A,2016-08-16,US 201615238428 A;;US 201314025482 A;;US 89022710 A;;US 24604509 P,2009-09-25,Cooperative thread array reduction and scan operations,"One embodiment of the present invention sets forth a technique for performing aggregation operations across multiple threads that execute independently. Aggregation is specified as part of a barrier synchronization or barrier arrival instruction, where in addition to performing the barrier synchronization or arrival, the instruction aggregates (using reduction or scan operations) values supplied by each thread. When a thread executes the barrier aggregation instruction the thread contributes to a scan or reduction result, and waits to execute any more instructions until after all of the threads have executed the barrier aggregation instruction. A reduction result is communicated to each thread after all of the threads have executed the barrier aggregation instruction and a scan result is communicated to each thread as the barrier aggregation instruction is executed by the thread.",NVIDIA CORP,FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS,NVIDIA CORPORATION (2010-09-23),https://lens.org/192-077-595-929-597,Granted Patent,yes,13,2,6,6,0,G06F9/522;;G06F9/522;;G06F8/458;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/30145;;G06F9/3851;;G06F9/3851,G06F9/30;;G06F9/38;;G06F9/45;;G06F9/52,,0,0,,,,ACTIVE
425,US,A1,US 2016/0357560 A1,062-112-357-643-216,2016-12-08,2016,US 201615238428 A,2016-08-16,US 201615238428 A;;US 201314025482 A;;US 89022710 A;;US 24604509 P,2009-09-25,COOPERATIVE THREAD ARRAY REDUCTION AND SCAN OPERATIONS,"One embodiment of the present invention sets forth a technique for performing aggregation operations across multiple threads that execute independently. Aggregation is specified as part of a barrier synchronization or barrier arrival instruction, where in addition to performing the barrier synchronization or arrival, the instruction aggregates (using reduction or scan operations) values supplied by each thread. When a thread executes the barrier aggregation instruction the thread contributes to a scan or reduction result, and waits to execute any more instructions until after all of the threads have executed the barrier aggregation instruction. A reduction result is communicated to each thread after all of the threads have executed the barrier aggregation instruction and a scan result is communicated to each thread as the barrier aggregation instruction is executed by the thread.",NVIDIA CORP,FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS,NVIDIA CORPORATION (2010-09-23),https://lens.org/062-112-357-643-216,Patent Application,yes,0,0,6,6,0,G06F9/522;;G06F9/522;;G06F8/458;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/30145;;G06F9/3851;;G06F9/3851,G06F9/30;;G06F9/38,,0,0,,,,ACTIVE
426,NO,D0,NO 20052747 D0,096-810-598-559-13X,2005-06-07,2005,NO 20052747 A,2005-06-07,US 86382504 A,2004-06-08,Fremgangsmate og apparat for ekspandering og separering av rorlengder i et borehull,,WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBI;;COON ROBERT JOE;;MAGUIRE PATRICK G;;HARRALL SIMON JOHN,,https://lens.org/096-810-598-559-13X,Patent Application,no,0,0,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,,0,0,,,,INACTIVE
427,CN,B,CN 101014857 B,104-108-268-230-946,2012-06-13,2012,CN 200580014881 A,2005-03-11,US 2005/0008148 W;;US 55287604 P;;US 57288404 P;;US 59934104 P,2004-03-12,Electron transfer dissociation for biopolymer sequence analysis,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",UNIV VIRGINIA,MARTO JARROD A;;COON JOSHUA J;;HUNT DONALD F;;SYKA JOHN E P,,https://lens.org/104-108-268-230-946,Granted Patent,no,0,0,20,20,0,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,0,0,,,,ACTIVE
428,US,B2,US 8692187 B2,149-624-309-356-996,2014-04-08,2014,US 201213422812 A,2012-03-16,US 201213422812 A;;US 42667509 A;;US 7914705 A;;US 55287604 P;;US 59934104 P;;US 57288404 P,2004-03-12,Electron transfer dissociation for biopolymer sequence analysis,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JAROD A;;UNIV VIRGINIA PATENT FOUND,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JAROD A,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2012-08-21);;UNIVERSITY OF VIRGINIA (2012-08-24),https://lens.org/149-624-309-356-996,Granted Patent,yes,18,2,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/50;;H01J49/00;;G01N33/68;;H01J49/04;;H01J49/42,250/282;;250/281;;250/288,55,49,004-660-596-110-998;;115-238-949-200-640;;001-606-043-013-366;;033-543-562-828-538;;118-237-876-274-626;;010-322-299-590-660;;100-670-378-310-085;;031-099-180-915-969;;017-432-116-832-017;;038-868-176-197-587;;039-744-701-942-955;;005-608-730-830-354;;132-515-506-234-445;;019-516-456-791-769;;098-112-355-585-100;;054-830-868-444-813;;025-523-151-463-02X;;054-947-093-781-361;;087-053-687-998-554;;043-094-889-380-749;;064-538-289-011-209;;056-323-467-883-90X;;044-059-272-957-811;;115-238-949-200-640;;002-246-946-074-338;;000-668-228-617-649;;060-261-856-877-988;;004-287-306-648-966;;116-488-492-444-589;;031-739-013-565-001;;071-937-348-115-14X;;010-880-868-431-579;;040-286-853-815-47X;;043-610-381-684-918;;060-106-417-058-040;;086-149-134-310-342;;030-460-807-381-496;;139-344-218-489-129;;036-293-959-621-316;;060-271-576-596-355;;125-695-351-039-457;;023-322-087-682-952;;029-989-480-458-141;;073-803-555-225-017;;009-873-623-830-140;;004-660-596-110-998;;006-171-750-125-393;;176-823-368-593-853;;095-651-157-807-431,10.1016/s1044-0305(01)00364-6;;12056562;;10.1021/ja973478k;;10.1002/mas.20004;;15389865;;10.1021/cr990076h;;11712248;;10.1021/ac034900k;;14750868;;10.1016/j.ijms.2004.05.005;;10.1016/j.jasms.2005.01.015;;15907703;;15983376;;pmc1172258;;10.1073/pnas.0503189102;;10.1016/s1044-0305(01)00357-9;;11908804;;10.1139/o04-043;;15284902;;10.1016/1044-0305(94)80016-2;;24226387;;10.1038/nbt0302-301;;11875433;;10.1021/pr0499491;;15473683;;pmc1570753;;10.1021/ja0526057;;16144411;;10.1021/ja00151a021;;10.1002/jms.458;;12644985;;10.1021/ac50035a017;;10.1021/ac50008a014;;10.1021/cr00079a003;;10.1002/0471721980;;10.1016/1044-0305(94)85067-4;;24226512;;0009305837;;9305837;;10.1038/38444;;11008759;;10.1021/ac000497v;;10.1021/ja973478k;;10.1021/ac0109671;;11811406;;10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.0.co;2-j;;10360331;;10.1002/(sici)1098-2787(1998)17:6<369::aid-mas1>3.3.co;2-a;;9530009;;10.1021/ac9710137;;10.1016/j.jasms.2003.12.014;;15047065;;10.1021/j100170a006;;10.1016/s1387-3806(00)00339-0;;10.1002/mas.20048;;15706594;;15762593;;10.1021/ac0483872;;pmc1564063;;10.1111/j.1749-6632.1992.tb38648.x;;1482093;;11838679;;10.1021/ac015618l;;10.1021/ja025966k;;12071744;;12124999;;10.1002/jms.346;;10.1016/s1044-0305(02)00384-7;;12056566;;2138240;;10.1016/0076-6879(90)82049-8;;10.1016/s0168-1176(96)04510-7;;10.1021/ac970399i;;10.1021/ac9605657;;8916454;;10.1016/s1044-0305(97)00023-8;;10.1021/ac9802832;;9737205;;15210983;;pmc470779;;10.1073/pnas.0402700101;;10.1021/pr0499794;;15253445;;10.1016/s1044-0305(01)00364-6;;12056562;;10.1021/ja035051l;;12797797;;10.1016/s1387-3806(03)00165-9;;10.1021/ja0736764;;17880074,"Wells et al. """"Dueling"" ESI: Instrumentation to Study Ion/Ion Reactions of Electrospray-generated Cations and Anions"", J Am Soc Mass Spectrom 2002, 13, 614-622.;;Zubarev et al. ""Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process"", J. Am. Chem. Soc. 1998, 120, 3265-3266.;;Douglas et al. ""Linear Ion Traps in Mass Spectrometry"", Mass Spectrometry Reviews, 2005, 24, 1-29.;;Aebersold, Ruedi et al.; ""Mass Spectrometry in Proteomics,"" Chem. Rev, vol. 101, No. 2, Feb. 2001, pp. 269-295.;;Amunugama, R., et al., ""Whole Protein Dissociation in a Quadrupole Ion Trap: Identification of an a Priori Unknown Modified Protein"", Feb. 1, 2004, Analytical Chemistry, vol. 76, No. 3, pp. 720-727.;;Bundy and Stephenson, ""Fragmentation of Multiply-Charged Macromolecules of Opposite Polarity in a Quadrupole Ion Trap,"" Proceedings of the 50th Conference of the American Society for Mass Spectrometry, Orlando, FL (2002).;;Coon et al., ""Anion dependence in the partitioning between proton and electron transfer in ion/ion reactions,"" International Journal of Mass Spectrometry, No. 236, pp. 33-42, Jun. 19, 2004.;;Coon, Joshua J. et al., ""Electron Transfer Dissociation of Peptide Anions,"" American Society for Mass Spectrometry, vol. 16, Nr. 6, Jun. 2005, pp. 880-882.;;Coon, et al., ""Electron Transfer Dissociation: A Non-ergodic process for the masses,"" ASMS Abstracts and Proceedings, Apr./May 2004.;;Coon, Joshua J. et al.: ""Protein Identification Using Sequential Ion/Ion Reactions and Tandem Mass Spectrometry"" Proceedings of the National Academy of Sciences of U.S.A. , vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468.;;Cooper et al., ""Characterization of Amino Acid Side Chain Losses in Electron Capture Dissociation,"" Journal of the American Society of Mass Spectrometry, 13, pp. 241-249, 2002.;;Creighton, T. E., ""Proteins-Structure and Molecular Properties"", 2nd Ed., 1993, W. H. Freeman and Company, New York.;;Decision of EP Opposition to EP1723416.;;Dryhurst, Deanna, et al., ""New Twists on H2A.Z: A Histone Variant with a Controversial Structural and Functional Past"", 2004, Biochem. Cell Biology, vol. 82, pp. 490-497.;;Eng et al., ""An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequence in a Protein Database"", J. Am. Soc. Mass Spectrometry, vol. 5, 1994, pp. 976-989.;;Ficarro et al., ""Phosphoproteome Analysis by Mass Spectrometry and its Application to Saccharomyces cerevisiae"", J. Am. Chem. Soc., vol. 20, 2002, pp. 301-305.;;Geer, Lewis Y., et al., ""Open Mass Spectrometry Search Algorithm"", 2004, Journal of Proteome Research, vol. 3, No. 5, pp. 958-964.;;Glish, personal communication, May 24, 2011.;;Gunawardena, et al., ""Electron Transfer Versus Proton Transfer in Gas-Phase Ion/Ion Reactions of Polyprotonated Peptides"", American Chem. Soc., vol. 127, 2005, pp. 12627-12639.;;Herron et al., ""Gas-Phase Electron Transfer Reactions from Multiply-Charged Anions to Rare Gas Cations"", J. Am. Chem. Soc., vol. 117, 1995, pp. 11555-11562.;;Hogan, Jason M., et al., ""Charge State Dependent Collision-Induced Dissociation of Native and Reduced Porcine Elastase"", Mar. 3, 2003, Journal of Mass Spectrometry, No. 38, pp. 245-256.;;Hunt, Donald F., et al., ""Electron Capture Negative Ion Chemical Ionization Mass Spectrometry"", Nov. 1978, Analytical Chemistry, vol. 50, No. 13, pp. 1781-1784.;;Hunt, Donald F., et al., ""Pulsed Positive Negative Ion Chemical Ionization Mass Spectrometry"", Dec. 1976, Analytical Chemistry, vol. 48, No. 14, pp. 2098-2104.;;Johnson, B. Connor, ""Posttranslational Covalent Modifications of Proteins"", 1893, Academic Press, New York, pp. 1-17.;;Kebarle and Chowdhury, ""Electron Affinities and Electron-Transfer Reactions,"" Chemical Reviews, 87, pp. 513-534, 1987.;;Kinter, Michael, ""Protein Sequencing and Identification Using Tandem Mass Spectrometry,"" John Wiley & Sons, 2000, pp. 6-23.;;Loo et al., ""Proton Transfer Reaction Studies of Multiply Charge Proteins in a High Mass-to-Charge Ratio Quadrupole Mass Spectrometry"", J. Am. Soc. Mass Spectrometry, vol. 5, 1994, pp. 1064-1071.;;Luger, Karolin, et al. ""Crystal Structure of the Nucleosome Core Particle at 2.8 A Resolution"", Sep. 18, 1997, Nature, vol. 389, pp. 251-260.;;Martin et al., ""Subfemtomole MS and MS/MS Peptide Sequence Analysis Using Nano-HPLC Micro-ESI Fourier Transform Ion Cyclotron Resonance Mass Spectrometry"", Anal. Chem., vol. 72, 2000, pp. 4266-4274.;;McLafferty et al., ""Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process"", J. Am. Chem. Soc., vol. 120, 1998, pp. 3265-3266.;;McLuckey et al., ""Ion Parking During Ion/Ion Reactions in Electrodynamic Ion Traps,"" Analytical Chemistry, 74, pp. 336-346, 2002.;;McLuckey et al., ""Ion/Ion Chemistry of High-Mass Multiply Charged Ions"", Mass Spectrometry Reviews, vol. 17, 1998, pp. 369-407.;;McLuckey et al., ""Ion/Ion Proton-Transfer Kinetics: Implications for Analysis of Ions Derived from Electrospray of Protein Mixtures"", Anal. Chem., vol. 70, 1998, pp. 1198-1202.;;Newton, Kelly A., et al., ""Generation and Manipulation of Sodium Cationized Peptides in the Gas Phase"", 2004, J.Am. Soc. Mass. Spectrom., No. 15, pp. 607-615.;;Ogorzalek Loo et al., ""Evidence of Charge Inversion in the Reaction of Singly Charged Anions with Multiply Charged Macroions,"" Journal of Physical Chemistry, 95, 6412-6415, 1991.;;Payne and Glish, ""Gas-phase ion/ion interactions between peptides or proteins and iron ions in a quadrupole ion trap,"" International Journal of Mass Spectrometry, 204, pp. 47-54, 2001.;;Pitteri and McLuckey, ""Recent Developments in the Ion/Ion Chemistry of High-Mass Multiply Charged Ions,"" Mass Spectrometry Reviews, vol. 24, pp. 931-958 (2005).;;Pitteri et al., ""Electron Transfer Ion/Ion Reactions in a Three-Dimensional Quadrupole Ion Trap: Reactions of Doubly and Triply Protonated Peptides With SO2,"" Analytical Chemistry, 77, pp. 1831-1839, 2005.;;Rattan, Suresh, I. S., et al., ""Protein Synthesis, Posttranslational Modifications, and Aginga"", 1992, Annals New York Academy of Sciences, No. 663, pp. 48-62.;;Reid, Gavin E. et al.: ""Tandem Mass Spectrometry of Ribonuclease A and B: N-Linked Glycosylation Site Analysis of Whole Protein Ions"" Analytical Chemistry , vol. 74, No. 3, Feb. 1, 2002, pp. 577-583, XP002385857.;;Reid, Gavin E., et al., ""Gas-Phase Concentration, Purification, and Identification of Whole Proteins from Complex Mixtures"", Feb. 18, 2002, American Chemical Society, vol. 124, No. 25, pp. 7353-7362.;;Reid, Gavin E., et al., ""Top Down Protein Characterization Via Tandem Mass Spectrometry"", Jul. 3, 2002, Journal of Mass Spectrometry, No. 37, pp. 663-675.;;Schwartz et al., ""A Two-Dimensional Quadrupole Ion Trap Mass Spectrometer"", J. Am. Soc. Mass Spectrometry, vol. 13, 2002, pp. 659-669.;;Seifter, Sam, et al., ""Analysis for Protein Modifications and Nonprotein Cofactors"", 1990, Methods in Enzymology, vol. 182, pp. 626-646.;;Stephenson and McLuckey, ""Adaptation of the Paul Trap for study of the reaction of multiply charged cations with singly charged anions,"" International Journal of Mass Spectrometry and Ion Processes, 162, pp. 89-106, 1997.;;Stephenson et al., ""Anion Effects on Storage and Resonance Ejection of High Mass-to-Charge Cations in Quadrupole Ion Trap Mass Spectrometry"", Anal. Science, vol. 69, 1997, pp. 3760-3766.;;Stephenson et al., ""Ion/Ion Proton Transfer Reactions for Protein Mixture Analysis"", Anal. Chem., vol. 68, 1996, pp. 4026-4032.;;Stephenson et al., ""Ion-Ion Proton Transfer Reactions of Bio-Ions Involving Noncovalent Interactions: Holomyoglobin"", J. Am. Soc. Mass Spectrometry, vol. 8, 1997, pp. 637-644.;;Stephenson et al., ""Simplification of Product Ion Spectra Derived from Multiply Charged Ions via Ion/Ion Chemistry"", Anal. Chem., vol. 70, 1998, pp. 3533-3544.;;Syka et al., ""Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry"", PNAS, vol. 101, No. 26, Jun. 2004, pp. 9528-9533.;;Syka, John E. P., et al., ""Novel Linear Quadrupole Ion Trap/FT Mass Spectrometer: Performance Characterization and Use in the Comparative Analysis of Histone H3 Post-Translational Modifications"", 2004, Journal of Proteome Research, vol. 3, No. 3, pp. 621-626.;;Wells et al., ""'Dueling' ESI: Instrumentation to Study Ion/Ion Reactions of Electrospray-generated Cations and Anions,"" Journal of the American Society of Mass Spectrometry, 13, pp. 614-622, 2002.;;Wells, J. Mitchell, et al., ""Formation and Characterization of Protein-Protein Complexes in Vacuo"", 2003, Journal American Chem. Society, vol. 125, No. 24, pp. 7238-7249.;;Wu and McLuckey, ""Ion/ion reactions of multiply charged nucleic acid anions: electron transfer, proton transfer, and ion attachment,"" International Journal of Mass Spectrometry, 228, 577-579, 2003.;;Xia et al., ""Effect of Cation Charge-Site Identity and Position on Electron-Transfer Dissociation of Polypeptide Cations,"" Journal of the American Chemical Society, 129, pp. 12232-12243, May 22, 2007.",ACTIVE
429,CA,C,CA 2559260 C,016-935-031-244-580,2015-05-12,2015,CA 2559260 A,2005-03-11,US 55287604 P;;US 57288404 P;;US 59934104 P;;US 2005/0008148 W,2004-03-12,ELECTRON TRANSFER DISSOCIATION FOR BIOPOLYMER SEQUENCE ANALYSIS,"The present invention relates to a method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",UNIV VIRGINIA PATENT FOUND,SYKA JOHN EDWARD PHILIP;;HUNT DONALD F;;COON JOSHUA J;;MARTO JARROD A,,https://lens.org/016-935-031-244-580,Granted Patent,no,0,0,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,H01J49/04;;G01N27/00;;G01N33/483;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/42,,0,0,,,,ACTIVE
430,US,A1,US 2011/0078417 A1,016-893-616-337-093,2011-03-31,2011,US 89022710 A,2010-09-24,US 89022710 A;;US 24604509 P,2009-09-25,COOPERATIVE THREAD ARRAY REDUCTION AND SCAN OPERATIONS,"One embodiment of the present invention sets forth a technique for performing aggregation operations across multiple threads that execute independently. Aggregation is specified as part of a barrier synchronization or barrier arrival instruction, where in addition to performing the barrier synchronization or arrival, the instruction aggregates (using reduction or scan operations) values supplied by each thread. When a thread executes the barrier aggregation instruction the thread contributes to a scan or reduction result, and waits to execute any more instructions until after all of the threads have executed the barrier aggregation instruction. A reduction result is communicated to each thread after all of the threads have executed the barrier aggregation instruction and a scan result is communicated to each thread as the barrier aggregation instruction is executed by the thread.",FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS,FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS,NVIDIA CORPORATION (2010-09-23),https://lens.org/016-893-616-337-093,Patent Application,yes,7,80,6,6,0,G06F9/522;;G06F9/522;;G06F8/458;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/30145;;G06F9/3851;;G06F9/3851,G06F9/38,712/216;;X712E09045,0,0,,,,ACTIVE
431,NO,B1,NO 333830 B1,197-009-567-608-769,2013-09-30,2013,NO 20052747 A,2005-06-07,US 86382504 A,2004-06-08,Metode for midlertidig separering av en første borehullsdel på et borehull fra en annen borehullsdel på borehullet.,"Betraktningsmåter tilknyttet den nåværende oppfinnelsen skaffer til veie en anordning og en metode for utvidelse av en rørform. I et aspekt, vil betraktningsmåter av den nåværende oppfinnelsen skaffe til veie ekspanderverktøy som har minst to ekspanderledd som er radialt forlengbare fra ekspanderverktøyet i kontakt med en omliggende innvendig overflate på rørformen, hvor minst to ekspanderledd er radialt forlengbare til forskjellige tider og aksialt plassert etter radial utvidelse. I en annen aspekt, inkluderer betraktningsmåtene en metode for isolering av den første delen på et borehull fra den andre delen på et borehull som består av å finne en utvidbar rørform innenfor borehullet mellom den første og den andre delen, hvor den utvidbare rørformen består av en svekket del, og isolerer den første delen fra den andre delen på borehullet, og utvider den utvidbare rørformen nærmest den svekkede delen for å kunne dele den utvidbare rørformen.",WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBIE;;COON ROBERT JOE;;MAGUIRE PATRICK G;;HARRALL SIMON JOHN,,https://lens.org/197-009-567-608-769,Granted Patent,no,0,0,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B17/00;;E21B/;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,,0,0,,,,INACTIVE
432,EP,A1,EP 1723416 A1,023-949-165-270-419,2006-11-22,2006,EP 05727506 A,2005-03-11,US 2005/0008148 W;;US 55287604 P;;US 57288404 P;;US 59934104 P,2004-03-12,ELECTRON TRANSFER DISSOCIATION FOR BIOPOLYMER SEQUENCE ANALYSIS,"The invention relates to a method of fragmenting positively charged peptide ions in an RF field mass spectrometer or an RF'field ion containment device, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide ion, resulting in the fragmentation of the positively charged sample ion. The invention also provides a method of performing sequence analysis of a peptide or protein by mass spectrometry, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide or protein ion, resulting in the fragmentation of the positively charged sample ion.",UNIV VIRGINIA,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD A,,https://lens.org/023-949-165-270-419,Patent Application,yes,0,1,20,20,0,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,0,0,,,,INACTIVE
433,NO,L,NO 20052747 L,008-156-755-869-17X,2005-12-09,2005,NO 20052747 A,2005-06-07,US 86382504 A,2004-06-08,Fremgangsmate og apparat for ekspandering og separering av rorlengder i et borehull,"Betraktningsmåter tilknyttet den nåværende oppfinnelsen skaffer til veie en anordning og en metode for utvidelse av en rørform. I et aspekt, vil betraktningsmåter av den nåværende oppfinnelsen skaffe til veie ekspanderverktøy som har minst to ekspanderledd som er radialt forlengbare fra ekspanderverktøyet i kontakt med en omliggende innvendig overflate på rørformen, hvor minst to ekspanderledd er radialt forlengbare til forskjellige tider og aksialt plassert etter radial utvidelse. I en annen aspekt, inkluderer betraktningsmåtene en metode for isolering av den første delen på et borehull fra den andre delen på et borehull som består av å finne en utvidbar rørform innenfor borehullet mellom den første og den andre delen, hvor den utvidbare rørformen består av en svekket del, og isolerer den første delen fra den andre delen på borehullet, og utvider den utvidbare rørformen nærmest den svekkede delen for å kunne dele den utvidbare rørformen.",WEATHERFORD LAMB,SIMPSON NEIL ANDREW ABERCROMBI;;COON ROBERT JOE;;MAGUIRE PATRICK G;;HARRALL SIMON JOHN,,https://lens.org/008-156-755-869-17X,Abstract,no,0,0,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,,0,0,,,,INACTIVE
434,EP,B1,EP 1723416 B1,129-384-793-124-891,2010-09-01,2010,EP 05727506 A,2005-03-11,US 2005/0008148 W;;US 55287604 P;;US 57288404 P;;US 59934104 P,2004-03-12,ELECTRON TRANSFER DISSOCIATION FOR BIOPOLYMER SEQUENCE ANALYSIS,"The invention relates to a method of fragmenting positively charged peptide ions in an RF field mass spectrometer or an RF'field ion containment device, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide ion, resulting in the fragmentation of the positively charged sample ion. The invention also provides a method of performing sequence analysis of a peptide or protein by mass spectrometry, wherein a gas-phase anion is used to transfer an electron to a positively charged sample ion which is a peptide or protein ion, resulting in the fragmentation of the positively charged sample ion.",UNIV VIRGINIA,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD A,,https://lens.org/129-384-793-124-891,Granted Patent,yes,1,0,20,20,0,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/53;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,3,0,,,"AEBERSOLD R ET AL: ""Mass spectrometry in proteomics"" CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 101, no. 2, February 2001 (2001-02), pages 269-295, XP002306061 ISSN: 0009-2665;;SYKA JOHN E P ET AL: ""Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry."" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 29 JUN 2004, vol. 101, no. 26, 29 June 2004 (2004-06-29), pages 9528-9533, XP009051646 ISSN: 0027-8424;;COON JOSHUA J ET AL: ""Electron transfer dissociation of peptide anions."" June 2005 (2005-06), JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY. JUN 2005, VOL. 16, NR. 6, PAGE(S) 880 - 882 , XP004904047 ISSN: 1044-0305 the whole document",INACTIVE
435,US,A1,US 2012/0184042 A1,147-664-249-826-493,2012-07-19,2012,US 201213422812 A,2012-03-16,US 201213422812 A;;US 42667509 A;;US 7914705 A;;US 55287604 P;;US 59934104 P;;US 57288404 P,2004-03-12,Electron Transfer Dissociation for Biopolymer Sequence Analysis,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD A;;UNIV VIRGINIA PATENT FOUND,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD A,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2012-08-21);;UNIVERSITY OF VIRGINIA (2012-08-24),https://lens.org/147-664-249-826-493,Patent Application,yes,8,4,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/50;;G01N27/62;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,436/86;;436/173;;436/140,3,3,004-660-596-110-998;;115-238-949-200-640;;001-606-043-013-366,10.1016/s1044-0305(01)00364-6;;12056562;;10.1021/ja973478k;;10.1002/mas.20004;;15389865,"Wells et al. '""'Dueling"" ESI: Instrumentation to Study Ion/Ion Reactions of Electrospray-generated Cations and Anions"", J Am Soc Mass Spectrom 2002, 13, 614-622;;Zubarev et al. ""Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process"", J. Am. Chem. Soc. 1998, 120, 3265-3266;;Douglas et al. ""LINEAR ION TRAPS IN MASS SPECTROMETRY"", Mass Spectrometry Reviews, 2005, 24, 1-29",ACTIVE
436,GB,B,GB 2415001 B,017-358-443-601-758,2008-11-26,2008,GB 0511598 A,2005-06-07,US 86382504 A,2004-06-08,Method and apparatus for expanding and separating tubulars in a wellbore,,WEATHERFORD LAMB,HARRALL SIMON JOHN;;MAGUIRE PATRICK G;;COON ROBERT J;;SIMPSON NEIL ANDREW ABERCROMBI,,https://lens.org/017-358-443-601-758,Granted Patent,no,2,0,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B43/10;;E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/12,,0,0,,,,INACTIVE
437,DE,C3,DE 2359033 C3,135-274-838-298-626,1981-10-22,1981,DE 2359033 A,1973-11-27,US 30994772 A,1972-11-27,DE 2359033 C3,,"THE CORNELIUS CO.,, ST.LOUIS PARK, MINN., US","HASSELL, DAVID ALLEN, COON RAPIDS, MINN., US;;MCMILLIN, JOHN RICHARD, MAPLEWOOD, MINN., US",,https://lens.org/135-274-838-298-626,Granted Patent,no,0,0,9,9,0,F25D31/002;;B67D1/0058;;B01F23/2363;;F25D31/002;;B67D1/0058;;B01F23/2363,B01F1/00;;B01F3/04;;F25D31/00,,0,0,,,,EXPIRED
438,US,B2,US 7373990 B2,133-990-793-143-51X,2008-05-20,2008,US 86382504 A,2004-06-08,US 86382504 A;;US 96908901 A;;US 46969099 A,1999-12-22,Method and apparatus for expanding and separating tubulars in a wellbore,"Embodiments of the present invention provide an apparatus and method for expanding a tubular. In one aspect, embodiments of the prevent invention provide an expander tool having at least two expansion members radially extendable from the expander tool into contact with a surrounding inside surface of the tubular, the at least two expansion members radially extendable at different times and axially spaced after radially extending. In another aspect, embodiments include a method for isolating a first portion of a wellbore from a second portion of a wellbore comprising locating an expandable tubular within the wellbore between the first and second portions, the expandable tubular having a weakened portion therein, isolating the first portion from the second portion of the wellbore, and expanding the expandable tubular proximate to the weakened portion to sever the expandable tubular.",WEATHERFORD LAMB,HARRALL SIMON JOHN;;MAGUIRE PATRICK G;;COON ROBERT J;;SIMPSON NEIL ANDREW ABERCROMBI,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2004-09-28),https://lens.org/133-990-793-143-51X,Granted Patent,yes,100,22,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B19/16;;E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,166/380;;166/207,2,0,,,"GB Search Report, Application No. GB0519435.2, dated Oct. 20, 2005.;;U.K. Search Report, GB Application No. GB0511598.5, dated Aug. 11, 2005.",EXPIRED
439,US,A1,US 2009/0230302 A1,007-736-773-767-438,2009-09-17,2009,US 42667509 A,2009-04-20,US 42667509 A;;US 7914705 A;;US 55287604 P;;US 59934104 P;;US 57288404 P,2004-03-12,Electron Transfer Dissociation for Biopolymer Sequence Analysis,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",UNIV VIRGINIA,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JAROD A,,https://lens.org/007-736-773-767-438,Patent Application,yes,11,8,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N24/00;;B01D59/44;;G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,250/282;;436/173,0,0,,,,DISCONTINUED
440,US,A1,US 2005/0011650 A1,086-762-211-392-464,2005-01-20,2005,US 86382504 A,2004-06-08,US 86382504 A;;US 96908901 A;;US 46969099 A,1999-12-22,Method and apparatus for expanding and separating tubulars in a wellbore,"Embodiments of the present invention provide an apparatus and method for expanding a tubular. In one aspect, embodiments of the prevent invention provide an expander tool having at least two expansion members radially extendable from the expander tool into contact with a surrounding inside surface of the tubular, the at least two expansion members radially extendable at different times and axially spaced after radially extending. In another aspect, embodiments include a method for isolating a first portion of a wellbore from a second portion of a wellbore comprising locating an expandable tubular within the wellbore between the first and second portions, the expandable tubular having a weakened portion therein, isolating the first portion from the second portion of the wellbore, and expanding the expandable tubular proximate to the weakened portion to sever the expandable tubular.",WEATHERFORD LAMB,HARRALL SIMON JOHN;;MAGUIRE PATRICK G;;COON ROBERT J;;SIMPSON NEIL ANDREW ABERCROMBI,WEATHERFORD TECHNOLOGY HOLDINGS LLC (2014-09-01);;WEATHERFORD/LAMB INC (2004-09-28),https://lens.org/086-762-211-392-464,Patent Application,yes,85,37,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,16638;;166/207;;166/55.7,0,0,,,,EXPIRED
441,WO,A1,WO 2005/090978 A1,161-757-410-274-809,2005-09-29,2005,US 2005/0008148 W,2005-03-11,US 59934104 P;;US 57288404 P;;US 55287604 P,2004-03-12,ELECTRON TRANSFER DISSOCIATION FOR BIOPOLYMER SEQUENCE ANALYSIS,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",UNIV VIRGINIA;;HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD A,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN EDWARD PHILIP;;MARTO JARROD A,,https://lens.org/161-757-410-274-809,Patent Application,yes,3,79,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,,11,11,033-543-562-828-538;;073-803-555-225-017;;100-670-378-310-085;;139-344-218-489-129;;040-286-853-815-47X;;054-947-093-781-361;;025-523-151-463-02X;;030-460-807-381-496;;044-059-272-957-811;;005-608-730-830-354;;039-744-701-942-955,10.1021/cr990076h;;11712248;;15210983;;pmc470779;;10.1073/pnas.0402700101;;10.1016/j.jasms.2005.01.015;;15907703;;2138240;;10.1016/0076-6879(90)82049-8;;10.1111/j.1749-6632.1992.tb38648.x;;1482093;;10.1021/ac50008a014;;10.1021/ac50035a017;;10.1016/s1044-0305(02)00384-7;;12056566;;11008759;;10.1021/ac000497v;;10.1038/nbt0302-301;;11875433;;10.1016/1044-0305(94)80016-2;;24226387,"AEBERSOLD R ET AL: ""Mass spectrometry in proteomics"", CHEMICAL REVIEWS, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 101, no. 2, February 2001 (2001-02-01), pages 269 - 295, XP002306061, ISSN: 0009-2665;;SYKA JOHN E P ET AL: ""Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 29 JUN 2004, vol. 101, no. 26, 29 June 2004 (2004-06-29), pages 9528 - 9533, XP009051646, ISSN: 0027-8424;;COON JOSHUA J ET AL: ""Electron transfer dissociation of peptide anions."", June 2005, JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY. JUN 2005, VOL. 16, NR. 6, PAGE(S) 880 - 882, ISSN: 1044-0305, XP004904047;;SEIFTER ET AL., METH ENZYMOL, vol. 182, 1990, pages 626 - 646;;RATTAN ET AL., ANN NY ACAD SCI, vol. 663, 1992, pages 48 - 62;;HUNT ET AL., ANAL. CHEM., vol. 48, 1976, pages 2098;;HUNT ET AL., ANAL. CHEM., vol. 50, 1978, pages 1781 - 1784;;SCHWARTZ, J. AM. SOC. MASS SPECTROM., vol. 13, 2002, pages 659 - 669;;MARTIN ET AL., ANAL CHEM., vol. 72, 2000, pages 4266 - 4274;;FICARRO ET AL., NAT. BIOTECHNOL., vol. 20, 2002, pages 301 - 305;;ENG ET AL., J AM. SOC. MASS SPECTROM., vol. 5, 1994, pages 976 - 989",PENDING
442,CA,C,CA 2509317 C,193-965-409-527-757,2009-08-04,2009,CA 2509317 A,2005-06-07,US 86382504 A,2004-06-08,METHOD AND APPARATUS FOR EXPANDING AND SEPARATING TUBULARS IN A WELLBORE,"Embodiments of the present invention provide an apparatus and method fo r expanding a tubular. In one aspect, embodiments of the prevent invention provide an expander tool having at least two expansion members radially extendable from the expander tool into contact with a surrounding inside surface of the tubular, the at least two expansion members radially extendable at different times and axially spaced after radially extending. In another aspect, embodiments include a method for isolating a first portion of a wellbore from a second portion of a wellbore comprising locating an expandable tubular within the wellbore between the first and second portions , the expandable tubular having a weakened portion therein, isolating the first portion from the second portion of the wellbore, and expanding the expandable tubular proximate to the weakened portion to sever the expandable tubular.",WEATHERFORD LAMB,HARRALL SIMON JOHN;;MAGUIRE PATRICK G;;COON ROBERT J;;SIMPSON NEIL ANDREW ABERCROMBIE,,https://lens.org/193-965-409-527-757,Granted Patent,no,0,0,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B29/08;;E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,,0,0,,,,INACTIVE
443,CA,A1,CA 2509317 A1,011-301-149-439-643,2005-12-08,2005,CA 2509317 A,2005-06-07,US 86382504 A,2004-06-08,METHOD AND APPARATUS FOR EXPANDING AND SEPARATING TUBULARS IN A WELLBORE,"Embodiments of the present invention provide an apparatus and method fo r expanding a tubular. In one aspect, embodiments of the prevent invention provide an expander tool having at least two expansion members radially extendable from the expander tool into contact with a surrounding inside surface of the tubular, the at least two expansion members radially extendable at different times and axially spaced after radially extending. In another aspect, embodiments include a method for isolating a first portion of a wellbore from a second portion of a wellbore comprising locating an expandable tubular within the wellbore between the first and second portions , the expandable tubular having a weakened portion therein, isolating the first portion from the second portion of the wellbore, and expanding the expandable tubular proximate to the weakened portion to sever the expandable tubular.",WEATHERFORD LAMB,HARRALL SIMON JOHN;;SIMPSON NEIL ANDREW ABERCROMBI;;COON ROBERT J;;MAGUIRE PATRICK G,,https://lens.org/011-301-149-439-643,Patent Application,no,0,0,15,15,0,E21B29/00;;E21B43/084;;E21B43/103;;E21B43/105;;E21B43/106;;E21B29/00;;E21B33/12;;E21B43/10;;E21B43/103;;E21B43/105;;E21B43/106;;E21B43/084;;E21B43/105;;E21B29/00;;E21B43/106;;E21B43/103,E21B/;;E21B17/00;;E21B17/08;;E21B29/00;;E21B29/08;;E21B33/12;;E21B33/14;;E21B43/08;;E21B43/10;;E21B43/12,,0,0,,,,INACTIVE
444,US,B2,US 9417875 B2,098-069-787-964-998,2016-08-16,2016,US 201314025482 A,2013-09-12,US 201314025482 A;;US 89022710 A;;US 24604509 P,2009-09-25,Cooperative thread array reduction and scan operations,"One embodiment of the present invention sets forth a technique for performing aggregation operations across multiple threads that execute independently. Aggregation is specified as part of a barrier synchronization or barrier arrival instruction, where in addition to performing the barrier synchronization or arrival, the instruction aggregates (using reduction or scan operations) values supplied by each thread. When a thread executes the barrier aggregation instruction the thread contributes to a scan or reduction result, and waits to execute any more instructions until after all of the threads have executed the barrier aggregation instruction. A reduction result is communicated to each thread after all of the threads have executed the barrier aggregation instruction and a scan result is communicated to each thread as the barrier aggregation instruction is executed by the thread.",NVIDIA CORP,FAHS BRIAN;;SIU MING Y;;COON BRETT W;;NICKOLLS JOHN R;;NYLAND LARS,NVIDIA CORPORATION (2010-09-23),https://lens.org/098-069-787-964-998,Granted Patent,yes,4,0,6,6,0,G06F9/522;;G06F9/522;;G06F8/458;;G06F9/3004;;G06F9/3004;;G06F9/30087;;G06F9/30087;;G06F9/30145;;G06F9/3851;;G06F9/3851,G06F9/30;;G06F9/38;;G06F9/52;;G06F15/00,,0,0,,,,ACTIVE
445,US,A1,US 2005/0199804 A1,181-103-851-923-715,2005-09-15,2005,US 7914705 A,2005-03-14,US 7914705 A;;US 55287604 P;;US 57288404 P;;US 59934104 P,2004-03-12,Electron transfer dissociation for biopolymer sequence analysis,"The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.",HUNT DONALD F.;;COON JOSHUA J.;;SYKA JOHN E.P.;;MARTO JARROD A.,HUNT DONALD F;;COON JOSHUA J;;SYKA JOHN E P;;MARTO JARROD A,UNIVERSITY OF VIRGINIA PATENT FOUNDATION (2005-06-08);;UNIVERSITY OF VIRGINIA (2006-03-17),https://lens.org/181-103-851-923-715,Patent Application,yes,2,146,20,20,72,G01N33/6848;;H01J49/0072;;H01J49/423;;Y10T436/24;;Y10T436/212;;Y10T436/24;;Y10T436/212;;H01J49/423;;G01N33/6848;;H01J49/0072,G01N33/50;;G01N33/68;;H01J49/00;;H01J49/04;;H01J49/42,250/290,0,0,,,,ACTIVE
446,US,B2,US 8732713 B2,113-465-394-930-136,2014-05-20,2014,US 201113247819 A,2011-09-28,US 201113247819 A;;US 38791110 P,2010-09-29,Thread group scheduler for computing on a parallel thread processor,"A parallel thread processor executes thread groups belonging to multiple cooperative thread arrays (CTAs). At each cycle of the parallel thread processor, an instruction scheduler selects a thread group to be issued for execution during a subsequent cycle. The instruction scheduler selects a thread group to issue for execution by (i) identifying a pool of available thread groups, (ii) identifying a CTA that has the greatest seniority value, and (iii) selecting the thread group that has the greatest credit value from within the CTA with the greatest seniority value.",COON BRETT W;;LINDHOLM JOHN ERIK;;STOLL ROBERT J;;WANG NICHOLAS;;CHOQUETTE JACK HILAIRE;;NICKOLLS KATHLEEN ELLIOTT;;NVIDIA CORP,COON BRETT W;;NICKOLLS JOHN R;;LINDHOLM JOHN ERIK;;STOLL ROBERT J;;WANG NICHOLAS;;CHOQUETTE JACK HILAIRE,NVIDIA CORPORATION (2011-09-28),https://lens.org/113-465-394-930-136,Granted Patent,yes,4,13,2,2,0,G06F9/4881;;G06F2209/483;;G06F9/4881;;G06F2209/483,G06F9/46,718/102,3,3,041-820-330-826-333;;007-944-769-744-459;;000-174-813-227-430,10.1109/mm.2008.31;;10.1145/1454115.1454152;;10.1145/1669112.1669119,"Erik Lindholm, John Nickolls, Stuart Oberman, John Montrym, Nvidia Tesla: A Unified Graphics and Computing Architecture, Mar.-Apr. 2008, IEEE Micro, p. 39-55.;;Bingsheng He, Wenbin Fang, Qiong Luo, Naga K. Govindaraju, Tuyong Wang, Mars: A MapReduce Framework on Graphics Processors, PACT'08, Oct. 25-29, 2008, Toronto, Ontario, Canada, p. 260-269.;;George L. Yuan, Ali Bakhoda, Tor M. Aamodt, Complexity Effective Memory Access Scheduling for Many-Core Accelerator Architectures, MICRO'09, Dec. 12-16, 2009, New York, NY, USA, p. 34-44.",ACTIVE
447,US,B1,US 7634621 B1,129-566-526-143-016,2009-12-15,2009,US 55667706 A,2006-11-03,US 55667706 A;;US 88973004 A,2004-07-13,Register file allocation,"Circuits, methods, and apparatus that provide the die area and power savings of a single-ported memory with the performance advantages of a multiported memory. One example provides register allocation methods for storing data in a multiple-bank register file. In a thin register allocation method, data for a process is stored in a single bank. In this way, different processes use different banks to avoid conflicts. In a fat register allocation method, processes store data in each bank. In this way, if one process uses a large number of registers, those registers are spread among the banks, avoiding a situation where one bank is filled and other processes are forced to share a reduced number of banks. In a hybrid register allocation method, processes store data in more than one bank, but fewer than all the banks. Each of these methods may be combined in varying ways.",NVIDIA CORP,COON BRETT W;;LINDHOLM JOHN ERIK;;TAROLLI GARY;;TZVETKOV SVETOSLAV D;;NICKOLLS JOHN R;;SIU MING Y,NVIDIA CORPORATION (2006-11-02),https://lens.org/129-566-526-143-016,Granted Patent,yes,8,39,1,16,0,G06F9/3012;;G06F9/30123;;G06F9/3824;;G06F9/3851;;G06F9/3885;;G06F12/0223;;Y02D10/00;;G06F9/3012;;G06F9/3885;;G06F9/30123;;G06F12/0223;;G06F9/3824;;G06F9/3851;;Y02D10/00,G06F12/00,711/149,0,0,,,,ACTIVE
448,US,B2,US 9189242 B2,185-162-420-336-899,2015-11-17,2015,US 88529910 A,2010-09-17,US 88529910 A;;US 24562609 P,2009-09-24,Credit-based streaming multiprocessor warp scheduling,One embodiment of the present invention sets forth a technique for ensuring cache access instructions are scheduled for execution in a multi-threaded system to improve cache locality and system performance. A credit-based technique may be used to control instruction by instruction scheduling for each warp in a group so that the group of warps is processed uniformly. A credit is computed for each warp and the credit contributes to a weight for each warp. The weight is used to select instructions for the warps that are issued for execution.,LINDHOLM JOHN ERIK;;COON BRETT W;;WIERZBICKI JERED;;STOLL ROBERT J;;OBERMAN STUART F;;NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;WIERZBICKI JERED;;STOLL ROBERT J;;OBERMAN STUART F,NVIDIA CORPORATION (2010-08-25),https://lens.org/185-162-420-336-899,Granted Patent,yes,9,3,2,2,0,G06F9/3851;;G06F9/3851;;G06F9/3836;;G06F9/3836;;G06F9/3885;;G06F9/3885;;G06F9/3887;;G06F9/3887;;G06F9/3889;;G06F9/3889,G06F9/50;;G06F9/38,,5,4,050-483-545-912-345;;110-761-783-794-489;;041-256-648-886-50X;;041-820-330-826-333,10.1109/micro.2007.4408272;;10.1109/lcn.2001.990776;;10.1109/90.958328;;10.1109/mm.2008.31,"Fung et al., ""Dynamic Warp Formation and Scheduling for Efficient GPU Control Flow"", Dec. 2007, Proceedings of the 40th Annual IEEE/ACM International Symposium on Microarchitecture, pp. 407-420.;;Baatz et al., ""Adaptive Scatternet Support for Bluetooth using Sniff mode"", Nov. 2001, IEEE, Proceedings. LCN 2001. 26th Annual IEEE Conference on Local Computer Networks, pp. 112-120.;;Bensaou et al., ""Credit Based Fair Queueing (CBFQ): A Simple Service-Scheduling Algorithm for Packet-Switched Networks"", Oct. 2001, IEEE/ACM Transactions on Networking, vol. 9, No. 5, pp. 591-604.;;Lindholm et. al., ""NVIDIA Testla: A Unified Graphics and Computing Architecture"", 2008, IEEE Micro, vol. 28, Issue 2, pp. 39-55.;;Kanter, ""Nvidia's GT200: Inside a Parallel Processor"", Sep. 2008, from www.realworldtech.com/gt200/9/, pp. 1-3.",ACTIVE
449,EP,B1,EP 2062284 B1,197-030-215-573-60X,2018-08-15,2018,EP 07841375 A,2007-08-24,US 2007/0076823 W;;US 84019806 P,2006-08-25,DATA-DEPENDENT SELECTION OF DISSOCIATION TYPE IN A MASS SPECTROMETER,,THERMO FINNIGAN LLC;;COON JOSHUA J,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,,https://lens.org/197-030-215-573-60X,Granted Patent,yes,1,0,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/00,,1,1,105-501-002-630-018,10.1021/ac061457f;;pmc2522365;;17222010,"DANIELLE L. SWANEY ET AL: ""Supplemental Activation Method for High-Efficiency Electron-Transfer Dissociation of Doubly Protonated Peptide Precursors"", ANALYTICAL CHEMISTRY, vol. 79, no. 2, 8 December 2006 (2006-12-08), US, pages 477 - 485, XP055245210, ISSN: 0003-2700, DOI: 10.1021/ac061457f",ACTIVE
450,CA,A1,CA 2657809 A1,118-615-048-343-206,2008-02-28,2008,CA 2657809 A,2007-08-24,US 84019806 P;;US 2007/0076823 W,2006-08-25,DATA-DEPENDENT SELECTION OF DISSOCIATION TYPE IN A MASS SPECTROMETER,"Methods and apparatus for data-dependent mass spectrometric MS/MS or MSn analysis are disclosed. The methods may include determination of the charge state of an ion species of interest, followed by automated selection of a di ssociation type (e.g., CAD, ETD, or ETD followed by a non-dissociative charg e reduction or collisional activation) based at least partially on the deter mined charge state. The ion species of interest is then dissociated in accor dance with the selected dissociation type, and an MS/MS or MSn spectrum of t he resultant product ions may be acquired.",THERMO FINNIGAN LLC,COON JOSHUA J;;SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R,,https://lens.org/118-615-048-343-206,Patent Application,no,0,0,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/00,,0,0,,,,ACTIVE
451,US,A1,US 2012/0089792 A1,102-834-760-897-033,2012-04-12,2012,US 201113247855 A,2011-09-28,US 201113247855 A;;US 38794410 P,2010-09-29,EFFICIENT IMPLEMENTATION OF ARRAYS OF STRUCTURES ON SIMT AND SIMD ARCHITECTURES,"One embodiment of the present invention sets forth a technique providing an optimized way to allocate and access memory across a plurality of thread/data lanes. Specifically, the device driver receives an instruction targeted to a memory set up as an array of structures of arrays. The device driver computes an address within the memory using information about the number of thread/data lanes and parameters from the instruction itself. The result is a memory allocation and access approach where the device driver properly computes the target address in the memory. Advantageously, processing efficiency is improved where memory in a parallel processing subsystem is internally stored and accessed as an array of structures of arrays, proportional to the SIMT/SIMD group width (the number of threads or lanes per execution group).",FAHS BRIAN;;NICKOLLS JOHN R;;NICKOLLS KATHLEEN ELLIOTT;;MORETON HENRY PACKARD;;COON BRETT W,FAHS BRIAN;;NICKOLLS JOHN R;;NICKOLLS KATHLEEN ELLIOTT;;MORETON HENRY PACKARD;;COON BRETT W,NVIDIA CORPORATION (2011-09-28);;LINARES MEDICAL DEVICES LLC (2009-04-09),https://lens.org/102-834-760-897-033,Patent Application,yes,5,43,2,2,0,G06F9/3009;;G06F9/30123;;G06F9/345;;G06F9/3824;;G06F9/3887;;G06F12/0207;;G06T1/20;;G06F9/3851;;G06F12/0207;;G06F9/3887;;G06F9/3824;;G06F9/3009;;G06F9/345;;G06F9/30123;;G06T1/20;;G06F9/30036;;G06F9/3851;;G06F9/3885,G06F12/00,711/154;;X711E12001,0,0,,,,ACTIVE
452,WO,A3,WO 2006/116759 A3,145-184-919-309-706,2007-03-29,2007,US 2006/0016552 W,2006-04-28,US 67575705 P;;US 41328806 A,2005-04-28,POLE MOUNTING SYSTEM,"A pole mounting system (10) includes a pole having at least one channel configured to receive a finger of a spike. A neck of the spike extends out of the channel and attaches to a connector. Different connectors may be configured to enable different devices to be suspended on the pole. Wire management may be provided within the channel and optionally through the K-base (12) . The pole may be supported on a K-base having a central hub (60) formed as a pentagon with legs (62) extending from four of its five sides. The ends of the legs may splay to form clefts that receive a flat outer perimeter of the central hub, so that the legs may be bolted to the central hub. A pole- shaped indentation is formed on a top surface of the hub to enable the pole of the pole mounting system to be attached to the K-base.",BRETFORD MFG INC;;PETRICK CHRISTOPHER;;COON ROBERT;;GUNDERSON BJORN;;DOAN JIMMY-QUANG VIET;;KRAPFL CLIFFORD;;FREESE JOHN,PETRICK CHRISTOPHER;;COON ROBERT;;GUNDERSON BJORN;;DOAN JIMMY-QUANG VIET;;KRAPFL CLIFFORD;;FREESE JOHN,,https://lens.org/145-184-919-309-706,Search Report,yes,5,0,4,13,0,F16M11/16;;F16M11/2064;;F16M11/24;;F16M11/42;;F16M2200/068;;F16M11/2064;;F16M2200/068;;F16M11/16;;F16M11/24;;F16M11/42,F16M11/24,,0,0,,,,PENDING
453,EP,A2,EP 2062284 A2,123-946-145-546-918,2009-05-27,2009,EP 07841375 A,2007-08-24,US 2007/0076823 W;;US 84019806 P,2006-08-25,DATA-DEPENDENT SELECTION OF DISSOCIATION TYPE IN A MASS SPECTROMETER,,THERMO FINNIGAN LLC;;COON JOSHUA J,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,,https://lens.org/123-946-145-546-918,Patent Application,yes,0,0,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/00,,0,0,,,,ACTIVE
454,WO,A3,WO 2008/025014 A3,164-233-251-807-939,2008-11-13,2008,US 2007/0076823 W,2007-08-24,US 84019806 P,2006-08-25,DATA-DEPENDENT SELECTION OF DISSOCIATION TYPE IN A MASS SPECTROMETER,"Methods and apparatus for data-dependent mass spectrometric MS/MS or MSn analysis are disclosed. The methods may include determination of the charge state of an ion species of interest, followed by automated selection of a dissociation type (e.g., CAD, ETD, or ETD followed by a non-dissociative charge reduction or collisional activation) based at least partially on the determined charge state. The ion species of interest is then dissociated in accordance with the selected dissociation type, and an MS/MS or MSn spectrum of the resultant product ions may be acquired.",THERMO FINNIGAN LLC;;SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,,https://lens.org/164-233-251-807-939,Search Report,yes,8,0,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/00,,3,3,010-447-139-594-880;;071-937-348-115-14X;;051-076-446-686-723,16713712;;10.1016/j.jasms.2006.02.003;;10.1002/mas.20048;;15706594;;17097932;;10.1016/j.bbapap.2006.09.016,"TABB ET AL: ""Determination of Peptide and Protein Ion Charge States by Fourier Transformation of Isotope-Resolved Mass Spectra"", JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, ELSEVIER SCIENCE INC, US, vol. 17, no. 7, 1 July 2006 (2006-07-01), pages 903 - 915, XP005517959, ISSN: 1044-0305;;PITTERI S J ET AL: ""Recent developments in the ion/ion chemistry of high-mass multiply charged ions"", MASS SPECTROMETRY REVIEWS NOVEMBER/DECEMBER 2005 JOHN WILEY AND SONS INC. US, vol. 24, no. 6, November 2005 (2005-11-01), pages 931 - 958, XP007905556;;STINGL ET AL: ""Application of different fragmentation techniques for the analysis of phosphopeptides using a hybrid linear ion trap-FTICR mass spectrometer"", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, vol. 1764, no. 12, 14 December 2006 (2006-12-14), pages 1842 - 1852, XP005803449, ISSN: 1570-9639",PENDING
455,US,A1,US 2008/0109611 A1,190-130-353-162-829,2008-05-08,2008,US 55564906 A,2006-11-01,US 55564906 A;;US 88973004 A,2004-07-13,OPERAND COLLECTOR ARCHITECTURE,"An apparatus and method for simulating a multi-ported memory using lower port count memories as banks. A collector units gather source operands from the banks as needed to process program instructions. The collector units also gather constants that are used as operands. When all of the source operands needed to process a program instruction have been gathered, a collector unit outputs the source operands to an execution unit while avoiding writeback conflicts to registers specified by the program instruction that may be accessed by other execution units.",LIU SAMUEL;;LINDHOLM JOHN ERIK;;SIU MING Y;;COON BRETT W;;OBERMAN STUART F,LIU SAMUEL;;LINDHOLM JOHN ERIK;;SIU MING Y;;COON BRETT W;;OBERMAN STUART F,NVIDIA CORPORATION (2006-10-30),https://lens.org/190-130-353-162-829,Patent Application,yes,19,57,15,16,0,G06F9/3012;;G06F9/30123;;G06F9/30167;;G06F9/3824;;G06F9/3851;;G06F9/3885;;G06F12/02;;G06F12/06;;G06F9/30;;G06F9/3012;;G06F9/30167;;G06F9/30123;;G06F9/3885;;G06F9/3851;;G06F9/3824,G06F13/00,711/149,0,0,,,,ACTIVE
456,US,B1,US 7680988 B1,013-753-265-494-295,2010-03-16,2010,US 55456306 A,2006-10-30,US 55456306 A,2006-10-30,Single interconnect providing read and write access to a memory shared by concurrent threads,"A shared memory is usable by concurrent threads in a multithreaded processor, with any addressable storage location in the shared memory being readable and writeable by any of the threads. Processing engines that execute the threads are coupled to the shared memory via an interconnect that transfers data in only one direction (e.g., from the shared memory to the processing engines); the same interconnect supports both read and write operations. The interconnect advantageously supports multiple parallel read or write operations.",NVIDIA CORP,NICKOLLS JOHN R;;COON BRETT W;;SIU MING Y;;OBERMAN STUART F;;LIU SAMUEL,NVIDIA CORPORATION (2006-10-24),https://lens.org/013-753-265-494-295,Granted Patent,yes,28,91,1,1,0,G06F12/084;;G06F12/084;;G06F9/544;;G06F9/544;;G06F15/167;;G06F15/167;;Y02D10/00;;Y02D10/00,G06F13/16,711/149;;711/130;;711/131,11,1,020-961-679-464-619,10.1109/40.621209,"Cell Microprocessor www.wikipedia.org, downloaded at.;;Cell Architecture Explained Version 2, Introduction and Index, downloaded at http://www.blachford.info/computer/Cell/Cell0-v2.html on Feb. 7, 2007.;;Eggers et al. ""Simultaneous multithreading: a platform for next-generation processors"" IEEE Micro, Sep./Oct. 1997 (vol. 17, No. 5) pp. 12-19.;;Gschwind et al. ""Synergistic Processing in Cell's Multicore Architecture"", IEEE Computer Society, vol. 26, Issue 2 (Mar. 2006) pp. 10-24.;;Marr et al. ""Hyper-Threading Technology Architecture and Microarchitecture"", Intel Technology Journal, vol. 6 Issue 1 Published Feb. 14, 2002.;;Office Action dated Dec. 8, 2008, U.S. Appl. No. 11/554,552, filed Oct. 30, 2006, 15 pages.;;Office Action dated Jun. 3, 2009, U.S. Appl. No. 11/554,552, filed Oct. 30, 2006, 14 pages.;;U.S. Appl. No. 11/554,542, filed Jul. 17, 2009, 8 pages.;;U.S Appl. No. 11/554,546, filed Aug. 5, 2009, 12 pages.;;U.S. Appl. No. 11/554,552, filed Oct. 14, 2009, 15 pages.;;U.S. Appl. No. 11/554,542, Office Action dated Dec. 8, 2009, 9 pages.",ACTIVE
457,CN,B,CN 101558470 B,059-930-594-567-583,2011-04-13,2011,CN 200780031593 A,2007-08-24,US 2007/0076823 W;;US 84019806 P,2006-08-25,Data-dependent selection of dissociation type in a mass spectrometer,"Methods and apparatus for data-dependent mass spectrometric MS/MS or MSn analysis are disclosed. The methods may include determination of the charge state of an ion species of interest, followed by automated selection of a dissociation type (e.g., CAD, ETD, or ETD followed by a non-dissociative charge reduction or collisional activation) based at least partially on the determined charge state. Theion species of interest is then dissociated in accordance with the selected dissociation type, and an MS/MS or MSn spectrum of the resultant product ions may be acquired.",THERMO FINNIGAN LLC;;SCHWARTZ JAE C,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,,https://lens.org/059-930-594-567-583,Granted Patent,no,0,0,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/00,,0,0,,,,ACTIVE
458,CA,C,CA 2657809 C,028-520-978-923-819,2013-01-22,2013,CA 2657809 A,2007-08-24,US 84019806 P;;US 2007/0076823 W,2006-08-25,DATA-DEPENDENT SELECTION OF DISSOCIATION TYPE IN A MASS SPECTROMETER,"Methods and apparatus for data-dependent mass spectrometric MS/MS or MSn analysis are disclosed. The methods may include determination of the charge state of an ion species of interest, followed by automated selection of a dissociation type (e.g., CAD, ETD, or ETD followed by a non-dissociative charge reduction or collisional activation) based at least partially on the determined charge state. The ion species of interest is then dissociated in accordance with the selected dissociation type, and an MS/MS or MSn spectrum of the resultant product ions may be acquired.",THERMO FINNIGAN LLC;;COON JOSHUA J,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,,https://lens.org/028-520-978-923-819,Granted Patent,no,0,0,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/00,,0,0,,,,ACTIVE
459,WO,A2,WO 2006/116759 A2,045-370-286-812-03X,2006-11-02,2006,US 2006/0016552 W,2006-04-28,US 67575705 P;;US 41328806 A,2005-04-28,POLE MOUNTING SYSTEM,"A pole mounting system (10) includes a pole having at least one channel configured to receive a finger of a spike. A neck of the spike extends out of the channel and attaches to a connector. Different connectors may be configured to enable different devices to be suspended on the pole. Wire management may be provided within the channel and optionally through the K-base (12) . The pole may be supported on a K-base having a central hub (60) formed as a pentagon with legs (62) extending from four of its five sides. The ends of the legs may splay to form clefts that receive a flat outer perimeter of the central hub, so that the legs may be bolted to the central hub. A pole- shaped indentation is formed on a top surface of the hub to enable the pole of the pole mounting system to be attached to the K-base.",BRETFORD MFG INC;;PETRICK CHRISTOPHER;;COON ROBERT;;GUNDERSON BJORN;;DOAN JIMMY-QUANG VIET;;KRAPFL CLIFFORD;;FREESE JOHN,PETRICK CHRISTOPHER;;COON ROBERT;;GUNDERSON BJORN;;DOAN JIMMY-QUANG VIET;;KRAPFL CLIFFORD;;FREESE JOHN,,https://lens.org/045-370-286-812-03X,Patent Application,yes,0,2,4,13,0,F16M11/16;;F16M11/2064;;F16M11/24;;F16M11/42;;F16M2200/068;;F16M11/2064;;F16M2200/068;;F16M11/16;;F16M11/24;;F16M11/42,F16M11/24,,0,0,,,,PENDING
460,US,A1,US 2011/0072244 A1,060-691-961-915-755,2011-03-24,2011,US 88529910 A,2010-09-17,US 88529910 A;;US 24562609 P,2009-09-24,Credit-Based Streaming Multiprocessor Warp Scheduling,One embodiment of the present invention sets forth a technique for ensuring cache access instructions are scheduled for execution in a multi-threaded system to improve cache locality and system performance. A credit-based technique may be used to control instruction by instruction scheduling for each warp in a group so that the group of warps is processed uniformly. A credit is computed for each warp and the credit contributes to a weight for each warp. The weight is used to select instructions for the warps that are issued for execution.,LINDHOLM JOHN ERIK;;COON BRETT W;;WIERZBICKI JERED;;STOLL ROBERT J;;OBERMAN STUART F,LINDHOLM JOHN ERIK;;COON BRETT W;;WIERZBICKI JERED;;STOLL ROBERT J;;OBERMAN STUART F,NVIDIA CORPORATION (2010-08-25),https://lens.org/060-691-961-915-755,Patent Application,yes,9,30,2,2,0,G06F9/3851;;G06F9/3851;;G06F9/3836;;G06F9/3836;;G06F9/3885;;G06F9/3885;;G06F9/3887;;G06F9/3887;;G06F9/3889;;G06F9/3889,G06F9/38;;G06F9/312,712/214;;X712E09033;;X712E09045,5,4,015-719-967-016-62X;;110-761-783-794-489;;041-256-648-886-50X;;041-820-330-826-333,10.1109/micro.2007.30;;10.1109/lcn.2001.990776;;10.1109/90.958328;;10.1109/mm.2008.31,"Fung et al., ""Dynamic Warp Formation and Scheduling for Efficient GPU Control Flow"", Dec. 2007, Proceedings of the 40th Annual IEEE/ACM International Symposium on Microarchitecture, Pages 407-420;;Baatz et al., ""Adaptive Scatternet Support for Bluetooth using Sniff mode"", Nov. 2001, IEEE, Proceedings. LCN 2001. 26th Annual IEEE Conference on Local Computer Networks, Pages 112-120;;Bensaou et al., ""Credit Based Fair Queueing (CBFQ): A Simple Service-Scheduling Algorithm for Packet-Switched Networks"", Oct. 2001, IEEE/ACM Transactions on Networking, Vol. 9, No. 5, Pages 591-604;;Lindholm et. al., ""NVIDIA Testla: A Unified Graphics and Computing Architecture"", 2008, IEEE Micro, Vol. 28, Issue 2, pp. 39-55;;Kanter, ""Nvidia's GT200: Inside a Parallel Processor"", Sept. 2008, from www.realworldtech.com/gt200/9/, pp 1-3",ACTIVE
461,US,B2,US 7834881 B2,154-288-389-874-03X,2010-11-16,2010,US 55564906 A,2006-11-01,US 55564906 A;;US 88973004 A,2004-07-13,Operand collector architecture,"An apparatus and method for simulating a multi-ported memory using lower port count memories as banks. A collector units gather source operands from the banks as needed to process program instructions. The collector units also gather constants that are used as operands. When all of the source operands needed to process a program instruction have been gathered, a collector unit outputs the source operands to an execution unit while avoiding writeback conflicts to registers specified by the program instruction that may be accessed by other execution units.",NVIDIA CORP,LIU SAMUEL;;LINDHOLM JOHN ERIK;;SIU MING Y;;COON BRETT W;;OBERMAN STUART F,NVIDIA CORPORATION (2006-10-30),https://lens.org/154-288-389-874-03X,Granted Patent,yes,25,21,15,16,0,G06F9/3012;;G06F9/30123;;G06F9/30167;;G06F9/3824;;G06F9/3851;;G06F9/3885;;G06F12/02;;G06F12/06;;G06F9/30;;G06F9/3012;;G06F9/30167;;G06F9/30123;;G06F9/3885;;G06F9/3851;;G06F9/3824,G09G5/36;;G06F15/80;;G09G5/39,345/557;;345/531;;345/505,7,2,020-961-679-464-619;;112-381-177-738-637,10.1109/40.621209;;10.1145/165123.165148,"Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;Carl A. Waldspurger, et al. ""Register Relocation: Flexible contexts for Multithreading"", Proceedings of the Annual International Symposium on Computer Architecture, vol. Symp. 20, May 16, 1993 pp. 120-130.;;English Abstract of JP 62-242243 (provided as explanation of relevance).;;English Translation of JP 6-332721 (provided as explanation of relevance).;;English Translation of JP 11-184674 (provided as explanation of relevance).;;English Translation of JP 2003-241961 (provided as explanation of relevance).;;English Translation of JP 2003-256199 (provided as explanation of relevance).",ACTIVE
462,US,A1,US 2008/0048109 A1,022-672-697-182-115,2008-02-28,2008,US 84572307 A,2007-08-27,US 84572307 A;;US 84019806 P,2006-08-25,DATA-DEPENDENT SELECTION OF DISSOCIATION TYPE IN A MASS SPECTROMETER,"Methods and apparatus for data-dependent mass spectrometric MS/MS or MS n analysis are disclosed. The methods may include determination of the charge state of an ion species of interest, followed by automated selection of a dissociation type (e.g., CAD, ETD, or ETD followed by a non-dissociative charge reduction or collisional activation) based at least partially on the determined charge state. The ion species of interest is then dissociated in accordance with the selected dissociation type, and an MS/MS or MS n spectrum of the resultant product ions may be acquired.",SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,THERMO FINNIGAN LLC (2007-10-10),https://lens.org/022-672-697-182-115,Patent Application,yes,58,41,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/26,250/282;;250/281,0,0,,,,ACTIVE
463,US,B2,US 8168943 B2,028-303-744-793-889,2012-05-01,2012,US 84572307 A,2007-08-27,US 84572307 A;;US 84019806 P,2006-08-25,Data-dependent selection of dissociation type in a mass spectrometer,"Methods and apparatus for data-dependent mass spectrometric MS/MS or MS n analysis are disclosed. The methods may include determination of the charge state of an ion species of interest, followed by automated selection of a dissociation type (e.g., CAD, ETD, or ETD followed by a non-dissociative charge reduction or collisional activation) based at least partially on the determined charge state. The ion species of interest is then dissociated in accordance with the selected dissociation type, and an MS/MS or MS n spectrum of the resultant product ions may be acquired.",SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J;;THERMO FINNIGAN LLC,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,THERMO FINNIGAN LLC (2007-10-10),https://lens.org/028-303-744-793-889,Granted Patent,yes,59,17,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/00,250/282;;250/281,13,13,010-447-139-594-880;;071-937-348-115-14X;;051-076-446-686-723;;024-454-618-465-14X;;031-586-741-745-073;;080-114-445-909-16X;;002-945-511-159-271;;024-705-636-418-703;;057-281-986-867-77X;;037-036-735-725-967;;049-001-787-231-550;;039-624-579-153-840;;167-382-092-474-898,16713712;;10.1016/j.jasms.2006.02.003;;10.1002/mas.20048;;15706594;;17097932;;10.1016/j.bbapap.2006.09.016;;16030315;;pmc2291721;;12096141;;10.1074/mcp.t100003-mcp200;;10.1002/pmic.200401090;;15846843;;16112986;;10.1074/mcp.m500097-mcp200;;10.1002/pmic.200300415;;12833509;;10.1074/mcp.m300140-mcp200;;14752058;;10.1016/j.jasms.2003.11.003;;14998545;;10.1002/(sici)1097-0231(19970615)11:9<1015::aid-rcm958>3.0.co;2-h;;9204576;;10.1016/s1044-0305(97)00284-5;;9879360;;14766282;;10.1016/j.jasms.2003.10.006,"David L. Tabb, et al, ""Determination of Peptide and Protein Ion Charge States by Fourier Transformation of Isotope-Resolved Mass Spectra,"" Journal of the American Society for Mass Spectrometry, Elsevier Science Inc. (US), vol. 17 ( No. 7), pp. 903-915, (2006).;;Sharon J. Pitteri, et al., ""Recent Developments in the Ion/Ion Chemistry of High-Mass Multiply Charged Ions,"" Mass Spectrometry Reviews, John Wiley & Sons Inc. (US), vol. 24 ( No. 6), pp. 931-958, (2005).;;Christoph Stingl, et al., ""Application of Different Fragmentation Techniques for the Analysis of Phosphopeptides Using a Hybrid Linear Ion Trap-FTICR Mass Spectrometer,"" Biochimica et Biophysica Acta (BBA)-Proteins & Proteomics, Elsevier, vol. 176 ( No. 12), pp. 1842-1852, (2006).;;Cox et al., ""Multiple Reaction Monitoring as a Method for Identifying Protein Posttranslational Modifications,"" J. Biomolecular Tech., vol. 16 (No. 2), p. 83-90, (2005).;;Greenbaum et al., ""Chemical Approaches for Functionally Probing the Proteome,"" Molecular & Cellular Proteomics 1.1, p. 60-68, (2002).;;Huq et al., ""Mapping of phosphorylation sites of nuclear corepressor receptor interacting protein 140 by liquid chromatography-tandem mass spectroscopy,"" Proteomics, vol. 5, p. 2157-2166, (2005).;;Knudsen et al., ""Proteomic Analysis of Schistosoma mansoni Cercarial Secretions,"" Molecular & Cellular Proteomics 4.12, p. 1862-1875, (2005).;;Le Blanc et al., ""Unique scanning capabilities of a new hybrid linear ion trap mass spectrometer (Q Trap) used for high sensitivity proteomics applications,"" Proteomics, vol. 3, p. 859-869, (2003).;;Medzihradszky et al., ""O-Sulfonation of Serine and Threonine-Mass Spectrometric Detection and Characterization of a New Posttranslational Modification in Diverse Proteins Throughout the Eukaryotes,"" Molecular & Cellular Proteomics 3.5, p. 429-443, (2004).;;Sandra et al., ""The Q-Trap Mass Spectrometer, a Novel Tool in the Study of Protein Glycosylation,"" J Am Soc Mass Spectrom, vol. 15, p. 413-423, (2004).;;Shevchenko et al., ""Rapid 'de Novo' Peptide Sequencing by a Combination of Nanoelectrospray, Isotopic Labeling and a Quadrupole/Time-of-flight Mass Spectrometer,"" Rapid Comm in Mass Spectrom, vol. 11, p. 1015-1024, (1997).;;Zhang et al., ""A Universal Algorithm for Fast and Automated Charge State Deconvolution of Electrospray Mass-to-Charge Ratio Spectra,"" J Am Soc Mass Spectrom, vol. 9, p. 225-233, (1998).;;Wenner et al., ""Factors that Affect Ion Trap Data-Dependent MS/MS in Proteomics,"" J Am Soc Mass Spectrom, vol. 15, p. 150-157, (2004).",ACTIVE
464,WO,A2,WO 2008/025014 A2,005-240-068-523-022,2008-02-28,2008,US 2007/0076823 W,2007-08-24,US 84019806 P,2006-08-25,DATA-DEPENDENT SELECTION OF DISSOCIATION TYPE IN A MASS SPECTROMETER,"Methods and apparatus for data-dependent mass spectrometric MS/MS or MSn analysis are disclosed. The methods may include determination of the charge state of an ion species of interest, followed by automated selection of a dissociation type (e.g., CAD, ETD, or ETD followed by a non-dissociative charge reduction or collisional activation) based at least partially on the determined charge state. The ion species of interest is then dissociated in accordance with the selected dissociation type, and an MS/MS or MSn spectrum of the resultant product ions may be acquired.",THERMO FINNIGAN LLC;;SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,SCHWARTZ JAE C;;SYKA JOHN E P;;HUHMER ANDREAS F R;;COON JOSHUA J,,https://lens.org/005-240-068-523-022,Patent Application,yes,0,8,12,12,0,H01J49/0031;;H01J49/0045;;H01J49/0031;;H01J49/0045,H01J49/02,,0,0,,,,PENDING
465,US,S,US D0549015 S,051-224-571-251-034,2007-08-21,2007,US 25857806 F,2006-04-24,US 25857806 F,2006-04-24,Flat panel display stand,,BRETFORD MFG INC,PETRICK CHRISTOPHER;;COON ROBERT;;KRAPFL CLIFFORD;;FREESE JOHN B;;GUNDERSON BJORN;;DOAN JIMMY-QUANG VIET,BRETFORD MANUFACTURING INC (2006-04-10),https://lens.org/051-224-571-251-034,Design Right,no,0,11,1,1,0,,,0606;;D 6498,0,0,,,,EXPIRED
466,US,B2,US 8405665 B2,150-502-204-422-619,2013-03-26,2013,US 201213466043 A,2012-05-07,US 201213466043 A;;US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,Programmable graphics processor for multithreaded execution of programs,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P;;NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,,https://lens.org/150-502-204-422-619,Granted Patent,yes,2,6,3,21,0,G06T15/005;;G06T15/005,G06F13/14;;G06F15/16;;G06F15/80;;G06T1/20,345/505;;345/502;;345/506;;345/520,0,0,,,,EXPIRED
467,US,A1,US 2012/0026175 A1,004-731-095-696-682,2012-02-02,2012,US 201113270215 A,2011-10-10,US 201113270215 A;;US 93399307 A;;US 30580305 A;;US 86398506 P,2005-12-16,HIERARCHICAL PROCESSOR ARRAY,"Apparatuses and methods are presented for a hierarchical processor. The processor comprises, at a first level of hierarchy, a plurality of similarly structured first level components, wherein each of the plurality of similarly structured first level components includes at least one combined function module capable of performing multiple classes of graphics operations, each of the multiple classes of graphics operations being associated with a different stage of graphics processing. The processor comprises, at a second level of hierarchy, a plurality of similarly structured second level components positioned within each one of the plurality of similarly structured first level components, wherein each of the plurality of similarly structured second level components is capable of carrying out different operations from the multiple classes of graphics operations, wherein each first level component is adapted to distribute work to the plurality of similarly structured second level components positioned within the first level component.",LINDHOLM JOHN ERIK;;MONTRYM JOHN S;;KILGARIFF EMMETT M;;MOY SIMON S;;TREICHLER SEAN JEFFREY;;COON BRETT W;;KIRK DAVID;;DANSKIN JOHN;;NVIDIA CORP,LINDHOLM JOHN ERIK;;MONTRYM JOHN S;;KILGARIFF EMMETT M;;MOY SIMON S;;TREICHLER SEAN JEFFREY;;COON BRETT W;;KIRK DAVID;;DANSKIN JOHN,,https://lens.org/004-731-095-696-682,Patent Application,yes,3,1,4,5,0,G06F9/5044;;G06T1/20;;G06T15/005;;G06F9/3851;;G06F9/3887;;G06T1/20;;G06F9/5044;;G06T15/005;;G06F9/3851;;G06F9/3887,G06T1/00,345/501,0,0,,,,ACTIVE
468,US,B1,US 7711990 B1,027-969-959-766-137,2010-05-04,2010,US 30295205 A,2005-12-13,US 30295205 A,2005-12-13,Apparatus and method for debugging a graphics processing unit in response to a debug instruction,A system includes a graphics processing unit with a processor responsive to a debug instruction that initiates the storage of execution state information. A memory stores the execution state information. A central processing unit executes a debugging program to analyze the execution state information.,NVIDIA CORP,NICKOLLS JOHN R;;ALLEN ROGER L;;CABRAL BRIAN K;;COON BRETT W;;KELLER ROBERT C,NVIDIA CORPORATION (2006-03-16),https://lens.org/027-969-959-766-137,Granted Patent,yes,24,39,1,1,0,G06F11/3648;;G06F11/3648,G06F11/00,714/37,0,0,,,,ACTIVE
469,US,A1,US 2006/0245147 A1,042-309-805-740-890,2006-11-02,2006,US 41328806 A,2006-04-28,US 41328806 A;;US 67575705 P,2005-04-28,Pole mounting system,"A pole mounting system includes a pole having at least one channel, and a spike having a finger configured to be received in the channel of the pole. The finger is attached to a neck that is configured to extend out of the channel and connect to a connector. The connector may be configured in a number of different ways depending on the particular type of device to be suspended on the pole. For example, the connector may be configured to connect to different types of arms that may be used to hold a flat panel display, or may be configured to hold other things such as a table. The finger is elongate and configured to engage the interior of the channel when the weight of the flat panel display is placed on the spike. Optionally, a spring-loaded pin may be provided to temporarily hold the spike in place while the spike is screwed into place in the channel through the use of set screws. Wire management may be provided within the channel.",BRETFORD MFG INC,PETRICK CHRIS;;COON ROBERT;;KRAPFL CLIFFORD;;DOAN JIMMY-QUANG V;;FREESE JOHN B;;GUNDERSON BJORN,BRETFORD MANUFACTURING INC (2006-04-28),https://lens.org/042-309-805-740-890,Patent Application,yes,8,0,4,13,0,F16M11/16;;F16M11/2064;;F16M11/24;;F16M11/42;;F16M2200/068;;F16M11/2064;;F16M2200/068;;F16M11/16;;F16M11/24;;F16M11/42,H02B1/00,361/600,0,0,,,,INACTIVE
470,US,B2,US 9659339 B2,125-538-099-942-425,2017-05-23,2017,US 201313850175 A,2013-03-25,US 201313850175 A;;US 201213466043 A;;US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,Programmable graphics processor for multithreaded execution of programs,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,NVIDIA CORPORATION (2012-10-29),https://lens.org/125-538-099-942-425,Granted Patent,yes,10,4,5,21,0,G06T1/20;;G06T1/20;;G06F9/38;;G06F9/3851;;G06F9/3851,G06T1/20;;G06F9/38,,4,1,121-973-716-200-832,10.1109/40.918001,"Khailany et al, “Imagine: Media Processing With Streams”, Mar.-Apr. 2001, pp. 35-46, IEEE Micro.;;Owens et al, “Comparing Reyes and OpenGL on a Stream Architecture”, Proceedings of the 2002 Eurographics/SIGGRAPH Workshop on Graphics Hardware, 10 pages.;;Aaron Lanterman, “Multicore and GPU Programming for Video Games” Georgia Institute Technology, webpage: http://users.ece.gatech.edu/lanterma/mpg/ece4893—xbox360—vs—ps3—4up.pdf, 6 pages.;;Dave Baumann, “ATI Xenos: Xbox 360 Graphics Demystified”, Published Jun. 13, 2005, Consumer Graphics, last updated Mar. 21, 2007, 23 pages.",ACTIVE
471,US,A1,US 2023/0099927 A1,142-265-243-498-564,2023-03-30,2023,US 202117449644 A,2021-09-30,US 202117449644 A,2021-09-30,ANALYZING PRODUCTS AND DETERMINING ALTERNATIVES USING ARTIFICIAL INTELLIGENCE,"A product analyzing system and method may include receiving a scan of a product, retrieving a plurality of individual data of one or more individuals, determining how the product will affect the plurality of individual data of the one or more individuals and whether the product complies with the individual data of the one or more individuals, generating an alert corresponding to the product based on the determining, and sending the alert to a user device before purchase of the product.",KYNDRYL INC,WHITMAN TODD RUSSELL;;PERRINO JOHN P;;COON ROBERT EUGENE;;GAVIN ROBERT RYAN;;OSBURN GARY L,KYNDRYL INC (2021-11-18);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2021-09-30),https://lens.org/142-265-243-498-564,Patent Application,yes,10,0,1,1,0,G06Q30/0641;;G06Q30/0631;;G06Q30/0641;;G06Q30/0631,G06Q30/06,,1,0,,,"Chain Drug Review; ""Drug chains' smartphone apps get smarter""; 08/05/2013; Chain Drug Review 35.12: 34(1). Racher Press, Inc. (Year: 2013)",PENDING
472,US,B2,US 7703737 B2,146-480-191-815-966,2010-04-27,2010,US 41328806 A,2006-04-28,US 41328806 A;;US 67575705 P,2005-04-28,Pole mounting system,"A pole mounting system includes a pole having at least one channel, and a spike having a finger configured to be received in the channel of the pole. The finger is attached to a neck that is configured to extend out of the channel and connect to a connector. The connector may be configured in a number of different ways depending on the particular type of device to be suspended on the pole. For example, the connector may be configured to connect to different types of arms that may be used to hold a flat panel display, or may be configured to hold other things such as a table. The finger is elongate and configured to engage the interior of the channel when the weight of the flat panel display is placed on the spike. Optionally, a spring-loaded pin may be provided to temporarily hold the spike in place while the spike is screwed into place in the channel through the use of set screws. Wire management may be provided within the channel.",BRETFORD MFG INC,PETRICK CHRISTOPHER;;COON ROBERT;;KRAPFL CLIFFORD;;DOAN JIMMY-QUANG VIET;;FREESE JOHN B;;GUNDERSON BJORN,BRETFORD MANUFACTURING INC (2006-04-28),https://lens.org/146-480-191-815-966,Granted Patent,yes,12,5,4,13,0,F16M11/16;;F16M11/2064;;F16M11/24;;F16M11/42;;F16M2200/068;;F16M11/2064;;F16M2200/068;;F16M11/16;;F16M11/24;;F16M11/42,F16M11/00,248/407;;248/408;;248/146;;248/423,3,0,,,"International Search Report and Written Opinion, dated Nov. 3, 2006 from corresponding PCT patent application No. PCT/US2006/016552.;;Invitation To Pay Additional Fees with partial International Search dated Sep. 22, 2006 from corresponding PCT patent application No. PCT/CA2006/016552.;;International Preliminary Report on Patentability from corresponding PCT patent application No. PCT/US2006/016552.",INACTIVE
473,US,B2,US 8237705 B2,024-582-534-835-912,2012-08-07,2012,US 201113270215 A,2011-10-10,US 201113270215 A;;US 93399307 A;;US 30580305 A;;US 86398506 P,2005-12-16,Hierarchical processor array,"Apparatuses and methods are presented for a hierarchical processor. The processor comprises, at a first level of hierarchy, a plurality of similarly structured first level components, wherein each of the plurality of similarly structured first level components includes at least one combined function module capable of performing multiple classes of graphics operations, each of the multiple classes of graphics operations being associated with a different stage of graphics processing. The processor comprises, at a second level of hierarchy, a plurality of similarly structured second level components positioned within each one of the plurality of similarly structured first level components, wherein each of the plurality of similarly structured second level components is capable of carrying out different operations from the multiple classes of graphics operations, wherein each first level component is adapted to distribute work to the plurality of similarly structured second level components positioned within the first level component.",LINDHOLM JOHN ERIK;;MONTRYM JOHN S;;KILGARIFF EMMETT M;;MOY SIMON S;;TREICHLER SEAN JEFFREY;;COON BRETT W;;KIRK DAVID;;DANSKIN JOHN;;NVIDIA CORP,LINDHOLM JOHN ERIK;;MONTRYM JOHN S;;KILGARIFF EMMETT M;;MOY SIMON S;;TREICHLER SEAN JEFFREY;;COON BRETT W;;KIRK DAVID;;DANSKIN JOHN,,https://lens.org/024-582-534-835-912,Granted Patent,yes,13,0,4,5,0,G06F9/5044;;G06T1/20;;G06T15/005;;G06F9/3851;;G06F9/3887;;G06T1/20;;G06F9/5044;;G06T15/005;;G06F9/3851;;G06F9/3887,G06T1/20;;G06T5/00;;G06T15/10;;G06T15/50,345/419;;345/426;;345/427;;345/506,0,0,,,,ACTIVE
474,US,B2,US 8860737 B2,063-883-575-028-811,2014-10-14,2014,US 45863306 A,2006-07-19,US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,Programmable graphics processor for multithreaded execution of programs,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P;;NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,NVIDIA CORPORATION (2006-06-28),https://lens.org/063-883-575-028-811,Granted Patent,yes,52,1,2,21,0,G06T15/005;;G06T15/005;;G06F12/0811;;G06F12/0811;;G06F12/0815;;G06F12/0815;;G06F12/0875;;G06F12/0875;;G06T15/10;;G06T15/10,G06F15/16;;G06F12/08;;G06F15/80;;G06T1/20;;G06T15/00;;G06T15/10,345/505;;345/502;;345/506,11,4,020-961-679-464-619;;018-485-097-317-022;;002-062-256-975-845;;111-207-670-000-134,10.1109/40.621209;;10.1145/882262.882301;;10.1145/263326.263382;;10.1145/232973.232993,"Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;Sen, P., Cammarano, M., Hanrahan, P. ""Shadow Silhouette Maps"" Jul. 2003, ACM Tansactions on Graphics 22, 3, 521-526.;;English abstract of JP 2003-35589 with additional translated information.;;Translated Japanese Office Action dated Jun. 9, 2008 (provided as an explanation of relevance of Citation No. B1).;;Hinton, et al, ""The Microarchitecture of the Pentium 4 Processor,"" Intel Technology Journal Q1, 2001, pp. 1-12.;;Intel, IA-32 Intel Architecture Software Developer's Manual, vol. 1, pp. 11-23 through 11-25. 2004.;;Intel, IA-32 Intel Architecture Software Developer's Manual, vol. 2B, p. 4-72. 2004.;;Lo, et al. ""Converting Thread-Level Parallelism to Instruction-Level Parallelism via Simultaneous Multithreading,"" ACM Transactions on Computer Systems, vol. 15, No. 3, Aug. 1997, pp. 322-354.;;Tullsen, et al. ""Exploiting Choice: Instruction Fetch and Issue on an Implementable Simultaneous Multithreading Processor,"" Proceedings of the 23rd Annual International Symposium on Computer Architecture, May 1996, pp. 1-12.;;Office Action in U.S. Appl. No. 12/649,201, mailed Feb. 3, 2011.;;Office Action, U.S. Appl. No. 12/649,201 dated Jul. 13, 2011.",ACTIVE
475,US,B2,US 10016849 B2,000-330-604-071-080,2018-07-10,2018,US 201414161202 A,2014-01-22,DE 102011079679 A;;EP 2012063943 W,2011-07-22,Method for welding a weld-on element onto a counterpart,"A method for welding a weld-on element onto a component is proposed, comprising at least the step that, before the welding process, at least one of the parts being connected is wetted with a wetting agent over the full area and uniformly in layer thickness in a welding region.",FORD GLOBAL TECH LLC,ROTHEUT DIETMAR;;KUEHN GERALD;;COON THEODORE JOHN;;CARTER JASON;;BRUTTO MELISSA MARIE;;LAWRENCE DAVID J,FORD GLOBAL TECHNOLOGIES LLC (2014-01-20),https://lens.org/000-330-604-071-080,Granted Patent,yes,21,0,9,9,0,B23K31/02;;B23K35/36;;B23K35/36;;B23K35/36;;B23K9/201;;B23K9/201;;B23K9/201;;B23K9/235;;B23K9/235;;B23K9/235,B23K35/02;;B23K9/20;;B23K9/235;;B23K35/36,,0,0,,,,ACTIVE
476,US,A1,US 2014/0131319 A1,103-280-482-558-385,2014-05-15,2014,US 201414161202 A,2014-01-22,DE 102011079679 A;;EP 2012063943 W,2011-07-22,Method For Welding A Weld-On Element Onto A Counterpart,"A method for welding a weld-on element onto a component is proposed, comprising at least the step that, before the welding process, at least one of the parts being connected is wetted with a wetting agent over the full area and uniformly in layer thickness in a welding region.",FORD GLOBAL TECH LLC,ROTHEUT DIETMAR;;KUEHN GERALD;;COON THEODORE JOHN;;CARTER JASON;;BRUTTO MELISSA MARIE;;LAWRENCE DAVID J,FORD GLOBAL TECHNOLOGIES LLC (2014-01-20),https://lens.org/103-280-482-558-385,Patent Application,yes,21,1,9,9,0,B23K31/02;;B23K35/36;;B23K35/36;;B23K35/36;;B23K9/201;;B23K9/201;;B23K9/201;;B23K9/235;;B23K9/235;;B23K9/235,B23K35/36;;B23K9/235,219/72;;296/191,0,0,,,,ACTIVE
477,US,A1,US 2014/0285500 A1,016-305-419-464-778,2014-09-25,2014,US 201313850175 A,2013-03-25,US 201313850175 A;;US 201213466043 A;;US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,PROGRAMMABLE GRAPHICS PROCESSOR FOR MULTITHREADED EXECUTION OF PROGRAMS,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,,https://lens.org/016-305-419-464-778,Patent Application,yes,2,18,5,21,0,G06T1/20;;G06T1/20;;G06F9/38;;G06F9/3851;;G06F9/3851,G06T1/20,345/506,0,0,,,,EXPIRED
478,US,B1,US 8174531 B1,174-822-218-505-750,2012-05-08,2012,US 64920109 A,2009-12-29,US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,Programmable graphics processor for multithreaded execution of programs,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P;;NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,NVIDIA CORPORATION (2012-10-29),https://lens.org/174-822-218-505-750,Granted Patent,yes,53,15,3,21,0,G06T15/005;;G06T15/005,G06F15/16;;G06F13/14;;G06F15/80;;G06T1/20,345/505;;345/502;;345/506;;345/520,9,4,002-062-256-975-845;;111-207-670-000-134;;020-961-679-464-619;;018-485-097-317-022,10.1145/263326.263382;;10.1145/232973.232993;;10.1109/40.621209;;10.1145/882262.882301,"Intel, IA-32 Intel Architecture Software Developer's Manual, vol. 1, pp. 11-23 through 11-25. 2004.;;Intel, IA-32 Intel Architecture Software Developer's Manual, vol. 2B, p. 4-72. 2004.;;Lo, et al. ""Converting Thread-Level Parallelism to Instruction-Level Parallelism via Simultaneous Multithreading,"" ACM Transactions on Computer Systems, vol. 15, No. 3, Aug. 1997, pp. 322-354.;;Tullsen, et al. ""Exploiting Choice: Instruction Fetch and Issue on an Implementable Simultaneous Multithreading Processor,"" Proceedings of the 23rd Annual International Symposium on Computer Architecture, May 1996, pp. 1-12.;;Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;English abstract of JP 2003-35589 with additional translated information.;;Translated copy of Japanese Office Action dated Jun. 9, 2008 (provided as an explanation of relevance of Citation No. B1).;;Hinton, et al. ""The Microarchitecture of the Pentium 4 Processor,"" Intel Technology Journal Q1, 2001, pp. 1-12.;;Sen et al., ""Shadow Silhouette Maps"" Jul. 2003, ACM transactions on Graphics 22, 3, pp. 521-526.",EXPIRED
479,US,A1,US 2006/0243869 A1,199-000-160-389-930,2006-11-02,2006,US 41482906 A,2006-04-28,US 41482906 A;;US 67575705 P,2005-04-28,K-base for a pole mounting system,"A K-base for a pole mounting system includes a central hub formed as a pentagon with legs extending from four of the five sides of the pentagon. The ends of the legs may splay to form clefts configured to receive a flat outer perimeter of the central hub so that the legs may be bolted to the central hub. The ends of the legs and the fifth unoccupied side of the pentagon may be formed to approximate a disk. In the central region of the central hub, on the top surface, an indentation may be formed to approximate an outer perimeter of a pole configured to be attached to the K-base. On the bottom surface, the central region may contain a depression sized to receive a washer and optionally a weight. Bolts extending through the washer and optionally through the weight may be used to connect the K-base to a pole. The washer may be formed to distribute stress from the bolts on the central hub.",BRETFORD MFG INC,PETRICK CHRIS;;COON ROBERT;;KRAPFL CLIFFORD;;DOAN JIMMY-QUANG VIET;;FREESE JOHN B;;GUNDERSON BJORN,BRETFORD MANUFACTURING INC (2006-04-26),https://lens.org/199-000-160-389-930,Patent Application,yes,21,6,2,13,0,A47B81/064;;F16M11/16;;F16M11/28;;F16M11/42;;F16M11/04;;F16M11/046;;F16M11/105;;F16M11/2064;;F16M2200/028;;F16M2200/08;;A47B81/064;;F16M11/28;;F16M11/42;;F16M11/16;;F16M11/046;;F16M11/2064;;F16M2200/028;;F16M11/04;;F16M2200/08;;F16M11/105,A47B91/00,248/188.7,0,0,,,,INACTIVE
480,US,B2,US 8077174 B2,175-330-793-526-22X,2011-12-13,2011,US 93399307 A,2007-11-01,US 93399307 A;;US 30580305 A;;US 86398506 P,2005-12-16,Hierarchical processor array,"Apparatuses and methods are presented for a hierarchical processor. The processor comprises, at a first level of hierarchy, a plurality of similarly structured first level components, wherein each of the plurality of similarly structured first level components includes at least one combined function module capable of performing multiple classes of graphics operations, each of the multiple classes of graphics operations being associated with a different stage of graphics processing. The processor comprises, at a second level of hierarchy, a plurality of similarly structured second level components positioned within each one of the plurality of similarly structured first level components, wherein each of the plurality of similarly structured second level components is capable of carrying out different operations from the multiple classes of graphics operations, wherein each first level component is adapted to distribute work to the plurality of similarly structured second level components positioned within the first level component.",LINDHOLM JOHN ERIK;;MONTRYM JOHN S;;KILGARIFF EMMETT M;;MOY SIMON S;;TREICHLER SEAN JEFFREY;;COON BRETT W;;KIRK DAVID;;DANSKIN JOHN;;NVIDIA CORP,LINDHOLM JOHN ERIK;;MONTRYM JOHN S;;KILGARIFF EMMETT M;;MOY SIMON S;;TREICHLER SEAN JEFFREY;;COON BRETT W;;KIRK DAVID;;DANSKIN JOHN,NVIDIA CORPORATION (2008-01-23),https://lens.org/175-330-793-526-22X,Granted Patent,yes,5,4,4,5,0,G06F9/5044;;G06T1/20;;G06T15/005;;G06F9/3851;;G06F9/3887;;G06T1/20;;G06F9/5044;;G06T15/005;;G06F9/3851;;G06F9/3887,G06T1/20;;G06T5/00;;G06T15/10;;G06T15/50,345/419;;345/426;;345/427;;345/506,0,0,,,,ACTIVE
481,US,A1,US 2012/0218267 A1,064-729-263-303-053,2012-08-30,2012,US 201213466043 A,2012-05-07,US 201213466043 A;;US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,PROGRAMMABLE GRAPHICS PROCESSOR FOR MULTITHREADED EXECUTION OF PROGRAMS,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,,https://lens.org/064-729-263-303-053,Patent Application,yes,2,0,3,21,0,G06T15/005;;G06T15/005,G06T1/00;;G06T17/20;;G06T1/20,345/423;;345/501;;345/506,0,0,,,,EXPIRED
482,US,B2,US 7703728 B2,121-955-437-340-833,2010-04-27,2010,US 41482906 A,2006-04-28,US 41482906 A;;US 67575705 P,2005-04-28,K-base for a pole mounting system,"A K-base for a pole mounting system includes a central hub formed as a pentagon with legs extending from four of the five sides of the pentagon. The ends of the legs may splay to form clefts configured to receive a flat outer perimeter of the central hub so that the legs may be bolted to the central hub. The ends of the legs and the fifth unoccupied side of the pentagon may be formed to approximate a disk. In the central region of the central hub, on the top surface, an indentation may be formed to approximate an outer perimeter of a pole configured to be attached to the K-base. On the bottom surface, the central region may contain a depression sized to receive a washer and optionally a weight. Bolts extending through the washer and optionally through the weight may be used to connect the K-base to a pole. The washer may be formed to distribute stress from the bolts on the central hub.",BRETFORD MFG INC,PETRICK CHRISTOPHER;;COON ROBERT;;KRAPFL CLIFFORD;;DOAN JIMMY-QUANG VIET;;FREESE JOHN B;;GUNDERSON BJORN,BRETFORD MANUFACTURING INC (2006-04-26),https://lens.org/121-955-437-340-833,Granted Patent,yes,21,8,2,13,0,A47B81/064;;F16M11/16;;F16M11/28;;F16M11/42;;F16M11/04;;F16M11/046;;F16M11/105;;F16M11/2064;;F16M2200/028;;F16M2200/08;;A47B81/064;;F16M11/28;;F16M11/42;;F16M11/16;;F16M11/046;;F16M11/2064;;F16M2200/028;;F16M11/04;;F16M2200/08;;F16M11/105,F16M11/20,248/188.7;;248/188.1,0,0,,,,INACTIVE
483,EP,A1,EP 1408304 A1,090-419-432-696-476,2004-04-14,2004,EP 03078065 A,2003-09-26,US 26651502 A,2002-10-08,Control System and Method for off-board application processing,"An improved application processing system (18A, 18B, 18C, 18D, 18E) which utilizes both on-board components and off-board components connected via wireless data transfer devices (62, 64). On-board the vehicle is a user interface, or a microphone (22), which receives data in the form of human speech from the user (20), and components for digitization (56) and feature extraction (58) of the data with the data then being sent to an off-board processing system (66), which may include a speech recognition system (72) and a voice-enabled program application (74). After the data has been processed by the off-board system (66), the data is retransmitted to the on-board system, where the processed data (76) is converted from text to speech (78), reconstructed as speech (79), or displayed. The display or speech is then distributed to the drive or occupants by a radio (80), handheld device, or a display unit (84).",DELPHI TECH INC,MOODY PETER A;;COON BRADLEY S;;KADY MARK A;;WILHELM ANDREW L;;JOHN VINOD G,,https://lens.org/090-419-432-696-476,Patent Application,yes,4,2,2,2,0,G01C21/36;;G08G1/096811;;G08G1/096816;;G08G1/096872;;G08G1/0969;;G10L15/30;;G08G1/096811;;G08G1/096872;;G08G1/096816;;G10L15/30;;G08G1/0969;;G01C21/36,G01C21/36;;G08G1/0968;;G08G1/0969;;G10L15/28,,0,0,,,,DISCONTINUED
484,US,A1,US 2004/0068370 A1,182-783-799-617-873,2004-04-08,2004,US 26651502 A,2002-10-08,US 26651502 A,2002-10-08,Use of distributed speech recognition (DSR) for off-board application processing,"
    An improved application processing system ( 18 A, 18 B, 18 C, 18 D, 18 E) which utilizes both on-board components and off-board components connected via wireless data transfer devices ( 62, 64 ). On-board the vehicle is a user interface, or a microphone ( 22 ), which receives data in the form of human speech from the user ( 20 ), and components for digitization ( 56 ) and feature extraction ( 58 ) of the data with the data then being sent to an off-board processing system ( 66 ), which may include a speech recognition system ( 72 ) and a voice-enabled program application ( 74 ). After the data has been processed by the off-board system ( 66 ), the data is retransmitted to the on-board system, where the processed data ( 76 ) is converted from text to speech ( 78 ), reconstructed as speech ( 79 ), or displayed. The display or speech is then distributed to the drive or occupants by a radio ( 80 ), handheld device, or a display unit ( 84 ). 
",MOODY PETER A.;;COON BRADLEY S.;;KADY MARK A.;;WILHELM ANDREW L.;;JOHN VINOD G.,MOODY PETER A;;COON BRADLEY S;;KADY MARK A;;WILHELM ANDREW L;;JOHN VINOD G,DELPHI TECHNOLOGIES INC (2002-09-25),https://lens.org/182-783-799-617-873,Patent Application,yes,0,8,2,2,0,G08G1/096811;;G08G1/096811;;G01C21/36;;G01C21/36;;G08G1/096816;;G08G1/096816;;G08G1/096872;;G08G1/096872;;G08G1/0969;;G08G1/0969;;G10L15/30;;G10L15/30,G01C21/36;;G08G1/0968;;G08G1/0969;;G10L15/28,701/213;;701/1,0,0,,,,DISCONTINUED
485,US,A1,US 2017/0256022 A1,003-407-747-123-273,2017-09-07,2017,US 201715603294 A,2017-05-23,US 201715603294 A;;US 201313850175 A;;US 201213466043 A;;US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,PROGRAMMABLE GRAPHICS PROCESSOR FOR MULTITHREADED EXECUTION OF PROGRAMS,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,NVIDIA CORPORATION (2012-10-29),https://lens.org/003-407-747-123-273,Patent Application,yes,0,0,5,21,0,G06T1/20;;G06T1/20;;G06F9/38;;G06F9/3851;;G06F9/3851,G06T1/20;;G06F9/38,,0,0,,,,EXPIRED
486,US,B2,US 10217184 B2,136-164-751-727-466,2019-02-26,2019,US 201715603294 A,2017-05-23,US 201715603294 A;;US 201313850175 A;;US 201213466043 A;;US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,Programmable graphics processor for multithreaded execution of programs,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,NVIDIA CORPORATION (2012-10-29),https://lens.org/136-164-751-727-466,Granted Patent,yes,10,1,5,21,0,G06T1/20;;G06T1/20;;G06F9/38;;G06F9/3851;;G06F9/3851,G06T1/20;;G06F9/38,,3,1,121-973-716-200-832,10.1109/40.918001,"Khailany et al, “Imagine: Media Processing With Streams”, Mar.-Apr. 2001, pp. 35-46, IEEE Micro.;;Owens et al, “Comparing Reyes and OpenGL on a Stream Architecture”, Proceedings of the 2002 Eurographics/SIGGRAPH Workshop on Graphics Hardware, 10 pages.;;Dave Baumann, “ATI Xenos: Xbox 360 Graphics Demystified”, Published Jun. 13, 2005, Consumer Graphics, last updated Mar. 21, 2007, 23 pages.",EXPIRED
487,US,A1,US 2008/0143730 A1,039-149-908-743-324,2008-06-19,2008,US 93399307 A,2007-11-01,US 93399307 A;;US 30580305 A;;US 86398506 P,2005-12-16,HIERARCHICAL PROCESSOR ARRAY,"Apparatuses and methods are presented for a hierarchical processor. The processor comprises, at a first level of hierarchy, a plurality of similarly structured first level components, wherein each of the plurality of similarly structured first level components includes at least one combined function module capable of performing multiple classes of graphics operations, each of the multiple classes of graphics operations being associated with a different stage of graphics processing. The processor comprises, at a second level of hierarchy, a plurality of similarly structured second level components positioned within each one of the plurality of similarly structured first level components, wherein each of the plurality of similarly structured second level components is capable of carrying out different operations from the multiple classes of graphics operations, wherein each first level component is adapted to distribute work to the plurality of similarly structured second level components positioned within the first level component.",NVIDIA CORP,LINDHOLM JOHN ERIK;;MONTRYM JOHN S;;KILGARIFF EMMETT M;;MOY SIMON S;;TREICHLER SEAN JEFFREY;;COON BRETT W;;KIRK DAVID;;DANSKIN JOHN,NVIDIA CORPORATION (2008-01-23),https://lens.org/039-149-908-743-324,Patent Application,yes,5,34,4,5,0,G06F9/5044;;G06T1/20;;G06T15/005;;G06F9/3851;;G06F9/3887;;G06T1/20;;G06F9/5044;;G06T15/005;;G06F9/3851;;G06F9/3887,G06F15/00,345/501,0,0,,,,ACTIVE
488,US,B1,US 7600155 B1,087-553-845-451-759,2009-10-06,2009,US 30295005 A,2005-12-13,US 30295005 A,2005-12-13,Apparatus and method for monitoring and debugging a graphics processing unit,A system has a graphics processing unit with a processor to monitor selected criteria and circuitry to initiate the storage of execution state information when the selected criteria reaches a specified state. A memory stores execution state information. A central processing unit executes a debugging program to analyze the execution state information.,NVIDIA CORP,NICKOLLS JOHN R;;ALLEN ROGER L;;CABRAL BRIAN K;;COON BRETT W;;KELLER ROBERT C,NVIDIA CORPORATION (2006-03-16),https://lens.org/087-553-845-451-759,Granted Patent,yes,23,50,1,1,0,G06F11/36;;G06F11/36,G06F11/00,714/38,0,0,,,,ACTIVE
489,US,A9,US 2016/0300319 A9,058-039-905-090-34X,2016-10-13,2016,US 201313850175 A,2013-03-25,US 201313850175 A;;US 201213466043 A;;US 64920109 A;;US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,PROGRAMMABLE GRAPHICS PROCESSOR FOR MULTITHREADED EXECUTION OF PROGRAMS,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",NVIDIA CORP,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,NVIDIA CORPORATION (2012-10-29),https://lens.org/058-039-905-090-34X,Amended Application,yes,0,0,5,21,0,G06T1/20;;G06T1/20;;G06F9/38;;G06F9/3851;;G06F9/3851,G06T1/20,,0,0,,,,EXPIRED
490,US,A1,US 2008/0024506 A1,145-381-409-711-01X,2008-01-31,2008,US 45863306 A,2006-07-19,US 45863306 A;;US 69671403 A;;US 73643703 A;;US 29261405 A,2003-10-29,A Programmable Graphics Processor For Multithreaded Execution of Programs,"A processing unit includes multiple execution pipelines, each of which is coupled to a first input section for receiving input data for pixel processing and a second input section for receiving input data for vertex processing and to a first output section for storing processed pixel data and a second output section for storing processed vertex data. The processed vertex data is rasterized and scan converted into pixel data that is used as the input data for pixel processing. The processed pixel data is output to a raster analyzer.",LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,LINDHOLM JOHN ERIK;;COON BRETT W;;OBERMAN STUART F;;SIU MING Y;;GERLACH MATTHEW P,NVIDIA CORPORATION (2006-06-28),https://lens.org/145-381-409-711-01X,Patent Application,yes,50,7,2,21,0,G06T15/005;;G06T15/005;;G06F12/0811;;G06F12/0811;;G06F12/0815;;G06F12/0815;;G06F12/0875;;G06F12/0875;;G06T15/10;;G06T15/10,G06T1/20,345/506,0,0,,,,EXPIRED
491,US,S,US D0549493 S,183-122-318-766-113,2007-08-28,2007,US 25857606 F,2006-04-24,US 25857606 F,2006-04-24,Display support pole,,BRETFORD MFG INC,PETRICK CHRISTOPHER;;COON ROBERT;;KRAPFL CLIFFORD;;FREESE JOHN B;;GUNDERSON BJORN;;DOAN JIMMY-QUANG VIET,BRETTFORD MANUFACTURING INC (2006-04-11),https://lens.org/183-122-318-766-113,Design Right,no,0,4,1,1,0,,,0606;;D 6495,0,0,,,,EXPIRED
492,US,A1,US 2012/0110586 A1,029-065-194-574-918,2012-05-03,2012,US 201113247819 A,2011-09-28,US 201113247819 A;;US 38791110 P,2010-09-29,THREAD GROUP SCHEDULER FOR COMPUTING ON A PARALLEL THREAD PROCESSOR,"A parallel thread processor executes thread groups belonging to multiple cooperative thread arrays (CTAs). At each cycle of the parallel thread processor, an instruction scheduler selects a thread group to be issued for execution during a subsequent cycle. The instruction scheduler selects a thread group to issue for execution by (i) identifying a pool of available thread groups, (ii) identifying a CTA that has the greatest seniority value, and (iii) selecting the thread group that has the greatest credit value from within the CTA with the greatest seniority value.",COON BRETT W;;NICKOLLS JOHN R;;LINDHOLM JOHN ERIK;;STOLL ROBERT J;;WANG NICHOLAS;;CHOQUETTE JACK HILAIRE;;NICKOLLS KATHLEEN ELLIOTT,COON BRETT W;;NICKOLLS JOHN R;;LINDHOLM JOHN ERIK;;STOLL ROBERT J;;WANG NICHOLAS;;CHOQUETTE JACK HILAIRE;;NICKOLLS KATHLEEN ELLIOTT,NVIDIA CORPORATION (2011-09-28),https://lens.org/029-065-194-574-918,Patent Application,yes,4,34,2,2,0,G06F9/4881;;G06F2209/483;;G06F9/4881;;G06F2209/483,G06F9/46,718/102,3,3,041-820-330-826-333;;007-944-769-744-459;;000-174-813-227-430,10.1109/mm.2008.31;;10.1145/1454115.1454152;;10.1145/1669112.1669119,"Erik Lindholm, John Nickolls, Stuart Oberman, John Montrym, NVIDIA TESLA: A UNIFIED GRAPHICS AND COMPUTING ARCHITECTURE, MARCH-APRIL 2008, IEEE Micro, pg 39-55;;Bingsheng He, Wenbin Fang, Qiong Luo, Naga K. Govindaraju, Tuyong Wang, Mars: A MapReduce Framework on Graphics Processors, PACT'08, October 25-29, 2008, Toronto, Ontario, Canada, pg 260-269;;George L. Yuan, Ali Bakhoda, Tor M. Aamodt, Complexity Effective Memory Access Scheduling for Many-Core Accelerator Architectures, MICRO'09, December 12-16, 2009, New York, NY, USA, pg 34-44",ACTIVE
493,CN,A,CN 115551401 A,158-600-414-961-928,2022-12-30,2022,CN 202280001767 A,2022-04-19,US 202163176853 P;;US 2022/0025369 W,2021-04-19,Visual linear and discrete dimming for ophthalmoscopes and otoscopes and other medical examination or diagnostic instruments,"Medical examination or diagnostic instruments and methods of operating such instruments are disclosed. The method may include coupling an instrument head to a handle to form a medical examination or diagnostic instrument; the characteristics of the handle are detected through the instrument head; and based at least in part on detecting the characteristic of the handle, determining a handle type associated with the handle by the instrument head, or detecting the characteristic of the instrument head by the handle, and determining an instrument head type associated with the instrument head based at least in part on detecting the characteristic of the instrument head. In some embodiments, the emission of light may be controlled to be approximately linear with respect to a user input signal as perceived by a user.",WELCH ALLYN INC,BABSON DAVID M;;COON III KENNETH V;;PERKINS DAVID G;;KNOOP JOHN P;;LEDWITH JEFFREY S,,https://lens.org/158-600-414-961-928,Patent Application,no,0,0,4,4,0,A61B1/227;;A61B1/00105;;A61B1/00006;;A61B1/00124;;A61B1/00032;;A61B1/00108;;A61B1/00105;;A61B1/0684;;A61B1/227;;A61B3/0008;;A61B3/1208,A61B1/00;;A61B1/227,,0,0,,,,PENDING
494,US,B2,US 8176265 B2,058-520-509-098-885,2012-05-08,2012,US 201113165638 A,2011-06-21,US 201113165638 A;;US 55454206 A,2006-10-30,Shared single-access memory with management of multiple parallel requests,"A memory is used by concurrent threads in a multithreaded processor. Any addressable storage location is accessible by any of the concurrent threads, but only one location at a time is accessible. The memory is coupled to parallel processing engines that generate a group of parallel memory access requests, each specifying a target address that might be the same or different for different requests. Serialization logic selects one of the target addresses and determines which of the requests specify the selected target address. All such requests are allowed to proceed in parallel, while other requests are deferred. Deferred requests may be regenerated and processed through the serialization logic so that a group of requests can be satisfied by accessing each different target address in the group exactly once.",COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C;;NVIDIA CORP,COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C,,https://lens.org/058-520-509-098-885,Granted Patent,yes,31,14,4,4,0,G06F12/084;;Y02D10/00;;G06F12/084;;Y02D10/00,G06F12/00,711/150;;711/151;;711/152;;711/154;;711/158;;711/163;;711/167;;711/168,10,1,020-961-679-464-619,10.1109/40.621209,"U.S. Appl. No. 11/554,546, Office Action dated Aug. 5, 2009, 12 pages.;;U.S. Appl. No. 11/554,563, Office Action dated Sep. 14, 2009, 11 pages.;;U.S. Appl. No. 11/554,546, Office Action dated Jan. 25, 2010, 12 pages.;;U.S. Appl. No. 11/554,546, Office Action mailed May 26, 2010, 13 pages.;;Cell Architecture Explained Version 2, Introduction and Index, downloaded at http://www.blachford.info/computer/Cell/CellO v2.html on Feb. 7, 2007.;;Cell Microprocessor www.wikipedia.org, downloaded at http://en.wikipedia.org/w/index.php?title=Cell-microprocessor&oldid=57781754, dated Jun. 9, 2006.;;Eggers et al. ""Simultaneous multithreading: A platform for next-generation processors"" IEEE Micro, Sep./Oct. 1997 (vol. 17, No. 5) pp. 12-19.;;Gschwind et al. ""Synergistic Processing in Cell's Multicore Architecture"", IEEE Computer Society, vol. 26, Issue 2 (Mar. 2006) pp. 10-24.;;Marr et al., ""Hyper-Threading Technology Architecture and Microarchitecture"", Intel Technology Journal, Q1, 2002.;;U.S. Appl. No. 11/554,563, Office Action dated Dec. 22, 2008, 17 pages.",ACTIVE
495,US,A1,US 2012/0221808 A1,081-350-107-646-53X,2012-08-30,2012,US 201213466057 A,2012-05-07,US 201213466057 A;;US 201113165638 A;;US 55454206 A,2006-10-30,SHARED SINGLE-ACCESS MEMORY WITH MANAGEMENT OF MULTIPLE PARALLEL REQUESTS,"A memory is used by concurrent threads in a multithreaded processor. Any addressable storage location is accessible by any of the concurrent threads, but only one location at a time is accessible. The memory is coupled to parallel processing engines that generate a group of parallel memory access requests, each specifying a target address that might be the same or different for different requests. Serialization logic selects one of the target addresses and determines which of the requests specify the selected target address. All such requests are allowed to proceed in parallel, while other requests are deferred. Deferred requests may be regenerated and processed through the serialization logic so that a group of requests can be satisfied by accessing each different target address in the group exactly once.",COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C;;NVIDIA CORP,COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C,,https://lens.org/081-350-107-646-53X,Patent Application,yes,1,12,4,4,0,G06F12/084;;Y02D10/00;;G06F12/084;;Y02D10/00,G06F12/00,711/154;;X711E12001,0,0,,,,ACTIVE
496,US,B2,US 8645638 B2,030-775-906-234-308,2014-02-04,2014,US 201213466057 A,2012-05-07,US 201213466057 A;;US 201113165638 A;;US 55454206 A,2006-10-30,Shared single-access memory with management of multiple parallel requests,"A memory is used by concurrent threads in a multithreaded processor. Any addressable storage location is accessible by any of the concurrent threads, but only one location at a time is accessible. The memory is coupled to parallel processing engines that generate a group of parallel memory access requests, each specifying a target address that might be the same or different for different requests. Serialization logic selects one of the target addresses and determines which of the requests specify the selected target address. All such requests are allowed to proceed in parallel, while other requests are deferred. Deferred requests may be regenerated and processed through the serialization logic so that a group of requests can be satisfied by accessing each different target address in the group exactly once.",COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C;;NVIDIA CORP,COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C,,https://lens.org/030-775-906-234-308,Granted Patent,yes,1,0,4,4,0,G06F12/084;;Y02D10/00;;G06F12/084;;Y02D10/00,G06F13/00;;G06F12/00,711/150;;711/151;;711/152;;711/154;;711/158;;711/163;;711/167;;711/168,0,0,,,,ACTIVE
497,US,B1,US 8108625 B1,116-659-403-450-308,2012-01-31,2012,US 55454606 A,2006-10-30,US 55454606 A,2006-10-30,Shared memory with parallel access and access conflict resolution mechanism,"Concurrent threads in a multithreaded processor share access to a memory, with any location in the shared memory being accessible by any thread. In one embodiment, the shared memory has multiple independently-addressable memory banks, and one location per bank can be accessed in parallel. Parallel processing engines executing the threads generate a group of parallel memory access requests. Address conflict logic determines whether the requests can be satisfied in parallel (e.g., based on bank access constraints) and serializes the requests to the extent needed to avoid conflicts. In some embodiments, data read from one address in the shared memory can be broadcast to multiple processing engines.",COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C;;NVIDIA CORP,COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C,NVIDIA CORPORATION (2006-10-24);;NVVIDIA CORPORATION (2007-09-04),https://lens.org/116-659-403-450-308,Granted Patent,yes,29,59,1,1,0,G06F13/1663;;G06F13/1663,G06F12/00,711/150;;711/127;;711/157;;711/151;;711/152;;711/154;;711/158;;711/163;;711/167;;711/168,14,1,020-961-679-464-619,10.1109/40.621209,"Office Action dated Jun. 3, 2009, U.S. Appl. No. 11/554,552, filed Oct. 30, 2006, 14 pages.;;Office Action dated Dec. 8, 2008, U.S. Appl. No. 11/554,552, filed Oct. 30, 2006, 15 pages.;;U.S. Appl. No. 11/554,563, Office Action dated Dec. 22, 2008, 17 pages.;;U.S. Appl. No. 11/554,563, Office Action dated Sep. 14, 2009, 11 pages.;;U.S. Appl. No. 11/554,542, Office Action dated Dec. 8, 2009, 9 pages.;;U.S. Appl. No. 11/554,542, Office Action dated Jul. 17, 2009, 8 pages.;;U.S. Appl. No. 11/554,552, Office Action dated Oct. 14, 2009, 15 pages.;;U.S. Appl. No. 11/554,552, Office Action dated Mar. 23, 2010, 16 pages.;;Cell Architecture Explained Version 2, Introduction and Index, downloaded at http://www.blachford.info/computer/Cell/CellO v2.html on Feb. 7, 2007.;;Cell Microprocessor www.wikipedia.org, downloaded at http://en.wikipedia.org/w/index.php?title=Cell-microprocessor&oldid=57781754, dated Jun. 9, 2006.;;Eggers et al. ""Simultaneous multithreading: A platform for next-generation processors"" IEEE Micro, Sep./Oct. 1997 (vol. 17, No. 5) pp. 12-19.;;Gschwind et al. ""Synergistic Processing in Cell's Multicore Architecture"", IEEE Computer Society, vol. 26, Issue 2 (Mar. 2006) pp. 10-24.;;Marr et al., ""Hyper-Threading Technology Architecture and Microarchitecture"", Intel Technology Journal, Q1, 2002.;;U.S. Appl. No. 11/554,542, Office Action dated Jun. 3, 2010, 10 pages.",ACTIVE
498,US,A1,US 2011/0252204 A1,045-026-282-223-42X,2011-10-13,2011,US 201113165638 A,2011-06-21,US 201113165638 A;;US 55454206 A,2006-10-30,SHARED SINGLE ACCESS MEMORY WITH MANAGEMENT OF MULTIPLE PARALLEL REQUESTS,"A memory is used by concurrent threads in a multithreaded processor. Any addressable storage location is accessible by any of the concurrent threads, but only one location at a time is accessible. The memory is coupled to parallel processing engines that generate a group of parallel memory access requests, each specifying a target address that might be the same or different for different requests. Serialization logic selects one of the target addresses and determines which of the requests specify the selected target address. All such requests are allowed to proceed in parallel, while other requests are deferred. Deferred requests may be regenerated and processed through the serialization logic so that a group of requests can be satisfied by accessing each different target address in the group exactly once.",NVIDIA CORP,COON BRETT W;;SIU MING Y;;XU WEIZHONG;;OBERMAN STUART F;;NICKOLLS JOHN R;;MILLS PETER C,,https://lens.org/045-026-282-223-42X,Patent Application,yes,0,36,4,4,0,G06F12/084;;Y02D10/00;;G06F12/084;;Y02D10/00,G06F12/08,711/150;;X711E12016,0,0,,,,ACTIVE
499,US,B1,US 6408654 B1,064-383-776-014-040,2002-06-25,2002,US 32914499 A,1999-06-09,US 32914499 A,1999-06-09,Filament forming apparatus and a cooling apparatus for and method of inducing a uniform air flow between a filament forming area and the cooling apparatus,"
    A filament forming apparatus and cooling apparatus for and method of inducing a uniform air flow between a filament forming area beneath a bushing and the cooling apparatus are disclosed. The cooling apparatus includes an air housing extending beneath the bushing. The air housing has a top wall and side walls defining an air chamber therebetween. 
",OWENS CORNING FIBERGLAS TECH,BOESSNECK DOUGLAS SCOTT;;GAO GUANG;;WOLF DAVID HERMAN;;SNEDDEN ANDREW LAWRENCE;;PRESCOTT PATRICK JOHN;;SRINIVASAN SESHADRI;;COON JEFFREY,OWENS-CORNING FIBERGLAS TECHNOLOGY INC (1999-07-21),https://lens.org/064-383-776-014-040,Granted Patent,yes,28,16,3,3,0,C03B37/0213;;Y02P40/57;;C03B37/0213;;Y02P40/57,C03B37/02,65/434;;65/481;;65/498;;65/512,0,0,,,,EXPIRED
500,WO,A1,WO 2005/021451 A1,143-619-394-613-031,2005-03-10,2005,US 2004/0028103 W,2004-08-27,US 49854103 P;;US 52325203 P,2003-08-28,PROCESS FOR MAKING LOW-OH GLASS ARTICLES AND LOW-OH OPTICAL RESONATOR,Disclosed are optical resonators having low OH content in at least the near-surface region and a process for making low OH glass article by chlorine treatment of consolidated glass of the article. Cl2 gas was used to remove OH from depth as deep as 350 m from the surface of the consolidated glass. The process can be used for treating flame-polished preformed optical resonator disks. A new process involving hot pressing or thermal reflowing for making planar optical resonator disks without the use of flame polishing is also disclosed.,CORNING INC;;STEWART RONALD L;;UKRAINCZYK LJERKA;;COON JEFFREY;;LASALA JOHN E;;QUINN CANDACE J;;SABIA ROBERT;;TINGLEY JAMES E;;WHALEN JOSEPH M,STEWART RONALD L;;UKRAINCZYK LJERKA;;COON JEFFREY;;LASALA JOHN E;;QUINN CANDACE J;;SABIA ROBERT;;TINGLEY JAMES E;;WHALEN JOSEPH M,,https://lens.org/143-619-394-613-031,Patent Application,yes,5,0,2,2,0,C03B19/12;;C03B19/1453;;C03B32/00;;C03B32/005;;C03B2201/075;;C03B2201/23;;C03B2201/31;;C03C3/06;;C03C23/008;;C03C2201/23;;C03C2201/31;;C03C2203/50;;G02B6/29311;;G02B6/29343;;G02B6/29343;;C03B2201/075;;C03C3/06;;G02B6/29311;;C03C2201/31;;C03B2201/31;;C03B32/00;;C03B19/1453;;C03B2201/23;;C03B32/005;;C03C2201/23;;C03C2203/50;;C03C23/008;;C03B19/12,C03B19/12;;C03B19/14;;C03B32/00;;C03C3/06;;C03C23/00;;G02B6/34,,4,4,025-645-398-117-933;;043-674-928-955-99X;;080-366-328-336-973;;035-271-160-760-178,18040293;;10.1364/ol.26.000256;;10.1016/s0022-3093(94)00525-7;;10.1021/j100636a008;;19865436;;10.1364/ol.21.000453,"ILCHENKO V S ET AL: ""MICROTORUS: A HIGH-FINESSE MICROCAVITY WITH WHISPERING-GALLERY MODES"", OPTICS LETTERS, OPTICAL SOCIETY OF AMERICA, WASHINGTON, US, vol. 26, no. 5, 1 March 2001 (2001-03-01), pages 256 - 258, XP001019548, ISSN: 0146-9592;;KLEIN K-F ET AL: ""Diffusion behaviour of fluorine in silica glass"", JOURNAL OF NON-CRYSTALLINE SOLIDS, NORTH-HOLLAND PUBLISHING COMPANY, AMSTERDAM, NL, vol. 181, no. 3, February 1995 (1995-02-01), pages 266 - 273, XP004173446, ISSN: 0022-3093;;HAIR M L ET AL: ""CHLORINATION OF SILICA SURFACES"", JOURNAL OF PHYSICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 77, no. 17, 1973, pages 2070 - 2075, XP001183738, ISSN: 0022-3654;;GORODETSKY M L ET AL: ""ULTIMATE Q OF OPTICAL MICROSPHERE RESONATORS"", OPTICS LETTERS, OPTICAL SOCIETY OF AMERICA, WASHINGTON, US, vol. 21, no. 7, 1 April 1996 (1996-04-01), pages 453 - 455, XP000559762, ISSN: 0146-9592",PENDING
501,DE,C2,DE 3713223 C2,152-345-624-534-533,1991-10-10,1991,DE 3713223 A,1987-04-18,US 88904286 A,1986-07-25,DE 3713223 C2,,"AMERICAN STANDARD INC., NEW YORK, N.Y., US","ANDERSEN, GARRY EUGENE, LA CROSSE, WIS., US;;QUINN, JAMES ROBERT, COON VALLEY, WIS., US;;LINNERT, PETER JOHN, LA CROSSE, WIS., US",,https://lens.org/152-345-624-534-533,Granted Patent,no,0,2,10,10,0,F04B39/1086;;F04B39/1086,F04B39/00;;F04B39/10,,0,0,,,,EXPIRED
502,US,A1,US 2005/0044893 A1,070-694-635-770-34X,2005-03-03,2005,US 92661904 A,2004-08-25,US 92661904 A;;US 52325203 P;;US 49854103 P,2003-08-28,Process for making low-OH glass articles and low-OH optical resonator,Disclosed are optical resonators having low OH content in at least the near-surface region and a process for making low OH glass article by chlorine treatment of consolidated glass of the article. Cl 2 gas was used to remove OH from depth as deep as 350 μm from the surface of the consolidated glass. The process can be used for treating flame-polished preformed optical resonator disks. A new process involving hot pressing or thermal reflowing for making planar optical resonator disks without the use of flame polishing is also disclosed.,COON JEFFREY;;LASALA JOHN E.;;QUINN CANDACE J.;;SABIA ROBERT;;STEWART RONALD L.;;TINGLEY JAMES E.;;UKRAINCZYK LJERKA;;WHALEN JOSEPH M.,COON JEFFREY;;LASALA JOHN E;;QUINN CANDACE J;;SABIA ROBERT;;STEWART RONALD L;;TINGLEY JAMES E;;UKRAINCZYK LJERKA;;WHALEN JOSEPH M,CORNING INCORPORATED (2004-08-05),https://lens.org/070-694-635-770-34X,Patent Application,yes,4,20,2,2,0,C03B19/12;;C03B19/1453;;C03B32/00;;C03B32/005;;C03B2201/075;;C03B2201/23;;C03B2201/31;;C03C3/06;;C03C23/008;;C03C2201/23;;C03C2201/31;;C03C2203/50;;G02B6/29311;;G02B6/29343;;G02B6/29343;;C03B2201/075;;C03C3/06;;G02B6/29311;;C03C2201/31;;C03B2201/31;;C03B32/00;;C03B19/1453;;C03B2201/23;;C03B32/005;;C03C2201/23;;C03C2203/50;;C03C23/008;;C03B19/12,C03B19/12;;C03B19/14;;C03B32/00;;C03C3/06;;C03C23/00;;G02B6/34,65/32.1;;65/32.2,0,0,,,,DISCONTINUED
503,US,B1,US 6776636 B1,065-029-497-851-721,2004-08-17,2004,US 70716800 A,2000-11-06,US 70716800 A;;US 16357599 P,1999-11-05,PBR with TEC bypass and wet disconnect/connect feature,"
    A wet connect/disconnect arrangement is disclosed for a downhole system that allows installation of various tools and/or a string and subsequent electrical connection to the downhole system in a wet environment. Several embodiments are disclosed, all of which produce a clean, reliable connection. Exemplary embodiments include an upper section being mechanically and electrically joined to an intermediate section with electrical connectors for being joined at a lower section. The intermediate section further has auxiliary connectors that may be protected by a cover and remain unmated in a first connected application being therefore available for future use. The upper section may be removed leaving the intermediate section in place whereby the unmated connectors are available to rejoin a new upper section. Different types of connectors are also disclosed. 
",BAKER HUGHES INC,CAMERON DAVID;;MILLER RUSSELL A;;SMITH ROBERT C;;MYRON WALTER;;BAUGH JOHN L;;MODY RUSTOM K;;COON ROBERT J;;CARMODY MICHAEL A,BAKER HUGHES INCORPORATED (2001-05-03),https://lens.org/065-029-497-851-721,Granted Patent,yes,17,79,2,25,0,E21B17/028;;H01R13/523;;E21B17/028;;H01R13/523,E21B17/02;;H01R13/523,439191;;439426,0,0,,,,EXPIRED
504,US,A1,US 2017/0109489 A1,192-821-698-460-050,2017-04-20,2017,US 201615390177 A,2016-12-23,US 201615390177 A;;US 201314079388 A,2013-11-13,MEDICAL INSTRUMENT WITH REMAINING VISITS INDICATOR,A medical instrument includes a remaining visits indicator. The remaining visits indicator visually identifies a number of patient visits that can be completed before recharging the medical instrument.,WELCH ALLYN INC,LANE JOHN A;;MEYERSON CRAIG M;;FALLAT DAVID M;;NGUYEN VUONG B;;ST PIERRE SHAWN C;;COON KENNETH V;;GARRANT MICHAEL D,,https://lens.org/192-821-698-460-050,Patent Application,yes,2,2,4,4,0,A61B5/02055;;A61B5/02055;;A61B5/021;;A61B5/022;;A61B5/024;;A61B5/14552;;A61B5/742;;A61B2560/0204;;A61B2560/0204;;A61B2560/0437;;A61B2560/0437;;G16H40/40;;G16H40/40;;G16H40/20;;G16H40/20,G06F19/00;;A61B5/00;;A61B5/0205;;A61B5/1455,,0,0,,,,ACTIVE
505,US,A1,US 2003/0211768 A1,062-763-911-012-833,2003-11-13,2003,US 40452903 A,2003-04-01,US 40452903 A;;US 70716800 A;;US 16357599 P,1999-11-05,Prb with tec bypass and wet disconnect/connect feature,"
   A wet connect/disconnect arrangement is disclosed for a downhole system that allows installation of various tools and/or a string and subsequent electrical connection to the downhole system in a wet environment. Several embodiments are disclosed, all of which produce a clean, reliable connection. 
",CAMERON DAVID;;MILLER RUSSELL A.;;SMITH ROBERT C.;;MYRON WALTER;;BAUGH JOHN L.;;MODY RUSTOM K.;;COON ROBERT J.;;CARMODY MICHAEL A.,CAMERON DAVID;;MILLER RUSSELL A;;SMITH ROBERT C;;MYRON WALTER;;BAUGH JOHN L;;MODY RUSTOM K;;COON ROBERT J;;CARMODY MICHAEL A,,https://lens.org/062-763-911-012-833,Patent Application,yes,14,45,2,25,0,E21B17/028;;H01R13/523;;E21B17/028;;H01R13/523,E21B17/02;;H01R13/523,439/191,0,0,,,,DISCONTINUED
506,US,B2,US 9560976 B2,019-844-398-183-417,2017-02-07,2017,US 201314079388 A,2013-11-13,US 201314079388 A,2013-11-13,Medical instrument with remaining visits indicator,A medical instrument includes a remaining visits indicator. The remaining visits indicator visually identifies a number of patient visits that can be completed before recharging the medical instrument.,WELCH ALLYN INC,LANE JOHN A;;MEYERSON CRAIG M;;FALLAT DAVID M;;NGUYEN VUONG B;;ST PIERRE SHAWN C;;COON III KENNETH V;;GARRANT MICHAEL D,WELCH ALLYN INC (2013-10-24),https://lens.org/019-844-398-183-417,Granted Patent,yes,15,3,4,4,0,A61B5/02055;;A61B5/02055;;A61B5/021;;A61B5/022;;A61B5/024;;A61B5/14552;;A61B5/742;;A61B2560/0204;;A61B2560/0204;;A61B2560/0437;;A61B2560/0437;;G16H40/40;;G16H40/40;;G16H40/20;;G16H40/20,A61B5/02;;A61B5/00;;A61B5/0205;;A61B5/021;;A61B5/1455;;G06F19/00,,2,0,,,"Cardiac Science, Instruction Manual for Cardiac Science 5300 and Cardiac Science 5350 Vital Signs Monitor (70-00582-01 A), date accessed May 14, 2013, 182 pgs.;;Welch Allyn, Vital Signs Monitor 300 Series Directions for Use, date accessed May 14, 2013, 108 pgs.",ACTIVE
507,US,B2,US 9990468 B2,120-792-249-432-351,2018-06-05,2018,US 201615390177 A,2016-12-23,US 201615390177 A;;US 201314079388 A,2013-11-13,Medical instrument with remaining visits indicator,A medical instrument includes a remaining visits indicator. The remaining visits indicator visually identifies a number of patient visits that can be completed before recharging the medical instrument.,WELCH ALLYN INC,LANE JOHN A;;MEYERSON CRAIG M;;FALLAT DAVID M;;NGUYEN VUONG B;;ST PIERRE SHAWN C;;COON III KENNETH V;;GARRANT MICHAEL D,,https://lens.org/120-792-249-432-351,Granted Patent,yes,13,0,4,4,0,A61B5/02055;;A61B5/02055;;A61B5/021;;A61B5/022;;A61B5/024;;A61B5/14552;;A61B5/742;;A61B2560/0204;;A61B2560/0204;;A61B2560/0437;;A61B2560/0437;;G16H40/40;;G16H40/40;;G16H40/20;;G16H40/20,A61B5/02;;A61B5/00;;A61B5/0205;;A61B5/022;;A61B5/024;;A61B5/1455;;G06F19/00,,2,0,,,"Cardiac Science, Instruction Manual for Cardiac Science 5300 and Cardiac Science 5350 Vital Signs Monitor (70-00582-01 A), date accessed May 14, 2013, 182 pgs.;;Welch Allyn, Vital Signs Monitor 300 Series Directions for Use, date accessed May 14, 2013, 108 pgs.",ACTIVE
508,US,A1,US 2015/0133742 A1,094-070-610-466-611,2015-05-14,2015,US 201314079388 A,2013-11-13,US 201314079388 A,2013-11-13,MEDICAL INSTRUMENT WITH REMAINING VISITS INDICATOR,A medical instrument includes a remaining visits indicator. The remaining visits indicator visually identifies a number of patient visits that can be completed before recharging the medical instrument.,WELCH ALLYN INC,LANE JOHN A;;MEYERSON CRAIG M;;FALLAT DAVID M;;NGUYEN VUONG B;;ST PIERRE SHAWN C;;COON III KENNETH V;;GARRANT MICHAEL D,WELCH ALLYN INC (2013-10-24),https://lens.org/094-070-610-466-611,Patent Application,yes,4,6,4,4,0,A61B5/02055;;A61B5/02055;;A61B5/021;;A61B5/022;;A61B5/024;;A61B5/14552;;A61B5/742;;A61B2560/0204;;A61B2560/0204;;A61B2560/0437;;A61B2560/0437;;G16H40/40;;G16H40/40;;G16H40/20;;G16H40/20,A61B5/0205;;A61B5/00;;A61B5/021;;A61B5/1455,600/301,0,0,,,,ACTIVE
509,EP,B1,EP 2483772 B1,117-538-226-031-836,2015-11-11,2015,EP 10821124 A,2010-09-28,US 56983109 A;;US 2010/0050592 W,2009-09-29,TRAP HANDLER ARCHITECTURE FOR A PARALLEL PROCESSING UNIT,,NVIDIA CORP,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING;;THORN TOMMY;;WANG NICHOLAS,,https://lens.org/117-538-226-031-836,Granted Patent,yes,7,0,8,8,0,G06F9/327;;G06F9/327;;G06F9/3851;;G06F9/3851;;G06F9/3861;;G06F9/3861,G06F9/38;;G06F9/32,,0,0,,,,ACTIVE
510,EP,A4,EP 2483772 A4,010-696-364-779-491,2014-04-02,2014,EP 10821124 A,2010-09-28,US 56983109 A;;US 2010/0050592 W,2009-09-29,TRAP HANDLER ARCHITECTURE FOR A PARALLEL PROCESSING UNIT,,NVIDIA CORP,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING;;THORN TOMMY;;WANG NICHOLAS,,https://lens.org/010-696-364-779-491,Search Report,no,3,0,8,8,0,G06F9/327;;G06F9/327;;G06F9/3851;;G06F9/3851;;G06F9/3861;;G06F9/3861,G06F9/38;;G06F9/32,,1,0,,,See also references of WO 2011041330A1,ACTIVE
511,CN,A,CN 102648449 A,062-446-632-932-320,2012-08-22,2012,CN 201080054127 A,2010-09-28,US 2010/0050592 W;;US 56983109 A,2009-09-29,Trap handler architecture for a parallel processing unit,A trap handler architecture is incorporated into a parallel processing subsystem such as a GPU. The trap handler architecture minimizes design complexity and verification efforts for concurrently executing threads by imposing a property that all thread groups associated with a streaming multi-processor are either all executing within their respective code segments or are all executing within the trap handler code segment.,NVIDIA CORP,SHEBANOW MICHAEL C;;JACK CHOQUETTE;;COON BRETT W;;HEINRICH STEVEN J;;ARAVIND KALAIAH;;NICKOLLS JOHN R;;DANIEL SALINAS;;MING SIU;;TOMMY THORN;;NICHOLAS WANG,,https://lens.org/062-446-632-932-320,Patent Application,no,6,13,8,8,0,G06F9/327;;G06F9/327;;G06F9/3851;;G06F9/3851;;G06F9/3861;;G06F9/3861,G06F7/38,,0,0,,,,ACTIVE
512,EP,A1,EP 2483772 A1,098-410-529-236-898,2012-08-08,2012,EP 10821124 A,2010-09-28,US 56983109 A;;US 2010/0050592 W,2009-09-29,TRAP HANDLER ARCHITECTURE FOR A PARALLEL PROCESSING UNIT,,NVIDIA CORP,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING;;THORN TOMMY;;WANG NICHOLAS,,https://lens.org/098-410-529-236-898,Patent Application,yes,0,0,8,8,0,G06F9/327;;G06F9/327;;G06F9/3851;;G06F9/3851;;G06F9/3861;;G06F9/3861,G06F9/38;;G06F9/32,,0,0,,,,ACTIVE
513,WO,A1,WO 2011/041330 A1,005-344-799-334-416,2011-04-07,2011,US 2010/0050592 W,2010-09-28,US 56983109 A,2009-09-29,TRAP HANDLER ARCHITECTURE FOR A PARALLEL PROCESSING UNIT,A trap handler architecture is incorporated into a parallel processing subsystem such as a GPU. The trap handler architecture minimizes design complexity and verification efforts for concurrently executing threads by imposing a property that all thread groups associated with a streaming multi-processor are either all executing within their respective code segments or are all executing within the trap handler code segment.,NVIDIA CORP;;SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING;;THORN TOMMY;;WANG NICHOLAS,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING;;THORN TOMMY;;WANG NICHOLAS,,https://lens.org/005-344-799-334-416,Patent Application,yes,5,2,8,8,0,G06F9/327;;G06F9/327;;G06F9/3851;;G06F9/3851;;G06F9/3861;;G06F9/3861,G06F7/38,,1,0,,,See also references of EP 2483772A4,PENDING
514,US,B2,US 8522000 B2,124-579-342-028-049,2013-08-27,2013,US 56983109 A,2009-09-29,US 56983109 A,2009-09-29,Trap handler architecture for a parallel processing unit,A trap handler architecture is incorporated into a parallel processing subsystem such as a GPU. The trap handler architecture minimizes design complexity and verification efforts for concurrently executing threads by imposing a property that all thread groups associated with a streaming multi-processor are either all executing within their respective code segments or are all executing within the trap handler code segment.,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING Y;;THORN TOMMY;;WANG NICHOLAS;;NVIDIA CORP,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING Y;;THORN TOMMY;;WANG NICHOLAS,NVIDIA CORPORATION (2009-09-29),https://lens.org/124-579-342-028-049,Granted Patent,yes,9,10,8,8,0,G06F9/327;;G06F9/327;;G06F9/3851;;G06F9/3851;;G06F9/3861;;G06F9/3861,G06F9/00,712/244;;712/225,2,1,020-961-679-464-619,10.1109/40.621209,"Eggers, et al. ""Simultaneous Multithreading: A Platform for Next-Generation Processors,"" IEEE Micro, vol. 17, No. 5, pp. 12-19, Sep./Oct. 1997.;;International Search Report, PCT Appl. No. PCT/US 10/50592, mailed Dec. 16, 2010.",ACTIVE
515,US,A1,US 2011/0078427 A1,061-833-258-582-933,2011-03-31,2011,US 56983109 A,2009-09-29,US 56983109 A,2009-09-29,TRAP HANDLER ARCHITECTURE FOR A PARALLEL PROCESSING UNIT,A trap handler architecture is incorporated into a parallel processing subsystem such as a GPU. The trap handler architecture minimizes design complexity and verification efforts for concurrently executing threads by imposing a property that all thread groups associated with a streaming multi-processor are either all executing within their respective code segments or are all executing within the trap handler code segment.,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING Y;;THORN TOMMY;;WANG NICHOLAS,SHEBANOW MICHAEL C;;CHOQUETTE JACK;;COON BRETT W;;HEINRICH STEVEN J;;KALAIAH ARAVIND;;NICKOLLS JOHN R;;SALINAS DANIEL;;SIU MING Y;;THORN TOMMY;;WANG NICHOLAS,NVIDIA CORPORATION (2009-09-29),https://lens.org/061-833-258-582-933,Patent Application,yes,6,69,8,8,0,G06F9/327;;G06F9/327;;G06F9/3851;;G06F9/3851;;G06F9/3861;;G06F9/3861,G06F9/38,712/244;;X712E09045,0,0,,,,ACTIVE
516,US,A1,US 2011/0078381 A1,022-729-923-837-437,2011-03-31,2011,US 89047610 A,2010-09-24,US 89047610 A;;US 24604409 P,2009-09-25,Cache Operations and Policies For A Multi-Threaded Client,A method for managing a parallel cache hierarchy in a processing unit. The method including receiving an instruction that includes a cache operations modifier that identifies a level of the parallel cache hierarchy in which to cache data associated with the instruction; and implementing a cache replacement policy based on the cache operations modifier.,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN,NVIDIA CORPORATION (2010-09-23),https://lens.org/022-729-923-837-437,Patent Application,yes,9,41,2,2,0,G06F12/0842;;G06F12/0842;;G06F12/0897;;G06F12/0897,G06F12/08;;G06F12/00,711/122;;711/133;;X711E12001;;X711E12024;;X711E12022,0,0,,,,ACTIVE
517,US,B2,US 9952977 B2,045-512-915-025-620,2018-04-24,2018,US 89047610 A,2010-09-24,US 89047610 A;;US 24604409 P,2009-09-25,Cache operations and policies for a multi-threaded client,A method for managing a parallel cache hierarchy in a processing unit. The method including receiving an instruction that includes a cache operations modifier that identifies a level of the parallel cache hierarchy in which to cache data associated with the instruction; and implementing a cache replacement policy based on the cache operations modifier.,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN;;NVIDIA CORP,HEINRICH STEVEN JAMES;;MINKIN ALEXANDER L;;COON BRETT W;;SELVANESAN RAJESHWARAN;;GLANVILLE ROBERT STEVEN;;MCCARVER CHARLES;;RAJENDRAN ANJANA;;CARLTON STEWART GLENN;;NICKOLLS JOHN R;;FAHS BRIAN,NVIDIA CORPORATION (2010-09-23),https://lens.org/045-512-915-025-620,Granted Patent,yes,9,17,2,2,0,G06F12/0842;;G06F12/0842;;G06F12/0897;;G06F12/0897,G06F12/00;;G06F12/0842;;G06F12/0897,,0,0,,,,ACTIVE
518,GB,B,GB 2505813 B,098-386-261-781-299,2017-06-28,2017,GB 201321874 A,2012-05-15,IB 2012052413 W;;US 201113150420 A,2011-06-01,Integrated key server,,IBM,PETER KENNETH SZWED;;RICHARD GUSEFSKI;;EDWARD CHENCINSKI;;GARRY JOSEPH SULLIVAN;;JAMES RICHARD COON;;KLAUS WERNER;;THOMAS BRIAN MATHIAS;;MICHAEL JOSEPH JORDAN;;JOHN DAYKA;;MARCO KRAEMER;;STEVEN GARDNER GLASSEN,,https://lens.org/098-386-261-781-299,Granted Patent,no,4,0,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,H04L9/08,,0,0,,,,ACTIVE
519,DE,T5,DE 112012002307 T5,055-447-464-600-837,2014-02-20,2014,DE 112012002307 T,2012-05-15,US 201113150420 A;;IB 2012052413 W,2011-06-01,Integrierter Schlüssel-Server,"Es wird ein Computerprogrammprodukt für das integrierte Bereitstellen eines Schlüssels bereitgestellt. Das Computerprogrammprodukt beinhaltet ein durch einen Verarbeitungsschaltkreis lesbares physisches Speichermedium, auf dem Befehle zur Ausführung durch den Verarbeitungsschaltkreis zur Durchführung eines Verfahrens gespeichert sind. Das Verfahren beinhaltet das Verwenden einer Smartcard aus zwei oder mehreren Smartcards mit einem Support-Element aus zwei oder mehreren Support-Elementen zum Erstellen eines Verschlüsselungsschlüssels und das Speichern des Verschlüsselungsschlüssels in einer verschlüsselten Datei, die nur durch die Smartcard und das Support-Element, die zum Erstellen des Verschlüsselungsschlüssels verwendet wurden, entschlüsselt werden kann.",IBM,SZWED PETER KENNETH;;GUSEFSKI RICHARD;;CHENCINSKI EDWARD;;COON JAMES RICHARD;;MATHIAS THOMAS BRIAN;;JORDAN MICHAEL JOSEPH;;SULLIVAN GARRY JOSEPH;;GLASSEN STEVEN GARDNER;;WERNER KLAUS;;DAYKA JOHN;;KRAEMER MARCO,,https://lens.org/055-447-464-600-837,Patent Application,no,0,0,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,H04L9/32,,0,0,,,,ACTIVE
520,WO,A1,WO 2012/164423 A1,090-986-730-059-599,2012-12-06,2012,IB 2012052413 W,2012-05-15,US 201113150420 A,2011-06-01,INTEGRATED KEY SERVER,A computer program product for integrated key serving is provided. The computer program product includes a tangible storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method. The method includes using a smart card of two or more smart cards with a support element of two or more support elements to create an encryption key and storing the encryption key in an encrypted file that can only be decrypted by the smart card and the support element used to create the encryption key.,IBM;;IBM UK;;IBM CHINA INVEST CO LTD;;SZWED PETER KENNETH;;GUSEFSKI RICHARD;;CHENCINSKI EDWARD;;SULLIVAN GARRY JOSEPH;;COON JAMES RICHARD;;WERNER KLAUS;;MATHIAS THOMAS BRIAN;;JORDAN MICHAEL JOSEPH;;DAYKA JOHN;;KRAEMER MARCO;;GLASSEN STEVEN GARDNER,SZWED PETER KENNETH;;GUSEFSKI RICHARD;;CHENCINSKI EDWARD;;SULLIVAN GARRY JOSEPH;;COON JAMES RICHARD;;WERNER KLAUS;;MATHIAS THOMAS BRIAN;;JORDAN MICHAEL JOSEPH;;DAYKA JOHN;;KRAEMER MARCO;;GLASSEN STEVEN GARDNER,,https://lens.org/090-986-730-059-599,Patent Application,yes,4,0,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,H04L9/32,,0,0,,,,PENDING
521,GB,A,GB 2505813 A,114-439-793-747-58X,2014-03-12,2014,GB 201321874 A,2012-05-15,IB 2012052413 W;;US 201113150420 A,2011-06-01,Integrated key server,A computer program product for integrated key serving is provided. The computer program product includes a tangible storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method. The method includes using a smart card of two or more smart cards with a support element of two or more support elements to create an encryption key and storing the encryption key in an encrypted file that can only be decrypted by the smart card and the support element used to create the encryption key.,IBM,SZWED PETER KENNETH;;GUSEFSKI RICHARD;;CHENCINSKI EDWARD;;SULLIVAN GARRY JOSEPH;;COON JAMES RICHARD;;WERNER KLAUS;;MATHIAS THOMAS BRIAN;;JORDAN MICHAEL JOSEPH;;DAYKA JOHN;;KRAEMER MARCO;;GLASSEN STEVEN GARDNER,,https://lens.org/114-439-793-747-58X,Patent Application,no,4,0,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,H04L9/08,,0,0,,,,ACTIVE
522,CN,A,CN 103563292 A,181-109-601-786-997,2014-02-05,2014,CN 201280024241 A,2012-05-15,IB 2012052413 W;;US 201113150420 A,2011-06-01,Integrated key server,A computer program product for integrated key serving is provided. The computer program product includes a tangible storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method. The method includes using a smart card of two or more smart cards with a support element of two or more support elements to create an encryption key and storing the encryption key in an encrypted file that can only be decrypted by the smart card and the support element used to create the encryption key.,IBM,SZWED PETER KENNETH;;GUSEFSKI RICHARD;;CHENCINSKI EDWARD;;SULLIVAN GARRY JOSEPH;;COON JAMES RICHARD;;WERNER KLAUS;;MATHIAS THOMAS BRIAN;;JORDAN MICHAEL JOSEPH;;DAYKA JOHN;;KRAEMER MARCO;;GLASSEN STEVEN GARDNER,,https://lens.org/181-109-601-786-997,Patent Application,no,5,0,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,H04L9/32,,0,0,,,,INACTIVE
523,DE,B4,DE 112012002307 B4,145-862-821-735-539,2023-01-12,2023,DE 112012002307 T,2012-05-15,US 201113150420 A;;IB 2012052413 W,2011-06-01,Integrierter Schlüssel-Server,"Verfahren zum integrierten Bereitstellen eines Schlüssels, wobei das Verfahren aufweist:Verwenden einer Smartcard aus zwei oder mehreren Smartcards mit einem Support-Element aus zwei oder mehreren Support-Elementen zum Erstellen eines Verschlüsselungsschlüssels; undSpeichern des Verschlüsselungsschlüssels und eine Seriennummer des Support-Elements in einer verschlüsselten Datei, wobei das Speichern in einer Weise ausgeführt wird, dass der Verschlüsselungsschlüssel nur durch einen privaten Schlüssel der Smartcard und des Support-Elements, die zum Erstellen des durch die Seriennummer identifizierten Verschlüsselungsschlüssels verwendet wurden, entschlüsselt werden kann.",IBM,SZWED PETER KENNETH;;GUSEFSKI RICHARD;;CHENCINSKI EDWARD;;SULLIVAN GARRY JOSEPH;;COON JAMES RICHARD;;WERNER KLAUS;;MATHIAS THOMAS BRIAN;;JORDAN MICHAEL JOSEPH;;DAYKA JOHN;;KRAEMER MARCO;;GLASSEN STEVEN GARDNER,,https://lens.org/145-862-821-735-539,Granted Patent,no,1,0,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,H04L9/32;;G06F21/34;;G06F21/62;;H04L9/08,,0,0,,,,ACTIVE
524,WO,A1,WO 2019/143668 A1,024-382-260-114-555,2019-07-25,2019,US 2019/0013775 W,2019-01-16,US 201916248482 A;;US 201862617929 P,2018-01-16,PHYSICAL ASSESSMENT DEVICE,"In a physical assessment device, an instrument head is provided for attachment to a plurality of instrument handles having different power profiles. The instrument head contains an illumination assembly including at least one LED as well as a drive circuit for detecting a power profile of an attached instrument handle and converting variable voltages received from the attached instrument handle to a constant current for powering the at least one LED based on the power profile. Accordingly, the instrument head enables use with a plurality of instrument handles, including those originally configured for use only with incandescent light sources.",WELCH ALLYN INC,LIA RAYMOND;;SLAWSON STEVEN;;VIVENZIO ROBERT;;STROM JOHN;;MCMAHON MICHAEL;;PERKINS DAVID;;COON KENNETH;;DELUCIA PAUL;;WEITZEL RICHARD;;WAWRO THADDEUS;;MARTIN SCOTT;;GUO LEI;;KNIERIEM ALAN;;BABSON DAVID,,https://lens.org/024-382-260-114-555,Patent Application,yes,12,6,2,9,0,A61B1/00105;;A61B1/0669;;A61B1/0684;;A61B1/227,A61B1/00;;A61B1/06;;A61B1/227;;A61B1/267,,0,0,,,,PENDING
525,US,A1,US 2012/0308011 A1,113-583-512-815-84X,2012-12-06,2012,US 201113150420 A,2011-06-01,US 201113150420 A,2011-06-01,INTEGRATED KEY SERVER,A computer program product for integrated key serving is provided. The computer program product includes a tangible storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method. The method includes using a smart card of two or more smart cards with a support element of two or more support elements to create an encryption key and storing the encryption key in an encrypted file that can only be decrypted by the smart card and the support element used to create the encryption key.,CHENCINSKI EDWARD W;;COON JAMES R;;DAYKA JOHN C;;GLASSEN STEVEN G;;GUSEFSKI RICHARD J;;JORDAN MICHAEL J;;KRAEMER MARCO;;MATHIAS THOMAS B;;SZWED PETER K;;SULLIVAN GARRY J;;WERNER KLAUS;;IBM,CHENCINSKI EDWARD W;;COON JAMES R;;DAYKA JOHN C;;GLASSEN STEVEN G;;GUSEFSKI RICHARD J;;JORDAN MICHAEL J;;KRAEMER MARCO;;MATHIAS THOMAS B;;SZWED PETER K;;SULLIVAN GARRY J;;WERNER KLAUS,INTERNATIONAL BUSINESS MACHINES CORPORATION (2011-05-24),https://lens.org/113-583-512-815-84X,Patent Application,yes,0,5,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,H04L9/08;;H04L9/00,380/278;;380/44,0,0,,,,INACTIVE
526,US,B2,US 8582778 B2,073-019-392-767-452,2013-11-12,2013,US 201113150420 A,2011-06-01,US 201113150420 A,2011-06-01,Integrated key server,A computer program product for integrated key serving is provided. The computer program product includes a tangible storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method. The method includes using a smart card of two or more smart cards with a support element of two or more support elements to create an encryption key and storing the encryption key in an encrypted file that can only be decrypted by the smart card and the support element used to create the encryption key.,CHENCINSKI EDWARD W;;COON JAMES R;;DAYKA JOHN C;;GLASSEN STEVEN G;;GUSEFSKI RICHARD J;;JORDAN MICHAEL J;;KRAEMER MARCO;;MATHIAS THOMAS B;;SZWED PETER K;;SULLIVAN GARRY J;;WERNER KLAUS;;IBM,CHENCINSKI EDWARD W;;COON JAMES R;;DAYKA JOHN C;;GLASSEN STEVEN G;;GUSEFSKI RICHARD J;;JORDAN MICHAEL J;;KRAEMER MARCO;;MATHIAS THOMAS B;;SZWED PETER K;;SULLIVAN GARRY J;;WERNER KLAUS,INTERNATIONAL BUSINESS MACHINES CORPORATION (2011-05-24),https://lens.org/073-019-392-767-452,Granted Patent,yes,5,0,10,10,0,H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0877;;H04L9/0894;;H04L9/0822;;H04L9/0825;;H04L9/0894;;H04L9/0877,G06F21/00,380/278;;726/9;;713/284,2,0,,,"International Search Report of the International Searching Authority for Application No. PCT/IB2012/052413; Date of Mailing Sep. 13, 2012.;;Written Opinion of the International Searching Authority for Application No. PCT/IB2012/052413; Date of Mailing Sep. 13, 2012.",INACTIVE
527,US,A1,US 2022/0007927 A1,086-126-682-848-133,2022-01-13,2022,US 202117483347 A,2021-09-23,US 202117483347 A;;US 201916248482 A;;US 201929676212 F;;US 201929676213 F;;US 201862617929 P,2018-01-16,PHYSICAL ASSESSMENT DEVICE,"An instrument head is provided for attachment to a plurality of instrument handles having different power profiles. The instrument head contains an illumination assembly including at least one LED as well as a drive circuit for detecting a power profile of an attached instrument handle and converting variable voltages received from the attached instrument handle to a constant current for powering the at least one LED based on the power profile. Accordingly, the instrument head enables use with a plurality of instrument handles, including those originally configured for use only with incandescent light sources.",WELCH ALLYN INC,LIA RAYMOND A;;SLAWSON STEVEN R;;VIVENZIO ROBERT L;;STROM JOHN R;;MCMAHON MICHAEL T;;PERKINS DAVID G;;COON KENNETH V;;DELUCIA PAUL;;WEITZEL RICHARD H;;WAWRO THADDEUS J;;MARTIN SCOTT ANDREW;;GUO LEI,WELCH ALLYN INC (2019-01-24),https://lens.org/086-126-682-848-133,Patent Application,yes,0,0,4,9,0,A61B1/00006;;A61B1/00032;;A61B1/00052;;A61B1/00105;;A61B1/00108;;A61B1/00124;;A61B1/00128;;A61B1/00195;;A61B1/227;;A61B3/0091;;A61B3/1208;;A61B3/12;;A61B1/227;;A61B1/00006;;A61B3/0091;;A61B1/00032;;A61B3/1208;;A61B1/00052;;A61B1/00124;;A61B1/00128;;A61B1/00105;;A61B1/00108;;A61B1/00195,A61B1/00;;A61B1/227;;A61B3/00;;A61B3/12,,0,0,,,,PENDING
528,AU,A1,AU 2003/297248 A1,107-606-403-044-187,2004-04-30,2004,AU 2003/297248 A,2003-09-15,US 41077302 P;;US 0328991 W,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING",,1 800 CONTACTS INC,OLIVER JOANNE MERCIA;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH LAWRENCE;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;COON JONHTAN C;;CHEONG DESMOND CHZE SEONG;;NEWMAN STEPHEN D;;MCCALLUM KEVIN KIT;;CHRISTY BRUCE VERNER III,,https://lens.org/107-606-403-044-187,Patent Application,no,0,0,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;A45C11/04;;B65D/;;B65D1/00,,0,0,,,,DISCONTINUED
529,US,B2,US 8069979 B2,142-804-851-941-873,2011-12-06,2011,US 90210310 A,2010-10-11,US 90210310 A;;US 52738305 A;;US 0328991 W;;US 41077302 P,2002-09-13,"Contact lens package and storage case, holder, and system and method of making and using","A reusable holder for contact lens cases includes a base, at least one receptacle formed in the base configured to receive a contact lens case, and a time keeping device formed in the base. The time keeping device may include an indicator for the at least one receptacle that indicates a period of time that has lapsed since the contact lens case currently in the at least one receptacle was placed therein to denote a need to discard the contact lens case and a contact lens associated with the contact lens case.",NEWMAN STEPHEN D;;COON JONATHAN C;;MCCALLUM KEVIN K;;CHRISTY III BRUCE V;;CHEON DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;1 800 CONTACTS INC,NEWMAN STEPHEN D;;COON JONATHAN C;;MCCALLUM KEVIN K;;CHRISTY III BRUCE V;;CHEON DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN,1-800 CONTACTS INC (2003-11-20),https://lens.org/142-804-851-941-873,Granted Patent,yes,40,14,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/04;;A45C11/00;;B65D/;;B65D1/00;;B65D85/00;;G04B47/00,206/5.1;;206/459.1;;134/901,0,0,,,,EXPIRED
530,EP,A2,EP 1556279 A2,014-078-094-799-069,2005-07-27,2005,EP 03756809 A,2003-09-15,US 0328991 W;;US 41077302 P,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING",,1 800 CONTACTS INC,NEWMAN STEPHEN D;;MCCALLUM KEVIN KIT;;CHRISTY BRUCE VERNER III;;OLIVER JOANNE MERCIA;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH LAWRENCE;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;COON JONHTAN C;;CHEONG DESMOND CHZE SEONG,,https://lens.org/014-078-094-799-069,Patent Application,yes,0,0,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;A45C11/04;;B65D/;;B65D1/00;;B65D85/00,,0,0,,,,DISCONTINUED
531,US,A1,US 2007/0000792 A1,084-746-234-905-143,2007-01-04,2007,US 52738305 A,2005-03-11,US 52738305 A;;US 41077302 P;;US 0328991 W,2002-09-13,"Contact lens package and storage case, holder, and system and method of making and using","A contact lens package that is reusable as a case to store a contact lens between uses includes a bottom member having a well with an inside generally concave shape, and a wall rising above the well and ending in a top rim defining an opening; a temporary seal comprising a moisture-proof film sealed across the top rim to seal the opening, thus defining a volume within the package, the volume containing a contact lens and contact lens fluid; and a cap secured to the bottom member covering the temporary seal, the cap being removable to give access to the temporary seal and replaceable on the bottom member thereafter to provide storage of the contact lens between uses thereof. The contact lens package and storage case can be used as part of a system having a generally flat base member with two receptacles and indicia identifying one of the receptacles as being for a left eye contact lens package and the other of the receptacles as being for a right eye contact lens package; and a plurality of contact lens packages each comprising: a bottom member configured to be received by one of said receptacles and held securely onto the base; a cap secured to the bottom member to enclose a volume; and a contact lens and contact lens fluid within the volume; wherein the plurality of contact lens packages include a generally equal plural number of packages containing a contact lens to be used in the left eye of a contact lens wearer and packages containing a contact lens to be used in the right eye of a contact lens wearer.",NEWMAN STEPHEN D;;COON JONTHAN C;;MCCALLUM KEVIN K;;CHRISTY BRUCE V III;;CHEONG DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN,NEWMAN STEPHEN D;;COON JONTHAN C;;MCCALLUM KEVIN K;;CHRISTY BRUCE V III;;CHEONG DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN,1-800 CONTACTS INC (2003-11-20),https://lens.org/084-746-234-905-143,Patent Application,yes,14,47,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;A45C11/04;;B65D/;;B65D1/00,206/5.1,0,0,,,,EXPIRED
532,EP,A4,EP 1556279 A4,103-324-624-547-844,2006-08-30,2006,EP 03756809 A,2003-09-15,US 0328991 W;;US 41077302 P,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING",,1 800 CONTACTS INC,NEWMAN STEPHEN D;;MCCALLUM KEVIN KIT;;CHRISTY BRUCE VERNER III;;OLIVER JOANNE MERCIA;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH LAWRENCE;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;COON JONHTAN C;;CHEONG DESMOND CHZE SEONG,,https://lens.org/103-324-624-547-844,Search Report,no,9,0,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;A45C11/04;;B65D/;;B65D1/00;;B65D85/00,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2000, no. 26 1 July 2002 (2002-07-01);;PATENT ABSTRACTS OF JAPAN vol. 2002, no. 09 4 September 2002 (2002-09-04);;PATENT ABSTRACTS OF JAPAN vol. 1995, no. 05 30 June 1995 (1995-06-30)",DISCONTINUED
533,WO,A2,WO 2004/024573 A2,026-459-383-817-731,2004-03-25,2004,US 0328991 W,2003-09-15,US 41077302 P,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING","A contact lens package (10) that is reusable as a case to store a contact lens between uses includes a bottom member (15) having a well with an inside generally concave shape, and a wall rising above the well and ending in a top rim (11) defining an opening; a temporary seal (16) sealed across the top rim to seal the opening and a cap (14) secured to the bottom member covering the temporary seal.",1 800 CONTACTS INC;;NEWMAN STEPHEN D;;MCCALLUM KEVIN KIT;;CHRISTY BRUCE VERNER III;;OLIVER JOANNE MERCIA;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH LAWRENCE;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;COON JONHTAN C;;CHEONG DESMOND CHZE SEONG,NEWMAN STEPHEN D;;MCCALLUM KEVIN KIT;;CHRISTY BRUCE VERNER III;;OLIVER JOANNE MERCIA;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH LAWRENCE;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;COON JONHTAN C;;CHEONG DESMOND CHZE SEONG,,https://lens.org/026-459-383-817-731,Patent Application,yes,0,20,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;A45C11/04;;B65D/;;B65D1/00,,0,0,,,,PENDING
534,US,B2,US 7832551 B2,124-649-400-042-49X,2010-11-16,2010,US 52738305 A,2005-03-11,US 52738305 A;;US 41077302 P;;US 0328991 W,2002-09-13,"Contact lens package and storage case, holder, and system and method of making and using","A contact lens package that is reusable as a case to store a contact lens between uses includes a lid, a base, one or more receptacles for a contact lens case, and a time keeping device. The time keeping device comprises an indicator for each one or more receptacles that indicates a period of time that has elapsed since the contact lens case currently in the receptacle was placed therein. When the period of time has expired, the indicator denotes a need to discard both the contact lens case and a contact lens associated with the contact lens case.",1 800 CONTACTS INC,NEWMAN STEPHEN D;;COON JONTHAN C;;MCCALLUM KEVIN K;;CHRISTY III BRUCE V;;CHEONG DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN,1-800 CONTACTS INC (2003-11-20),https://lens.org/124-649-400-042-49X,Granted Patent,yes,22,13,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/04;;A45C11/00;;B65D/;;B65D1/00;;B65D85/00;;G04B47/00,206/5.1;;206/459.1;;134/901,0,0,,,,ACTIVE
535,WO,A3,WO 2004/024573 A3,190-048-480-343-945,2004-05-06,2004,US 0328991 W,2003-09-15,US 41077302 P,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING","A contact lens package (10) that is reusable as a case to store a contact lens between uses includes a bottom member (15) having a well with an inside generally concave shape, and a wall rising above the well and ending in a top rim (11) defining an opening; a temporary seal (16) sealed across the top rim to seal the opening and a cap (14) secured to the bottom member covering the temporary seal.",1 800 CONTACTS INC;;NEWMAN STEPHEN D;;MCCALLUM KEVIN KIT;;CHRISTY BRUCE VERNER III;;OLIVER JOANNE MERCIA;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH LAWRENCE;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;COON JONHTAN C;;CHEONG DESMOND CHZE SEONG,NEWMAN STEPHEN D;;MCCALLUM KEVIN KIT;;CHRISTY BRUCE VERNER III;;OLIVER JOANNE MERCIA;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH LAWRENCE;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;COON JONHTAN C;;CHEONG DESMOND CHZE SEONG,,https://lens.org/190-048-480-343-945,Search Report,yes,3,0,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;A45C11/04;;B65D/;;B65D1/00,,0,0,,,,PENDING
536,CA,A1,CA 2498678 A1,146-540-958-298-08X,2004-03-25,2004,CA 2498678 A,2003-09-15,US 41077302 P;;US 0328991 W,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING","A contact lens package (10) that is reusable as a case to store a contact le ns between uses includes a bottom member (15) having a well with an inside generally concave shape, and a wall rising above the well and ending in a to p rim (11) defining an opening; a temporary seal (16) sealed across the top ri m to seal the opening and a cap (14) secured to the bottom member covering the temporary seal.",1 800 CONTACTS INC,COON JONATHAN C;;CHEONG DESMOND CHZE SEONG;;ROSSETTI ANTHONY J;;MCCALLUM KEVIN KIT;;RAVITCH JOHN;;NEWMAN STEPHEN D;;OLIVER JOANNE MERCIA;;CHRISTY BRUCE VERNER III;;HOUSTON JONAH LAWRENCE;;WONG RACHEL;;ZEH MARK A;;DEAKIN LYNDA,,https://lens.org/146-540-958-298-08X,Patent Application,no,0,0,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;A45C11/04;;B65D/;;B65D1/00,,0,0,,,,DISCONTINUED
537,US,A1,US 2011/0031137 A1,175-331-051-137-086,2011-02-10,2011,US 90210310 A,2010-10-11,US 90210310 A;;US 52738305 A;;US 0328991 W;;US 41077302 P,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING","A contact lens package that is reusable as a case to store a contact lens between uses includes a bottom member having a well with an inside generally concave shape, and a wall rising above the well and ending in a top rim defining an opening; a temporary seal comprising a moisture-proof film sealed across the top rim to seal the opening, thus defining a volume within the package, the volume containing a contact lens and contact lens fluid; and a cap secured to the bottom member covering the temporary seal, the cap being removable to give access to the temporary seal and replaceable on the bottom member thereafter to provide storage of the contact lens between uses thereof. The contact lens package and storage case can be used as part of a system having a generally flat base member with two receptacles and indicia identifying one of the receptacles as being for a left eye contact lens package and the other of the receptacles as being for a right eye contact lens package; and a plurality of contact lens packages each comprising: a bottom member configured to be received by one of said receptacles and held securely onto the base; a cap secured to the bottom member to enclose a volume; and a contact lens and contact lens fluid within the volume; wherein the plurality of contact lens packages include a generally equal plural number of packages containing a contact lens to be used in the left eye of a contact lens wearer and packages containing a contact lens to be used in the right eye of a contact lens wearer.",1 800 CONTACTS INC,NEWMAN STEPHEN D;;COON JONTHAN C;;MCCALLUM KEVIN K;;CHRISTY III BRUCE V;;CHEONG DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN,1-800 CONTACTS INC (2003-11-20),https://lens.org/175-331-051-137-086,Patent Application,yes,30,0,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/04;;A45C11/00;;B65D/;;B65D1/00,206/5.1,0,0,,,,EXPIRED
538,US,A1,US 2012/0055817 A1,003-788-116-594-230,2012-03-08,2012,US 201113286840 A,2011-11-01,US 201113286840 A;;US 90210310 A;;US 52738305 A;;US 0328991 W;;US 41077302 P,2002-09-13,"CONTACT LENS PACKAGE AND STORAGE CASE, HOLDER, AND SYSTEM AND METHOD OF MAKING AND USING","A contact lens package that is reusable as a case to store a contact lens between uses includes a lid, a base, one or more receptacles for a contact lens case, and a time keeping device. The time keeping device comprises an indicator for each one or more receptacles that indicates a period of time that has elapsed since the contact lens case currently in the receptacle was placed therein. When the period of time has expired, the indicator denotes a need to discard both the contact lens case and a contact lens associated with the contact lens case.",NEWMAN STEPHEN D;;COON JONTHAN C;;MCCALLUM KEVIN K;;CHRISTY III BRUCE V;;CHEONG DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN;;1 800 CONTACTS INC,NEWMAN STEPHEN D;;COON JONTHAN C;;MCCALLUM KEVIN K;;CHRISTY III BRUCE V;;CHEONG DESMOND C S;;OLIVER JOANNE M;;ZEH MARK A;;DEAKIN LYNDA;;WONG RACHEL;;HOUSTON JONAH L;;ROSSETTI ANTHONY J;;RAVITCH JOHN,1-800 CONTACTS INC (2003-11-20),https://lens.org/003-788-116-594-230,Patent Application,yes,0,20,13,13,0,A45C11/005;;B65D21/0204;;B65D83/0418;;B65D2585/545;;Y10S134/901;;Y02W30/80;;A45C11/005;;B65D2585/545;;B65D83/0418;;B65D21/0204;;Y10S134/901;;Y02W30/80,A45C11/00;;B65D77/00;;A45C11/04;;B65D/;;B65D1/00,206/216,0,0,,,,DISCONTINUED
539,CN,A,CN 111629644 A,165-245-857-438-773,2020-09-04,2020,CN 201980008866 A,2019-01-16,US 201862617929 P;;US 201916248482 A;;US 2019/0013775 W,2018-01-16,Physical assessment device,"In a physical assessment device, an instrument head is provided for attachment to a plurality of instrument handles having different power profiles. The instrument head contains an illumination assembly including at least one LED as well as a drive circuit for detecting a power profile of an attached instrument handle and converting variable voltages received from the attached instrument handle toa constant current for powering the at least one LED based on the power profile. Accordingly, the instrument head enables use with a plurality of instrument handles, including those originally configured for use only with incandescent light sources.",WELCH ALLYN INC,LIA RAYMOND A;;SLAWSON STEVEN R;;VIVENZIO ROBERT L;;STROM JOHN R;;MCMAHON MICHAEL T;;PERKINS DAVID G;;COON KENNETH V;;DELUCIA PAUL;;WEITZEL RICHARD H;;WAWRO THADDEUS J;;MARTIN SCOTT A;;GUO LEI;;KNIERIEM ALAN S;;BABSON DAVID M,,https://lens.org/165-245-857-438-773,Patent Application,no,4,0,2,9,0,A61B1/00105;;A61B1/0669;;A61B1/0684;;A61B1/227,A61B1/00;;A61B1/06;;A61B1/227;;A61B1/267,,0,0,,,,PENDING
540,CA,A1,CA 3150736 A1,096-371-040-471-049,2021-02-18,2021,CA 3150736 A,2020-08-13,US 201962886660 P;;US 2020/0046116 W,2019-08-14,PROCESS OF MAKING CFTR MODULATORS,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/096-371-040-471-049,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
541,US,A1,US 2021/0047345 A1,088-625-605-965-255,2021-02-18,2021,US 202016992419 A,2020-08-13,US 202016992419 A;;US 201962886660 P,2019-08-14,PROCESS OF MAKING CFTR MODULATORS,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2020-08-10);;VERTEX PHARMACEUTICALS INCORPORATED (2020-07-30);;VERTEX PHARMACEUTIALS (SAN DIEGO) LLC (2002-10-21),https://lens.org/088-625-605-965-255,Patent Application,yes,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D513/22;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14,,0,0,,,,ACTIVE
542,US,A1,US 2023/0399343 A1,154-830-896-700-090,2023-12-14,2023,US 202318093142 A,2023-01-04,US 202318093142 A;;US 202016992419 A;;US 201962886660 P,2019-08-14,PROCESS OF MAKING CFTR MODULATORS,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/154-830-896-700-090,Patent Application,yes,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D513/22;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14,,0,0,,,,PENDING
543,US,B2,US 11584761 B2,091-541-142-116-731,2023-02-21,2023,US 202016992419 A,2020-08-13,US 202016992419 A;;US 201962886660 P,2019-08-14,Process of making CFTR modulators,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2020-08-10);;VERTEX PHARMACEUTICALS INCORPORATED (2020-07-30);;VERTEX PHARMACEUTIALS (SAN DIEGO) LLC (2002-10-21),https://lens.org/091-541-142-116-731,Granted Patent,yes,118,2,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D513/22;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14,,26,5,021-201-815-497-277;;103-406-692-390-577;;007-439-541-841-087;;075-656-809-634-642;;051-392-666-499-166,28930490;;10.1164/rccm.201704-0717oc;;pmc5768901;;10.1021/jo01329a020;;28483454;;10.1016/j.bmc.2017.04.034;;10.1021/acs.jmedchem.6b01889;;28418664;;10.1021/acs.jmedchem.6b01889.s001;;8627606;;10.1021/jm9508651,"Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 128583-07-3, Entered STN: Aug. 3, 1990.;;Donaldson, S.H. et al. (2017) “Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR orF508del/G551D-CFTR”, Am. J. Respir. Crit. Care Med., 197(2): 214-224.;;International Patent Application No. PCT/U2020/026331: International Search Report and Written Opinion, dated May 29, 2020 (14 pages).;;International Patent Application No. PCT/US2019/018042: International Search Report and Written Opinion, dated Apr. 17, 2019 (10 pages).;;International Patent Application No. PCT/US2019/061171: International Search Report and Written Opinion, dated Feb. 12, 2020 (14 pages).;;International Patent Application No. PCT/US2021/053853: International Search Report and Written Opinion, dated Dec. 21, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053855: International Search Report and Written Opinion, dated Jan. 3, 2022 (12 pages).;;International Patent Application No. PCT/US2021/053856: International Search Report and Written Opinion, dated Dec. 22, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053858: International Search Report and Written Opinion, dated Mar. 17, 2022 (14 pages).;;International Patent Application No. PCT/US2021/053860: International Search Report and Written Opinion, dated Dec. 23, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053861: International Search Report and Written Opinion, dated Dec. 22, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053862: International Search Report and Written Opinion, dated Dec. 22, 2021 (12 pages).;;International Patent Application No. PCT/US2021/053863: International Search Report and Written Opinion, dated Feb. 4, 2022 (16 pages).;;International Patent Application No. PCT/US2021/053864: International Search Report and Written Opinion, dated Mar. 15, 2022 (17 pages).;;International Patent Application No. PCT/US2021/053865: International Search Report and Written Opinion, dated Jan. 26, 2022 (16 pages).;;Newkome, G.R. et al. (1979) “Nicotinic Acid Crown Ethers. Synthesis, Reactions, and Complexation of Nicotinonitrile Macrocycles”, J Org Chem, 44(15): 2639-2697.;;Nishida, H. et al. (2017) “Exploration of pyrrole derivatives to find an effective potassium competitive acid blocker with moderately long-lasting suppression of gastric acid secretion”, Bioorg Med Chem, 25(13): 3447-3460.;;Prashantha, G. et al. (2017) “Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide”, J Med Chem, 60(9): 3795-3803.;;Rewcastle, G.W. et al. (1996) “Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]-pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor”, J Med Chem, 39(9): 1823-1835.;;“Symdeko in Cystic Fibrosis Patients”, ClinicalTrials.gov, Jul. 23, 2018 (Apr. 23, 2018), XP055661778, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/record/NCT03506061 [retrieved on Jan. 24, 2020].;;U.S. Appl. No. 16/992,419, filed Aug. 13, 2021, by Angell et al.;;U.S. Appl. No. 16/992,441, filed Aug. 13, 2021, by Shi et al.;;U.S. Appl. No. 16/992,448, filed Aug. 13, 2021, by Anderson et al.;;U.S. Appl. No. 16/992,675, filed Aug. 13, 2021, by Abela et al.;;U.S. Appl. No. 17/546,649, filed Dec. 9, 2021, by Borek et al.;;U.S. Appl. No. 17/600,829, filed Oct. 1, 2021, by Abela et al.",ACTIVE
544,AU,A1,AU 2020/330570 A1,103-781-416-450-726,2022-03-17,2022,AU 2020/330570 A,2020-08-13,US 201962886660 P;;US 2020/0046116 W,2019-08-14,Process of making CFTR modulators,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/103-781-416-450-726,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
545,KR,A,KR 20220064365 A,041-692-117-562-558,2022-05-18,2022,KR 20227006124 A,2020-08-13,US 201962886660 P;;US 2020/0046116 W,2019-08-14,CFTR 조절제의 제조 방법,"본 개시는 화합물 I, 및 이의 약학적으로 허용 가능한 염을 합성하는 방법을 제공한다. JPEGpct00456.jpg3472 (화합물 I)",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/041-692-117-562-558,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D513/22;;A61K31/435;;A61P11/00;;C07D207/08;;C07D207/09;;C07D231/20;;C07D401/04;;C07D401/14,,0,0,,,,PENDING
546,CN,A,CN 114555556 A,128-972-044-888-426,2022-05-27,2022,CN 202080071701 A,2020-08-13,US 201962886660 P;;US 2020/0046116 W,2019-08-14,Process for preparing CFTR modulators,The present disclosure provides methods for the synthesis of Compound I and pharmaceutically acceptable salts thereof.,FEREX PHARMACEUTICAL LTD COMPANY,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN JOSEPH;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON CHRISTOPHER D;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FREEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;CHOU JOEY,,https://lens.org/128-972-044-888-426,Patent Application,no,3,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D207/26;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
547,EP,A1,EP 4013741 A1,013-916-074-084-967,2022-06-22,2022,EP 20761961 A,2020-08-13,US 201962886660 P;;US 2020/0046116 W,2019-08-14,PROCESS OF MAKING CFTR MODULATORS,,VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/013-916-074-084-967,Patent Application,yes,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
548,TW,A,TW 202120517 A,192-344-950-789-925,2021-06-01,2021,TW 109127315 A,2020-08-12,US 201962886660 P,2019-08-14,Process of making CFTR modulators,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/192-344-950-789-925,Patent of Addition,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D513/22;;A61K31/4353;;A61P11/00,,0,0,,,,PENDING
549,ZA,B,ZA 202201793 B,057-300-113-647-269,2023-06-28,2023,ZA 202201793 A,2022-02-10,US 201962886660 P;;US 2020/0046116 W,2019-08-14,PROCESS OF MAKING CFTR MODULATORS,,VERTEX PHARMA,PAUL ANGELL;;JOHN E COCHRAN;;BENJAMIN J LITTLER;;DAVID ANDREW SIESEL;;ARMANDO URBINA;;COREY DON ANDERSON;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;TIMOTHY RICHARD COON;;BRYAN FRIEMAN;;PETER GROOTENHUIS;;SARA SABINA HADIDA RUAH;;JASON MCCARTNEY;;MARK THOMAS MILLER;;PRASUNA PARASELLI;;FABRICE PIERRE;;SARA E SWIFT;;JINGLAN ZHOU,,https://lens.org/057-300-113-647-269,Granted Patent,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,,0,0,,,,ACTIVE
550,WO,A1,WO 2021/030554 A1,079-228-191-255-505,2021-02-18,2021,US 2020/0046116 W,2020-08-13,US 201962886660 P,2019-08-14,PROCESS OF MAKING CFTR MODULATORS,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN;;GROOTENHUIS PETER,,https://lens.org/079-228-191-255-505,Patent Application,yes,8,11,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,17,15,103-406-692-390-577;;051-392-666-499-166;;064-283-996-955-602;;007-439-541-841-087;;075-656-809-634-642;;027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;077-295-491-167-117;;007-364-858-655-289;;055-872-369-256-262,10.1021/jo01329a020;;8627606;;10.1021/jm9508651;;10.1002/ejoc.201801270;;28483454;;10.1016/j.bmc.2017.04.034;;10.1021/acs.jmedchem.6b01889;;28418664;;10.1021/acs.jmedchem.6b01889.s001;;1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1002/0471220574;;10.1002/jps.2600660104;;833720;;27750013;;10.1021/acs.joc.6b02207,"NEWKOME G.R. ET AL: ""Nicotinic Acid Crown Ethers. Synthesis, Reactions, and Complexation of Nicotinonitrile macrocycles"", JOURNAL OF ORGANIC CHEMISTRY, vol. 44, no. 15, 1 January 1979 (1979-01-01), pages 2639 - 2697, XP055732460;;REWCASTLE G W ET AL: ""TYROSINE KINASE INHIBITORS. 10. ISOMERIC 4-Ú(3-BROMOPHENYL)AMINO3?4 PYRIDOÚD3?4-PYRIMIDINES ARE POTENT ATP BINDING SITE INHIBITORS OF THETYROSINE KINASE FUNCTION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 9, 26 April 1996 (1996-04-26), pages 1823 - 1835, XP000671261, ISSN: 0022-2623, DOI: 10.1021/JM9508651;;ARTEM YU. CHEREPAKHA ET AL: ""Hetaryl Bromides Bearing the SO 2 F Group - Versatile Substrates for Palladium-Catalyzed C-C Coupling Reactions"", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2018, no. 47, 19 December 2018 (2018-12-19), DE, pages 6682 - 6692, XP055733124, ISSN: 1434-193X, DOI: 10.1002/ejoc.201801270;;NISHIDA HARUYUKI ET AL: ""Exploration of pyrrole derivatives to find an effective potassium-competitive acid blocker with moderately long-lasting suppression of gastric acid secretion"", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, NL, vol. 25, no. 13, 27 April 2017 (2017-04-27), pages 3447 - 3460, XP085037327, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2017.04.034;;PRASHANTHA GUNAGA ET AL: ""Selective I Kur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 9, 28 April 2017 (2017-04-28), US, pages 3795 - 3803, XP055733118, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b01889;;CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, 1990, pages 863 - 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;P. J. KOCIENSKI: ""Protecting Groups"", 2005, THIEME;;GREENEWUTS: ""Protective Groups in Organic Synthesis"", 2007, JOHN WILEY & SONS;;S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;J. ORG. CHEM., vol. 81, 2016, pages 11235 - 11249;;SYNTHESIS, 1985, pages 35 - 38",PENDING
551,AU,A8,AU 2020/330570 A8,074-712-926-608-66X,2022-03-31,2022,AU 2020/330570 A,2020-08-13,US 201962886660 P;;US 2020/0046116 W,2019-08-14,Process of making CFTR modulators,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/074-712-926-608-66X,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
552,MX,A,MX 2022001829 A,005-888-725-937-48X,2022-06-08,2022,MX 2022001829 A,2020-08-13,US 201962886660 P;;US 2020/0046116 W,2019-08-14,PROCESS OF MAKING CFTR MODULATORS.,"The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ZHOU JINGLAN;;COCHRAN JOHN E;;ANGELL PAUL;;URBINA ARMANDO;;MCCARTNEY JASON;;PARASELLI PRASUNA;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;HADIDA RUAH SARA SABINA;;LITTLER BENJAMIN J;;ANDERSON COREY DON;;FRIEMAN BRYAN;;PIERRE FABRICE;;SWIFT SARA E;;GROOTENHUIS (FALLECIDO) PETER;;SIESEL DAVID,,https://lens.org/005-888-725-937-48X,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
553,AR,A1,AR 119770 A1,124-762-757-647-349,2022-01-12,2022,AR P200102307 A,2020-08-13,US 201962886660 P,2019-08-14,PROCESO DE ELABORACIÓN DE MODULADORES DE CFTR,"Reivindicación 1: Un método para preparar el Compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, que comprende convertir un compuesto de fórmula (2), o una sal de este, en el compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, donde: Xᵃ se selecciona de F, Cl, Br, I y -OSO₂R; R se selecciona de -alquilo C₁₋₁₀, -haloalquilo C₁₋₁₀, y arilo opcionalmente sustituido con -alquilo C₁₋₁₀, -haloalquilo C₁₋₁₀, halo o nitro; y Xᶜ se selecciona de F, Cl, Br e I. Reivindicación 2: El método de la reivindicación 1, donde la conversión del compuesto de fórmula (2), o una sal de este, en el Compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, comprende las etapas de: 1) combinar el compuesto de fórmula (2), o una sal de este, con al menos una primera base para producir un compuesto de fórmula (3), o una sal de este; y 2) combinar el compuesto de fórmula (3), o una sal de este, con el compuesto de fórmula (4), o una sal de este, y al menos una segunda base para producir el Compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, donde en el compuesto de fórmula (3), o una sal de este: Xᵃ se selecciona de F, CI, Br, I y -OSO₂R; y R se selecciona de -alquilo C₁₋₁₀, -haloalquilo C₁₋₁₀, y arilo opcionalmente sustituido con -alquilo C₁₋₁₀, -haloalquilo C₁₋₁₀, halo o nitro. Reivindicación 4: El método de la reivindicación 1, donde el compuesto de fórmula (2), o una sal de este, se prepara convirtiendo un compuesto de fórmula (5), o una sal de este, en el compuesto de fórmula (2), o una sal de este, donde en el compuesto de fórmula (5), o una sal de este: Xᵃ se selecciona de F, CI, Br, I y -OSO₂R; R se selecciona de -alquilo C₁₋₁₀, -haloalquilo C₁₋₁₀, y arilo opcionalmente sustituido con -alquilo C₁₋₁₀, -haloalquilo C₁₋₁₀, halo o nitro; Xᶜ se selecciona de F, CI, Br e I; y donde: R¹ es hidrógeno y R² es un grupo protector de nitrógeno monovalente; R¹ y R² se seleccionan independientemente de grupos protectores de nitrógeno monovalentes; o R¹ y R², junto con los átomos a los que están unidos, forman un grupo protector de nitrógeno. Reivindicación 11: Un método para preparar el Compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, que comprende convertir un compuesto de fórmula (6), o una sal de este, en el compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, donde en el compuesto de fórmula (6), o una sal de este, Xᶜ se selecciona de F, CI, Br e I.",VERTEX PHARMA,ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER DECEASED;;HADIDA RUAH SARA SABINA;;MCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN,,https://lens.org/124-762-757-647-349,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D401/04;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/14,,0,0,,,,PENDING
554,BR,A2,BR 112022002604 A2,098-572-738-264-686,2022-05-03,2022,BR 112022002604 A,2020-08-13,US 2020/0046116 W;;US 201962886660 P,2019-08-14,Processo de produção de moduladores de cftr,processo de produção de moduladores de cftr. a divulgação fornece processos para sintetizar o composto i e sais farmaceuticamente aceitáveis deste.,VERTEX PHARMA,URBINA ARMANDO;;BENJAMIN J LITTLER;;FRIEMAN BRYAN;;COREY DON ANDERSON;;DAVID ANDREW SIESEL;;PIERRE FABRICE;;MCCARTNEY JASON;;JEREMY J CLEMENS;;ZHOU JINGLAN;;JOHN E COCHRAN;;MARK THOMAS MILLER;;ANGELL PAUL;;GROOTENHUIS PETER;;PARASELLI PRASUNA;;SARA E SWIFT;;SARA SABINA HADIDA RUAH;;CLEVELAND THOMAS;;TIMOTHY RICHARD COON,,https://lens.org/098-572-738-264-686,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
555,UY,A,UY 38837 A,182-956-034-914-190,2021-02-26,2021,UY 38837 A,2020-08-13,US 201962886660 P,2019-08-14,PROCESO DE ELABORACIÓN DE MODULADORES DE CFTR,"La descripción proporciona procesos para sintetizar el Compuesto I, y sus sales farmacéuticamente aceptables.",VERTEX PHARMA,CLEMENS JEREMY J;;ANDERSON COREY DON;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN;;ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO;;GROOTENHUIS PETER,,https://lens.org/182-956-034-914-190,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,A61P11/00;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
556,CO,A2,CO 2022002637 A2,030-446-283-716-556,2022-06-21,2022,CO 2022002637 A,2022-03-04,US 2020/0046116 W;;US 201962886660 P,2019-08-14,Proceso de fabricación de moduladores de cftr,"La descripción proporciona procesos para sintetizar el compuesto I, y sales farmacéuticamente aceptables del mismo. Compuesto I",VERTEX PHARMA,ANDERSON COREY DON;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN;;GROOTENHUIS PETER (DECEASED);;HADIDA RUAH SARA SABINA;;MCCARTNEY JASON;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SWIFT SARA E;;ZHOU JINGLAN;;ANGELL PAUL;;COCHRAN JOHN E;;LITTLER BENJAMIN J;;SIESEL DAVID ANDREW;;URBINA ARMANDO,,https://lens.org/030-446-283-716-556,Patent Application,no,0,0,22,22,0,C07D207/08;;C07D207/26;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/71;;C07D213/74;;C07D213/82;;C07D401/04;;C07D401/14;;C07D513/22;;C07D513/22;;C07D401/14;;C07D401/04;;C07D213/61;;C07D213/62;;C07D213/74;;C07D213/70;;C07D207/09;;C07D207/08;;C07D231/20;;C07D513/22;;C07D213/74;;C07D213/71;;C07D207/08;;C07D213/62;;C07D213/61;;C07D213/70;;C07D213/82;;C07D401/14;;C07D207/09;;C07D401/04;;C07D231/20;;C07D513/22;;A61K31/435;;A61P11/00;;C07D231/20;;C07D401/14;;C07D401/04;;C07D207/08;;C07D207/09;;C07D207/08;;C07D213/71;;C07D213/82;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,C07D207/08;;C07D207/09;;C07D213/61;;C07D213/62;;C07D213/70;;C07D213/74;;C07D231/20;;C07D401/04;;C07D401/14;;C07D513/22,,0,0,,,,PENDING
557,CY,T1,CY 1123487 T1,082-988-387-448-480,2022-03-24,2022,CY 201101013 T,2020-10-26,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,ΔΙΑΜΟΡΦΩΤΕΣ ΤΟΥ ΡΥΘΜΙΣΤΗ ΑΓΩΓΙΜΟΤΗΤΑΣ ΔΙΑΜΕΜΒΡΑΝΗΣ ΚΥΣΤΙΚΗΣ ΙΝΩΣΗΣ,"Η παρούσα εφεύρεση χαρακτηρίζει ένωση του τύπου Ι ή φαρμακευτικώς αποδεκτό άλας αυτής, όπου R1, R2, R3, W, X, Υ, Ζ, n, o, p, και q ορίζονται στο παρόν, για τη θεραπεία προκαλούμενων από CFTR ασθενειών, όπως κυστικής ίνωσης. Η παρούσα εφεύρεση επίσης χαρακτηρίζει φαρμακευτικές συνθέσεις, μέθοδο θεραπείας, και κιτ αυτών.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON,,https://lens.org/082-988-387-448-480,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,ACTIVE
558,CN,A,CN 116670143 A,011-363-748-097-132,2023-08-29,2023,CN 202180082146 A,2021-10-06,US 202063088799 P;;US 2021/0053861 W,2020-10-07,Modulators of cystic fibrosis transmembrane conductance regulators,"The present disclosure provides modulators of cystic fibrosis transmembrane conductance regulatory factor (CFTR), the modulators having a core structure (I); pharmaceutical compositions containing at least one such modulator; methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions; a combination pharmaceutical composition and a combination therapy; and processes and intermediates for preparing such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM STEFFEN;;ANDERSON CHRISTOPHER D;;ARUMUGAM VIDYA;;CHOU JOEY;;CLEMENS JOHN;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DINH AMANDA;;DWIGHT TERRY A;;FANNING LEV T D;;FREEMAN BRYAN A;;GROOTENHUIS PETER;;HADIDA RUAH SARA SABINA;;ISHIHARA YASUO;;KRENITZKY PAVEL;;MILLER MARK THOMAS;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;VALDEZ LUIS;;CHOU JOEY,,https://lens.org/011-363-748-097-132,Patent Application,no,0,0,18,18,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/04;;C07D515/14,C07D515/04,,0,0,,,,PENDING
559,CN,A,CN 116783204 A,020-487-093-653-978,2023-09-19,2023,CN 202180081900 A,2021-10-06,US 202063088935 P;;US 2021/0053860 W,2020-10-07,Modulators of cystic fibrosis transmembrane conductance regulators,"The present disclosure provides modulators of cystic fibrosis transmembrane conductance regulatory factor (CFTR), the modulators having a core structure: pharmaceutical compositions containing at least one such modulator; methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions; a combination pharmaceutical composition and a combination therapy; and processes and intermediates for preparing such modulators. # imgabs0 #",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER RUSSELL;;ABRAHAM STEFFEN;;ANDERSON CHRISTOPHER D;;ARUMUGAM VIDYA;;CHOU JOEY;;CLEMENS JOHN;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TERRY A;;FANNING LEV T D;;FREEMAN BRYAN A;;GROOTENHUIS PETER;;GUREVICH ALEKSANDR VLADIMIROVICH;;HADIDA RUAH SARA SABINA;;ISHIHARA YASUO;;KHATUYA HARDIK;;KRENITZKY PAVEL;;MELILLO VITO;;MILLER MARK THOMAS;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALINA;;TRAN JOE A;;UY JOHNNY;;VALDEZ LUIS;;CHOU JOEY,,https://lens.org/020-487-093-653-978,Patent Application,no,0,0,19,19,0,C07D515/04;;A61P43/00;;C07D515/04;;A61P43/00;;C07D515/04;;A61K31/519;;A61P43/00;;A61K45/06;;C07D515/08,C07D515/08;;A61K31/529;;A61P1/00;;A61P1/18;;A61P11/00;;A61P43/00,,0,0,,,,PENDING
560,AU,A1,AU 2020/220185 A1,125-867-655-710-391,2020-09-10,2020,AU 2020/220185 A,2020-08-21,AU 2020/220185 A;;AU 2015/328174 A;;US 201462060182 P;;US 201562153120 P;;US 201562114767 P;;US 2015/0054316 W,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula (I): W OZ, x z' (R1)n A B (R2)p (Y)0 C (R3)q (1) or a pharmaceutically acceptable salt thereof, where R 1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/125-867-655-710-391,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D209/18;;A01N41/06;;A61K31/18,,0,0,,,,ACTIVE
561,AR,A1,AR 102180 A1,166-450-036-044-354,2017-02-08,2017,AR P150103214 A,2015-10-06,US 201462060182 P,2014-10-06,MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA,"Para el tratamiento de enfermedades mediadas por CFTR, como fibrosis quística. La presente también caracteriza composiciones farmacéuticas, método de tratamiento y sus kits. Reivindicación 1: Un compuesto de la fórmula (1), una de sus sales farmacéuticamente aceptables, en donde, de modo independiente para cada aparición: Anillo A es un anillo arilo C₆₋₁₀; anillo cicloalquilo C₃₋₁₀; o un anillo heteroarilo o heterocíclico C₃₋₁₄, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, O, S, N o NR; Anillo B es un anillo cicloalquilo C₃₋₁₀; un anillo arilo C₆₋₁₀; o un anillo heteroarilo o heterocíclico C₄₋₁₀, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, O, S, N o NR; Anillo C es un anillo arilo C₆₋₁₀; un anillo heteroarilo o heterocíclico C₃₋₁₄, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, N, NR, O ó S; o un anillo cicloalquilo C₃₋₁₀; W es O, NR o S; X es O ó NR; Y es, de modo independiente, CRR, CO, O, S, SO, SO₂, S(O)NH o NR; Z es NR o CHR; R¹ es halo; CN; F₅S; SiR₃; OH; NRR; alquilo C₁₋₆ o fluoroalquilo; alcoxi C₁₋₆ o fluoroalcoxi; alquenilo C₁₋₆; alquinilo C₁₋₆, (alquilen C₁₋₉)-R⁴, en donde hasta cuatro unidades de CH₂ son reemplazadas, de modo independiente, con O, CO, S, SO, SO₂ o NR; arilo C₆₋₁₀; anillo heteroarilo o heterocíclico C₃₋₁₀, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, O, S, N o NR; o cicloalquilo C₃₋₁₀; R² es halo; OH; NRR; azida; CN; CO₂R; alquilo C₁₋₆ o fluoroalquilo; alcoxi C₁₋₆ o fluoroalcoxi; alquenilo C₁₋₆; alquinilo C₁₋₆; arilo C₆₋₁₀; anillo heteroarilo o heterocíclico C₃₋₁₃, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, O, S, N o NR; cicloalquilo C₃₋₁₀; o un (alquilen C₁₋₉)-R⁴, en donde hasta cuatro unidades de CH₂ son reemplazadas, de modo independiente, con O, CO, S, SO, SO₂ o NR; dos R² pueden formar un grupo =CH₂ u =O; R³ es halo; CN; OH; CO₂R; alquilo C₁₋₆ o fluoroalquilo; alquenilo C₁₋₆; alquinilo C₁₋₆; alcoxi C₁₋₆ o fluoroalcoxi; o arilo C₆₋₁₀; anillo heteroarilo o heterocíclico C₃₋₁₀, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, O, S, N o NR; cicloalquilo C₃₋₁₀; o un (alquilen C₁₋₉)-R⁴, en donde hasta cuatro unidades de CH₂ son reemplazadas, de modo independiente, con O, CO, S, SO, SO₂ o NR; dos R³ pueden formar un grupo =CH₂ u =O; R⁴ es H; azida; CF₃; CHF₂; OR; CCH; CO₂R; OH; arilo C₆₋₁₀, heteroarilo C₃₋₁₀ o heterocicloalquilo, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, O, S, N o NR; cicloalquilo C₃₋₁₀; NRR, NRCOR, CONRR, CN, halo o SO₂R; R es, de modo independiente, H; OH; CO₂H; CO₂-alquilo C₁₋₆; alquilo C₁₋₆; alquenilo C₁₋₆; alquinilo C₁₋₆; arilo C₆₋₁₀; heteroarilo C₃₋₁₀ o heterocicloalquilo, en donde cualquiera de 1 a 4 átomos de anillo son, de modo independiente, O, S, N o NR; o cicloalquilo C₃₋₁₀; n es 0, 1, 2 ó 3; o es 0 1, 2, 3, 4 ó 5; p es 0, 1, 2 ó 3; y q es 0, 1, 2, 3, 4 ó 5; ⁻ ⁻ ⁻ ⁻ ⁻ es un enlace simple o un enlace doble; siempre que los restos que contienen anillo B y anillo C se sustituyan en posiciones adyacentes en el anillo A.",VERTEX PHARMA,MARK THOMAS MILLER;;COREY ANDERSON;;VIJAYALAKSMI ARUMUGAM;;BRIAN RICHARD BEAR;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;ERICA CONROY;;TIMOTHY RICHARD COON;;BRYAN A FRIEMAN;;PETER DIEDERIK JAN GROOTENHUIS;;RAYMOND STANLEY GROSS;;SARA SABINA HADIDA-RUAH;;KHATUYA HARIPADA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;CHUN LIN;;GULIN ERDGOGAN CHIEH - MARELIUS;;VITO MELILLO;;JASON MCARTNEY;;GEORGIA MGAUGHEY NICHOLLS;;FABRICE JEAN DENIS PIERRE;;ALINA SILINA;;ANDREAS P TERMIN;;JOHNNY UY;;JINGLAN ZHOU,,https://lens.org/166-450-036-044-354,Patent Application,no,0,0,1,68,0,,C07D209/42;;A61K31/403;;A61K31/415;;A61K31/4245;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/47;;A61K31/497;;A61K31/505;;A61K31/506;;A61K31/517;;A61K31/5377;;A61K31/55;;A61P3/00;;A61P5/00;;A61P11/00;;C07D213/81;;C07D231/14;;C07D239/557;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/14;;C07D409/04;;C07D413/12;;C07D413/14;;C07D417/12;;C07D471/04;;C07D471/06;;C07D491/107,,0,0,,,,PENDING
562,CN,A,CN 107690281 A,167-556-446-401-889,2018-02-13,2018,CN 201580066301 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTRmediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",MILLER MARK THOMAS,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/167-556-446-401-889,Patent Application,no,1,5,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,3,1,061-669-166-608-882,10.1021/jm00070a012;;8410980,"MARTIN WINN ET,AL.: ""2-(Alkylamino)nicotinic acid and analogs. Potent Angiotensin II Antagonists"", 《J.MED.CHEM.》;;JADWIGA SOLODUCHO: ""Synthesis of Some Pyrido[2,3-c][1,2,6]triazonine Derivatives"", 《JOURNAL F. PRAKT. CHEMIE.》;;B.C. JAIN ET,AL.: ""Studies in sulphanilamides. part XIII. Reaction with dicarboxylic acids. Some new N1- and N4-acyl and heterocyclic derivatives"", 《JOURNAL OF THE INDIAN CHEMICAL SOCIETY》",ACTIVE
563,AU,A1,AU 2023/201404 A1,001-503-784-383-645,2023-04-06,2023,AU 2023/201404 A,2023-03-07,AU 2023/201404 A;;AU 2020/220185 A;;AU 2015/328174 A;;US 201462060182 P;;US 201562153120 P;;US 201562114767 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"Abstract The present invention features a compound of formula I: z~ A B (R2)p (Y). C (R3)q I, or a pharmaceutically acceptable salt thereof, where R 1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/001-503-784-383-645,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D209/18;;A01N41/06;;A61K31/18,,0,0,,,,PENDING
564,EP,A4,EP 3203840 A4,126-311-786-902-345,2018-08-15,2018,EP 15849396 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/126-311-786-902-345,Search Report,no,4,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,9,6,012-371-996-064-723;;034-587-611-086-755;;009-891-282-676-18X;;039-573-265-223-407;;078-417-508-507-333;;061-669-166-608-882,10.1016/j.bmcl.2003.10.049;;14698169;;22104146;;10.1016/j.bmcl.2011.10.041;;10.1039/b009154p;;10.1021/jm0111346;;12061878;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1021/jm00070a012;;8410980,"KETTLE J G ET AL: ""N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 14, no. 2, 1 January 2004 (2004-01-01), pages 405 - 408, XP002393948, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2003.10.049;;ANILKUMAR GOPINADHAN N ET AL: ""II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 22, no. 1, 20 October 2011 (2011-10-20), pages 713 - 717, XP029121479, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2011.10.041;;SOLODUCHO ET AL: ""Synthesis of Some Pyrido<2,3-c><1,2,6>triazinone derivatives"", JOURNAL FÜR PRAKTISCHE CHEMIE - CHEMIKER-ZEITUNG,, vol. 331, no. 3, 1 January 1989 (1989-01-01), pages 503 - 506, XP009504111, ISSN: 0941-1216;;PASSARELLA D ET AL: ""Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition"", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, ROYAL SOCIETY OF CHEMISTRY, GB, no. 2, 1 January 2001 (2001-01-01), pages 127 - 129, XP003017354, ISSN: 0300-922X, DOI: 10.1039/B009154P;;MATTER H ET AL: ""Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 45, no. 13, 1 January 2002 (2002-01-01), pages 2749 - 2769, XP002256632, ISSN: 0022-2623, DOI: 10.1021/JM0111346;;HOPKINS C R ET AL: ""Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 21, 1 November 2006 (2006-11-01), pages 5659 - 5663, XP027966155, ISSN: 0960-894X, [retrieved on 20061101];;JAIN B C ET AL: ""STUDIES IN SULPHANILAMIDES. PART XIII. REACTION WITH DICARBOXYLIC ACIDS. SOME NEW N1- AND N4-ACYL AND HETEROCYCLIC DERIVATIVES"", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, INDIAN CHEMICAL SOCIETY, IN, vol. 24, 1 January 1947 (1947-01-01), pages 173 - 176, XP002037442, ISSN: 0019-4522;;WINN M ET AL: ""2-(ALKYLAMINO)NICOTINC ACID AND ANALOGS. POTENT ANGIOTENSIN II ANTAGONISTS"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 36, no. 18, 1 January 1993 (1993-01-01), pages 2676 - 2688, XP002281129, ISSN: 0022-2623, DOI: 10.1021/JM00070A012;;See also references of WO 2016057572A1",ACTIVE
565,CN,A,CN 112279808 A,145-226-683-644-323,2021-01-29,2021,CN 202011206273 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;CN 201580066301 A,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention relates to modulators of cystic fibrosis transmembrane conductance regulators, characterized by a compound of formula (I): or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p and q are as defined herein, for use in the treatment of CFTR-mediated diseases such as cystic fibrosis. The invention also features pharmaceutical compositions, methodsof treatment thereof, and kits.",VERTEX PHARMA,MARK THOMAS MILLER;;ANDERSON CLINT;;VIJAYALAKSMI ARUMUGAM;;BRIAN RICHARD BEAR;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROTENKHEJS PETER DIDERIK JAN;;GROSS REJMOND STENLI;;ADIDA-RUA SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHIA-CHING;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;CHOW JERRY,,https://lens.org/145-226-683-644-323,Patent Application,no,3,1,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D213/82;;A61K31/4035;;A61K31/404;;A61K31/415;;A61K31/4155;;A61K31/416;;A61K31/4245;;A61K31/4439;;A61K31/444;;A61K31/4545;;A61K31/455;;A61K31/4709;;A61K31/4725;;A61K31/4965;;A61P1/18;;A61P11/00;;C07D209/42;;C07D209/44;;C07D213/81;;C07D213/85;;C07D217/26;;C07D231/12;;C07D231/14;;C07D231/56;;C07D241/24;;C07D401/04;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/14,,4,2,078-417-508-507-333;;061-669-166-608-882,10.1016/j.bmcl.2006.08.003;;16919947;;10.1021/jm00070a012;;8410980,"JADWIGA SOLODUCHO: ""Synthesis of Some Pyrido[2,3-c][1,2,6]triazonine Derivatives"", JOURNAL F. PRAKT. CHEMIE.;;COREY R. HOPKINS ET AL.: ""Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-c binding agents with potential application to the treatment of osteoporosis"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS;;MARTIN WINN ET,AL.: ""2-(Alkylamino)nicotinic acid and analogs. Potent AngiotensinⅡAntagonists"", J.MED.CHEM.;;REGISTRY: ""RN：1026625-71-7，915701-34-7，915701-32-5，220678-97-7 et al."", STN",PENDING
566,US,A2,US 2017/0196862 A2,142-690-148-497-456,2017-07-13,2017,US 201514876525 A,2015-10-06,US 201514876525 A;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CIEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CIEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/142-690-148-497-456,Amended Application,no,0,1,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/506;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;C07D209/42;;C07D213/82;;C07D213/84;;C07D231/12;;C07D231/14;;C07D401/12;;C07D401/14;;C07D405/14;;C07D417/12,,0,0,,,,ACTIVE
567,LT,T,LT 3203840 T,182-270-336-384-694,2020-10-26,2020,LT 15849396 T,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/182-270-336-384-694,Unknown,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,PENDING
568,DK,T3,DK 3203840 T3,015-493-432-471-256,2020-08-31,2020,DK 15849396 T,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORER AF CYSTISK FIBROSE-TRANSMEMBRANKONDUKTANSREGULATOR,,VERTEX PHARMA,ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;MILLER MARK THOMAS;;ANDERSON COREY;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/015-493-432-471-256,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,ACTIVE
569,BR,A2,BR 112017007167 A2,102-732-597-943-871,2018-04-10,2018,BR 112017007167 A,2015-10-06,US 2015/0054316 W;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,moduladores do regulador de condutância transmembranar de fibrose cística,"a presente invenção apresenta um composto de fórmula i: i, ou um sal farmaceuticamente aceitável do mesmo, em que r1, r2, r3, w, x, y, z, n, o, p e q são definidos nesse documento, para o tratamento de doenças mediadas pelo cftr, como a fibrose cística. a presente invenção também fornece composições farmacêuticas, método de tratamento e kits dos mesmos.",VERTEX PHARMA,ALINA SILINA;;ANDREAS P TERMIN;;BRIAN RICHARD BEAR;;BRYAN A FRIEMAN;;CHUN-CHIEH LIN;;COREY ANDERSON;;ERICA CONROY;;FABRICE JEAN DENIS PIERRE;;GEORGIA MCGAUGHEY NICHOLLS;;GULIN ERDOGAN MARELIUS;;HARIPADA KHATUYA;;HAYLEY MARIE BINCH;;JASON MCCARTNEY;;JEREMY J CLEMENS;;JINGLAN ZHOU;;JOHNNY UY;;MARK THOMAS MILLER;;PAUL JOHN KRENITSKY;;PETER DIEDERIK JAN GROOTENHUIS;;PRAMOD VIRUPAX JOSHI;;RAYMOND STANLEY GROSS;;SARA SABINA HADIDA-RUAH;;THOMAS CLEVELAND;;TIMOTHY RICHARD COON;;VIJAYALAKSMI ARUMUGAM;;VITO MELILLO,,https://lens.org/102-732-597-943-871,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/18;;A01N41/06,,0,0,,,,ACTIVE
570,SG,A,SG 10201913603Q A,199-420-462-882-027,2020-02-27,2020,SG 10201913603Q A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/199-420-462-882-027,Unknown,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,,,0,0,,,,PENDING
571,JP,A,JP 2021138751 A,020-440-514-194-944,2021-09-16,2021,JP 2021096627 A,2021-06-09,JP 2017518241 A;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"To provide methods of treating CFTR-mediated diseases, such as cystic fibrosis.SOLUTION: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions, treatment methods and kits thereof.SELECTED DRAWING: None",VERTEX PHARMA,MARK THOMAS MILLER;;COREY ANDERSON;;VIJAYALAKSMI ARUMUGAM;;BRIAN RICHARD BEAR;;HAYLEY MARIE BINCH;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;ERICA CONROY;;TIMOTHY RICHARD COON;;BRYAN A FRIEMAN;;PETER DIEDERIK JAN GROOTENHUIS;;RAYMOND STANLEY GROSS;;SARA SABINA HADIDA-RUAH;;HARIPADA KHATUYA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;LIN CHUN-CHIEH;;GULIN ERDOGAN MARELIUS;;VITO MELILLO;;MCCARTNEY JASON;;GEORGIA MCGAUGHEY NICHOLLS;;FABRICE JEAN DENIS PIERRE;;SILINA ALINA;;ANDREAS P TERMIN;;JOHNNY UY;;ZHOU JINGLAN,,https://lens.org/020-440-514-194-944,Patent Application,no,6,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D207/34;;A61K31/40;;A61K31/4035;;A61K31/404;;A61K31/415;;A61K31/4155;;A61K31/416;;A61K31/4184;;A61K31/4196;;A61K31/421;;A61K31/4245;;A61K31/427;;A61K31/437;;A61K31/4418;;A61K31/4427;;A61K31/443;;A61K31/4433;;A61K31/4439;;A61K31/444;;A61K31/4545;;A61K31/47;;A61K31/4709;;A61K31/472;;A61K31/4725;;A61K31/473;;A61K31/496;;A61K31/4965;;A61K31/497;;A61K31/505;;A61K31/506;;A61K31/5377;;A61K31/55;;A61K31/551;;A61K45/00;;A61P11/08;;A61P29/00;;A61P31/00;;A61P31/04;;A61P43/00;;C07D209/42;;C07D209/44;;C07D213/73;;C07D213/81;;C07D213/82;;C07D215/54;;C07D217/26;;C07D223/16;;C07D231/12;;C07D231/14;;C07D231/56;;C07D235/24;;C07D239/34;;C07D241/24;;C07D249/10;;C07D263/34;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/06;;C07D403/10;;C07D403/12;;C07D405/04;;C07D405/12;;C07D405/14;;C07D409/04;;C07D409/12;;C07D409/14;;C07D413/14;;C07D417/12;;C07D417/14;;C07D451/02;;C07D471/04;;C07D471/08;;C07D487/08;;C07D491/052;;C07D491/08;;C07D491/107,,0,0,,,,PENDING
572,ZA,B,ZA 201703054 B,029-225-314-079-330,2023-03-29,2023,ZA 201703054 A,2017-05-03,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON,,https://lens.org/029-225-314-079-330,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,,,0,0,,,,ACTIVE
573,CN,A,CN 112250627 A,152-097-504-377-553,2021-01-22,2021,CN 202011206272 A,2015-10-06,CN 202011206272 A;;CN 201580066301 A;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention relates to modulators of a cystic fibrosis transmembrane conductance regulator. The present invention is characterized by compounds of formula (I): or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p and q are as defined herein, for use in the treatment of CFTR-mediated diseases such as cystic fibrosis. The invention is also characterized by pharmaceutical compositions, methods of treatment thereof, and kits.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON CHARLES;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHIA-CHING;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;CHOW JERRY,,https://lens.org/152-097-504-377-553,Patent Application,no,2,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D213/82;;A61K31/4035;;A61K31/404;;A61K31/415;;A61K31/4155;;A61K31/416;;A61K31/4245;;A61K31/4439;;A61K31/444;;A61K31/4545;;A61K31/455;;A61K31/4709;;A61K31/4725;;A61K31/4965;;A61P1/18;;A61P11/00;;C07D209/42;;C07D209/44;;C07D213/81;;C07D213/85;;C07D217/26;;C07D231/12;;C07D231/14;;C07D231/56;;C07D241/24;;C07D401/04;;C07D401/12;;C07D403/10;;C07D405/14;;C07D413/14,,2,0,,,"CHEMSPIDER: ""CAS RN 1026625-71-7"";;COREY R. HOPKINS等: ""Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-c binding agents with potential application to the treatment of osteoporosis""",ACTIVE
574,HR,T1,HR P20201603 T1,185-653-018-345-478,2021-02-19,2021,HR P20201603 T,2020-10-07,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;EP 15849396 A;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/185-653-018-345-478,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,ACTIVE
575,WO,A1,WO 2016/057572 A1,034-722-344-764-177,2016-04-14,2016,US 2015/0054316 W,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/034-722-344-764-177,Patent Application,yes,63,61,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,19,10,027-495-322-764-618;;062-658-814-888-724;;115-252-470-991-090;;147-561-926-460-635;;059-603-579-320-605;;139-606-967-003-103;;009-491-011-950-586;;016-134-959-107-874;;029-966-049-767-156;;007-364-858-655-289,1695717;;10.1038/346366a0;;10.1016/0092-8674(90)90196-l;;2344617;;10.1126/science.2570460;;2570460;;2236053;;pmc54973;;10.1073/pnas.87.21.8447;;10.1096/fasebj.4.10.2197151;;2197151;;10.1038/354526a0;;1722027;;7539001;;10.1074/jbc.270.21.12347;;10.1080/00397919608003838;;10.1016/b978-0-12-386009-5.00003-5;;10.1002/jps.2600660104;;833720,"DATABASE PubChem 19 August 2012 (2012-08-19), Database accession no. 58132855;;DATABASE PubChem 19 November 2009 (2009-11-19), Database accession no. 44419393;;DATABASE PubChem 16 July 2005 (2005-07-16), Database accession no. 2545578;;DATABASE PubChem 2 December 2010 (2010-12-02), Database accession no. 49774135;;CUTTING, G. R. ET AL., NATURE, vol. 346, 1990, pages 366 - 369;;DEAN, M. ET AL., CELL, vol. 61, no. 863, 1990, pages 870;;KEREM, B-S. ET AL., SCIENCE, vol. 245, 1989, pages 1073 - 1080;;KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 8447 - 8451;;QUINTON, P. M., FASEB J., vol. 4, 1990, pages 2709 - 2727;;DALEMANS ET AL., NATURE LOND., vol. 354, 1991, pages 526 - 528;;PASYKFOSKETT, J. CELL. BIOCHEM., vol. 270, 1995, pages 12347 - 50;;T. HIGUCHIV. STELLA: ""Bioreversible Carriers in Drug Design"", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article ""Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series"";;JUDKINS ET AL., SYNTHETIC COMMUNICATIONS, vol. 26, no. 23, 1996, pages 4351 - 4367;;R. SILVERMAN: ""The Organic Chemistry of Drug Design and Drug Action"", 2004, ELSEVIER ACADEMIC PRESS;;S. L. HARBESONR. D. TUNG: ""Deuterium In Drug Discovery and Development"", ANN. REP. MED. CHEM., vol. 46, 2011, pages 403 - 417;;S. M. BERGE ET AL.: ""pharmaceutically acceptable salts"", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;J. SWARBRICKJ. C. BOYLAN: ""Encyclopedia of Pharmaceutical Technology"", 1988, MARCEL DEKKER;;See also references of EP 3203840A4",PENDING
576,US,B2,US 9782408 B2,074-678-584-751-194,2017-10-10,2017,US 201514876525 A,2015-10-06,US 201514876525 A;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/074-678-584-751-194,Granted Patent,yes,112,22,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/506;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;C07D209/42;;C07D213/82;;C07D213/84;;C07D231/12;;C07D231/14;;C07D401/12;;C07D401/14;;C07D405/14;;C07D417/12,,7,0,,,"CAPLUS 1965 51408.;;CAPLUS 1965 51409.;;International Search Report, International Preliminary Report on Patentability, and Written Opinion of the International Searching Authority for International Application No. PCT/US15/54316, dated Feb. 5, 2016, (11 pages).;;NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database, PubChem CID: 2545578, modified Jan. 16, 2016, https://pubchem.ncbi.nlm.alh.gov/compound/2545578.;;NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database, PubChem CID: 44419393, modified Jan. 16, 2016, https://pubchem.ncbi.nim.nih.gov/compound/44419393.;;NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database, PubChem CID: 49774135, modified Jan. 16, 2016, https://pubchem.ncbi.nlm.nih.gov/compound/49774135.;;NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database, PubChem CID: 58132855, modified Jan. 16, 2016, https://pubchem.ncbi.nlm.nih.gov/compound/58132855.",ACTIVE
577,AU,A8,AU 2015/328174 A8,094-528-835-735-183,2017-05-04,2017,AU 2015/328174 A,2015-10-06,US 201462060182 P;;US 201562153120 P;;US 201562114767 P;;US 2015/0054316 W,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/094-528-835-735-183,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,ACTIVE
578,AU,B2,AU 2015/328174 B2,110-713-755-914-23X,2020-05-21,2020,AU 2015/328174 A,2015-10-06,US 201462060182 P;;US 201562153120 P;;US 201562114767 P;;US 2015/0054316 W,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/110-713-755-914-23X,Granted Patent,no,1,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D209/18;;A01N41/06;;A61K31/18,,0,0,,,,ACTIVE
579,MA,A,MA 41051 A,117-342-231-496-22X,2017-08-16,2017,MA 41051 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATEURS DU RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE,"La présente invention concerne un composé de formule (i): (i) ou un sel pharmaceutiquement acceptable de celui-ci, où r1, r2, r3, w, x, y, z, n, o, p et q sont tels que définis dans la description, lequel composé est utile pour le traitement de maladies médiées par le cftr, telles que la mucoviscidose. La présente invention concerne également des compositions pharmaceutiques, une méthode de traitement et des kits correspondants.",VERTEX PHARMA,ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;JOSHI PRAMOD VIRUPAX;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MCCARTNEY JASON;;MELILLO VITO;;MILLER MARK THOMAS;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/117-342-231-496-22X,Unknown,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,ACTIVE
580,ES,T3,ES 2823850 T3,164-682-505-529-742,2021-05-10,2021,ES 15849396 T,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,Moduladores de regulador de conductancia transmembrana de fibrosis quística,"Un compuesto de fórmula Ib-iii: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, en donde: El anillo B es un anillo C6-C10 arilo, C3-C10 heteroarilo o anillo heterocíclico en donde entre 1 y 4 átomos del anillo son independientemente O, S, N o NR; El anillo C es un C3-C14 heteroarilo o un anillo heterocíclico en donde entre 1 y 4 átomos del anillo son independientemente N, O o S, y en donde un nitrógeno en el anillo C es el punto de unión al anillo de piridina; y en donde, independientemente para cada aparición: R1 es halo; CN; F5S; SiR3; OH; NRR; C1-C6 alquilo o fluoroalquilo; C1-C6 alcoxi o fluoroalcoxi; C1-C6 alquenilo; C1-C6 alquinilo; (C1-C9 alquileno)-R4 en donde hasta cuatro unidades CH2 se reemplazan independientemente con O, CO, S, SO, SO2 o NR; C6-C10 arilo; C3-C10 heteroarilo o anillo heterocíclico en donde entre 1 y 4 átomos del anillo son independientemente O, S, N o NR; o C3-C10 cicloalquilo; R2 es halo; OH; NRR; azida; CN; CO2R; C1-C6 alquilo o fluoroalquilo; C1-C6 alcoxi o fluoroalcoxi; C1-C6 3alquenilo; C1-C6 alquinilo; C6-C10 arilo; C3-C13 heteroarilo o anillo heterocíclico en donde entre 1 y 4 átomos del anillo son independientemente O, S, N o NR; C3-C10 cicloalquilo; o un alquilo (C1-C9 alquileno)-R4 en donde hasta cuatro unidades CH2 se sustituyen independientemente con O, CO, S, SO, SO2 o NR; o dos grupos R2 tomados juntos pueden formar un grupo =CH2 o =O; R3 es halo; CN; CO2R; C1-C6 alquilo o fluoroalquilo; C1-C6 alquenilo; C1-C6 alquinilo; C1-C6 alcoxi o fluoroalcoxi; o C6-C10 arilo; C3-C10 heteroarilo o anillo heterocíclico en donde entre 1 y 4 átomos del anillo son independientemente O, S, N o NR; C3-C10 cicloalquilo; o un alquilo (C1-C9 alquileno)-R4 en donde hasta cuatro CH2 unidades están independientemente reemplazados con O, CO, S, SO, SO2 o NR; o dos grupos R3 tomados juntos pueden formar un grupo =CH2 o =O; R4 es H; azida; CF3; CHF2; O; CCH; CO2R; OH; C6-C10 arilo, C3-C10 heteroarilo o heterocicloalquilo en los que entre 1 y 4 átomos del anillo son independientemente O, S, N o NR; C3-C10 cicloalquilo; NRR, NRCOR, CONRR, CN, halo o SO2R; R es independientemente H; OH; CO2H; CO2C1-C6 alquilo; C1-C6 alquilo; C1-C6 alquenilo; C1-C6 alquinilo; C6-C10 arilo; C3-C10 heteroarilo o heterocicloalquilo en donde entre 1 y 4 átomos del anillo son independientemente O, S, N o NR; o C3-C10 cicloalquilo; n es 0, 1, 2 o 3; p es 0, 1, 2 o 3; y q es 0, 1, 2, 3, 4, o 5; en donde cada uno de los grupos específicos para las variables R1-R4 puede estar opcionalmente sustituido con uno o más grupos seleccionados entre halo, fosfo, OH, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, fluoroalquilo, alquilo, alquenilo, alquinilo, nitro, CN, hidroxilo, y alquilo (C1-C9 alquileno)-S en donde hasta 4 unidades CH2 se sustituyen independientemente con O, S, SO2, SO, CO, NH, N-alquilo, N-alquenilo o N-alquinilo, y E es H, arilo, cicloalquilo, heterocicloalquilo, heteroarilo, alcoxi, CN, o CF3, en donde además cada uno de los grupos arilo, cicloalquilo, heterocicloalquilo, y heteroarilo está opcionalmente sustituido con uno o más grupos seleccionados de halo, alquilo, amino, CN, alquenilo, alquinilo y alcoxi; y cuando dos grupos alcoxi están unidos al mismo átomo o átomos adyacentes, los dos grupos alcoxi pueden formar un anillo junto con el (los) átomo(s) a los que están unidos; y en donde el término ""amino"" se refiere a NH2 que está opcionalmente sustituido con uno o dos grupos seleccionados independientemente de alquilo, cicloalquilo y heterocicloalquilo.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/164-682-505-529-742,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,ACTIVE
581,CA,A1,CA 2963792 A1,174-170-321-477-208,2016-04-14,2016,CA 2963792 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features compounds of formula (lb): and pharmaceutically acceptable salts thereof, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, methods of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN;;ANDERSON COREY,,https://lens.org/174-170-321-477-208,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,PENDING
582,US,A1,US 2018/0185364 A1,186-990-400-804-827,2018-07-05,2018,US 201715675000 A,2017-08-11,US 201715675000 A;;US 201514876525 A;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/186-990-400-804-827,Patent Application,yes,0,1,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/506;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;C07D209/42;;C07D213/82;;C07D213/84;;C07D231/12;;C07D231/14;;C07D401/12;;C07D401/14;;C07D405/14;;C07D417/12,,0,0,,,,ACTIVE
583,AR,A2,AR 120708 A2,104-383-519-980-124,2022-03-09,2022,AR P200103429 A,2020-12-10,AR P200103429 A,2020-12-10,COMPUESTOS MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUÍSTICA Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDEN,Se proveen además composiciones farmacéuticas que comprenden a éstos compuestos junto con otro u otros agentes terapéuticos adicionales.,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN;;CHIEH - MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCARTNEY JASON;;NICHOLLS GEORGIA MGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/104-383-519-980-124,Amended Application,no,0,0,1,1,0,,C07D231/14;;A61K31/415,,0,0,,,,PENDING
584,SG,A,SG 11201702817S A,033-043-744-035-511,2017-05-30,2017,SG 11201702817S A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/033-043-744-035-511,Unknown,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,PENDING
585,EP,A1,EP 3203840 A1,099-563-296-461-173,2017-08-16,2017,EP 15849396 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/099-563-296-461-173,Patent Application,yes,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,ACTIVE
586,PL,T3,PL 3203840 T3,142-533-312-550-660,2021-01-11,2021,PL 15849396 T,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;EP 15849396 A;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/142-533-312-550-660,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,PENDING
587,US,B2,US 10758534 B2,182-089-308-231-416,2020-09-01,2020,US 201916258024 A,2019-01-25,US 201916258024 A;;US 201715675000 A;;US 201514876525 A;;US 201562153120 P;;US 201562114767 P;;US 201462060182 P,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/182-089-308-231-416,Granted Patent,yes,222,2,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D213/82;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;A61K31/506;;C07D209/18;;C07D209/42;;C07D209/49;;C07D213/64;;C07D213/73;;C07D213/84;;C07D231/12;;C07D231/14;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/14;;C07D407/12;;C07D413/14;;C07D417/12,,43,14,034-587-611-086-755;;013-937-078-602-349;;096-312-557-325-378;;078-417-508-507-333;;012-371-996-064-723;;103-052-069-575-996;;039-573-265-223-407;;064-116-226-667-307;;009-891-282-676-18X;;006-026-497-014-33X;;010-718-962-322-429;;061-669-166-608-882;;045-406-285-588-795;;079-362-981-419-890,22104146;;10.1016/j.bmcl.2011.10.041;;23394148;;10.1021/ol400049m;;10.1055/s-0035-1561339;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1016/j.bmcl.2003.10.049;;14698169;;10.1021/jo01296a034;;10.1021/jm0111346;;12061878;;24392786;;10.1517/13543776.2014.876412;;10.1039/b009154p;;10.1016/s1569-1993(16)30138-2;;25981758;;pmc4764353;;10.1056/nejmoa1409547;;10.1021/jm00070a012;;8410980;;10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744;;10.1055/s-1999-3685,"Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” Biogranic & Medicinal Chemistry Letters, 22(1):713-717.;;Belikov, V.G., (2007) Farmatsevticheskaya khimiya (Pharmaceutical Chemistry), Moscow: MEDpress-inform, pp. 27-29.;;Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” Organic Lett, 15(5):1056-1059.;;Chen, Y. (Jan. 26, 2016) “N-Monoacylation of Sulfonimidamides” Synthesis, 48(7):1019-1028.;;Database Caplus, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-UCLAF [online]. Retrieved Jan. 6, 2017 (1 page).;;Database Caplus, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages).;;Database Pubchem, CID: 20050716. Compound Summary, 1-[2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20050716, on Dec. 3, 2019 (7 pages).;;Database Pubchem, CID: 20091118. Compound Summary, [4-(5-Hexylpyrimidin-2-yl)phenyl] 2-methoxypropanoate. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20091118, on Dec. 3, 2019 (9 pages).;;Database Pubchem, CID: 20120819. Compound Summary, 4-(Cyclopentyloxy)-3-fluorobenzene-1-sulfonyl chloride. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20120819, on Dec. 3, 2019 (8 pages).;;Database Pubchem, CID: 2545578. Compound Summary, T5339296. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2545578, on Jan. 22, 2016 (9 pages).;;Database Pubchem, CID: 44419393. Compound Summary, CHEMBL374189. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/44419393, on Jan. 22, 2016 (11 pages).;;Database Pubchem, CID: 49774135. Compound Summary, SCHEMBL13395127. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016 [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/49774135, on Jan. 22, 2016 (10 pages).;;Database Pubchem, CID: 58132855. Compound Summary, SCHEMBL831192. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database; Modify Date: Jan. 16, 2016 [online]. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/58132855, on Jan. 22, 2016 (10 pages).;;Dorwald, F. A. (2006) “Side Reactions in Organic Synthesis” Wiley: VCH, Weinheim p. IX of Preface p. 1-15.;;Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemistry Letters, 16(21):5659-5663.;;International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, dated Feb. 5, 2016 (11 pages).;;International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, dated Jun. 6, 2017 (11 pages).;;International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, dated Jan. 3, 2018 (10 pages).;;International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, dated Feb. 27, 2018 (10 pages).;;International Patent Application No. PCT/US2018/036610: International Search Report and Written Opinion, dated Sep. 19, 2018 (9 pages).;;International Patent Application No. PCT/US2018/040427: International Search Report and Written Opinion, dated Oct. 9, 2018 (15 pages).;;International Patent Application No. PCT/US2018/042415: International Search Report and Written Opinion, dated Oct. 31, 2018 (12 pages).;;International Patent Application No. PCT/US2018/042486: International Search Report and Written Opinion, dated Nov. 7, 2018 (13 pages).;;International Patent Application No. PCT/US2018/044963: International Search Report and Written Opinion, dated Sep. 25, 2018 (15 pages).;;International Patent Application No. PCT/US2018/056772: International Search Report and Written Opinion, dated Jan. 29, 2019 (13 pages).;;Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some New N1- and N4-ACYL and Heterocycic Derivatives” Journal of the Indian Chemical Society, 24:173-176.;;Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” Bioorganic & Medicinal Chemistry Letters, 14(2): 405-408.;;Lai, J.T. et al. (1980) “Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions,” Journal of Organic Chemistry, 45(8):1513-1514.;;Matter, H. et al. (2002) “Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzy1-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” Journal of Medicinal Chemistry, 45(13):2749-2769.;;Norman, P. (2014) “Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386, and WO2013038390,” Expert Opinion on Therapeutic Patents, 24(7):829-837.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 15/721,390, dated Sep. 4, 2019.;;Notman, N. (2016) “2Heavy drugs gaining momentum” [online] Retrieved from the internet: https://www.chemistryworld.com/features/2heavy-drugs-gaining-momentum/1010186.article, on Oct. 7, 2019.;;Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” Journal of the Chemical Society, Perkin Transactions 1, 127-129.;;Rosebraugh, C.J. (2015) “Highlights of Presecribing Information for Orkambi,” [online] Retrieved from the Internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf, on Aug. 24, 2017.;;Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32.;;Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” Journal für Pracktische Chemie, 331(3):503-506.;;Tullis, E. et al. (2018) “Preliminary safety and efficacy of triple-combination CFTR modulator regimens,” Respirology, 23(51):33.;;Uttamsingh, V. et al. (2016) “WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies” Journal of Cystic Fibrosis, 15:S22.;;Wainwright, C.E. et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” The New England Journal of Medicine, 373(3):220-231.;;Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” Journal of Medicinal Chemistry, 36(18):2676-2688.;;Venkatesh, S. et al. (2000) “Role of the development scientist in compound lead selection and optimization” J. Pharm. Sci. 89(2), 145-154.;;Verado, G. et al. (1999) “Reductive One Batch Synthesis of N-Substituted Pyrrolidines from Primary Amines and 2,5-Dimethoxytetrahydrofuran” Synthesis, (1):74-79.;;Vertex Pharmaceuticals, Inc. (Mar. 28, 2017) “Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People With Cystic Fibrosis” [online] Retrieved from the Internet: http://investors.vrtx.com/static-files/f15217ac-4a8b-436a-9215-79144ec2e59b, on Oct. 10, 2019.",ACTIVE
588,AU,B2,AU 2020/220185 B2,016-997-154-947-271,2022-12-08,2022,AU 2020/220185 A,2020-08-21,AU 2020/220185 A;;AU 2015/328174 A;;US 201462060182 P;;US 201562153120 P;;US 201562114767 P;;US 2015/0054316 W,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula (I): W OZ, x z' (R1)n A B (R2)p (Y)0 C (R3)q (1) or a pharmaceutically acceptable salt thereof, where R 1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/016-997-154-947-271,Granted Patent,no,4,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D209/18;;A01N41/06;;A61K31/18,,6,4,012-371-996-064-723;;034-587-611-086-755;;039-573-265-223-407;;078-417-508-507-333,10.1016/j.bmcl.2003.10.049;;14698169;;22104146;;10.1016/j.bmcl.2011.10.041;;10.1021/jm0111346;;12061878;;10.1016/j.bmcl.2006.08.003;;16919947,"JAIN B C ET AL, ""STUDIES IN SULPHANILAMIDES. PART XIII. REACTION WITH DICARBOXYLIC ACIDS. SOME NEW N1- AND N4-ACYL AND HETEROCYCLIC DERIVATIVES"", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, (1947-01-01), vol. 24, pages 173 - 176;;KETTLE J G ET AL, ""N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (2004-01-01), vol. 14, no. 2, pages 405 - 408;;ANILKUMAR GOPINADHAN N ET AL, ""II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (2011-10-20), vol. 22, no. 1, pages 713 - 717;;SOLODUCHO ET AL, ""Synthesis of Some Pyrido2,3-c1,2,6triazinone derivatives"", JOURNAL FÜR PRAKTISCHE CHEMIE - CHEMIKER-ZEITUNG,, (1989-01-01), vol. 331, no. 3, ISSN 0941-1216, pages 503 - 506;;MATTER H ET AL, ""Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa"" J. MED. CHEM, vol 45, no 13, pages 2749-2769;;HOPKINS C R ET AL, ""Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis"", BIOORG. & MED. CHEM. LETT, vol. 16, no. 21, pages 5659-5663",ACTIVE
589,US,A1,US 2019/0269683 A1,058-123-947-131-359,2019-09-05,2019,US 201916258024 A,2019-01-25,US 201916258024 A;;US 201715675000 A;;US 201514876525 A;;US 201562153120 P;;US 201562114767 P;;US 201462060182 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HALEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/058-123-947-131-359,Patent Application,yes,2,17,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/506;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;C07D209/18;;C07D209/42;;C07D209/49;;C07D213/64;;C07D213/73;;C07D213/82;;C07D213/84;;C07D231/12;;C07D231/14;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/14;;C07D407/12;;C07D413/14;;C07D417/12,,0,0,,,,ACTIVE
590,UA,C2,UA 125245 C2,083-699-317-700-615,2022-02-09,2022,UA A201704446 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R1, R2, Я3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/083-699-317-700-615,Limited Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,,,0,0,,,,ACTIVE
591,MX,A,MX 2017004543 A,164-085-079-069-409,2017-10-04,2017,MX 2017004543 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR.,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,SARA SABINA HADIDA-RUAH;;MARK THOMAS MILLER;;BRIAN RICHARD BEAR;;VIJAYALAKSMI ARUMUGAM;;JOHNNY UY;;BRYAN A FRIEMAN;;HAYLEY MARIE BINCH;;PETER DIEDERIK JAN GROOTENHUIS;;ALINA SILINA;;JASON MCCARTNEY;;COREY ANDERSON;;ANDREAS P TERMIN;;JEREMY J CLEMENS;;THOMAS CLEVELAND;;ERICA CONROY;;TIMOTHY RICHARD COON;;RAYMOND STANLEY GROSS;;HARIPADA KHATUYA;;PRAMOD VIRUPAX JOSHI;;PAUL JOHN KRENITSKY;;CHUN- CHIEH LIN;;GULIN ERDOGAN MARELIUS;;VITO MELILLO;;JINGIAN ZHOU;;FABRICE JEAN DENIS PIERRE;;GEORGIA MCGAUGHEY NICHOLLS,,https://lens.org/164-085-079-069-409,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,PENDING
592,US,A1,US 2021/0052584 A1,038-815-509-139-870,2021-02-25,2021,US 202016836155 A,2020-03-31,US 202016836155 A;;US 201916258024 A;;US 201715675000 A;;US 201514876525 A;;US 201562153120 P;;US 201562114767 P;;US 201462060182 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/038-815-509-139-870,Patent Application,yes,0,5,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/506;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;C07D209/18;;C07D209/42;;C07D209/49;;C07D213/64;;C07D213/73;;C07D213/82;;C07D213/84;;C07D231/12;;C07D231/14;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/14;;C07D407/12;;C07D413/14;;C07D417/12,,0,0,,,,ACTIVE
593,MA,A,MA 54649 A,044-163-059-301-32X,2022-04-27,2022,MA 54649 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATEURS DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE,,VERTEX PHARMA,ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;JOSHI PRAMOD VIRUPAX;;KHATUYA HARIPADA;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MCCARTNEY JASON;;MELILLO VITO;;MILLER MARK THOMAS;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/044-163-059-301-32X,Unknown,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,PENDING
594,TW,A,TW 202140422 A,125-685-347-273-962,2021-11-01,2021,TW 110126003 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated disease, such as cystic fibrosis. The present invention also features pharmaceutical composition, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/125-685-347-273-962,Patent of Addition,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07C311/38;;C07D207/34;;C07D209/02;;C07D213/60;;C07D215/16;;C07D217/22;;C07D223/16;;C07D231/10;;C07D233/66;;C07D235/24;;C07D239/28;;C07D241/14;;C07D249/10;;C07D263/34;;C07D401/00;;C07D403/12;;C07D405/00;;C07D409/12;;C07D413/14;;C07D417/12,,0,0,,,,PENDING
595,EP,A1,EP 4159717 A1,105-199-778-684-131,2023-04-05,2023,EP 22194095 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;EP 20188642 A;;EP 15849396 A;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula I:
  
or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/105-199-778-684-131,Patent Application,yes,4,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D209/42;;A61K31/404;;A61K31/4439;;A61P11/00;;C07D401/12,,1,1,078-417-508-507-333,10.1016/j.bmcl.2006.08.003;;16919947,"HOPKINS C R ET AL: ""Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-@c binding agents with potential application to the treatment of osteoporosis"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 16, no. 21, 1 November 2006 (2006-11-01), pages 5659 - 5663, XP027966155, ISSN: 0960-894X, [retrieved on 20061101]",PENDING
596,EP,B1,EP 3203840 B1,177-094-473-070-922,2020-08-05,2020,EP 15849396 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/177-094-473-070-922,Granted Patent,yes,5,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,12,0,,,"KETTLE J G ET AL: ""N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 14, no. 2, 1 January 2004 (2004-01-01), pages 405-408, XP002393948, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2003.10.049;;ANILKUMAR GOPINADHAN N ET AL: ""II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 22, no. 1, 20 October 2011 (2011-10-20), pages 713-717, XP029121479, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2011.10.041;;SOLODUCHO ET AL: ""Synthesis of Some Pyrido<2,3-c><1,2,6>triazinone derivatives"", JOURNAL FÜR PRAKTISCHE CHEMIE - CHEMIKER-ZEITUNG,, vol. 331, no. 3, 1 January 1989 (1989-01-01), pages 503-506, XP009504111, ISSN: 0941-1216;;PASSARELLA D ET AL: ""Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition"", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, ROYAL SOCIETY OF CHEMISTRY, GB, no. 2, 1 January 2001 (2001-01-01), pages 127-129, XP003017354, ISSN: 0300-922X, DOI: 10.1039/B009154P;;MATTER H ET AL: ""Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 45, no. 13, 1 January 2002 (2002-01-01), pages 2749-2769, XP002256632, ISSN: 0022-2623, DOI: 10.1021/JM0111346;;HOPKINS C R ET AL: ""Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 21, 1 November 2006 (2006-11-01), pages 5659-5663, XP027966155, ISSN: 0960-894X [retrieved on 2006-11-01];;JAIN B C ET AL: ""STUDIES IN SULPHANILAMIDES. PART XIII. REACTION WITH DICARBOXYLIC ACIDS. SOME NEW N1- AND N4-ACYL AND HETEROCYCLIC DERIVATIVES"", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, INDIAN CHEMICAL SOCIETY, IN, vol. 24, 1 January 1947 (1947-01-01), pages 173-176, XP002037442, ISSN: 0019-4522;;WINN M ET AL: ""2-(ALKYLAMINO)NICOTINC ACID AND ANALOGS. POTENT ANGIOTENSIN II ANTAGONISTS"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 36, no. 18, 1 January 1993 (1993-01-01), pages 2676-2688, XP002281129, ISSN: 0022-2623, DOI: 10.1021/JM00070A012;;DATABASE PUBCHEM [Online] 19 August 2012 XP055428480 Retrieved from NCBI Database accession no. CID 58132855;;DATABASE PUBCHEM [Online] 19 November 2009 XP055428484 Retrieved from NCBI Database accession no. CID 44419393;;DATABASE PUBCHEM [Online] 16 July 2005 XP055428486 Retrieved from NCBI Database accession no. CID 2545578;;DATABASE PUBCHEM [Online] 02 December 2010 XP055428489 Retrieved from NCBI Database accession no. CID 49774135",ACTIVE
597,MX,A,MX 2021001903 A,039-433-711-122-557,2021-04-28,2021,MX 2021001903 A,2017-04-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR.,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,HADIDA-RUAH SARA SABINA;;MILLER MARK THOMAS;;BEAR BRIAN RICHARD;;ARUMUGAM VIJAYALAKSMI;;ZHOU JINGLAN;;FRIEMAN BRYAN A;;BINCH HAYLEY MARIE;;GROOTENHUIS PETER DIEDERIK JAN;;SILINA ALINA;;MCCARTNEY JASON;;ANDERSON COREY;;PIERRE FABRICE JEAN DENIS;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;GROSS RAYMOND STANLEY;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;NICHOLLS GEORGIA MCGAUGHEY;;UY JOHNNY;;LIN CHUN-CHIEH;;P TERMIN ANDREAS,,https://lens.org/039-433-711-122-557,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,PENDING
598,US,B2,US 10258624 B2,119-625-987-210-976,2019-04-16,2019,US 201715675000 A,2017-08-11,US 201715675000 A;;US 201514876525 A;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/119-625-987-210-976,Granted Patent,yes,137,21,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D213/82;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;A61K31/506;;C07D209/18;;C07D209/42;;C07D209/49;;C07D213/64;;C07D213/73;;C07D213/84;;C07D231/12;;C07D231/14;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/14;;C07D407/12;;C07D413/14;;C07D417/12,,23,8,034-587-611-086-755;;013-937-078-602-349;;096-312-557-325-378;;078-417-508-507-333;;012-371-996-064-723;;039-573-265-223-407;;009-891-282-676-18X;;061-669-166-608-882,22104146;;10.1016/j.bmcl.2011.10.041;;23394148;;10.1021/ol400049m;;10.1055/s-0035-1561339;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1016/j.bmcl.2003.10.049;;14698169;;10.1021/jm0111346;;12061878;;10.1039/b009154p;;10.1021/jm00070a012;;8410980,"R. “The Organic Chemistry of Drug Design and Drug Action,” 2004, Elsevier, pp. 29-32.;;Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” Biogranic & Medicinal Chemistry Letters, 22(1):713-717.;;Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” Organic Lett, 15(5):1056-1059.;;Chen, Y. (Jan. 26, 2016) “N-Monoacylation of Sulfonimidamides” Synthesis, 48(7):1019-1028.;;Database CAPLUS, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-UCLAF [online]. Retrieved Jan. 6, 2017 (1 page).;;Database CAPLUS, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages).;;Database PubChem, CID: 2545578. Compound Summary, T5339296. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2545578, on Jan. 22, 2016 (9 pages).;;Database PubChem, CID: 44419393. Compound Summary, CHEMBL374189. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/44419393, on Jan. 22, 2016 (11 pages).;;Database PubChem, CID: 49774135. Compound Summary, SCHEMBL13395127. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016 [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/49774135, on Jan. 22, 2016 (10 pages).;;Database PubChem, CID: 58132855. Compound Summary, SCHEMBL831192. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database; Modify Date: Jan. 16, 2016 [online]. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/58132855, on Jan. 22, 2016 (10 pages).;;Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemistry Letters, 16(21):5659-5663.;;International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, dated Feb. 5, 2016 (11 pages).;;International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, dated Jun. 6, 2017 (15 pages).;;International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, dated Jan. 3, 2018 (10 pages).;;International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, dated Feb. 27, 2018 (10 pages).;;Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some New N1- and N4-Acyl and Heterocycic Derivatives” Journal of the Indian Chemical Society, 24:173-176.;;Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” Bioorganic & Medicinal Chemistry Letters, 14(2): 405-408.;;Matter, H. et al. (2002) “Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” Journal of Medicinal Chemistry, 45(13):2749-2769.;;Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” Journal of the Chemical Society, Perkin Transactions 1, 127-129.;;Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32.;;Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” Journal für Pracktische Chemie, 331(3):503-506.;;U.S. Appl. No. 15/836,627, filed Dec. 8, 2017, by Abela et al.;;Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” Journal of Medicinal Chemistry, 36(18):2676-2688.",ACTIVE
599,US,A1,US 2023/0233560 A1,167-743-274-849-516,2023-07-27,2023,US 202217865220 A,2022-07-14,US 202217865220 A;;US 202016836155 A;;US 201916258024 A;;US 201715675000 A;;US 201514876525 A;;US 201562153120 P;;US 201562114767 P;;US 201462060182 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/167-743-274-849-516,Patent Application,yes,2,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/506;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;C07D209/18;;C07D209/42;;C07D209/49;;C07D213/64;;C07D213/73;;C07D213/82;;C07D213/84;;C07D231/12;;C07D231/14;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/14;;C07D407/12;;C07D413/14;;C07D417/12,,0,0,,,,PENDING
600,RS,B1,RS 60906 B1,026-726-223-186-612,2020-11-30,2020,RS P20201210 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W;;EP 15849396 A,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/026-726-223-186-612,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,ACTIVE
601,TW,B,TW I735416 B,016-636-199-048-719,2021-08-11,2021,TW 104132917 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/016-636-199-048-719,Granted Patent,no,1,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,,,0,0,,,,ACTIVE
602,TW,A,TW 201713617 A,017-054-026-906-62X,2017-04-16,2017,TW 104132917 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula I:or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/017-054-026-906-62X,Patent of Addition,no,0,4,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07C311/38;;C07D207/34;;C07D209/02;;C07D213/60;;C07D215/16;;C07D217/22;;C07D223/16;;C07D231/10;;C07D233/66;;C07D235/24;;C07D239/28;;C07D241/14;;C07D249/10;;C07D263/34;;C07D401/00;;C07D403/12;;C07D405/00;;C07D409/12;;C07D413/14;;C07D417/12,,0,0,,,,ACTIVE
603,KR,A,KR 20170064549 A,078-509-855-057-785,2017-06-09,2017,KR 20177012317 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"본 발명은 CFTR 매개 질환, 예컨대 낭성 섬유증의 치료를 위한 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 특색으로 한다. 본 발명은 또한 제약 조성물, 치료 방법, 및 그의 키트를 특색으로 한다. <화학식 I>여기서 R, R, R, W, X, Y, Z, n, o, p, 및 q는 본원에 정의되어 있다.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/078-509-855-057-785,Patent Application,no,1,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D401/12;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14,,0,0,,,,ACTIVE
604,EP,B1,EP 3798214 B1,106-275-657-455-509,2022-09-14,2022,EP 20188642 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;EP 15849396 A;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/106-275-657-455-509,Granted Patent,yes,1,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D403/12;;A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D407/12;;C07D413/14,,1,1,061-669-166-608-882,10.1021/jm00070a012;;8410980,"WINN M,ET AL: ""2-(ALKYLAMINO)NICOTINC ACID AND ANALOGS. POTENT ANGIOTENSIN II ANTAGONISTS"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 36, no. 18, 1 January 1993 (1993-01-01), US , pages 2676 - 2688, XP002281129, ISSN: 0022-2623, DOI: 10.1021/jm00070a012",ACTIVE
605,CO,A2,CO 2017004538 A2,155-619-121-643-804,2017-11-10,2017,CO 2017004538 A,2017-05-05,US 2015/0054316 W;;US 201462060182 P;;US 201562153120 P;;US 201562114767 P,2014-10-06,Moduladores del regulador de la conductancia transmembrana de la fibrosis quística,"La presente invención caracteriza un compuesto de la fórmula I, una de sus sales farmacéuticamente aceptables, donde R1, R2, R3, W, X, Y, Z, n, o, p y q se definen en la presente, para el tratamiento de enfermedades mediadas por CFTR, como fibrosis quística.La presente invención también caracteriza composiciones farmacéuticas, método de tratamiento y sus kits.",VERTEX PHARMA,ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;HADIDA-RUAH SARA SABINA;;MILLER MARK THOMAS;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/155-619-121-643-804,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,PENDING
606,SG,A,SG 10201902963P A,194-817-963-283-851,2019-05-30,2019,SG 10201902963P A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/194-817-963-283-851,Unknown,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,,,0,0,,,,PENDING
607,US,B2,US 11426407 B2,036-377-709-968-817,2022-08-30,2022,US 202016836155 A,2020-03-31,US 202016836155 A;;US 201916258024 A;;US 201715675000 A;;US 201514876525 A;;US 201562153120 P;;US 201562114767 P;;US 201462060182 P,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,VERTEX PHARMACEUTICALS (SAN DIEGO) LLC (2015-11-18);;VERTEX PHARMACEUTICALS INCORPORATED (2015-11-09),https://lens.org/036-377-709-968-817,Granted Patent,yes,268,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D213/82;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;A61K31/506;;C07D209/18;;C07D209/42;;C07D209/49;;C07D213/64;;C07D213/73;;C07D213/84;;C07D231/12;;C07D231/14;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/14;;C07D407/12;;C07D413/14;;C07D417/12,,101,39,034-587-611-086-755;;019-580-410-758-652;;102-930-132-246-061;;013-937-078-602-349;;030-344-533-512-103;;009-214-187-079-899;;104-949-654-022-72X;;011-850-681-025-027;;096-312-557-325-378;;119-132-751-946-922;;063-867-427-592-138;;002-186-545-851-173;;011-459-178-850-597;;181-512-135-393-079;;078-417-508-507-333;;170-189-696-205-940;;012-371-996-064-723;;016-315-186-852-575;;103-052-069-575-996;;039-573-265-223-407;;022-265-272-874-951;;029-362-218-879-507;;064-116-226-667-307;;009-891-282-676-18X;;042-420-274-722-532;;030-350-705-205-427;;067-187-844-310-10X;;006-026-497-014-33X;;045-406-285-588-795;;079-362-981-419-890;;040-107-243-792-147;;010-718-962-322-429;;061-669-166-608-882;;118-007-112-303-323;;087-626-907-619-006;;144-170-754-278-61X;;115-350-648-150-731;;038-005-480-898-683;;001-641-923-364-301,22104146;;10.1016/j.bmcl.2011.10.041;;10.1002/anie.200700039;;17886815;;10.1002/anie.201708903;;29024330;;23394148;;10.1021/ol400049m;;24973281;;10.1016/s2213-2600(14)70132-8;;10.3410/f.725446625.793506150;;10.1023/a:1016241927429;;7494814;;10.1007/3-540-69178-2_5;;10.4155/fmc-2019-0183;;31538524;;10.1055/s-0035-1561339;;31034626;;10.1002/jlcr.3743;;10.1021/jacs.5b05144;;pmc4490774;;26088401;;10.1021/jm4007998;;24294889;;pmc6510372;;10.1111/cts.12610;;30694595;;10.1021/cen-09427-cover;;10.1016/j.bmcl.2006.08.003;;16919947;;10.1002/9780470571224.pse414;;10.1016/j.bmcl.2003.10.049;;14698169;;10.2533/chimia.2008.260;;10.1021/jo01296a034;;10.1021/jm0111346;;12061878;;27169762;;10.1002/jlcr.3383;;31987762;;10.1016/j.jcf.2020.01.005;;pmc10657649;;24392786;;10.1517/13543776.2014.876412;;10.1039/b009154p;;10.1021/acs.jmedchem.8b01808;;30640460;;28591114;;10.1038/nbt0617-493;;25650311;;10.1016/j.bmc.2014.12.056;;10.1016/s1569-1993(16)30138-2;;10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744;;10.1055/s-1999-3685;;10.1007/978-1-4939-1598-9_9;;25981758;;pmc4764353;;10.1056/nejmoa1409547;;10.1021/jm00070a012;;8410980;;10.1021/cen-v087n025.p036;;17100633;;10.2174/138955706778742768;;10.1021/cc9800071;;10746014;;15286737;;10.1038/nrd1470;;pmc2838761;;20178582;;10.1186/1423-0127-17-13;;10.1016/s0169-409x(02)00003-0;;11922947,"Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” Biogranic & Medicinal Chemistry Letters, 22(1):713-717.;;Atzrodt J, Derdau V, Fey T, Zimmermann J. “The Renaissance of H/D Exchange” Angew. Chem. Int. Ed. 2007: 46, 7744-7765.;;Atzrodt J, Derdau V, Kerr W, Reid M. “C—H functionalization for hydrogen isotope exchange” Angew. Chem. Int. Ed. 2018: 57, 3022-3047.;;Bhattacharya, S. et al. (1999) Polymorphism in Pharmaceutical Solids: Thermoanalytical and Crystallographic Methods (Brittain H. ed., 2d ed. Informa Healthcare USA, Inc. 2009) 318-335.;;Belikov, V.G., (2007) Farmatsevticheskaya khimiya (Pharmaceutical Chemistry), Moscow: MEDpress-inform, pp. 27-29.;;Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” Organic Lett, 15(5): 1056-1059.;;Boyle, M. “A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial,” The Lancet Respiratory Medicine (Jul. 1, 2014) Retrieved from the Internet: https://www-clinicalkeycom-ez03.infotrieve.com/#!/content/playContent/1-s2.0S2213260014701328?returnurl=null&referrer=null.;;Braman, V.; Liu, J. F.; Harbeson, S.; Uttamsingh, V.; Bridson, G.; Wu, L.; Shipley, J. E. “Preliminary Clinical Outcomes for CTP-354, a Novel Subtype-Selective GABA(A) Modulator” Presented at the American Neurological Association (ANA) 2014 Annual Meeting, Baltimore, MD, Oct. 12-14, 2014.;;Byrn, S. et al. (1995) “Pharmaceutical solids: A strategic approach to regulatory considerations,” (12): 945-954.;;Caira, M. R. (1998) “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 163-208.;;Cargnin S, Serafini M, Pirali T. “A primer of deuterium in drug design” Future Med. Chem. 2019; 11(16): 2039-2042.;;Chen, Y. (Jan. 26, 2016) “N-Monoacylation of Sulfonimidamides” Synthesis, 48(7):1019-1028.;;Czeskis B, Elmore, CS, Haight A, Hesk D, Maxwell BD, Miller SA, Raglione T, Schildknegt K, Traverse JF, Wang P. “Deuterated active pharmaceutical ingredients: A science-based proposal for synthesis, analysis, and control. Part 1: Framing the problem” J. Label. Compd. Radiopharm. 2019, 62: 690-694. DOI: 10.1002/jlcr.3743.;;Dao HT, Li C, Michaudel Q, Maxwell BD, Baran PS. J. Am. Chem. Soc. 2015; 137, 8046-8049.;;Database CAPLUS, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-UCLAF [online]. Retrieved Jan. 6, 2017 (1 page).;;Database CAPLUS, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages).;;Database Pubchem, CID: 20050716. Compound Summary, 1-[2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20050716, on Dec. 3, 2019 (7 pages).;;Database Pubchem, CID: 20091118. Compound Summary, [4-(5-Hexylpyrimidin-2-yl)phenyl] 2-methoxypropanoate. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20091118, on Dec. 3, 2019 (9 pages).;;Database Pubchem, CID: 20120819. Compound Summary, 4-(Cyclopentyloxy)-3-fluorobenzene-1-sulfonylchloride. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Nov. 30, 2019. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/20120819, on Dec. 3, 2019 (8 pages).;;Database Pubchem, CID: 2545578. Compound Summary, T5339296. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2545578, on Jan. 22, 2016 (9 pages).;;Database Pubchem, CID: 44419393. Compound Summary, CHEMBL374189. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016. [online]. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/44419393, on Jan. 22, 2016 (11 pages).;;Database Pubchem, CID: 49774135. Compound Summary, SCHEMBL13395127. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information; Modify Date: Jan. 16, 2016 [online], Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/49774135, on Jan. 22, 2016 (10 pages).;;Database Pubchem, CID: 58132855. Compound Summary, SCHEMBL831192. NIH, U.S. National Library of Medicine, National Center for Biotechnology Information, PubChem Open Chemistry Database; Modify Date: Jan. 16, 2016 [online]. Retrieved from: https://pubchem.ncbi.nlm.nih.gov/compound/58132855, on Jan. 22, 2016 (10 pages).;;Dorwald, F. A. (2006) “Side Reactions in Organic Synthesis” Wiley: VCH, Weinheim p. IX of Preface p. 1-15.;;Gant TG. “Using Deuterium in Drug Discovery: Leaving the Label in the Drug” J Med. Chem. 2014; 57(9): 3595-3611.;;VARUN GARG, JINSHAN SHEN, CHONGHUA LI, SAGAR AGARWAL, ASFIHA GEBRE, SARAH ROBERTSON, JIAYIN HUANG, LINDA HAN, LICONG JIANG, KRISTI: ""Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor"", CTS - CLINICAL AND TRANSLATIONAL SCIENCE, WILEYBLACKWELL PUB., US, vol. 12, no. 3, 1 May 2019 (2019-05-01), US , pages 267 - 275, XP055719490, ISSN: 1752-8054, DOI: 10.1111/cts.12610;;Halford B. “The deuterium switcheroo” Chemical & Engineering News 2016; 94(27), 32-36.;;Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemistry Letters, 16(21):5659-5663.;;International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, dated Feb. 5, 2016 (11 pages).;;International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, dated Jun. 6, 2017 (11 pages).;;International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, dated Jan. 3, 2018 (10 pages).;;International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, dated Feb. 27, 2018 (10 pages).;;International Patent Application No. PCT/US2018/036610: International Search Report and Written Opinion, dated Sep. 19, 2018 (9 pages).;;International Patent Application No. PCT/US2018/040427: International Search Report and Written Opinion, dated Oct. 9, 2018 (15 pages).;;International Patent Application No. PCT/US2018/042415: International Search Report and Written Opinion, dated Oct. 31, 2018 (12 pages).;;International Patent Application No. PCT/US2018/042486: International Search Report and Written Opinion, dated Nov. 7, 2018 (13 pages).;;International Patent Application No. PCT/US2018/044963: International Search Report and Written Opinion, dated Sep. 25, 2018 (15 pages).;;International Patent Application No. PCT/US2018/056772: International Search Report and Written Opinion, dated Jan. 29, 2019 (13 pages).;;International Patent Application No. PCT/US2018/063871: International Search Report and Written Opinion, dated Feb. 25, 2019 (16 pages).;;International Patent Application No. PCT/US2019/016537: International Search Report and Written Opinion, dated Apr. 23, 2019 (13 pages).;;International Patent Application No. PCT/US2018/064522: International Search Report and Written Opinion, dated Jun. 25, 2019 (21 pages).;;International Patent Application No. PCT/US2019/018042: International Search Report and Written Opinion, dated Apr. 17, 2019 (10 pages).;;International Patent Application No. PCT/US2019/024890: International Search Report and Written Opinion, dated Jun. 17, 2019 (13 pages).;;International Patent Application No. PCT/US2019/026075: International Search Report and Written Opinion, dated Jun. 17, 2019 (13 pages).;;International Patent Application No. PCT/US2019/027202: International Search Report and Written Opinion, dated Jun. 17, 2019 (10 pages).;;International Patent Application No. PCT/US2020/028699: International Search Report and Written Opinion, dated Jul. 20, 2020 (9 pages).;;International Patent Application No. PCT/US2020/034199: International Search Report and Written Opinion, dated Aug. 11, 2020 (15 pages).;;Ivanisevic, I. (2011) “Uses of X-Ray Powder Diffraction in the Pharmaceutical Industry,” Pharm. Form. Qual. 30-33.;;Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some New N1- and N4-Acyl and Heterocyclic Derivatives” Journal of the Indian Chemical Society, 24:173-176.;;Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” Bioorganic & Medicinal Chemistry Letters, 14(2): 405-408.;;IRIS KIELTSCH, PATRICK EISENBERGER, KYRILL STANEK, ANTONIO TO: ""LAUREATES: AWARDS AND HONORS SCS FALL MEETING 2007 260 Recent Advances in Electrophilic CF 3 -Transfer Using Hypervalent Iodine(III) Reagents"", CHIMIA CHIMIA SCHWEIZERISCHE CHEMISCHE GESELLSCHAFT ISSN, vol. 62, no. 62, 1 January 2008 (2008-01-01), pages 260 - 263, XP055591571, DOI: 10.2533/chimia.2008.260;;Lai, J.T. et al. (1980) “Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions,” Journal of Organic Chemistry, 45(8):1513-1514.;;Liu, J. F. et al. “CTP-354: A Novel Deuterated Subtype-Selective GABA(A) Modulator for Treatment of Neuropathic Pain, Spasticity and Anxiety Disorders” Presented at the American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, FL, Dec. 2-6, 2012.;;Matter, H. et al. (2002) “Design and Quantitative Structure-Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” Journal of Medicinal Chemistry, 45(13):2749-2769.;;Maxwell BD, Tran SB, Lago M, Li J, and Bonacorsi Jr SJ. “The syntheses of [14C]BMS-823778 for use in a human ADME clinical study and of [13CD313CD2]BMT-094817, a stable-isotope labeled standard of a newly detected human metabolite” J. Label. Compd. Radiopharm. 2016; 59, 255-259.;;MONTEMAYOR KRISTINA; CLAUDIO ABIGAIL T.; CARSON SARA; LECHTZIN NOAH; CHRISTIANSON MINDY S.; WEST NATALIE E.: ""Unmasking catamenial hemoptysis in the era of CFTR modulator therapy"", JOURNAL OF CYSTIC FIBROSIS, ELSEVIER, NL, vol. 19, no. 4, 24 January 2020 (2020-01-24), NL , XP086202454, ISSN: 1569-1993, DOI: 10.1016/j.jcf.2020.01.005;;NCT03029455 “A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis”. Vertex Pharmaceuticals Incorporated, Retrieved from the Internet: https://clinicaltrials.gov/ct2/show/study/NCT03029455.;;Norman, P. (2014) “Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386, and WO2013038390,” Expert Opinion on Therapeutic Patents, 24(7):829-837.;;Notman, N. (2016) “2Heavy drugs gaining momentum” [online] Retrieved from the internet: https://www.chemistryworld.com/features/2heavy-drugs-gaining-momentum/1010186.article, on Oct. 7, 2019.;;Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” Journal of the Chemical Society, Perkin Transactions 1, 127-129.;;Pirali T, Serafini M, Cargnin S, Genazzani AA. “Applications of Deuterium in Medicinal Chemistry” J Med. Chem. 2019; 62(11): 5276-5297.;;CHEN, QUN; ZHU, GUO-BIAO: ""Synthesis of 3,3,3-trifluoro-2,2-dimethylpropionic acid"", HUAXUE SHIJI - CHEMICAL REAGENTS, BEIJING : HUAXUE HUAXUE SHIJI KEJI QINGBAO ZHONGXINZHAN, CN, vol. 38, no. 4, 1 January 2016 (2016-01-01), CN , pages 386 - 388, XP009513488, ISSN: 0258-3283, DOI: 10.13822/j.cnki.hxsj.2016.04.026;;Rosebraugh, C.J. (2015) “Highlights of Prescribing Information for Orkambi,” [online] Retrieved from the Internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf, on Aug. 24, 2017.;;Schmidt C. “First deuterated drug approved” Nat. Biotechnol. 2017, 35, 493-494.;;Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32.;;Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” Journal für Pracktische Chemie, 331(3):503-506.;;HWANG TSONG-LONG; WANG WEN-HUI; WANG TING-YI; YU HUANG-PING; HSIEH PEI-WEN: ""Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3"", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 5, 16 January 2015 (2015-01-16), AMSTERDAM, NL, pages 1123 - 1134, XP029199003, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2014.12.056;;Tullis, E. et al. (2018) “Preliminary safety and efficacy of triple-combination CFTR modulator regimens,” Respirology, 23(51):33.;;U.S. Appl. No. 16/620,265, filed Dec. 6, 2019, by Chen et al.;;U.S. Appl. No. 16/625,028, filed Dec. 20, 2019, by Chu et al.;;U.S. Appl. No. 16/994,875, filed Aug. 17, 2020, by Abela et al.;;Uttamsingh, V. et al. (2016) “WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies” Journal of Cystic Fibrosis, 15:S22.;;Venkatesh, S. et al. (2000) “Role of the development scientist in compound lead selection and optimization” J. Pharm. Sci. 89(2), 145-154.;;Verado, G. et al. (1999) “Reductive One Batch Synthesis of N-Substituted Pyrrolidines from Primary Amines and 2,5-Dimethoxytetrahydrofuran” Synthesis, (1):74-79.;;Vertex Pharmaceuticals, Inc. (Mar. 28, 2017) “Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People With Cystic Fibrosis” [online] Retrieved from the Internet: http://investors.vrtx.com/static-files/f15217ac-4a8b-436a-9215-79144ec2e59b, on Oct. 10, 2019.;;Vertex Pharmaceuticals, Inc. (Jul. 18, 2017) “Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)”, Retrieved from the Internet: URL: http://investors.vrtx.com/news-releases/news-release-details/vertex/announces-positive-phase-1-phase-2-data-three-different [retrieved on Mar. 27, 2019].;;Vertex Pharmaceuticals, Inc. (Nov. 3, 2017) “Vertex announces presentations of data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF,” Health and Medicine Week, vol. 3, p. 196.;;“Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis” (Aug. 15, 2016) Retrieved from the Internet: https://www.businesswire.com/news/home/20160815006099/en/Vertex-Update-Ongoing-Phase-3-Program-VX-661.;;Vodak, D. (2014) “Design and Development of HPMCAS-Based Spray-Dried Dispersions,” 303-322.;;Wainwright, C.E. et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” The New England Journal of Medicine, 373(3):220-231.;;Willson T. M. et al. (1996) “Bone targeted drugs 2. Synthesis of estrogens with hydroxyapatite affinity,” Bioorg. & Med. Chem. Lett., (6): 1047-1050.;;Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” Journal of Medicinal Chemistry, 36(18):2676-2688.;;Yarnell AT. “Heavy-Hydrogen Drugs Turn Heads, Again” Chemical & Engineering News 2009; 87(25), 36-39.;;Soloducho, J. et al. “Synthesis of Some Pyrido[3,2g][1,2,5]triazocine Derivatives,” Polish Journal of Chemistry, Jan. 1, 1985, vol. 59, No. 10-12, pp. 1115-1120.;;Chemical Abstracts Service, CAS Registry No. 204017-11-8. CA Index Name: 1H-Indole-2-carboxamide, 1-[[2,4-bis(trifluoromethyl)phenyl]methyl]-2,3-dihydro-N-(phenylsulfonyl)-. Entered STN: Apr. 12, 1998.;;Chemical Abstracts Service, CAS Registry No. 220678-97-7. CA Index Name: 1H-Indole-2-carboxamide, 1-[(3,4-dichlorophenyl)methyl]-N-(phenylsulfonyl)-. Entered STN: Mar. 24, 1999.;;Chemical Abstracts Service, CAS Registry No. 220678-99-9. CA Index Name: 1H-Indole-2-carboxamide, 1-[(3,4-dichlorophenyl)methyl]-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-. Entered STN: Mar. 24, 1999.;;Chemical Abstracts Service, CAS Registry No. 412005-98-2. CA Index Name: 1H-Indole-2-carboxamide, 3-(4-methoxyphenyl)-N-(phenylsulfonyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-. Entered STN: May 7, 2002.;;Chemical Abstracts Service, CAS Registry No. 895575-67-4. CA Index Name: 1H-Indole-2-carboxamide,1-[(3-chlorophenyl)methyl]-4-nitro-N-(2-thienylsulfonyl)-. Jun. 30, 2006.;;Chemical Abstracts Service, CAS Registry No. 895575-68-5. CA Index Name: 1H-Indole-2-carboxamide,4-amino-1-[(3-chlorophenyl)methyl]-N-(2-thienylsulfonyl)-. Jul. 23, 2006.;;Notice of Allowance and Fee(s) Due for U.S. Appl. No. 16/620,265, dated Sep. 30, 2021.;;U.S. Appl. No. 17/475,606, filed Sep. 15, 2021, by Chu et al.;;U.S. Appl. No. 17/505,699, filed Oct. 20, 2021, by Alcacio et al.;;Brown et al. (2006) “On scaffolds and hopping in medicinal Chemistry,” Mini-reviews in medicinal chemistry, vol. 6, 11(13), 1217-1229.;;European Patent Application No. 15849396.5 (Patent No. 3203840): Notice of Opposition by Elkington and Fife, LLP, dated May 5, 2021 (19 pages).;;Ghose et al. (1999) Knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery- qualitive and quantitative characterization of known drug databases, J. Comb. Chem.1(1), 55-68.;;Kola et al. (2004) “Can the pharmaceutical indUS-try reduce attrition rates?” Nature Reviews Drug Discovery, 3(8), 711-715.;;Shih et al. (2010) “Pyrazole compound BPR1P0034 with potent and selective anti-influenza virUS- activity” Journal of Biomedical Science, 17:13.;;Walters et al. (2002) “Prediction of ‘drug-likeness’,” Advanced Drug Delivery Reviews, 54(3), 255-271.;;Kratkiy kurs molekulyarnoy biologii (A Concise Course in Molecular Biology), edited by P.V. Sergeev, M., 1975, p. 10.;;Kholodov, L.E. et al., Klinicheskaya farmakokinetika (Clinical Pharmacokinetics), M., Meditsina, 1985, pp. 83-98, 134-138, 160, 378-380.",ACTIVE
608,MA,B1,MA 41051 B1,167-846-769-188-969,2020-11-30,2020,MA 41051 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W,2014-10-06,Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose,"La présente invention concerne un composé de formule (i): (i) ou un sel pharmaceutiquement acceptable de celui-ci, où r1, r2, r3, w, x, y, z, n, o, p et q sont tels que définis dans la description, lequel composé est utile pour le traitement de maladies médiées par le cftr, telles que la mucoviscidose. La présente invention concerne également des compositions pharmaceutiques, une méthode de traitement et des kits correspondants.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/167-846-769-188-969,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14,,0,0,,,,ACTIVE
609,US,A1,US 2016/0095858 A1,052-353-751-985-42X,2016-04-07,2016,US 201514876525 A,2015-10-06,US 201514876525 A;;US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,Modulators of Cystic Fibrosis Transmembrane Conductance Regulator,"The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;HARIPADA KHATUYA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/052-353-751-985-42X,Patent Application,yes,0,74,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A61K31/506;;A61J1/03;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4418;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/497;;C07D209/42;;C07D213/82;;C07D213/84;;C07D231/12;;C07D231/14;;C07D401/12;;C07D401/14;;C07D405/14;;C07D417/12,,2,0,,,CAPLUS 1965 51408;;CAPLUS 1965 51409,ACTIVE
610,HU,T2,HU E051972 T2,106-765-318-412-08X,2021-04-28,2021,HU E15849396 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/106-765-318-412-08X,Amended Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,PENDING
611,EP,A1,EP 3798214 A1,136-847-645-466-680,2021-03-31,2021,EP 20188642 A,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;EP 15849396 A;;US 2015/0054316 W,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,"The present invention features a compound of formula I:
  
or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/136-847-645-466-680,Patent Application,yes,1,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,C07D403/12;;A01N41/06;;A61K31/18;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D407/12;;C07D413/14,,4,1,061-669-166-608-882,10.1021/jm00070a012;;8410980,"WINN M ET AL: ""2-(ALKYLAMINO)NICOTINC ACID AND ANALOGS. POTENT ANGIOTENSIN II ANTAGONISTS"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 36, no. 18, 1 January 1993 (1993-01-01), pages 2676 - 2688, XP002281129, ISSN: 0022-2623, DOI: 10.1021/JM00070A012;;SOLODUCHO ET AL: ""Synthesis of Some Pyrido<2,3-c><1,2,6>triazinone derivatives"", JOURNAL FÜR PRAKTISCHE CHEMIE/CHEMIKER-ZEITUNG, J.A. BARTH, vol. 331, no. 3, 1 January 1989 (1989-01-01), pages 503 - 506, XP009504111, ISSN: 0941-1216;;JAIN B C ET AL: ""STUDIES IN SULPHANILAMIDES. PART XIV. SOME NEW N4-HETEROCYCLIC ACYL-SULPHANILAMIDES"", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, INDIAN CHEMICAL SOCIETY, IN, vol. 24, 1 January 1947 (1947-01-01), pages 177 - 180, XP009504109, ISSN: 0019-4522;;SOLODUCHO ET AL: ""Synthesis of some pyrido<3,2g><1,2,5>tiazocine derivatives"", POLISH JOURNAL OF CHEMISTRY, POLSKIE TOWARZYSTWO CHEMICZNE, POLISH CHEMICAL SOCIETY, PL, vol. 59, no. 10-12, 1 January 1985 (1985-01-01), pages 1115 - 1120, XP009504112, ISSN: 0137-5083",ACTIVE
612,CN,A,CN 116601158 A,027-159-923-844-098,2023-08-15,2023,CN 202180082021 A,2021-10-06,US 202063088686 P;;US 2021/0053858 W,2020-10-07,Modulators of cystic fibrosis transmembrane conductance regulators,"The present disclosure provides: a modulator of cystic fibrosis transmembrane conductance regulatory factor (CFTR), the modulator having a core structure (I); pharmaceutical compositions containing at least one such modulator; methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions; combination pharmaceutical compositions and combination therapies employing these modulators; and processes and intermediates for preparing such modulators.",VERTEX PHARMA,MCCARTNEY JASON;;ABELA ALEXANDER R;;ABRAHAM SANTOSH;;ANDERSON CHRISTOPHER D;;ARUMUGAM VIVEK;;ZHOU JIACHENG;;CLEMENS JOHN;;CLEVELAND THOMAS;;COON TIMOTHY RICHARD;;DWIGHT TIMOTHY A;;FANNING LEV T D;;FREEMAN BRYAN A;;GROOTENHUIS PETER;;GUREVICH ALEKSANDR V;;HADIDA RUAH SARA S;;ISHIHARA YASUO;;KATUJA HANNU;;KRENICKI PETER;;MELILLO VITO;;MILLER MARK T;;PARASELLI PRASUNA;;PIERRE FABRICE;;SILINA ALESSANDRO;;TRAN JAMES A;;UY JOHNNY;;VALDEZ LUIS;;VICKERS THOMAS;;ZHOU JIACHENG,,https://lens.org/027-159-923-844-098,Patent Application,no,0,0,20,20,0,C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/08;;C07D519/00;;C07D515/18;;A61P11/00;;C07D515/04;;A61K31/519;;A61K31/403;;A61K45/06;;A61P43/00;;A61P11/00;;C07D515/08;;C07D515/18;;A61K2300/00,C07D519/00,,0,0,,,,PENDING
613,CL,A1,CL 2017000824 A1,068-252-224-453-243,2018-01-19,2018,CL 2017000824 A,2017-04-04,US 201462060182 P;;US 201562114767 P;;US 201562153120 P,2014-10-06,Moduladores de regulador de conducta de transmembranas de fibrosis cística,"<p>LA PRESENTE INVENCIÓN CARACTERIZA UN COMPUESTO DE LA FÓRMULA I, LA CUAL, UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, DONDE R1, R2, R3, W, X, Y, Z, N, O, P Y Q SE DEFINEN EN LA PRESENTE, PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR CFTR, COMO FIBROSIS QUÍSTICA. LA PRESENTE INVENCIÓN TAMBIÉN CARACTERIZA COMPOSICIONES FARMACÉUTICAS, MÉTODO DE TRATAMIENTO Y SUS KITS.</p>",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/068-252-224-453-243,Patent Application,no,0,2,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,PENDING
614,AU,A1,AU 2015/328174 A1,121-180-555-339-728,2017-04-27,2017,AU 2015/328174 A,2015-10-06,US 201462060182 P;;US 201562153120 P;;US 201562114767 P;;US 2015/0054316 W,2014-10-06,Modulators of cystic fibrosis transmembrane conductance regulator,"The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R",VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDGOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/121-180-555-339-728,Patent Application,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/06;;A61K31/18,,0,0,,,,ACTIVE
615,SI,T1,SI 3203840 T1,145-527-391-327-878,2020-10-30,2020,SI 201531355 T,2015-10-06,US 201462060182 P;;US 201562114767 P;;US 201562153120 P;;US 2015/0054316 W;;EP 15849396 A,2014-10-06,MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,,VERTEX PHARMA,MILLER MARK THOMAS;;ANDERSON COREY;;ARUMUGAM VIJAYALAKSMI;;BEAR BRIAN RICHARD;;BINCH HAYLEY MARIE;;CLEMENS JEREMY J;;CLEVELAND THOMAS;;CONROY ERICA;;COON TIMOTHY RICHARD;;FRIEMAN BRYAN A;;GROOTENHUIS PETER DIEDERIK JAN;;GROSS RAYMOND STANLEY;;HADIDA-RUAH SARA SABINA;;KHATUYA HARIPADA;;JOSHI PRAMOD VIRUPAX;;KRENITSKY PAUL JOHN;;LIN CHUN-CHIEH;;MARELIUS GULIN ERDOGAN;;MELILLO VITO;;MCCARTNEY JASON;;NICHOLLS GEORGIA MCGAUGHEY;;PIERRE FABRICE JEAN DENIS;;SILINA ALINA;;TERMIN ANDREAS P;;UY JOHNNY;;ZHOU JINGLAN,,https://lens.org/145-527-391-327-878,Granted Patent,no,0,0,67,68,0,C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61P11/00;;A61P43/00;;Y02A50/30;;A61K31/506;;A61K31/497;;C07D407/12;;A61K31/404;;A61K31/4418;;C07D403/12;;A61K31/44;;A61K31/4525;;A61P11/00;;C07D231/12;;C07D405/14;;C07D401/14;;C07D213/64;;C07D213/73;;C07D209/49;;A61J1/035;;A61K31/4545;;C07D403/10;;A61K31/415;;C07D231/20;;C07D413/14;;A61P43/00;;C07D213/84;;C07D231/14;;C07D235/24;;C07D417/12;;A61K31/444;;C07D209/42;;C07D239/34;;A61K31/4439;;A61K31/496;;C07D401/12;;C07D213/82;;C07D401/04;;A61K31/4709;;C07D209/18;;A61K31/36;;A61K31/404;;A61K31/415;;A61K31/444;;A61K31/47;;C07D209/42;;C07D213/82;;C07D231/14;;C07D401/12;;C07D209/18;;C07D209/49;;C07D213/64;;C07D213/73;;C07D231/20;;C07D235/24;;C07D239/34;;C07D401/04;;C07D403/10;;C07D403/12;;C07D407/12;;C07D413/14;;A61K31/404;;A61K31/415;;A61K31/44;;A61K31/4439;;A61K31/444;;A61K31/4525;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61P11/00;;A61P43/00;;A61K31/506;;C07D213/82;;A61K31/4418;;A61K31/444;;A61K31/44;;C07D213/84;;C07D231/14;;A61K31/415;;C07D209/42;;A61K31/404;;C07D401/12;;A61K31/4439;;C07D401/14;;C07D231/12;;A61K31/497;;C07D417/12;;C07D405/14;;A61K31/4545;;A61K31/4709;;A61K31/496;;A61K31/4525;;A61J1/035;;C07D403/12;;C07D413/14;;C07D213/73;;C07D231/20;;C07D401/04;;C07D235/24;;C07D403/10;;C07D239/34;;C07D407/12;;C07D209/18;;C07D209/49;;C07D213/64,A01N41/00;;A61K31/00;;C07D209/00;;C07D213/00;;C07D231/00;;C07D235/00;;C07D239/00;;C07D401/00;;C07D403/00;;C07D407/00;;C07D413/00,,0,0,,,,ACTIVE
